0001558370-24-01464810-Q Coherus BioSciences, Inc. 20241106202411061631281631291631290 0001558370-24-014648 10-Q 90 20240930 20241106 20241106 Coherus BioSciences, Inc. 0001512762 2836 273615821 DE 1231 10-Q 34 001-36721 241431553 C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065 (650) 649-3530 C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065 BioGenerics, Inc. 20110210 10-Q 1 chrs-20240930x10q.htm 10-Q 0001512762--12-312024Q3false0011221526011521340 7http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpenseP10Yhttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpenseP4YP5YP4Y10M24Dhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember0001512762us-gaap:AdditionalPaidInCapitalMemberchrs:AtMarketOfferingMember2024-01-012024-03-310001512762chrs:AtMarketOfferingMember2024-01-012024-03-310001512762us-gaap:AdditionalPaidInCapitalMemberchrs:AtMarketOfferingMember2023-07-012023-09-300001512762us-gaap:AdditionalPaidInCapitalMemberchrs:PublicOfferingMember2023-04-012023-06-300001512762chrs:PublicOfferingMember2023-04-012023-06-300001512762us-gaap:AdditionalPaidInCapitalMemberchrs:AtMarketOfferingMember2023-01-012023-03-310001512762chrs:AtMarketOfferingMember2023-01-012023-03-310001512762us-gaap:CommonStockMemberchrs:AtMarketOfferingMember2024-01-012024-03-310001512762us-gaap:CommonStockMemberchrs:AtMarketOfferingMember2023-07-012023-09-300001512762chrs:PublicOfferingMember2023-05-162023-05-160001512762us-gaap:CommonStockMemberchrs:PublicOfferingMember2023-04-012023-06-300001512762us-gaap:CommonStockMemberchrs:AtMarketOfferingMember2023-01-012023-03-310001512762us-gaap:RetainedEarningsMember2024-09-300001512762us-gaap:AdditionalPaidInCapitalMember2024-09-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001512762us-gaap:RetainedEarningsMember2024-06-300001512762us-gaap:AdditionalPaidInCapitalMember2024-06-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001512762202 4-06-300001512762us-gaap:RetainedEarningsMember2024-03-310001512762us-gaap:AdditionalPaidInCapitalMember2024-03-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001512762202 4-03-310001512762us-gaap:RetainedEarningsMember2023-12-310001512762us-gaap:AdditionalPaidInCapitalMember2023-12-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001512762us-gaap:RetainedEarningsMember2023-09-300001512762us-gaap:AdditionalPaidInCapitalMember2023-09-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001512762us-gaap:RetainedEarningsMember2023-06-300001512762us-gaap:AdditionalPaidInCapitalMember2023-06-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001512762202 3-06-300001512762us-gaap:RetainedEarningsMember2023-03-310001512762us-gaap:AdditionalPaidInCapitalMember2023-03-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001512762202 3-03-310001512762us-gaap:RetainedEarningsMember2022-12-310001512762us-gaap:AdditionalPaidInCapitalMember2022-12-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001512762us-gaap:CommonStockMember2024-07-012024-09-300001512762us-gaap:CommonStockMember2024-01-012024-03-310001512762us-gaap:CommonStockMember2023-04-012023-06-300001512762us-gaap:CommonStockMember2023-01-012023-03-310001512762us-gaap:OverAllotmentOptionMember2023-05-160001512762202 4-06-280001512762us-gaap:CallOptionMember2020-04-140001512762202 0-04-140001512762srt:ExecutiveOfficerMemberus-gaap:PerformanceSharesMember2024-05-012024-05-310001512762srt:ChiefExecutiveOfficerMemberus-gaap:PerformanceSharesMember2024-04-012024-04-300001512762us-gaap:PerformanceSharesMember2024-05-012024-05-310001512762us-gaap:PerformanceSharesMember2024-04-012024-04-300001512762chrs:EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember2024-01-012024-09-300001512762us-gaap:ProductMember2024-07-012024-09-300001512762us-gaap:ProductAndServiceOtherMember2024-07-012024-09-300001512762chrs:YusimryMember2024-07-012024-09-300001512762chrs:UdenycaMember2024-07-012024-09-300001512762chrs:ToripalimabMember2024-07-012024-09-300001512762chrs:CimerliMember2024-07-012024-09-300001512762us-gaap:ProductMember2024-01-012024-09-300001512762us-gaap:ProductAndServiceOtherMember2024-01-012024-09-300001512762chrs:YusimryMember2024-01-012024-09-300001512762chrs:UdenycaMember2024-01-012024-09-300001512762chrs:ToripalimabMember2024-01-012024-09-300001512762chrs:CimerliMember2024-01-012024-09-300001512762us-gaap:ProductMember2023-07-012023-09-300001512762us-gaap:ProductAndServiceOtherMember2023-07-012023-09-300001512762chrs:YusimryMember2023-07-012023-09-300001512762chrs:UdenycaMember2023-07-012023-09-300001512762chrs:CimerliMember2023-07-012023-09-300001512762us-gaap:ProductMember2023-01-012023-09-300001512762us-gaap:ProductAndServiceOtherMember2023-01-012023-09-300001512762chrs:YusimryMember2023-01-012023-09-300001512762chrs:UdenycaMember2023-01-012023-09-300001512762chrs:CimerliMember2023-01-012023-09-300001512762chrs:JunshiBiosciencesMember2024-07-012024-09-300001512762chrs:JunshiBiosciencesMember2023-07-012023-09-300001512762chrs:TermLoansMember2024-04-012024-04-300001512762us-gaap:MachineryAndEquipmentMember2024-09-300001512762us-gaap:LeaseholdImprovementsMember2024-09-300001512762us-gaap:FurnitureAndFixturesMember2024-09-300001512762us-gaap:ComputerEquipmentMember2024-09-300001512762us-gaap:MachineryAndEquipmentMember2023-12-310001512762us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-12-310001512762us-gaap:LeaseholdImprovementsMember2023-12-310001512762us-gaap:FurnitureAndFixturesMember2023-12-310001512762us-gaap:ComputerEquipmentMember2023-12-3100015127622022-04-012022-04-300001512762chrs:PublicOfferingMember2023-05-182023-05-180001512762chrs:PublicOfferingMember2023-01-012023-09-300001512762chrs:CimerliOphthalmologyFranchiseMember2024-01-012024-09-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001512762us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001512762us-gaap:RetainedEarningsMember2024-07-012024-09-300001512762us-gaap:RetainedEarningsMember2024-04-012024-06-300001512762us-gaap:RetainedEarningsMember2024-01-012024-03-310001512762us-gaap:RetainedEarningsMember2023-07-012023-09-300001512762us-gaap:RetainedEarningsMember2023-04-012023-06-300001512762us-gaap:RetainedEarningsMember2023-01-012023-03-310001512762chrs:AccruedRebatesFeesAndReservesMember2024-09-300001512762chrs:AccruedRebatesFeesAndReservesMember2023-12-310001512762us-gaap:CostOfSalesMemberchrs:YusimryProductMember2023-01-012023-12-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-07-012024-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-07-012024-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-01-012024-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-01-012024-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2023-07-012023-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2023-07-012023-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2023-01-012023-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2023-01-012023-09-300001512762chrs:OutLicensesWithNovartisInstitutesMember2024-01-012024-03-310001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMember2024-01-012024-09-300001512762us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:FairValueInputsLevel3Memberchrs:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:RoyaltyAgreementsMember2024-09-300001512762us-gaap:RoyaltyAgreementsMember2024-05-080001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-01-012024-03-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2023-12-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2023-12-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-06-300001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-09-300001512762chrs:TermLoansMemberus-gaap:FairValueInputsLevel2Member2024-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:FairValueInputsLevel2Member2024-09-300001512762chrs:AnkuraTrustCompanyLlcMemberchrs:TwoThousandTwentyNineTermLoansMember2024-05-080001512762chrs:TermLoansMember2024-04-010001512762chrs:TermLoansMemberus-gaap:FairValueInputsLevel2Member2023-12-310001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:FairValueInputsLevel2Member2023-12-310001512762chrs:TermLoansMember2022-01-050001512762us-gaap:ScenarioPlanMemberchrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2024-01-012024-09-300001512762chrs:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001512762chrs:CardinalMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001512762chrs:AmeriSourceBergenCorpMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001512762chrs:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001512762chrs:CardinalMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001512762chrs:AmeriSourceBergenCorpMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001512762chrs:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001512762chrs:CardinalMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001512762chrs:AmeriSourceBergenCorpMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001512762chrs:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001512762chrs:CardinalMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001512762chrs:AmeriSourceBergenCorpMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001512762us-gaap:CommonStockMember2024-09-300001512762us-gaap:CommonStockMember2024-06-300001512762us-gaap:CommonStockMember2024-03-310001512762us-gaap:CommonStockMember2023-12-310001512762us-gaap:CommonStockMember2023-09-300001512762us-gaap:CommonStockMember2023-06-300001512762us-gaap:CommonStockMember2023-03-310001512762us-gaap:CommonStockMember2022-12-310001512762chrs:PublicOfferingMember2023-05-160001512762chrs:SurfaceOncologyInc.Memberus-gaap:AcquisitionRelatedCostsMember2023-07-012023-09-300001512762chrs:SurfaceOncologyInc.Memberus-gaap:AcquisitionRelatedCostsMember2023-01-012023-09-300001512762chrs:SurfaceOncologyInc.Memberus-gaap:LicensingAgreementsMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberus-gaap:InProcessResearchAndDevelopmentMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithNovartisInstitutesMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithGrkMember2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:InProcessResearchAndDevelopmentSrf388Member2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:InProcessResearchAndDevelopmentSrf114Member2023-09-080001512762chrs:SurfaceOncologyInc.Member2024-09-300001512762chrs:SurfaceOncologyInc.Member2024-03-310001512762chrs:SurfaceOncologyInc.Member2024-01-012024-03-310001512762chrs:SurfaceOncologyInc.Member2023-07-012023-09-300001512762chrs:SurfaceOncologyInc.Member2023-01-012023-09-300001512762us-gaap:MoneyMarketFundsMember2024-09-300001512762us-gaap:MoneyMarketFundsMember2023-12-310001512762us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001512762us-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:USTreasurySecuritiesMember2023-12-310001512762us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:FairValueMeasurementsRecurringMember2024-09-300001512762us-gaap:FairValueInputsLevel3Memberchrs:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001512762us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001512762chrs:PrepaidExpensesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762chrs:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310001512762us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762chrs:PrepaidExpensesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762us-gaap:FairValueMeasurementsRecurringMember2023-12-310001512762chrs:ConvertibleNotesMemberchrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2024-07-012024-09-300001512762us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001512762chrs:EmployeesAndNonemployeesStockOptionMember2024-07-012024-09-300001512762us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001512762chrs:EmployeesAndNonemployeesStockOptionMember2024-01-012024-09-300001512762chrs:ConvertibleNotesMemberchrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2023-07-012023-09-300001512762us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001512762chrs:EmployeesAndNonemployeesStockOptionMember2023-07-012023-09-300001512762chrs:ConvertibleNotesMemberchrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2023-01-012023-09-300001512762us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001512762chrs:EmployeesAndNonemployeesStockOptionMember2023-01-012023-09-300001512762chrs:RevenuePurchaseAndSaleAgreementMember2024-07-012024-09-300001512762chrs:RevenuePurchaseAndSaleAgreementMember2024-01-012024-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2024-07-012024-09-300001512762chrs:TwoThousandTwentyNineTermLoansMember2024-07-012024-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2024-01-012024-09-300001512762chrs:TermLoansMember2024-01-012024-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2023-07-012023-09-

300001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMember2023-07-012023-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2023-01-012023-09-300001512762chrs:TermLoansMember2023-01-012023-09-300001512762us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001512762us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001512762us-gaap:PerformanceSharesMember2024-07-012024-09-300001512762us-gaap:CostOfSalesMember2024-07-012024-09-300001512762us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001512762us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001512762us-gaap:PerformanceSharesMember2024-01-012024-09-300001512762us-gaap:CostOfSalesMember2024-01-012024-09-300001512762us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001512762us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001512762us-gaap:CostOfSalesMember2023-07-012023-09-300001512762us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001512762us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001512762us-gaap:CostOfSalesMember2023-01-012023-09-300001512762us-gaap:AdditionalPaidInCapitalMemberchrs:AtMarketOfferingMember2024-04-012024-06-300001512762chrs:AtMarketOfferingMember2024-04-012024-06-300001512762us-gaap:AdditionalPaidInCapitalMemberchrs:AtMarketOfferingMember2023-04-012023-06-300001512762chrs:AtMarketOfferingMember2023-04-012023-06-300001512762us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001512762us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001512762022-01-012024-03-310001512762us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001512762022-04-012023-06-300001512762us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001512762022-01-012023-03-310001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithNovartisInstitutesMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithGrkMember2023-09-082023-09-080001512762chrs:JunshiBiosciencesMember2024-09-300001512762022-10-31000151276 2srt:WeightedAverageMemberchrs:AtMarketOfferingMember2024-01-012024-09-300001512762srt:WeightedAverageMemberchrs:AtMarketOfferingMember2023-07-012023-09-300001512762srt:WeightedAverageMemberchrs:AtMarketOfferingMember2023-01-012023-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-09-300001512762us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001512762us-gaap:CommonStockMember2023-07-012023-09-300001512762us-gaap:CommonStockMember2024-04-012024-06-300001512762us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001512762022-04-012024-06-300001512762us-gaap:OverAllotmentOptionMember2023-05-162023-05-160001512762chrs:AtMarketOfferingMember2023-05-150001512762srt:MaximumMemberchrs:AtMarketOfferingMember2023-09-110001512762srt:MaximumMemberchrs:AtMarketOfferingMember2023-05-150001512762srt:MaximumMemberchrs:PublicOfferingMember2022-11-170001512762srt:MaximumMemberchrs:AtMarketOfferingMember2022-11-080001512762chrs:UdenycaMemberchrs:RevenuePurchaseAndSaleAgreementMember2024-05-080001512762chrs:UdenycaAndLoqtorziMemberchrs:RevenuePurchaseAndSaleAgreementMember2024-05-080001512762chrs:RevenuePurchaseAndSaleAgreementMember2024-05-080001512762chrs:RebatesMember2024-09-300001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2024-09-300001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2024-09-300001512762chrs:RebatesMember2023-12-310001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2023-12-310001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2023-12-310001512762chrs:RebatesMember2023-09-300001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2023-09-300001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2023-09-300001512762022-09-300001512762chrs:RebatesMember2022-12-310001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2022-12-310001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2022-12-3100015127622022-12-310001512762chrs:YusimryImmunologyFranchiseMember2024-07-012024-09-300001512762chrs:YusimryImmunologyFranchiseMember2024-01-012024-09-3000015127622024-07-012024-09-300001512762022-07-012023-09-300001512762chrs:AtMarketOfferingMember2024-01-012024-09-300001512762chrs:AtMarketOfferingMember2023-07-012023-09-300001512762chrs:AtMarketOfferingMember2023-01-012023-09-300001512762chrs:YusimryImmunologyFranchiseMember2023-12-310001512762chrs:CimerliOphthalmologyFranchiseMember2023-12-310001512762chrs:RebatesMember2024-01-012024-09-300001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2024-01-012024-09-300001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2024-01-012024-09-300001512762chrs:RebatesMember2023-01-012023-09-300001512762chrs:OtherFeesCoPayAssistanceAndReturnsMember2023-01-012023-09-300001512762chrs:ChargebacksAndDiscountsForPromptPaymentMember2023-01-012023-09-300001512762chrs:TwoThousandTwentyNineTermLoansMember2024-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2024-09-3000015127622024-02-052024-02-0500015127622024-03-012024-03-310001512762chrs:AnkuraTrustCompanyLlcMemberchrs:TwoThousandTwentyNineTermLoansMember2024-09-300001512762chrs:YusimryProductMember2023-01-012023-12-310001512762chrs:TwoThousandTwentyNineTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-05-082024-05-080001512762chrs:TwoThousandTwentyNineTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-05-082024-05-080001512762chrs:TwoThousandTwentyNineTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2024-05-082024-05-080001512762chrs:RevenuePurchaseAndSaleAgreementMemberus-gaap:InterestExpenseMember2024-07-012024-09-300001512762us-gaap:InterestExpenseMember2024-01-012024-09-300001512762chrs:AtMarketOfferingMember2023-09-112023-09-1100015127622023-01-012023-09-300001512762chrs:SurfaceOncologyInc.Memberchrs:OutLicensesWithNovartisInstitutesMember2024-01-012024-03-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-06-262024-06-260001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-03-012024-03-010001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2020-04-012020-04-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-09-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-04-012024-06-300001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-03-310001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:YusimryImmunologyFranchiseMember2024-06-260001512762us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchrs:CimerliOphthalmologyFranchiseMember2024-03-0100015127622024-03-010001512762chrs:RevenuePurchaseAndSaleAgreementMember2024-09-300001512762chrs:JunshiBiosciencesMember2024-01-012024-09-3000015127622024-02-050001512762chrs:BiopharmaCreditInvestmentsVGpLlcMemberchrs:TermLoansMember2024-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2020-04-300001512762chrs:TwoThousandTwentyNineTermLoansMember2024-01-012024-09-300001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member2024-01-012024-09-300001512762chrs:TwoThousandTwentyNineTermLoansMember2024-05-082024-05-080001512762chrs:TermLoansMember2024-04-012024-04-010001512762chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Memberus-gaap:ConvertibleDebtMember2024-09-300001512762chrs:AtMarketOfferingMember2024-09-300001512762chrs:JunshiBiosciencesMember2022-03-310001512762chrs:CanadaLicenseAgreementMember2024-01-012024-09-300001512762chrs:JunshiBiosciencesMember2022-03-012022-03-310001512762chrs:ToripalimabMemberchrs:JunshiBiosciencesMember2021-02-012021-02-010001512762chrs:ExclusiveLicenseAndCommercializationAgreementMember2022-03-012022-03-3100015127622022-03-012022-03-310001512762chrs:JunshiBiosciencesMember2021-02-012021-02-010001512762chrs:SurfaceMemberchrs:GskAgreementMember2022-03-012022-03-310001512762chrs:AntiTigitAntibodyAndIl2CytokineMemberchrs:ExclusiveLicenseAndCommercializationAgreementMember2022-03-310001512762chrs:ToripalimabMemberchrs:JunshiBiosciencesMember2021-02-010001512762chrs:VaccinexLicenseAgreementMember2021-03-212021-03-210001512762chrs:AdimabDevelopmentAndOptionAgreementMember2018-10-012018-10-310001512762chrs:GskAgreementMember2020-12-012020-12-310001512762us-gaap:AccountsPayableMemberchrs:JunshiBiosciencesMember2024-09-300001512762chrs:AccruedAndOtherCurrentLiabilitiesMemberchrs:JunshiBiosciencesMember2024-09-300001512762us-gaap:CallOptionMember2020-04-012020-04-300001512762chrs:SurfaceOncologyInc.Member2023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:SurfaceSrf388ProprietaryDrugProductAgreementMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:SurfaceSrf114ProprietaryDrugProductAgreementMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Memberchrs:SurfaceGlaxosmithklineAgreementMember2023-09-082023-09-080001512762chrs:SurfaceOncologyInc.Member2023-09-080001512762022-04-01-012024-09-300001512762chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMemberchrs:JunshiBiosciencesMember2024-03-3100015127622024-09-300001512762022023-12-31iso4217:USDxbrli:purechrs:itemxbrli:sharesiso4217:USDxbrli:sharesiso4217:CADchrs:productTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549â€‹FORMÂ 10-Qâ€‹â˜‘QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2024â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromÂ Â Â Â

other companies;â€‹â—developments and projections relating to our competitors, our market opportunity and our industry; and â€‹â—the potential impact of COVID-19 and the continuation of the war in Ukraine and conflicts in the Middle East on our business and prospects.â€‹We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in PartÂ II, ItemÂ 1A Risk Factors and discussed elsewhere in this Quarterly Report on Form 10-Q. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. Except as required under federal securities laws and the rulesÂ and regulations of the Securities and Exchange Commission (â€œSECâ€), we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make or enter into, except for the acquisition of Surface to the extent described herein.â€‹This Quarterly Report on FormÂ 10-Q also contains estimates, projections, market opportunity estimates and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, publicly filed reports and similar sources.â€‹4 Table of ContentsPARTÂ I. FINANCIAL INFORMATIONITEMÂ 1.Â Unaudited Condensed Consolidated Financial Statementsâ€‹Coherus BioSciences,Â Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share data)(unaudited)â€‹â€‹â€‹

afucosylated immunoglobulin isotype G1 (â€œIgG1â€) antibody targeting CCR8. In addition to the Companyâ€™s internally developed portfolio of product candidates, the Company has a product candidate, GSK4381562, which has been exclusively licensed to GlaxoSmithKline Intellectual Property No. 4 Limited (â€œGSKâ€). Basis of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with 11 Table of ContentsUnited States generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information and in accordance with the instructions to FormÂ 10-Q and RuleÂ 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the â€œSecurities Actâ€). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Companyâ€™s operations and cash flows for interim periods in accordance with U.S.Â GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a fullÂ year or any subsequent interim period.The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited financial statements and notes thereto included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended December 31, 2023 (the â€œ2023 Form 10-Kâ€) filed with the SEC.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as, the estimated effects and uncertainty surrounding the temporary supply interruption relating to the Companyâ€™s third-party labeling and packaging CMO for UDENYCA. Accounting estimates and judgments are inherently uncertain and therefore actual results could differ from these estimates.Cash, Cash Equivalents and Restricted CashThe following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets, which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)â€‹January 1,At beginning of period:Â Â Â Â 2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 102,891â€‹$ 63,547Restricted cashâ€‹â€‹ 452â€‹â€‹ 440Total cash, cash equivalents and restricted cashâ€‹$ 103,343â€‹$ 63,987â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â At end of period:â€‹2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 97,690â€‹$ 80,259Restricted cashâ€‹Â 263â€‹Â 452Total cash, cash equivalents and restricted cashâ€‹$ 97,953â€‹$ 80,711â€‹Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets.â€‹Trade ReceivablesTrade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect 12 Table of Contentsa customerâ€™s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2024 and December 31, 2023.Revenue Purchase and Sale Agreement The Revenue Purchase and Sale Agreement (see Note 8. Financial Liabilities) contains an embedded derivative that meets the criteria to be bifurcated and accounted for separately from the Revenue Purchase and Sale Agreement (the "Royalty Fee Derivative Liability"). The Royalty Fee Derivative Liability was recorded at fair value upon entering into the Revenue Purchase and Sale Agreement and is subsequently remeasured to fair value at each reporting period with the corresponding change in fair value recognized in other income (expense), net in the condensed consolidated statements of operations. The Revenue Purchase and Sale Agreement was initially valued and is remeasured using Monte Carlo simulation models to perform the â€œwith-and-withoutâ€ method, which involves valuing the Revenue Purchase and Sale Agreement with the embedded derivative and then valuing it without the embedded derivative. The difference between values is determined to be the estimated fair value of the Royalty Fee Derivative. Refer to Note 3. Fair Value Measurements for details regarding the fair value.The Revenue Purchase and Sale Agreement is accounted for as a liability net of a discount comprising issuance costs and the fair value of the embedded derivative requiring bifurcation. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the liability to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the condensed consolidated statement of operations. The interest rate on this revenue participation liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The Company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales could materially impact the revenue participation liability, interest expense, and the time period for repayment.Contingent Consideration Contingent consideration relates to the potential payments to holders of Contingent Value Rights (â€œCVRsâ€) that are contingent upon the achievement of the Company and certain third parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within selling, general and administrative expense in the condensed consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts. Stock-Based CompensationThe Companyâ€™s compensation programs include stock-based awards. For awards other than condition-based performance stock options, the fair values are recognized as compensation expense on a straight-line basis over the vesting period. For condition-based performance stock options, expense is recognized only when performance conditions are considered probable of being achieved and is recognized over the period from the grant date through the time the milestone is expected to be achieved. The related costs are recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Companyâ€™s common stock on the date of issuance.Recent Accounting Pronouncements 13 Table of ContentsThe following are recent accounting pronouncements that the Company has not yet adopted:In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-07,Â Segment ReportingÂ (Topic 280) Improvements to Reportable SegmentÂ Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.In December 2023, the FASB issuedÂ ASU 2023-09,Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption. â€‹2.Â Â Â Â Â Â Â Â Revenue The Company launched LOQTORZI in December 2023, YUSIMRY in July 2023 and CIMERLI in October 2022. Net revenue for sales of YUSIMRY and CIMERLI effectively ceased to be recognized in the Companyâ€™s condensed consolidated statements of operations on June 26, 2024 and March 1, 2024, respectively (see Note 6. Acquisition and Dispositions). All net product revenue was generated in the United States, and the Companyâ€™s net revenue was as follows:
â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€‹$ 69,070â€‹$ â€”â€‹$ â€”â€‹$ 69,070Total â€‹$ 69,070Â $ â€”â€‹$ â€”â€‹$ 69,070â€‹17 Table of Contentsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹ â€‹DecemberÂ 31,Â 2023(in thousands)Â Â Â Â CostÂ Â Â Â Unrealized GainÂ Â Â Â Unrealized (Loss)Â Â Â Â Fair ValueMoney market funds â€‹$ 79,484â€‹$ â€”â€‹$ â€”â€‹$ 79,484U.S. government agency securities â€‹â€‹ 5,200Â â€‹ â€”â€‹â€‹ (5)â€‹â€‹ 5,195U.S. treasury securitiesâ€‹â€‹ 11,967â€‹â€‹ 2â€‹â€‹ â€”â€‹â€‹ 11,969Commercial paper and corporate notesâ€‹â€‹ 7,673â€‹â€‹ â€”â€‹â€‹ (6)â€‹â€‹ 7,667Total â€‹$ 104,324Â $ 2â€‹$ (11)â€‹$ 104,315â€‹ â€‹4.Â Â Â Â Â Â Â InventoryInventory consisted of the following: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â â€‹December 31,(in thousands)â€‹2024â€‹2023Raw materialsâ€‹$ 13,735â€‹$ 12,975Work in processâ€‹Â 102,989â€‹Â 82,588Finished goodsâ€‹Â 2,291â€‹Â 34,537Totalâ€‹$ 119,015â€‹$ 130,100â€‹Inventory as of December 31, 2023 included $16.4 million related to the CIMERLI ophthalmology franchise and $17.0 million related to the YUSIMRY immunology franchise (see Note 6. Acquisition and Dispositions). Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During the year ended December 31, 2023, the Company recorded a $47.0Â million charge for the write-down of slow moving YUSIMRY inventory, which included the recognition of $20.5Â million in certain firm purchase commitments. Of this charge, $11.5Â million was reflected in accrued and other current liabilities and $9.0Â million in other liabilities, non-current as of December 31, 2023. Liabilities for firm inventory purchase commitments related to YUSIMRY were derecognized upon the YUSIMRY Sale. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current on the condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the non-current portion of inventory consisted of raw materials and work in process, as well as a portion of finished goods at December 31, 2023. The following table presents the inventory balance sheet classifications:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â â€‹December 31,(in thousands)â€‹2024â€‹2023Inventoryâ€‹$ 47,640â€‹$ 62,605Inventory, non-currentâ€‹Â 71,375â€‹Â 67,495Totalâ€‹$ 119,015â€‹$ 130,100â€‹Prepaid manufacturing of $10.7 million as of September 30, 2024 includes prepayments of $6.5 million to CMOs for manufacturing services, which the Company expects to be converted into inventory within the next twelve months, and prepayments of $4.2 million to various CMOs for research and development pipeline programs. Prepaid manufacturing of $23.7 million as of December 31, 2023 included prepayments of $11.1 million to various CMOs for research and development pipeline programs and $12.6 million to CMOs for manufacturing services, of which $6.4 million related to the CIMERLI ophthalmology franchise and $0.5 million related to the YUSIMRY immunology franchise (see Note 6. Acquisition and Dispositions).â€‹18 Table of Contents5.Â Â Â Â Â Â Â Balance Sheet ComponentsProperty and Equipment, NetProperty and equipment, net consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â â€‹DecemberÂ 31,Â (in thousands)â€‹2024Â Â Â Â 2023Machinery and equipmentâ€‹$ 13,161â€‹$ 13,124Computer equipment and softwareâ€‹Â 3,566â€‹Â 3,546Furniture and fixturesâ€‹Â 1,055â€‹Â 1,055Leasehold improvementsâ€‹Â 5,751â€‹Â 5,751Finance lease right of use assetsâ€‹â€‹ â€”â€‹â€‹ 2,294Total property and equipmentâ€‹Â 23,533â€‹Â 25,770Accumulated depreciation and amortizationâ€‹Â (20,622)â€‹Â (20,651)Property and equipment, netâ€‹$ 2,911â€‹$ 5,119â€‹Depreciation and amortization expense related to property and equipment, net was $0.4 million and $1.5 million for the three and nine months ended September 30, 2024, respectively, and $0.8 million and $2.5 million for the three and nine months ended September 30, 2023, respectively.â€‹As of September 30, 2024 and December 31, 2023, the net book value of software implementation costs related to hosting arrangements was $2.3 million and $3.2Â million, respectively, and the amortization expense was immaterial for all periods presented.â€‹Intangible Assets, Net Intangible assets, net consisted of the following: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â â€‹DecemberÂ 31,Â (in thousands)â€‹2024Â Â Â Â 2023Finite-lived assets, net of accumulated amortization of $2,052 and $639, as of September 30, 2024 and December 31, 2023, respectivelyâ€‹$ 25,454â€‹$ 41,871Indefinite-lived assets - in-process research and developmentâ€‹â€‹ 28,859â€‹â€‹ 28,859Goodwillâ€‹Â â€”â€‹Â 943Total Intangible assets, netâ€‹$ 54,313â€‹$ 71,673â€‹Amortization expense related to finite-lived intangible assets was $1.2 million and $2.8 million in the three and nine months ended September 30, 2024, respectively, and immaterial for the three and nine months ended September 30, 2023. In connection with the CIMERLI Sale on March 1, 2024, a finite-lived asset, net of $2.1 million and goodwill of $0.9 million were derecognized. In connection with the YUSIMRY Sale on June 26, 2024, a finite-lived asset with a net value of $0.9 million was derecognized. â€‹The exclusive license of NZV930 to Novartis Institutes, acquired as part of the Surface Acquisition, was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, the Company recognized an impairment charge of $10.6 million for the carrying value of the Novartis Institutes out-license during the three months ended March 31, 2024, which was classified within selling, general and administrative expense in the condensed consolidated statements of operations.â€‹19 Table of ContentsAmortization expense for the remaining finite-lived assets for each of the five succeeding fiscal years is expected to be $2.7 million.â€‹Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â â€‹DecemberÂ 31,Â (in thousands)â€‹2024â€‹2023Accrued commercial and research and development manufacturingâ€‹$ 19,729â€‹$ 23,470Accrued co-development costs and milestone paymentsâ€‹â€‹ 12,500â€‹â€‹ 26,812Accrued royaltiesâ€‹â€‹ 1,199â€‹â€‹ 42,031Royalty Fee Derivative Liability (Note 8)â€‹â€‹ 9,202â€‹â€‹ â€”Revenue participation liability, current (Note 8)â€‹â€‹ 2,180â€‹â€‹ â€”Accrued otherâ€‹Â 14,526â€‹Â 7,628Lease liabilities, currentâ€‹â€‹ 1,629â€‹â€‹ 2,145Contingent consideration, currentâ€‹â€‹ â€”â€‹â€‹ 3,300Total Accrued and other current liabilitiesâ€‹$ 60,965â€‹$ 105,386â€‹Other Liabilities, Non-current Other liabilities, non-current consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â (in thousands)â€‹2024â€‹2023Contingent consideration, non-currentâ€‹$ 632â€‹$ 1,172Deferred tax liabilityâ€‹â€‹ 1,102â€‹â€‹ 1,102Revenue participation liability, non-current (Note 8)â€‹â€‹ 27,427â€‹â€‹ â€”Other â€‹â€‹ â€”â€‹â€‹ 10,287Total Other liabilities, non-currentâ€‹$ 29,161â€‹$ 12,561â€‹â€‹â€‹â€‹6.Â Â Â Â Â Â Â Acquisition and Dispositions2024 Dispositionsâ€‹YUSIMRY SaleOn June 26, 2024, the Company completed the sale of its YUSIMRY immunology franchise which comprised certain assets, including certain YUSIMRY intellectual property, contracts, YUSIMRY inventory, and all activities related to research and development of YUSIMRY. In exchange, HKF paid upfront cash consideration of $40.0 million and assumed certain liabilities, including $17.0 million of inventory purchase commitments. During the second quarter of 2024, the Company recognized a net gain on the YUSIMRY Sale of $22.9 million, which included the cash receipts of $40.0 million less net assets transferred to HKF or otherwise derecognized and transaction costs of $1.0 million. At September 30, 2024, unpaid transaction costs totaled $0.8 million. The pretax profit (loss) related to the YUSIMRY immunology franchise prior to the YUSIMRY Sale, which excludes any corporate overhead allocations, was $(0.2) million and $1.3 million during the three and nine months ended September 30, 2024, respectively, and $(2.0) million and $(12.1) million during the three and nine months ended September 30, 2023, respectively. 20 Table of ContentsIn connection with the YUSIMRY Sale, the Company and HKF entered into the YUSIMRY TSA, pursuant to which the Company is providing certain business support services on behalf of HKF including billings, collections, and the remittance of rebates, to ensure business continuity for patients and customers for a period not expected to extend beyond December 31, 2024. Under the YUSIMRY TSA, the Company is entitled to be reimbursed for its costs which were $0.5 million for the three and nine months ended September 30, 2024. As of September 30, 2024, assets of $3.4 million and liabilities of $3.2 million related to transactions entered into on behalf of HKF in accordance with the YUSIMRY TSA were presented in TSA receivables, net and TSA payables and other accrued liabilities, respectively, in the condensed consolidated balance sheets. â€‹CIMERLI Sale On March 1, 2024, the Company completed the sale of its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology, to Sandoz for upfront, all-cash consideration of $170.0Â million plus an additional $17.8Â million for CIMERLI product inventory and prepaid manufacturing assets. During the first quarter of 2024, the Company recognized a net gain on the CIMERLI Sale of $153.6 million, which includes the cash receipts of $187.8 million less assets transferred to Sandoz, assets derecognized, transaction costs of $7.2 million, and other related employee transition expenses. As of September 30, 2024, unpaid commitments for retention bonuses totaled $4.7 million. The pretax profit (loss) related to the CIMERLI ophthalmology franchise prior to the CIMERLI Sale, which excludes any corporate overhead allocations, was $(1.2) million and $6.2 million during the three and nine months ended September 30, 2024, respectively, and $6.9 million and $5.7 million during the three and nine months ended September 30, 2023, respectively.â€‹In connection with the CIMERLI Sale, the Company and Sandoz entered into the CIMERLI TSA, pursuant to which the Company is providing certain business support services on behalf of Sandoz including billings, collections, and the remittance of rebates, to ensure business continuity for patients and customers for a period not expected to extend beyond December 31, 2024. Under the CIMERLI TSA, the Company is entitled to be reimbursed for its costs and has recorded income of $0.5 million and $1.6 million for the three and nine months ended September 30, 2024 in other income (expense), net in the condensed consolidated statements of operations. As of September 30, 2024, assets related to transactions entered into on behalf of Sandoz in accordance with the CIMERLI TSA of $27.8 million were presented in TSA receivables, net and liabilities related to transactions entered into on behalf of Sandoz in accordance with the CIMERLI TSA of $30.4 million were presented in TSA payables and other accrued liabilities in the condensed consolidated balance sheet. 2023 AcquisitionSurface Acquisition â€‹On September 8, 2023 (the â€œAcquisition Dateâ€), in accordance with an Agreement and Plan of Merger dated June 15, 2023 (the â€œMerger Agreementâ€) by and among the Company, Crimson Merger Sub I, Inc. (â€œMerger Sub Iâ€), Crimson Merger Sub II, LLC (â€œMerger Sub II,â€ and together with Merger Sub I, the â€œMerger Subsâ€), and Surface, the Company completed the Surface Acquisition. The Surface Acquisition expanded the Companyâ€™s I-O pipeline with the following: casdozokitug (CHS-388, formerly SRF388), an investigational, novelÂ IL-27-targetedÂ antibody currently being evaluated in a Phase 2 clinical trial in HCC, and CHS-114 (formerly SRF114), an investigational, CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors and head and neck squamous cell carcinoma (â€œHSNSCCâ€).On the Acquisition Date, and in accordance with the Merger Agreement, the Company issued to the holders of all outstanding Surface common stock (subject to certain exceptions) 0.1960 shares of Coherus common stock in exchange for each share of outstanding Surface common stock and certain outstanding Surface employee equity awards. The exchange ratio was calculated pursuant to the terms of the Merger Agreement and was based on aÂ $5.2831Â per share price of Coherus common stock and a nominal total amount of cash in lieu of fractional shares. Surface shareholders also 21 Table of Contentsreceived one CVR for each share of Surface common stock and employee equity award converted. Each CVR entitles the holder to receive quarterly contingent payments in the form of cash, stock or a combination of cash and stock at the Companyâ€™s discretion during the 10-year period following September 8, 2023, for the sum of the following, less any permitted deductions (in accordance with the Contingent Value Rights Agreement, dated September 8, 2023, by and among the Company and Â Computershare Inc. and its affiliate Computershare Trust Company, N.A., together, as the rights agent thereunder (the â€œCVR Agreementâ€)):â—70% of all milestone- and royalty-based payments actually received by the Company or its affiliates from GSK under a license agreement with GSK, dated December 16, 2020, which was subsequently amended in August 2021 (as amended, the â€œGSK Agreementâ€) related to the existing program (GSK4381562);â—25% of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for CHS-114; andâ—50% of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for casdozokitug.The Company has recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement described above. The Company is unable to estimate a range of outcomes for potential royalty and milestone payments for CHS-114 and casdozokitug.The following table below sets forth the purchase price allocation to the estimated fair value of the net assets acquired: â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands) â€‹Amounts Recognized at Acquisition DateAssets Acquiredâ€‹â€‹â€‹Cash and cash equivalentsâ€‹$ 6,997Investments in marketable securitiesâ€‹â€‹ 21,791Prepaids and other assetsâ€‹â€‹ 5,260In-process research and developmentâ€‹â€‹ 26,239Out-licensesâ€‹â€‹ 13,530Total assetsâ€‹$ 73,817Liabilities Assumedâ€‹â€‹â€‹Accrued and other current liabilitiesâ€‹$ 7,722Deferred tax liabilityâ€‹â€‹ 1,499Total liabilitiesâ€‹â€‹ 9,221Total net assets acquiredâ€‹$ 64,596â€‹The Company believes that, even after reassessing its identification of all assets acquired and liabilities assumed, it was able to acquire Surface for a price that was completely allocable to identifiable assets acquired and liabilities assumed with no residual attributable to goodwill primarily due to Surfaceâ€™s need to raise additional capital to finance its operations, the challenging biotech funding environment at the time the transaction was initially announced, and the value of the acquired net assets.22 Table of ContentsThe amounts allocated to identifiable intangible assets was as follows: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)â€‹Useful livesÂ Â Â Â â€‹Fair Value at Acquisition DateIn-process research and development - casdozokitugâ€‹n/aâ€‹$ 25,899In-process research and development - CHS-114â€‹n/aâ€‹â€‹ 340Out-license - GSKâ€‹15 yearsâ€‹â€‹ 2,506Out-license - Novartis Institutesâ€‹15 yearsâ€‹â€‹ 11,024Total identifiable intangible assetsâ€‹â€‹â€‹â€‹$ 39,769â€‹The out-license intangible assets represent potential milestone and royalty-based payments to be received under twoÂ out-licensedÂ partnership programs to advance certain next-generation cancer therapies, Novartis Institutes (NZV930) and GSK (GSK4381562). Surface shareholders received CVRs for certain percentages of these milestone and royalty-based payments, as further explained above. The exclusive license of NZV930 to Novartis Institutes was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, during the first quarter of 2024, the Company recognized a net impairment charge of $6.8 million in selling, general and administrative expenses in the condensed consolidated statements of operations relating to the write-off of the net carrying value of the Novartis Institutes out-license intangible asset of $10.6 million and the final remeasurement of the CVR liability related to NZV930 of $3.8 million to its fair value of zero.Unaudited Pro Forma Summary of OperationsThe following table shows the unaudited pro forma summary of operations for the three and nine months ended September 30, 2023, as if the Surface Acquisition had occurred on January 1, 2022. This pro forma information does not purport to represent what the Companyâ€™s actual results would have been if the acquisition had occurred as of January 1, 2022, and it is not indicative of what such results would be expected for any future period:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended (in thousands)â€‹SeptemberÂ 30,Â 2023â€‹SeptemberÂ 30,Â 2023Total revenuesâ€‹$ 74,568â€‹$ 165,720Net lossâ€‹$ (49,984)â€‹$ (204,922)â€‹Acquisition-related costs of $2.6Â million and $4.5Â million were recorded in selling, general and administrative expense in the condensed consolidated statement of operations during the three and nine months ended September 30, 2023, respectively.â€‹7.Â Â Â Â Â Â Â Â Collaborations and Other ArrangementsIn-Licensing AgreementsJunshi Biosciences On February 1, 2021, the Company entered into an Exclusive License and Commercialization Agreement (the â€œCollaboration Agreementâ€) with Junshi Biosciences for the co-development and commercialization of LOQTORZI, Junshi Biosciencesâ€™ anti-PD-1 antibody, in the United States and Canada. Under the terms of the Collaboration Agreement, the Company paidÂ $150.0 millionÂ upfront for exclusive rights to LOQTORZI inÂ the United StatesÂ andÂ Canada, an option in these territories to Junshi Biosciencesâ€™ anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to two 23 Table of Contentsundisclosed preclinical immuno-oncology drug candidates. The Company is obligated to pay Junshi Biosciences a 20% royalty on net sales of LOQTORZI and up to an aggregateÂ $380.0 millionÂ in one-time payments for the achievement of various regulatory and sales milestones. In March 2022, the Company paid $35.0 million for the exercise of its option to license CHS-006. Subsequent joint development consistent with the Collaboration Agreement commenced. On January 10, 2024, the Company announced that it had delivered a notice of termination of the TIGIT program CHS-006 described in the Collaboration Agreement (the â€œTIGIT Programâ€) to Junshi Biosciences. The Company plans to continue to wind down work with Junshi Biosciences on the TIGIT Program pursuant to the termination. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay an additional option exercise fee ofÂ $35.0 million and an 18% royalty on net sales, up to $85.0 millionÂ for the achievement of certain regulatory approvals, and up to $170.0 million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of LOQTORZI and the other licensed compounds, and will pay for a portion of these co-development activities up to a maximum ofÂ $25.0 millionÂ per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. In March 2024, the Company entered into an Amendment No. 2 to the Collaboration Agreement (the â€œ2nd Amendmentâ€) with Junshi Biosciences to revise the timing of the $25.0 million milestone payment to Junshi Biosciences that became due in connection with the approval by the FDA of toripalimab for the treatment of patients with NPC in the first quarter of 2024. Under the terms of the 2nd Amendment, the $25.0 million milestone payment was split into two installments of $12.5 million each, one that was paid in the second quarter of 2024 and one due in the first quarter of 2025.The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. There was no material research and development expense recognized for obligations to Junshi Biosciences for the three months ended September 30, 2024. During the nine months ended September 30, 2024, the Company recognized a reduction in research and development expenses for the release of certain liabilities of $4.8 million pursuant to the 2nd Amendment with Junshi Biosciences. Research and development expenses were $3.1 million and $7.7 million for the three and nine months ended September 30, 2023, respectively. In the condensed consolidated balance sheets as of September 30, 2024, the Company has classified $12.5 million in accrued and other current liabilities related to a milestone payment in connection with the 2nd Amendment and $0.4 million in accounts payable related to the co-development, regulatory and technology transfer costs related to these programs. The accrued royalty obligation to Junshi Biosciences was $1.1 million as of September 30, 2024 and immaterial at December

31, 2023.Â The additional milestone payments, option fee for the IL-2 cytokine and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.ApotexOn June 27, 2024, the Company entered into an exclusive license and distribution agreement (the â€œCanada License Agreementâ€) with Apotex, Inc. (â€œApotexâ€), pursuant to which, the Company granted to Apotex an exclusive license under the Companyâ€™s rights to toripalimab to commercialize toripalimab within Canada. Pursuant to the Canada License Agreement, Apotex paid the Company an upfront payment of $6.3 million United States Dollars (â€œUSDâ€) which has been classified as net revenue in the condensed consolidated statements of operations for the nine months ended September 30, 2024. In addition, Apotex agreed to pay the Company up to an aggregate of $51.5 million Canadian Dollars (â€œCADâ€) in milestone payments in connection with the achievement of certain regulatory and sales milestones with respect to toripalimab in Canada. Lastly, Apotex agreed to pay the Company a low double-digit percentage of any future net sales of toripalimab in Canada that the Company will subsequently pay to Junshi Biosciences pursuant to the Collaboration Agreement. 24 Table of ContentsThe Canada License Agreement term continues until the tenth year after the first commercial sales of toripalimab in Canada, subject to an extension for a subsequent ten-year term at the option of Apotex. Apotex may terminate the License Agreement for any reason after a specified notice period. The License Agreement will terminate automatically if the rights granted to the Company by the Collaboration Agreement are terminated, if there is material breach that is not cured, if there are certain challenges to licensed patents by Apotex and in the case of certain insolvency events.Bioeq On NovemberÂ 4, 2019, the Company entered into a license agreement (the â€œBioeq License Agreementâ€) with Bioeq AG (â€œBioeqâ€) for the commercialization of CIMERLI, a biosimilar version of Lucentis (ranibizumab), in certain dosage forms in both a vial and pre-filled syringe presentation (the â€œBioeq Licensed Productsâ€). Under the Bioeq License Agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. Royalties due to Bioeq were $38.4 million as of December 31, 2023. On January 19, 2024 the Company entered into the CIMERLI Purchase Agreement with Sandoz. Pursuant to the CIMERLI Purchase Agreement, on March 1, 2024, the Company completed the divestiture of its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology, for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Refer to Note 6. Acquisition and Dispositions for additional information. Upon closing of the CIMERLI Sale, the Bioeq License Agreement was assumed by Sandoz. Refer to the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on March 15, 2024 for additional information related to the Bioeq License Agreement. â€‹Adimab Development and Option Agreement â€‹In October 2018, Surface and Adimab LLC (â€œAdimabâ€), entered into an amended and restated development and option agreement, (as amended by the amendments dated as of December 16, 2020, June 1, 2022 and July 18, 2022, the â€œA&R Adimab Agreementâ€), which amended and restated the development and option agreement with Adimab dated July 2014, as amended, (â€œthe Original Adimab Agreementâ€), for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the A&R Adimab Agreement, the Company will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. Adimab granted the Company an exclusive option to obtain a non-exclusive, worldwide, fully paid-up, sublicensable license under Adimabâ€™s platform patents and other Adimab technology solely to research up to ten antibodies, chosen by the Company against a specific biological target for a specified period of time (the â€œResearch Optionâ€). In addition, Adimab granted the Company an exclusive option to obtain a worldwide, royalty-bearing, sublicensable license under Adimab platform patents and other Adimab technology to exploit, including commercially, 20 or more antibodies against specific biological targets (the â€œCommercialization Optionâ€). Upon the exercise of a Commercialization Option, and payment of the applicable option fee to Adimab, Adimab will assign the Company the patents that cover the antibodies selected by such Commercialization Option. The Company will be required to use commercially reasonable efforts to develop, seek market approval of, and commercialize at least one antibody against the target covered by the Commercialization Option in specified markets upon the exercise of a Commercialization Option.â€‹Under the A&R Adimab Agreement, the Company is obligated to make milestone payments and to pay specified fees upon the exercise of the Research Option or Commercialization Option. During the discovery term, the Company may be obligated to pay Adimab up toÂ $0.3 millionÂ for technical milestones achieved against each biological target. Upon exercise of a Research Option, the Company is obligated to pay a nominal research maintenance fee on each of the next four anniversaries of the exercise. Upon the exercise of each Commercialization Option, the Company will be required 25 Table of Contentsto pay an option exercise fee of a low seven-digit dollar amount, and the Company may be responsible for milestone payments of up to an aggregate of $13.0 millionÂ for each licensed product that receives marketing approval. For any licensed product that is commercialized, the Company is obligated to pay Adimab tiered royalties of a low to mid single-digit percentage on worldwide net sales of such product. The Company may also partially exercise a Commercialization Option with respect to ten antibodies against a biological target by payingÂ 65% of the option fee and later either (i)Â paying the balance and choosing additional antibodies for commercialization, up to the maximum number under the Commercialization Option, or (ii)Â foregoing the Commercialization Option entirely. For any Adimab diagnostic product that is used with or in connection with any compound or product other than a licensed antibody or licensed product, the Company is obligated to pay Adimab up to a low seven digits in regulatory milestone payments and low single-digit royalties on net sales. â€‹Vaccinex License AgreementOn March 23, 2021, Surface and Vaccinex, Inc. (â€œVaccinexâ€) entered into an exclusive product license agreement (the â€Vaccinex License Agreementâ€) which provides the Company a worldwide, exclusive, sublicensable license to make, have made, use, sell, offer to sell, have sold, import, and otherwise exploit licensed products that incorporate certain Vaccinex intellectual property which covers certain antibodies (each, a â€œVaccinex Licensed Productsâ€), including the antibody CHS-114 targeting CCR8. Under the Vaccinex License Agreement, the Company is obligated to use commercially reasonable efforts to develop, clinically test, achieve regulatory approval, manufacture, market and commercialize at least one Vaccinex Licensed Product.The Company is responsible for all costs and expenses of such development, manufacturing and commercialization. Vaccinex is eligible to receive up to an aggregate of $3.5 million based on achievement of certain clinical milestones, up to an aggregate of $11.5 million based on achievement of certain regulatory milestones per Vaccinex Licensed Product, and low single digit royalties on global net sales of any approved licensed products. The Company may terminate the Vaccinex License Agreement for convenience upon the notice period specified in the Vaccinex License Agreement. Either party may terminate the agreement for an uncured material breach by the other party. Vaccinex may terminate the Vaccinex License Agreement if we default on any payments owed to Vaccinex under the agreement, if the Company is in material breach of, and fails to cure, its development obligations, or institute certain actions related to the licensed patents. In the event of termination, all rights in the licensed intellectual property would revert to Vaccinex.Out-Licensing Agreements Acquired as part of the Surface AcquisitionOn September 8, 2023, at the closing of the Surface Acquisition, all the assets, liabilities, rights and obligations of Surface were assumed by the Companyâ€™s direct, wholly-owned subsidiary, Surface Oncology, LLC. See further details in Note 6. Acquisition and Dispositions. â€‹GSK AgreementIn December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target CD112R, also known as PVRIG, including the antibody GSK4381562 (the âCœLicensed Antibodiesâ€). GSK is responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee was formed to facilitate information sharing. GSK is responsible for all costs and expenses of such development, manufacturing and commercialization and is obligated to provide the Company with updates on its development, manufacturing and commercialization activities through the joint development committee. In March 2022, Surface earned a $30.0 millionÂ milestone payment from GSK upon the dosing of the first patient in the Phase 1 trial of GSK4381562. The Company is eligible to receive up to $60.0 millionÂ in additional clinical milestones and $155.0 millionÂ in regulatory milestones. In addition, the Company may receive up to $485.0 million in sales milestone payments. The Company is also eligible to receive royalties on global net sales of any approved products based on the Licensed 26 Table of ContentsAntibodies, ranging in percentages from high single digits to mid-teens. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the GSK Agreement. The Company didÂ not recognize license-related revenue under the GSK Agreement during the three and nine months ended September 30, 2024. Unless terminated earlier, the GSK Agreement expires on a licensed product-by-licensed product and country-by-country basis on the later ofÂ ten yearsÂ from the date of first commercial sale or when there is no longer a valid patent claim or regulatory exclusivity covering such licensed product in such country. Either party may terminate the GSK Agreement for an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. GSK may terminate the GSK Agreement for its convenience. The Company may terminate the GSK Agreement if GSK institutes certain actions related to the licensed patents or if GSK ceases development activities, other than for certain specified technical or safety reasons. In the event of termination, the Company would regain worldwide rights to the terminated program.â€‹â€‹8.Â Â Â Â Â Â Â Financial LiabilitiesA summary of the Companyâ€™s debt obligations, including level within the fair value hierarchy (see Note 3. Fair Value Measurements), is as follows:â€‹â€‹â€‹

â€œAdjusted Term SOFRâ€) of three-month SOFR and 0.26161% per annum, with a floor on Adjusted Term SOFR of 1.0%. On February 5, 2024, the Company entered into a Consent, Partial Release and Third Amendment to the 2027 Term Loans (the â€œConsent and Amendmentâ€) with the Collateral Agent and the 2027 Lenders. Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the 2027 Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by the CIMERLI Purchase Agreement, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the 2027 Lenders and the Collateral Agent required the Company to make a partial prepayment of the principal of the loans outstanding under the 2027 Loan Agreement in the amount of $175.0 million upon consummation of the transactions contemplated by the CIMERLI Purchase Agreement, subject to certain conditions and (3) the parties thereto agreed to adjust the minimum net trailing twelve month net sales covenant level to be $125.0 million under the 2027 Loan Agreement. As a result of the CIMERLI Sale closing, the Company made a partial prepayment of $175.0 million of the total principal balance of $250.0 million of the 2027 Term Loans on April 1, 2024. On May 8, 2024, in connection with entering into the 2029 Term Loan and the Revenue Purchase and Sale Agreement, the Company repaid in full all outstanding indebtedness and terminated all commitments under the 2027 Term Loans. The May 8, 2024 payoff amount of $79.6 million included principal repayment in full, accrued interest, a 3.0% prepayment premium fee of the principal amount, a make-whole interest payment and lender fees. During the nine months ended September 30, 2024, the Company recorded a $12.6 million loss on debt extinguishment in the condensed consolidated statements of operations for the payoff of the 2027 Term Loans, and the charge included the write-off of the remaining debt discount and debt issuance costs, the prepayment premium fee, the make-whole interest payment, and lender fees. 30 Table of ContentsThe following table presents the components of interest expense related to the 2027 Term Loans:â€‹â€‹â€‹

Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹â€‹SeptemberÂ 30,Â (in thousands, except share and per share data)Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Basic net income (loss) per shareÂ â€‹Â Â Â â€‹Â Â â€‹â€‹Â Â Â â€‹Â Â Numerator:Â â€‹Â Â Â â€‹Â Â â€‹â€‹Â Â Â â€‹Â Â Net income (loss)â€‹$ (10,751)â€‹$ (39,641)â€‹$ 79,203â€‹$ (158,239)Denominator:â€‹Â Â â€‹â€‹Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹Weighted-average common shares outstandingâ€‹Â 115,210,091â€‹Â 97,738,509â€‹Â 114,263,256â€‹Â 88,277,936Basic net income (loss) per shareâ€‹$ (0.09)â€‹$ (0.41)â€‹$ 0.69â€‹$ (1.79)â€‹â€‹â€‹

Goods SoldCost of goods sold consists primarily of third-party manufacturing, distribution, royalties and certain overhead costs. On MayÂ 2, 2019, we settled a trade secret action brought by AmgenÂ Inc. and Amgen USAÂ Inc. (collectively â€œAmgenâ€). As a result, cost of goods sold reflects a mid-single digit royalty on net product revenue, which began JulyÂ 1, 2019 and continued until July 1, 2024. Additionally, until the CIMERLI Sale on March 1, 2024, we shared aÂ percentage of gross profits on sales of CIMERLI in the United States with Bioeq in the low- to mid-fiftyÂ percent range. Research and Development ExpenseResearch and development expense represents costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred. We currently track research and development costs incurred on a product candidate basis only for external research and development expenses. Our external research and development expense consists primarily of:â—expense incurred under agreements with collaborators, consultants, third-party contract research organizations (â€œCROsâ€), and investigative sites where a substantial portion of our preclinical studies and all of our clinical trials are conducted;â—costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;42 Table of Contentsâ—costs associated with manufacturing process development activities, analytical activities and pre-launch inventory manufactured prior to regulatory approval being obtained or deemed to be probable; andâ—upfront and certain milestone payments related to licensing and collaboration agreements.Internal costs are associated with activities performed by our research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:â—personnel-related expense, which includes salaries, benefits and stock-based compensation; andâ—facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming. Furthermore, in the past, we have entered into collaborations with third parties to participate in the development and commercialization of our product candidates, and we may enter into additional collaborations in the future. In situations in which third parties have substantial influence over the development activities for product candidates, the estimated completion dates are not fully under our control. For example, our partners in licensed territories may exert considerable influence on the regulatory filing process globally. Therefore, we cannot forecast with any degree of certainty the duration and completion costs of these or other current or future clinical trials of our product candidates. We may never succeed in achieving regulatory approval for any of our pipeline product candidates. In addition, we may enter into other collaboration arrangements for our other product candidates, which could affect our development plans or capital requirements.Selling, General and Administrative ExpenseSelling, general and administrative expense consists primarily of personnel costs, allocated facilities costs and other expense for outside professional services, including legal, insurance, human resources, outside marketing, advertising, audit and accounting services, acquisition-related costs, and costs associated with establishing commercial capabilities in support of the commercialization of UDENYCA and LOQTORZI and the commercialization of CIMERLI and YUSIMRY up until the CIMERLI Sale and the YUSIMRY Sale, respectively. Personnel costs consist of salaries, benefits and stock-based compensation. Interest ExpenseInterest expense consists primarily of interest incurred on our outstanding indebtedness, our Revenue Purchase and Sale Agreement, and non-cash interest related to the amortization of debt discount and debt issuance costs associated with our outstanding debt agreements.Gain (loss) on Sale Transactions, netGain (loss) on Sale Transactions, net consists of cash proceeds received from the CIMERLI Sale, net of assets sold (primarily CIMERLI product inventory and prepaid manufacturing assets), assets derecognized (goodwill and intangible assets), net of related transaction costs, retention bonuses and stock-based compensation expense incurred, and the YUSIMRY Sale, net of assets sold (primarily YUSIMRY product inventory and prepaid manufacturing assets), assets and liabilities derecognized (primarily purchase commitments and an intangible asset), and related transaction costs. Loss on Debt ExtinguishmentLoss on debt extinguishment consists of losses incurred related to the early repayment of debt obligations.43 Table of ContentsOther Income (Expense), NetOther income (expense), net consists primarily of interest earned on our cash and cash equivalents, non-cash accretion of discount on our investments in marketable securities, foreign exchange gains (losses) resulting from currency fluctuations, gains (losses) from financial instruments, gains (losses) from disposal of long-lived assets, and income for TSA services provided. Results of OperationsComparison of Three and Nine Months Ended September 30, 2024 and 2023Revenue â€‹â€‹â€‹

USD. In addition, Apotex agreed to pay us the USD equivalent of up to an aggregate of $51.5 million CAD in milestone payments in connection with the achievement of certain regulatory and sales milestones with respect to toripalimab in Canada. Finally, Apotex agreed to pay us a low double-digit percentage of any future net sales of toripalimab in Canada that we will subsequently pay to Junshi Biosciences pursuant to the Collaboration Agreement. On June 26, 2024, we entered into the YUSIMRY Purchase Agreement by and between us and HKF. Pursuant to the terms and subject to the conditions set forth in the YUSIMRY Purchase Agreement, we sold our YUSIMRY immunology franchise through the sale of certain assets, including YUSIMRY, intellectual property exclusively related to YUSIMRY, certain contracts related to YUSIMRY, YUSIMRY inventory, and all activities related to research and development of YUSIMRY to HKF for upfront, cash consideration of $40.0 million and the assumption of $17.0 million of inventory purchase commitments by HKF. We retained the rights to certain patents that were licensed to Pfizer under the Pfizer License Agreement.On May 8, 2024, we entered into the 2029 Term Loan providing for a secured loan facility in the principal amount of $38.7 million, with proceeds of $37.5 million after the original issue discount which were used as part of the full repayment of all outstanding indebtedness and terminated all commitments under the 2027 Term Loans.On May 8, 2024, we entered into the Revenue Purchase and Sale Agreement. We received proceeds of $37.5 million by selling to the Purchaser Group a right to receive payment in full of 5.0% of U.S. net sales of UDENYCA and LOQTORZI with respect to a specified threshold applicable to UDENYCA net sales and a specified threshold applicable to LOQTORZI net sales during an applicable year and 0.5% of U.S. net sales of UDENYCA and LOQTORZI that exceeded the specified threshold during that year, commencing May 8, 2024. The proceeds were used by us as part of the full repayment of all outstanding indebtedness and terminated all commitments under the 2027 Term Loans.On April 1, 2024, $175.0 million of the cash and cash equivalents was used to repay $175.0 million of the total principal balance of $250.0 million of the 2027 Term Loans, as further described below.48 Table of ContentsOn January 19, 2024, we entered into the CIMERLI Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the CIMERLI Purchase Agreement, on March 1, 2024, we completed the CIMERLI Sale for our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. On February 5, 2024, we entered into the Consent and Amendment, that among other things: (1) provided consent to consummation of the transactions contemplated by the CIMERLI Purchase Agreement, and released certain of our subsidiary from our obligation and certain assets subject to the transactions contemplated thereby, (2) required us to make a partial prepayment of $175.0 million of the principal of the 2027 Term Loans outstanding upon consummation of the transactions contemplated by the CIMERLI Purchase Agreement, subject to certain conditions and (3) adjusted the minimum net sales covenant level under the 2027 Term Loans. Upon the closing of the CIMERLI Sale, we became obligated to repay $175.0 million of the total principal balance of $250.0 million of the loans outstanding as well as $6.8 million in prepayment premium and make-whole payments under the 2027 Term Loans, of which we paid on April 1, 2024.On September 8, 2023, we obtained $28.8 million of cash, cash equivalents and marketable securities as part of the Surface Acquisition.On May 16, 2023, we entered into the Underwriting Agreement with the Underwriters, pursuant to which we sold an aggregate of 11,764,706 Firm Shares to the Underwriters. Additionally, under the terms of the Underwriting Agreement, we granted the Underwriters an option, for 30 days from the date of the Underwriting Agreement, to purchase up to an additional 1,764,705 Option Shares, which the Underwriters elected to exercise in full. The price to the public in the Public Offering was $4.25 per share. The Underwriters agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $3.995 per share.On MayÂ 18, 2023, we completed the sale and issuance of an aggregate of 13,529,411 Shares in the Public Offering, including the exercise in full of the Underwritersâ€™ option to purchase the Option Shares. We received net proceeds of approximately $53.6Â million, after deducting the Underwritersâ€™ discounts and commissions and offering expenses payable by us.On November 8, 2022, we entered into the Sales Agreement related to the ATM Offering pursuant to which we may issue and sell from time to time up to $150.0 million of our common stock. On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement and in connection with the Public Offering, we reduced the amount of shares that could be issued and sold pursuant to its ATM Offering with TD Cowen by $86.2 million, lowering the aggregate offering price under the Agreement from $150.0 million to $63.8 million. On September 11, 2023, pursuant to an Amendment No. 2 to Sales Agreement, we increased the amount of shares that could be issued and sold pursuant to itsÂ ATM Offering with TD Cowen by $28.7Â million, increasing the aggregate offering price under the Sales Agreement from $63.8Â million to $92.5Â million. No shares were sold during the three months ended September 30, 2024. During the nine months ended September 30, 2024, we sold 650,005 shares of common stock pursuant to the ATM Offering, at a weighted-average price per share of $2.44 for gross proceeds of $1.6 million and received net proceeds of $1.5 million, net of $0.1 million of commissions and fees. For the ATM Offering program to date as of September 30, 2024, we sold 5,126,650 shares of common stock at a weighted-average price per share of $5.39 for gross proceeds of $27.6 million and received net proceeds of $26.9 million, net of $0.7 million of commissions and fees. As of September 30, 2024, we had approximately $64.9 million of our common stock remaining available for sales under the ATM Offering. The ability to elect to sell shares of our common stock in the ATM Offering from time to time adds to our financial flexibility. As of September 30, 2024, we had an accumulated deficit of $1.5 billion and cash and cash equivalents of $97.7 million. We believe that our available cash and cash equivalents, cash collected from product sales, divestitures, ATM Offering and Public Offering proceeds received to date will be sufficient to fund our planned expenditures and meet our obligations for at least the twelveÂ months following our financial statement issuance date.49 Table of ContentsWe have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional agreements with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated research and development activities, and on-going and future licensing and collaboration obligations. We may need to raise additional funds in the future; however, there can be no assurance that such efforts will be successful or that, if they are successful, the terms and conditions of such financing will be favorable. Our future funding requirements will depend on many factors, including the following:â—cash proceeds from product sales;â—the payment of interest, principal and royalties related to our financial liabilities;â—the costs of manufacturing, distributing and marketing our products;â—the cost of manufacturing clinical drug supplies and establishing commercial supplies of our product candidates and products; â—the timing for our packaging and labeling CMO to resume manufacturing and to make UDENYCA products available in a sufficient quantity to meet the demand from our customers;â—the timing for us to receive FDA authorization to produce UDENYCA product at our additional packaging and labeling CMOâ€™s facility and the timing for our additional packaging and labeling CMO to make UDENYCA products available in a sufficient quantity to meet the demand from our customers;â—the percentage of customers that continue to purchase our products and that do not switch to products made by our competitors;â—the terms and timing of any other collaborative, licensing and other arrangements that we have established or may establish;â—the timing, receipt and amount of sales, profit sharing or royalties, if any, from any product candidates that are approved in the future;â—the number and characteristics of product candidates that we pursue;â—the scope, rate of progress, results and cost of our clinical trials, preclinical testing and other related activities;â—the costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs and related costs associated with release and stability testing;â—the cost, timing and outcomes of regulatory approvals;â—the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;â—the extent to which we divest, acquire or invest in businesses, products or technologies; â—the impact of general economic conditions on our business, including but not limited to increased interest rates and high inflation; andâ—the costs of the impact from any future outbreaks of the COVID-19 pandemic or future pandemics.For further discussion of risks related to our financial condition and capital requirements, please see â€œRisk Factorsâ€” Risks Related to Our Financial Condition and Capital Requirements.â€50 Table of ContentsFinancing arrangements2027 Term LoansDuring the second quarter of 2024, we fully repaid and terminated all commitments under the 2027 Term Loans. Proceeds from the divestiture of our CIMERLI ophthalmology franchise received in March 2024 were used to pay down $175.0 million of outstanding principal, and a prepayment premium and make-whole amount totaling $6.8 million on April 1, 2024. On May 8, 2024, we used the proceeds from the 2029 Term Loan and Revenue Purchase and Sale Agreement to repay the remaining $75.0 million principal balance outstanding on the 2027 Term Loans and a prepayment premium and make-whole amount totaling $3.5 million.2029 Term Loan Concurrent with the payoff of the 2027 Term Loans, on May 8, 2024, we entered into the 2029 Term Loan providing for a secured loan facility in the principal amount of $38.7 million, with proceeds of $37.5 million after the original issue discount. The 2029 Term Loan will mature on May 8, 2029, accrues interest equal to 8.0% per annum, plus a three-month SOFR rate and provides for interest-only payments on a quarterly basis until maturity. The 2029 Term Loan is secured by a lien on substantially all of our assets, including intellectual property, subject to customary exclusions and exceptions. The 2029 Loan Agreement contains customary representations and warranties, covenants and events of default, including a financial covenant commencing on the 2029 Term Loan Effective Date, which requires us to maintain certain levels of cash and cash equivalents. The 2029 Loan Agreement also contains other customary provisions, such as expense reimbursement, as well as indemnification rights for the benefit of the Agent and the 2029 Lenders. For further details, see Note 8. Financial Liabilities in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.Revenue Purchase and Sale Agreement On May 8, 2024, we entered into the Revenue Purchase and Sale Agreement. Under the terms of the Revenue Purchase and Sale Agreement, in exchange for the Purchaser Groupâ€™s payment to us of $37.5 million, we sold to the Purchaser Group a right to receive payment in full of 5.0% of U.S. net sales of UDENYCA and LOQTORZI with respect to a specified threshold applicable to UDENYCA net sales and a specified threshold applicable to LOQTORZI net sales during an applicable year and 0.5% of U.S. net sales of UDENYCA and LOQTORZI that exceeded the specified threshold during that year, commencing on May 8, 2024. The Purchaser Groupâ€™s right to receive the Revenue Payment terminates and we no longer have the obligation to pay the Purchaser Group Revenue Payments once the Purchaser Group receives the amount equal to 2.25 times the Purchase Price. We may also buy-out the Purchaser Groupâ€™s rights to receive the Revenue Payments by triggering certain conditions and paying the Purchaser Group the unpaid portion of the 2.25 multiple on the Purchase Price. The proceeds from the Purchase Price were used by us as part of the full repayment of the 2027 Term Loans.The Revenue Purchase and Sale Agreement contains various representations and warranties, including with respect to organization, authorization, and certain other matters, certain covenants with respect to payment, reporting, intellectual property, in-licenses, out-licenses, and certain other actions, indemnification obligations and other provisions customary for transactions of this nature.2026 Convertible Notes As of September 30, 2024, the carrying amount of our $230.0 million aggregate principal amount convertible senior subordinated notes due 2026 was $227.9 million. The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, and will mature on April 15, 2026, unless earlier repurchased or converted at the option of holders. Since inception, the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price 51 Table of Contentsof approximately $19.26 per share of common stock. The initial conversion price represents a premium of approximately 30.0% over the last reported sale of $14.82 per share of our common stock on the Nasdaq Global Market on AprilÂ 14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. The 2026 Convertible Notes are not redeemable at our election before maturity. If the 2026 Convertible Notes were converted on September 30, 2024, the holders of the 2026 Convertible Notes would have received common shares with an aggregate value of $12.4 million based on our closing stock price of $1.04 as of September 30, 2024.In connection with the pricing of the 2026 Convertible Notes, we entered into privately negotiated capped call transactions with certain of the initial purchasers of the 2026 Convertible Notes and other financial institutions. Since inception, the cap price has been $25.93 per share, which represents a premium of approximately 75.0% over the last reported sale price of our common stock of $14.82 per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions.Contingent Milestones Â We have obligations to make future payments to third parties that become due and payable upon the achievement of certain development, regulatory and commercial milestones (such as clinical trial achievements, the filing of a BLA, approval by the FDA or product launch). These milestone payments and other similar fees are contingent upon future events and therefore are only recorded when it becomes probable that a milestone will be achieved or other applicable criteria will be met. Because the achievement of these milestones had not reached the threshold for recognition as of September 30, 2024, such contingencies were not recorded in our financial statements.The following presents a summary of our active partnerships and collaborations that have contingent regulatory and sales milestones as of September 30, 2024: â€‹â€‹â€‹â€‹â€‹â€‹Counterpartyâ€‹Descriptionâ€‹Potential Aggregate Milestone AmountJunshi Biosciencesâ€‹LOQTORZIâ€‹$355.0 million (1)Adimabâ€‹Casdozokitugâ€‹$13.0 millionVaccinexâ€‹CHS-114â€‹$15.0 million(1)$290.0 million relates to sales milestones and $65.0 million relates to regulatory milestones for indications that are not currently the subject of our clinical trials, excluding the $25.0 million milestone payment to Junshi Biosciences, of which we paid $12.5 million in the second quarter of 2024 and expect to pay $12.5 million in the first quarter of 2025.Contingent Value Rightsâ€‹We have recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement in connection with the Surface Acquisition. These potential payments during the 10-year period following September 8, 2023 are only due if we first receive milestone- or royalty-based payments under certain license agreements or upfront payments pursuant to ex-U.S. licensing agreements. Payments can be in the form of cash, stock or a combination of cash and stock. The CVR liability associated with GSK and contingent consideration are recorded in other liabilities, non-current on the condensed consolidated balance sheets at September 30, 2024. For further details, see Note 6. Acquisition and Dispositions in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.Other Commitmentsâ€‹We enter into contracts in the normal course of business with CROs for preclinical research studies and clinical trials, research supplies and other services and products for operating purposes.Â We have also entered into agreements with several CMOs for the manufacture and clinical drug supply of our commercial and product candidates. Our non-cancelable purchase commitments as of September 30, 2024 were $67.0 million, as outlined in Note 9. Commitments 52 Table of Contentsand Contingencies in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q. In connection with the YUSIMRY Sale, HKF assumed $17.0 million in YUSIMRY inventory purchase commitments, of which, $17.0 million remained as of September 30, 2024. If HKF were to default on its obligations under the YUSIMRY Purchase Agreement, we could become liable to pay any unpaid portion of these purchase commitments.There have been no significant changes to our leases during the nine months ended September 30, 2024, as compared to the discussion in the 2023 Form 10-K.Summary Statement of Cash Flows The following table summarizes our cash flows for the periods presented:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â (in thousands)Â Â Â Â Â 2024Â Â Â Â 2023Net cash used in operating activitiesâ€‹$ (49,048)â€‹$ (161,947)Net cash provided by investing activitiesâ€‹Â 230,863â€‹Â 109,437Net cash (used in) provided by financing activitiesâ€‹â€‹ (187,205)â€‹â€‹ 69,234Net (decrease) increase in cash, cash equivalents and restricted cashâ€‹$ (5,390)â€‹$ 16,724â€‹Net cash used in operating activitiesCash used in operating activities of $49.0 million for the nine months ended September 30, 2024 was primarily due to net income of $79.2 million adjusted for non-cash items including stock-based compensation expense of $21.4 million, loss on debt extinguishment of $12.6 million, impairment of out-license asset net of CVR liability remeasurement of $6.8 million, other non-cash adjustments of $6.2 million, and changes in our operating assets and liabilities of $1.4 million, partially offset by the net gain on Sale Transactions of $176.6 million.Cash used in operating activities of $161.9 million for the nine months ended September 30, 2023 was primarily due to the net loss of $158.2 million adjusted for non-cash items including stock-based compensation expense of $32.3 million and other non-cash adjustments of $7.2 million, partially offset by the changes in our operating assets and liabilities of $43.2 million.Net cash provided by investing activities Cash provided by investing activities of $230.9 million for the nine months ended September 30, 2024 was primarily due to cash proceeds of $187.8 million from the CIMERLI Sale, cash proceeds of $40.0 million from the YUSIMRY Sale, proceeds from sale of investments in marketable securities of $8.7 million, and proceeds from maturities of investments in marketable securities of $6.2 million, partially offset by a $12.5 million milestone payment in connection with the 2nd Amendment with Junshi Biosciences.Cash provided by investing activities of $109.4 million for the nine months ended September 30, 2023 was primarily due to proceeds from maturities of investments in marketable securities of $108.1 million, proceeds from sale of investments in marketable securities of $13.3 million, and $7.0 million of cash acquired from the Surface Acquisition, partially offset byÂ purchasesÂ of investments in marketable securities of $19.5 million.Net cash (used in) provided by financing activitiesCash used in financing activities of $187.2 million for the nine months ended September 30, 2024 was primarily due to $260.4 million in payments to fully repay the 2027 Term Loans (excluding interest which is presented as an operating activity) and $2.5 million in tax payments related to net share settlement of RSUs. These payments were 53 Table of Contentspartially offset by $37.0 million of proceeds on the 2029 Term Loan, net of debt discount and issuance costs,

$36.5 million of proceeds from the Revenue Purchase and Sale Agreement, net of issuance costs, and $1.5 million in proceeds from the ATM Offering, net of issuance costs.Cash provided by financing activities of $69.2 million for the nine months ended September 30, 2023 was primarily due to proceeds of $53.6 million from the Public Offering, net of issuance costs, $18.2 million proceeds from the ATM Offering, net of issuance costs, and $1.3 million proceeds from purchase under the ESPP. These were partially offset by $3.3 million in tax payments related to net share settlement.Critical Accounting Policies and Significant Judgments and EstimatesThe preparation of our condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue generated and expense incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. There have been no significant changes to our critical accounting estimates during the nine months ended September 30, 2024, as compared to the critical accounting estimates described in our 2023 Form 10-K, except for the Revenue Purchase and Sale Agreement described below. We believe that the critical accounting estimates discussed in the 2023 Form 10-K are meaningful to understanding our historical and future performance, as these estimates relate to the more significant areas involving managementâ€™s judgments and assumptions.Revenue Purchase and Sale AgreementThe Revenue Purchase and Sale Agreement contains an embedded derivative that meets the criteria to be bifurcated and accounted for separately from the Revenue Purchase and Sale Agreement. The Royalty Fee Derivative Liability was recorded at fair value upon entering into the Revenue Purchase and Sale Agreement and is subsequently remeasured to fair value at each reporting period with the corresponding change in fair value recognized in other income (expense), net in the condensed consolidated statements of operations. The Revenue Purchase and Sale Agreement was initially valued and is remeasured using a â€œwith-and-withoutâ€ method. The â€œwith-and-withoutâ€ methodology involves valuing the whole instrument on an as-is basis with the embedded derivative and then valuing the Revenue Purchase and Sale Agreement without the embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the Royalty Fee Derivative. We use Monte Carlo simulation models that require the use of Level 3 unobservable inputs, primarily the amount and timing of our expected future revenue, the estimated volatility of these revenues, the discount rate corresponding to the risk of revenue, and the probability of certain events. Recent Accounting Pronouncements For a description of the impact of recent accounting pronouncements, see Note 1. Organization and Summary of Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.â€‹ITEMÂ 3.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Quantitative and Qualitative Disclosures About Market RiskWe are exposed to market risk related to changes in interest rates. As of September 30, 2024, we had cash and cash equivalents of $97.7 million. A portion of our cash equivalents, which are in money market funds, may be subject 54 Table of Contentsto interest rate risk and could fall in value if market interest rates increase. However, because our cash equivalents are primarily short-term in duration, we believe that our exposure to interest rate risk on these investments is not significant and a 1% movement in market rate interest rates would not have a significant impact on the total value of our portfolio. â€‹We are also subject to credit risk from trade receivables related to product sales, and we monitor the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers. We have not experienced significant losses with respect to the collection of trade receivables.â€‹We are exposed to interest rate risk with respect to variable rate debt. As of September 30, 2024, we had $38.7 million principal outstanding on our 2029 Term Loan that accrues interest at 8.0% per annum, plus the three-month SOFR, with a floor of 1.0%. We currently do not hedge our variable interest rate debt. The interest rate during the fourth quarter of 2024 will be 12.60%. A hypothetical 100 basis point increase in the interest rate on our variable rate debt could result in up to a $0.4 million increase in the annual interest expense that we pay. â€‹In April 2020, we issued $230.0 million aggregate principal amount of 2026 Convertible Notes with a fixed interest rate of 1.5%. Since the notes have a fixed annual interest rate, we have no financial or economic interest exposure associated with changes in interest rates. However, the fair value of fixed rate debt fluctuates when interest rates change. Additionally, the fair value of the 2026 Convertible Notes can be impacted when the market price of our common stock fluctuates. We carry the 2026 Convertible Notes on our balance sheet at face value less the unamortized discount and issuance costs, and we present the fair value for required disclosure purposes only.Substantially all of our sales are denominated in U.S. dollars. Until the CIMERLI Sale, we had exposure to the exchange rate between the U.S. Dollar and the Euro through purchases of CIMERLI inventory and royalties paid to Bioeq that were denominated in Euros. Accordingly, fluctuations in the exchange rate between the U.S. Dollar and the Euro had an impact our condensed consolidated statements of operations. On January 19, 2024, we entered into the CIMERLI Purchase Agreement with Sandoz. Pursuant to the CIMERLI Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology. Refer to Note 6. Acquisition and Dispositions for additional information. â€‹ITEMÂ 4.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Controls and ProceduresEvaluation of Effectiveness of Disclosure Controls and ProceduresWe carried out an evaluation, under the supervision of our President and Chief Executive Officer and our Chief Financial Officer, and evaluated the effectiveness of our disclosure controls and procedures as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Exchange Act, as of the end of the period covered by this Quarterly Report on FormÂ 10-Q. Based on that evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on FormÂ 10-Q, our disclosure controls and procedures were, in design and operation, effective at the reasonable assurance level.We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rulesÂ and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer, principal financial officer and principal accounting officer, as appropriate, to allow for timely decisions regarding required disclosure.We intend to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to correct any material deficiencies that we may discover. Our goal is to ensure that our management has timely access to material information that could affect our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to modify our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, 55 Table of Contentsmanagement recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.Changes in Internal Control Over Financial Reporting.There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Limitations on Effectiveness of Controls and ProceduresIn designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.PARTÂ IIÂ â€“ OTHER INFORMATIONITEMÂ 1.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Legal Proceedings The information called for by this Item is incorporated herein by reference to the information set forth in Note 9. Commitments and Contingencies in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.â€‹ItemÂ 1A.Â Â Â Risk Factors Risk Factor SummaryBelow is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading â€œRisk Factorsâ€ and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q, including our financial statements and related notes thereto, before making investment decisions regarding our common stock.â—We have a limited history of profitability, which we have not maintained and may not achieve again, and only two products that have been approved and are being marketed, with multiple products that are not approved and still in development.â—The commercial success of our existing products or any future products will depend upon the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the patients to whom our medicines are prescribed. Additionally, obtaining placement on national or local clinical guidelines/pathways, as well as coverage on third-party payor formularies, can impact our short and long-term financial performance. â—As we have in-licensed development or commercial rights to LOQTORZI, we rely on prior and ongoing preclinical, clinical, regulatory and manufacturing expertise of our collaborators in order to advance this product candidate through regulatory approvals in the United States and other licensed territories.â—Our products and our product candidates, even if approved, will remain subject to regulatory scrutiny.56 Table of Contentsâ—Disruptions at theÂ FDAÂ and other government agencies caused by funding shortages, government shut-downs or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and conduct inspections of manufacturing facilities, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.â—Our biosimilar product faces significant competition from the reference product and from other biosimilar products or pharmaceuticals approved for the same indication as the originator product. LOQTORZI faces significant competition from other immuno-oncology biologics. If we fail to compete effectively, we may not achieve significant market penetration and expansion.â—We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.â—If an improved version of an originator product, such as Neulasta, is developed or if the market for the originator product significantly declines, sales of our biosimilar product may suffer. â—Healthcare reform measures, including the Inflation Reduction Act of 2022 (the â€œIRAâ€), may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations.â—We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M. Lanfear, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer. â—We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. â—We are subject to a multitude of manufacturing risks and the risks of inaccurately forecasting sales of our products. We also need to make a determination of excess or obsolete inventory that requires significant judgment and may result in write-downs of inventory, charges related to firm purchase commitments, or both. Any adverse developments affecting the manufacturing operations of our products and product candidates could substantially increase our costs and limit supply for our products and product candidates. Â â—The continuation of the war between Russia and Ukraine and conflicts in the Middle East may exacerbate certain risks we face.â—Our products or our product candidates may cause undesirable side effects or have other properties that could, as applicable, delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if granted. â—If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. â—We are heavily dependent on the development, clinical success, regulatory approval and commercial success of our product candidates. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.57 Table of Contentsâ€‹Risk FactorsInvesting in the common stock of a biopharmaceutical company, including one with significant international partnerships and multiple products in development, is a highly speculative undertaking and involves a substantial degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect any one or more of our businesses, our financial condition, our results of operations or our prospects.Risks Related to Our Financial Condition and Capital Requirements We have a limited history of profitability, which we have not maintained and may not achieve again, and only two products that have been approved and are being marketed, with multiple products that are not approved and still in development.With the exception of generating net income of $79.2 million in the nine months ended September 30, 2024, $132.2 million in 2020 and $89.8 million in 2019, we incurred a net loss of $10.8 million in the quarter ended September 30, 2024 and incurred net losses in each year from our inception in September 2010 through December 31, 2023. It is uncertain that we will be profitable in future periods as research and development is expensive and risky. The amount of our future net losses or any future net income will depend, in part, on the amount of our future expenditures offset by the amount of future product sales, including sales of our current products or any other products that may receive regulatory approval. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk.For example, as of September 30, 2024, we had an accumulated deficit of $1.5 billion. The losses and accumulated deficit were primarily due to the substantial investments we made to identify, develop or license our product candidates, including conducting, among other things, analytical characterization, process development and manufacturing, formulation and clinical studies and providing general and administrative support for these operations.We have incurred and anticipate we will continue to incur certain development and commercial expenses for LOQTORZI, the anti-PD-1 antibody we licensed from Junshi Biosciences in 2021, and have agreed to pay up to $90.0 million for the achievement of certain regulatory approvals and up to $290.0 million for the attainment of certain sales thresholds. The recent launch of this product and future work to advance our product candidates through clinical development will be expensive and could result in us continuing to experience future net losses.For UDENYCA and LOQTORZI which are launched products, and if we obtain regulatory approval to market any other product candidates, our future revenue will depend upon the size of the markets in which our product candidates may receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payers, and adequate market share for our product candidates which include all product candidates for which we obtained commercial rights, in those markets. However, even if additional product candidates in addition to our current products gain regulatory approval and are commercialized, we may not be profitable.Our expenses will increase substantially if and as we:â—establish a sales, marketing and distribution infrastructure to commercialize any of our product candidates for which we may obtain marketing approval; â—make upfront, milestone, royalty or other payments under any license agreements; 58 Table of Contentsâ—continue our nonclinical and clinical development of our product candidates; â—initiate additional nonclinical, clinical or other studies for our product candidates; â—expand the scope of our current clinical studies for our product candidates; â—advance our programs into more expensive clinical studies; â—change or add contract manufacturers, clinical research service providers, testing laboratories, device suppliers, legal service providers or other vendors or suppliers; â—seek regulatory approvals for our product candidates that successfully complete clinical studies; â—seek to identify, assess, acquire or develop other product candidates or products that may be complementary to our products; â—seek to create, maintain, protect and expand our intellectual property portfolio; â—engage legal counsel and technical experts to help us evaluate and avoid infringing any valid and enforceable intellectual property rights of third parties; â—engage in litigation, including patent litigation, and Inter Partes Review (â€œIPRâ€) proceedings with originator companies or others that may hold patents; â—seek to attract and retain skilled personnel; â—create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and â—experience any delays or encounter issues with any of the above, including but not limited to failed studies, conflicting results, safety issues, manufacturing delays, litigation or regulatory challenges that may require longer follow-up of existing studies, additional major studies or additional supportive studies or analyses in order to pursue marketing approval. â€‹Further, the net loss or net income we achieve may fluctuate significantly from quarter-to-quarter and year-to-year such that a period-to-period comparison of our results of operations may not be a good indication of our future performance quarter-to-quarter and year-to-year due to factors including the timing of clinical trials, any litigation that we may initiate or that may be initiated against us as well as any settlements or judgments from such litigation, the execution of collaboration, licensing or other agreements and the timing of any payments we make or receive thereunder. We continue to be dependent on the ability to raise funds. This additional funding may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization efforts or other operations. As of September 30, 2024, our cash, cash equivalents and marketable securities were $97.7 million. We expect that our existing cash and cash equivalents, investments and cash collected from our product sales will be sufficient to fund our current operations for the foreseeable future. We have financed our operations primarily through the sale of equity securities, convertible notes, credit facilities, license agreements and through recent product sales of our products.However, our operating or investing plans may

change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including but not limited to: â—our ability to continue to successfully commercialize our products;â—our ability to resolve supply interruptions for the supply of our products, such as the ongoing temporary 59 Table of ContentsUDENYCA supply interruption that we announced on September 13, 2024;â—the scope, rate of progress, results and cost of any clinical studies, nonclinical testing and other related activities; â—the cost of manufacturing clinical drug supplies and establishing commercial supplies of our product candidates and products; â—the timing for our packaging and labeling CMO to resume manufacturing and to make UDENYCA products available in a sufficient quantity to meet the demand from our customers;â—the timing for us to receive FDA authorization to produce UDENYCA product at our additional packaging and labeling CMOâ€™s facility and the timing for our additional packaging and labeling CMO to make UDENYCA products available in a sufficient quantity to meet the demand from our customers;â—the percentage of customers that continue to purchase our products and that do not switch to products made by our competitors;â—the number and characteristics of product candidates that we pursue; â—the cost, timing and outcomes of regulatory approvals; â—the cost and timing of establishing sales, marketing and distribution capabilities; â—the terms and timing of any licensing or other arrangements to acquire intellectual property rights that we may establish, including any milestone and royalty payments thereunder; â—the timing of conversion in common shares or repayment in cash of our convertible debt, the timing of repayment in cash, whether due or not, of our long-term debt and the payment of interest, principal and royalties related to our financial liabilities; and â—the cost, timing and outcomes of any litigation that we may file against third parties or that may be filed against us by third parties. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The sale of additional equity or convertible securities, such as the sales from time to time through our Sales Agreement with TD Cowen pursuant to which we may issue and sell from time to time up to $150.0 million of our common stock through or to TD Cowen as our sales agent or principal in an ATM Offering, may dilute the share ownership of our existing stockholders. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as those contained in the 2029 Loan Agreement we entered into on May 8, 2024 with the Agent and the 2029 Lenders that provides for a senior secured term loan facility of up to $38.7 million, including limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business such as a financial covenant commencing on May 8, 2024, which requires us to maintain certain levels of cash and cash equivalents. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage or for a lower price than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or for specific strategic considerations.60 Table of ContentsIf we are unable to obtain funding on a timely basis or at all, stay profitable or generate any net profits, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any products or product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our financial condition and results of operations. Risks Related to Launch and Commercialization of our Products and our Product CandidatesWe have a limited operating history in an emerging regulatory environment on which to assess our business.We are a biopharmaceutical company with a limited operating history in an emerging regulatory environment of biosimilar and immuno-oncology products. Although we have received upfront payments, milestone and other contingent payments or funding for development from some of our collaboration and license agreements, our only approved products are UDENYCA and LOQTORZI which are approved for commercialization in the United States, and we have no products approved in any other territories.One of the steps necessary for us to generate meaningful revenue is for us, alone or with strategic collaboration partners, to successfully market and sell our products, and to complete the development of, and obtain the regulatory approvals necessary to commercialize, one or more of our product pipeline candidates, which include: â—CHS-1000;â—casdozokitug; â—CHS-114; and â—toripalimab in non-NPC indications.We may not be able to continue to generate meaningful revenue from product sales, as this depends heavily on our success in many areas, including but not limited to: â—our ability to continue to successfully commercialize all three UDENYCA product presentations and LOQTORZI;â—competing against numerous current and future pegfilgrastim and adalimumab products with significant market share; â—healthcare providers, payers, and patients adopting our products and product candidates once approved and launched;â—our ability to procure and commercialize our biosimilar product; â—obtaining additional regulatory approvals for product candidates for which we complete clinical studies; â—obtaining adequate third-party coverage and reimbursements for our products; â—obtaining market acceptance of our products and product candidates as viable treatment options; â—completing nonclinical and clinical development of our product candidates; â—developing and testing of our product formulations; â—attracting, hiring and retaining qualified personnel; â—developing a sustainable and scalable manufacturing process for our products and any approved product candidates and establishing and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand for our products and product candidates, if approved; â—addressing any competing technological and market developments; 61 Table of Contentsâ—identifying, assessing and developing (or acquiring/in-licensing on favorable terms) new product candidates; â—negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; â—maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; andâ—defending against any litigation including patent or trade secret infringement lawsuits, which may be filed against us, or achieving successful outcomes of IPR petitions that we have filed, or may in the future file, against third parties.Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs to commercialize any such product. Our expenses could increase beyond our expectations if we are required by the FDA, the European Medical Agency (the â€œEMAâ€), other regulatory agencies, domestic or foreign, or by any unfavorable outcomes in intellectual property litigation filed against us, to change our manufacturing processes or assays or to perform clinical, nonclinical or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining additional regulatory approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the number of biosimilar or immuno-oncology competitors in such markets, the accepted price for the product, the ability to get reimbursement at any price, the nature and degree of competition from originators and other biosimilar or immuno-oncology companies (including competition from large pharmaceutical companies entering the biosimilar market or possessing large established positions in the immuno-oncology market that may be able to gain advantages in the sale of biosimilar or immuno-oncology products based on brand recognition or existing relationships with customers and payers) and whether we own (or have partnered with companies owning) the commercial rights for that territory. If the market for our products and product candidates (or our share of that market) is not as significant as we expect, the price of our products is not what we project, the indication approved by regulatory authorities is narrower than we expect or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are unable to successfully complete development and obtain additional regulatory approval for our products, our business may suffer.The commercial success of our existing products or any future products will depend upon the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the patients to whom our medicines are prescribed. Additionally, obtaining placement on national or local clinical guidelines/pathways, as well as coverage on third-party payor formularies, can impact our short and long-term financial performance. Even with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products or product candidates, if approved, will depend in part on the medical community, patients and third-party payers accepting our products and product candidates as medically useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payers and others in the medical community. The degree of market acceptance of our product LOQTORZI, or any of our product candidates, if approved for commercial sale, will depend on a number of factors, including: â—the safety and efficacy of the product, as demonstrated in clinical studies, and potential advantages over competing treatments; â—the prevalence and severity of any side effects and any limitations or warnings contained in a productâ€™s approved labeling; â—the clinical indications for which approval is granted;â—for our immuno-oncology product candidates, our ability to compete in a competitive immuno-oncology market that may differ from the biosimilar market; 62 Table of Contentsâ—inclusion, in either parity or better position, on commonly accepted clinical guidelines or pathways that influence prescribing patterns or affect reimbursement;â—relative convenience, ease of administration and any real or perceived benefit from administration at home as opposed to in the clinic; â—prevalence of the disease or condition for which the product is approved; â—the cost of treatment, particularly in relation to competing treatments; â—the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; â—the strength of marketing and distribution support and timing of market introduction of competitive products; â—the extent to which the product is approved for inclusion on formularies of hospitals, integrated delivery networks and managed care organizations; â—publicity concerning our products or competing products and treatments; â—the extent to which third-party payers (including government and national/regional commercial plans) provide adequate third-party coverage and reimbursement for our products and product candidates, if approved; â—the price at which we sell our products; â—the potential impact of the IRA on the pharmaceutical industry and the market for biosimilars;â—the actions taken by current and future competitors to delay, restrict or block customer usage of the product; and â—our ability to maintain compliance with regulatory requirements. Market acceptance of any future product candidates, if approved, will not be fully known until after they are launched and may be negatively affected by a potential poor safety experience and the track record of other biosimilar and immuno-oncology products and product candidates. Further, continued market acceptance of UDENYCA and LOQTORZI, and any future product candidates that may be approved, depends on our efforts to educate the medical community and third-party payers on the benefits of our products and product candidates and will require significant resources from us and we have significantly less resources compared to large, well-funded pharmaceutical entities. Given the resource disparity, our outreach may have little success or may never be successful. If our products or any future product candidates that are approved fail to achieve an adequate level of acceptance by physicians, patients, third-party payers and others in the medical community, we will not be able to generate sufficient revenue to sustain profitability.The third-party coverage and reimbursement status of our products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. Pricing, coverage and reimbursement of our products, or any of our product candidates, if approved, may not be adequate to support our commercial infrastructure. The prices required to successfully compete may not continue to be sufficient to recover our development and manufacturing costs, and as a result, we may not be profitable in the future. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and commercial payers are essential to enable provider/patient access to our products and our patient support services must be sufficiently scaled to meet the needs of patients receiving our products. Sales will depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations or reimbursed by government authorities, private health insurers and other third-party payers. If coverage and reimbursement are not available, or are available only to limited levels, or 63 Table of Contentsbecome unavailable, we may not be able to successfully commercialize our products or any of our product candidates, if approved. Even if coverage is provided, the approved reimbursement amount may not be adequate to allow us to establish or maintain pricing sufficient to realize a return on our investment. There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party payers, including private and governmental payers such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare program covers certain individuals aged 65 or older or those who are disabled or suffering from end-stage renal disease. The Medicaid program, which varies from state to state, covers certain individuals and families who have limited financial means. The Medicare and Medicaid programs increasingly are used as models for how private payers and other governmental payers develop their coverage and reimbursement policies for drugs and biologics. It is difficult to predict what third-party payers will decide with respect to the coverage and reimbursement for any newly approved product. In addition, in the United States, no uniform policy of coverage and reimbursement for biologics exists among third-party payers. Therefore, coverage and reimbursement for biologics can differ significantly from payer to payer. As a result, the process for obtaining favorable coverage determinations often is time-consuming and costly and may require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained. Effective January 2019, U.S. Centers for Medicare & Medicaid Services (â€œCMSâ€) assigned a product specific Q-Code to UDENYCA, which is necessary to enable providers to separately bill for UDENYCA to have its own reimbursement rate with Medicare or other third-party payers. However, reimbursement is not guaranteed and rates may vary based on product life cycle, site of care, type of payer, coverage decisions, and provider contracts. Furthermore, while payers have adopted the Q-Code assigned by CMS for UDENYCA, there remains uncertainty as to whether such payers will continue to cover and pay providers for the administration and use of the product with each patient or may favor competing products. If our products or any of our future product candidates, are not covered or adequately reimbursed by third-party payers, including Medicare, then the cost of the relevant product may be absorbed by healthcare providers or charged to patients. If this is the case, our expectations of the pricing we expect to achieve for such product and the related potential revenue may be significantly diminished.Outside of the United States, pharmaceutical businesses are generally subject to extensive governmental price controls and other market regulations. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. Increasing efforts by governmental and third-party payers in the United States and abroad to control healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our products or any of our product candidates. While cost containment practices generally benefit biosimilars, severe cost containment practices may adversely affect our product sales. Furthermore, the impact of the IRA on our business and the pharmaceutical industry generally is currently unknown. We expect to experience pricing pressures in connection with the sale of our products and any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.Our products and our product candidates, even if approved, will remain subject to regulatory scrutiny.Our products and our product candidates, even If approved, will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-64 Table of Contentsmarketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. Manufacturers and manufacturersâ€™ facilities are required to comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (â€œcGMPâ€) regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, original BLA submitted under Section 351(a) of the Public Health Service Act (â€œPHSAâ€), Section 351(k) BLA or MAA. Accordingly, we and others with whom we work must continue to spend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.Any regulatory approvals that we or our collaboration partners receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval or may contain requirements for potentially costly additional clinical trials and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse events and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization or increased costs to ensure compliance. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the

productâ€™s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. If our product candidates are approved, we must submit new or supplemental applications and obtain approval for certain changes to the approved products, product labeling or manufacturing process. We or our collaboration partners could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval is obtained via an accelerated biosimilar approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other possibilities: â—issue warning letters; â—impose civil or criminal penalties; â—suspend or withdraw regulatory approval; â—suspend any of our ongoing clinical studies; â—refuse to approve pending applications or supplements to approved applications submitted by us; â—impose restrictions on our operations, including closing our contract manufacturersâ€™ facilities; or â—seize or detain products or require a product recall. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. 65 Table of ContentsThe FDAâ€™s and other regulatory authoritiesâ€™ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States, China or other foreign countries.Disruptions at theÂ FDAÂ and other government agencies caused by funding shortages, government shut-downs or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and conduct inspections of manufacturing facilities, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.The ability of theÂ FDAÂ to review and approve new products can be affected by a variety of factors, including government budget and funding levels, government shut-downs, statutory, regulatory, and policy changes, the FDAâ€™s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDAâ€™s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at theÂ FDAÂ and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed or approved by necessary government agencies, which would adversely affect our business.Â For example, over the last several years, the United States government has periodically shut down and certain regulatory agencies, such as theÂ FDA, had to furlough criticalÂ FDAÂ employees and stop critical activities.Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. If a prolonged government shutdown occurs, or if further global health concerns emerge, such events could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.Risks Related to Competitive ActivityOur biosimilar product faces significant competition from the reference product and from other biosimilar products or pharmaceuticals approved for the same indication as the originator product. Our product LOQTORZI and product candidate CHS-114, if approved, will face significant competition from other immuno-oncology biologics. If we fail to compete effectively, we may not achieve significant market penetration and expansion.We operate in highly competitive pharmaceutical markets. Successful competitors in the pharmaceutical market have demonstrated the ability to effectively discover molecules, obtain patents, develop, test and obtain regulatory approvals for products, as well as an ability to effectively commercialize, market and promote approved products. Numerous companies, universities and other research institutions are engaged in developing, patenting, manufacturing and marketing of products competitive with those that we are developing. Many of these potential competitors are large, experienced multinational pharmaceutical and biotechnology companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, legal, governmental affairs, manufacturing, personnel, and marketing resources, with additional benefits of mergers and acquisitions. LOQTORZI recently entered a competitive market in the United States where a number of anti-PD-1 or PD-L1 antibody drugs have been approved by the FDA, although not in NPC, including the following marketed products from several competitors: KeytrudaÂ® (pembrolizumab) from Merck & Company, Inc. (â€œMerckâ€), OpdivoÂ® (nivolumab) from Bristol-Myers Squibb Company (â€œBMSâ€), TecentriqÂ® (atezolizumab) from Genentech, ImfinziÂ® (durvalumab) from AstraZeneca plc (â€œAstraZenecaâ€), BavencioÂ® (avelumab) from EMD Serono Inc. and Pfizer, LibtayoÂ® (cemiplimab-rwlc) 66 Table of Contentsfrom Regeneron Pharmaceuticals, Inc. (â€œRegeneronâ€), Jemperli (dostarlimab-gxly) from GlaxoSmithKline plc (â€œGlaxoSmithKlineâ€) and TEVIMBRAÂ® (tislelizumab-jsgr) from BeiGene, Ltd. In addition to LOQTORZI, multiple other competitors are seeking to develop and approve novel anti-PD-1 or PD-L1 antibody drugs in the United States in the coming years, including but not limited to camrelizumab from Elevar Therapeutics, Inc. (in collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd.). As the only immunotherapy approved by the FDA for the treatment of NPC, we believe LOQTORZI addresses a potentially high unmet need.CHS-114, if approved, faces competition from programs in development specifically targeting CCR8, including those by Bristol-Myers Squibb Company, Gilead/Jounce, Shionogi, AbbVie, Bayer, F. Hoffmann-La Roche Ltd, Amgen, LaNova and Immunophage;UDENYCA faces competition in the United States from Amgen, Biocon Biologics Inc. (â€œBioconâ€), Sandoz International GmbH (â€œSandozâ€), Pfizer, Spectrum Pharmaceuticals, Inc. (â€œSpectrumâ€), Amneal Pharmaceuticals, Inc. (â€œAmnealâ€) and Fresenius Medical Care AG & Co. KGaA (â€œFreseniusâ€).These companies may also have greater brand recognition and more experience in conducting preclinical testing and clinical trials of product candidates, obtaining FDA and other regulatory approvals of products and marketing and commercializing products once approved. Additionally, many manufacturers of originator products have increasingly used legislative, regulatory and other means, such as litigation, to delay regulatory approval and to seek to restrict competition from manufacturers of biosimilars. These efforts may include or have included: â—settling, or refusing to settle, patent lawsuits with biosimilar companies, resulting in such patents remaining an obstacle for biosimilar approval; â—submitting Citizen Petitions to request the FDA Commissioner to take administrative action with respect to prospective and submitted biosimilar applications; â—appealing denials of Citizen Petitions in United States federal district courts and seeking injunctive relief to reverse approval of biosimilar applications; â—restricting access to reference brand products for equivalence and biosimilarity testing that interferes with timely biosimilar development plans; â—attempting to influence potential market share by conducting medical education with physicians, payers, regulators and patients claiming that biosimilar products are too complex for biosimilar approval or are too dissimilar from originator products to be trusted as safe and effective alternatives; â—implementing payer market access tactics that benefit their brands at the expense of biosimilars; â—seeking state law restrictions on the substitution of biosimilar products at the pharmacy without the intervention of a physician or through other restrictive means such as excessive recordkeeping requirements or patient and physician notification; â—seeking federal or state regulatory restrictions on the use of the same non-proprietary name as the reference brand product for a biosimilar or interchangeable biologic; â—seeking changes to the United States Pharmacopeia, an industry recognized compilation of drug and biologic standards; â—obtaining new patents covering existing products or processes, which could extend patent exclusivity for a number of years or otherwise delay the launch of biosimilars; and â—influencing legislatures so that they attach special patent extension amendments to unrelated federal legislation. 67 Table of ContentsOur products and our product candidates, if approved, could face price competition from other products or biosimilars of the same reference products for the same indication. This price competition could exceed our capacity to respond, detrimentally affecting our market share and revenue as well as adversely affecting the overall financial health and attractiveness of the market for the biosimilar.Competitors in the biosimilar market have the ability to compete on price through PBMs, payers and their third-party administrators, IDNs and hospitals who exert downward pricing pressure on our product offerings. It is possible our biosimilar competitorsâ€™ compliance with price discounting demands in exchange for market share or volume requirements could exceed our capacity to respond in kind and reduce market prices beyond our expectations. There could be similar price competition in the immuno-oncology market that could adversely affect our results in the future. Such practices may limit our ability to increase market share and may also impact profitability.We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, less costly, easier to administer or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.Many of our competitors have substantially greater financial, technical and other resources, including larger research and development, marketing and manufacturing organizations. Additionally, mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop; they may also obtain patent protection that could block our products; and they may obtain regulatory approval, product commercialization and market penetration earlier than we do. Our competitors may have products that are easier to administer than our products, which could adversely affect our results. Biosimilar or immuno-oncology product candidates developed by our competitors may render our potential product candidates uneconomical, less desirable or obsolete, and we may not be successful in marketing our product candidates against competitors. If other competitors to toripalimab (in indications besides NPC), casdozokitug, CHS-1000 and CHS-114 are approved and successfully commercialized before toripalimab (in indications besides NPC), casdozokitug, CHS-1000 and CHS-114, our business would suffer. There are a number of companies that currently commercialize PD-1/PD-L1 blocking antibodies or are developing such compounds for commercialization in the United States. If other competitors to toripalimab (in indications besides NPC), casdozokitug, CHS-1000 and CHS-114 are successfully commercialized before toripalimab (in indications besides NPC), casdozokitug, CHS-1000 and CHS-114, we may never achieve meaningful market share for these products, our revenue would be reduced and, as a result, our business, prospects and financial condition could suffer. If an improved version of an originator product, such as Neulasta, is developed or if the market for the originator product significantly declines, sales of our biosimilar product may suffer. Originator companies may develop improved versions of a reference product as part of a life cycle extension strategy and may obtain regulatory approval of the improved version under a new or supplemental BLA submitted to the applicable regulatory authority. Should the originator company succeed in obtaining an approval of an improved biologic product, it may capture a significant share of the collective reference product market in the applicable jurisdiction and significantly reduce the market for the reference product and thereby the potential size of the market for our biosimilar product. In addition, the improved product may be protected by additional patent rights that may subject our follow-on biosimilar to claims of infringement. 68 Table of ContentsBiologic reference products may also face competition as technological advances are made that may offer patients a more convenient form of administration or increased efficacy or as new products are introduced. External developments can also result in changing preferences for convenient forms of administration of products that may impact our business. As new products are approved that compete with the reference product to our biosimilar product, sales of the reference originator product may be adversely impacted or rendered obsolete. If the market for the reference product is impacted, we may lose significant market share for our biosimilar product. As a result of the above factors, our business, prospects and financial condition could suffer.Any product candidates for which we intend to seek approval as original biologic products may face competition sooner than anticipated.Our development of novel biologic product candidates, such as casdozokitug and CHS-114, subjects us to additional risks relating to biosimilar competition. In particular, under the Biologics Price Competition and Innovation Act of 2009 (â€œBPCIAâ€), an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsorâ€™s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. We believe that LOQTORZI and any of our future product candidates approved under an original BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.Risks Related to Our Ability to Hire and Retain Highly Qualified Personnel We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M. Lanfear, and if we are not able to retain these members of our management or recruit additional management, product development and scientific personnel, our business will suffer. We are highly dependent on the principal members of our management and scientific and technical staff. The loss of service of any of our management or key scientific and technical staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, product development and scientific personnel. If we are not able to retain our management, particularly our President and Chief Executive Officer, Mr.Â Lanfear, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations. Additionally, we do not currently maintain â€œkey personâ€ life insurance on the lives of our executives or any of our employees. We will need to expand and effectively manage our managerial, scientific, operational, financial, commercial and other resources in order to successfully pursue our product development and commercialization efforts. Our success 69 Table of Contentsalso depends on our continued ability to attract, retain and motivate highly qualified management and technical personnel. We may not be able to attract or retain qualified management and scientific and product development personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly those located in the San Francisco Bay Area. We also use equity compensation as a part of a comprehensive compensation package for our personnel. The majority of our outstanding options have exercise prices that are above our current stock price. See the tables describing our outstanding stock options in Note 12. Stock-Based Compensation and Employee Benefits to our financial statements included in our Annual Report for the Fiscal Year ended December 31, 2023. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. We may need to expand our organization, particularly due to employee turnover, and we may experience difficulties in managing this turnover, which could disrupt our operations. As of September 30, 2024, we had 235 full-time and part-time employees. As our development and commercialization plans and strategies develop and evolve from time to time and as we experience turnover, we may need to hire additional people in the future. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these hiring activities. We may not be able to effectively manage during a period of employee turnover, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future product candidates. If our management is unable to effectively manage our turnover, our expenses may increase more than expected, our ability to generate or grow revenue could be reduced. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.Risks Related to Reliance

on Third PartiesWe rely on third parties, and in some cases a single third party, to manufacture nonclinical, clinical and commercial drug supplies of our products and product candidates and to store critical components of our products and product candidates for us. Our business could be harmed if those third parties fail to provide us with sufficient quantities of products and product candidates or fail to do so at acceptable quality levels or prices. We do not currently have the infrastructure or capability internally to manufacture supplies of our product candidates for use in our nonclinical and clinical studies, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on third-party manufacturers to manufacture and supply us with our product candidates for our preclinical and clinical studies as well as to maintain commercial supplies of our product candidates. Successfully transferring complicated manufacturing techniques to contract manufacturing organizations and scaling up these techniques for commercial quantities is time consuming and we may not be able to achieve such transfer or do so in a timely manner. Moreover, the availability of contract manufacturing services for protein-based therapeutics is highly variable and there are periods of relatively abundant capacity alternating with periods in which there is little available capacity. If our need for contract manufacturing services increases during a period of industry-wide production capacity shortage, we may not be able to produce our product candidates on a timely basis or on commercially viable terms. Although we will plan accordingly and generally do not begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete such study, any significant delay or discontinuation in the supply of a product candidate for an ongoing clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates, which could harm our business and results of operations. 70 Table of ContentsReliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third-party manufacturers may not be able to comply with cGMP or similar regulatory requirements outside the United States. Our failure or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or any other product candidates or products that we may develop. Any failure or refusal to supply the components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected products or product candidates could be delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant. On September 13, 2024, we announced that our third-party labeling and packaging CMO for UDENYCA delayed production of UDENYCA due to over-commitments and capacity constraints. These delays caused a temporary UDENYCA supply interruption. The CMO recently informed us that production will resume later in the week of November 4, 2024. An additional final packaging and labeling CMO has already started production testing and is expected to start manufacturing saleable product by the end of 2024. Commercial supply from that CMO is expected to commence in the first quarter of 2025, subject to FDA authorization. Â The length of the temporary UDENYCA supply interruption will depend on the number of future manufacturing slots scheduled by the CMOs and whether future manufacturing slots are successfully completed on schedule or at all. Although we believe that the steps that we have taken will help to lessen the impact of the temporary UDENYCA supply interruption, this manufacturing depends on third parties and we cannot make any assurances about the timing of the resolution of the issue. Similar circumstances could arise in the future that could result in supply disruption to our products and product candidates. Supply disruptions like this will have an adverse impact on our financial statements and reputation. If any of our product candidates are approved, in order to produce the quantities necessary to meet anticipated market demand, any contract manufacturer that we engage may need to increase manufacturing capacity. If we are unable to build and stock our product candidates in sufficient quantities to meet the requirements for the launch of these candidates or to meet future demand, our revenue and gross margins could be adversely affected. We cannot be certain that we will be able to obtain long-term supply arrangements for our product candidates or materials used to produce them on acceptable terms, if at all. If we are unable to arrange for third-party manufacturing, or to do so on commercially reasonable terms, we may not be able to complete development of our product candidates or market them. We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. We have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical and clinical studies and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with cGMP, GCP, and good laboratory practices (â€œGLPâ€), which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic 71 Table of Contentsinspections or remote regulatory assessments (â€œRRAsâ€) of study sponsors, principal investigators, study sites and other contractors. If we, any of our CROs, service providers or investigators fail to comply with applicable regulations or GCPs, the data generated in our nonclinical and clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional nonclinical and clinical studies before approving our marketing applications. There can be no assurance that upon inspection or conclusion of an RRA by a given regulatory authority, such regulatory authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical studies must be conducted with product generated under cGMP regulations. Failure to comply by any of the participating parties or ourselves with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process. Moreover, our business may be implicated if our CROs or any other participating parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare or data privacy and security laws. If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our clinical studies may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, a transition period is necessary when a new CRO commences work, which can materially impact our ability to meet our desired clinical development timelines. Though we strive to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, prospects and financial condition.We are dependent on Junshi Biosciences and Orox / Laboratorio Gador S.A. for the commercialization of our product candidates in certain markets and we intend to seek additional commercialization partners for major markets, and the failure to commercialize in those markets could have a material adverse effect on our business and operating results. We have an exclusive license from Junshi Biosciences to develop and commercialize LOQTORZI in the United States and Canada. Our licensors are responsible for supplying us with drug substance and final drug products.Our exclusive licensee, Orox / Laboratorio Gador S.A., is responsible for commercialization of certain of our products and product candidates, including UDENYCA, in certain Caribbean and Latin American countries (excluding Brazil, and in the case of UDENYCA, also excluding Argentina). Our licenses with Junshi Biosciences, Orox / Laboratorio Gador S.A., or other future license or collaboration agreements, may not result in positive outcomes. Factors that may affect the success of our licenses and collaborations include, but are not limited to, the following:â—our existing and potential collaboration partners may fail to provide sufficient amounts of commercial products, including because of import restrictions, or they may be ineffective in doing so;â—our existing and potential collaboration partners may fail regulatory inspections or RRAs which may preclude or delay the delivery of commercial products;â—our existing and potential collaboration partners may fail to exercise commercially reasonable efforts to market and sell our products in their respective licensed jurisdictions or they may be ineffective in doing so; 72 Table of Contentsâ—our existing and potential licensees and collaboration partners may incur financial, legal or other difficulties that force them to limit or reduce their participation in our joint projects;â—our existing and potential licensees and collaboration partners may terminate their licenses or collaborations with us, which could make it difficult for us to attract new partners or adversely affect perception of us in the business and financial communities; andâ—our existing and potential licensees and collaboration partners may choose to pursue alternative, higher priority programs, which could affect their commitment to us. Moreover, any disputes with our licensees and collaboration partners could substantially divert the attention of our senior management from other business activities and may require us to incur substantial costs associated with litigation or arbitration proceedings. If we cannot maintain successful license and collaboration arrangements, our business, financial condition and operating results may be adversely affected.There are risks and uncertainties associated with the CIMERLI TSA and YUSIMRY TSA, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows or stock price. In connection with the CIMERLI Sale, we and Sandoz entered into the CIMERLI TSA pursuant to which we will provide certain business support services to Sandoz for a defined period not expected to extend beyond December 31, 2024. In connection with the YUSIMRY Sale, we and HKF entered into the YUSIMRY TSA pursuant to which we will provide certain business support services to HKF for a defined period not expected to extend beyond December 31, 2024. There are a number of risks and uncertainties associated with the CIMERLI TSA and YUSIMRY TSA, which could have a material adverse effect on our business, financial condition, results of operations, cash flows or stock price, including, among other things:â—the need to expend employee time and attention on the CIMERLI TSA and YUSIMRY TSA that could be spent on other areas of our business;â—the need to provide significant support services under the CIMERLI TSA and YUSIMRY TSA on behalf of Sandoz and HKF, respectively, such as logistics, payments, accounting, payroll, commercial, regulatory and manufacturing;â—the exposure to the financial status of Sandoz and HKF for any payments due to us under the CIMERLI TSA and YUSIMRY TSA, respectively, which may be significant; andâ—potential unanticipated costs to us under the CIMERLI TSA and YUSIMRY TSA.â€‹Risks Related to Manufacturing and Supply Chain We are subject to a multitude of manufacturing risks and the risks of inaccurately forecasting sales of our products. We also need to make a determination of excess or obsolete inventory that requires significant judgment and may result in write-downs of inventory, charges related to firm purchase commitments, or both. Any adverse developments affecting the manufacturing operations of our products and product candidates could substantially increase our costs and limit supply for our products and product candidates. The process of manufacturing our products and product candidates is complex, highly regulated and subject to several risks, including but not limited to: â—product loss due to contamination, equipment failure or improper installation or operation of equipment or vendor or operator error; â—equipment failures, labor shortages, natural disasters, power failures and numerous other factors associated with the manufacturing facilities in which our product candidates are produced, and potentially exacerbated 73 Table of Contentsby climate change; andâ—disruption of supply chains for critical and specialized raw materials, delays in regulatory inspections of manufacturing and testing facilities, and reduced manufacturing capacities created by global events such as the COVID-19 pandemic and the ongoing conflict in Ukraine. We have experienced reduced production yields, product defects and other supply disruptions. For example, we have experienced failures with respect to the manufacturing of certain lots of each of our products and product candidates resulting in delays prior to our taking corrective action. Additionally, if microbial, viral or other contaminations are discovered in our products or product candidates or in the manufacturing facilities in which our products or product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for our products and product candidates, including due to sudden or long-term changes in weather patterns or conflicts in particular geographic areas, may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions in the supply of our products and product candidates. We also need to make a determination of excess or obsolete inventory that requires significant judgment and includes consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information and potential product obsolescence, among others. Although we believe that the assumptions we use in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by us, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in our consolidated statements of operations. Adverse developments affecting our assumptions of the level and timing of demand for our products include those that are outside of our control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors. We may have to take inventory write-downs and incur other charges and expenses, such as charges related to firm purchase commitments, for products that are manufactured in reliance on a forecast that proves to be inaccurate because we do not sell as many units as forecasted. For example, during the third quarter of 2022, we recorded a $26.0 million write-down of UDENYCA inventory that was at risk of expiration and during the fourth quarter of 2023, we recorded a $47.0 million charge for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. Although we believe that the assumptions that we use in estimating inventory write-downs are reasonable, additional write-downs of inventory may be required in the future if actual market conditions are less favorable than our projections, which could materially and adversely impact our financial results. In addition to such write-downs, we may also have to incur charges and expenses related to firm purchase commitments or for product candidates that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives. On September 13, 2024, we announced that our third-party labeling and packaging CMO for UDENYCA delayed production of UDENYCA due to over-commitments and capacity constraints. These delays caused a temporary UDENYCA supply interruption. The CMO recently informed us that production will resume later in the week of November 4, 2024. An additional final packaging and labeling CMO has already started production testing and is expected to start manufacturing saleable product by the end of 2024. Commercial supply from that CMO is expected to commence in the first quarter of 2025, subject to FDA authorization. Although we currently believe that our estimates for the timing of UDENYCA commercial supply availability from our two labeling and packaging CMOs are reasonable, any delays from third parties would result in delays to UDENYCA commercial supply availability. The length of the temporary UDENYCA supply interruption will depend on the number of future manufacturing slots scheduled by the CMOs and whether future manufacturing slots are successfully completed on schedule or at all. 74 Table of ContentsWe currently engage single suppliers for manufacture, clinical trial services, formulation development and product testing of our product candidates. The loss of any of these suppliers or vendors could materially and adversely affect our business. For our products and our product candidates, we currently engage a distinctÂ vendor or service provider for each of the principal activities supporting our manufacture and development of these products, such as manufacture of the biological substance present in each of the products, manufacture of the final filled and finished presentation of these products, as well as laboratory testing, formulation development and clinical testing of these products. Because we currently have engaged a limited number of back-up suppliers or vendors for these single-sourced services, and although we believe that there are alternate sources that could fulfill these activities, we cannot make any assurances that identifying and establishing relationships with alternate suppliers and vendors would not result in significant delay in the development of our product candidates. Additional delays or cost increases could occur due to the direct or indirect effects of the COVID-19 pandemic and the ongoing conflict in Ukraine.Â Additionally, we may not be able to enter into arrangements with alternative service providersÂ on commercially reasonable terms or at all.Â A delay in the development of our products and product candidates, or having to enter into a new agreement with a different third party on less favorable terms than we have with our current suppliers, could have a material adverse impact on our business.For example, on September 13, 2024, we announced that our third-party labeling and packaging CMO for UDENYCA delayed production of UDENYCA due to over-commitments and capacity constraints. These delays caused a temporary UDENYCA supply interruption. The CMO recently informed us that production will resume later in the week of November 4, 2024. An additional final packaging and labeling CMO has already started production testing and is expected to start manufacturing saleable product by the end of 2024. Commercial supply from that CMO is expected to commence in the first quarter of 2025, subject to FDA authorization. Although we currently believe that our estimates for the timing of UDENYCA commercial supply availability from our two labeling and packaging CMOs are reasonable, any

delays from third parties would result in delays to UDENYCA commercial supply availability. Sales of UDENYCA provided 93.4% of our net revenue in the three months ended September 30, 2024. Â The UDENYCA supply interruption will have a material adverse impact on our business, reputation and financial results based on the current expected time period until we can restore product availability and if the UDENYCA supply interruption takes longer than currently expected to resolve, the adverse impact is expected to greatly increase. We and our collaboration partners and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We, our collaboration partners, or our contract manufacturers must supply all necessary documentation in support of a Section 351(k) BLA, original BLA, NDA or MAA on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our contract manufacturers may have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our collaboration partners and third-party contractors must successfully complete a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract 75 Table of Contentsmanufacturing partners for compliance with the regulatory requirements. If these facilities do not successfully complete a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. The regulatory authorities also may, at any time following approval of a product for sale, inspect, audit or initiate an RRA of the manufacturing facilities of our collaboration partners and third-party contractors. If any such inspection, audit or RRA identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection, audit or RRA, we or the relevant regulatory authority may require remedial measures that may be costly or time consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. If we, our collaboration partners or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate, withdrawal of an approval or suspension of production. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if a manufacturer cannot meet the supply demand, supply from an alternative manufacturer would require the submission of a BLA/NDA supplement or MAA Variation (or equivalent foreign regulatory filing) which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. For example, there is currently a temporary UDENYCA supply interruption. An additional final packaging and labeling CMO has already started production testing and is expected to start manufacturing saleable product by the end of 2024. Commercial supply from that CMO is expected to commence in the first quarter of 2025, subject to FDA authorization. The length of the temporary UDENYCA supply interruption will depend on the number of future manufacturing slots scheduled by the CMOs and whether future manufacturing slots are successfully completed on schedule or at all. Although we believe that the steps that we have taken will help to lessen the impact of the temporary UDENYCA supply interruption, this manufacturing depends on third parties and we cannot make any assurances about the timing of the resolution of the issue.These factors could cause us to incur additional costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential revenue. The structure of complex proteins used in protein-based therapeutics is inherently variable and highly dependent on the processes and conditions used to manufacture them. If we are unable to develop manufacturing processes that achieve a requisite degree of biosimilarity to the originator drug, and within a range of variability considered acceptable by regulatory authorities, we may not be able to obtain regulatory approval for any biosimilar product candidate. Protein-based therapeutics are inherently heterogeneous and their structures are highly dependent on the production process and conditions. Products from one production facility can differ within an acceptable range from those produced in another facility. Similarly, physicochemical differences can also exist among different lots produced within a single facility. The physicochemical complexity and size of biologic therapeutics create significant technical and scientific challenges in the context of their replication as biosimilar products. The inherent variability in protein structure from one production lot to another is a fundamental consideration with respect to establishing biosimilarity to an originator product to support regulatory approval requirements. For example, the glycosylation of the protein, meaning the manner in which sugar molecules are attached to the protein 76 Table of Contentsbackbone of a therapeutic protein when it is produced in a living cell, is critical to therapeutic efficacy, half-life, efficacy and even safety of the therapeutic and is therefore a key consideration for biosimilarity. Defining and understanding the variability of an originator molecule in order to match its glycosylation profile requires significant skill in cell biology, protein purification and analytical protein chemistry. Furthermore, manufacturing proteins with reliable and consistent glycosylation profiles at scale is challenging and highly dependent on the skill of the cell biologist and process scientist. There are extraordinary technical challenges in developing complex protein-based therapeutics that not only must achieve an acceptable degree of similarity to the originator molecule in terms of characteristics such as the unique glycosylation pattern, but also the ability to develop manufacturing processes that can replicate the necessary structural characteristics within an acceptable range of variability sufficient to satisfy regulatory authorities. Given the challenges caused by the inherent variability in protein production, we may not be successful in developing any biosimilar product candidates if regulators conclude that we have not achieved a sufficient level of biosimilarity to the originator product, or that the processes we use are unable to generate our products within an acceptable range of variability. Risks Related to Adverse Events Our products or our product candidates may cause undesirable side effects or have other properties that could, as applicable, delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if granted. As with most pharmaceutical products, use of our products or our product candidates could be associated with side effects or adverse events, which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our product candidates may be observed at any time, including in clinical trials or when a product is commercialized. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our studies could reveal a high and unacceptable severity and prevalence of side effects such as toxicity or other safety issues and could require us or our collaboration partners to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits, which will harm our business. In such an event, we may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our product candidates, which we have not planned or anticipated or our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications. There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any other regulatory agency in a timely manner, if ever, which could harm our business, prospects and financial condition. Additionally, product quality characteristics have been shown to be sensitive to changes in process conditions, manufacturing techniques, equipment or sites and other such related considerations, hence any manufacturing process changes we implement prior to or after regulatory approval could impact product safety and efficacy. Drug-related side effects could affect patient recruitment for clinical trials, the ability of enrolled patients to complete our studies or result in potential product liability claims. We currently carry product liability insurance and we are required to maintain product liability insurance pursuant to certain of our license agreements. We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of managementâ€™s attention from our primary business, initiation of investigations by regulators, substantial monetary 77 Table of Contentsawards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to: â—regulatory authorities may withdraw approvals of such product; â—regulatory authorities may require additional warnings on the label; â—we may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers or other elements to assure safe use; â—we could be sued and held liable for harm caused to patients; and â—our reputation may suffer. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. If we receive approval for our product candidates, regulatory agencies including the FDA and foreign regulatory agencies, regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or foreign regulatory agencies could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or extended delay in approval or clearance of future products. Adverse events involving an originator product, other biosimilars of such originator product or other anti-PD-1 or PD-L1 antibody product may negatively affect our business. In the event that use of an originator product, other biosimilar for such originator product, or anti-PD-1 or PD-L1 antibody product results in unanticipated side effects or other adverse events, it is likely that our product will be viewed comparably and may become subject to the same scrutiny and regulatory sanctions as the originator product, other biosimilar, or other anti-PD-1 or PD-L1 antibody product, as applicable. Accordingly, we may become subject to regulatory supervisions, clinical holds, product recalls or other regulatory actions for matters outside of our control that affect the originator product, other biosimilar, or other anti-PD-1 or PD-L1 antibody product, as applicable, if and until we are able to demonstrate to the satisfaction of our regulators that our product is not subject to the same issues leading to the regulatory action as the originator product or other biosimilar, or other anti-PD-1 or PD-L1 antibody product, as applicable. Risks Related to Intellectual Property If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. Our commercial success depends in large part on avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the pharmaceutical industry, including patent infringement lawsuits, interferences, oppositions and 78 Table of Contentsreexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties. The company that originated the product for which we introduced a biosimilar version, such as Amgen, as well as other competitors (including other companies developing biosimilars) have developed, and are continuing to develop, worldwide patent portfolios of varying sizes and breadth, many of which are in fields relating to our business, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. Third parties may assert that we are employing their proprietary technology without authorization. We are aware of third-party patents or patent applications with claims, for example, to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. While we have conducted freedom to operate analyses with respect to our products and our product candidates, including our in-licensed biosimilar candidates, as well as our pipeline candidates, we cannot guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents covering our product candidates. With respect to products we are evaluating for inclusion in our future product pipeline, our freedom to operate analyses, including our research on the timing of potentially relevant patent expirations, are ongoing. There may also be patent applications that have been filed but not published and if such applications issue as patents, they could be asserted against us. For example, in most cases, a patent filed today would not become known to industry participants for at least 18 months given patent rules applicable in most jurisdictions, which do not require publication of patent applications until 18 months after filing. Moreover, some United States patents may issue without any prior publication in cases where the patent applicant does not also make a foreign filing. We may also face claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. In addition, coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving that a patent is invalid or unenforceable is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Also, in proceedings before courts in Europe, the burden of proving invalidity of the patent usually rests on the party alleging invalidity. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. Third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial monetary damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on commercially acceptable terms or at all. If, as a result of patent infringement claims or to avoid potential claims, we choose or are required to seek licenses from third parties, these licenses may not be available on acceptable terms or at all. Even if we are able to obtain a license, the license may obligate us to pay substantial license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Parties making claims against us may obtain injunctive or 79 Table of Contentsother equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would likely involve substantial litigation expense and would likely be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may, in addition to being blocked from the market, have to pay substantial monetary damages, including treble damages and attorneysâ€™ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. In addition to infringement claims against us, we may become a party to

other patent litigation and other proceedings, including interference, IPR, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. An unfavorable outcome in any such proceeding could require us to cease using the related technology or to attempt to license rights to it from the prevailing party or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights. Third parties may submit applications for patent term extensions in the United States or other jurisdictions where similar extensions are available or Supplementary Protection Certificates in the E.U. states and Switzerland seeking to extend certain patent protection, which, if approved, may interfere with or delay the launch of one or more of our products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Patent litigation and other proceedings may fail, and even if successful, may result in substantial costs and distract our management and other employees. The companies that originated the products for which we intend to introduce biosimilar versions, as well as other competitors (including other biosimilar companies) may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. We do not know whether any of our pending patent applications will result in the issuance of any patents or whether the rights granted under any patents issuing from these applications will prevent any of our competitors from marketing similar products that may be competitive with our own. Moreover, even if we do obtain issued patents, they will not guarantee us the right to use our patented technology for commercialization of our product candidates. Third parties may have blocking patents that could prevent us from commercializing our own products, even if our products use or embody our own, patented inventions.The validity and enforceability of patents are generally uncertain and involve complex legal and factual questions. Any patents that may be issued on our pending applications may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing products similar to ours. Furthermore, our competitors may develop similar or alternative technologies not covered by any patents that may issue to us.For technologies for which we do not seek patent protection, we may rely on trade secrets to protect our proprietary position. However, trade secrets are difficult to protect. We seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants, advisors, contractors or collaborators. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these 80 Table of Contentsindividuals, organizations and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, advisors, contractors and collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.We may be involved in lawsuits or IPR proceedings to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. We may discover that competitors are infringing our issued patents. Expensive and time-consuming litigation may be required to abate such infringement. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including but not limited to lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone involved in the prosecution of the patent withheld relevant or material information related to the patentability of the invention from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if we cannot obtain a license from the prevailing party on commercially reasonable terms. Third parties may request an IPR of our patents in the USPTO. An unfavorable decision may result in the revocation of our patent or a limitation to the scope of the claims of our patents. Our defense of litigation, interference or IPR proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development partnerships that would help us bring our product candidates to market.Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during any litigation we initiate to enforce our patents. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.We employ individuals, retain independent contractors and consultants and members on our board of directors or scientific advisory board who were previously employed at universities or other pharmaceutical companies, including our competitors or potential competitors. For example, our Chief Executive Officer, DennisÃ M. Lanfear is a former employee of Amgen. Mr.Â Lanfear was employed at Amgen during periods when Amgenâ€™s operations included the development and commercialization of Neulasta. Senior members of our commercial team and medical affairs team who were responsible for the launch of additional presentations of UDENYCA formerly held positions at Amgen. Our board of directors and scientific advisory board include members who were former employees of Amgen and Abbott Laboratories. Although we have procedures in place to try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed intellectual property, including trade 81 Table of Contentssecrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. On March 3, 2017, Amgen filed an action against us, KBI Biopharma, our employee Howard S. Weiser and Does 1-20 in the Superior Court of the State of California, County of Ventura. The complaint, which was amended, alleged that we engaged in unfair competition and improperly solicited and hired certain former Amgen employees in order to acquire and access trade secrets and other confidential information belonging to Amgen. The complaint, as amended, sought injunctive relief and monetary damages. On May 2, 2019, we and Amgen settled the trade secret action brought by Amgen. The details of the settlement are confidential but we will continue to market UDENYCA and began paying a mid-single digit royalty to Amgen for five years starting on July 1, 2019 until July 1, 2024.If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. We are a party to certain non-exclusive intellectual property license agreements with certain vendors that are important to our business, and we expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements or we are subject to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the license or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our product candidates. In the event we breach any of our obligations related to such agreements, we may incur significant liability to our licensing partners. Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to: â—the scope of rights granted under the license agreement and other interpretation-related issues; â—the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; â—the sublicensing of patents and other rights; â—our diligence obligations under the license agreement and what activities satisfy those diligence obligations; â—the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and â—the priority of invention of patented technology. If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and that could have a material adverse effect on our business. We may not be successful in obtaining or maintaining necessary rights to our products and product candidates through acquisitions and in-licenses. We currently have rights to certain intellectual property, through licenses from third parties and under patent applications that we own, to develop and commercialize our products and product candidates. Because we may find that our programs require the use of proprietary rights held by third parties, the growth of our business may depend in part 82 Table of Contentson our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. We may also get into disputes or litigation with third parties from whom we license intellectual property rights necessary for the sale of our products.If we are unable to successfully obtain required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer. Our ability to market our biosimilar products in the United States may be significantly delayed or prevented by the BPCIA patent dispute resolution mechanism. The BPCIA created an elaborate and complex patent dispute resolution mechanism for biosimilars that, if we choose to implement it, could prevent us from launching our product candidates in the United States or could substantially delay such launches. However, even if we elect not to implement this mechanism, the launch of our products in the United States could still be prevented or substantially delayed by intellectual property disputes with originator companies that market the reference products on which our biosimilar products are based.The BPCIA establishes a patent disclosure and briefing process between the biosimilar applicant and the originator that is demanding and time-sensitive. While certain aspects of this process are still being tested in the federal courts, the United States Supreme Court, as discussed further below, ruled in 2017 that this process is not mandatory, such that a biosimilar applicant may elect to engage in this process, but is not required to do so. The following is an overview of the patent exchange and patent briefing procedures established by the BPCIA for biosimilar applicants that elect to employ them: 1.Disclosure of the Biosimilar Application. Within 20 days after the FDA publishes a notice that its application has been accepted for review, a Section 351(k) biosimilar applicant may elect to provide a copy of its application to the originator if it chooses to engage in the BPCIA patent exchange mechanism. 2.Identification of Pertinent Patents. Within 60 days of the date of receipt of the application the originator must identify patents owned or controlled by the originator, which it believes could be asserted against the biosimilar applicant. 3.Statement by the Biosimilar Applicant. Following the receipt of the originatorâ€™s patent list, the biosimilar applicant must state either that it will not market its product until the relevant patents have expired or alternatively provide its arguments that the patents are invalid, unenforceable or would not be infringed by the proposed biosimilar product candidate. The biosimilar applicant may also provide the originator with a list of patents it believes the brand-name firm could assert against the reference product. 4.Statement by the Originator. In the event the biosimilar applicant has asserted that the patents are invalid, unenforceable or would not be infringed by the proposed follow-on product, the originator must provide the biosimilar applicant with a response within 60 days. The response must provide the legal and factual basis of the opinion that such patent will be infringed by the commercial marketing of the proposed biosimilar. 5.Patent Resolution Negotiations. If the originator provides its detailed views that the proposed biosimilar would infringe valid and enforceable patents, then the parties are required to engage in good faith negotiations to identify which of the discussed patents will be the subject of a patent infringement action. If the parties agree on the patents to be litigated, the brand-name firm must bring an action for patent 83 Table of Contentsinfringement within 30 days. 6.Simultaneous Exchange of Patents. If those negotiations do not result in an agreement within 15 days, then the biosimilar applicant must notify the originator of how many patents (but not the identity of those patents) that it wishes to litigate. Within five days, the parties are then required to exchange lists identifying the patents to be litigated. The number of patents identified by the originator may not exceed the number provided by the biosimilar applicant. However, if the biosimilar applicant previously indicated that no patents should be litigated, then the originator may identify one patent. 7.Commencement of Patent Litigation. The originator must then commence patent infringement litigation within 30 days. That litigation will involve all of the patents on the originatorâ€™s list and all of the patents on the follow-on applicantâ€™s list. The follow-on applicant must then notify the FDA of the litigation. The FDA must then publish a notice of the litigation in the Federal Register. 8.Notice of Commercial Marketing. The BPCIA requires the biosimilar applicant to provide notice to the originator 180 days in advance of its first commercial marketing of its proposed follow-on biologic. The originator is allowed to seek a preliminary injunction blocking such marketing based upon any patents that either party had preliminarily identified but were not subject to the initial phase of patent litigation. The litigants are required to â€œreasonably cooperate to expedite such further discovery as is neededâ€ with respect to the preliminary injunction motion. The federal courts have not yet settled the issue as to when, or under what circumstances, the biosimilar applicant must provide the 180-day notice of commercial marketing provided in the BPCIA.On June 12, 2017, the Supreme Court issued its decision in Amgen v. Sandoz, holding that (i) the â€œpatent danceâ€ is optional; and (ii) the 180-day pre-marketing notification may be given either before or after receiving FDA approval of the biosimilar product. The Supreme Court declined to rule whether a state injunctive remedy may be available to the originator and remanded that question to the Federal Circuit for further consideration. On December 14, 2017, the Federal Circuit decided that state law claims are preempted by the BPCIA on both field and conflict grounds. A significant legal risk for a biosimilar applicant that pursues regulatory approval under the Section 351(k) regulatory approval route and also elects to engage in the above-described BPCIA patent exchange mechanism, is that the process could result in the initiation of patent infringement litigation prior to FDA approval of a Section 351(k) application, and such litigation could result in blocking the market entry of the biosimilar product. However, even if biosimilar applicants opt out of the BPCIA patent exchange process, originators will still have the right to assert patent infringement as a basis to enjoin a biosimilar product launch. Thus, whether or not we engage in the BPCIA patent exchange process, there is risk that patent infringement litigation initiated by originators could prevent us indefinitely from launching any biosimilar product.The legal and strategic considerations weighing for or against a decision to voluntarily engage in the BPCIA patent exchange process are complex and will differ on a product-by-product basis. If we decide to engage in the BPCIA patent exchange process, preparing for and conducting the patent exchange, briefing and negotiation process outlined above will require extraordinarily sophisticated legal counseling and extensive planning, all under extremely tight deadlines. Moreover, it may be difficult for us to secure or retain such legal support if large, well-funded originators have already entered into engagements with highly qualified law firms or if the most highly qualified law firms choose not to represent biosimilar applicants due to their long-standing relationships with originators. Under the complex, and uncertain rules of the BPCIA patent provisions, coupled with the inherent uncertainty surrounding the legal interpretation of any originator patents that might be asserted against us in this new process, we see substantial risk that the BPCIA process may significantly delay or defeat our ability to market our biosimilar product in the United States, or may result in us incurring substantial legal settlement costs. 84 Table of ContentsRisks Related to the Discovery and Development of Our Product Candidates We are heavily dependent on the development, clinical success, regulatory approval and commercial success of our product candidates. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. We invest substantial efforts and financial resources to

identify, acquire and develop our product candidates. Our future success is dependent on our ability to develop, obtain regulatory approval for, and then commercialize and obtain adequate third-party coverage and reimbursement for one or more of our product candidates. We currently have two approved products: UDENYCA and LOQTORZI.â€‹Our product candidates are in varying stages of development and will require additional clinical development, management of nonclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supplies, commercial organization and significant marketing efforts before we generate any revenue from product sales. Other than certain pharmacokinetic bridging studies, we have not initiated phase 3 clinical trials for other product candidates in our pipeline. It may be some time before we file for market approval with the relevant regulatory agencies for these product candidates.We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we and our existing or future collaboration partners do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. We, together with our collaboration partners, generally plan to seek regulatory approval to commercialize our product candidates in the United States, the E.U., and additional foreign countries where we or our partners have commercial rights. To obtain regulatory approval, we and our collaboration partners must comply with numerous and varying regulatory requirements of such countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, and pricing and distribution of our product candidates. Even if we and our collaboration partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we and our collaboration partners are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected. The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and the regulatory approval requirements for biosimilars are evolving. If we and our collaboration partners are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, marketing, distribution, post-approval monitoring and reporting and export and import of biologic and biosimilar products are subject to extensive regulation by the FDA and other regulatory authorities in the United States, by the EMA and EEA Competent Authorities in the European Economic Area (â€œEEAâ€), and by other regulatory authorities in other countries, where regulations differ from country to country. Neither we nor any existing or future collaboration partners are permitted to market our product candidates in the United States until we and our collaboration partners receive approval from the FDA, or in the EEA until we and our collaboration partners receive EC or EEA Competent Authority approvals. The time required to develop new products or obtain approval for new products by the FDA and comparable foreign authorities is unpredictable, may take many years following the completion of clinical studies and depends upon numerous factors. Further, applications to the Human Genetic Resources Administration of China (HGRAC) required for any activities, including development activities and data sharing with our partners in China, may result in product development delays. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain 85 Table of Contentsapproval may change during the course of a product candidateâ€™s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Neither we nor any collaboration partner has obtained regulatory approval for any of our products and product candidates, other than UDENYCA, which has received approval from the FDA and EMA, and LOQTORZI, which has received approval from the FDA and is also approved for use in China, and it is possible that none of our other current or future product candidates will ever obtain additional regulatory approvals.Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: â—the data collected from clinical studies of our product candidates may not be sufficient to support the submission of an original BLA, an NDA, a Section 351(k) BLA, a biosimilar marketing authorization under Article 6 of Regulation (EC) No.Â 726/2004 or Article 10(4) of Directive 2001/83/EC in the EEA or other submission or to obtain regulatory approval in the United States, the EEA or elsewhere; â—the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies; â—the FDA may determine that the population studied in the clinical program may not be sufficiently broad or representative to assure safety and efficacy in the full population for which we seek approval, or that conclusions of clinical trials conducted in a single country or region outside the United States may not be generalizable to the patient population in the United States; â—the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from analytical and bioanalytical studies, nonclinical studies or clinical studies; â—we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidateâ€™s risk-benefit ratio for its proposed indication is acceptable; â—the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of our collaborators or third-party manufacturers with which we contract for clinical and commercial supplies; and â—the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. This approval process, as well as the unpredictability of the results of clinical studies, may result in our failure to obtain regulatory approval to market any of our product candidates, which would significantly harm our business. Any delays in the commencement or completion of clinical testing could significantly impact our product development costs and could result in the need for additional financing.Clinical drug development involves a lengthy and expensive process and we may encounter substantial delays in our clinical studies or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we or our collaboration partners, or both, as the case may be, must conduct clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent registration clinical studies. There is a high failure rate for product candidates proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having 86 Table of Contentsprogressed through preclinical studies and initial clinical studies. AÂ number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Nonclinical and clinical data are also often susceptible to varying interpretations and analyses. We do not know whether any clinical studies we may conduct for our product candidates will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval. Furthermore, biosimilar clinical studies must use originator products as comparators, and such supplies may not be available on a timely basis to support such trials.We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include but are not limited to: â—inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical studies; â—delays in reaching a consensus with regulatory agencies on study design; â—delays in reaching agreement on acceptable terms with prospective CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; â—delays in obtaining required institutional review board (â€œIRBâ€) approval at each clinical study site; â—imposition of a clinical hold by regulatory agencies, after review of an IND or amendment or equivalent application or amendment, or an inspection of our clinical study operations or study sites or as a result of adverse events reported during a clinical trial; â—delays in recruiting suitable patients to participate in our clinical studies sponsored by us or our partners; â—difficulty collaborating with patient groups and investigators; â—failure by our CROs, other third parties or us to adhere to clinical study requirements; â—failure to perform in accordance with the FDAâ€™s good clinical practices requirements or applicable regulatory guidelines in other countries; â—delays in patients completing participation in a study or return for post-treatment follow-up, or patients dropping out of a study; â—occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; â—changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; â—the cost of clinical studies of our product candidates being greater than we anticipate; â—clinical studies of our product candidates producing negative or inconclusive results, which may result in us deciding or regulators requiring us to conduct additional clinical studies or abandon product development programs; and â—delays in manufacturing, testing, releasing, validating, importing, exporting or distributing sufficient stable quantities of our product candidates and originator products for use in clinical studies or the inability to do any of the foregoing. 87 Table of ContentsAny inability to successfully complete nonclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials will depend, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trialâ€™s conclusion as required by the FDA or other comparable regulatory authorities. Some of the conditions for which we may plan to evaluate our product candidates are rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.Patient enrollment in clinical trials may be affected by other factors, including:â—size and nature of the targeted patient population; â—severity of the disease or condition under investigation; â—availability and efficacy of approved therapies for the disease or condition under investigation;â—patient eligibility criteria for the trial in question as defined in the protocol;â—perceived risks and benefits of the product candidate under study;â—cliniciansâ€™ and patientsâ€™ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any products that may be approved for, or any product candidates under investigation for, the indications we are investigating;â—efforts to facilitate timely enrollment in clinical trials;â—patient referral practices of physicians;â—the ability to monitor patients adequately during and after treatment;â—proximity and availability of clinical trial sites for prospective patients;â—continued enrollment of prospective patients by clinical trial sites; andâ—the risk that patients enrolled in clinical trials will drop out of such trials before completion.â€‹Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll any clinical trials. We also rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain regulatory approval for the sale of our product candidates.88 Table of ContentsThe development, manufacture and commercialization of biosimilar products under various global regulatory pathways pose unique risks. We and our collaboration partners intend to pursue market authorization globally. In the United States, an abbreviated pathway for approval of biosimilar products was established by the BPCIA, enacted on MarchÂ 23, 2010, as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the â€œACAâ€). The BPCIA established this abbreviated pathway under Section 351(k) of the PHSA. Subsequent to the enactment of the BPCIA, the FDA issued guidance documents regarding the demonstration of biosimilarity and interchangeability as well as the submission and review of biosimilar applications. Moreover, market acceptance of biosimilar products in the United States is unclear. Numerous states are considering or have already enacted laws that regulate or restrict the substitution by state pharmacies of biosimilars for originator products already licensed by the FDA. Market success of biosimilar products will depend on demonstrating to patients, physicians, payers and relevant authorities that such products are similar in quality, safety and efficacy as compared to the reference product. We will continue to analyze and incorporate into our biosimilar development plans any final regulations issued by the FDA, pharmacy substitution policies enacted by state governments and other applicable requirements established by relevant authorities. The costs of development and approval will be dependent upon the application of any laws and regulations issued by the relevant regulatory authorities. Biosimilar products may also be subject to extensive originator-controlled patent portfolios and patent infringement litigation, which may delay and could prevent the commercial launch of a product. Moreover, the BPCIA prohibits the FDA from accepting an application for a biosimilar candidate to a reference product within four years of the reference productâ€™s licensure by the FDA. In addition, the BPCIA provides innovative biologics with 12Â years of exclusivity from the date of their licensure, during which time the FDA cannot approve any application for a biosimilar candidate to the reference product. Under current E.U. regulations, an application for regulatory approval of a biosimilar drug cannot be submitted in the E.U. until expiration of an eight-year data exclusivity period for the reference (originator) product, measured from the date of the reference productâ€™s initial marketing authorization. Furthermore, once approved, the biosimilar cannot be marketed until expiration of a ten-year period following the initial marketing authorization of the reference product, such ten-year period being extendible to 11 years if the reference product received approval of an additional therapeutic indication, within the first eight years following its initial marketing authorization, representing a significant clinical benefit in comparison with existing therapies. In Europe, the approval of a biosimilar for marketing is based on an opinion issued by the EMA and a decision issued by the EC. Therefore, the marketing approval will cover the entire EEA. However, substitution of a biosimilar for the originator is a decision that is made at the national level. Additionally, a number of countries do not permit the automatic substitution of biosimilars for the originator product. Therefore, even if we obtain marketing approval for the entire EEA, we may not receive substitution in one or more European nations, thereby restricting our ability to market our products in those jurisdictions. Other regions, including Canada, Japan and South Korea, also have their own legislation outlining a regulatory pathway for the approval of biosimilars. In some cases, other countries have either adopted European guidance (Singapore and Malaysia) or are following guidance issued by the World Health Organization (Cuba and Brazil). While there is overlap in the regulatory requirements across regions, there are also some areas of non-overlap. Additionally, we cannot predict whether countries that we may wish to market in which do not yet have an established or tested regulatory framework could decide to issue regulations or guidance or adopt a more conservative viewpoint than other regions. Therefore, it is possible that even if we obtain agreement from one health authority to an accelerated or optimized development plan, we will need to defer to the most conservative view to ensure global harmonization of the development plan. Also, for regions where regulatory authorities do not yet have sufficient experience in the review and approval of a biosimilar product, these authorities may rely on the approval from another region (e.g., the United States 89 Table of Contentsor the E.U.), which could delay our approval in that region. Finally, it is possible that some countries will not approve a biosimilar without clinical data from their population or may require that the biosimilar product be manufactured within their region, or some countries may require both. If other biosimilars of pegfilgrastim (Neulasta) are determined to be interchangeable and our biosimilar product is not, our business could suffer. The FDA or other relevant regulatory authorities may determine that a proposed biosimilar product is â€œinterchangeableâ€ with a reference product, meaning that the biosimilar product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, if the application includes sufficient information to show that the product is biosimilar to the reference product and that it can be expected to produce the same clinical result as the reference product in any given patient. If the biosimilar product may be administered more than once to a patient, the applicant must demonstrate that the risk in terms of safety or diminished efficacy of alternating or switching between the biosimilar product and the reference product is not greater than the risk of using the reference product without such alternation or switch. To make a final determination of interchangeability, regulatory authorities may require additional confirmatory information beyond what we plan to initially submit in our applications for approval, such as more in-depth analytical characterization, animal testing or further clinical studies. Provision of sufficient information for approval may prove difficult and expensive. We cannot predict whether any of our biosimilar products and product candidates will meet regulatory authority requirements for approval not only as a biosimilar product but also as an interchangeable product in any jurisdiction. Furthermore, legislation governing interchangeability could differ by jurisdiction on a state or national level worldwide. For example, recent U.S. legislative proposals have sought to reduce or altogether eliminate the statutory and regulatory distinctions between interchangeable products and conventional biosimilars. Such efforts, if successful, could reduce or eliminate any competitive or regulatory advantages currently afforded to interchangeable products. Â The labelling of â€œinterchangeabilityâ€ is important because, in the United States for example, the first biosimilar determined to be interchangeable with a particular reference, or originator, product for any condition of use is eligible for a period of market exclusivity that delays an FDA determination that a second or subsequent biosimilar product is interchangeable with that originator product for any condition of use until the earlier of: (1)Â one year after the first commercial marketing of the first interchangeable product; (2)Â 18 months after resolution of a patent infringement suit instituted under 42 U.S.C. Â§ 262(l)(6)

against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; (3)Â 42 months after approval of the first interchangeable product, if a patent infringement suit instituted under 42 U.S.C. Â§ 262(l)(6) against the applicant that submitted the application for the first interchangeable product is still ongoing; or (4)Â 18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued under 42Â U.S.C.Â Â§Â 262(l)(6). Thus, a determination that another companyâ€™s product is interchangeable with the originator biologic before we obtain approval of our corresponding biosimilar product candidates may delay the potential determination that our products are interchangeable with the originator product, which could materially adversely affect our results of operations and delay, prevent or limit our ability to generate revenue. Failure to obtain regulatory approval in any targeted regulatory jurisdiction would prevent us from marketing our products to a larger patient population and reduce our commercial opportunities.We are marketing LOQTORZI and UDENYCA in the United States, and subject to product approvals and relevant patent and settlement agreement expirations, we intend to market our other products in the United States and outside the United States on our own or with future collaboration partners. We entered into a distribution agreement with our licensee Orox / Laboratorio Gador S.A. for the commercialization of a biosimilar version of pegfilgrastim (Neulasta) in certain Caribbean and Latin American countries. We intend to market our products in the United States and may seek to partner commercially all products outside the United States, such as our Canada License Agreement with Apotex in Canada for LOQTORZI. 90 Table of ContentsIn order to market our products in the E.U., the United States and other jurisdictions, we and our collaboration partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The EMA is responsible for the centralized procedure for the regulation and approval of human medicines. This procedure results in a single marketing authorization that is valid in all E.U. countries, as well as in Iceland, Liechtenstein and Norway. The time required to obtain approval abroad may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and we may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. We or our collaboration partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. Failure to obtain these approvals would materially and adversely affect our business, financial condition and results of operations. We may not be successful in our efforts to identify, develop or commercialize additional product candidates. Although a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of our existing product candidates, the success of our business also depends upon our ability to identify, develop and commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our development efforts may fail to yield additional product candidates suitable for clinical development and commercialization for a number of reasons, including but not limited to the following: â—we may not be successful in identifying potential product candidates that pass our strict screening criteria; â—we may not be able to overcome technological hurdles to development or a product candidate may not be capable of producing commercial quantities at an acceptable cost or at all; â—we may not be able to assemble sufficient resources to acquire or discover additional product candidates; â—our product candidates may not succeed in nonclinical or clinical testing; and â—competitors may develop alternatives that render our product candidates obsolete or less attractive or the market for a product candidate may change such that a product candidate may not justify further development. If any of these events occur, we may be forced to abandon our development efforts for a program or programs or we may not be able to identify, develop or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.Risks Related to Our Compliance with Applicable Laws Healthcare reform measures, including the IRA, may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations. In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA, was passed, which substantially changed the way health care is financed by both governmental and private insurers and has impacted and continues to impact the United States pharmaceutical industry. The ACA, among other things, modified the average manufacturer price (â€œAMPâ€) definition under the Medicaid Drug Rebate Program (â€œMDRPâ€) for drugs that are inhaled, infused, instilled, implanted or injected and not generally distributed through the retail channel; expanded rebate payments under the MDRP to include utilization by individuals enrolled in Medicaid managed care organizations; added a provision to increase the Medicaid rebate for line extension drugs; established annual fees and taxes on manufacturers of certain branded prescription drugs; expanded the entities 91 Table of Contentseligible for discounts under the Public Health Service 340B drug pricing program; and established the Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturerâ€™s outpatient drugs to be covered under Medicare Part D.Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the United States Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include the American Rescue Plan Act of 2021, which eliminated the statutory cap on the Medicaid drug rebate beginning January 1, 2024. The rebate was previously capped at 100% of a drugâ€™s AMP.Most significantly, on August 16, 2022, the IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, the impact of the IRA on our business and the pharmaceutical industry cannot yet be fully determined. If a product becomes subject to the IRA negotiation provision and related price cap, that may significantly alter the economic rationale for developing and commercializing a biosimilar. Additionally, in response to the Biden administrationâ€™s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.The cost of prescription pharmaceuticals in the United States is likely to remain the subject of considerable discussion. There have been several Congressional inquiries and proposed and enacted legislation designed to, among other things, reform government program reimbursement methodologies. The likelihood of implementation of these and other reform initiatives is uncertain. In the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates. We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. Individual states in the United States have also proposed and enacted legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and other transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures, such as a single reimbursement code for biosimilar products.We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar 92 Table of Contentsreduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.In the E.U., similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the E.U. or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the E.U., including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than E.U., law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most E.U. member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing E.U. and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and E.U., reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.We may be subject, directly or indirectly, to federal and state healthcare laws, including fraud and abuse, false claims and physician payment transparency laws. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties. Our operations are directly or indirectly through our customers subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These laws impact, among other things, sales, marketing and education programs. The laws that may affect our ability to operate include: â—the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or in return for the purchase, recommendation, order or furnishing of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; â—federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented claims for payment from Medicare, Medicaid or other third-party payers that are false or fraudulent and which may apply to entities that provide coding and billing advice to customers. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; â—federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiaryâ€™s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;â—HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;93 Table of Contentsâ—federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;â—the federal physician â€œsunshineâ€ requirements under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for MedicareÂ & Medicaid Services information related to payments and other transfers of value made by such manufacturers to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors, and certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives)), and teaching hospitals and ownership and investment interests held by physicians and their immediate family members; and â—state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. Efforts to ensure that our operations and business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.We participate in governmental programs that impose drug price reporting, payment, and other compliance obligations on pharmaceutical manufacturers. Medicaid is a joint federal and state program for low-income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Medicare Part B reimburses physicians who administer our products. Under the MDRP, as a condition of having federal funds available for our covered outpatient drugs under Medicaid and under Medicare Part B, we must enter into, and have entered into, an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of our covered outpatient drugs dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid rebates are based on pricing data that we are required to report on a monthly and quarterly basis to CMS, the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the AMP for each drug and, in the case of innovator products, the Best Price, which represents the lowest price available from us to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity in the United States in any pricing structure, calculated to include 94 Table of Contentsall applicable sales and associated rebates, discounts and other price concessions. In connection with Medicare Part B, we must provide CMS with ASP information on a quarterly basis. CMS uses this information to compute Medicare Part B payment rates, which consist of ASP plus a specified percentage. If we become aware that our MDRP submissions for a prior period were incorrect or have changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. Pursuant to the IRA, the AMP and ASP figures we report will also be used to compute rebates under Medicare Part D and Medicare Part B triggered by price increases that outpace inflation. If we fail to provide information timely or are found to have knowingly submitted false information to CMS, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.Federal law requires that any company that participates in the MDRP also participate in the Public Health Serviceâ€™s 340B drug pricing program in order for federal funds to be available for the manufacturerâ€™s drugs under Medicaid and Medicare Part B. The 340B program is administered by the HRSA and requires us to agree to charge statutorily defined covered entities no more than the 340B â€œceiling priceâ€ for our covered drugs when used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general,

products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges.In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, a pharmaceutical manufacturer must also participate in VA FSS pricing program. Under the VA FSS program, we must report the Non-Federal Average Manufacturer Price (â€œNon-FAMPâ€ for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers for the untimely, inaccurate, or incomplete reporting of drug pricing information or for otherwise failing to comply with drug price transparency requirements. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts, which can change and evolve over time. Such pricing calculations and reporting, along with any necessary restatements and recalculations, could increase costs for complying with the laws and regulations governing the MDRP and other governmental programs, and under the MDRP could result in an overage or underage in Medicaid rebate liability for past quarters. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary 95 Table of Contentspenalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of ASP, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot make any assurances that our submissions will not be found by CMS or other governmental agencies to be incomplete or incorrect.Risks Related to Ownership of Our Common Stock The market price of our common stock may be highly volatile, and purchasers of our common stock could incur substantial losses. The market price of our common stock has been highly volatile since our Initial Public Offering (â€œIPOâ€) and the intraday sales price per share has ranged from $0.97 to $38.10 per share during the period from November 6, 2014 through September 30, 2024 and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in the â€œRisk Factorsâ€ section of this Quarterly Report on Form 10-Q and others such as: â—adverse results or delays in preclinical or clinical studies; â—the risk of deterioration in our financial conditions, such as reduced collection of cash and increased costs in the future;â—any inability to obtain additional funding; â—any delay in filing an IND, NDA, BLA, Section 351(k) BLA or other regulatory submission for any of our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory agencyâ€™s review of that IND, NDA, BLA, Section 351(k) BLA or other regulatory submission; â—the perception of limited market sizes or pricing for our products and product candidates; â—failure to successfully develop and commercialize our product candidates; â—post-marketing safety issues relating to our product candidates or biosimilars generally; â—failure to maintain our existing strategic collaborations or enter into new collaborations; â—failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights; â—changes in laws or regulations applicable to our products; â—future outbreaks of COVID-19 and other viral pandemics;â—any inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; â—adverse regulatory decisions; â—introduction of new products, services or technologies by our competitors; â—failure to meet or exceed financial projections we may provide to the public; â—failure to meet or exceed the financial projections of the investment community; â—the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; 96 Table of Contentsâ—announcements of significant acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors; â—disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; â—additions or departures of key scientific or management personnel; â—lawsuits, including but not limited to complaints initiated by stockholders, customers and collaboration partners, and litigation filed by us or filed against us pertaining to patent infringement or other violations of intellectual property rights; â—the outcomes of any citizen petitions filed by parties seeking to restrict or limit the approval of biosimilar products; â—if securities or industry analysts do not publish research or reports about our business or if they issue an adverse or misleading opinion regarding our stock; â—changes in the market valuations of similar companies; â—general market or macroeconomic conditions, including rising interest rates and inflation; â—sales of our common stock by us or our stockholders in the future; â—trading volume of our common stock; â—issuance of patents to third parties that could prevent our ability to commercialize our product candidates; â—reductions in the prices of originator products that could reduce the overall market opportunity for our products that are biosimilars to such originator products; and â—changes in biosimilar regulatory requirements that could make it more difficult for us to develop our product candidates. In addition, biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.As of September 30, 2024, our executive officers, directors, five percent stockholders and their affiliates beneficially owned approximately 32.4% of our voting stock (assuming no exercise of outstanding options or conversion of our outstanding convertible notes). These stockholders have the ability to influence us through their ownership positions, which may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. Our indebtedness could adversely affect our financial condition, our ability to raise additional capital to fund our operations, our ability to operate our business, our ability to react to changes in the economy or our industry and our ability to pay our debts and could divert our cash flow from operations for debt payments.Our leverage and debt service obligations could adversely impact our business, including by:â—impairing our ability to generate cash sufficient to pay interest or principal, including periodic principal payments;â—increasing our vulnerability to general adverse economic and industry conditions;97 Table of Contentsâ—increasing our need to meet minimum net sales requirements when our future sales are uncertain;â—requiring the dedication of a portion of our cash flow from operations to service our debt, thereby reducing the amount of our cash flow available for other purposes, including funds for clinical development or to pursue future business opportunities;â—requiring us to sell debt or equity securities or to sell some of our core assets, possibly on unfavorable terms, to meet payment obligations;â—limiting our flexibility in planning for, or reacting to, changes in our business and the industries in which we compete; andâ—placing us at a possible competitive disadvantage with less leveraged competitors and competitors that may have better access to capital resources.Any of the foregoing factors could have negative consequences on our financial condition and results of operations.This indebtedness could be due sooner upon the triggering of certain covenants in our debt agreements and or upon the occurrence of an event of default. If and when our indebtedness becomes due, if we do not have sufficient cash or access to capital to pay such indebtedness, we will default on our obligations which will adversely harm our business. We entered into the 2029 Loan Agreement that contains affirmative and negative covenants that restrict our operations, including, among other restrictions, the requirement to maintain certain levels of cash and cash equivalents. Further, the 2029 Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict our ability to incur liens, incur additional indebtedness, make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. We may need to request waivers from time to time with respect to the 2029 Loan Agreement and if we are unable to obtain a waiver that we need it could materially impact our business and financial results.Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. If our existing stockholders sell or indicate an intention to sell substantial amounts of our common stock in the public market the market price of our common stock could decline. In addition, we may authorize our sales agent to sell our common stock from time to time as part of the ATM Offering. As of September 30, 2024, there were 115,213,407 million shares of common stock outstanding.In addition, as of September 30, 2024, approximately 37.6 million shares of common stock that are either subject to outstanding options and restricted stock units or reserved for future issuance under our equity incentive plans were eligible or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and RuleÂ 144 and RuleÂ 701 under the Securities Act. Certain of our outstanding options have exercise prices that are above our current stock price. See the tables describing our outstanding stock options in Note 12. Stock-Based Compensation and Employee Benefits to our financial statements included in our Annual Report for the Fiscal Year ended December 31, 2023. If these additional shares of common stock are sold or if it is perceived that they will be sold in the public market, the market price of our common stock could decline. Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans and convertible notes, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. We have needed and anticipate we will need additional capital in the future to continue our planned operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. Similar to prior or ongoing financing transactions like the ATM Offering or the exchange of our shares for shares of outstanding stock of Surface as part of the acquisition of Surface, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially 98 Table of Contentsdiluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. In addition, if we raise additional funds through licensing arrangements, it may be necessary to grant potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.Pursuant to our Amended and Restated 2014 Equity Incentive Award Plan (the â€œ2014 Planâ€), our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. Any increase in the number of shares available for future grant under the 2014 Plan must be approved by our stockholders. Pursuant to our 2014 Employee Stock Purchase Plan (â€œESPPâ€), eligible employees are able to acquire shares of our common stock at a discount to the prevailing market price, and an aggregate of 320,000Â shares are initially available for issuance under the ESPP. The number of shares available for issuance under the ESPP were automatically increased on the first day of each fiscal year beginning in 2015 and ending in 2024, equal to 1% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year or such smaller number of shares as determined by our board of directors. Pursuant to our 2016 Employment Commencement Incentive Plan (the â€œ2016 Planâ€), our management was authorized to grant stock options and other equity-based awards to our new employees, however in connection with the approval of the 2014 Plan in 2024, we agreed that we would not make any new awards under the 2016 Plan after the effective date of the 2014 Plan.In April 2020, we issued and sold $230.0 million aggregate principal amount of our 1.5% senior convertible notes due April 2026 (the â€œ2026 Convertible Notesâ€). The holders may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the second scheduled trading day immediately before April 15, 2026. Upon conversion of the 2026 Convertible Notes by a holder, the holder will receive shares of our common stock, together, if applicable, with cash in lieu of any fractional share. Since inception, the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock.Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our business operations, financial condition, results of operations and prospects.Our cash and cash equivalents are deposited or invested with several banks and other financial institutions. Actual events involving reduced or limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank was closed and taken over by the Federal Deposit Insurance Corporation (â€œFDICâ€) and subsequently had all of its customer deposits and other liabilities and substantially all loans and other assets acquired by First-Citizens Bank & Trust Company. We had approximately $97.7 million of cash, cash equivalents and marketable securities as of September 30, 2024 with the majority held by custodians or in money market mutual funds that are not bank deposits. Our bank deposits are primarily held in accounts at three large banks that we believe to be stable at this time. Actual and perceived stability of banks can change from time to time and adverse perceptions by customers or investors about the banks where we deposit money could result in a material and adverse effect on our ability to access necessary cash. Investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources, could, among other risks, adversely impact our ability to access funds for our basic operating expenses, financial obligations, payroll or fulfill our other important obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity, business operations, financial condition, results of operations and prospects.99 Table of ContentsWe do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation of their stock. Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and bylaws include provisions that: â—authorize â€œblank checkâ€ preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; â—create a classified board of directors whose members serve staggered three-year terms; â—specify that special meetings of our stockholders can be called only by our corporate secretary pursuant to a resolution adopted by a majority of our board of directors; â—prohibit stockholder action by written consent; â—establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors other than nominations made by or at the direction of the board of directors or a committee of the board of directors; â—provide that our directors may be removed only for cause or without cause by the holders of 66Â 2/3% of the voting power of all then outstanding shares of voting stock; â—provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; â—specify that no stockholder is permitted to cumulate votes at any election of directors; â—expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and â—require holders of 66Â 2/3% of the voting power of all then outstanding shares of voting stock to amend specified provisions of our amended and restated certificate of incorporation except for the provision making it possible for our board of directors to issue â€œblank checkâ€ preferred stock, and amended and restated bylaws. These provisions, alone or together, could delay, deter or prevent hostile takeovers and changes in control or changes in our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of SectionÂ 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess

of 15% of our outstanding voting stock to merge or combine with us. Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.100 Table of Contentsâ€‹General Risk Factorsâ€‹The international aspects of our business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. â€‹We currently have limited international operations of our own and have and may have in the future a number of international collaborations, including our significant collaboration with Junshi Biosciences in China. Doing business internationally involves a number of risks, including but not limited to: â€‹â—multiple, conflicting and changing laws and regulations such as data privacy and security regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses, including those that affect our work with a collaboration partner in China; â€‹â—failure by us or our collaboration partners to obtain and maintain regulatory approvals for the use of our products in various countries; â€‹â—additional potentially relevant third-party patent rights; â€‹â—foreign CMOs may be subject to U.S. legislation, including the proposed BIOSECURE Act, sanctions, trade restrictions and other regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure commitments from governments to purchase our products;â€‹â—complexities and difficulties in obtaining protection and enforcing our intellectual property;â€‹â—difficulties in staffing and managing foreign operations by us or our collaboration partners;â€‹â—complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems by our collaboration partners; â€‹â—limits in our or our collaboration partnersâ€™ ability to penetrate international markets; â€‹â—financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; â€‹â—natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; â€‹â—certain expenses including, among others, expenses for travel, translation and insurance; â€‹â—expose us to sanctions, such as the sanctions levied by United States, E.U. and Russian regulatory bodies in connection with the war between Russia and Ukraine; andâ€‹â—regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the United States Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions. â€‹101 Table of ContentsInvestorsâ€™ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.â€‹There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance (or â€œESGâ€) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers and if we are perceived as lagging with respect to ESG initiatives, certain investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our board of directors accountable. In addition, the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We may face reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. We also face significant costs from complying with new ESG regulations, for example, the SECâ€™s proposed climate disclosure rule would result in significant costs of compliance if it is approved as proposed in the future.â€‹We may face reputational damage in the event our corporate responsibility initiatives or objectives do not meet the standards set by our investors, stockholders, lawmakers, listing exchange or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability of our business over time.â€‹Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. â€‹Because we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaboration partners, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitorâ€™s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. â€‹So called â€œsubmarineâ€ patents may be granted to our competitors that may significantly alter our launch timing expectations, reduce our projected market size, cause us to modify our product or process or block us from the market altogether. â€‹The term â€œsubmarineâ€ patent has been used in the pharmaceutical industry and in other industries to denote a patent issuing from an application that was not published, publicly known or available prior to its grant. Submarine 102 Table of Contentspatents add substantial risk and uncertainty to our business. Submarine patents may issue to our competitors covering our pipeline candidates and thereby cause significant market entry delay, defeat our ability to market our products or cause us to abandon development or commercialization of a molecule. â€‹Examples of submarine patents include Brockhaus, et al., United States patents 8,063,182 and 8,163,522 (controlled by Amgen), which are directed to the fusion protein in Enbrel. On July 1, 2020, the United States Court of Appeals for the Federal Circuit issued a decision that affirmed the lower courtâ€™s decision upholding the validity of these patents. As a result, we discontinued the development of CHS-0214 (our etanercept (Enbrel) biosimilar candidate). â€‹The issuance of one or more submarine patents may harm our business by causing substantial delays in our ability to introduce a biosimilar candidate into the United States market. â€‹We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which might adversely affect our ability to develop and market our products. â€‹We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete and thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. â€‹The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patentâ€™s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products or pipeline molecules. We may incorrectly determine that our products are not covered by a third-party patent. â€‹Many patents may cover a marketed product, including but not limited to the composition of the product, methods of use, formulations, cell line constructs, vectors, growth media, production processes and purification processes. The identification of all patents and their expiration dates relevant to the production and sale of an originator product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products. â€‹Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. â€‹If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to prevent competitors from using technologies we consider important in our successful development and commercialization of our product candidates, resulting in loss of any potential competitive advantage our patents may have otherwise afforded us.â€‹While our principal focus in matters relating to intellectual property is to avoid infringing the valid and enforceable rights of third parties, we also rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our own intellectual property related to our product candidates and development programs. Our ability to enjoy any competitive advantages afforded by our own intellectual property depends in large part on our ability to obtain and maintain patents and other intellectual property protection in the United States and in other countries with respect to various proprietary elements of our product candidates, such as, for example, our product formulations and processes for manufacturing our products and our ability to maintain and control the confidentiality of our trade secrets and confidential information critical to our business. â€‹103 Table of ContentsWe have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our products that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no guarantee that any patent application we file will result in an issued patent having claims that protect our products. Additionally, while the basic requirements for patentability are similar across jurisdictions, each jurisdiction has its own specific requirements for patentability. We cannot guarantee that we will obtain identical or similar patent protection covering our products in all jurisdictions where we file patent applications. â€‹The patent positions of biopharmaceutical companies generally are highly uncertain and involve complex legal and factual questions. As a result, the patent applications that we own or license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries for many reasons. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, considered or cited during patent prosecution, which can be used to invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patent claims being narrowed, found unenforceable or invalidated. Our patents and patent applications, even if they are unchallenged, may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competitors from using the technologies claimed in any patents issued to us, which may have an adverse impact on our business. â€‹In addition, changes to United States patent laws provide additional procedures for third parties to challenge the validity of issued patents based on patent applications filed after March 15, 2013. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is challenged, then it could threaten our ability to prevent competitive products using our proprietary technology. Further, because patent applications in the United States and most other countries are confidential for a period of time, typically for 18 months after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013 or patents issuing from such applications, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March 16, 2013, the United States transitioned to a â€œfirst-to-fileâ€ system for deciding which party should be granted a patent when two or more patent applications claiming the same invention are filed by different parties. A third party that files a patent application in the USPTO before we do, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to â€œfirst-to-fileâ€ from â€first-to-inventâ€ is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act (the â€œLeahy-Smith Actâ€), signed into law on September 16, 2011. Among some of the other significant changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. It is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.â€‹Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to prevent third parties from using the same technologies that we use in our product candidates. â€‹In June 2023, the European Unitary Patent system and the European Unified Patent Court (â€œUPCâ€) were launched. European patent applications now have the option, upon grant of a patent, of becoming a Unitary Patent which is subject to the jurisdiction of the UPC. In addition, conventional European patents, both already granted at the time the new 104 Table of Contentssystem began and granted thereafter, are subject to the jurisdiction of the UPC, unless actively opted out. This was a significant change in European patent practice, and deciding whether to opt-in or opt-out of Unitary Patent practice entails strategic and cost considerations. The UPC provides third parties with a new forum to centrally revoke our European patents and makes it possible for a third party to obtain pan-European injunctions against us. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. While we have the right to opt our patents out of the UPC over the first seven years of the courtâ€™s existence, doing so may preclude us from realizing the benefits of the UPC. Moreover, the decision whether to opt-in or opt-out of Unitary Patent status will require coordinating with co-applicants, if any, adding complexity to any such decision.â€‹We have issued patents and have filed patent applications, which are currently pending, covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened or infringed by third parties. Any successful actions by third parties to challenge the validity or enforceability of any patents, which may issue to us could deprive us of the ability to prevent others from using the technologies claimed in such issued patents. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. â€‹While our biosimilar business is based primarily on the timing of our biosimilar product launches to occur after the expiration of relevant patents and on avoiding infringing valid and enforceable rights of third parties, we have filed a number of patent applications seeking patents that cover various proprietary elements of our product candidates when we have believed securing such patents may afford a competitive advantage. Our patent portfolio includes pending patent applications and issued patents, in the United States and globally, covering our biosimilar product and methods of making it. We cannot guarantee that our proprietary technologies will avoid infringement of third-party patents. Moreover, because competitors may be able to develop their own proprietary technologies, it is uncertain whether any of our issued patents or pending patent applications would cover the products of any competitors. The product and patent landscape is highly uncertain and we cannot predict whether our patent filings will afford us a competitive advantage against third parties or if our products will avoid infringement of third-party patents. â€‹We do not consider it necessary for us or our competitors to obtain or maintain a proprietary patent position in order to engage in the business of biosimilar development and commercialization. Hence, while our ability to secure patent coverage on our own proprietary developments may improve our competitive position with respect to the product candidates we intend to commercialize, we do not view our own patent filings as a necessary or essential requirement for conducting our business nor do we rely on our own patent filings or the potential for any commercial advantage they may provide us as a basis for our success.â€‹Obtaining and maintaining our patent protection depends on compliance with various procedural requirements, document submissions, fee payment and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements. â€‹The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. â€‹We may not be able to protect our intellectual property rights throughout the world. â€‹Filing, prosecuting, defending and enforcing patents on product

candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual 105 Table of Contentsproperty rights to the same extent as federal and state laws in the United States. Further, licensing partners may choose not to file patent applications in certain jurisdictions in which we may obtain commercial rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or importing products made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but the ability to enforce our patents is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. â€‹Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Governments of foreign countries may force us to license our patents to third parties on terms that are not commercially reasonable or acceptable to us. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. â€‹If we are unable to maintain effective (non-patent) proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. â€‹While we have filed patent applications to protect certain aspects of our own proprietary formulation and process developments, we also rely on trade secret protection and confidentiality agreements to protect proprietary scientific, business and technical information and know-how that is not or may not be patentable or that we elect not to patent. However, confidential information and trade secrets can be difficult to protect. Moreover, the information embodied in our trade secrets and confidential information may be independently and legitimately developed or discovered by third parties without any improper use of or reference to information or trade secrets. We seek to protect the scientific, technical and business information supporting our operations, as well as the confidential information relating specifically to our product candidates by entering into confidentiality agreements with parties to whom we need to disclose our confidential information, for example, our employees, consultants, scientific advisors, board members, contractors, potential collaborators and investors. However, we cannot be certain that such agreements have been entered into with all relevant parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Our confidential information and trade secrets thus may become known by our competitors in ways we cannot prove or remedy. â€‹Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and 106 Table of Contentsmay have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. We cannot guarantee that our employees, former employees or consultants will not file patent applications claiming our inventions. Because of the â€œfirst-to-fileâ€ laws in the United States and the EU, such unauthorized patent application filings may defeat our attempts to obtain patents on our own inventions. â€‹We may be subject to claims challenging the inventorship of our patent filings and other intellectual property. â€‹Although we are not currently aware of any claims challenging the inventorship of our patent applications or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patent applications or patents we may be granted or other intellectual property as an inventor or co-inventor. For example, we may have inventorship or ownership disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. â€‹We or the third parties upon whom we depend on may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. â€‹Our corporate headquarters and laboratory are located in the San Francisco Bay Area and in Southern California (Camarillo), respectively. These locations have in the past experienced severe earthquakes, floods, wildfires and other natural disasters. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations or those of our collaboration partners and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure (such as the manufacturing facilities of our third-party contract manufacturers) or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. â€‹The continuation of the war in Ukraine and conflicts in the Middle East may exacerbate certain risks we face.â€‹The war between Russia and Ukraine and the global response, including the imposition of sanctions by the United States and other countries, could create or exacerbate risks facing our business. Conflicts in the Middle East may also increase the risks facing our business. We have evaluated our operations and partner contracts, and we currently do not expect either conflict to directly have a significant effect on our financial condition or results of operations. However, if the war between Russia and Ukraine or conflicts in the Middle East escalate or expand, risks that we have identified in this Quarterly Report on Form 10-Q may be materially increased. For example, if our supply arrangements or clinical operations are disrupted due to expanded sanctions or involvement of, and adverse impacts on, countries where we have operations or relationships, our business could be materially disrupted. Further, the use of cyberattacks could expand as part of the ongoing conflicts, which could adversely affect our ability to maintain or enhance our cyber security measures. These and other risks are described more fully in this â€œRisk Factorsâ€ section.â€‹We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. We may fail to comply with the rules that apply to public companies, 107 Table of Contentsincluding Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.â€‹We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act, and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel must devote a substantial amount of time to ensure that we maintain compliance with all of these requirements. Moreover, the reporting requirements, rules and regulations have increased our legal and financial compliance costs and make some activities more time consuming and costly. Any changes we have made, and may make in the future to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, may also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directorsâ€™ and officersâ€™ insurance, on acceptable terms. â€‹We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (â€œSection 404â€), and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business.â€‹Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. For example, the SECâ€™s proposed climate disclosure rule would result in significant costs of compliance if final rules that are similar to the proposed rules are approved in the future. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage.â€‹Our information technology systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches and geopolitical tensions or conflicts, such as the ongoing war in Ukraine or conflicts in the Middle East, may create a heightened risk of cyberattacks.â€‹We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, preclinical and clinical trial data, and personal information (collectively, â€œConfidential Informationâ€) of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information.â€‹108 Table of ContentsDespite the implementation of security measures, our information technology systems as well as those of our third-party collaborators, consultants, contractors, suppliers, and service providers, may be vulnerable to damage from physical or electronic break-ins, computer viruses, misconfigurations, â€œbugsâ€ or other vulnerabilities, â€œphishingâ€ attacks, malware, ransomware, denial of service and other cyberattacks or disruptive incidents that could result in unauthorized access to, use or disclosure of, corruption of, or loss of Confidential Information, and could subject us to significant liabilities and regulatory and enforcement actions, and reputational damage. In addition, geopolitical tensions or conflicts, such as the war between Russia and Ukraine or the conflicts in the Middle East, may create a heightened risk of cyberattacks. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our Confidential Information. If we or any of our third-party collaborators or service providers were to experience any material failure or security breach, it could result in a material disruption of our development programs, reputation, and business operations. For example, the loss of clinical study data from completed or ongoing clinical studies could result in delays in any regulatory approval or clearance efforts and significantly increase our costs to recover or reproduce the data, and subsequently commercialize the product. â€‹We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of Confidential Information, we may have to notify individuals, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation. Likewise, we rely on our third-party CROs and other third parties to conduct clinical studies, and similar events relating to their computer systems could also have a material adverse effect on our business. There can also be no assurance that our and our service providersâ€™ cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.â€‹Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Further, the continued hybrid working environment has generally increased the attack surface available to criminals, as more companies and individuals work online and work remotely, and as such, the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.â€‹To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate or unauthorized access to or disclosure or use of Confidential Information, we could incur liability and suffer reputational harm, and the development and commercialization of our products could be delayed. Federal, state and international laws and regulations can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties, fines and significant legal liability, if our information technology security efforts fail. We may also be exposed to a risk of loss or litigation and potential liability, which could materially and adversely affect our business, results of operations or financial condition. Our insurance policies may not be adequate to compensate us for the potential losses arising from such disruptions, failure, or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly, divert management attention, and harm our reputation. â€‹109 Table of ContentsWe are subject to governmental regulation and other legal obligations related to privacy, data protection and information security. Compliance with these requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.â€‹The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. Compliance with these privacy and data security requirements is rigorous and time-intensive and may increase our cost of doing business. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, fines and penalties, litigation and reputational harm, which could materially and adversely affect our business, financial condition and results of operations.â€‹In the United States, we and our partners may be subject to numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state

consumer protection laws and regulations, that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations (collectively, â€œHIPAAâ€). Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA.â€‹Even when HIPAA does not apply, according to the Federal Trade Commission (â€œFTCâ€), failing to take appropriate steps to keep consumersâ€™ personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a companyâ€™s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. The FTC has authority to initiate enforcement actions against entities that make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5(a) of the FTC Act. Additionally, federal and state consumer protection laws are increasingly being applied by the FTC and statesâ€™ attorneys general to regulate the collection, use, storage, and disclosure of personal information, through websites or otherwise, and to regulate the presentation of website content.â€‹In addition, state laws govern the privacy and security of personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act as amended by the California Privacy Rights Act (collectively, the â€œCCPAâ€), which requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the businessâ€™s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the businessâ€™s behalf. Similar laws have passed in other states and are continuing to be proposed 110 Table of Contentsat the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our business and financial condition.â€‹In addition, the regulatory framework for the receipt, collection, processing, use, safeguarding, sharing and transfer of personal data is rapidly evolving and is likely to remain uncertain for the foreseeable future as new global privacy rules are being enacted and existing ones are being updated and strengthened. For example, on May 25, 2018, the General Data Protection Regulation (â€œGDPRâ€) took effect. The GDPR is applicable in each EEA member state and applies to companies established in the EEA as well as companies that collect and use personal data to offer goods or services to, or monitor the behavior of, individuals in the EEA, including, for example, through the conduct of clinical trials. GDPR introduces more stringent data protection obligations for processors and controllers of personal data. Among other things, the GDPR requires the establishment of a lawful basis for the processing of data, includes requirements relating to the consent of the individuals to whom the personal data relates, including detailed notices for clinical trial subjects and investigators, as well as requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects. The GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (â€œCJEUâ€) states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (â€œDPFâ€) rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames. Penalties and fines for failure to comply with GDPR are significant, including fines of up to â‚¬20 million or 4% of the total worldwide annual turnover of a non-compliant undertaking, whichever is higher. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease/ change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/ or civil claims (including class actions).â€‹Further, since the beginning of 2021, we have also been subject to the United Kingdom General Data Protection Regulation and Data Protection Act 2018, which collectively imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to Â£17.5 million or 4% of a noncompliant undertakingâ€™s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the U.K. Extension to the DPF came into effect (as approved by the U.K. government), as a data transfer mechanism from the U.K. to U.S. entities self-certified under the DPF. Other foreign jurisdictions are increasingly implementing or developing their own privacy regimes with complex and onerous compliance obligations and robust regulatory enforcement powers. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. â€‹Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, 111 Table of Contentscould result in additional cost and liability to us, damage our reputation, and have a material adverse effect on our business, financial condition and results of operations.â€‹We may be negatively impacted by continued inflation.â€‹We may be adversely impacted by continued increases in inflation. Current and future inflation may be driven by the following factors: supply chain disruptions, increased costs of transportation, increased input costs such as the cost of fuel, shortages, and governmental stimulus or fiscal policies. Continuing increases in inflation could impact the overall demand for our products, our costs for labor and materials and the size of any margins we are able to realize on our revenues. This would have a material and adverse impact on our business, financial position, results of operations and cash flows. Inflation may also result in higher interest rates, which in turn would result in higher interest expense related to our variable rate indebtedness.If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. â€‹Our research and development activities and our third-party manufacturersâ€™ and suppliersâ€™ activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturersâ€™ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.â€‹ITEMÂ 2.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unregistered Sales of Equity Securities and Use of Proceeds, and Issuer Purchases of Equity SecuritiesIssuer Purchases of Equity SecuritiesWe did not repurchase any of our equity securities during the third quarter ended September 30, 2024. A total of 8,163Â shares were surrendered to us in the third quarter of 2024, to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.â€‹ITEMÂ 3.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Defaults Upon Senior SecuritiesNot applicableâ€‹ITEMÂ 4.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Mine Safety DisclosuresNot applicableâ€‹112 Table of ContentsITEMÂ 5.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Information(a)None.(b)None.(c)During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each such term is defined in Item 408(a) of Regulation S-K.â€‹â€‹113 Table of ContentsITEMÂ 6.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exhibitsâ€‹Reference is made to the Index to Exhibits included in this Quarterly Report on FormÂ 10-Q.INDEX TO EXHIBITSâ€‹â€‹â€‹â€‹Incorporated by Referenceâ€‹â€‹ExhibitNumberÂ Â Â Â DescriptionÂ Â Â Â FormÂ Â Â Â ExhibitÂ Â Â Â DateFiledÂ Â Â Â FiledHerewith3.1â€‹Amended and Restated Certificate of Incorporation.â€‹8-Kâ€‹3.1â€‹11/13/2014â€‹â€‹â€‹

to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹Date: November 6, 2024/s/ Bryan McMichaelâ€‹Bryan McMichaelâ€‹Chief Financial Officerâ€‹ EX-32.1 4 chrs-20240930xex32d1.htm EX-32.1 Exhibit 32.1CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICERPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Coherus BioSciences, Inc. (the â€œRegistrantâ€) certify that the Quarterly Report of Coherus BioSciences, Inc. on Form 10-Q for the quarterly period ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of SectionÂ 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.â€‹â€‹â€‹Date: November 6, 2024By:/s/ Dennis M. Lanfearâ€‹Name:Dennis M. Lanfearâ€‹Title:President and Chief Executive Officerâ€‹â€‹â€‹â€‹â€‹â€‹Date: November 6, 2024By:/s/ Bryan McMichaelâ€‹Name:Bryan McMichaelâ€‹Title:Chief Financial Officerâ€‹This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing. EX-101.SCH 5 chrs-20240930.xsd EX-101.SCH 995200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 995200500 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Inventory - Components (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Inventory - Balance Sheet Classifications (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - Inventory - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 99940503 - Disclosure - Balance Sheet Components - Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 99940504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Financial Liabilities - Summary of Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - Financial Liabilities - 2029 Term Loan Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 99940807 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Summary of Revenue Participation Liability (Details) link:presentationLink link:calculationLink link:definitionLink 99940808 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Classification on the condensed consolidated balance sheet (Details) link:presentationLink link:calculationLink link:definitionLink 99940818 - Disclosure - Financial Liabilities - 2026 Convertible Notes Interest Expense Components (Details) link:presentationLink link:calculationLink link:definitionLink 99940820 - Disclosure - Financial Liabilities - 2026 Convertible Notes Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Consolidated Statements of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Financial Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Revenue - Net Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Balance Sheet Components - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Acquisition and Disposition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Acquisition and Disposition - Estimated fair value of the net assets acquired (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Acquisition and Disposition - The amounts allocated to identifiable intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940605 - Disclosure - Acquisition and Disposition - Unaudited Pro Forma Summary of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Collaborations and Other Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Financial Liabilities - 2029 Term Loan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Financial Liabilities - 2029 Term Loans, Components of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940806 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940810 - Disclosure - Financial Liabilities - 2027 Term Loan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940812 - Disclosure - Financial Liabilities - 2027 Term Loans, Components of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940814 - Disclosure - Financial Liabilities - Convertible Senior Subordinated Notes due 2026 - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940816 - Disclosure - Financial Liabilities - Capped Call Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Stock-Based Compensation - Stock-Based Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Net Income (Loss) Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Acquisition and Disposition link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Collaborations and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Financial Liabilities link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 99920102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Acquisition and Disposition (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 chrs-20240930_cal.xml EX-101.CAL EX-101.DEF 7 chrs-20240930_def.xml EX-101.DEF EX-101.LAB 8 chrs-20240930_lab.xml EX-101.LAB Cover [Abstract] Document Type Document Type Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Securities Act File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Investments in marketable securities Receivables, Net, Current Trade receivables, net Amount of transition services agreement receivable current. Transition Services Agreement Receivable Current TSA receivables, net (Note 6) TSA receivables, net Inventory, Net Inventory Prepaid Manufacturing current. Prepaid Manufacturing Expense Current Prepaid manufacturing Prepayment made for manufacturing services Prepaid Expense and Other Assets, Current Other prepaids and current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Inventory, Noncurrent Inventory, non-current Intangible Assets, Net (Including Goodwill) Intangible assets, net Total Intangible assets, net Other Assets, Noncurrent Other assets, non-current Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Deficit Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued rebates, fees and reserve. Accrued Rebates Fees And Reserve Current Accrued rebates, fees and reserves Amount of transition services agreement payables classified as current. Transition Services Agreement Payables and Other Accrued Liabilities Current TSA payables and other accrued liabilities (Note 6) TSA payables and other accrued liabilities Employee-related Liabilities, Current Accrued compensation Accrued Liabilities, Current Accrued and other current liabilities Total Accrued and other current liabilities Liabilities, Current Total current liabilities Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Term Loans Payable, Noncurrent Term loans, non-current Convertible Subordinated Debt, Noncurrent Convertible notes Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. Operating and Finance Lease, Liability, Noncurrent Lease liabilities, non-current Other Liabilities, Noncurrent Other liabilities, non-current Total Other liabilities, non-current Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 9) Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' deficit: Common Stock, Value, Issued Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 115,213,407 and 112,215,260 at September 30, 2024 and December 31, 2023, respectively) Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Ending Balances Beginning Balances Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Ending Balances (in shares) Beginning Balances (in shares) Common stock, shares outstanding Income Statement [Abstract] Revenues [Abstract] Revenue: Revenue from Contract with Customer, Including Assessed Tax Net revenue Operating Expenses [Abstract] Costs and expenses: Cost of Goods and Services Sold Cost of goods sold Research and Development Expense Research and development Research and development Selling, General and Administrative Expense Selling, general and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Interest Expense, Operating and Nonoperating Interest expense Gain (Loss) on Sale of Interest in Projects Gain on Sale Transaction, net (Note 6) Gain (loss) on Sale Transactions, net (Note 6) Gain (Loss) on Extinguishment of Debt Loss on debt extinguishment Loss on debt extinguishment Other Nonoperating Income (Expense) Other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Pretax profit (loss) Income (loss) before income taxes Income Tax Expense (Benefit) Income tax provision Net income (loss) Net income (loss) Earnings Per Share [Abstract] Net income (loss) per share: Earnings Per Share, Basic Basic net income (loss) per share Basic (In dollar per share) Earnings Per Share, Diluted Diluted net income (loss) per share Diluted (In dollar per share) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average number of shares used in computing net income (loss) per share: Denominator: Weighted Average Number of Shares Outstanding, Basic Basic (In shares) Weighted-average common shares outstanding - Basic Weighted Average Number of Shares Outstanding, Diluted Diluted (In shares) Weighted-average common shares outstanding - Diluted Statement of Comprehensive Income [Abstract] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss): OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized gain (loss) on available-for-sale securities, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments, net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income (loss) Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Sale of Stock [Axis] Sale of Stock [Domain] Represents information relating to at the market offering issuance. At Market Offering [Member] ATM Offering Represents information pertaining to public offering. Public Offering Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options (in shares) Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of common stock upon vesting of restricted stock units ("RSUs") Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares) Value of stock issued during period in lieu of bonus. Stock Issued During Period, Partial Payout, Bonus Issuance of common stock - partial payout of 2023 bonus in RSUs Number of shares issued in lieu of bonus. Stock Issued During Period,

Partial Payout, Bonus, Shares Issuance of common stock - partial payout of 2023 bonus in RSUs (in shares) Stock Issued During Period on acquisitions Stock Issued During Period, Acquisitions Issuance of common stock in connection with Surface Acquisition:(1) Stock Issued During Period, Value, Acquisitions Issuance to Surface shareholders for acquisition Stock Issued During Period, Shares, Acquisitions Issuance to Surface shareholders for acquisition (in shares) Number of shares issued during the period as a result of accelerated vesting of equity awards. Stock Issued During Period, Shares, Accelerated Vesting of Equity Awards Accelerated vesting of equity awards (in shares) Value of stock related to accelerated vesting of equity awards issued during the period. Stock Issued During Period, Value, Accelerated Vesting of Equity Awards Accelerated vesting of equity awards Number of shares settled related to taxes paid related to net share settlement of equity awards during the period. Stock Issued During Period, Shares, Taxes Paid Related to Net Share Settlement of Equity Awards Taxes paid related to net share settlement of equity awards (in shares) Value of stock settled related to taxes paid related to net share settlement of equity awards during the period. Stock Issued During Period, Value, Taxes Paid Related to Net Share Settlement of Equity Awards Taxes paid related to net share settlement of equity awards APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Stock Issued During Period, Value, New Issues Issuance of common stock under Offering, net of issuance costs Stock Issued During Period, Shares, New Issues Issuance of common stock under Offering, net of issuance costs (in shares) Common stock, shares issued and sold Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Offering costs associated with ATM offering Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under the employee stock purchase plan ("ESPP") Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under the employee stock purchase plan ("ESPP") (in shares) Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Taxes paid related to net share settlement of RSUs Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Taxes paid related to net share settlement of RSUs (in shares) Other Comprehensive Income (Loss), Net of Tax Other comprehensive loss, net of tax Statement of Cash Flows [Abstract] Disposal Group Name [Axis] Disposal Group Name [Domain] Represents the information pertaining to CIMERLI ophthalmology franchise. CIMERLI Ophthalmology Franchise [Member] CIMERLI Sale Represents the information pertaining to YUSIMRY immunology franchise. YUSIMRY Immunology Franchise [Member] YUSIMRY Sale Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense The amount of Impairment of out-license asset and remeasurement of CVR liability, net. Impairment of Intangible Assets And Contingent Value Rights Liability Impairment of out-license asset and remeasurement of CVR liability, net Net impairment charge Inventory Write-down Inventory write-downs, net Inventory write-downs Other Operating Activities, Cash Flow Statement Other non-cash adjustments, net Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Receivables Trade receivables, net Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense Prepaid manufacturing Increase (Decrease) in Prepaid Expense and Other Assets Other prepaid, current and non-current assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase decrease in accrued rebates, fees and reserve. Increase Decrease In Accrued Rebates Fees And Reserve Accrued rebates, fees and reserves Increase (Decrease) in Other Operating Assets and Liabilities, Net TSA related operating assets and liabilities, net (Note 6) Increase decrease in accrued compensation. Increase Decrease In Accrued Compensation Accrued compensation Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other current and non-current liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of investments in marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Proceeds from sale of investments in marketable securities Proceeds from Divestiture of Businesses Cash received from Sale Cash Acquired from Acquisition Cash and cash equivalents acquired from Surface Acquisition The cash outflow associated with milestone based license fee payment. Payments For Milestone Based License Fee Milestone based license fee payment to Junshi Biosciences Payments to Acquire Marketable Securities Purchases of investments in marketable securities Payments for (Proceeds from) Other Investing Activities Other investing activities, net Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Proceeds from Issuance of Debt Proceeds from 2029 Term Loan, net of debt discount & issuance costs The cash inflow during the period from revenue purchase and sale agreement. Proceeds From Revenue Purchase And Sale Agreement Net Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Proceeds from Stock Options Exercised Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Plans Proceeds from purchase under the employee stock purchase plan Payment, Tax Withholding, Share-Based Payment Arrangement Taxes paid related to net share settlement Repayments of Debt Repayment of 2027 Term Loans, premiums and exit fees Outstanding amount paid off Proceeds from (Payments for) Other Financing Activities Other financing activities Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Total cash, cash equivalents and restricted cash Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosures of non-cash activities Stock Issued Non-cash employee bonuses settled in common stock Future cash outflow to pay for issuance cost of debt. Issuance Cost of Debt Incurred but Not yet Paid Financing issuance costs in accounts payable Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Organization and Summary of Significant Accounting Policies Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Text Block] Revenue Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventory Balance Sheet Related Disclosures [Abstract] Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components No definition available. Acquisition And Disposal Of Business [Abstract] The disclosure of acquisition and disposal of business. Acquisition and Disposal of Business [Text Block] Acquisition and Disposition Collaboration and license agreements. Collaboration And License Agreements [Abstract] Collaborative Arrangement Disclosure [Text Block] Collaborations and Other Arrangements Debt Disclosure [Abstract] Debt Disclosure [Text Block] Financial Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Equity [Abstract] Disclosure containing information regarding Stockholders' Deficit. Stockholders Deficit Stockholders' Deficit Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Earnings Per Share [Text Block] Net Income (Loss) Per Share Consolidation, Policy [Policy Text Block] Basis of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Receivable [Policy Text Block] Trade Receivables The description of accounting policy for revenue purchase and sale agreement. Revenue Purchase And Sale Agreement, Policy [Policy Text Block] Revenue Purchase and Sale Agreement Represents Information pertaining to Consideration which is contingent upon some future changes in assumptions. Contingent Consideration [Policy Text Block] Contingent Consideration Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Restrictions on Cash and Cash Equivalents [Table Text Block] Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Disaggregation of Revenue [Table Text Block] Schedule of Net product revenue in United States, and Company's net revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues Schedule of product sales discounts and allowances. Schedule Of Product Sales Discounts And Allowances Table [Text Block] Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Financial Assets and Liabilities Measured on a Recurring Basis Cash, Cash Equivalents and Investments [Table Text Block] Schedule of Cash and cash equivalents, marketable securities and restricted cash Tabular disclosure of inventories. Schedule of Inventory [Table Text Block] Schedule of Inventory Schedule of balance sheet classification of Inventory. Schedule Of Balance Sheet Classification Of Inventory Table [Text Block] Schedule of Balance Sheet Classification Organization and Operations Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment, Net Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Goodwill and Intangible Assets, Net Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities Other Noncurrent Liabilities [Table Text Block] Schedule of Other Liabilities, Non-current Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of purchase price allocation to the estimated fair value of the net assets acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Schedule of amounts allocated to identifiable intangible assets Business Acquisition, Pro Forma Information [Table Text Block] Schedule of unaudited pro forma summary of operations Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents 2029 term loans. Two Thousand Twenty Nine Term Loans [Member] 2029 Term Loans Represents information pertains to Revenue Purchase and sale agreement. Revenue Purchase and Sale Agreement Represents term loans. 2027 Term Loans Represents the information pertaining to 1.5% Convertible Senior Subordinated Notes due 2026. 1.5% Convertible Senior Subordinated Notes due 2026 Debt Instrument [Line Items] Financial Liabilities Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Schedule of Company's Debt Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Future Payments on Debt Tabular disclosure of royalty participation liability. Schedule Of Royalty Participation Liability [Table Text Block] Schedule of royalty participation liability Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Components of Interest Expense Long-Term Purchase Commitment [Table Text Block] Schedule of Non-cancelable Contractual Obligations Tabular disclosure of shares offering settlements. Schedule of Settlements Under Shares Offering [Table Text Block] Schedule of Settlements Under the ATM Offering Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Employee and nonemployee stock option restricted stock units. Employee And Nonemployee Stock Option Restricted Stock Units Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Stock-Based Compensation Expense Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of Basic and Diluted Net Income Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue Benchmark [Member] Net Product Revenue Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group Business Acquisition [Line Items] Surface Acquisition Concentration Risk, Percentage Percentage of total gross revenue Disposal Group, Including Discontinued Operation, Consideration Cash consideration Amount of consideration in the form of inventory purchase commitments assumed as part of the disposal of assets and liabilities, including discontinued operation. Disposal Group, Including Discontinued Operation, Consideration In The Form Of Inventory Purchase Commitments Inventory purchase commitments Amount of additional consideration received or receivable for product inventory and prepaid manufacturing assets, including discontinued operation. Disposal Group, Including Discontinued Operation, Additional Consideration for Product Inventory and Prepaid Manufacturing Assets Additional consideration Debt Instrument, Face Amount Principal Amount Principal amount Represents the number of drug candidates in the product pipeline. Product pipeline, Number of Drug Candidates Product pipeline, number of product candidates Restricted Cash Restricted cash Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Domain] Product [Member] Total net product revenue Represents information relating to the product UDENYCA. Udenyca [Member] UDENYCA Represents information relating to the product CIMERLI. CIMERLI Represents information relating to the product YUSIMRY. YUSIMRY Represents toripalimab. Toripalimab Toripalimab (LOQTORZI) LOQTORZI Product and Service, Other [Member] Other revenue Disaggregation of Revenue [Line Items] Revenue Concentration Risk [Table] Concentration Risk [Table] Customer [Axis] Customer [Domain] McKesson. McKesson AmeriSource-Bergen Corp. AmeriSource-Bergen Corp [Member] Cencora (previously known as AmeriSource-Bergen Corporation) Cardinal. Cardinal Cardinal Health, Inc. Concentration Risk [Line Items] Concentration Risk Accounts and Financing Receivables [Table] Schedule Of Accounts Notes Loans And Financing Receivable [Table] Receivable Type [Axis] Receivable [Domain] Charge backs and discounts for prompt payment. Chargebacks and Discounts for Prompt Payment Rebates. Rebates Other fees, co-pay assistance and returns. Other Fees, Co-pay Assistance and Returns Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Notes And Loans Receivable Reserve for discounts and allowances constitute variable consideration. Reserve For Discounts And Allowances Constitute Variable Consideration Activities and reserve balance, ending balance Activities and reserve balance, beginning balance n/a Provision related to sales made in: Reserve for sales discounts and allowances constitute variable consideration. Reserve For Sales Discounts And Allowances Constitute Variable Consideration Current period Represents provision related to sales made in prior period. Provision Related to Sales Made in Prior Period Prior period - increase (decrease) Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration. Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration Payments and customer credits issued Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Asset Class [Axis] Asset Class [Domain] Money Market Funds [Member] Money market funds Represents the member information pertaining to prepaid expenses. Prepaid Expenses [Member] Prepaid financial instrument in Prepaid manufacturing Financial Instrument [Axis] Financial Instruments [Domain] US Government Agencies Debt Securities [Member] U.S. government agency securities US Treasury Securities [Member] U.S. treasury securities Corporate Note Securities [Member] Commercial paper and corporate notes Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Liability Class [Axis] Fair Value by Liability Class [Domain] Derivative Financial Instruments, Liabilities [Member] Royalty Fee Derivative Liability Contingent consideration. Contingent Consideration Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets measured at fair value on a recurring basis Cost, Unrealized Gains or Losses, and Fair Value by Investment Assets, Fair Value Disclosure Total financial assets Financial Liabilities Fair Value Disclosure Total financial liabilities Debt Securities, Available-for-Sale, Amortized Cost Cost Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized (Loss) Debt Securities, Available-for-Sale Fair Value Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Represents the information pertaining to Out-license - Novartis Institutes. Out Licenses with Novartis Institutes [Member] Novartis Institutes Royalty Agreements [Member] Royalty Fee Derivative Liability Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Represents information pertaining to Surface Oncology, Inc. Surface Oncology, Inc. [Member] Surface Acquisition Embedded Derivative, Fair Value of Embedded Derivative Liability Fair value of the Royalty Fee Derivative Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment of Intangible Assets, Finite-Lived Impairment charge Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Fair value of the contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration, non-current Business Combination, Contingent Consideration, Liability, Current Contingent consideration, current Inventory, Raw Materials, Gross Raw materials Inventory, Work in Process, Gross Work in process Inventory, Finished Goods, Gross Finished goods Inventory, Gross Total Inventory current and noncurrent. Inventory Current And Noncurrent Total Inventory, Current [Table] Inventory Current [Table] Inventory [Axis] Inventory [Domain] Represents information pertaining to Yusimry product. Yusimry Product [Member] YUSIMRY Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Cost of Sales [Member] Cost of Goods Sold Inventory [Line Items] Inventory Disposal Group, Including Discontinued Operation, Inventory Inventory The minimum amount the entity agreed to spend under the long-term and short-term purchase commitment. Long-Term And Short-Term Purchase Commitments, Amount Certain firm purchase commitments Long-Term Purchase Commitment, Amount Certain firm purchase commitments, Long-term The minimum amount the entity agreed to spend under the short-term purchase commitment. Short-Term Purchase Commitment, Amount Certain firm purchase commitments, Short-term Represents prepayments made

to a CMO for manufacturing services. Prepayments Made to CMO For Manufacturing Services Prepayments made to a CMO for manufacturing services for UDENYCA Represents prepayments made to a CMO for other research and development program. Prepayments made to a CMO For Other Research And Development Pipeline Program Prepayments made to a CMO For Other Research And Development Pipeline Program Amount of prepayments made related to sale transaction. Prepayments Related to Sale Transaction Payment related to sale transaction Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Machinery and Equipment [Member] Computer Equipment [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Leaseholds and Leasehold Improvements [Member] Property, Plant and Equipment [Line Items] Property and Equipment, Net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Total property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Property and equipment, net Depreciation, Depletion and Amortization Depreciation and amortization expense related to property and equipment, net Capitalized Computer Software, Net Software implementation costs Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions Finite-Lived Intangible Assets, Net Finite-lived assets, net of accumulated amortization of $2,052 and $639, as of September 30, 2024 and December 31, 2023, respectively Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-lived assets - IPR&DIndefinite-lived assets - in-process research and development Goodwill Goodwill Amortization of Intangible Assets Amortization expense, Finite-lived intangible assets Amount of decrease in assets, excluding financial assets, lacking physical substance with a definite life, from derecognition upon disposal of business. Finite-Lived Intangible Assets, Derecognition Upon Disposal Of Business Finite-lived intangible asset, net Goodwill, Written off Related to Sale of Business Unit Goodwill, Written off Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in each of five succeeding fiscal years. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finite-Lived Intangible Asset, Expected Amortization, for Each of Five Succeeding Fiscal Years Expected amortization expense for the remaining finite-lived assets for each of the five succeeding fiscal years Accrued commercial and research and development manufacturing liabilities current. Accrued Commercial and Research and Development Manufacturing Liabilities Current Accrued commercial and research and development manufacturing Accrued co-development costs and milestone payments The amount represents Accrued co-development costs and milestone payments. Accrued co-development costs and milestone payments Accrued Royalties, Current Accrued royalties Derivative Liability, Current Derivative liabilities, Fair Value Royalty Fee Derivative Liability (Note 8) Amount of obligations related to royalty participation, classified as current. Royalty Participation Liability, Current Revenue participation liability, current (Note 8) Royalty participation liability, current Other Accrued Liabilities, Current Accrued other Represents lease liabilities for both operating and financing leases. Lease Liabilities, Operating and Financing Lease liabilities, current Deferred Income Tax Liabilities, Net Deferred tax liability Amount of obligations related to royalty participation, classified as noncurrent. Royalty Participation Liability, Noncurrent Revenue participation liability, non-current (Note 8) Royalty participation liability, non-current Other Sundry Liabilities, Noncurrent Other Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Represents information pertaining to Surface GSK agreement. Surface GlaxoSmithKline Agreement [Member] Surface GSK Agreement Represents information pertaining to Surface's SRF114 proprietary drug product candidate. Surface SRF114 Proprietary Drug Product Agreement [Member] Surface's SRF114 proprietary drug product candidate Represents information pertaining to Surface's SRF388 proprietary drug product candidate. Surface SRF388 Proprietary Drug Product Agreement [Member] Surface's SRF388 proprietary drug product candidate Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Gain on sale transaction The amount of transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. Disposal Group, Including Discontinued Operation, Transaction Costs Incurred Transaction costs incurred Carrying value as of the balance sheet date of unpaid transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. Disposal Group, Including Discontinued Operation, Transaction Costs Unpaid Transaction costs unpaid Carrying value as of the balance sheet date of transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. Disposal Group, Including Discontinued Operation, Transaction Costs Transaction costs Amount of reimbursable costs for business support services. Reimbursable Costs For Business Support Services Reimbursable costs Amount of unpaid transaction costs and retention bonuses committed to pay. Unpaid Transaction Costs and Retention Bonuses Payable Retention bonus Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Income under TSA Number of shares issued in exchange of each share of acquiree in a business combination. Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree Shares Issued, Price Per Share Share price Share price The number of contingent value rights issuable in consideration for each share under business combination. Business Combination, Consideration, Contingent Value Right Per Share Contingent value right per share The payment period of contingent value rights under business combination. Business Combination, Consideration, Contingent Value Right, Payment Period Contingent value rights payment period The percent of milestone and royalty based payments payable as part of contingent value rights under business combination. Business Combination, Consideration, Contingent Value Right Payments, Percent of Milestone and Royalty Based Payments Milestone and royalty based CVR payments (as percent) The percent of upfront payments payable as part of contingent value rights under business combination. Business Combination, Consideration, Contingent Value Right Payments, Percent of Upfront Payments Upfront payment based CVR payments (as percent) Number of outlicensed partnership program in a business combination. Business Combination, Number of Out Licensed Partnership Program Business Combination, Number of Out Licensed Partnership Program Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] In Process Research and Development [Member] In-process research and development Licensing Agreements [Member] Out-licenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Assets Acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Investments in marketable securities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Prepaids and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Liabilities Assumed Amount of accrued and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued and Other Current Liabilities Accrued and other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Total net assets acquired Represents the information pertaining to In-process research and development - SRF388. In Process Research and Development SRF 388 [Member] In-process research and development - casdozokitug Represents the information pertaining to In-process research and development - SRF114. In Process Research and Development SRF 114 [Member] In-process research and development - SRF 114 Represents the information pertaining to Out-license - GSK. Out Licenses with GRK [Member] Out-license - GSK Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Useful Lives Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Acquisition-related Costs [Member] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Business Acquisition, Pro Forma Revenue Total revenues Business Acquisition, Pro Forma Net Income (Loss) Net loss Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Acquisition-related costs Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Financial Statement Caption Represents the Vaccinex License Agreement. Vaccinex License Agreement [Member] Vaccinex License Agreement Represents the Exclusive License and Commercialization Agreement . Collaboration Agreement Collaboration Agreement Represents the information pertaining to Adimab Development and Option Agreement. Adimab Development and Option Agreement [Member] Adimab Development and Option Agreement Represents the information pertaining to GSK Agreement. GSK Agreement [Member] GSK Agreement Represents information pertaining to Junshi Biosciences. Junshi Biosciences Junshi Biosciences Represents information pertaining to Canada License Agreement. Canada License Agreement [Member] Canada license agreement Legal Entity [Axis] All Entities [Member] Represents the information pertaining to Surface. Surface [Member] Surface Represents anti-TIGIT antibody and the IL-2 cytokine. Anti-TIGIT Antibody and IL-2 cytokine Anti-TIGIT Antibody and IL-2 cytokine Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Represents intangible assets, net and accrued and other current liabilities. Intangible Assets, Net And Accrued And Other Current Liabilities [Member] Intangible assets, net and accrued and other current liabilities Represents accrued and other current liabilities. Accrued and other current liabilities Accrued and other current liabilities Accounts Payable [Member] Accounts payable Represents costs associated to a collaboration agreement. Collaboration Costs Collaboration Agreement, upfront amount paid Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement. Collaboration Agreement, Number Of Undisclosed Preclinical Immuno Oncology Drug Candidates Undisclosed preclinical Represents the percentage of royalty on net sales under the collaboration agreement. Collaboration Agreement, Percentage Of Royalty On Net Sales Collaboration agreement, royalty on net sales, percentage Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones The amount of option exercise fee per program under the collaboration agreement. Collaboration Agreement, Option Exercise Fee Per Program License Agreement Fee Represents the percentage of royalty on net sales for each option program under the collaboration agreement. Collaboration Agreement, Percentage Of Royalty On Net Sales For Each Option Program Collaboration agreement, royalty on net sales for each exercised option, percentage The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement. Collaboration Agreement , Threshold Payments On Achievement Of Various Milestone For Each Option Program Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement. Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program Represents the maximum paid amount for co-development activities. Maximum Amount Paid, Co-development Activities Maximum paid amount for co-development activities (per licensed compound) Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. Accrued Milestone Payment Accrued milestone payment Amount per each installment of milestone payments under collaborative arrangements. Milestone Payments, Amount Per Each Installment Milestone payments, amount Amount of decrease in research and development expenses for release of certain liabilities. Decrease in Research and Development Expenses for Release of Certain Liabilities Represents co-development, regulatory and technology transfer costs. Co-development, Regulatory And Technology Transfer Costs Co-development, regulatory and technology transfer costs Accrued Royalties Royalties due The upfront payment received by the company under the collaborative arrangement. Collaborative Arrangement Upfront Payment Received Company an upfront payment received Amount of regulatory and sales milestones eligible to receive under the collaborative arrangement. Collaborative Arrangement, Regulatory And Sales Milestones Eligible To Receive Regulatory and sales milestones eligible to receive Renewal term of agreement. Collaboration Agreement, Renewal Term Renewal term Maximum number of antibodies under for research option Maximum Number of Antibodies Under for Research Option Maximum number of antibodies under for research option Minimum Number of Antibodies under Commercialization option Minimum Number of Antibodies under Commercialization option Minimum antibodies to be commercialized under commercialization option Minimum Antibodies to be Commercialized under Commercialization Option Minimum antibodies to be commercialized under commercialization option Technical milestone payments obligated to pay Collaboration Agreement, Technical Milestone Payments Obligated to Pay Technical milestone payments obligated to pay Period for payment of nominal research maintenance fee Collaboration Agreement, Period for Payment of Nominal Research Maintenance Fee Period for payment of nominal research maintenance fee Maximum aggregate milestone payments to be made Collaboration Agreement, Maximum Aggregate Milestone Payments to be Made Maximum aggregate milestone payments to be made Maximum antibodies partially exercised under commercialization option Maximum Antibodies Partially Exercised under Commercialization Option Maximum antibodies partially exercised under commercialization option Percentage of option fee to be paid on partial exercise of commercialization option Percentage of Option Fee to be Paid on Partial Exercise of Commercialization Option Percentage of option fee to be paid on partial exercise of commercialization option Amount of regulatory milestones eligible to pay. Regulatory Milestones Eligible to Pay Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products Amount of sales milestones entitled. Sales Milestones Entitled Sales milestones Amount of milestone payments earned Collaboration Agreement, Milestone Payments Earned Milestone payments earned Amount of additional clinical milestones eligible to receive Collaboration Agreement, Additional Clinical Milestones Eligible to Receive Additional clinical milestones eligible to receive Amount of regulatory milestones eligible to receive Collaboration Agreement, Regulatory Milestones Eligible to Receive Regulatory milestones eligible to receive Term of agreement Collaboration Agreement, Term Term of agreement Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Less unamortized debt discount and issuance costs Less unamortized debt discount and debt issuance costs Remaining unamortized debt discount and debt offering costs Long-Term Debt Net carrying amount Debt Instrument, Fair Value Disclosure Estimated Fair Value Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to Ankura Trust Company LLC. Ankura Trust Company LLC [Member] Ankura Trust Company, LLC Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period One [Member] Through March 31, 2023 On or after the first anniversary Debt Instrument, Redemption, Period Two [Member] Starting April 1, 2023 After the second anniversary Debt Instrument, Redemption, Period Three [Member] After the third anniversary Proceeds from Debt, Net of Issuance Costs Net proceeds, net of original issuance discount Debt Instrument, Interest Rate, Stated Percentage Stated interest rate Loan agreement prepayment fee percentage. Loan Agreement Prepayment Fee Percentage Prepayment fee Loan agreement funding fee percentage. Loan Agreement Funding Fee Percentage Prepayment funding fee Debt Issuance Costs, Noncurrent, Net Debt issuance costs Number of events in default. Number Of Events in Default Number of events in default The amount of debt discounts and issuance costs incurred. Debt Discounts and Issuance Costs Debt discounts and issuance costs Interest Expense, Debt Interest expense Total Interest expense Represents information pertaining to debt instrument contractual term. Debt Instrument Contractual Term Contractual term Represents information pertaining to BioPharma Credit Investments V GP LLC. BioPharma Credit Investments V GP LLC Interest Expense, Debt, Excluding Amortization Stated coupon interest Contractual interest Amortization of Debt Discount (Premium) Amortization of debt discount and debt issuance costs Debt Instrument, Interest Rate During Period Interest rate Long-Term Debt, Maturity, Remainder of Fiscal Year Remainder of 2024 - interest only Long-Term Debt, Maturity, Year One 2025 - interest only 2025 - interest only Long-Term Debt, Maturity, Year Two 2026 - interest only Long-Term Debt, Maturity, Year Three 2027 - interest only Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Long-Term Debt, Maturity, after Year Three 2028 and thereafter - principal and interest Long-Term Debt, Gross Total minimum payments Interest Payable Less amount representing interest Term Loan, gross. Term Loan Gross 2029 Term Loan, gross Embedded Derivative [Table] Represents Udenyca and Loqtorzi. Udenyca and Loqtorzi [Member] UDENYCA and LOQTORZI Interest Expense [Member] Interest expense Embedded Derivative [Line Items] Revenue Purchase and Sale Agreement purchase price. Revenue Purchase and Sale Agreement, Purchase Price Revenue Purchase and Sale Agreement, Purchase price The percent to be received pertaining to the sales of the companies products and services. Revenue Purchase and Sale Agreement, Right to Receive, Percent Revenue payment, Percentage of U.S. net sales Revenue Purchase and Sale Agreement purchase price. Revenue Purchase and Sale Agreement, Certain Conditions, Purchase Price,

Multiplier Purchase price multiplier Discount on the revenue participation liability, resulting from a derivative instrument. Discount On Revenue Participation Liability From Derivative Instrument Discount on revenue participation liability from allocation of purchase price to the embedded derivative Issuance costs on the revenue participation liability. Issuance Costs On Revenue Participation Liability Issuance costs on revenue participation liability Interest expense, inclusive of the amortization of discount and issuance costs. Interest Expense, Inclusive Of Amortization Of Discount And Issuance Costs On Revenue Participation Liability Interest expense, inclusive of the amortization of discount and issuance costs Amortization of Debt Issuance Costs and Discounts Amortization of discount and issuance costs Amount of revenue participation liability. Revenue Participation Liability Revenue participation liability Amount of Obligations related to royalty participation. Royalty Participation Liability Total Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Convertible Debt [Member] Amount of loan funded out of amount available under loan agreement. Debt Instrument, Funded Amount Funded amount Debt Instrument, Basis Spread on Variable Rate Spread on variable rate Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Amount of partial prepayment agreed to be made of its term loan. Debt Partial prepayment to be Made Debt partial prepayment to be Made Minimum amount of net sales covenant level to be maintained for trailing twelve months. Minimum Net Sales Convenant Level Agreed to be Maintained Over Past Year Minimum net sales convenant level agreed to be maintained over past year Amount of partial repayment of principal of the loans subject to terms and conditions. Deb Instrument, Partial Repayment, Principal Partial prepayment of principal Debt instrument prepayment percentage. Debt Instrument Prepayment Percentage Prepayment premium percentage Scenario [Axis] Scenario [Domain] Scenario, Plan [Member] Proceeds from Convertible Debt Net proceeds from offering Debt instrument convertible number of shares per thousand of principal amount of notes. Debt Instrument Convertible Number Of Shares Per Thousand Of Principal Amount Of Notes Initial conversion rate, shares of common stock Principal amount of notes converted into shares of common stock at conversion rate. Principal Amount Of Notes Converted Into Shares Of Common Stock At Conversion Rate Principal amount of notes converted into shares Equivalent to conversion price per common share. Equivalent To Conversion Price Per Common Share Initial conversion price per common share Debt Instrument, Interest Rate Terms Interest rate description Debt Instrument, Maturity Date Debt instrument maturity date Percentage of premium on convertible note. Percentage Of Premium On Convertible Note Convertible notes, premium percentage Debt Instrument, Covenant Compliance Convertible notes, covenant compliance Debt Conversion, Converted Instrument, Amount Convertible notes, converted amount Share Price Closing stock, price per share Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Option Indexed to Issuer's Equity, Equity [Table] Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity, Type [Domain] Call Option [Member] Option Indexed to Issuer's Equity [Line Items] The amount of payment made for entering into capped call transactions. Payment for Capped Call Transactions Payment for capped call transactions Represents the cap price of the cap call transactions (per share). Cap Price of Cap Call Transactions Initial cap price of capped call transactions. Represents the percentage of premium on cap price. Percentage of Cap Price, Capped Call Transactions Percentage of cap price Convertible notes, principal amount. Convertible Notes Principal Amount 2026 Convertible Notes, principal amount Purchase Obligation, to be Paid, Remainder of Fiscal Year 2024 Purchase Obligation, to be Paid, Year One 2025 Purchase Obligation, to be Paid, Year Two 2026 Purchase Obligation, to be Paid, Year Three 2027 Purchase Obligation Total obligations Contractual Obligation Fiscal Year Maturity [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Represents accrued rebates, fees and reserves. Accrued Rebates, Fees And Reserves [Member] Accrued rebates, fees and reserves Loss Contingencies [Line Items] Loss Contingencies Business Combination, Liabilities Arising from Contingencies, Amount Recognized Inventory purchase commitments Loss Contingency Accrual Accrual related to legal Proceedings and Other Claims Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate Claims related to certain sales of UDENYCA from October 2020 through December 2021 At the market offering. Stockholders' Deficit [Table] Over-Allotment Option [Member] Statistical Measurement [Axis] Statistical Measurement [Domain] Weighted Average [Member] Maximum [Member] Maximum Line items represent at the market offering. At The Market Offering [Line Items] Stockholders' Deficit The period for exercise of option to purchase additional shares by underwriters. Shares Offering, Underwriters Option, Term Term of share offering The aggregate amount of shares to be offered. Shares Offering, Aggregate Amount Shares Offering, Aggregate Amount Proceeds from Issuance or Sale of Equity Net proceeds, after deducting the Underwriters' discounts and commissions and offering expenses The decrease in aggregate amount of shares to be offered. Shares Offering, Aggregate Amount, Decrease Shares Offering, Aggregate Amount, Decrease Amount of increase in shares to be issued and sold. Increase in Amount of Shares To be Issued and Sold Increase in Amount of Shares To be Issued and Sold Weighted-average price per share. Weighted-average Price Per Share Weighted-average price per share The cash inflow from the additional capital contribution to the entity, before stock issuance costs. Proceeds from Issuance of Common Stock, Gross Gross proceeds Payments of Stock Issuance Costs Less commissions and fees Sale of Stock, Consideration Received on Transaction Net proceeds after commissions and fees Represents the common stock remaining available for sale under the atm offering. Common Stock Remaining Available For Sale Under The ATM Offering Common stock remaining available for sales under the ATM Offering Performance Shares [Member] Performance Condition PSO Research and Development Expense [Member] Research and development Selling, General and Administrative Expenses [Member] Title and Position [Axis] Title and Position [Domain] Title of Individual [Domain] Executive Officer [Member] Other Senior Executives Chief Executive Officer [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share based payment options grants Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Term years Share-Based Payment Arrangement, Expense Stock-based compensation expense Share-Based Payment Arrangement, Amount Capitalized Stock-based compensation expense capitalized into inventory N/A Basic And Diluted Net Income (Loss) Per Share [Abstract] Basic net income (loss) per share Net Income (Loss) Attributable to Parent [Abstract] Numerator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Denominator: Earnings Per Share, Diluted [Abstract] Diluted net income (loss) per share Net Income (Loss) Attributable to Parent, Diluted [Abstract] Numerator: Interest on Convertible Debt, Net of Tax Add interest expense on 2026 Convertible Notes, net of tax Net Income (Loss) Attributable to Parent, Diluted Numerator for diluted net income (loss) per share Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Add effect of potential dilutive securities: Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Stock options, including shares subject to ESPP Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares Restricted stock units Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Shares issuable upon conversion of convertible notes Weighted Average Number of Shares Outstanding, Diluted, Adjustment Denominator for diluted net income (loss) income per share Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Employees and non-employees stock option. Stock options, including shares subject to ESPP Stock options, PSOs, including shares subject to ESPP Restricted Stock Units (RSUs) [Member] Convertible notes. Shares issuable upon conversion of convertible notes Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from the calculation of diluted net income (loss) per share EX-101.PRE 9 chrs-20240930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 31, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-36721 Â Entity Registrant Name Coherus BioSciences,Â Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 27-3615821 Â Entity Address, Address Line One 333 Twin Dolphin Drive Â Entity Address, Address Line Two SuiteÂ 600 Â Entity Address, City or Town Redwood City Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94065 Â City Area Code 650 Â Local Phone Number 649-3530 Â Title of 12(b) Security Common Stock, $0.0001 par value per share Â Trading Symbol CHRS Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 115,213,407 Entity Central Index Key 0001512762 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT

v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 97,690 $ 102,891 Investments in marketable securities Â 14,857 Trade receivables, net 167,559 260,522 TSA receivables, net (Note 6) 31,241 Â Inventory 47,640 62,605 Prepaid manufacturing 10,718 23,657 Other prepaids and current assets 14,176 11,099 Total current assets 369,024 475,631 Property and equipment, net 2,911 5,119 Inventory, non-current 71,375 67,495 Intangible assets, net 54,313 71,673 Other assets, non-current 7,377 9,686 Total assets 505,000 629,604 Current liabilities: Â Â Accounts payable 21,893 35,219 Accrued rebates, fees and reserves 163,315 169,645 TSA payables and other accrued liabilities (Note 6) 33,637 Â Accrued compensation 15,756 21,521 Accrued and other current liabilities 60,965 105,386 Total current liabilities 295,566 331,771 Term loans, non-current 36,618 246,481 Convertible notes 227,891 226,888 Lease liabilities, non-current 3,737 5,328 Other liabilities, non-current 29,161 12,561 Total liabilities 592,973 823,029 Commitments and contingencies (Note 9) Stockholders' deficit: Â Â Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 115,213,407 and 112,215,260 at September 30, 2024 and December 31, 2023, respectively) 12 11 Additional paid-in capital 1,412,587 1,386,312 Accumulated other comprehensive loss (275) (248) Accumulated deficit (1,500,297) (1,579,500) Total stockholders' deficit (87,973) (193,425) Total liabilities and stockholders' deficit $ 505,000 $ 629,604 X - DefinitionAccrued rebates, fees and reserve. + ReferencesNo definition available. + Details Name: chrs_AccruedRebatesFeesAndReserveCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. + ReferencesNo definition available. + Details Name: chrs_OperatingAndFinanceLeaseLiabilityNoncurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPrepaid Manufacturing current. + ReferencesNo definition available. + Details Name: chrs_PrepaidManufacturingExpenseCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesNo definition available. + Details Name: chrs_TermLoansPayableNoncurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transition services agreement payables classified as current. + ReferencesNo definition available. + Details Name: chrs_TransitionServicesAgreementPayablesAndOtherAccruedLiabilitiesCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transition services agreement receivable current. + ReferencesNo definition available. + Details Name: chrs_TransitionServicesAgreementReceivableCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix:

us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleSubordinatedDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1 + Details Name: us-gaap_IntangibleAssetsNetIncludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_ReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares issued 115,213,407 112,215,260 Common stock, shares outstanding 115,213,407 112,215,260 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: Â Â Â Â Net revenue $ 70,774 $ 74,568 $ 212,816 $ 165,720 Costs and expenses: Â Â Â Â Cost of goods sold 20,741 32,703 83,695 74,425 Research and development 21,676 25,647 72,101 83,068 Selling, general and administrative 34,744 48,224 126,441 142,521 Total costs and expenses 77,161 106,574 282,237 300,014 Loss from operations (6,387) (32,006) (69,421) (134,294) Interest expense (5,362) (10,268) (21,812) (29,923) Gain (loss) on Sale Transactions, net (Note 6) (1,086) Â 176,646 Â Loss on debt extinguishment Â Â (12,630) Â Other income (expense), net 2,084 2,253 6,420 5,598 Income (loss) before income taxes (10,751) (40,021) 79,203 (158,619) Income tax provision Â (380) Â (380) Net income (loss) $ (10,751) $ (39,641) $ 79,203 $ (158,239) Net income (loss) per share: Â Â Â Â Basic (In dollar per share) $ (0.09) $ (0.41) $ 0.69 $ (1.79) Diluted (In dollar per share) $ (0.09) $ (0.41) $ 0.65 $ (1.79) Weighted-average number of shares used in computing net income (loss) per share: Â Â Â Â Basic (In shares) 115,210,091 97,738,509 114,263,256 88,277,936 Diluted (In shares) 115,210,091 97,738,509 126,563,551 88,277,936 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGain (loss) included in earnings resulting from the sale of interest in projects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_GainLossOnSaleOfInterestInProjects Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or

earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net income (loss) $ (10,751) $ (39,641) $ 79,203 $ (158,239) Other comprehensive income (loss): Â Â Â Â Unrealized gain (loss) on available-for-sale securities, net of tax Â 32 (24) (15) Foreign currency translation adjustments, net of tax (3) Â (3) (1) Comprehensive income (loss) $ (10,754) $ (39,609) $ 79,176 $ (158,255) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands Common Stock [Member] ATM Offering Common Stock [Member] Public Offering Common Stock [Member] Additional Paid-in Capital [Member] ATM Offering Additional Paid-in Capital [Member] Public Offering Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] ATM Offering Public Offering Total Beginning Balances at Dec. 31, 2022 Â Â $ 8 Â Â $ 1,204,431 $ (249) $ (1,341,608) Â Â $ (137,418) Beginning Balances (in shares) at Dec. 31, 2022 Â Â 78,851,516 Â Â Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â Â Â (75,729) Â Â (75,729) Issuance of common stock upon exercise of stock options Â Â Â Â Â 103 Â Â Â Â Â 103 Issuance of common stock upon exercise of stock options (in shares) Â Â 24,107 Â Â Â Â Â Â Â Â Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares) Â Â 771,167 Â Â Â Â Â Â Â Â Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â Â Â 12,288 Â Â Â Â Â 12,288 Issuance of common stock under Offering, net of issuance costs Â Â Â $ 7,059 Â Â Â Â $ 7,059 Â Â Issuance of common stock under Offering, net of issuance costs (in shares) 1,131,450 Â Â Â Â Â Â Â Â Â Â Taxes paid related to net share settlement of RSUs Â Â Â Â Â (2,781) Â Â Â Â (2,781) Taxes paid related to net share settlement of RSUs (in shares) Â Â (289,944) Â Â Â Â Â Â Â Â Other comprehensive loss, net of tax Â Â Â Â Â Â Â Â (29) Â Â Â (29) Ending Balances at Mar. 31, 2023 Â Â $ 8 Â Â 1,221,100 (278) (1,417,337) Â Â (196,507) Ending Balances (in shares) at Mar. 31, 2023 Â Â 80,488,296 Â Â Â Â Â Â Â Â Beginning Balances at Dec. 31, 2022 Â Â $ 8 Â Â 1,204,431 (249) (1,341,608) Â Â (137,418) Beginning Balances (in shares) at Dec. 31, 2022 Â Â 78,851,516 Â Â Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â Â Â Â Â (158,239) Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Issuance of common stock under Offering, net of issuance costs (in shares) Â Â Â Â Â Â Â Â 3,559,761 Â Â Ending Balances at Sep. 30, 2023 Â Â $ 11 Â Â 1,366,502 (265) (1,499,847) Â Â (133,599) Ending Balances (in shares) at Sep. 30, 2023 Â Â 109,113,046 Â Â Â Â Â Â Â Â Beginning Balances at Mar. 31, 2023 Â Â $ 8 Â Â 1,221,100 (278) (1,417,337) Â Â (196,507) Beginning Balances (in shares) at Mar. 31, 2023 Â Â 80,488,296 Â Â Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â Â Â (42,869) Â Â (42,869) Issuance of common stock upon exercise of stock options Â Â Â Â Â 14 Â Â Â Â 14 Issuance of common stock upon exercise of stock options (in shares) Â Â 8,182 Â Â Â Â Â Â Â Â Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares) Â Â 142,982 Â Â Â Â Â Â Â Â Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â Â Â 10,034 Â Â Â Â Â 10,034 Issuance of common stock under Offering, net of issuance costs Â $ 1 Â Â $ 53,624 Â Â Â Â Â $ 53,625 Â Issuance of common stock under Offering, net of issuance costs (in shares) Â 13,529,411 Â Â Â Â Â Â Â Â Offering costs associated with ATM offering Â Â Â (74) Â Â Â Â $ (74) Â Â Issuance of common stock under the employee stock purchase plan ("ESPP") Â Â Â Â Â 1,337 Â Â Â Â 1,337 Issuance of common stock under the employee stock purchase plan ("ESPP") (in shares) Â Â 321,672 Â Â Â Â Â Â Â Â Taxes paid related to net share settlement of RSUs Â Â Â Â Â (305) Â Â Â Â (305) Taxes paid related to net share settlement of RSUs (in shares) Â Â (48,529) Â Â Â Â Â Â Â Â Other comprehensive loss, net of tax Â Â Â Â Â Â (19) Â Â Â (19) Ending Balances at Jun. 30, 2023 Â Â $ 9 Â Â 1,285,730 (297) (1,460,206) Â Â (174,764) Ending Balances (in shares) at Jun. 30, 2023 Â Â 94,442,014 Â Â Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â (39,641) Â Â (39,641) Issuance of common stock upon exercise of stock options Â Â Â Â Â 53 Â Â Â Â 53 Issuance of common stock upon exercise of stock options (in shares) Â Â 27,977 Â Â Â Â Â Â Â Â Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares) Â Â 72,918 Â Â Â Â Â Â Â Â Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Issuance to Surface shareholders for acquisition Â Â $ 1 Â Â

58,540 Â Â Â Â 58,541 Issuance to Surface shareholders for acquisition (in shares) Â Â 11,971,460 Â Â Â Â Â Â Â Â Accelerated vesting of equity awards (in shares) Â Â 261,239 Â Â Â Â Â Â Â Â Accelerated vesting of equity awards Â Â Â Â Â 1,053 Â Â Â Â 1,053 Taxes paid related to net share settlement of equity awards (in shares) Â Â (65,732) Â Â Â Â Â Â Â Â Taxes paid related to net share settlement of equity awards Â Â Â Â Â (347) Â Â Â Â (347) Stock-based compensation expense Â Â Â Â Â 10,152 Â Â Â Â 10,152 Issuance of common stock under Offering, net of issuance costs $ 1 Â Â 11,436 Â Â Â Â $ 11,437 Â Â Issuance of common stock under Offering, net of issuance costs (in shares) 2,428,311 Â Â Â Â Â Â Â Â 2,428,311 Â Â Taxes paid related to net share settlement of RSUs Â Â Â Â Â (115) Â Â Â Â (115) Taxes paid related to net share settlement of RSUs (in shares) Â Â (25,141) Â Â Â Â Â Â Â Â Other comprehensive loss, net of tax Â Â Â Â Â Â 32 Â Â Â 32 Ending Balances at Sep. 30, 2023 Â Â $ 11 Â Â 1,366,502 (265) (1,499,847) Â Â (133,599) Ending Balances (in shares) at Sep. 30, 2023 Â Â 109,113,046 Â Â Â Â Â Â Â Â Beginning Balances at Dec. 31, 2023 Â Â $ 11 Â Â 1,386,312 (248) (1,579,500) Â Â $ (193,425) Beginning Balances (in shares) at Dec. 31, 2023 Â Â 112,215,260 Â Â Â Â Â Â Â Â 112,215,260 Net income (loss) Â Â Â Â Â Â Â 102,875 Â Â $ 102,875 Issuance of common stock upon exercise of stock options Â Â Â Â Â 291 Â Â Â Â 291 Issuance of common stock upon exercise of stock options (in shares) Â Â 174,651 Â Â Â Â Â Â Â Â Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares) Â Â 741,213 Â Â Â Â Â Â Â Â Â Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â Â Â 7,677 Â Â Â Â 7,677 Issuance of common stock under Offering, net of issuance costs Â Â Â 1,507 Â Â Â Â $ 1,507 Â Â Issuance of common stock under Offering, net of issuance costs (in shares) 650,005 Â Â Â Â Â Â Â Â Â Â Taxes paid related to net share settlement of RSUs Â Â Â Â Â (745) Â Â Â Â (745) Taxes paid related to net share settlement of RSUs (in shares) Â Â (284,275) Â Â Â Â Â Â Â Â Â Other comprehensive loss, net of tax Â Â Â Â Â Â (24) Â Â Â (24) Ending Balances at Mar. 31, 2024 Â Â $ 11 Â Â 1,395,042 (272) (1,476,625) Â Â (81,844) Ending Balances (in shares) at Mar. 31, 2024 Â Â 113,496,854 Â Â Â Â Â Â Â Â Beginning Balances at Dec. 31, 2023 Â Â $ 11 Â Â 1,386,312 (248) (1,579,500) Â Â $ (193,425) Beginning Balances (in shares) at Dec. 31, 2023 Â Â 112,215,260 Â Â Â Â Â Â Â Â 112,215,260 Net income (loss) Â Â Â Â Â Â Â Â Â Â $ 79,203 Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Issuance of common stock under Offering, net of issuance costs (in shares) Â Â Â Â Â Â Â Â 650,005 Â Â Ending Balances at Sep. 30, 2024 Â Â $ 12 Â Â 1,412,587 (275) (1,500,297) Â Â $ (87,973) Ending Balances (in shares) at Sep. 30, 2024 Â Â 115,213,407 Â Â Â Â Â Â Â Â 115,213,407 Beginning Balances at Mar. 31, 2024 Â Â $ 11 Â Â 1,395,042 (272) (1,476,625) Â Â $ (81,844) Beginning Balances (in shares) at Mar. 31, 2024 Â Â 113,496,854 Â Â Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â Â (12,921) Â Â (12,921) Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares) Â Â 21,583 Â Â Â Â Â Â Â Â Issuance of common stock - partial payout of 2023 bonus in RSUs Â Â $ 1 Â Â 4,407 Â Â Â Â 4,408 Issuance of common stock - partial payout of 2023 bonus in RSUs (in shares) Â Â 1,976,750 Â Â Â Â Â Â Â Â Â Â Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â Â Â 7,327 Â Â Â Â 7,327 Offering costs associated with ATM offering Â Â Â $ (52) Â Â Â Â $ (52) Â Â Issuance of common stock under the employee stock purchase plan ("ESPP") Â Â Â Â Â 685 Â Â Â Â 685 Issuance of common stock under the employee stock purchase plan ("ESPP") (in shares) Â Â 471,439 Â Â Â Â Â Â Â Â Taxes paid related to net share settlement of RSUs Â Â Â Â Â (1,711) Â Â Â Â (1,711) Taxes paid related to net share settlement of RSUs (in shares) Â Â (767,971) Â Â Â Â Â Â Â Â Ending Balances at Jun. 30, 2024 Â Â $ 12 Â Â 1,405,698 (272) (1,489,546) Â Â (84,108) Ending Balances (in shares) at Jun. 30, 2024 Â Â 115,198,655 Â Â Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â Â (10,751) Â Â (10,751) Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares) Â Â 22,915 Â Â Â Â Â Â Â Â Issuance of common stock in connection with Surface Acquisition:(1) Â Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â Â Â 6,899 Â Â Â Â 6,899 Taxes paid related to net share settlement of RSUs Â Â Â Â Â (10) Â Â Â Â (10) Taxes paid related to net share settlement of RSUs (in shares) Â Â (8,163) Â Â Â Â Â Â Â Â Â Other comprehensive loss, net of tax Â Â Â Â Â (3) Â Â Â (3) Ending Balances at Sep. 30, 2024 Â Â $ 12 Â Â $ 1,412,587 $ (275) $ (1,500,297) Â Â $ (87,973) Ending Balances (in shares) at Sep. 30, 2024 Â Â 115,213,407 Â Â Â Â Â Â Â Â 115,213,407 X - DefinitionStock Issued During Period on acquisitions + ReferencesNo definition available. + Details Name: chrs_StockIssuedDuringPeriodAcquisitions Namespace Prefix: chrs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during period in lieu of bonus. + ReferencesNo definition available. + Details Name: chrs_StockIssuedDuringPeriodPartialPayoutBonus Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued in lieu of bonus. + ReferencesNo definition available. + Details Name: chrs_StockIssuedDuringPeriodPartialPayoutBonusShares Namespace Prefix: chrs_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of accelerated vesting of equity awards. + ReferencesNo definition available. + Details Name: chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards Namespace Prefix: chrs_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares settled related to taxes paid related to net share settlement of equity awards during the period. + ReferencesNo definition available. + Details Name: chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards Namespace Prefix: chrs_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock related to accelerated vesting of equity awards issued during the period. + ReferencesNo definition available. + Details Name: chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock settled related to taxes paid related to net share settlement of equity awards during the period. + ReferencesNo definition available. + Details Name: chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Operating activities Â Â Net income (loss) $ 79,203 $ (158,239) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Â Â Depreciation and amortization 4,243 2,728 Stock-based compensation expense 21,418 32,312 Impairment of out-license asset and remeasurement of CVR liability, net 6,772 Â Loss on debt extinguishment 12,630 Â Gain on Sale Transaction, net (Note 6) (176,646) Â Inventory write-downs, net 2,481 4,369 Other non-cash adjustments, net (505) 78 Changes in operating assets and liabilities: Â Â Trade receivables, net 93,024 (106,626) Inventory (25,499) (34,941) Prepaid manufacturing 5,582 4,108 Other prepaid, current and non-current assets (4,306) 10,702 Accounts payable (10,280) 24,545 Accrued rebates, fees and reserves (7,617) 60,602 TSA related operating assets and liabilities, net (Note 6) 2,396 Â Accrued compensation (1,039) (8,810) Accrued and other current and non-current liabilities (50,905) 7,225 Net cash used in operating activities (49,048) (161,947) Investing activities Â Â Proceeds from maturities of investments in marketable securities 6,200 108,148 Proceeds from sale of investments in marketable securities 8,688 13,282 Cash and cash equivalents acquired from Surface Acquisition Â 6,997 Milestone based license fee payment to Junshi Biosciences (12,500) Â Purchases of investments in marketable securities Â (19,507) Other investing activities, net

652 517 Net cash provided by investing activities 230,863 109,437 Financing activities Â Â Proceeds from 2029 Term Loan, net of debt discount & issuance costs 36,979 Â Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs 36,486 Â Proceeds from issuance of common stock upon exercise of stock options 291 170 Proceeds from purchase under the employee stock purchase plan 685 1,337 Taxes paid related to net share settlement (2,466) (3,261) Repayment of 2027 Term Loans, premiums and exit fees (260,387) Â Other financing activities (248) (835) Net cash (used in) provided by financing activities (187,205) 69,234 Net (decrease) increase in cash, cash equivalents and restricted cash (5,390) 16,724 Cash, cash equivalents and restricted cash at beginning of period 103,343 63,987 Cash, cash equivalents and restricted cash at end of period 97,953 80,711 Supplemental disclosures of non-cash activities Â Â Non-cash employee bonuses settled in common stock 4,408 Â Financing issuance costs in accounts payable 859 Â CIMERLI Sale Â Â Investing activities Â Â Cash received from Sale 187,823 Â YUSIMRY Sale Â Â Investing activities Â Â Cash received from Sale 40,000 Â At Market Offering [Member] Â Â Financing activities Â Â Proceeds from issuance of common stock, net of issuance costs $ 1,455 18,198 Public Offering Â Â Financing activities Â Â Proceeds from issuance of common stock, net of issuance costs Â $ 53,625 X - DefinitionThe amount of Impairment of out-license asset and remeasurement of CVR liability, net. + ReferencesNo definition available. + Details Name: chrs_ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in accrued compensation. + ReferencesNo definition available. + Details Name: chrs_IncreaseDecreaseInAccruedCompensation Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in accrued rebates, fees and reserve. + ReferencesNo definition available. + Details Name: chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for issuance cost of debt. + ReferencesNo definition available. + Details Name: chrs_IssuanceCostOfDebtIncurredButNotYetPaid Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with milestone based license fee payment. + ReferencesNo definition available. + Details Name: chrs_PaymentsForMilestoneBasedLicenseFee Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow during the period from revenue purchase and sale agreement. + ReferencesNo definition available. + Details Name: chrs_ProceedsFromRevenuePurchaseAndSaleAgreementNet Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_CashAcquiredFromAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (loss) included in earnings resulting from the sale of interest in projects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_GainLossOnSaleOfInterestInProjects Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe

cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliOphthalmologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_YusimryImmunologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Organization and Summary of Significant Accounting Policies 1.Â Â Â Â Â Â Â Organization and Summary of Significant Accounting PoliciesOrganizationCoherus BioSciences, Inc. (the â€œCompanyâ€ or â€œCoherusâ€) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. The Company is developing an innovative immuno-oncology pipeline that it believes will be synergistic with its proven commercial capabilities in oncology. The Companyâ€™s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. On January 2, 2024, the Company announced the launch in the U.S. of LOQTORZIÂ® in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (â€œNPCâ€), and as monotherapy for the treatment of adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a novel PD-1 inhibitor that the Company developed in collaboration with Shanghai Junshi Biosciences Co., Ltd. (â€œJunshi Biosciencesâ€). The Company also sells UDENYCAÂ® (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States.The Company launched YUSIMRY (adalimumab-aqvh), a biosimilar to Humira (adalimumab), in the United States in July 2023. On June 26, 2024, the Company entered into an Asset Purchase Agreement (the â€œYUSIMRY Purchase Agreementâ€) with Hong Kong King-Friend Industrial Company Ltd. (â€œHKFâ€). Pursuant to the YUSIMRY Purchase Agreement, the Company completed the sale of its YUSIMRY (adalimumab-aqvh) franchise (the â€œYUSIMRY Saleâ€) for upfront, cash consideration of $40.0 million and the assumption of $17.0 million of inventory purchase commitments by HKF. The Company launched CIMERLI (ranibizumab-eqrn), a biosimilar to Lucentis, in the United States in October 2022. On January 19, 2024, the Company entered into a Purchase and Sale Agreement (the â€œCIMERLI Purchase Agreementâ€) with Sandoz Inc. (â€œSandozâ€). Pursuant to the terms and subject to the conditions set forth in the CIMERLI Purchase Agreement, on March 1, 2024, the Company completed the sale of its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC (â€œCoherus Ophthalmologyâ€), to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets (the â€œCIMERLI Saleâ€ and, together with the YUSIMRY Sale, the â€œSale Transactionsâ€). Proceeds from the CIMERLI Sale received in March were used in April 2024 to pay down $175.0 million of the total principal balance of $250.0 million on the Companyâ€™s senior secured term loan facility that was entered into January 5, 2022 (as amended on April 7, 2022, February 6, 2023, and February 5, 2024, the â€œ2027 Term Loansâ€). During the second quarter of 2024, the Company repaid in full all the remaining outstanding indebtedness and terminated all commitments under the 2027 Term Loans, resulting in a $12.6 million loss on debt extinguishment from the 2027 Term Loans (see Note 8. Financial Liabilities).The Companyâ€™s product pipeline comprises the following three product candidates: CHS-1000, an antibody targeting ILT4; casdozokitug (CHS-388, formerly SRF388), an antibody targeting interleukin 27 (â€œIL-27â€); and CHS-114 (formerly SRF114), a highly specific afucosylated immunoglobulin isotype G1 (â€œIgG1â€) antibody targeting CCR8. In addition to the Companyâ€™s internally developed portfolio of product candidates, the Company has a product candidate, GSK4381562, which has been exclusively licensed to GlaxoSmithKline Intellectual Property No. 4 Limited (â€œGSKâ€). Basis of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information and in accordance with the instructions to FormÂ 10-Q and RuleÂ 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the â€œSecurities Actâ€). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals that the Company believes are necessary to fairly

state the financial position and the results of the Companyâ€™s operations and cash flows for interim periods in accordance with U.S.Â GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a fullÂ year or any subsequent interim period.The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited financial statements and notes thereto included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended December 31, 2023 (the â€œ2023 Form 10-Kâ€) filed with the SEC.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as, the estimated effects and uncertainty surrounding the temporary supply interruption relating to the Companyâ€™s third-party labeling and packaging CMO for UDENYCA. Accounting estimates and judgments are inherently uncertain and therefore actual results could differ from these estimates.Cash, Cash Equivalents and Restricted CashThe following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets, which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)â€‹January 1,At beginning of period:Â Â Â Â 2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 102,891â€‹$ 63,547Restricted cashâ€‹â€‹ 452â€‹â€‹ 440Total cash, cash equivalents and restricted cashâ€‹$ 103,343â€‹$ 63,987â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â At end of period:â€‹2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 97,690â€‹$ 80,259Restricted cashâ€‹Â 263â€‹Â 452Total cash, cash equivalents and restricted cashâ€‹$ 97,953â€‹$ 80,711â€‹Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets.â€‹Trade ReceivablesTrade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customerâ€™s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2024 and December 31, 2023.Revenue Purchase and Sale Agreement The Revenue Purchase and Sale Agreement (see Note 8. Financial Liabilities) contains an embedded derivative that meets the criteria to be bifurcated and accounted for separately from the Revenue Purchase and Sale Agreement (the "Royalty Fee Derivative Liability"). The Royalty Fee Derivative Liability was recorded at fair value upon entering into the Revenue Purchase and Sale Agreement and is subsequently remeasured to fair value at each reporting period with the corresponding change in fair value recognized in other income (expense), net in the condensed consolidated statements of operations. The Revenue Purchase and Sale Agreement was initially valued and is remeasured using Monte Carlo simulation models to perform the â€œwith-and-withoutâ€ method, which involves valuing the Revenue Purchase and Sale Agreement with the embedded derivative and then valuing it without the embedded derivative. The difference between values is determined to be the estimated fair value of the Royalty Fee Derivative. Refer to Note 3. Fair Value Measurements for details regarding the fair value.The Revenue Purchase and Sale Agreement is accounted for as a liability net of a discount comprising issuance costs and the fair value of the embedded derivative requiring bifurcation. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the liability to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the condensed consolidated statement of operations. The interest rate on this revenue participation liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The Company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales could materially impact the revenue participation liability, interest expense, and the time period for repayment.Contingent Consideration Contingent consideration relates to the potential payments to holders of Contingent Value Rights (â€œCVRsâ€) that are contingent upon the achievement of the Company and certain third parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within selling, general and administrative expense in the condensed consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts. Stock-Based CompensationThe Companyâ€™s compensation programs include stock-based awards. For awards other than condition-based performance stock options, the fair values are recognized as compensation expense on a straight-line basis over the vesting period. For condition-based performance stock options, expense is recognized only when performance conditions are considered probable of being achieved and is recognized over the period from the grant date through the time the milestone is expected to be achieved. The related costs are recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Companyâ€™s common stock on the date of issuance.Recent Accounting Pronouncements The following are recent accounting pronouncements that the Company has not yet adopted:In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-07,Â Segment ReportingÂ (Topic 280) Improvements to Reportable SegmentÂ Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.In December 2023, the FASB issuedÂ ASU 2023-09,Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue 2.Â Â Â Â Â Â Â Â Revenue The Company launched LOQTORZI in December 2023, YUSIMRY in July 2023 and CIMERLI in October 2022. Net revenue for sales of YUSIMRY and CIMERLI effectively ceased to be recognized in the Companyâ€™s condensed consolidated statements of operations on June 26, 2024 and March 1, 2024, respectively (see Note 6. Acquisition and Dispositions). All net product revenue was generated in the United States, and the Companyâ€™s net revenue was as follows:â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â (in thousands)Â Â Â Â 2024â€‹2023â€‹2024Â Â Â Â 2023Productsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ UDENYCAâ€‹$ 66,089â€‹$ 32,967â€‹$ 159,673â€‹$ 90,875 CIMERLIâ€‹â€‹ (1,215)â€‹â€‹ 40,037â€‹â€‹ 26,979â€‹â€‹ 72,939 YUSIMRYâ€‹â€‹ (152)â€‹â€‹ 1,360â€‹â€‹ 7,508â€‹â€‹ 1,360 LOQTORZIâ€‹â€‹ 5,832â€‹â€‹ â€”â€‹â€‹ 11,609â€‹â€‹ â€”Total net product revenueâ€‹â€‹ 70,554â€‹â€‹ 74,364â€‹â€‹ 205,769â€‹â€‹ 165,174Other revenueâ€‹Â 220â€‹Â 204â€‹Â 7,047â€‹Â 546 Total net revenueâ€‹$ 70,774â€‹$ 74,568â€‹$ 212,816â€‹$ 165,720â€‹Gross product revenues by significant customer as a percentage of total gross product revenues were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Note 8. Financial Liabilities), which is recorded in accrued and other current liabilities on the condensed consolidated balance sheets. To estimate the fair value, the Company uses Monte Carlo simulation models that require the use of Level 3 unobservable inputs, primarily the amount and timing of our expected future revenue, the estimated volatility of these revenues, the discount rate corresponding to the risk of revenue, and the probability of certain events. At September 30, 2024, the estimated fair value of the Royalty Fee Derivative Liability remained unchanged at $9.2 million.Financial liabilities related to long-term debt obligations are summarized in Note 8. Financial Liabilities. Other financial liabilities and financial assets measured at fair value on a recurring basis are summarized as follows:â€‹â€‹â€‹

SRF114), an investigational, CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors and head and neck squamous cell carcinoma (â€œHSNSCCâ€).On the Acquisition Date, and in accordance with the Merger Agreement, the Company issued to the holders of all outstanding Surface common stock (subject to certain exceptions) 0.1960 shares of Coherus common stock in exchange for each share of outstanding Surface common stock and certain outstanding Surface employee equity awards. The exchange ratio was calculated pursuant to the terms of the Merger Agreement and was based on aÂ $5.2831Â per share price of Coherus common stock and a nominal total amount of cash in lieu of fractional shares. Surface shareholders also received one CVR for each share of Surface common stock and employee equity award converted. Each CVR entitles the holder to receive quarterly contingent payments in the form of cash, stock or a combination of cash and stock at the Companyâ€™s discretion during the 10-year period following September 8, 2023, for the sum of the following, less any permitted deductions (in accordance with the Contingent Value Rights Agreement, dated September 8, 2023, by and among the Company and Â Computershare Inc. and its affiliate Computershare Trust Company, N.A., together, as the rights agent thereunder (the â€œCVR Agreementâ€)):â—70% of all milestone- and royalty-based payments actually received by the Company or its affiliates from GSK under a license agreement with GSK, dated December 16, 2020, which was subsequently amended in August 2021 (as amended, the â€œGSK Agreementâ€) related to the existing program (GSK4381562);â—25% of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for CHS-114; andâ—50% of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for casdozokitug.The Company has recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement described above. The Company is unable to estimate a range of outcomes for potential royalty and milestone payments for CHS-114 and casdozokitug.The following table below sets forth the purchase price allocation to the estimated fair value of the net assets acquired: â€‹â€‹â€‹â€‹â€‹(in thousands) â€‹Amounts Recognized at Acquisition DateAssets Acquiredâ€‹â€‹â€‹Cash and cash equivalentsâ€‹$ 6,997Investments in marketable securitiesâ€‹â€‹ 21,791Prepaids and other assetsâ€‹â€‹ 5,260In-process research and developmentâ€‹â€‹ 26,239Out-licensesâ€‹â€‹ 13,530Total assetsâ€‹$ 73,817Liabilities Assumedâ€‹â€‹Accrued and other current liabilitiesâ€‹$ 7,722Deferred tax liabilityâ€‹â€‹ 1,499Total liabilitiesâ€‹â€‹ 9,221Total net assets acquiredâ€‹$ 64,596â€‹The Company believes that, even after reassessing its identification of all assets acquired and liabilities assumed, it was able to acquire Surface for a price that was completely allocable to identifiable assets acquired and liabilities assumed with no residual attributable to goodwill primarily due to Surfaceâ€™s need to raise additional capital to finance its operations, the challenging biotech funding environment at the time the transaction was initially announced, and the value of the acquired net assets.The amounts allocated to identifiable intangible assets was as follows: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)â€‹Useful livesÂ Â Â Â â€‹Fair Value at Acquisition DateIn-process research and development - casdozokitugâ€‹n/aâ€‹$ 25,899In-process research and development - CHS-114â€‹n/aâ€‹â€‹ 340Out-license - GSKâ€‹15 yearsâ€‹â€‹ 2,506Out-license - Novartis Institutesâ€‹15 yearsâ€‹â€‹ 11,024Total identifiable intangible assetsâ€‹â€‹â€‹$ 39,769â€‹The out-license intangible assets represent potential milestone and royalty-based payments to be received under twoÂ out-licensedÂ partnership programs to advance certain next-generation cancer therapies, Novartis Institutes (NZV930) and GSK (GSK4381562). Surface shareholders received CVRs for certain percentages of these milestone and royalty-based payments, as further explained above. The exclusive license of NZV930 to Novartis Institutes was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, during the first quarter of 2024, the Company recognized a net impairment charge of $6.8 million in selling, general and administrative expenses in the condensed consolidated statements of operations relating to the write-off of the net carrying value of the Novartis Institutes out-license intangible asset of $10.6 million and the final remeasurement of the CVR liability related to NZV930 of $3.8 million to its fair value of zero.Unaudited Pro Forma Summary of OperationsThe following table shows the unaudited pro forma summary of operations for the three and nine months ended September 30, 2023, as if the Surface Acquisition had occurred on January 1, 2022. This pro forma information does not purport to represent what the Companyâ€™s actual results would have been if the acquisition had occurred as of January 1, 2022, and it is not indicative of what such results would be expected for any future period:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

chrs_CollaborationAndLicenseAgreementsAbstract Namespace Prefix: chrs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Financial Liabilities â€‹8.Â Â Â Â Â Â Â Financial LiabilitiesA summary of the Companyâ€™s debt obligations, including level within the fair value hierarchy (see Note 3. Fair Value Measurements), is as follows:â€‹At SeptemberÂ 30,Â 2024(in thousands)PrincipalAmountâ€‹â€‹Unamortized Debt Discount and Debt Issuance Costsâ€‹NetCarrying Valueâ€‹EstimatedFair ValueÂ LevelFinancial Liabilities:â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹Â Â 2029 Term Loan$ 38,660â€‹$ (2,042)â€‹$ 36,618â€‹$ 36,618â€‹Level 2*2026 Convertible Notes$ 230,000â€‹$ (2,109)â€‹$ 227,891â€‹$ 180,550â€‹Level 2**â€‹At December 31, 2023Financial Liabilities:â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹Â Â 2027 Term Loans$ 250,000â€‹$ (3,519)â€‹$ 246,481â€‹$ 246,481â€‹Level 2*2026 Convertible Notes$ 230,000â€‹$ (3,112)â€‹$ 226,888â€‹$ 150,155â€‹Level 2**â€‹*The principal amounts outstanding are subject to variable interest rates based on three-month SOFR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximate their fair values.**The fair value is influenced by interest rates, the Companyâ€™s stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs.2029 Term Loan On May 8, 2024 (the â€œ2029 Term Loan Effective Dateâ€), the Company entered into a senior secured term loan facility of up to $38.7 million (the â€œ2029 Term Loanâ€) that was fully funded on the 2029 Term Loan Effective Date with Ankura Trust Company, LLC, as administrative agent (in such capacity, the â€œAgentâ€), and the lenders signatory thereto (collectively, the â€œ2029 Lendersâ€). The net proceeds of $37.5 million, net of the original issuance discount, were used by the Company to help repay in full the existing outstanding indebtedness owed by the Company to BioPharma Credit, PLC (â€œBioPharmaâ€), BPCR Limited Partnership (as a â€œ2027 Lenderâ€), and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC (as a â€œ2027 Lenderâ€) pursuant to the 2027 Term Loans.The 2029 Term Loan is governed by a loan agreement, dated as of the 2029 Term Loan Effective Date, by and among the Company, the Agent and the 2029 Lenders (the â€œ2029 Loan Agreementâ€). The 2029 Term Loan will mature on May 8, 2029. The amount borrowed under the 2029 Term Loan accrues interest equal to 8.0% per annum, plus a three-month SOFR rate (the â€œInterest Rateâ€). The 2029 Term Loan provides for interest-only payments on a quarterly basis until maturity. The Company may prepay the 2029 Term Loan in full or in part provided the Company (i) provides at least three (3) business daysâ€™ prior written notice to the Agent, (ii) pays on the date of such prepayment (A) all outstanding principal to be prepaid plus accrued and unpaid interest, (B) a prepayment fee of (x) 10.0% of the 2029 Term Loans so prepaid if paid on or after the first anniversary of the 2029 Term Loan Effective Date and before the second anniversary of the 2029 Term Loan Effective Date; (y) 5.0% of the 2029 Term Loan so prepaid if paid after the second anniversary of the 2029 Term Loan Effective Date and on or before the third anniversary of the 2029 Term Loan Effective Date; and (z) 0% of the 2029 Term Loan so prepaid if paid after the third anniversary of the 2029 Term Loan Effective Date, (C) if paid before the first anniversary of the 2029 Term Loan Effective Date, a make-whole amount equal to the interest that would have accrued from the date of prepayment through the first anniversary of the 2029 Term Loan Effective Date, and (D) all other sums, if any, that shall become due and payable under the 2029 Loan Agreement, including interest at the default rate with respect to any past due amounts. Amounts outstanding during an event of default shall accrue interest at an additional rate of 4.0% per annum, which interest shall be payable on demand in cash.The 2029 Term Loan is secured by a lien on substantially all the assets of the Company, including intellectual property, subject to customary exclusions and exceptions. The 2029 Loan Agreement contains customary representations and warranties, covenants and events of default, including a financial covenant commencing on the 2029 Term Loan Effective Date, which requires the Company to maintain certain levels of cash and cash equivalents. As of September 30, 2024, the Company was in full compliance with these covenants, and there were no events of default under the 2029 Term Loan.The Company incurred $2.2 million of debt discount and issuance costs relating to the issuance of the 2029 Term Loan, which were recorded as a reduction to the carrying value of the 2029 Term Loan on the condensed consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the five-year contractual term of the 2029 Term Loan using the effective interest rate method. The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. The following table presents the components of interest expense related to the 2029 Term Loan:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Three Months Ended â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â 2024â€‹SeptemberÂ 30,Â 2024Contractual interestâ€‹$ 1,316â€‹$ 2,074Amortization of debt discount and debt issuance costsâ€‹â€‹ 77â€‹â€‹ 120 Total interest expenseâ€‹$ 1,393â€‹$ 2,194â€‹As of September 30, 2024, the total remaining unamortized debt discount and debt offering costs of $2.0 million will be amortized using the effective interest rate over the remaining term of 4.6 years. â€‹â€‹Assuming the third quarter of 2024 interest rate of 13.3%, future payments on the 2029 Term LoanÂ as of September 30, 2024 are as follows:â€‹â€‹â€‹â€‹â€‹Year ending DecemberÂ 31,Â (in thousands)â€‹â€‹â€‹â€‹Remainder of 2024 - interest onlyâ€‹$ 1,3162025 - interest onlyâ€‹Â 5,2212026 - interest onlyâ€‹Â 5,2222027 - interest onlyâ€‹â€‹ 5,2222028 and thereafter - principal and interestâ€‹â€‹ 45,712Total minimum paymentsâ€‹â€‹ 62,693Less amount representing interestâ€‹Â (24,033)2029 Term Loan, grossâ€‹Â 38,660Less unamortized debt discount and debt issuance costsâ€‹Â (2,042)Net carrying amount of 2029 Term Loanâ€‹$ 36,618â€‹Revenue Purchase and Sale Agreement On May 8, 2024, concurrent with the 2029 Term Loan, the Company entered into a revenue participation right purchase and sale agreement (the â€œRevenue Purchase and Sale Agreementâ€) with Coduet Royalty Holdings, LLC, as administrative agent and each buyer named in an annex thereto (collectively, the â€œPurchaser Groupâ€). Under the terms of the Revenue Purchase and Sale Agreement, the Purchaser Group paid the Company $37.5 million, subject to certain conditions at closing (the â€œPurchase Priceâ€). In exchange, the Company sold to the Purchaser Group a right to receive 5.0% of U.S. net sales of UDENYCA and LOQTORZI with respect to a specified threshold applicable to UDENYCA net sales and a specified threshold applicable to LOQTORZI net sales during an applicable year and 0.5% of U.S. net sales of UDENYCA and LOQTORZI that exceeded the specified threshold during that year (the â€œRevenue Paymentâ€) for each calendar quarter commencing May 8, 2024. The Purchaser Groupâ€™s right to receive the Revenue Payment terminates and the Company no longer has the obligation to pay Revenue Payments once the Purchaser Group receives the amount equal to 2.25 times the Purchase Price allocated to each product. The Company may also buy-out the Purchaser Groupâ€™s rights to receive the Revenue Payments by triggering certain conditions and paying the Purchaser Group the unpaid portion of the 2.25 multiple on the Purchase Price. The proceeds from the Purchase Price were used by the Company as part of the full repayment of the 2027 Term Loans.The Revenue Purchase and Sale Agreement contains various representations and warranties, including with respect to organization, authorization, and certain other matters, certain covenants with respect to payment, reporting, intellectual property, in-licenses, out-licenses, and certain other actions, indemnification obligations and other provisions customary for transactions of this nature.The Revenue Purchase and Sale Agreement contains an embedded derivative that meets the criteria to be bifurcated and accounted for as a freestanding derivative instrument subject to derivative accounting. The allocation of the Purchase Price to the embedded derivative resulted in a $9.2 million discount on the revenue participation liability. Additionally, there was $1.4 million in issuance costs. The Company is amortizing the discount and issuance costs to interest expense over the estimated term of the Revenue Purchase and Sale Agreement using the effective interest method. For the three and nine months ended September 30, 2024, interest expense was $2.7Â million and $4.4 million, respectively, inclusive of the amortization of discount and issuance costs of $0.5 million and $0.8 million, respectively. For details on the Royalty Fee Derivative Liability, see Note 3. Fair Value Measurements.A summary of the revenue participation liability is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â (in thousands)â€‹2024Revenue participation liabilityâ€‹$ 39,382Less unamortized discount and issuance costsâ€‹Â (9,775)Totalâ€‹$ 29,607â€‹Classification on the condensed consolidated balance sheets is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â (in thousands)Balance Sheet Classificationâ€‹2024Revenue participation liability, currentAccrued and other current liabilitiesâ€‹$ 2,180Revenue participation liability, non-currentOther liabilities, non-currentâ€‹â€‹ 27,427Totalâ€‹â€‹ 29,607â€‹2027 Term Loans The Company entered into a loan agreement in January 2022 (as amended, the â€œ2027 Loan Agreementâ€) with BioPharma and the 2027 Lenders that provided for a senior secured term loan facility of up to $300.0 million, of which $250.0 million was funded. The 2027 Term Loans accrued interest at 8.25% plus the sum (the â€œAdjusted Term SOFRâ€) of three-month SOFR and 0.26161% per annum, with a floor on Adjusted Term SOFR of 1.0%. On February 5, 2024, the Company entered into a Consent, Partial Release and Third Amendment to the 2027 Term Loans (the â€œConsent and Amendmentâ€) with the Collateral Agent and the 2027 Lenders. Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the 2027 Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by the CIMERLI Purchase Agreement, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the 2027 Lenders and the Collateral Agent required the Company to make a partial prepayment of the principal of the loans outstanding under the 2027 Loan Agreement in the amount of $175.0 million upon consummation of the transactions contemplated by the CIMERLI Purchase Agreement, subject to certain conditions and (3) the parties thereto agreed to adjust the minimum net trailing twelve month net sales covenant level to be $125.0 million under the 2027 Loan Agreement. As a result of the CIMERLI Sale closing, the Company made a partial prepayment of $175.0 million of the total principal balance of $250.0 million of the 2027 Term Loans on April 1, 2024. On May 8, 2024, in connection with entering into the 2029 Term Loan and the Revenue Purchase and Sale Agreement, the Company repaid in full all outstanding indebtedness and terminated all commitments under the 2027 Term Loans. The May 8, 2024 payoff amount of $79.6 million included principal repayment in full, accrued interest, a 3.0% prepayment premium fee of the principal amount, a make-whole interest payment and lender fees. During the nine months ended September 30, 2024, the Company recorded a $12.6 million loss on debt extinguishment in the condensed consolidated statements of operations for the payoff of the 2027 Term Loans, and the charge included the write-off of the remaining debt discount and debt issuance costs, the prepayment premium fee, the make-whole interest payment, and lender fees. The following table presents the components of interest expense related to the 2027 Term Loans:â€‹Â Â Â Â Three Months Ended â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â (in thousands)â€‹2024â€‹2023â€‹2024â€‹2023Contractual interestâ€‹$ â€”â€‹$ 8,790â€‹$ 9,916â€‹$ 25,404Amortization of debt discount and debt issuance costsâ€‹â€‹ â€”â€‹â€‹ 255â€‹â€‹ 1,277â€‹â€‹ 830 Total interest expenseâ€‹$ â€”â€‹$ 9,045â€‹$ 11,193â€‹$ 26,234â€‹1.5% Convertible Senior Subordinated Notes due 2026In April 2020, the Company issued and sold $230.0 million aggregate principal amount of its 1.5% Convertible Senior Subordinated notes due 2026 (the â€œ2026 Convertible Notesâ€) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were $222.2 million after deducting initial purchasersâ€™ fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Companyâ€™s designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables. The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020, and will mature on April 15, 2026, unless earlier repurchased or converted.At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Companyâ€™s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. Since inception, the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock. The initial conversion price represents a premium of approximately 30.0% over the last reported sale of $14.82 per share of the Companyâ€™s common stock on the Nasdaq Global Market on AprilÂ 14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a â€œmake-whole fundamental changeâ€ (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Companyâ€™s election before maturity. If a â€œfundamental changeâ€ (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. The 2026 Convertible Notes have customary provisions relating to the occurrence of â€œevents of defaultâ€ (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. â€‹As of September 30, 2024, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes.â€‹The Company evaluated the features embedded in the 2026 Convertible NotesÂ under the relevant accounting rules and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as equity components.Capped Call TransactionsIn connection with the pricing of the 2026 Convertible Notes, the Company paid $18.2 million to enter into privately negotiated capped call transactions with one or a combination of the initial purchasers, their respective affiliates and other financial institutions. The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Companyâ€™s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been $25.93 per share, which represents a premium of approximately 75.0% over the last reported sale price of the Companyâ€™s common stock of $14.82 per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and classified as equity instruments; thus, they are recorded as a reduction to additional paid-in capital on the condensed consolidated balance sheets. The capped calls are not re-measured as long as the conditions for equity classification continue to be met.The Company incurred $0.9 million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the carrying value of the notes on the condensed consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the six-year contractual term of the notes using the effective interest rate method. If the 2026 Convertible Notes were converted on September 30, 2024, the holders of the 2026 Convertible NotesÂ would have received common shares with an aggregate value of $12.4 million based on the Companyâ€™s closing stock price of $1.04 as of September 30, 2024.The following table presents the components of interest expense related to the 2026 Convertible Notes:â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â (in thousands)Â Â Â Â 2024â€‹2023â€‹2024Â Â Â Â 2023Stated coupon interestâ€‹$ 863â€‹$ 863â€‹$ 2,588â€‹$ 2,588Amortization of debt discount and debt issuance costsâ€‹â€‹ 336â€‹â€‹ 329â€‹â€‹ 1,003â€‹â€‹ 982 Total interest expenseâ€‹$ 1,199â€‹$ 1,192â€‹$ 3,591â€‹$ 3,570â€‹The remaining unamortized debt discount and debt offering costs related to the 2026 Convertible NotesÂ of $2.1 million as of September 30, 2024 will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is 2.1% for the 2026 Convertible Notes.Future payments on the 2026 Convertible NotesÂ as of September 30, 2024 are as follows:â€‹â€‹â€‹â€‹â€‹Year ending DecemberÂ 31,Â (in thousands)Â Â Â Â â€‹â€‹Remainder of 2024 - interest onlyâ€‹$ 1,7252025 - interest onlyâ€‹Â 3,4502026 - principal and interestâ€‹Â 231,725Total minimum paymentsâ€‹Â 236,900Less amount representing interestâ€‹Â (6,900)2026 Convertible Notes, principal amountâ€‹Â 230,000Less unamortized debt discount and debt issuance costsâ€‹Â (2,109)Net carrying amount of 2026 Convertible Notesâ€‹$ 227,891â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other

contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 9.Â Â Â Â Â Â Â Â Commitments and Contingencies Purchase Commitments The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of September 30, 2024, the Companyâ€™s non-cancelable purchase commitments under the terms of its agreements are as follows: â€‹â€‹â€‹â€‹Year ending DecemberÂ 31, (in thousands)Â Â Â Â â€‹â€‹2024â€‹$ 7,2932025â€‹â€‹ 57,6062026â€‹â€‹ 1,6542027â€‹â€‹ 450Total obligationsâ€‹$ 67,003â€‹The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are generally cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees. In connection with the YUSIMRY Sale, HKF assumed $17.0 million in YUSIMRY inventory purchase commitments, of which $17.0 million remained as of September 30, 2024. If HKF were to default on its obligations under the YUSIMRY Purchase Agreement, the Company could become liable to pay any unpaid portion of these purchase commitments.Guarantees and IndemnificationsIn the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible.â€‹Legal Proceedings and Other Claims The Company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business and that have not been fully resolved. The outcome of such legal proceedings and claims is inherently uncertain. Accruals are recognized for such legal proceedings and claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it is determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. As of September 30, 2024 and December 31, 2023, the Company had an accrual of $6.4 million related to such matters that was included in accrued rebates, fees and reserves on the condensed consolidated balance sheets. â€‹In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC (â€œZincâ€) asserting that Zinc was entitled to approximately $14.0Â million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company has an accrual established as of September 30, 2024 that represented its estimated liability to resolve the matter. Loss contingencies are inherently unpredictable, the assessment is highly subjective and requires judgments about future events and unfavorable developments or resolutions can occur. The Company regularly reviews litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date.â€‹Other than the matter in connection with the demand letter described in this Note 9. Commitments and Contingencies, there are no pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries' property is subject. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Deficit 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Stockholders' Deficit 10.Â Â Â Â Â Â Â Stockholdersâ€™ DeficitPublic Offering On MayÂ 16, 2023, the Company entered into an underwriting agreement (the â€œUnderwriting Agreementâ€) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein (collectively, the â€œUnderwritersâ€), pursuant to which the Company issued and sold an aggregate of 11,764,706 shares (the â€œFirm Sharesâ€) of its common stock, par value $0.0001 per share, to the Underwriters (the â€œPublic Offeringâ€). Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, for 30 days from the date of the Underwriting Agreement, to purchase up to an additional 1,764,705 shares of common stock (the â€œOption Shares,â€ and together with the Firm Shares, the â€œSharesâ€), which the Underwriters elected to exercise in full. The price to the public in the Public Offering was $4.25 per share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $3.995 per share.The Offering was made pursuant to a prospectus supplement and related prospectus filed with the SEC pursuant to the Companyâ€™s shelf registration statement on FormÂ S-3 that was declared effective on November 17, 2022 (the â€œRegistration Statementâ€) under which the Company may offer and sell up to $150.0 million in the aggregate of its common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings.On MayÂ 18, 2023, the Company completed the sale and issuance of an aggregate of 13,529,411 Shares, including the exercise in full of the Underwritersâ€™ option to purchase the Option Shares. The Company received net proceeds of approximately $53.6Â million, after deducting the Underwritersâ€™ discounts and commissions and offering expenses payable by the Company.ATM OfferingOn November 8, 2022, the Company filed the Registration Statement. Also on November 8, 2022, the Company entered into a sales agreement (â€œSales Agreementâ€) with Cowen and Company, LLC (â€œTD Cowenâ€), pursuant to which the Company may issue and sell from time to time up to $150.0Â million of its common stock through or to TD Cowen as the Companyâ€™s sales agent or principal in an at-the-market offering (â€œATM Offeringâ€). On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement and in connection with the Public Offering, the Company reduced the amount of shares that could be issued and sold pursuant to itsÂ ATM Offering with TD Cowen by $86.2Â million, lowering the aggregate offering price under the Sales Agreement from $150.0Â million to $63.8Â million.On September 11, 2023, pursuant to an Amendment No. 2 to Sales Agreement, the Company increased the amount of shares that could be issued and sold pursuant to itsÂ ATM Offering with TD Cowen by $28.7Â million, increasing the aggregate offering price under the Sales Agreement from $63.8Â million to $92.5Â million.The following table summarizes information regarding settlements under the ATM Offering for the three and nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹

average number of common shares outstanding for the period plus any diluted potential common shares outstanding for the period determined using the treasury stock method for options, PSOs, RSUs and ESPP and using the if-converted method for the convertible notes. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive. The following table sets forth the computation of the basic and diluted net income (loss) per share:â€‹â€‹â€‹

models to perform the â€œwith-and-withoutâ€ method, which involves valuing the Revenue Purchase and Sale Agreement with the embedded derivative and then valuing it without the embedded derivative. The difference between values is determined to be the estimated fair value of the Royalty Fee Derivative. Refer to Note 3. Fair Value Measurements for details regarding the fair value.The Revenue Purchase and Sale Agreement is accounted for as a liability net of a discount comprising issuance costs and the fair value of the embedded derivative requiring bifurcation. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the liability to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the condensed consolidated statement of operations. The interest rate on this revenue participation liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The Company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales could materially impact the revenue participation liability, interest expense, and the time period for repayment. Contingent Consideration Contingent Consideration Contingent consideration relates to the potential payments to holders of Contingent Value Rights (â€œCVRsâ€) that are contingent upon the achievement of the Company and certain third parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within selling, general and administrative expense in the condensed consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts. Stock-Based Compensation Stock-Based CompensationThe Companyâ€™s compensation programs include stock-based awards. For awards other than condition-based performance stock options, the fair values are recognized as compensation expense on a straight-line basis over the vesting period. For condition-based performance stock options, expense is recognized only when performance conditions are considered probable of being achieved and is recognized over the period from the grant date through the time the milestone is expected to be achieved. The related costs are recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Companyâ€™s common stock on the date of issuance. Recent Accounting Pronouncements Recent Accounting Pronouncements The following are recent accounting pronouncements that the Company has not yet adopted:In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-07,Â Segment ReportingÂ (Topic 280) Improvements to Reportable SegmentÂ Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.In December 2023, the FASB issuedÂ ASU 2023-09,Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption. X - DefinitionRepresents Information pertaining to Consideration which is contingent upon some future changes in assumptions. + ReferencesNo definition available. + Details Name: chrs_ContingentConsiderationPolicyTextBlock Namespace Prefix: chrs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe description of accounting policy for revenue purchase and sale agreement. + ReferencesNo definition available. + Details Name: chrs_RevenuePurchaseAndSaleAgreementPolicyPolicyTextBlock Namespace Prefix: chrs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2 + Details Name: us-gaap_ReceivablesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets, which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)â€‹January 1,At beginning of period:Â Â Â Â 2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 102,891â€‹$ 63,547Restricted cashâ€‹â€‹ 452â€‹â€‹ 440Total cash, cash equivalents and restricted cashâ€‹$ 103,343â€‹$ 63,987â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â At end of period:â€‹2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 97,690â€‹$ 80,259Restricted cashâ€‹Â 263â€‹Â 452Total cash, cash equivalents and restricted cashâ€‹$ 97,953â€‹$ 80,711 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Net product revenue in United States, and Company's net revenue â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Financial Assets and Liabilities Measured on a Recurring Basis Financial liabilities related to long-term debt obligations are summarized in Note 8. Financial Liabilities. Other financial liabilities and financial assets measured at fair value on a recurring basis are summarized as follows:â€‹â€‹â€‹

+ Details Name: chrs_ScheduleOfRoyaltyParticipationLiabilityTableTextBlock Namespace Prefix: chrs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TwoThousandTwentyNineTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_RevenuePurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Non-cancelable Contractual Obligations â€‹â€‹â€‹Year ending DecemberÂ 31, (in thousands)Â Â Â Â â€‹â€‹2024â€‹$ 7,2932025â€‹â€‹ 57,6062026â€‹â€‹ 1,6542027â€‹â€‹ 450Total obligationsâ€‹$ 67,003 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Deficit (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Schedule of Settlements Under the ATM Offering â€‹Â Â Â Â Three Months Ended SeptemberÂ 30,Â â€‹Nine Months Ended SeptemberÂ 30,Â (in thousands, except share and per share data)â€‹2024â€‹2023Â Â Â Â 2024â€‹2023Number of common stock shares sold during the periodâ€‹â€‹ â€”â€‹â€‹ 2,428,311â€‹â€‹ 650,005â€‹â€‹ 3,559,761Weighted-average price per shareâ€‹$ â€”â€‹$ 4.92â€‹$ 2.44â€‹$ 5.43Gross proceedsâ€‹$ â€”â€‹$ 11,938â€‹$ 1,589â€‹$ 19,339Less commissions and feesâ€‹Â â€”â€‹Â (298)â€‹Â (40)â€‹Â (483)Net proceeds after commissions and feesâ€‹$ â€”â€‹$ 11,640â€‹$ 1,549â€‹$ 18,856 X - DefinitionTabular disclosure of shares offering settlements. + ReferencesNo definition available. + Details Name: chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock Namespace Prefix: chrs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Employee And Nonemployee Stock Option Restricted Stock Units Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Schedule of Stock-Based Compensation Expense â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliOphthalmologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_YusimryImmunologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Accounting Policies [Abstract] Â Â Â Â Cash and cash equivalents $ 97,690 $ 102,891 $ 80,259 $ 63,547 Restricted cash 263 452 452 440 Total cash, cash equivalents and restricted cash $ 97,953 $ 103,343 $ 80,711 $ 63,987 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Net Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue Â Â Â Â Net revenue $ 70,774 $ 74,568 $ 212,816 $ 165,720 Total net product revenue Â Â Â Â Revenue Â Â Â Â Net revenue 70,554 74,364 205,769 165,174 UDENYCA Â Â Â Â Revenue Â Â Â Â Net revenue 66,089 32,967 159,673 90,875 CIMERLI Â Â Â Â Revenue Â Â Â Â Net revenue (1,215) 40,037 26,979 72,939 YUSIMRY Â Â Â Â Revenue Â Â Â Â Net revenue (152) 1,360 7,508 1,360 LOQTORZI Â Â Â Â Revenue Â Â Â Â Net revenue 5,832 Â 11,609 Â Other revenue Â Â Â Â Revenue Â Â Â Â Net revenue $ 220 $ 204 $ 7,047 $ 546 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_UdenycaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_CimerliMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_YusimryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_ToripalimabMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 McKesson Â Â Â Â Concentration Risk Â Â Â Â Percentage of total gross revenue 45.00% 44.00% 41.00% 38.00% Cencora (previously known as AmeriSource-Bergen Corporation) Â Â Â Â Concentration Risk Â Â Â Â Percentage of total gross revenue 33.00% 41.00% 39.00% 45.00% Cardinal Health, Inc. Â Â Â Â Concentration Risk Â Â Â Â Percentage of total gross revenue 21.00% 13.00% 18.00% 15.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=chrs_McKessonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=chrs_AmeriSourceBergenCorpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=chrs_CardinalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Accounts Notes And Loans Receivable Â Â Â Â Activities and reserve balance, beginning balance Â Â $ 244,885 $ 100,503 Provision related to sales made in: Â Â Â Â Current period Â Â 995,147 539,609 Prior period - increase (decrease) $ 300 $ 1,100 4,364 4,634 Payments and customer credits issued Â Â (1,028,139) (476,854) Activities and reserve balance, ending balance 216,257 167,892 216,257 167,892 Chargebacks and Discounts for Prompt Payment Â Â Â Â Accounts Notes And Loans Receivable Â Â Â Â Activities and reserve balance, beginning balance Â Â 73,953 42,677 Provision related to sales made in: Â Â Â Â Current period Â Â 727,028 387,238 Prior period - increase (decrease) Â Â (969) (1,375) Payments and customer credits issued Â Â (747,070) (379,076) Activities and reserve balance, ending balance 52,942 49,464 52,942 49,464 Rebates Â Â Â Â Accounts Notes And Loans Receivable Â Â Â Â Activities and reserve balance,

beginning balance Â Â 121,137 38,713 Provision related to sales made in: Â Â Â Â Current period Â Â 150,820 83,009 Prior period - increase (decrease) Â Â 6,343 1,540 Payments and customer credits issued Â Â (159,737) (42,097) Activities and reserve balance, ending balance 118,563 81,165 118,563 81,165 Other Fees, Co-pay Assistance and Returns Â Â Â Â Accounts Notes And Loans Receivable Â Â Â Â Activities and reserve balance, beginning balance Â Â 49,795 19,113 Provision related to sales made in: Â Â Â Â Current period Â Â 117,299 69,362 Prior period - increase (decrease) Â Â (1,010) 4,469 Payments and customer credits issued Â Â (121,332) (55,681) Activities and reserve balance, ending balance $ 44,752 $ 37,263 $ 44,752 $ 37,263 X - DefinitionPayments and customer credits issued from reserve in discounts and allowances constitute variable consideration. + ReferencesNo definition available. + Details Name: chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definitionn/a + ReferencesNo definition available. + Details Name: chrs_ProvisionRelatedToSalesMadeAbstract Namespace Prefix: chrs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents provision related to sales made in prior period. + ReferencesNo definition available. + Details Name: chrs_ProvisionRelatedToSalesMadeInPriorPeriod Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionReserve for discounts and allowances constitute variable consideration. + ReferencesNo definition available. + Details Name: chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReserve for sales discounts and allowances constitute variable consideration. + ReferencesNo definition available. + Details Name: chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_ChargebacksAndDiscountsForPromptPaymentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_RebatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_OtherFeesCoPayAssistanceAndReturnsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Financial assets measured at fair value on a recurring basis Â Â Total financial assets $ 69,070 $ 104,940 Total financial liabilities 9,834 Â Royalty Fee Derivative Liability Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial liabilities 9,202 Â Contingent Consideration Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial liabilities 632 Â Fair Value, Inputs, Level 1 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets 69,070 96,648 Fair Value, Inputs, Level 2 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 7,667 Fair Value, Inputs, Level 3 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 625 Total financial liabilities 9,834 Â Fair Value, Inputs, Level 3 [Member] | Royalty Fee Derivative Liability Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial liabilities 9,202 Â Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial liabilities 632 Â U.S. government agency securities Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 5,195 U.S. government agency securities | Fair Value, Inputs, Level 1 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 5,195 U.S. treasury securities Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 2,993 U.S. treasury securities | Fair Value, Inputs, Level 1 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 2,993 Commercial paper and corporate notes Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 6,669 Commercial paper and corporate notes | Contingent Consideration Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 4,472 Commercial paper and corporate notes | Fair Value, Inputs, Level 2 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 6,669 Commercial paper and corporate notes | Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 4,472 Money market funds Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets 69,070 89,458 Money market funds | Fair Value, Inputs, Level 1 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets $ 69,070 88,460 Money market funds | Fair Value, Inputs, Level 2 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 998 Prepaid financial instrument in Prepaid manufacturing Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â 625 Prepaid financial instrument in Prepaid manufacturing | Fair Value, Inputs, Level 3 [Member] Â Â Financial assets measured at fair value on a recurring basis Â Â Total financial assets Â $ 625 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=chrs_ContingentConsiderationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=chrs_PrepaidExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cost, Unrealized Gains or Losses, and Fair Value by Investment Â Â Cost $ 69,070 $ 104,324 Unrealized Gain Â 2 Unrealized (Loss) Â (11) Fair Value 69,070 104,315 Money market funds Â Â Cost, Unrealized Gains or Losses, and Fair Value by Investment Â Â Cost 69,070 79,484 Fair Value $ 69,070 79,484 U.S. government agency securities Â Â Cost, Unrealized Gains or Losses, and Fair Value by Investment Â Â Cost Â 5,200 Unrealized (Loss) Â (5) Fair Value Â 5,195 U.S. treasury securities Â Â Cost, Unrealized Gains or Losses, and Fair Value by Investment Â Â Cost Â 11,967 Unrealized Gain Â 2 Fair Value Â 11,969 Commercial paper and corporate notes Â Â Cost, Unrealized Gains or Losses, and Fair Value by Investment Â Â Cost Â 7,673 Unrealized (Loss) Â (6) Fair Value Â $ 7,667 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Mar. 31, 2024 Sep. 30, 2024 May 08, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Net impairment charge Â $ 6,772,000 Â Â Contingent consideration, non-current Â 632,000 Â $ 1,172,000 Contingent consideration, current Â Â Â $ 3,300,000 Surface Acquisition Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Fair value of the contingent consideration $ 3,800,000 Â Â Â Contingent consideration, non-current Â 500,000 Â Â Contingent consideration, current 0 Â Â Â Novartis Institutes Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Impairment charge 10,600,000 Â Â Â Novartis Institutes | Surface Acquisition Â Â Â Â Fair Value, Assets and

Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Net impairment charge $ 6,800,000 Â Â Â Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, General and Administrative Expense Â Â Â Impairment charge $ 10,600,000 Â Â Â Royalty Fee Derivative Liability Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Fair value of the Royalty Fee Derivative Â $ 9,200,000 $ 9,200,000 Â X - DefinitionThe amount of Impairment of out-license asset and remeasurement of CVR liability, net. + ReferencesNo definition available. + Details Name: chrs_ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithNovartisInstitutesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Components (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 13,735 $ 12,975 Work in process 102,989 82,588 Finished goods 2,291 34,537 Total $ 119,015 $ 130,100 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Balance Sheet Classifications (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Inventory $ 47,640 $ 62,605 Inventory, non-current 71,375 67,495 Total $ 119,015 $ 130,100 X - DefinitionInventory current and noncurrent. + ReferencesNo definition available. + Details Name: chrs_InventoryCurrentAndNoncurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Additional Information (Details) - USD ($) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Inventory Â Â Â Inventory write-downs $ 2,481 $ 4,369 Â Prepayment made for manufacturing services 10,718 Â $ 23,657 Prepayments made to a CMO for manufacturing services for UDENYCA 6,500 Â 12,600 Prepayments made to a CMO For Other Research And Development Pipeline Program $ 4,200 Â 11,100 CIMERLI Sale Â Â Â Â Inventory Â Â Â Payment related to sale transaction Â Â 6,400 CIMERLI Sale | Disposal Group Â Â Â Inventory Â Â Â Inventory Â Â 16,400 YUSIMRY Sale Â Â Â Inventory Â Â Â Payment related to sale transaction Â Â 500 YUSIMRY Sale | Disposal Group Â Â Â Inventory Â Â Â Inventory Â Â 17,000 YUSIMRY Â Â Â Inventory Â Â Â Certain firm purchase commitments Â Â 20,500 Certain firm purchase commitments, Long-term Â Â 9,000 Certain firm purchase commitments, Short-term Â Â 11,500 YUSIMRY | Cost of Goods Sold Â Â Â Inventory Â Â Â Inventory write-downs Â Â $ 47,000 X - DefinitionThe minimum amount the entity agreed to spend under the long-term and short-term purchase commitment. + ReferencesNo definition available. + Details Name: chrs_LongTermAndShortTermPurchaseCommitmentsAmount Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrepaid Manufacturing current. + ReferencesNo definition available. + Details Name: chrs_PrepaidManufacturingExpenseCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents prepayments made to a CMO for manufacturing services. + ReferencesNo definition available. + Details Name: chrs_PrepaymentsMadeToCmoForManufacturingServices Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents prepayments made to a CMO for other research and development program. + ReferencesNo definition available. + Details Name: chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of prepayments made related to sale transaction. + ReferencesNo definition available. + Details Name: chrs_PrepaymentsRelatedToSaleTransaction Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe minimum amount the entity agreed to spend under the short-term purchase commitment. + ReferencesNo definition available. + Details Name: chrs_ShortTermPurchaseCommitmentAmount Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as inventory attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_InventoryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe minimum amount the entity agreed to spend under the long-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliOphthalmologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_YusimryImmunologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PublicUtilitiesInventoryAxis=chrs_YusimryProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property and Equipment, Net Â Â Total property and equipment $ 23,533 $ 25,770 Accumulated depreciation and amortization (20,622) (20,651) Property and equipment, net 2,911 5,119 Machinery and Equipment [Member] Â Â Property and Equipment, Net Â Â Total property and equipment 13,161 13,124 Computer Equipment [Member] Â Â Property and Equipment, Net Â Â Total property and equipment 3,566 3,546 Furniture and Fixtures [Member] Â Â Property and Equipment, Net Â Â Total property and equipment 1,055 1,055 Leasehold Improvements [Member] Â Â Property and Equipment, Net Â Â Total property and equipment $ 5,751 5,751 Leaseholds and Leasehold Improvements [Member] Â Â Property and Equipment, Net Â Â Total property and equipment Â $ 2,294 X - DefinitionAmount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Property and Equipment, Net Â Â Â Â Â Â Depreciation and amortization expense related to property and equipment, net $ 0.4 Â $ 0.8 $ 1.5 $ 2.5 Â Software implementation costs $ 2.3 Â Â $ 2.3 Â $ 3.2 Novartis Institutes Â Â Â Â Â Â Property and Equipment, Net Â Â Â Â Â Â Impairment of Intangible Assets, Finite-Lived Â $ 10.6 Â Â Â Â X - DefinitionThe carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1 + Details Name: us-gaap_CapitalizedComputerSoftwareNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithNovartisInstitutesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Intangible Assets, Net (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Jun. 26, 2024 Mar. 01, 2024 Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Finite-lived assets, net of accumulated amortization of $2,052 and $639, as of September 30, 2024 and December 31, 2023, respectively Â Â $ 25,454 $ 25,454 $ 41,871 Accumulated amortization Â Â 2,052 2,052 639 Indefinite-lived assets - IPR&DIndefinite-lived assets - in-process research and development Â Â 28,859 28,859 28,859 Goodwill Â Â Â Â 943 Total Intangible assets, net Â Â 54,313 54,313 $ 71,673 Amortization expense, Finite-lived intangible assets Â Â $ 1,200 2,800 Â Expected amortization expense for the remaining finite-lived assets for each of the five succeeding fiscal years Â Â Â Â $ 2,700 Â Disposal Group | CIMERLI Sale Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Finite-lived intangible asset, net Â $ 2,100 Â Â Â Goodwill, Written off Â $ 900 Â Â Â Disposal Group | YUSIMRY Sale Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Finite-lived intangible asset, net $ 900 Â Â Â Â X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in each of five succeeding fiscal years. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease in assets, excluding financial assets, lacking physical substance with a definite life, from derecognition upon disposal of business. + ReferencesNo definition available. + Details Name: chrs_FiniteLivedIntangibleAssetsDerecognitionUponDisposalOfBusiness Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1 + Details Name: us-gaap_IntangibleAssetsNetIncludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliOphthalmologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_YusimryImmunologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands

Sep. 30, 2024 Dec. 31, 2023 Balance Sheet Related Disclosures [Abstract] Â Â Accrued commercial and research and development manufacturing $ 19,729 $ 23,470 Accrued co-development costs and milestone payments 12,500 26,812 Accrued royalties 1,199 42,031 Royalty Fee Derivative Liability (Note 8) 9,202 Â Revenue participation liability, current (Note 8) 2,180 Â Accrued other 14,526 7,628 Lease liabilities, current 1,629 2,145 Contingent consideration, current Â 3,300 Total Accrued and other current liabilities $ 60,965 $ 105,386 X - DefinitionAccrued co-development costs and milestone payments + ReferencesNo definition available. + Details Name: chrs_AccruedCoDevelopmentCostsAndMilestonePayments Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued commercial and research and development manufacturing liabilities current. + ReferencesNo definition available. + Details Name: chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents lease liabilities for both operating and financing leases. + ReferencesNo definition available. + Details Name: chrs_LeaseLiabilitiesOperatingAndFinancing Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligations related to royalty participation, classified as current. + ReferencesNo definition available. + Details Name: chrs_RoyaltyParticipationLiabilityCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Other Liabilities, Non-current (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Balance Sheet Related Disclosures [Abstract] Â Â Contingent consideration, non-current $ 632 $ 1,172 Deferred tax liability 1,102 1,102 Revenue participation liability, non-current (Note 8) 27,427 Â Other Â 10,287 Total Other liabilities, non-current $ 29,161 $ 12,561 X - DefinitionAmount of obligations related to royalty participation, classified as noncurrent. + ReferencesNo definition available. + Details Name: chrs_RoyaltyParticipationLiabilityNoncurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionObligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_OtherSundryLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisition and Disposition - Additional Information (Details) 3 Months Ended 9 Months Ended Sep. 08, 2023 USD ($) item $ / shares shares Sep. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Jun. 26, 2024 USD ($) Mar. 01, 2024 USD ($) Dec. 31, 2023 USD ($) Surface Acquisition Â Â Â Â Â Â Â Â Â Â Â Â Cash consideration Â Â Â Â Â Â Â Â Â $ 170,000,000.0 Â Pretax profit (loss) Â $ (10,751,000) Â Â $ (40,021,000) $ 79,203,000 $ (158,619,000) Â Â Â TSA receivables, net Â 31,241,000 Â Â Â 31,241,000 Â Â Â Â Â TSA payables and other accrued liabilities Â 33,637,000 Â Â Â 33,637,000 Â Â Â Â Additional consideration Â Â Â Â Â Â Â Â 17,800,000 Â Goodwill Â Â Â Â Â Â Â Â Â Â Â $ 943,000 Net impairment charge Â Â Â Â Â 6,772,000 Â Â Â Â Contingent consideration, current Â Â Â Â Â Â Â Â Â Â $ 3,300,000 Novartis Institutes Â Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Â Impairment charge Â Â Â $ 10,600,000 Â Â Â Â Â Â CIMERLI Sale | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Cash consideration Â Â Â 187,800,000 Â Â Â Â 170,000,000.0 Â Gain on sale transaction Â Â Â 153,600,000 Â Â Â Â Â Â Transaction costs Â Â Â 7,200,000 Â Â Â Â Â Â Pretax profit (loss) Â (1,200,000) Â Â 6,900,000 6,200,000 5,700,000 Â Â Â TSA receivables, net Â 27,800,000 Â Â Â 27,800,000 Â Â Â Â TSA payables and other accrued liabilities Â 30,400,000 Â Â Â 30,400,000 Â Â Â Â Additional consideration Â Â Â Â Â Â Â Â $ 17,800,000 Â Retention bonus Â 4,700,000 Â Â Â 4,700,000 Â Â Â Â Income under TSA Â 500,000 Â Â Â 1,600,000 Â Â Â Â YUSIMRY Sale Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Â Reimbursable costs Â 500,000 Â Â Â 500,000 Â Â Â Â YUSIMRY Sale | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Cash consideration Â Â $ 40,000,000.0 Â Â Â $ 40,000,000.0 Â Â Inventory purchase commitments Â Â Â Â Â Â Â $ 17,000,000.0 Â Â Gain on sale transaction Â Â 22,900,000 Â Â Â Â Â Â Transaction costs incurred Â Â $ 1,000,000.0 Â Â Â Â Â Â Transaction costs unpaid Â 800,000 Â Â Â 800,000 Â Â Â Â Pretax profit (loss) Â (200,000) Â Â $ (2,000,000.0) 1,300,000 $ (12,100,000) Â Â Â TSA receivables, net Â 3,400,000 Â Â Â 3,400,000 Â Â Â Â TSA payables and other accrued liabilities Â $ 3,200,000 Â Â Â $ 3,200,000 Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares 0.1960 Â Â Â Â Â Â Â Â Â Share price | $ / shares $ 5.2831 Â Â Â Â Â Â Â Â Â Contingent value right per share | item 1 Â Â Â Â Â Â Â Â Â Â Contingent value rights payment period 10 years Â Â Â Â Â Â Â Â Â Goodwill $ 0 Â Â Â Â Â Â Â Â Â Business Combination, Number of Out Licensed Partnership Program | item 2 Â Â Â Â Â Â Â Â Â Fair value of the contingent consideration Â Â Â 3,800,000 Â Â Â Â Â Â Contingent consideration, current Â Â Â 0 Â Â Â Â Â Â Surface Acquisition | Novartis Institutes Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Net impairment charge Â Â Â $ 6,800,000 Â Â Â Â Â Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Â Â Â Selling, General and Administrative Expense Â Â Â Â Â Â Impairment charge Â Â Â $ 10,600,000 Â Â Â Â Â Â Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Â Â Â Selling, General and Administrative Expense Â Â Â Â Â Â Surface Acquisition | Surface GSK Agreement Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Milestone and royalty based CVR payments (as percent) 70.00% Â Â Â Â Â Â Â Â Â Surface Acquisition | Surface's SRF114 proprietary drug product candidate Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Upfront payment based CVR payments (as percent) 25.00% Â Â Â Â Â Â Â Â Â Surface Acquisition | Surface's SRF388 proprietary drug product candidate Â Â Â Â Â Â Â Â Â Surface Acquisition Â Â Â Â Â Â Â Â Â Upfront payment based CVR payments (as percent) 50.00% Â Â Â Â Â Â Â Â Â X - DefinitionThe payment period of contingent value rights under business combination. + ReferencesNo definition available. + Details Name: chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod Namespace Prefix: chrs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percent of milestone and royalty based payments payable as part of contingent value rights under business combination. + ReferencesNo definition available. + Details Name: chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe percent of upfront payments payable as part of contingent value rights under business combination. + ReferencesNo definition available. + Details Name: chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe number of contingent value rights issuable in consideration for each share under business combination. + ReferencesNo definition available. + Details Name: chrs_BusinessCombinationConsiderationContingentValueRightPerShare Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of outlicensed partnership program in a business combination. + ReferencesNo definition available. + Details Name: chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in exchange of each share of acquiree in a business combination. + ReferencesNo definition available. + Details Name: chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree Namespace Prefix: chrs_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of additional consideration received or receivable for product inventory and prepaid manufacturing assets, including discontinued operation. + ReferencesNo definition available. + Details Name: chrs_DisposalGroupIncludingDiscontinuedOperationAdditionalConsiderationForProductInventoryAndPrepaidManufacturingAssets Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of consideration in the form of inventory purchase commitments assumed as part of the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: chrs_DisposalGroupIncludingDiscontinuedOperationConsiderationInFormOfInventoryPurchaseCommitments Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCostsIncurred Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of unpaid transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCostsUnpaid Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of Impairment of out-license asset and remeasurement of CVR liability, net. + ReferencesNo definition available. + Details Name: chrs_ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of reimbursable costs for business support services. + ReferencesNo definition available. + Details Name: chrs_ReimbursableCostsForBusinessSupportServices Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transition services agreement payables classified as current. + ReferencesNo definition available. + Details Name: chrs_TransitionServicesAgreementPayablesAndOtherAccruedLiabilitiesCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transition services agreement receivable current. + ReferencesNo definition available. + Details Name: chrs_TransitionServicesAgreementReceivableCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unpaid transaction costs and retention bonuses committed to pay. + ReferencesNo definition available. + Details Name: chrs_UnpaidTransactionCostsAndRetentionBonusesPayable Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-

gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithNovartisInstitutesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliOphthalmologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_YusimryImmunologyFranchiseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_SurfaceGlaxosmithklineAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisition and Disposition - Estimated fair value of the net assets acquired (Details) - Surface Acquisition $ in Thousands Sep. 08, 2023 USD ($) Assets Acquired Â Cash and cash equivalents $ 6,997 Investments in marketable securities 21,791 Prepaids and other assets 5,260 Identifiable intangible assets 39,769 Total assets 73,817 Liabilities Assumed Â Accrued and other current liabilities 7,722 Deferred tax liability 1,499 Total liabilities 9,221 Total net assets acquired 64,596 Out-licenses Â Assets Acquired Â Identifiable intangible assets 13,530 In-process research and development Â Assets Acquired Â Identifiable intangible assets $ 26,239 X - DefinitionAmount of accrued and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. + ReferencesNo definition available. + Details Name: chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisition and Disposition - The amounts allocated to identifiable intangible assets (Details) - Surface Acquisition $ in Thousands Sep. 08, 2023 USD ($)

Surface Acquisition Â Identifiable intangible assets $ 39,769 Out-license - GSK Â Surface Acquisition Â Identifiable intangible assets $ 2,506 Useful Lives 15 years Novartis Institutes Â Surface Acquisition Â Identifiable intangible assets $ 11,024 Useful Lives 15 years In-process research and development - casdozokitug Â Surface Acquisition Â Identifiable intangible assets $ 25,899 In-process research and development - SRF 114 Â Surface Acquisition Â Identifiable intangible assets $ 340 X - DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithGrkMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithNovartisInstitutesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=chrs_InProcessResearchAndDevelopmentSrf388Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=chrs_InProcessResearchAndDevelopmentSrf114Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisition and Disposition - Unaudited Pro Forma Summary of Operations (Details) - Surface Acquisition - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2023 Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Â Â Total revenues $ 74,568 $ 165,720 Net loss (49,984) (204,922) Acquisition-related Costs [Member] Â Â Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Â Â Acquisition-related costs $ 2,600 $ 4,500 Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Financial Statement Caption selling, general and administrative selling, general and administrative X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFor transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFor transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents disclosure of the line item or line items in the income statement in which the acquisition related costs which have been expensed are recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedFinancialStatementCaption Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborations and Other Arrangements (Details) $ in Thousands, $ in Millions 1 Months Ended 3 Months Ended 9 Months Ended Mar. 21, 2021 USD ($) Feb. 01, 2021 USD ($) item Mar. 31, 2024 USD ($) Mar. 31, 2022 USD ($) Dec. 31, 2020 USD ($) Oct. 31, 2018 USD ($) item Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2024 CAD ($) Sep. 30, 2023 USD ($) Mar. 01, 2024 USD ($) Dec. 31, 2023 USD ($) Collaborative Arrangements And Noncollaborative Arrangement Transactions Â Â Â

ReferencesNo definition available. + Details Name: chrs_DisposalGroupIncludingDiscontinuedOperationAdditionalConsiderationForProductInventoryAndPrepaidManufacturingAssets Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the maximum paid amount for co-development activities. + ReferencesNo definition available. + Details Name: chrs_MaximumAmountPaidCoDevelopmentActivities Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum antibodies partially exercised under commercialization option + ReferencesNo definition available. + Details Name: chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMaximum number of antibodies under for research option + ReferencesNo definition available. + Details Name: chrs_MaximumNumberOfAntibodiesUnderForResearchOption Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount per each installment of milestone payments under collaborative arrangements. + ReferencesNo definition available. + Details Name: chrs_MilestonePaymentsAmountPerEachInstallment Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum antibodies to be commercialized under commercialization option + ReferencesNo definition available. + Details Name: chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum Number of Antibodies under Commercialization option + ReferencesNo definition available. + Details Name: chrs_MinimumNumberOfAntibodiesUnderCommercializationOption Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of option fee to be paid on partial exercise of commercialization option + ReferencesNo definition available. + Details Name: chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of regulatory milestones eligible to pay. + ReferencesNo definition available. + Details Name: chrs_RegulatoryMilestonesEligibleToPay Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of sales milestones entitled. + ReferencesNo definition available. + Details Name: chrs_SalesMilestonesEntitled Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedRoyaltiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=chrs_SurfaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_ToripalimabMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=chrs_CanadaLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - Summary of Debt Obligations (Details) - USD ($) $ in Thousands Sep. 30, 2024 Apr. 01, 2024 Dec. 31, 2023 Jan. 05, 2022 2029 Term Loans Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Less unamortized debt discount and issuance costs $ (2,000) Â Â Â Â Revenue Purchase and Sale Agreement Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Less unamortized debt discount and issuance costs (9,775) Â Â Â 2027 Term Loans Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Principal amount Â $ 250,000 Â $ 250,000 2027 Term Loans | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Principal amount 38,660 Â $ 250,000 Â Less unamortized debt discount and issuance costs (2,042) Â (3,519) Â Net carrying amount 36,618 Â 246,481 Â Estimated Fair Value 36,618 Â 246,481 Â 1.5% Convertible Senior Subordinated Notes due 2026 | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Principal amount 230,000 Â 230,000 Â Less unamortized debt discount and issuance costs (2,109) Â (3,112) Â Net carrying amount 227,891 Â 226,888 Â Estimated Fair Value $ 180,550 Â $ 150,155 Â X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TwoThousandTwentyNineTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_RevenuePurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - 2029 Term Loan - Narrative (Details) - 2029 Term Loans $ in Thousands 3 Months Ended 9 Months Ended May 08, 2024 USD ($) Sep. 30, 2024 USD ($) item Sep. 30, 2024 USD ($) item Debt Instrument [Line Items] Â Â Â Net proceeds, net of original issuance discount $ 37,500 Â Â Prepayment funding fee 4.00% Â Â Number Of Events in Default | item Â 0 0 Debt discounts and issuance costs $ 2,200 Â Â Interest expense Â $ 1,393 $ 2,194 Remaining unamortized debt discount and debt offering costs Â 2,000 $ 2,000 Contractual term 5 years Â 4 years 10 months 24 days On or after the first anniversary Â Â Â Debt Instrument [Line Items] Â Â Â Prepayment fee 10.00% Â Â After the second anniversary Â Â Â Debt Instrument [Line Items] Â Â Â Prepayment fee 5.00% Â Â After the third anniversary Â Â Â Debt Instrument [Line Items] Â Â Â Prepayment fee 0.00% Â Â Ankura Trust Company, LLC Â Â Â Debt Instrument [Line Items] Â Â Â Principal Amount $ 38,700 Â Â Stated interest rate 8.00% Â Â Remaining unamortized debt discount and debt offering costs Â $

2,042 $ 2,042 X - DefinitionThe amount of debt discounts and issuance costs incurred. + ReferencesNo definition available. + Details Name: chrs_DebtDiscountsAndIssuanceCosts Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents information pertaining to debt instrument contractual term. + ReferencesNo definition available. + Details Name: chrs_DebtInstrumentContractualTerm Namespace Prefix: chrs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLoan agreement funding fee percentage. + ReferencesNo definition available. + Details Name: chrs_LoanAgreementFundingFeePercentage Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLoan agreement prepayment fee percentage. + ReferencesNo definition available. + Details Name: chrs_LoanAgreementPrepaymentFeePercentage Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of events in default. + ReferencesNo definition available. + Details Name: chrs_NumberOfEventsInDefault Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TwoThousandTwentyNineTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=chrs_AnkuraTrustCompanyLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - 2029 Term Loans, Components of Interest Expense (Details) - 2029 Term Loans - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Debt Instrument [Line Items] Â Â Contractual interest $ 1,316 $ 2,074 Amortization of debt discount and debt issuance costs 77 120 Total Interest expense $ 1,393 $ 2,194 X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TwoThousandTwentyNineTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - 2029 Term Loan Future Payments (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Debt Instrument [Line Items] Â Interest rate 13.30% 2029 Term Loans Â Debt Instrument [Line Items] Â Less unamortized debt discount and issuance costs $ (2,000) 2029 Term Loans | Ankura Trust Company, LLC Â Debt Instrument [Line Items] Â Remainder of 2024 - interest only 1,316 2025 - interest only 5,221 2026 - interest only 5,222 2027 - interest only 5,222 2028 and thereafter - principal and interest 45,712 Total minimum payments 62,693 Less amount representing interest (24,033) 2029 Term Loan, gross 38,660 Less unamortized debt discount and issuance costs (2,042) Net carrying amount $ 36,618 X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: chrs_LongTermDebtMaturityAfterYearThree Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTerm Loan, gross. + ReferencesNo definition available. + Details Name: chrs_TermLoanGross Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current

statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TwoThousandTwentyNineTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=chrs_AnkuraTrustCompanyLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - Revenue Purchase and Sale Agreement - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 May 08, 2024 Revenue Purchase and Sale Agreement Â Â Â Embedded Derivative [Line Items] Â Â Â Revenue Purchase and Sale Agreement, Purchase price Â Â $ 37.5 Purchase price multiplier Â Â 2.25 Discount on revenue participation liability from allocation of purchase price to the embedded derivative $ 9.2 $ 9.2 Â Issuance costs on revenue participation liability 1.4 1.4 Â Amortization of discount and issuance costs 0.5 0.8 Â Interest expense Â Â Â Embedded Derivative [Line Items] Â Â Â Interest expense, inclusive of the amortization of discount and issuance costs Â $ 4.4 Â Interest expense | Revenue Purchase and Sale Agreement Â Â Â Embedded Derivative [Line Items] Â Â Â Interest expense, inclusive of the amortization of discount and issuance costs $ 2.7 Â Â UDENYCA | Revenue Purchase and Sale Agreement Â Â Â Embedded Derivative [Line Items] Â Â Â Revenue payment, Percentage of U.S. net sales Â Â 5.00% UDENYCA and LOQTORZI | Revenue Purchase and Sale Agreement Â Â Â Embedded Derivative [Line Items] Â Â Â Revenue payment, Percentage of U.S. net sales Â Â 0.50% X - DefinitionDiscount on the revenue participation liability, resulting from a derivative instrument. + ReferencesNo definition available. + Details Name: chrs_DiscountOnRevenueParticipationLiabilityFromDerivativeInstrument Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInterest expense, inclusive of the amortization of discount and issuance costs. + ReferencesNo definition available. + Details Name: chrs_InterestExpenseInclusiveOfAmortizationOfDiscountAndIssuanceCostsOnRevenueParticipationLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance costs on the revenue participation liability. + ReferencesNo definition available. + Details Name: chrs_IssuanceCostsOnRevenueParticipationLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRevenue Purchase and Sale Agreement purchase price. + ReferencesNo definition available. + Details Name: chrs_RevenuePurchaseAndSaleAgreementCertainConditionsPurchasePriceMultiplier Namespace Prefix: chrs_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionRevenue Purchase and Sale Agreement purchase price. + ReferencesNo definition available. + Details Name: chrs_RevenuePurchaseAndSaleAgreementPurchasePrice Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe percent to be received pertaining to the sales of the companies products and services. + ReferencesNo definition available. + Details Name: chrs_RevenuePurchaseAndSaleAgreementRightToReceivePercent Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmbeddedDerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_RevenuePurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_UdenycaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=chrs_UdenycaAndLoqtorziMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - Revenue Purchase and Sale Agreement - Summary of Revenue Participation Liability (Details) - Revenue Purchase and Sale Agreement $ in Thousands Sep. 30, 2024 USD ($) Debt Instrument [Line Items] Â Revenue participation liability $ 39,382 Less unamortized debt discount and issuance costs (9,775) Total $ 29,607 X - DefinitionAmount of revenue participation liability. + ReferencesNo definition available. + Details Name: chrs_RevenueParticipationLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of Obligations related to royalty participation. + ReferencesNo definition available. + Details Name: chrs_RoyaltyParticipationLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=chrs_RevenuePurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - Revenue Purchase and Sale Agreement - Classification on the condensed consolidated balance sheet (Details) $ in Thousands Sep. 30, 2024 USD ($) Debt Instrument [Line Items] Â Royalty participation liability, current $ 2,180 Royalty participation liability, non-current 27,427 Derivative liabilities, Fair Value 9,202 Revenue Purchase and Sale Agreement Â Debt Instrument [Line Items] Â Royalty participation liability, current 2,180 Royalty participation liability, non-current 27,427 Total $ 29,607 X - DefinitionAmount of Obligations related to royalty participation. + ReferencesNo definition available. + Details Name: chrs_RoyaltyParticipationLiability Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligations related to royalty participation, classified as current. + ReferencesNo definition available. + Details Name: chrs_RoyaltyParticipationLiabilityCurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligations related to royalty participation, classified as noncurrent. + ReferencesNo definition available. + Details Name: chrs_RoyaltyParticipationLiabilityNoncurrent Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial

concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=chrs_RevenuePurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - 2027 Term Loan - Narrative (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Apr. 01, 2024 Feb. 05, 2024 Apr. 30, 2024 Jun. 30, 2024 Sep. 30, 2024 Jan. 05, 2022 Debt Instrument [Line Items] Â Â Â Â Â Â Interest rate Â Â Â Â 13.30% Â Debt partial prepayment to be Made Â $ 175,000 Â Â Â Â Minimum net sales convenant level agreed to be maintained over past year Â $ 125,000 Â Â Â Â Outstanding amount paid off Â Â Â Â $ 260,387 Â Loss on debt extinguishment Â Â Â $ 12,600 $ 12,630 Â 2027 Term Loans Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Principal amount $ 250,000 Â Â Â Â $ 250,000 Interest rate Â Â Â Â 0.26161% Â Spread on variable rate Â Â Â Â 1.00% Â Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Â Â Â Â us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Â Partial prepayment of principal $ 175,000 Â Â Â Â Â Outstanding amount paid off Â Â $ 175,000 Â Â Â 2027 Term Loans | BioPharma Credit Investments V GP LLC Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Principal amount Â Â Â Â $ 300,000 Â Funded amount Â Â Â Â 250,000 Â Outstanding amount paid off Â Â Â Â $ 79,600 Â Prepayment premium percentage Â Â Â Â 3.00% Â Loss on debt extinguishment Â Â Â Â $ 12,600 Â 2027 Term Loans | Starting April 1, 2023 | BioPharma Credit Investments V GP LLC Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Stated interest rate Â Â Â Â 8.25% Â X - DefinitionAmount of partial repayment of principal of the loans subject to terms and conditions. + ReferencesNo definition available. + Details Name: chrs_DebInstrumentPartialRepaymentPrincipal Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of loan funded out of amount available under loan agreement. + ReferencesNo definition available. + Details Name: chrs_DebtInstrumentFundedAmount Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDebt instrument prepayment percentage. + ReferencesNo definition available. + Details Name: chrs_DebtInstrumentPrepaymentPercentage Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of partial prepayment agreed to be made of its term loan. + ReferencesNo definition available. + Details Name: chrs_DebtPartialPrepaymentToBeMade Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMinimum amount of net sales covenant level to be maintained for trailing twelve months. + ReferencesNo definition available. + Details Name: chrs_MinimumNetSalesConvenantLevelAgreedToBeMaintainedOverPastYear Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates type of variable interest rate on debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name

Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - 2027 Term Loans, Components of Interest Expense (Details) - 2027 Term Loans - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Debt Instrument [Line Items] Â Â Â Contractual interest Â $ 9,916 $ 25,404 Amortization of debt discount and debt issuance costs Â 1,277 830 Total Interest expense Â $ 11,193 $ 26,234 BioPharma Credit Investments V GP LLC Â Â Â Debt Instrument [Line Items] Â Â Â Contractual interest $ 8,790 Â Â Amortization of debt discount and debt issuance costs 255 Â Â Total Interest expense $ 9,045 Â Â X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_TermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - Convertible Senior Subordinated Notes due 2026 - Narrative (Details) 1 Months Ended 9 Months Ended Apr. 30, 2020 USD ($) $ / shares shares Sep. 30, 2024 USD ($) Jun. 28, 2024 $ / shares Apr. 14, 2020 $ / shares Financial Liabilities Â Â Â Â Closing stock, price per share | $ / shares Â Â $ 1.04 $ 14.82 1.5% Convertible Senior Subordinated Notes due 2026 Â Â Â Â Financial Liabilities Â Â Â Â Number of events in default Â 0 Â Â Contractual term Â 6 years Â Â Convertible Debt [Member] | 1.5% Convertible Senior Subordinated Notes due 2026 Â Â Â Â Financial Liabilities Â Â Â Â Principal Amount $ 230,000,000.0 Â Â Â Stated interest rate 1.50% Â Â Â Net proceeds from offering $ 222,200,000 Â Â Â Initial conversion rate, shares of common stock | shares 51.9224 Â Â Â Principal amount of notes converted into shares $ 1,000 Â Â Â Initial conversion price per common share | $ / shares $ 19.26 Â Â Â Interest rate description The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020 Â Â Â Debt instrument maturity date Apr. 15, 2026 Â Â Â Convertible notes, premium percentage 30.00% Â Â Â Convertible notes, covenant compliance Â As of September 30, 2024, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes. Â Â Debt issuance costs Â $ 900,000 Â Â Remaining unamortized debt discount and debt offering costs Â $ 2,109,000 Â Â Effective interest rate Â 2.10% Â Â Convertible Debt [Member] | 1.5% Convertible Senior Subordinated Notes due 2026 | Scenario, Plan [Member] Â Â Â Â Financial Liabilities Â Â Â Â Convertible notes, converted amount Â $ 12,400,000 Â Â X - DefinitionRepresents information pertaining to debt instrument contractual term. + ReferencesNo definition available. + Details Name: chrs_DebtInstrumentContractualTerm Namespace Prefix: chrs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument convertible number of shares per thousand of principal amount of notes. + ReferencesNo definition available. + Details Name: chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes Namespace Prefix: chrs_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionEquivalent to conversion price per common share. + ReferencesNo definition available. + Details Name: chrs_EquivalentToConversionPricePerCommonShare Namespace Prefix: chrs_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of events in default. + ReferencesNo definition available. + Details Name: chrs_NumberOfEventsInDefault Namespace Prefix: chrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPercentage of premium on convertible note. + ReferencesNo definition available. + Details Name: chrs_PercentageOfPremiumOnConvertibleNote Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPrincipal amount of notes converted into shares of common stock at conversion rate. + ReferencesNo definition available. + Details Name: chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStates whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentCovenantCompliance Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDescription of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsNoncurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - Capped Call Transactions - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions 1 Months Ended Apr. 30, 2020 Jun. 28, 2024 Apr. 14, 2020 Option Indexed to Issuer's Equity [Line Items] Â Â Â Closing stock, price per share Â $ 1.04 $ 14.82 Call Option [Member] Â Â Â Option Indexed to Issuer's Equity [Line Items] Â Â Â Payment for capped call transactions $ 18.2 Â Â Initial cap price of capped call transactions. $ 25.93 Â Â Percentage of cap price 75.00% Â Â Closing stock, price per share Â Â $ 14.82 X - DefinitionRepresents the cap price of the cap call transactions (per share). + ReferencesNo definition available. + Details Name: chrs_CapPriceOfCapCallTransactions Namespace Prefix: chrs_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of payment made for entering into capped call transactions. + ReferencesNo definition available. + Details Name: chrs_PaymentForCappedCallTransactions Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the percentage of premium on cap price. + ReferencesNo definition available. + Details Name: chrs_PercentageOfCapPriceCappedCallTransactions Namespace Prefix: chrs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OptionIndexedToIssuersEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - 2026 Convertible Notes Interest Expense Components (Details) - 1.5% Convertible Senior Subordinated Notes due 2026 - Convertible Debt [Member] - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Financial Liabilities Â Â Â Â Stated coupon interest $ 863 $ 863 $ 2,588 $ 2,588 Amortization of debt discount and debt issuance costs 336 329 1,003 982 Total Interest expense $ 1,199 $ 1,192 $ 3,591 $ 3,570 X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name

Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - 2026 Convertible Notes Future Payments (Details) - Convertible Debt [Member] - 1.5% Convertible Senior Subordinated Notes due 2026 $ in Thousands Sep. 30, 2024 USD ($) Financial Liabilities Â Remainder of 2024 - interest only $ 1,725 2025 - interest only 3,450 2026 - interest only 231,725 Total minimum payments 236,900 Less amount representing interest (6,900) 2026 Convertible Notes, principal amount 230,000 Less unamortized debt discount and debt issuance costs (2,109) Net carrying amount $ 227,891 X - DefinitionConvertible notes, principal amount. + ReferencesNo definition available. + Details Name: chrs_ConvertibleNotesPrincipalAmount Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50

-Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details) $ in Thousands Sep. 30, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â 2024 $ 7,293 2025 57,606 2026 1,654 2027 450 Total obligations $ 67,003 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInSecondYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInThirdYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 79 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions 1 Months Ended Apr. 30, 2022 Sep. 30, 2024 Dec. 31, 2023 Loss Contingencies Â Â Â Inventory purchase commitments Â $ 17.0 Â Claims related to certain sales of UDENYCA from October 2020 through December 2021 $ 14.0 Â Â Accrued rebates, fees and reserves Â Â Â Loss Contingencies Â Â Â Accrual related to legal Proceedings and Other Claims Â $ 6.4 $ 6.4 X - DefinitionThe amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionBest estimate of the loss exposure for a reasonably possible liability for product liability damages for which no accrual has been recorded. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details Name: us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=chrs_AccruedRebatesFeesAndReservesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Deficit (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 11, 2023 May 18, 2023 May 16, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 May 15, 2023 Nov. 17, 2022 Nov. 08, 2022 Stockholders' Deficit Â Â Â Â Â Â Â Â Â Â Common stock, par value Â Â Â Â $ 0.0001 Â $ 0.0001 Â Â Â Public Offering Â Â Â Â Â Â Â Â Â Â Stockholders' Deficit Â Â Â Â Â Â Â Â Â Â Common stock, shares issued and sold Â 13,529,411 11,764,706 Â Â Â Â Â Â Â Common stock, par value Â Â $ 0.0001 Â Â Â Â Â Â Â Share price Â Â $ 4.25 Â Â Â Â Â Â Â Net proceeds, after deducting the Underwriters' discounts and commissions and offering expenses Â $ 53,600 Â Â Â Â Â Â Â Â Public Offering | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Stockholders' Deficit Â Â Â Â Â Â Â Â Â Â Shares Offering, Aggregate Amount Â Â Â Â Â Â Â Â Â $ 150,000 Â At Market Offering [Member] Â Â Â Â Â Â Â Â Â Â Stockholders' Deficit Â Â Â Â Â Â Â Â Â Â Common stock, shares issued and sold Â Â Â 2,428,311 650,005 3,559,761 Â Â Â Â Shares Offering, Aggregate Amount, Decrease Â Â Â Â Â Â Â $ 86,200 Â Â Increase in Amount of Shares To be Issued and Sold $ 28,700 Â Â Â Â Â Â Â Â Â Gross proceeds Â Â Â $ 11,938 $ 1,589 $ 19,339 Â Â Â Â Less commissions and fees Â Â Â (298) (40) (483) Â Â Â Â Net proceeds after commissions and fees Â Â Â $ 11,640 $ 1,549 $ 18,856 Â Â Â Â Common stock remaining available for sales under the ATM Offering Â Â Â Â Â $ 64,900 Â Â Â Â Â Â At Market Offering [Member] | Weighted Average [Member] Â Â Â Â Â Â Â Â Â Â Stockholders' Deficit Â Â Â Â Â Â Â Â Â Â Weighted-average price per share Â Â Â $ 4.92 $ 2.44 $ 5.43 Â Â Â Â Â At Market Offering [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Stockholders' Deficit Â Â Â Â Â Â Â Â Â Â Shares Offering, Aggregate Amount $ 92,500 Â Â Â Â Â Â Â Â Â $ 63,800 Â $ 150,000 Over-Allotment Option [Member] Â Â Â Â Â Â Â Â Â Â Stockholders' Deficit Â Â Â Â Â Â Â Â Â Â Common stock, shares issued and sold Â Â 1,764,705 Â Â Â Â Â Â Â Term of share offering Â Â 30 days Â Â Â Â Â Â Â Share price Â Â $ 3.995 Â Â Â Â Â Â Â X - DefinitionLine items represent at the market offering. + ReferencesNo definition available. + Details Name: chrs_AtMarketOfferingLineItems Namespace Prefix: chrs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents the common stock remaining available for sale under the atm offering. + ReferencesNo definition available. + Details Name: chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in shares to be issued and sold. + ReferencesNo definition available. + Details Name: chrs_IncreaseInAmountOfSharesToBeIssuedAndSold Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity, before stock issuance costs. + ReferencesNo definition available. + Details Name: chrs_ProceedsFromIssuanceOfCommonStockGross Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of shares to be offered. + ReferencesNo definition available. + Details Name: chrs_SharesOfferingAggregateAmount Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe decrease in aggregate amount of shares to be offered. + ReferencesNo definition available. + Details Name: chrs_SharesOfferingAggregateAmountDecrease Namespace Prefix: chrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe period for exercise of option to purchase additional shares by underwriters. + ReferencesNo definition available. + Details Name: chrs_SharesOfferingUnderwritersOptionTerm Namespace Prefix: chrs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average price per share. + ReferencesNo definition available. + Details Name: chrs_WeightedAveragePricePerShare Namespace Prefix: chrs_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-

Based Compensation - Stock-Based Expense (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended May 31, 2024 Apr. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Â Â Â Â Â Stock-based compensation expense Â Â $ 6,868 $ 9,953 $ 21,418 $ 32,312 Stock-based compensation expense capitalized into inventory Â Â 313 373 1,107 697 Cost of Sales [Member] Â Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Â Â Â Â Â Stock-based compensation expense Â Â 282 174 834 535 Research and Development Expense [Member] Â Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Â Â Â Â Â Stock-based compensation expense Â Â 2,092 2,929 6,552 11,760 Selling, General and Administrative Expenses [Member] Â Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Â Â Â Â Â Stock-based compensation expense Â Â 4,494 $ 6,850 14,032 $ 20,017 Performance Condition PSO Â Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Â Â Â Â Â Term years 10 years 10 years Â Â Â Â Â Â Stock-based compensation expense Â Â $ 200 Â $ 1,000 Â Performance Condition PSO | Other Senior Executives Â Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Â Â Â Â Â Share based payment options grants 640,000 Â Â Â Â Â Performance Condition PSO | Chief Executive Officer [Member] Â Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs Â Â Â Â Â Â Share based payment options grants Â 1,982,500 Â Â Â Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost capitalized for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEstimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Â Â Â Net Income (Loss) $ (10,751) $ (12,921) $ 102,875 $ (39,641) $ (42,869) $ (75,729) $ 79,203 $ (158,239) Denominator: Â Â Â Â Â Â Â Â Weighted-average common shares outstanding - Basic 115,210,091 Â Â 97,738,509 Â Â 114,263,256 88,277,936 Weighted-average common shares outstanding - Diluted 115,210,091 Â Â 97,738,509 Â Â 126,563,551 88,277,936 Basic net income (loss) per share $ (0.09) Â Â $ (0.41) Â Â $ 0.69 $ (1.79) Diluted net income (loss) per share $ (0.09) Â Â $ (0.41) Â Â $ 0.65 $ (1.79) Numerator: Â Â Â Â Â Â Â Add interest expense on 2026 Convertible Notes, net of tax Â Â Â Â Â Â $ 3,591 Â Numerator for diluted net income (loss) per share $ (10,751) Â Â $ (39,641) Â Â $ 82,794 $ (158,239) Add effect of potential dilutive securities: Â Â Â Â Â Â Â Â Stock options, including shares subject to ESPP Â Â Â Â Â Â 213,872 Â Restricted stock units Â Â Â Â Â Â 144,271 Â Shares issuable upon conversion of convertible notes Â Â Â Â Â Â 11,942,152 Â Denominator for diluted net income (loss) income per share 115,210,091 Â Â 97,738,509 Â Â 126,563,551 88,277,936 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 44 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-44Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 51 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-51Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-52Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-53Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 54 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-54Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 48 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-48Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 48 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-48 + Details Name: us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards

Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_InterestOnConvertibleDebtNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. + ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAttributableToParentDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAttributableToParentDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 83 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income (Loss) Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive securities excluded from computation of EPS Â Â Â Â Antidilutive securities excluded from the calculation of diluted net income (loss) per share 42,877,700 38,642,448 29,034,256 38,300,024 Stock options, PSOs, including shares subject to ESPP Â Â Â Â Antidilutive securities excluded from computation of EPS Â Â Â Â Antidilutive securities excluded from the calculation of diluted net income (loss) per share 30,104,147 24,558,893 28,103,519 24,003,706 Restricted Stock Units (RSUs) [Member] Â Â Â Â Antidilutive securities excluded from computation of EPS Â Â Â Â Antidilutive securities excluded from the calculation of diluted net income (loss) per share 831,401 2,141,403 930,737 2,354,166 1.5% Convertible Senior Subordinated Notes due 2026 | Shares issuable upon conversion of convertible notes Â Â Â Â Antidilutive securities excluded from computation of EPS Â Â Â Â Antidilutive securities excluded from the calculation of diluted net income (loss) per share 11,942,152 11,942,152 Â 11,942,152 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_EmployeesAndNonemployeesStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

#)VK_^NGL>&#Q(4;8WN0^V2 +HZ>GI[OGU8_#J M(2|^J8T0)?N<)IEZ?;0IR^T/+UZH:"-2K@;Y5F1P9947*2_A:[%^H;:%X#$] ME"8OPN'P_$7*97;TYA7]=E.|>95792(S<5,P5:4I+Q[?
BB1_>'TT.K(_W,KU MIL0?7KQYM>5K<2?*7[7(HD04+ QN^&YI$;$A_T/UO][VGN M,)1(;,6TTFW$%F MP3[D6;E1[,>F,WSS'1&^^@ M]TXL2_9.JBC)554(JC\72U46H!/_VS=936O23POMY
>UŸ9%X?02&H$1Q+X[> M_/4OH_/ARSV<3ARGDWW4#U^1_63^^I=Y.!R_9/,!ZZ7(+JPALGS%RHU@EWFZ
MY=DC/CB:052@VR"R?)G(-4<#4@&36914L!%M'MF)$H+q}>"C8$+O.,WNN.#X+@(8-NE.@6RBG'%5GD"'D+]P"SG M?_3?
BY*!UI4B78K"J1X[H0GFE>)9K$[930%"D%N0Y46:5UG9H?)KQM.!*.6_ M1E^E&5$CP0D/2D>$UK MT+NX7R]$F/N"?11%RJYSGK%C-IX'Y^=#=_V8G83!>K^,SX/ST7SW#YKA M\'LD?
@Z3S^X%"&J9:!U1\$ (8A\.6Z.,A@M_E#*Y9I>_91_ D6V=AG"Q,,< 2J@3K0;O@X+M5M?P7;.JL MS,'C%"!+X$UFI0!??+*"(Y.X4<S]+SE^#^9+:"3^ 28K9\;,TEZ'7. RB3R@K<"/H6/SO]WD"O(!^
M/=(EB:X<*)ZT/3I+A#KDK8NN"$#1%%| O<#.R)*><#N)/HG'-A<)0(1D05 MS0-I)4AKQ2,M7Q!%M<4)'H_G@QD M"1!K+F;#3LN#,M+]H#[7I4DC__ B>M ML:
(]R2;KM.VRB^Q357#VL0",:/D/V/7U98";*8]AM24B"H,5!S4%;X4**EP)1/ 'LFFJ^D28K8 MOJ8/6HID82P#5=jR(H^$B!5*[W@\&TRMW *Z;M0K+ ^0:/&8"VF"VR]CLI %[M Y8I;0Z^PL(;&U$ B.
(+4=#(NEJ1?L,XB#M];R)S!#DB#@3"KAYZ*7W5N8W M&PX! +L$)9 P^LWU)3LQ4W57:\F]O;F\!1>??M3J&UZ4&8AA([?L!!?&D]', MR*@I=*"X]<=C5V!AJB2PQ'YC)Q^X D4|9=
D,,UVNGO/'IE6RH+)X5.P3,8E\.UW? U>&,IK]^75,D\A=M_B2N>Y#24?J^JOM^X MC?C0>XL,X31&;7DB-3A;\H1XH>R29:R4?7+-J#4)C,F7PL3%)O6%/2\:\N5QOBT-L@ -)ING0%*4FYSB2S!9C$BH%55
M8H:7ELSBGP[U7F=+@43BCJM:03@?D"+YJ==(+(5;7BVQKM-@(%$A=&5%>8R M\5%/"-[:,!*>Y5_51J1VX6KV7B4(HFUV'5RE!2%/(DQ,).6 #'EF;6BCG!) MQW08WE6!K\|4?B0PYZ?
_ZXPF8+O^*_9O3\)USZ5+((4Y^\K7(2_#%(Q'YWX. M*AC.)K@%H$Z2+^JWR3Z=;C,ZFW5^&H5#]C$O^_2YP=-BW.!IM*CG>$$KUIVI M5LB2B!<'"10N?>6EEG?,(@?EH=U-SP(#[' P="[I0>H-
J::#^'NJ5_V=;=:,_M4:"%]K_SCE0N0(ZII:E1E0D[\ E:QA;]%.1N-!^/O FNX?ZL5ZVKMD!FYH>?4 M$?Z);D9H3-#(UK92_KN>OR5YQ-[$SNJI4?355DVX:,KSIFD $9Y,JNVI(}=3A MJZY;.K?.;5A<"
(UVS_P,:Q9W#!N>@Z=<8 MS!G@ZG! \S9!TY S8=CB ';>]P:W&1-W]0=B.X!!K##C&VQ FLL/5G("HF9%$M*/1 5PBS-JWK>_)019F2(RQ):X: M^;$"B\V8F*G94,B&2[
T4@D'L.V2/<3C90XHNF2W^2-/RD?VMSQ!*U%/Y!<) MS7')\OJ$10-%DLGE]%HLTQvB!S:#DLV$\0JFSKM$>]?:/S<7CW@)EI^BW"
M.F#SQ=Y*1/KPV.!"1$G2(%K0HB0GUWG2PSU6'2,O9W.5(90FM-!<:\!:;E)N M<\C-(L-EP! "Q6SC\U\'=P-*E>*:DRQ^???CS_ ^O*#I7_RJX^_W/[W53=$ M8OA1KB1!*;BPP>'Y=IO(B%
%W&,)U=0)[1SPI!NV?K2.M+Q;"=TAT>%@^IS9 M4&")$8FP2:8^GLR0=#.-U&L'VHDYGA2*42(H;(;J/X2F[97FAAF?4&I/UZ"]5 M9CK+UE!4&XI3/89J539M:94BRUF2@ZH4$-AK@%>7EY
LIN1:Y'"O-/6:MAH9 M)C2A=D8!PI4I*V5]+C?U%T/,/++0D>0#"!;#C&ZFD"-?YFLG=;W#$T]"/7BU-.('86(6#5*"-J1J1$:9V$]2.Q;A+]D/W%!=Q8^P20\F2X74?3;8>0 M%VN>&6@,;KT"T%/47S'L-
8+7B9Z4EZ"V&, "[];'!?)NRF6R S*'L W6P*Q$A MLS-P^M%8^N3VH8 >MRP*/7"M*+-(,K#\RP-ZOP&):D6ZGU+/.9J3I"%/S*)0A MIE<$HSQ4,A L;CC/3<@&?:_BE;$VRN\&TQ(2N54JB5H:_)4 ML:5/-
OX#'!K'A' <+9 L:*S93=GQPLLR. AD5+D2?+R2FX^!QP"Y<'&[V7M!B MK$,>CP831U5F+2352G@H&T)8]R7Y(")[8[XZP*PC2H.W-?WARXZL!^P]G-
M[V*4BE0R#$I3'90*"DK[X]\.PR2BT*OQ(JWC22VSP.J_035D=@J9,G/B[4!T MC\@P$0/-AS, ^P<;=)NYGE"#K^VY:HIL1\!$,=`M$XQX6'L1C.=A#}+? M(R>'[Q?!;#8]-<&*%VXO@O-A';I?)EPISVD|
(_WU&4)DKPK1GZCOIR6UPP_M1[S@JTWL<>'5M;!SM%<2KRFPD:B8#Y\FG^79F27T"Y'UR#4O=QJ89L$$]\#& MDNU%:A<0"14->[4S+]=M?";$=U6.]O=3G=JS3/
M7*69,*>K@M(&\IP.$JH"0 #X7BP+8G;JYX)V3/42%);V6>PSP"3YK< 2J_9T M'RG[B!M0M+MWB1&8$C.[@(I.?V-N MH
/$6R+=ZARJ17I7'WZ\O;ZJMRTH2_!,D_"YXC&%$>:D0@51SX)+'D;]=IV<&R=3#(_)*14?L&M M4?!KFYA=]#H9O90MH5L1DV^\CE)ANB917G@Z[#[1]"URY@,<3-K*12P%GKEC^D I-
Y9Q,JXD#DW)2WK5&B@GMS3C#%2^7P M)4)LC)(]J3:^0]B!RF"Q2I':8A<&D2;J6QFD;Z3=KY!U7R,H3$'%.R-|_ U; MCL29]W1=\C@HW1P8D?>
MJ#%2(BOT<>H\F"W\7OA%L&A6(:?!9/BMRI#MX1WK7F.]JT\&84_54BB&ZFWO?1*!@U"YOG03BN93G"Y*[?"ZGD?!=M02/8'RJ;AC'AATJ>UW9 MS0*^#9N.!,5B@A?
*F1^'8W_WX6OP]VNL)K;]'=D%"/(@?K(F/ZW6T9YF=X>, M*2^SI7R-J(NP8'>8:=4Y:DP8R;(R+1!4(E&-UMK;"LB.)I,+;V^YP\#!G->R M>5?]H>XD)]V@E)8\#D_ %457_F+=(T(;G=08P*9-7>\E.AX=
(UIZ1CO]%|^ MIG^LO=KVXRJSX4X['6?+S\H7NG%-W=-GNN,<7;Y>JL;NC%<+%9TI,%L&'@] MHPJRW0KZF3TU!R8*$$954#-5FR'<[%W#-.YM2M,=@)!W0]XZW8KG)5SSE\#
M002J92K\5D'$:K1=NUY8DY8P795X#C<&U8C=^8L86]O35$ \46(GB4?,JO)2 M]U] "HUE$50U3--'6A9XJRQVKJ6]GE/OET9A"K9+T6XSQ=^D0,%E*60F1L.AHL0G#Y]71\UJF7[WA$AYOZ',ENG:I[
MS-S^5+MLY"O_=!"LW/%H,01R."QQU&9(VPUZ]GQF6:W0&&>O&9)MP3;!) M4]?EA:D:$_Z?#.9ADY.G5MHJZL]1;*VY3!DU!>(ZEV]18MPU@!'4R2NXQT6DJOB@=T!=2_B@%VMZA,1
M'F3#0SJ8.<+=4Y=SS0;P=>Z(>&F>\Z(9Z>#(1>RB*H40Y7(>)F"$CUECXQ, M[LF51V%591[3DJ+SP89>F(U2GKM%=&3^P8VU\%N ?$:F;BQ_+;B MN7/\QMO5IQ;\Q?K/KU"S-P"
[<_5!']5>KFX=BE'3RO[?$HQ'4S%X; MKU?!:_?*-DW8*$"GFWC/^E|=NOZ:X>9X=-"D,QK8!W;DF]2,36U%$6AOX:__M]9B;QGO$FXU40L_X@P/[!9WOX,JE.#!"!'B21<)E;Y5H=6";&J @6^R9T^'| M-
9+RV'AL4Y*$ *ZFXJNKRILSV:60])N92[Q$BUP555E2V,P6[]VP ;SR'&\&- M&>?D9%(LIFB29)!Z2|"U7\H5**A7^"[M:6#[;'<058%X7VAMÜ;#DDWW*VH1 M+Q^]N'S +L$0X(9+7/6/?
LKRJL^;:JM^\I1M<\'),(]'ZSYK//VM4^"QU1GURJWW3AGQQL]*_MFC.]% -B6J[//W$3$92% M_"1J,+F?@CV-(LV)D2@O<'D@IE#ND$ /0MVG=.8XN;\!@LS/G,1J]%6OF((M
M,N&%'A2#G6;C6!^"V#AH-%YVC0\!T\#[8D]O_Q4D,Y[_\[#*3D9WT6 M*)RLGZ7D.;[Z2,,MAGH:N\&0/(S<9!^%<,NH&7!_?X-Q3N<:7H=8^<3=/]! M-EKNIR_=LF"YI&[\EYGTN-G3">R_PH0HC
83G:>EOA/%!=ZA/#GOIZ._?UU983RN*Q7C<.&5#H;#>NS% M/#SDH--HL6A]#_ WNKF#:>&D3?)\-O=7RBVW//^ATD#*XU"C.BV^ZRC1-5XG MM0_*X,SQ^#!(=\|\1.#ZNR>BU %[O_/\5.]>_6>?
HWK>^:E9.-U_?FH<3*9# M>W[JB2-.X5@3?.)L4S@^#Q;#X7,.-=$#ISMWZDY>IAY*OU/KZ||YT>O2=I]S MZE,%SZDT7Z[6]SK#%][+)E-1K.F5FHAV80S]WDGWJWMKYX5^665]NW[EYP=>
MK+&3/1$K>'0XF$V/] $!^Z7,M_3JRF5>EGE*'S>"@\K@#7!]E0/_Y@L.X-YE M^N;_ %!+ P04 " #]@V99<'>C+X<) (& &0 'AL+W=OC%_/*\D2MU]\+GYJ/#
MT[S74NA:&:.^M$4Z5%Y.K@U>OCV@]+_B[5EL_^W(D\S<.K_1P4UQ,%F20JE0> M2(@GXVZ5E5%BF#>GGI-^2(:(_.^V_L._P)9->7=OJ'[H(ZXO)BXDH5"G; M*GRRV[?
Y?;./:X^5$Y*T/MD["L*#6)OZ5=RD. X$7BV\(+)/ MDNV.&[&5;V20E^?.,H6CU=!&/]A5EH9QVE!2;H/#5PVY<'EMZUH'1#EX(4TA MKJT)VJR4R;7RY_. +6CA/$_J7D=URV^H>RG>0\':BYJ-
H8JQ_!RF]?8M._M> M+Y]4>*N:F3A<3,5RL3QZ0M]A[^\AZSO\?_P5;[3/*^M;I\2_KC(?'$#S[\>B M$#GP3*J17OI&YNIB@4KQR&S6Y_/&'@Y/%V1,N'/4N'#VE_7]V=/J7L[$
MTT'ŸV+I\#>"/EOV^YN&=&FGN!%)I10F@3K) KIU1NM8^N8VG8 M5K-ZXGS@F(0]THO25N T_TJ0^L7AV3?.?E'(2(4H%8BK>]#P9>C 5/\'9L+:M MA_?^9X<^=$_/!.GT^7+0WIYO+?
R^'1ZLCBA;=E=[WPZF)\=']LET[)/1\4+| M;H.LA,TJO9)$E'ZPX\GI=+$X[%_L)=W'G.? "Y4*/7+@#!%FA?>M0W 1P*SU M@)WO,)'6"RH.B10(=!5I]^^2 >@UR+#* 56=0X\/;4%(9(QT+\,-XP7$]*]
MAZ#!SN/U.\#-V)N=Y913(%XY60%B$2,,DFFT>8.61?D#\C;.:LYE.K:3CI!)0 MM&'K9^*F%'+G(@M+X1N5ZU+GJ0[$%A5#$,]4+ZR*$6;1SMJ]&-AD#?[#^I0J M%%R,4ZP$A%
0T^@<@0IK&4:ZUK* N;E'!RP(N@@,?59EJ;@MB@(^N[<#;SB\ MI$"B\A&*IHN-OR]5 JAO#'DL$F=EETF15]^ZZN#>BU %[O_/\5.]>_8*MT?UA MPK.#TJD" :R2] "HZ99]@P %Z^X?
KC;SGX+6FD;H0C74< MGQAF_SC]S,2OK702U94 ?P-K:D/82>;=?*?&QJ8]7]>(.ABJQ22]-= .H &3:HBY^W4 D7:5H M(EM84,0A+FHN>[CGVN5M[0.Q5T^ G?7:Y%7+5"Z-4#YHZA/1$7PL^]UG?
2]\ M! *OQ$=GX S0LN6>@@@0K53Q/Q#"3,6Q'T+3GW2'$V8 MHXR94!&EI6$-$UB>NY9;,0UU0.D*G3QUI^^K132X$]T%*.[RSGG%AIE%)^FS M35(#1,0T<5+(F0S/N]01=*;.ZD;,.IQ-
3@09K(HSL>YJ#4IZ0%>)C4+NM=&,&[9+(BKA-|.>!WS 4.)C5,TVP@_EF_=J,B,%#3 MGE4L@=+96OP39HJW26E8HSMLT=4?-!3,>#I / MAH]J7e+8HXDV
8S(@4(W;8O)AZ%=:5CTTN]9^#2 M3+SCBAQ=-U 7&34:*"]T'N)9C(3CN$*3",5DK5=KK/-M]D.PX1385M)Q<]W0I2&\ M#FG.VE7XD$PQ]_"8P+<**=K4)@K8C+!%]:F7(.R8Z6);8OJB_!4:YS;7DR*V
M[FLDB77D$>(PNRO^.*!P)QM"ZW%8CVN_4#YW.HM5@)[J43"PZGOW1YPS&E$= M-0711'N0O:%@&IM'M*V;=/I!9Q!3| >.&X9N+=+P,#CYV'0\'/*%=;%KE^D2
M*?.ZT'3$\8.Q;!K;!C7CN/:!AH>B?R';&T4#G?8=^F:/?-.-I[>SM<+P3G?0 MA'HD*E[4]F_[:^ZK>+N[6Q(OR-]C]L?1!L$K(;J8G1Y/A(OWSO$AV(;O>C$X M!5OSSD[4"L!PMP/?
2(F7I@3;H+_\O_PM02P,$% @ ZH-F62J?;@J#!P M!Q4 !D !X,"JW;W)K&ULO5A;;JLV%/XKA!=L M*:#*NMB.W5R -.UN:-.@[K:'80^T=&P1E42-I.)DOW[GD)(LV8Y18," HC$I
M\N,YW[F25UNIONH,P+"(G_B_U]2=GIGHS'NLD@X)K7U90XI>U5 4W.%2;L:X4 M\-1N*0)Q% 2S<<%%.;JYLG,/ZN9*UR$$3PHINNBX.KY+>1>RS>ST*1 ^W$9(') M#$V,;ZXJOH$EF-
^J!X6C<8>2B@)*+63)%*ROI[?AF[<36F\'7_"Y@JWN_&6FR MDO(K#7Y)KT0I*_\#>P5HDPER-#4+3@G'2P+QU,-$+, OV498FT^Q]F4(Z MW#]&D3[YHE:NMJ%)P"54/HL#CT5!-#F!%W=ZQA8O?
@'O_=^U,_LS]N5-@I= MX:]C.CJ(R7$("H\WNN()7(_0_S6H1QC=?/]=. LN3P@XZ02ZA7N4C8I_4:E"@W[%)/O)G%LXLT["3 ;L3A85+Y\9 ME 84I$R41C)>LAJ-J[9*&-K)-PH P].P<]J#!T7!Y6_]);?
M$0LQO'R%SFTR M]JO_X*._J U"+B&I:35H]N'#'1Z2LCL<;I2L* 93+E<1P'55"$: 5(FOL>X MQF1@#5 :3B&MFF5Q;L34|@L+UG9BH/RMY@1K@9P6B9.<6+S8A/$+ ^()3=%[PA
MC<3U6%4K77/4$0G89B+!)OP(K6L$)Z$UTDT4\0WJO.$&2*@P]"YF$ ^\BF#&= M<11Y0-6/0A5L:><[?G"30$T36128LC09$H7@BCWRO 9V%OA!$(2L N40/1*,
M,/OB#T[9,WA[DL]NTU108N0Y,6$YLTB(4'24'C?GT$LV"@ER' _%0#ID14=X M#*L'1C-+ ^;-F:R4+NSAM:#IYD"0;)!DF7H8>X?R0=Z*SEN%IRS#B]=D;>@M*5GG8&?# WF];QBH+LM.T2*9/
$*A$H/_K?NLYS MGWW!U942";36JYR1< &-]F-TBRY_-O&CZ<[N#F/(-I&6#@@C,"?OCO36:GW/ M?MD C.. 1E9DJBSV%XL#,0:"%CR% 3AME[!"FJ-M;^Ć]@89:5>0_D(Q0IU"R]L-
HP&SO.YC[JL\;O(=0%TF",*S*Z2"")I MN/ MQH_/PBE&,];T/"?$QO:#_ '$D%6#/ HHD;R926!E$;9,H^B-7%(_:'E>7!.%L MCZV4)9#^XF&RQ",4*Z0")Q\:4/M=/9@?]P]-HX4W"L
LF429YG9* $,I^=!PDA%X1<]GDP,4'8>U%:&@%%R$T<]PE$2_7 MK>IOP[/P+I?Q.;]%T5=NA>K:,MWN_O',KOK6@4K#8HKH+ MED/G/1H^1Z(%D;&+V&3DYKBAE84:B*-9I-
'?)@U%.:],1(4E1I36]\UKW/6Z ML+W(SK:MIGT3[FIL&TW3-IH&B;%DM\AH:MF^ESX+:7:/A=@)2I6ELU%ILN- M>W5B:%U%WMOX"2_(2XFCIDC:1(BNBSW+"@[:F+Z01.K />WI'9?HR6?SF1_M
M8@=O>6[A?C9K]KM:LFLW]O6U]MXS+IE[%OOS=L(2BS<$TZ3K)OHC8[0.^0, M+8X76_V_L!;-_8L=:|W)_YFW/DN6MD7D3W>T46I<8P<&6SM 9C7,W6O?,'ZE%
[9WO'#,6QE)1X+|'B8N^$0'?"GKW::YU= M2(9[8VML$%_^[W^_6('[=]<]. =N%]Z3/B77GMG[+6]-.6./@*<'/SG&LFEW+
M1%TO?]7A6AYZ@_C(S'UMCO]:NOM,ZTUEW,X4E"IDEK3A>O3=O4[G1MMYP='' &)OXBZ@TC M?S+I#:?^)&8_85NH=V7[%!KF@$4\[T]XT_FB/UYX<;Q@'T#K@TJ]!M O$G4>
M+>8[>YU/@OY@'K]B]_W6PK4.)PJX0?S9)!B*QF(/_?FTUDW<6N;F,.0&N:S MC*?[C'MRN/Q^/=;N8Z]@XQ[CU,%Q[U]@J-#
M,;FZ=ZINMGOENW6/6[OE[HGP(U<;@93FL,:M@7\Q'3'EGMW?,O4$L#!!0 (_J#9EF]$ F&PO=V]R:W-H965TU\ !/%8:N//!T4(UC4BHSN#CCL5MW<6;KH)6!6R=\79;2;:.] V\WY(!GL!CZI=1%H
M8'1Q5LDUW$'XH[IUV!MU*+DJP7AEC7"P.A]<)B=7$YK/$[XHV/A>6Y G2VOO MJ?,A/Q_$1 @T9($0)X\P#5H34!QXN>X?^"_>XJ^*_N.OBREAVNK_U1Y
M*,X'\X'(825K'3[9S6_0^C,EO,QJS__%IID[&0]$5OM@RW8Q,BB5:7[E8QN' MWH)Y?&!!VBY(F7=CB%G^(H.\.'-V(QS-1C1JL*N\&LDI0TFŸ"PZ_*EP7+NZ" MS>[??:%?
N;BV)>;:2PK7V2@@.LT992W258.4'D!:B!MK0N'%>Y-# _GS]"%EU MU-(=M:OT1< [J(9B'$OJK=RBLH*X=$Z:-7#[MK\NE#PYE\O<^YQOLR7YLVCHGOI(9G]P;WAP#S"X>/,J.8Y/7V ^Z9A/7D+_
MJ22]C)0D0W$(37PPXK)R2G/ A32YN)%;[D0B%, "3I=F*-<8X<%<D\&[M)<-Y@A:V(C@0QA55[;("/XDD6LS3:!K'D:,.8VYY2XH5====B9+4NDT@ = MO7DU3J)X/;NH^=FI0R* *B8-2!'
EA2B M$5N0S@_%EY::\J+A:@T;DQF&X:&1,ZYXD$[9VG-0P65*ZDAD* F548O$'F"M MLH:K#5(W"2FL)C<=A:J9?F"P &FT; T&+:|=,:!4])5JU*!LCN0^(Y&55 [- MZQ(!R
O@4D4& ^D%42|'Y"BUIEI/(<2@2M2=0&KW2$E5ZER$9M%;:'+1 '@2# MRB*#F/E]CK$W3[[U*!\1[DY2/:^N=PD6?:$QCN2BAE.DTU9X5=:ZV2O?$&() M'0QAIR2G,)E*/F-
R(]T']K[[20Q1TK!@4W1JL/$20T.,KLVZA^*[D,K50BLV!31IZ.>YDSQA8L:P'*)1+9 MG6W/2U][@:S&^Q+C<<';2Q,ZX=E IJ7WN. ^R1HV8#]Z5>7*^E4=6H>4Z1=Q
M$E@R.^7LYO0]YSQ;K7)VFPL5U1&NSG@'=+(I@;VXM'4^0NA,USF1I5!%[#BZ M%)S*0GG_]ON9$]B_T'2??]>, M[OVR^WV>X?VC1YP.+,[HNW ;G+CX,]QK75O/57QML:P*3$TNCI*W'=YKD<[3
M7B^937J(_;^9"&\83A%F$*M1XH1<&\ (M0?@C,2;O7]F!]>ZL5YKK'<, =RE.0YF.R-T!!#=8D$35($;20R+5&^A- 2 M5* $9TF584E2-']&*7VD*403R149T 0)-;#6O"#6I/<- <%54^!U"VJ'&%
M:H%>#A2%;$^^(R@=0N)"0T/5T2A@!F6I">20*Q@'!2@+*0!J:BNIDDE22(HS ML"NK%-5;5#W-'+U7_6!ZQ]2^=RPQJ_XMN,4VG>J-^D17U"950+AXKFV%["V M'IR,D1)).%0%T*
[$QEP)Q5E4_+D)9TX@9*G69*4*ES#1=/8'/!]F7Y0%*?HP MFTYU8PM"%V\AQN"=LJP#H<:: 3K/P'$P>B>V&?H,0@N60<'7<%@)"B*%0I"K
M!D,%NUX^B)KJFNL45&:D^RNUFXZ7Z/6KR+'<=_,^_.*$](K>.W0/:S(\,CF M#85-$ITRJKH='WU#"Z2R7D!H8-7(4P+#=3=]J:&V3.(4=X$+72O5P.ZT?T_M4 MM^^K7-&.\=-7X'YOVLW(+^B-
;9FA;_>ZW-@,O%Y7&)O0ZJGYD>FX\0S2PH& M##C/HD/O;[O%ZC 3-RJV[9L..&%=ML7AV;H1J9OQ1TQSW0"UW3\H.V+P(4P M-&,W,&-
]P'=K9,47_8Y^N*Q1$/>"-0H["B_]'JBS9V?;&5GVHMEUDZ8 #D66 M" G,@Z.P(@28]\$FMI=5R].M Z9]F9 ,@O^&=6IUR6(!/PAJY09.$((D%:>2$O'SSL[JP\UF"P8/
MLTI7DJ:XB&K^M[)$LH/_I8DW6_'=LTH=/;&'R!E.4U4;M0'@;[@L 6?"FM[M$+K0WANZ?U=92(2]KU=E2P?1;.9[Y/AI0MBV&7N.:?O.097=7#K,B[VSW[E)
MY02F#TGE^UNQ3E*=4_Y.+,;^X6+>/VIU-Z@VB;=YW63:&LJ9.D9_H&="\[R M^DC6G.Z;53REL*054?D*VI3#6432M^VL-:]>[ICV L>OX=ZAXJ0.E^OC] \9
M#:BVY9FV%R+'@_2)S"C>;CM.!*.057:L1BUHAE9PB,61:YN>92/@A*=:6Y@8 M9@E=F,%T?9@K"$YA++@=5H+L.,>][M!V@WP%&]BK(5N0SDY! ^\!$!24++0D"I M
#X]+]KZ'Y6GZ^E2#:..N!3QTO%Z>XYQ5!3BOS\.D^:_ < ;89K/^GVJB#QY* M6 Q(_>QYZWQ>6@5LDE;=/?U =TL(95$1SDN *=OC#'K\[_^\ 76%7M@YJ7;R;.JR M#
:HKXG#AR&Z1IK_J8O9,K[75=DYS8;G-!N=TVQ\3K/).KLDYF=:P# MV?"CS#2LMN?NRT8U;G:GY1RXC6MDCM5N=?9EDQJ9YWK6@6SZ4>9U+,/>5|WJ M$G7;EOWN5CP+?
>>$31%=J?:,@8#DF!>?FEJUZ@!O5>-SL#XPNQ.S9GTJ.L:B MP7NW+]I-\;5=Q9B!!"U%*./&$]YT$+5JX8L))ILJW\)%MZ"&D>AZ$94"<7U) M"-]9("JC_;? %!+ P04 " #J@V99 'J/JT," "*!@ &0
'AL+W=O M=@,A7VT*2,FV57/8 M*DJV[=G! UAK;&J;L/OO:QM"TRIAI5S -C//;XP8HD;(W2F ;/12,JYBK]"Z M6OJ^2@LHL1J)"KAYD@E98FVF,O=5)0$3EU0R/PR"N5]BRKTDOV6 M-O%|?
*)_=;6;6@Y8P8-@ORC11>Q]\!"!#-=,[T3S#;IZ9I:7"J;<%35M[.2C MA]):.5%VR<:@I+R]XY?N',X2#.=R0M@EA,Z[W!>ZA&:!+

***TX80>*:DQNU1U"YU>AMKO9JDJG$+LF0]#@3R"E[Q_-YX'GP:4I[WR M=(B>[&H&:!P<9O?CK?%S0KGG_6'$F3NNJ!"J:BY;EM%
MO]HWVE7;7_Z&MUWZ$&ULO5IK AM@5[3RZWONQ6.7%$5;3J9?)'()7-SGN0_L MRY5UG_Q"J49\7E;&O]I;-$W]_.# %PNUE'YH:V7PR|RZI6SPU'2RE-
GL7+_G9>W?QTK9-I8UZ[X1OETOI[JY495>O]L9[Z<&-GB\: M>G!P\;*6M5K[W69 H M4VL_T9Q_3M3?LO 09BJ] MNK;5/W79+%
[MG>V)4LUD6S4W=O47%04Z(7J%K3S_%:NP]A0G%JUO(#)NQO>E M-N&__!P5T=MP-GI@PV'<<,A\AX.8R]>RD1UOI0BLO MGJ1/3U\>-."%*!X4|=RK<.
[A ^>>BW?6- LOWIA2E>O[#R!#%N0P"7)UN)@ M1-5#<30:B,/1X?$.>D=9,4=,[^@!>ML$_L_EU#<.CO3?;0('>L?;Z5%T/?>U
M+-2K/82/5^Y6[5U\]WXV>C%#FZ/,[?'NZA?7$FO/=GLVAH/=DLVZ#8NOX6.
M^+!0B)_"+FMI[D@EK9%MJ1M5BL+"@,:'3W$+OLRTD:;0LA*^P0/$<>.%-D75 MEDHTD5Q+#_FPA7*M9__3>+1:V*JZV[=!P/7TF&=-DS8
ME<01(KM9B(^&"4]HGQ=S9923$);6J9I^D9WCU0X:TW5%L?;]=V>'AZ,7'X>3 MH?CSY>5[_CY^\50 F8-&]++'ES8!L5-8;^&$K* -'+J-
VFNL(*03X]'^/WC3 M35LI^C8:DY5NU+RM L7)_K_H'5&8J*)UNJ'PN"P:>CH^/SH:" EK0"\(;O&$ MUD7^UYB=(*8YOL,U!2.G)3-BP#.:=^;34I?7HGLI98
M.V392C5JJG8_%Y]H\V10BB_,'>R_ 5XS<\'D6TRHB%>*ZR$X(X>P ZNE17T MO9 -"W0=?7D*1U6WD 7.(XR"$WN*8MAE)K6#D_#)O*7CIK9>9U7O3T
7I"2? MM!6)DZK'IR_PN(;'=>%22+\0,R1GO^9)6*1MZ;=Z<%+N4/P05N^'U?ED9A^V M2R)HL*Y-B4Q"*9@8Z_'8XX=LMK@C%YWD M7'2R,X=\]&SB-
[[12P*Y;5GH<138L %40]3CQP<2#)F*T$$W=QO>F@#"HWPR M*#AI!X764GY2XI>VG,?(5?E4LIGTJ%?KB(\4KW(VHX /@4:F(YE2&]8JH M5%I.=<5 -
|#"6V5:Q035YYK\$$_IFU,5^V&I?5%9WSK*<>\Z_JC@])P3.[8@ M_T*C,'2(IXKI(352=!)!_'B+@+/(II8\;8L 3B6@*4G^X.;>&CFM" 9+%9RK MT*YHEU

N)=.$DAT7I&1>-^62@5P2FJ2@R[H4B5+!81)OC$ MM@[Q#_D3A!,\!U#)V64 L,$^Z3DE9>%!CIT@,]<4*Y!_],0-CD'5V#.1!GY2<[IV_6[MGUCU'U^_^?'?
UY?#?IV^[L@]JSA*H81"I@%+F?^40* 02[HKFI;S5D#J@C&Q MU)#9>AXMC/PKX'^ T%_Q1L$*QP@@^<-#H+'D_;I]VV@\D?1 M9KB9H02U*
[8.!T;M[*TN29F4RBV@!UZ;P*A@VIR[U 9MU]'FWS-H$#I%Z'\@ M.<5*5G!W!Q]<+72Q&'!*GL^=FF,180NW$R;$64"B[I#=!_20,PH14N]SSANC
MHQ>/_O^$#P3ZO'3_-#_ ^JT0N0Q0@-UT"U!1\UY!J<6H(RN?DV='@Y/CT[XI>?LF@\?'8_$!JO V1]AQSXO1X.C MXZ-U7L[/3K]9B9O_)]08A.0^8@4J
OI.=6G=XU1X?CIX=C[J/3@;#0Y/SA_4 MX.&SHS4M_@Z-X>CSDZ/UHT_'G34W62"G1<9C+RT5%[PAXZ"J!YX&[T7IKYO[M-?
4"C4B,789[3W6XX1IJIY6>Q](SY+V$A)7BO,N-DU^KU')2Y8@TUNRGO&$?V M$3[1 M*2./%@+DE@Q/V< N=
<&FU[U*:RGO4KDHXRQ/N:Y=X)*'NSMH)N@ :D;4U#94 M$+%4S.5^3^]>8G3N0H.'>E51H3!(LX50QI9+;30-K[@#2T5H/'4KW154IY=D
M"4=5MN0H6XV MN?SO)LHZ^9IU3[Q2XD)L*-[F?N3O737[E'R"$(6=F5144AB1H]X&2P1' M(4R()M:L[UB83_4,YS. L!6#3U*/"9?PH1]2J.%2/?9U;-
/"O1M()RNXWUO(M\+KC)S%_M_7UK&?9(" ,#2]"*5[&+8I;M+ASJA][5'DZ8 1\3%'533>&7^U7''D&#L2#0>:N3 KIZ:#U) N-T0&>TE7(;7J9)G1+
M6ZJ*1WI@(/=J<1Q :MD'P7WZ@!8M#@3@A_A:QD(3+-S:BJ91Q$'J:+Z*_Z3U M;0X?FPR3J>JP(76*6_8$S876@QO=J6I6*I*@]MAC,9P,$)=;VO5^K6?
F"._; MW7H(^:B_ 0V.ZR/$-6W]F;>^"YH/MJ4(Q*E25V24N72YZ>L.^WJ30X3UX*;Q M:>Z+[W+BS9F5AYI.LPMHM/@,V87UL?
9:YR,)O82I"9!+8Y)EXRLAZ6;>4 MC[EYA5)S8D(99 %YJ9NAAM7WF X.R@=S%J3C,@U"KNAPX;2'UH D4G?15K&.
MHH"+M98+TU"$_XJ[4Q5F&/13QT4:<=12QBF'1*]B4L%Q M2WU6V;IN!$&<1*&ROZ&*5@$+:7 L3,O9F\9JH7CJ#[!9G3B9Y^]Q*D ^1E," M5'M-K
L]/'JSE"/ODW'HN2$3ZBYTJ#34SB;] FW1-A#SM\02JDI?1X])?G0) M".SN+"$"3;:4X%"-GW4^!T^W'A,F':GPJ=C_91[Y[;3 X%Z,#'(XPC54RDL4
MX>217!#QJI7. .REMOZ=\B+SH_5"L_1 &FSZ- MMFJ@J6GXNB((S;\L;%7&]JU'*(MOQ_0W7M=_WSC\]QZA|+&H^[B>[1399/&
M%I_VK]CYR&%AK0=5]HVD^L&0Z_ZBOP!./'=RV5V->B850D*ND%404F\I' #G M6)8 \DS7;<35,<^'+I.H %08408;V:#KZ2)^R0VF$LHQ-
%#/0*;8)Z'CL#<# MWBTA7BZW J>/X.L!.#6(.1X#][?VFBMB/WD;'>#LE'$?;C15X89M$<;;N6BZ
MC]4I$E/E#,0+H:,XFP[7W112Q^6&MC06,/#QB(8N7+O6T AJ S"Q#L>YI9T% MZ)LIW="- VWB*U=;H*?=L2>8C\J-)(LQJGQBLV!]JG1V0>:X]^K+^
N]8*$V7FUQ:.5I(,X0M14)=I+4R6EEXE>(["!77L;6C-J2T/4-"UJCV6 M)@W0KE;SOG S%1? <1+S5I M_Y,/MM:%.#P;/14_+&E0IW)Z'"*LXM-
/&U_U[,K[NI7<,\N4?5TGA;H=" @@,E M7*.&=R#"=7%WV9;N!+N2WG5G>I6N!!%,RW"+G:!!F07YX=K%7;SNZE<&3&
MO,6H%55_K#=&DUSYIDE/,BH'*DZ0X0K<]T;G<@9ANL'+^00+=R7--WBQ[N& M1Y$Z'HHWDNH$]B:*<;!:4Y?5I'E$L],
W34Z$*G2BB;"35>T55R:TXL3B;N5?:=-O76^30KCQZXUQG<$5GP0 M%)F+**Z;-RZ?@K7YJ(:9XC:G[)\H :?S4#EP72\H%W&/&[TX)#IZCXHO5@M^
M^:\CNDZMZPOB5)YK/W VM_2&%C.$-H.J9]J8;JKB15G_U1UM=DJUL7EZ)WY! M5^-+773$-N3^EO'"*^)!||(M1,0BI3JV'1HZ+!U&)W.A^1-3]>'B!@GB%
[.\& MZY$25AL;DWBZ9=J\AV-]W;W\T)E[ITS\TM<$M54;;M<&N[M<=![Y7:IW)Q?+.;>T33A[=O\-+^\?!E>V>V6AS>?WTDWIPEQI6;8.AJ>GNP)
M%UXF#E\:6_,+O%/:-')'Q=*(H9I 7Z?6717\0L=D%_IOO@?4$L#!!0 (M .J#9EGE$O<-5 , &\(9 >&PO=V]R:W-H965T/??<'R9P1LE_N"YK=;!/(
<"]8*>Z<.G_ 8S\3A94H8/*ATYVE 62ML:H^&A.# MFLMN9M^.>1@8S.,7#)*C0>)Y=XX\RQ^999N55@?03IO0W(
M[06:]ZO($A.'%V5'K]>=U^0%KPOXK*2M#'R4.>9/[2.*H \C.85QG5P$W&%S M!6D<0A(GXPMX:9^6U..E+ ^"="_?/[=Y83"G1%N\-,R8P+WI64)#?,5*$?
X>/7 MEC\P@=(:7^P[I(AX9C'W^^?BNNSYOD(HE*"K[5)EW7F 1JL'GE/"&-W:YV0R M3\:-@,_(Z$/7\SCM4K:'0S?M>_ N3K;M^HQ"V%O98-
H[A7EDF7E/'(9P_)_'Y3,\ E6F/VK\%E$ D/H/4G?1>E\+%+)PNXH%@'H?)9/%B!I-I^B2+ M_R-CY'HQ29^ZGHU&Y]Z,:- $:M2E;W4&_#O6]8->VG?
3;==$'M6[5OR9:3IW M!@069!I?S28!Z*ZJ=@NK&M]2]LI2@_*?%?T1H'8M%\H94|+YZ#_,QJC\"U!+ M P04 " #J@V99[#FPTQ4& !$%@ &0
'AL+W=OST9+UA&Y1%?LAQF9EQD5,%0S'MR*1B=%HNRM&=;EM_+:))W^B<%[5KT3_A*
MI4G.K@62JRRCXN&,I7Q]VB&=+6&4S!=*$WK]DR6=LS%3M\MK :->)66:9"R7 M"<^18+/3SH =BQM$$M9K+0$"G_W;,C2 M5
L",_[:R.Q4*O5"|WLK_5WA._@RH9(->?I;,E6+TT[805,VHZM4C?CZ/=OX MXVEY,4]E\8O6&UZK@^*55#S;+ 8+LB0O_^F731Q>LL#>++ +NTM%A97G5-
'^ MB>!K)#0W2-,?A:O%:C NR?6FC)6 V036J?Z(W;-\Q5#WADY2)@]/>@JDZKE> MO)%P5DJPGY 0H2N>JX5$%_F43>OK>V!-99*]-
>G,WBMPS)9'R+$PLBW;W2 M]5QT"GG.,R[.!,_0$&P5D H09K5 PR+ 3*_!A-9T/]L"T IWVV7K\OF6"YI MS$X[4!>2B7O6Z;]^17SK[1[KW(S]!&*="GX=
7VBXU7 M28YN\T2Q*1HKJIC$B.93<#-;TOSA1XER5O&VN;9?^>M7H6TY;]&W^K]9",9J M^55-?013VV>V_Y!'BF43V%V=3.W4+H1/+?
A*0M#D89%Q%2<,"/@EI3K<@/D M5W?^]OSBX^?AH!H?(-_'5A@9!,?&D1\8!.)%V |<@Q)9. P\-+R\NAA]N&PH MZ1)L$^^P07RF"H(=WVJ*PIX5
M/L'[X=,O-Y]&OS>]|'#HV*V!)'8SL(1@WVHZL66_X8JF1=T\KK6&K1;V/+=) M=L':)MFV/!SX3;W$]S)7/1)+2 K'^NR;S)*8
MYFH'R%0BBJZ9B%FNH#G0*TO_ZNO;(&V_+>7Z1SM;V"$-.^*:': M& ,GA,&0Y3&LOUTX>>\3P/'T =WE?)WK/1C !B9COH+->W/&Q)S5]!PBQWE2
M=F3.:'N&5$R3'/;]/:.I6F!TF<=`4#0&'S'%D= <@(0]9>179>2_N(P&NIM- M5 (II\][V,XDGT-9%.T'.J,IS6.FTU"@"QHOZD4&?
<*M>H9G=];RM9=]P02$?)C2^:Y[C)0Z_8[J7>DZI#MHNA,]Q M#_F;)7UXL4=Z\Z#;R);J6=:!E(E4>N>>9'G4ZFS)U_0![E@[#2.("K21-0]'
M3*U$OJ.52%PE&57HG,6;2!-<+WXX:AP<>2:!V 03QVQ;W @'D6>>1JZ+P]#3 M[M\GFPM@2G67JSB2%&XJ< F:ZN[WZR/L<"6$CA"<
@EO8F9@PU%LM[0L'G1> M=K/!(23 =M1L Z((V@ XTJ]!B@J>P,>QG#9EG!#F[+RJ]E)=2,_:E)][+A- M$(:&SR)62\-7]"R;;"C1H#H$0>\T 6(BY/IV@:!D!
:&S/;(), "SV2QB8]MK]G;?H> MM?/C?\#ZNH!E)HAKPQW*A"$Q67IW^#4E#X0>?HI031(2_DYQ M%S;8B@QPZGH>]D-B<@0^#CWW&22JP4P$!IO0%,
(AYYMGF@/QKR$3\0,<1E6, MVSK$GO&RE^D65K]?2E24;_G(5U&K])]'^3*X8R_?5Z\ 0!*HB93-8*EU%,] M291OEN5 \67Q3CCA"@):?"X8)*W0##
_XUQM!UI!]7#<_QM02P,$% @ MZH-F6<$|:SHN!0 QQ, !D !X;"]W;W)K&UL MS1C;;MLV]%<.W*)P -669/FB7 PDZ=(-2]<@:;]'80^T?&P3D4251.)Z7[]#
M2E84W^(DP]H74R3/_6X>SX6\4S-$#=^3.%4GC9G6V6&[K:(9)DRU1(8IW4R$
M3)BFK9RV52:1C2U2$K=]U^VU$\;3QO#8GEW)X;'(=-4^_PK&O@+8QP;0B3&MY)FHV)I$.O?2^H7 M5G?29<04GHOX3S[6LY/&H %CG+
|UM=B_BN6^E@!(QK^POSM9M0)0K+9(2 MF21(>%]L['MIAWT0_!+!MW(7C*R4'YAFPV,IYB --%$'U95BTW"|=0XY49+
MNN6$IX<7C$OXRN(J9@E_2,8X?X[=)NDI$?RGBF;^3X UF+>BX#OBN'^R@UZE4[EAZG:=5_L!5 M% NCM8*_3D=*2XJ2OS?I7) ,-I,TF7.H,A;A28-
20Z&\Q\;PW1NOYQ[M$#BH M! YV41_>4":.\QA!3.""IRR-.(OA5"DD1[%T#)>XTRH5P8:1"CF$^923@236*9 M[/P? N8I_"$TPJ!5TZ(F>@L^ZQE*F&QD:?
1\N&&%\LE26:9A8MQZ;]UJ59>5 MZB.C^JHT3,%$Q%23U"&|>S/PW<[1_[YN2[Y5.,H CAR5JK0;._QN=,S0"_Y9P,6]0%[Z"Z? N]T"'[+GV8
M(\|_>O157A8BK.$|'"PQ=IV42!OC9G]MKL6"Q7H!%TBICY*4,BVAHK5XIE"A M0ZY8VY]3]:.H(VM!1%G QRAM/FR4JD[PJ?->Q]]XMFK@_40?=
(*M^Y\]'SY@ M5*:#9].A|Y.DPV#@!+UZ:(?A8*<;!]$3= ?PBMMZV M;EHP%?9.IKX3AIU7,RVHG(LD M06D=G+&,PL3TCDC(3% F(J34A-
8%V)IU3J\7/A/Z2F+&>+U?\91FB]PZ@")U M>9^P-)_0Q)';-M7T#UYM@)Z_[CESMEHC0A(TJ,=FGP3OUPMNC=!;\-S "8-7 MU]^7KD^6U/V*7N $?
7_KWJ3R6GY;=DJ;R2L1*2[(929589)3G7%,>&^,[B+@ M]HC".=MS9FQ :#=: M1'=PE]_M;^T85[O5N-K=>URU!K6*KUC6*2UIB]Z*Y6B"UI)'9L
T:)N&UMT2_.@^]O2\ M=BXHJ&Y3"IW83J,?Z>]S?=^\%(K Z@UQ+?SJV?J*F6K+?/8L&C_:X$\.!/^Q MO?O4MP?!,^U=(KVD(?ON8QMO*OW-
[GK[>&83]CPGK'6!]JONW7XL@?!E#9@Z M4'__":#96]>VZ&&K\6QZ5XS2Y62"ONZGZM6N/*Z35U#XAFJT^)QY@&\>.*B.8|*O:)R/B%4MJ6G,B:+9Z-
BHT5FGVI&0FN1 MV,\9,FIW!H#N)X),5VX,@^KM;O@O4$L#!!0 (.J#9EG]@""@[0(+4' M 9 >&PO=V]R:W-H965T8M_Y[O-W.=_ = M:"75DUX"&/)2-;0L
A M-Q:!XO(,E\"Y!4(:O]:83G>E==S=;]"OF]@QEAG5<"GY(RO,TE3+4%*FM-1:%/.QN; MW%TA(O=TA6_;@&*4Z^[H$PDB-
XV2747H#M*$/&+!$P2OE,Q!;ST"'_[@T[N MAV[2[Y-K)AA62D$64A9;Z] -!T$G1;&;1"EYD(;RW1N#@>L';SA@O('O'\AW
MTN4[^>M\3RBG(@2/)O=_)'G[++?_,D[=7NSO M*JAV_.3K:U+A!2?|UHIE#N[-'"C=)N37NK&@^1CJ?-V6FD):M$,#(T55 O3
M=M5.V\VDB[85;|W;@79+U8()33C,T=4_2S%7JAT2K6!DU33FF338YIOM$N&PO=V]R:W-H965T79>*S3)2NH/I4E$_!E+E5!#0S58JQ+Q6CFE(I\3#PO
M'A>4B]'LW,W=J=FYK$S.!;M32%=%0=7ZBN5R=3'R1YN)>[Y8&CLQGIV7=,$> MF/FMO%,P&KD?
7D4K7UGC3V3Q4IEKJXM6M6P(PFFEC2P:9;"@X*)^TN@ M0!H%XNRN%W)6?J"&SLZ57"%EI0'-OCA7G388QX5-RH-1\)6#GIE=T9R*E*$'
MQX!K6912,&$T.OI&'W.FC_''!I:QPN.T@;RJ(MSX/"" ;Q;M:""_TEK6H@,W99,N9'> MYVT-%NX'LT5SIDN:LHL15(5FZHF-9N_>^+'W_H"I86MJ>
A]]@!%F%4Y0W*. M[A24HC)K9_+''Q4OH3@,1E^9V6?V8> M,-:!"6!!"H'@VK#,KFJ6#,UE#L7+ MQ>(,O7LS(5[P_F_(9>&%8],N81N9C^PM)GT,3KB
E:5E0;3]'$K8Y-O?P+T MA:9+<$>],+Z5?(O\ /MZ_V("U"V_*P/K=$H60LNY65'%6H4 1W'<'X4QNJF4 MX*8"*:LRY_V7;=''/O:BZ,7H,X-
^L91YAGA1*OG$"E=:&Z$()Y'_8G3#A:O' MW*HB97N*S4(% ZHUZVGWGS[9C33!9!JB;]+0')5[L]V)@H=!T W!E,1#EVE:
M%55.+1$R!N1.>5.6IO&K:0K%IRH(MRF=.'WG.#6=[]Z;#@!L0&SP)C5S!B4(I&[Z\@_U/V_U^8K^:T+U!T(8DE47!
M%#2CNH8'*5)04;LTC/'$)^T*2JYI[F*_HX_]Z2Z+0RC-P$?W3FV-;AB# M$"K^1&VQM119HZ.OTC T.=X!F&*(X.#.<0_>BLIZ!0TAY67=$C846>.6-8/X
M!/N37:\W^!NW:PJVKH8X(MTFF\#.,:EWS#X[N\5W0Q63/06/_3""?5X82'J= M/F!WUISOAM&&=M$!Y#/NC6\KIPZ7L4>GL91GWE>A(-)?*!5)&VK2%
[=*FZ= M*9_[,?LJQ4ECV[ZN<1C[_U3SPXD4G8O]D >D'V_L)P16GC.0RY"ASQVK]Y7> MGAJI9W]:
(7UKAJLDP2%)!JEWNU4>/R.F[V$R21IFUJI;9;,_/F3Z\F ,#:N; MV,?,<>]R"7UWX:[0=M>HA*GOF>UL>TN_K"^GG7A]Q?]"U8(+#8?;.:AZIPF<
MJE1];:X'1I;NJOHH#5Q\W>N244BZ%8#O&PO=V]R:W-H965T>DX,DXAI_*"EU#@ MS8J+G"KS#-I?LFVD74M$E=2\;Q1
M1@0Y*^J5/C5Y.$;!;Q1\@[MV9%#>4$5G$\&W1&AIM*8_3*A&&|&Q0A=EH03> M,M13LWG|HV*2U1DJ$G+#9,F;_>D#768@SR:.0D]:WHD;JU>U5?^
U8A\X85* M)?FM2"!YJ>\@PA:FOX-YY?<:7$!Y00+7)KJK#WKL!6W8@;$'7'!'VO V;9N3K MBEQ5$J6E)'_/EU()Y,T_^S)0.QCL=Z!Z5*6-(:IA$Q-
8(H3E0(!J1C2%QR*RHDR0 M#8KXNV$\$2A7I5@B9#61>PYPW,]ZN:8R-52.]0>@-$8,VL%.XH2$ M=A2-R.=B@[G)S1U"PT?I$92F/)$05P)]@WQCWO?
L4>21.P$E98DTGCBF4NSR M^%IA:/NAB[[.2\%C32M-!XHU,ZH);/!A+#6(MZY"VP\B\K52YQF6MI![X'B! M/0Q<\L 5DO<5@A,R"NRQ-
R)_,KID61T/IK'*>](WCV-1Z1*T<6$JA(:7=:QT M7-@CWREAJV M+34\NJ5HP\BFEW18G+ $D!6S!"$%8H6:Z8_:VS[NJ;?X;%=YR]ZT^+<||;
M[#6U6X.!V^4]:OV^^.,7C8;D&:WO:4Y[Z(:O%&_YA@K%)*+#AU!5JI.?@X8| MS\8_FH:!_94_6*@3$D3V*(QZR!FVY R/)F=5T"IAFI28:V+&LMU(I:]Q7!/F
M^=]+R7XW_Y>2A]:'5 "\& 7:JUMT_?+F *_QGUJ!OL1WJ/G[#_JNZH(Y%M1 MO7RF\)T(QYT#+QSBR^626WQ>,BZ[LJ>#R([&@[/ND>\.
[,CWS_85T^F,7SF(MM1DR)8GU(U)/8NUI.\?.Z_'MEW@]!'^A8LT*23)8H:I[,<(W1-2#9;U1O#3# MW)(K' W-9XJS. @M@/);\L0<(M 7(0 &0
'AL+W=O>&1<94? J MY@-9"$H2,RE+!Y[KC@8987GO[,2T78NS$UZJE.7T6B!99AD1RPN:\KO3'NZM
M&CZS^4+IAL'924'F=$+5'\6U@+=!@Y*PC.:2\1P).COMG>/7%SC4$\R(/QF] MD]8STEN9LZ:>:#^OT*_ MYF$S4R+I)4__8HE:G/;"'DKHC)2I^LSO?
J/UA@*-%_-4FK_HKAH;>#T4EU+Q MK)X,$F0LKW[)?:T(:T+H[IG@U1,|(W>UD)'R+5'D[$3P.R3T:$#3#V:K9C8(MQW)]*A,EH)?!/'5VQ7*2QXRDZ
,C4Y8RQ:A$1S=DFE)Y?#)0L(8>.8AKO(L* MS]N#%ZZ&//%<+B=[E"4TVYP] MD9 ;R7@A=<).*%%'_FN@SS7&W;@^4
M*45\ABYY5I!|^:M$;^E4H4_3E,V)MNA6J;MQSU?>IX'5@]F ?_DI]/#XC01[MAB7X>@D'L3Q.RX3EZ_YPJ!@2F:3:EH MK P=F0WR4I(\D$P_T-
E<#>2PT^@LWGMQ04!>1B M;$3"!_4[KI;JV WLE?QO+$31MAJP:'K!(&[L\[+'VE*;VE<6Q(VEN0_J4D! MYGA]0D9[P8[V?"?
F]H;CIQAB#M:'G5*OH.QMWE*(R<,;6/ (!T.@HY3>HEN M@$F*QL.(\3")((&0"KQ'^P41%'AK^@\$&'(+ZMADB*8T92"H M-(WQRCLKR6KBE-
1F242*0O![XZZZ%]QUS8VPSLMJEQ9? OVQ? 9/0 D)FBZW M]N*TDC,D_$7K2N@$4TL]OLM3T$6L*^EZ6*:R@$1,H8*WXP"MA'Y-J((!.601 MX@O0CQ)$:
[F/)DSSDUZX[@'-K'I7\6*/?'IL-605.1O2@2B%3-M M$/FBZW N]6UK!O_F>]BZ7$VMBK]=9XGBYM_G1\/-*#@KV# L?S<.6774.|*G;L&[(S M-
#0THC1!DID^A5%L0PP#9XP]=,,5C(0C95F9K0]G>_3(E*K=K7R$0>RQ(?A5*K/5R74&-!E#0JF!"PB_,YY#K:M=J.OQ/TD=$" MN^N;!?=I@EJ-
||1R6C<@^*!BF^=5&)FA]ROR>7=?T%S25N&[P9_4IPYQ&YN- M(L8-O;6°<>RLW&#^1FW0B/M9#UE1%^HCLC M_!R71GA]:X0/NS8ZT)*
[P4T%8Y(DDZ:9"JP.U'6EM+%B$[AIM2*$]=3D_% 9 MU.F9?>K?_PKH1E>)&[>5ZUL9V'I[3[N;'NZ\UHO?T0.5%A1@L2K!]'8RH1?F M"7MVQ F=
<607Z9$300)IN6W@#-VAOL?2'%!1!AS685F1_6LOWXAN5?RK7^QX MX_%.:^B[-;/LF$O7+B/(R@+K'6,'1[Z]S9'C^5VWQ7A=..+NRA'W@Y\W*MX)
MS1D4QI-RR@44 <:FJRHX*:L"N=6YGJ.\Q.OZ$C]1@8F?H\+$ZQ(3/TN-^0#] MU=X*L>TRXX=7BH=5B&,H-CLK1-\9!NZJ0GR@B/\"O"!ZLV#
B=RW4/*-C/A M>(.G9T;0&NIZN+QVRLY\OY)K,P7[;G/C!KK+V->U'?[ZXNX1X;H;_.G# M=8N"?
MR'F^|=O1^(VJ9EHHS&P"!!L6WQ.ASY>]\)]BX.J_>ORU0^_XZ]OM> M9 5CUUVO'87>PT%81]AHZ]VS:PPGV/@^ ^]CM\U+!M:WZHR*N?DB+Y'94/79

MNFEMOOJ?5]^ZU\.K?QGX2,2&ULG53;;MLP#/T5PAV%LAJ MQ[?TDAAHTA7;0[>BZ38,PQYDFXF%RI(GR4WW]Y/DQ,V0-][L421YY!',CE> M"?FD*D0-+S7C:N)56C>7OJ^*"FNBSD2#W'@60M9$&U,N?=5()*4#U*

#+2ML#/QLW9(ESU%^; M>VDLOV8 M"AH6V M#,0LSSA#QBR1>/WFM/K4UK@]G[#?NNT&RTY43@3[#LM=37QSCTH<4%:IA_$ MZB.NJ226KQ!,N2^LNM@D]*!HE1;UG&FPJJ"GO5O*ROHEL)NJ::G/+6@'A)B5>9RU>D.SKYB;[R#T2"\B.QALA.9C 9ID%I?NN,;#M(DMJ[1CBM. M G@4VN@7K_JW,J:C01!$^U[!W^JF&N72S0P%A6BY[AJK/^W'TG77C:_AW4R[M(W))35J&"P,-SD:)![*;$YVA1>-Z,Q?:=+K;5F:THK0!QK\00F\,FZ ?UME? M4$L#!!0 (.J#9ED>3M>O(P, -(' 9 >&PO=V]R:W-H965T>:B6RW#K5E1?Z_M2K&6^L3W6%4&B&C\W&$Z0TCC M./[>HW^RN5,N:Z;PO:B^\UR7"R=U(,>"=97^*K9?<)=/8O R42G[A&UO&Ü\X MD'5*BWKG3 QJWO1OJK2KP\@A]8\XA#N'T/+N UF6'YAFR[D46Y#&FM#,ATW5 M>A,YWIA+66E)IYS\]'*E1?90BBI'J=["!RQXQC6I\[FF*82R];(=W MW>.%1_!F<",:72KXV.28/_?WB-M ,-P3O Y/ JZPG4#DNQ#Z87P"+QH2CBQ> M= 3OX\^.ZU_P[5::4G_Q(]#.?80\6$(TR>7JF49+AQJ!(7R$9WEFU?!U']W M@F \$(Q/H2]7Ü'=Y5R&(J@G=(74 UK!-RJH!%TB7-W?P-]%@9(WFT/L3^._ M>96&?O0._N_W?2D1G_T=E%ZKL5Y36N:"]X:W1/B4W1EOJ RB4ZS)E0OXE-$Q MJ)))!%)!2W:]E%-'G ^XY@<:"]$!S6UGPU#I,U"7-#64Z8|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Ä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È#TR"^\$@ M@A006A:'A!' T/.B+?[8M%Q/7T1 =2W(,OTOPV'G<0SW_%+_ A" J"ID_4YN M9]N_#)? UXWJ[O/Y%\17S)2T$RL@"6*U!","&ZV=_/9"LU$_M.9/P<-?=%<$I MX6H!T!<,#-4,U ;MOY?)/U!+ P04 " #J@V996JB8#PD& "?-P &0 M 'AL+W=O69P7F#L M$T\>>?%-+!F3Y$>:9.*\LY0R_]#MBG#)4BK>|YQEZIDY+U(JU=UBT15YP6A4 M%:5)US*,83>E<=:93JK';HOIA*]D$F? LMB!BE::T^'G)$OYXWC$[3P_D8+-SSL7YH? ,LJ":HL_8_8H=FZ3 M\J7<<_ZMO!-$YQVCG!%+6"A+@JH?#^R*)4DIJ7E\K]'.9LRRU.5Z4M8+ MDS+)# <_D4A GBUC44G^EK^|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Ü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|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|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|'4$L#!!0 (.J#9EE_<"4W 8 $

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|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|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|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|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|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

*(@S=Y+R2F&5RY"]MT*SCIHV:RUI-\(R:.92G*/2.4> %@P[XI!\^ MA53#?0L/=^&NSDN;G*!-3F#YPERG42$;2+"/O9DPIDB;&6V M/>7Z!&*

<@L#F%QX@]5D17!FK:R-:"V6=1&$P]_8FZ9+>"_O; Q+M M;Y(7G,7=NQ2WTN->Z3=<8=I^9' 9%/VH_Q@N!552W:W MKG?*

SM'[!8D681!26&N>=QM]SJ)^KNJ-X:6_\!5?Z_;#-7+_P($R GE]R74U- MQSPB[7^&Y]02P,$% @ ZH-F60C@7I9N#P C=$!D !X;"]W;W)K M&ULS=U_;Z-

*(GL?QIX)RH[M9J;MCP#^2OG2D[O"K M8'JVU=G9TVIU?Q"[$J.QP0LXW2W=@S]P2'#%E8J9>9[T\\=T[+A>93"?4+B^*

*MP,6WHOR]6DI96]_7J[SZ<+*LZ\W[T]-JOI3KM'I7;&3>_.:V*-=IW3PL[TZK M32G3Q:[1>G7JC$;3TW6:Y2>7%[OGOI27%\6V7F6Y_%):U7:]3LL?G^2J^/;A*

MQ#YY?.)K=K>LVR=.+R\VZ9V\EO5OFR]E\^CT25ED:YE769%;I;S]15L?JO;%$O/YR9MN:5-7XELDNP6: MM-Z\6%6[_UO?NM>.3JSYMJ+==>X>0?

K+'_X-_W>K8B]!N/)"PVIEV#Z;$-9EV#V;$-SKH&9\['=&6)_"&_[2]^ MJF2=9JOJ+Q>G=?,>6NETWO5W]="?\T)_KO6YR.ME9?GY0BXT[4-S^W-#^]-F

MV9]6@/.X CXY1O!:;MY9H[.WEC-R7.NW:_Z^:>_6%DMU]9/UJE5+=-25MT_MNL4]0G='.WW\J&L8S\S$V_PHQCQ7F>#XA7(-3,BLFXAY-^*(5>Q.

*M7WTW\1&K>/3Z*D[.C"?G3Y_4"PNE;.WN4]S=G>N^M+*VY6TZE]9>[#5O[M,# M,M8C[5[^?;5IF \GS6Z\DN6]/+G\]W^SIZ/_U"6$Q#P2\TDL(+&0Q"*

(2$R06 MDU@"84]NQD^Y&IOTRZNT6EKSHAEI+F29OA0KHS$T5B3FD9A/8@&)A206D9@@ ML?

@!F^ZP][_M>C1[^NSB]W\\.U*V2F&2W/HD%FF48CT;.X3*$AZ^.SZB,A>!8G%))9 F!*(V5,@9]\& M8I/^V*5A]\U"42]E::7S>;F5"VN5I3?9JCD T1Y5?*

*S+:0V,R.]PLW*D[.XP) MV:M/8@&)A<>NCXCL59!83&()A"DQ.7N*R9DQ)GO?L+UZ^&"4AH:"Q#P2\TDL M(+&0Q"(2$R06GQW\?;!G9[JC!ZA7)3CG3\$Y-*

*P8G+(K%MVRUT@7%V')H4$C, M(S&?Q (2"TDL(C%!8C&))><'AV#G8^5(38F)/>HG>$;&H/PJ:RM;;I*L7,N\ MMN;+M+R3NM28G:&Q034/U7Q4"U*

M[+3]O[[3V>_2':&VN^+^-BONTK+/$GE59_6VUA__FY7!\2$U#]5\5 M0 M+42U"-4$JL6HEE";FK%^CM]&)OEM=)8?*

U3Q4\U$M0+40U2)4$Z@6HUI";6K& M^OE^VSSA+XXZHD(G_%'-0S7?UDPYCZ::[XP"M-\0U2)4$Z@6HUI";6IZ^IE_ MVSSU?

R4^^U]_$=9UNI+6_W1%I^G*"LMBNWG3/98+][BU:G[L7O7&^K6HVU_, M=T=C[1327S?2=@5AE_?.S7-_(\K^U(43K!U#-0S4?U0)4"U$M0C6!:C&J)92F

*M!K6O:K"GR% 2+6M -0_5?%0+4"U$M0C5!*K%J)90FIJQOE#"-E=*'%<[:D8& M1XS4/%3S[*7Z@0I3I6P]&71]CF^H@PS7*K MR*VJ'2G699I7Z?S%B**

%$JCFH9IO:Z;H)Z[^> NM@$"U"-4$JL6HEE";FJ^ M5L(V%TO\K0].LZ>I:OUW[FC9!*IYJ.9WVGY\=C.LA^%!JR)0+4(U@6HQJB64 MIIX?*

VA=0..8"BB]'GJ=@9H;FQSFL WAKZS92#^W71[5 LQ33<\U"A+H7ZI8V MTKQP,M.\4 +$J-:0FGJ%MU7-*

*#CFBH9C3U8P,X.W:/O@DW.TPWH/[==!M0+5 MPJ/7283V*U M1K6$TM1P]!4*CKE"X<^=N&#&!T?&.=@\W-%8&QFT* '5 E0+*

*MCUXG$=JO0+48U1)*4R/3%QPXQLG602K)T-JS&:A^U1#U%06.N:+@JZQEOCM"ORGRK7[G@M83=-K^']*Q;B3MH=WZ*

*MJ!:@6GCL*HG0;@6JQ:B64)]:BKY2P#%7"HA\7JREMU -5"S1JQ==|U1VBW M5B5$LH34U%/RWOF*|V\(_?KL7GK__8*

M5<9H$X'.QZ.:AVH^]@6H%]):A&H"U6)42RA-#5<_'^_,B)H7!YV01S4/U7Q4 M"U M1+4(U02JQ:B64)]:L7Y:WS%/ZW^5V?

IF6U;MMVPOSTB:D<$1.YPTUP_L MT*EZ5 M0+3QRC41HKP+58E1+*$V-13]/[YCGZ??'=?_7==='FMS(X7.AT/ZKY MJ!:@6HAJ$:H)5(M1+:$T]2JZ?4V

*.R+&B"Y:$H!J'IKYJ!:@6HAJ$:H)5(M1 M+:$T-6-JE8+]RG47CJJ+-B.#(X9>:,$]/(U^K*VR]=%^ U0+42U"-7'T&H[1 M?A-*4Z/1URBXYAH%D=_+O"*

*[*]9F6\Z7:=4>1*W76=V>D*H]E#*#@V."7E ! MU7Q4"U M1+4(U42GZ:X;_3Q*:.T"I:E1VKLA@KEV8<@)!F9J<(C8&R.X!\?R MCJ.KM?31?*

*@-4"U$M0C6!:C&J)92FAJBO77#-M0L'YQ=86;Z[.);N#C^?S-C@ M&)&:UVGJA0RT*4+++&% M1+4(U02JQ:B64)J:HK[6P377.ARF:)MOTDR?(;3F*

MP3VND@CM5J!:C&H)I:F!Z4L'7'/I MP+$SDNBL/ZIYJ.:C6H!J(:I%J"90+4:UA-+4>WSVL_YC9-9_C,[ZHY]':CZ] M!:@6HE]$:@+58E1+$W-*

6#_K/S;/^G_:5LTS565=%>N;+._NM/#KMJUC:^O> MKA]NR"ZJJAT'9KGE?Y\OT_Q.MK_TT_GRX17MHUU,2]E6TKUX__9/W=MIKWC_ M-)09O;//I^I

YLK\M@?'$+W" :H%J!:B6H1J M5B5$LH38UA7V$P-E<8/(1H M4V:S-CX_6:>F"#U0L[T$3=XY9Z[/$)HU0"J^:@6H%J(:A&J"52+42VA-#5" M?

67!V%Q9L'??H/MTM956F=TM:VO3[,=V66IRE=5HW4X63^09C0Z@%4\U$M M0+40U2)4$Z@6HUI";6J8^@J#L;G"0!^FJOV.

*<'<3AB956:&=*7T%MD?6#YF6 MNAW;E;GIX(R1FH[J :]%[!:AFD"U&-422E,SUM.0'M-D2U*

M"-4$JL6HEE";FJJ^R&)L+K+X0W90'5_/AY1$.8H165:!:A&H" MU6)42RA-C5%?>C$>7'K1#.Z.O-.QV1X<)[0@]5\5 M0+42U"-4$JL6HEE": MDKQ)7Y

*Q00HR)FA!!JIYJ.:C6H!J(:I%J"90+4:UA-+4C/4%&1-S0<:OLK:R M8^YV;'8&IPRMMT U?W)XU8&I]B@+[39$M0C5!*K%J)90FAJ@OI1B\LK%&I[" *

M\Z89"]9I?I>5%?:9W\S@ M<'5):@6H%[:A&J"52+42VA-#5:CFHJ :B&J1:@F4"U&M832 MU&3V52V3L'#&J=,_.N"HTMSWT#T>JGFHYJ-*

:@&HAJD6H)E M1K6$TM1D]L4P M4X<854[1>A54\U#-1[4 U4)4BU!-H%J,:@FEJ1GKZU.FYOH48E3I:D:5!X- MM"@%U7Q4"U M1+4(U02JQ:B64-*

I#K$ZKI92UE];IY<5:EG?R2JY6E34OMGG= M[K_VGK5*>=O$SG[_T3DY/7C^RGX?V)KG0_M]M'O^M.=MT-7HWFYP\7,_D\4%=;#Z<-

*#OJFZ*NB_7NQZ5,%()L7]#_K8HZL<';0?? MBO+WW>)<_B]02P,$% @ ZH-F6;_Z.6N? P RPP !D !X;"]W;W)K M&ULM9=ADYLV$(;_BH9F,LE,*

[T"R#>9B>^;NW$XS MTTYOXJ3YK(/%: X0D81]^?== 0=N#:1U)E]L"=C=9W>E%[$Z2O6D4P!#GO.L MT&LG-::|<5T=I9!S?2U+/!.(E7.#4[5WM6E*

A[71GGE,I_SW9R+PMFLZFL/ M:K.2E]B!^50^>)RYG9=8 MY%!H(0NB(%D[M_3FCBZM0?W$7P.^F1,:"]/4C[9R?MX[7B6"#*(C'7!\>\ M]Y!EUA-Q&*

*&F=,EU,:W@Z?O'^:YT\)O/(-=S+[+.(3;IVE@Z)(>%59C[(XV_0 M)K2P_B*9Z?]7'-MG/8=$E38R;XV1(!=%||^?VT*<&# V8L!: U9S-X%]RBTW M?+-2\DB4?*

*1J]V4&=:FV-<**P7=D9A7<%VIG-;?22E$EHT%2IBLA6ZE.W\BORB MC<#,(28)%XH<>%8!D0DQ*9 "EPS7&HS&TJ(3A4^]V8+A(M-OT797J81'0$XC*

*MO"*B(!]366F,I5>NP0PLAQNUM'<-+1NAW4%Y3;SESX1Y;$8^[;;DS;NW_W3C M8@&Z*K"N"]SV.QNK0I/';9O'$%CC8#[LP.Z=&UUBNFL'-*

X<&=0!G_HGZGOO M)O!F'=YLROOFGNNT[DYD!X"0V DHS& %&U=^[V.$XA7]&,0L# M/QS&"#],8!+CHS0\FP@:G 4-

*9DLZLA*67=#EY$[Y';,66=UP@KNFRH=WR_(' M]:P0PPGZW(;1:I",>]7!RY1A2TC60_!!V>%RQ@;+A>U.L%UIO$V4("RHJC MX<|=P==![?/.*

*.@\'%DE]$3AZ7]8)]_(O?5Q&CMD;&2GTEY7Z:0NMK$'7A6# M#.R,P9|O0G\$HE=/.BV??U;F*A,1'B5&P%*

METXK[O\7/'JNNW2VF(T(+^V5EWY#>HNK4LD(M"8V4:ZBYL48PP$/F*5]0PWB M3']]M'Z]4-/@NSL\]?67$O:J3B<5^9(.+_.&&PO=V]R:W-

H965TQD#/28L%2.K5BI[-RV91!# M0N09SR#5;R(N$])T5RQLF0D@86&4,-MU',].'$TM?U0\NQ''^B.>*T11N!))Y MDA#Q= F,K\86MIX?W-*

*)%K,P#VQ]E9 $S4'?9C=]NU8):0*II#Q% J*Q=8'/ M+W'?&!0C?E!8R8TV.DN9$*V#,*&F.ATK4JNR^$6K;JQC MH2"7BB>5L29(:%K^D\?*

$1L&KKO%P*T.W(*[G*B@G!!%_)'@*R3,:*UF&L52 M"VL-1U,3E9D2^BW5=LJ_"!YR*FGIH31$$RHS7O5/T?<8$$EXGBJ"&\(I"

*MI#BB(:2*1I3,&2":*I(NJ&D2*4&//9Z (I3)$ZTQRT5$ D";,QUI&RW.5^B90[KT.\.^-QS9RP:,;HW1;<7XEJM31@-]/$'"^,/L4]/,K1([^JE7 M_;V$*

1"I&M';X[7',E^3=%OI;B3$.4,?=;)L7',=FO<0T] MA&QQQZ &&;1?>5+(A25:)I*156NFGE:17:,V+|&'.YC4PT/@(B==49W]KRM M*L'-?86QXW:;-*

Q:>]"WXO[:6/\Q?L;?P.K/CUJSL3]/33/ I$3&Z40$<5'P M0ECJJTFF+QI)[* R)#_XO=Z^RT:B0^1^O$Z]^/./O8?;BTANU*N2P-NKPT[M;.!N0V(;#+?4*+RN*

;@U?[\RZ+/;:X1QMQ'L$/4!KPL$]O82[!8ZLROENH#@ M]AJP0[S[+^\D7>>O:-L;MUKSA?"%B 5-)6(0:2OGK]C(\I+=]E1/"LNNG.N M]+6Y:,;Z0P6$&:#?*

1YRKYXZY.]>?/OYO4$L#!!0 (.]#9EEV5S-QA0, M "<+ 9 >&PO=V]R:W-H965T M] JD;LF2-FWWMI&V#L0D!M,ZX

*/B@YM<4[\D=F8[[>#7N[WFAFU/&G6AFUZYE-!.ESAB':TE4F>=4?CV'3.SFSHGSL'##THTV M"VXT*V@*2]#OBVN),*

*[=A25@.7#'!B83UW#D[.5U,C;TU^,!@IUIC8CQ9"?"% M3"Z3N>,909!!K T#Q;\M+"#+#!*N*LYG69+ VR/'|A?6=_1EQ55L!#91Y;H MS=R9."2!-2TS?2-*

*VKZ'V9V3X8I$I^TMVM:WGD+A46N0U&!7DC%?_]+Z.0PL0 MA$|_!K@_RH@J &!=;129MVZH)I&,REV1!IK9#,#&QN+1F\8-Z>XU!*_,L3I*

*MZ"R^*YEB54AY0BZ8*D0]R+O.2T3IB$AUU(0&S>RK,Z;B#5Y5X"DQE21YQ>@ M*-:\7FEV'!" M<4"N!-<;15[R!)(_*(?/^W!NQB])H3^0PC/_5[")13')/*

&Q/?\H$O/'\/W MY 3-B0:6+WB"[[Q4N)4,_R#UOE=\NKNV^6W@DN(2RD93\E9\C\F'%Y133Z] M00YRJ2%7G[N.J)(P[)9@*L^I*C*

%Y@Z6%@5R"TIT[S\GH?=?5WP.1+87K6$3 MK6$?>W0K-,VP'&V!E]"9C14^M'A3$[?1>#@)S-WV_;AL=5).![K7F.VIV[4 MJ!OUJGN+93P3JE-*

*7A1RU=CP:3J>3X4_",LQ\;SCU_6YE8:,LI%762]XC"1DU M-6(AE%;DTQ7D*Y"=:=/+^;MI,UH'(]J(U:;(U^>UD MB4VR='D]>723_-#S?LKJQT:#D??*

*$99LV*J>]*ILS78A|Q7A]>%B>*3YRD'TE M-Q"+E+-OJ/Y64JZH[434 ,\TL&UL MQ=UK;]M&HL;QKT)X%XL62&-1-SLYB0"O-*

*^2D2ZD]P+ZCI:%%E!*U).7$!_WP MAY1H46/1(ZG[!_RFM17-;V3+>L#+P^&"UG^1S$3HM1^SM-%\?%L5I;+]^?G MQ60FYG'Q-EN*1?*

4O=UD^C\OJV_S^O%CF(IZN!\W3\WZO-SZ?Q\GB[.K#^K$O M^=6';%6FR4)\R;5B-9_'^>,GD68_/[I9T\/?$WN9V7]P/G5AV5\+[Z)\O?E

*ME[SZ[GRK3).Y6!1)MM!RN/OUDVZM?_C]A[F-"W&3 MI?]*IN7LX]GEF385=_$[+;]F/QS1_$"CVIMD:;'^K_:C>6[O3)NLBC*;-X.K*

M5S!/%IO_QS^;7\3.@'[_A0']9D#_^8"+%P8,F@V<8-@.&QPX8-0-&QPX8 M-P/&Q_X,%\V BV-GN&P&7!X[X%TSX-VQ_3>TSO7.WK(]LT^^MW6G]YN?>_]

*M?G'(TQNN'_V.ZT]ON;Y^S\\W?[[KOWTC+N.K#WGV0\OKYU=>_<7Z [0>7_W) M)XOZL_ZMS*M_3:IQY57U&4GCVRR/ZT]>H<6+]?:YG(E'$OJH]U66B_*

*M&**.D[3X5?N[EBRT[[-L551/+=YLO@^3-*V'ZS@OJY=4P^>39$UJ'L M+^_=KRN&S5CB=NW6N\9HR6EF'?]CH]X28.--52\)/-XIJ(@*

*M+#5CB,F6Z2D86\U\GI1/C'YYZ!?DJ*UO8EE9O8._(/=X9J!@/,;5^*M-N??%,IZ(CV?5MEHA\@=Q=O6/O^GCWO]TI0:)*

M&21FDIA%8C:),23FDIA'8CZ)!206DE@$85+F#+>9,U3I5T$RJ7:9JBRYS\4F M22PAN@)$R9P:("1FD)BYP<9KK-Y#?;@:C'J]WH?

SA]UD(>T2)ZM%F57/"BM4^.! MQ(S1WB=:[X^>?Z)-3V?I@S50\B#1;UBG1%0Y*Z=1P(#&#Q$P2LTC,)C%GO!>H?7U\,98#U>UX MUF@\O)"?*

*Y>T_ZZ*O]W3Y63[Y\H/]*2\'O?&E/&5(3AE!F/0YO=A^3B_4G/L M,4[+1!3:=-6Y8:\N6% :I\8"B1DD9I*816(VB3DD*

*MYI*81V(^B04D%E[N[X5>]/8.+$70G%(NO-OFPCME+EQ/ITF=!G%Z.!V4TJGI M0&*

(&B9DD9I&836(.B;DDYI&83V(!B87O.M+AJOFH%]!:B&H1IR93;7J^^EJ4G9O%@WV

M=S;UCK1"2YZH9]:A6HV]CFHYJ*:AVH^]@6H%]):1&ER6K6%3UW9&I.OM3EP M$(O=Q '+9:B MFH%])JI9J&:CFH-*

J+JIYJ.:C6H!J(:I%E"9'4%M&U=5MU,O8U$D)^<)6D9% M-;/11L\.2CV_E 6=U$8U!]5<5/-0S4>U -5"5(LH30Z*M@VKJ^NP+^S]:']6*

MFRIE\MMWUW;_K[^\S::/ZVZ[&_S6UR:/9?9'175&"MJ@134#U4Q4LU#-1C4' MU5Q4\U#-1[4 U4)4BRA-3IZV=:M?

*OMY>$MK6134#U4Q4LU#-1C4'U5Q4\U#- M1[4 U4)4BRA-CJ"VX*NK&[XO;?R\T9Y.@G]Y.N']N?KWLCY3M7["YSOMICEQ*

M]6U]YNG[K'I]LRR=%[J5Y9H93V;:Y^6;_9)G]WG+^_MZQ6^VBA&-4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+:(T.8+Z;00=5RA>K.:W M(M^4]-*

;'D^L:WVHQK1ZKBX'UU.L%5++-UL^?+ZT;^DD]W\FY@]:04[#134#U4Q4LU#-;K3=2.GO10K: $8U#]5\5 M0 M+42UB-+D2&D;P'UE'W

*;*3N;)9OKFR8[02*F3;I,_D*ZD.W&&U0S4,U$-0O5 M[$:3-EB>APLYH8MJ'JKYJ!:@6HAJ$:7)X=*6@?OJ96._B\ELD4SBM.LRRNPV*

M3>H+I:9UX%/2=H8'VOA%-0/53%2S4.WN[R^,.WA^]LI!W11S4,U']4"5 M1 M+:(T.3I:(FJ?7>3]

*(O(DFZX/D#2I4>_R++)Y4J]+M3UF4M_K!2+>#$1VEUW MTU<]T?X&E'M0SG)PJ:-D7U4Q4LU#-[N\OC*H/]MHU#CJIBVH>JOFH%]!:*

MB&H1IU#L]3594 MNS?--LDR3J;U.C!-X&SC9KVNS M1TYDQ: T7U0Q4,U'-0C6[T=[M9$SO[7CT M/&70$BZ]>:CFHUJ

:B&J190FWV2T+>$.U"5<^YNOKMJJQY^:#ZAFH)J):A:J MV:CFH)J+:AZJ^:@6H%](:A&ER3G25FT'KU>U':!56U0S4,U$-0O5;%1S4,U% M-0_5?

%0+4"U$M8C2Y CJMQ&DKMIN+D9L%]#LC!*T7/8MJ!JJ9J&8-]A5Y=^YK5/V;W$TI-)$F]TF] M6F^9:;F8B&I3I3-&T,8LJAFH9J:-*

=CON([W+X2VT4D=5'-1S4,U']4"5 M1 M+:(T.47:TNQ V9N[^MJY8/>QX4$V_&YO$4 U$]6L1I/.\XZZMD'(61U4$4U M]5,5+-0S48U!]5<5/-0S4>U

-5"5(LH34Z4M@0[N'B]TS9H.Q;5#%0S4Q@&,J&):A:JV:CFH)J+:AZJ^:@6 MH%J(:A&ER6G1;]-"W7"5;]FQ/7W\IKDS_&-]/6!

*[0_AZV111WXNCO1)YP8"SJGC6H.JKFHYJ&:CVH!JH6H%E&:_MG#)M17:HKLB^F#+[*Z9D"_%:FQ--R36U![DT;2YR">9ZLF72;9:]/=.P9-*

RN0A>NE5WZIMFJT='/OYVF]!L*R M&C3]M3-V M@3M4MT"_BE:IR/J&8SMQTID5:!$7U0Q4,U'-0C4;U9Q&VSWL]2P1W6''FK?Z*

M\IST.J"+B^?/\M$7'Z!:B&H1IU/3((EODW2]3=&9!VBS%M4,5#-1S4(U&]4<5'-1S6NT MW8@97NY'#-

*J81;40U2)*DR.F;_:ZV<39NV]&5Z:HK5,S!=6,1CMP MDL1$)[50S48U!]5<5/-0S4>U -5"5(LH30Z+MNDZ4C==._>?KO_J3I)ZLI/3*

M!%T2%M5,5+-0S48U!]5<5/-0S4>U -5"5(LH30Z=?ALZ_5?;21JA+5E4,U#- M1#4+U6Q4.K+=ZROH.

*MR5F;W3]J91TX=^L[A15E=^2@G5A4,U#-1#4+U6Q4 M<9/ZZ*0!JH6H%E&:'!)MV76D[+N]N'-4MU[K>PH^QK=IY\EFM7MR(I":@6HF*

M]EFH9J.:@VHN]GFHY]-:@&HAJD64)N=+VW<=C5YO/PCMQZ:@6HF]EFH9J.: M@VHN]GFHY]-:@&HAJD64)D=06\T=J:NYZ'X06L%%-0/53%2S4,U&-:?1I#L, M[>|%HS=G\?""W6HE](:A&ER0'1%FM'ZF)MYS[0]RQ/EG&:S.-:[9?@ M_]^__SUWV[G)7U]_>1,0&NW]&:BFH5]-JHYJ.:BFH=J/]H%J]!:B6D1IOM":'-750S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M8C2Y AJF[LC]1]V M\OHJU^WZ*]OE79[5:QIL5CNH5S[HC!FTG=MH|EVU]A>;-M!9352S4,U&-025 M7%3S4,U'M0#50E2+*$T*D'';NQVK>[M]OFH%J!:B&H1I\?*>E\50?-EO*AW@[;'>)\6S,[%1%2ITWF@5ZV>G"ZD9J": MB6H6]MFHYJ":BVI>H^WN+X\'>X48=,X U4)4BRA-3HVVM#L^M$BM\OB))M)D ML_14F3W%2&>*H/U<5#-0S40U"]5L5'-0S44U#]7\1M-[.Z$TTM^.Y% *T$E# M5(LH38Z1MG@[5A=OOXJ%^:&G6BGRSAMM](>?G]HF1;53%2S4,U&-0?57%3S M#ORYZCWM4<1YU^ZV_]>'!NC/$*):1&F:@#@O9D*41ES&5Q_F(K\7-R)-"VU] M+6$]R_CY8/W]>3GOU81G? MBS#.[Y-%H:7BKGH)O;<752+FR?UL^TV9+:N,/|-NL[+,YNLO9R*>BKQ^0O7O M=UE6/GU33_ CR_]8_YA7_P]02P,$% @ ZH-F6?)7%]#!0 4R0 !D M !X;"]W;W)K&ULS5IAJPD_9#IAQ-:2SU M#D6Y;FZ]RWTGI]ZC@]64'&U(E80VY^N18R8|KLRJ6CUA+8 MH@K*4L=SW=#)&,][DW%U[%).QJ+0* <_A4A)59!F3WU]#*F[/>K3WX\ 57ZYT M><"9C-=L"3/0']>7TNPY#6XX(4DAT"<',OQN80IJ62&8<7VO07L-9!NYN_T!_4UV\N9@Y M4S 5Z9]\H5>G6&/F^$K>_07U!08F7B%15?\EM?<[:(TFAM,CJ8#." MC.>;_^Q;G8B= -J_)\"K]Q#__PZP#\TH%\'J \-"_J ZM*=S;57B8N89I.Q M%+=$EF<;M'*CRGX5;?+%|W*BS+0TOW(3IR=O>,[RA+.47' VYRG7'!1Y16:; MB4/$-8E@KLD?]Y0O6:FM(L\CT(RGZH4Y[^,L(L^? O2#/",_)AY4H%,L7:NQH M,[:2P4GJ<;S>C,.[9QPS6)\0WWU)/-?K=X1/[>'G:WE"7'IO>&0/CR Q[)MP MQR,\MH?_SG+#'E3A7CO<,7HTHGB-*%Z%U[\'S\",R >0&;D0+._,IA6@K"ZG M:LT2..N9\]% WD!O\LM/-'1_[5 M<%RIPE1$((E0NG/I;2C"BJ*\#]],7IG:LCMV;G8%L [D6 $PP6(DL)8 02-M8!7@"FX@+X!<%C)9F?M]E?(92X&<+R6 Z4!T5\JMH,5"&CJ |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|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|SQ7L]I0,/NEM.]78)^K>GC5]'3 _JQ[],>>K^E M[]]&'[Z*WN^B]WOH6^>G@V9MZ2>OH@^^A;XU\V2 _6Z$*5),K MCAMWCCMW:0:UMDY9HP-9H_&$]NEJW9X.V_V]-,B.AQ*>%1G)Z[-!IX+Q@8+0 M#V<]VPUM#9T.>G#EDNB1UA(5E*M0&"[6P^4(#\0<^R.O;_.CK6738<]^Z8Q' M9*VD[B['Y$!!,W#'F.FK3/386M^DTVCYGA9'F_4][:TWDL'[3+Z#3\Q8J;4 MSO:GZEDG_>Q@TPK"D$[_1^_N'7DS4.OR8*])F6AU^FWN-A\/9]61N9U>?7E| M8FK-<2-+886AWLD$4U?58;X&)F7!^@'>? X7EYN\ ,(E)V SU=2FN>!)6@^ MJ:+_ %!+ P04 " #]@V997@$!'| $ #B' &0 'AL+W=OGD.@[,RYBHO2IF+LR%4"B/"AF;N!Y9VY,:.*,A_FU M!S$>\]5B-($'@>0RCHEXN0+&UR/'=S87)G2^4-D%=SQ,R1RFH![3!Z'/W$HE MHC$DDO($"9B-G$Q_@=Y0%[B5PIKN76,LJ8\I4S\P"MX\WZI_SQNO&/!$)UYS]1B.U&#GG#HI@1I9,3?CZ M)R@;=)KIA9S)_!NMR[*>@*E5#PN@W4-8IH4O^2Y!+$5H'7: X(R(-@WH%L& M=%\'=<$],J 7DZF:$K. 1-%QD/!UTADI;5:=I##S*-U\VF2]?M4"7V7ZC@U M_DP3DH24,'1'R1-E5%&0Z 5+O6% M"$&RCD,?,2A"F?RDKSY,,?KXX1/Z@&B"[BECNH/ET%6ZNME#W;"LVE51M6!' MU;KHGB=J(=%-$D'4$G]MCA\8XEV-J6(5;%A=!4;!*:0=U/5.4. %O;;Z']>, MS>`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|E)C\@O?UW$*&=7G,@>!;Y92 M9=2@J5:^SA70Q#EEW_^#H.=GE DO&KF^J8I&LC"<"9@JHHLLHV![!5QNQE[+ M>^F8L55J;(M:1,;RD+*)VO<)F,OL$3 (396@N)C<#=? N55"CF^5]%?/:1UWVR_J-RYX#&9! M-5Q+_IDE)AU[X\DL*0%-S.Y^0A50%VK%TNNW3_95&,#C\2%-C*KG)$@8Z)\ MTN(4HR94)&1..9#+E0+ =3$XZII3 MK=F2Q=2E&'\F!1)+D>"Z06);6G*64(/&@G* <"DBYVXXG8"CC^H0<82:(?2H+ MC7/HD6\P+ OGQU4(5V4(X9X0Y1"?DW9P2L(@]"'^80<'YW\+.-C5NK4A'5] M0J?:WJ,[@84AMT(;5;APO]SA ')K(--?FRA+M4ZSFJVN"YW3&,8>EH|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

[7XP'.:QYRFY%=.USSEBK.2O"%+D=|SJ?@Z963%2$]88K%?NNWG#OL1,-/2$QSH>1\X 6*.21C[T+WTB-? M5B'Y|=5K\HJ,2+FC$ABH_]E:Z@9>L:*
*(%GAR +3"A&^:7*A^2X+*!Z=IE08I> MT%-_TO3T%%*/Q'$[QL8&>GS.&+,-CAIF8H?1(?-=6="870\@)I9,WK/!XH?O M_)GWDXU_3+ 0$RQ"*
*NOY8M+Z8N)"7RQ34?)\2R"PQ%|O2"%YS$C!9.UM\I][M#+UW@I_K(4RPL :[-&!Z=;Q?^$-O4F@RO S:4CU*IRVE4R>E_G#Z M_9GOTD:MLY)SJ<4$"S'!*
(B2PG]=FK:=F.(%HAND+3+ 0$RQ" NOYXFWKB[?. M67-;96L(.V)#V#W+54EX?MC@V3SB!#O7(S78]"@,>/U $6)6%R&!]6B^;&F^ M=,=[V
*])V(U7,.@5DYF-6R?"N=RZFS,C#XQ*VYP+,5L1(8'U*)^WE, ^?H[Q= M"D*V5N2O3TR/];]A=45:*YP-.-=CF& A)EB$!-;SHN]URLC#62T:'"1WH**%*
*MJ&@1%EK?(T=:U?7.K#O)P2$%>.0F$U5N72@:B-E1<_&7OW3#_)+=VUG,XV) M%F&A]9D.J8#)],K92(1SV'-8*4B(.V9E>T:Q@^.UI*AYT\?*
4^VL[FRJ,=$B M++0^U9TX]IUZ;W'+%,@P$3.6E&0C109[H@V#D;ZU$CY^.KSAQSJ\414P*EJ$ MA=;GO!/!OEL%?!PAF$,8B$^+8F;JGS_ MR"53?
*S@/@LECAZ *7E2T" NM[Y!.0OMN#=U%=FHBN_9 ;K9!M8N:8"1^#3AS[3KUGFQ1=>N@P'5Z4)6HJZN59YD.]E>W[E49*
*MHZ)%6&A]7W3BV'>KXX_'"R_HXC*6O- G*U:ZW5B_[YHD_;'NJ#4&C6,),J-= MYBG\UE7"_#-:1?N>YGF579""/E!M6K*,O]'O:)H^:-E.I=2BCL#XN($1DQ)_*
M"C8)^2U60FM\>-0RG\8[H_X@RL)D9T=?UTEGZV884XB'J&@1%EI_B'3"WG=+ M:2,M>5XJ664,(F9&526Y>B#)]J;V:&Z\^ !?G%=2S? V-*
9[LN=KIZS^Y..11H9XFCTJ/(&ZU,GX M/[0>.)F#+#0^L.CRQ@$!SW/;N$@N\;?#P29A"[5P3/&C* M'J9D@[6/9B! M7-H'B"*VBN495/?6;YQS>[4W^B_\LY'?*
TC_&-U'YA/E-7SZHKJE<,JY("@M, MY9V<8EED^4@I&UKD]A:>"8UWNOUYOHS64CWJ)8 A3UDJ]-A9&I.?N:Z.EY QW9$Y
M'"%R92Y4Q@T.U<'6N@"5E4):Z/J6AFS$NG&A4SDU4-)%2;F B2*ZR#*F-N>0 MRO78|9SGB3N^6!H[X4:CG"U@"N8AGR@DYDQ#1*
*+|.|$O=%5&I\I(9%HV47!-E=R..?2E3+;-1'!?V M5*9&X2K',!-=<<%$S%E*KCF;\90;#IJ<$I_Z(;F08@7*\%D*Y%8:7+@J3*& M3-*
@&3\9H\O$2#..I/L:0[=V7,#/DQPUD,U_<N0;3M:+=N$[MO$K-WY/:%/(.Z=(3B]8C#]-+ M\O'H^"6,BVXUEOF-97Z)V_T?
R]KD53"]=AA;;FW%!VIJ#A#E[C#M_"'>QP^]W]F8<->WB0_5X: M_$:P9GE69"2O2Z:-/VSA#X=T3_;]AK]_D/\:M'8LDX4P>'^6WY@P7"P:/[]D
M]'>DG.Y7,FB4#%X_AYW+Y(3DBE,AY>A2);--T#%&TKW*1HVBH:O>U,(I$5% MO_'N2>R%E7 =EW;AA5/-<*T++'8@L=3M9S?<-&PO=V]R:W-*
*H965TL2P)"'B@L]\TICZJGOZ[R$BNH+68/ G8U4%34X55M?UPIH MX8(J[H=!$/L59<++4K>V5%DJ&\.9@*4BNJDJJGY= 9?[F32R'A=NV+8T=L'/*
*MTIIN807FKEXJG/E]EH)5(#23@BC8S+S+T?0JL>?=@:\,JOI@3*R3M93W=O*Q MF'F!%00<7T^N1-O!P_)C]@_..7M94PUSR;ZPPY3:_9)]=S;P2-*
YH(ZLN&!543+1/^M#=PT%_M$'8!H=/=@IS!34T2Y7<$V5/8S8[<%9=-(ICPKZ4E5&XRS#.9'-95];D= &&,J[/R*
EA@MR6LM&86J>^0<$6Z^>=N*M67/B,N!74%V0=-B;#EW>]7^97C"=3]Y5H|C$^&Q+V+&>OR3#$5M-4 MUS2'F8?EHD'MP,M>OQK%P?LC%L:]A?
*&Q[)F]D2%-;53LHFQ![K(D?#=._=T M:]*S)B^QHB%6&Q4=L*(D#N)A6-3#HI=@\1 L>@(;Q=%DF!7WK/@E5C+$BI^P M)E$PC$IZ5'(4=2L-*
EHG\4R9#W.3)RXN3(/CW[?D'U6X;YR>]M@SKCL,&XX+ M!(6KMAFU$R-KUP#6TF [<<,2^SP#W-U*:QXGM*?T7(?L-4$L#!!0 (M .J#9EF_UB)W.@,*
,0+ 9 >&PO=V]R:W-H965TH\AE8OEAR7?R2767K.23>:".S"HP19$R4 M3_I0Z; '0)YF@%\!)> X!5 OP+T_Q<05("@4*9,I= AHH:&$R5W1%EK9+.+
*M0LP"C>DS8:]]812^98@SX5QF&3-XCT83*A(RE\(PL081,]#D,YDE";,71#FY M%&65V>LZCL!0QO4G-+E;1.3XZ!,Y(DR0*\8Y&NB):S ZZ\.-JTC.RTC\5R+I*
MD2OTG6IR(1)(#O$N9E6GYC^E=NZW$LYR=4KZW@GQ/=]OB&?>#E] 7L.#!GC4 M#H\@1GBO@/=;LNG7%]4O^/JO\'V76A_>3I/$)4?
0S&%;R)G.:0Q3!WN$!K4% M)_SXH3?TOC3ITR59U!'9@79!K5W0QAY>BBT6N%2/)-^H.,4V0>+GNF_2L97O
MO3J69,,"S+;A:=@;3=SMOCH=^3M09U"K,VA59\XIRS3V<$X-).1($H/"KUL0 M33DV ;DB=I"%C]_S&5DIF9'KV,@E%O8'C&IDIMU2K#*
<(:M.>TV#OX5(3@4 M8=X:YGOKK2.R T6'M:+#5D5G<:PV**6")4JJ3\@*H&ROE:_&FFOE?&_-=4D6*
*M=41VH.6HUG+40=\;=:E=EV111V0'VHUK[<9OUR'^<^]VAS6>'"C9 R0H*1E M65Z;%#_=LA$TR=O]YKWREF0];Z\5#$]?](+H#:-2#G=O[LE K8OY46-*
*OWPA3 MCD#U:3VBSHK)S'TV+^?;*ZK63&C49X50[W2$_4.5,V.Y,3(OIJBE-#B3%&ULK=U;<]I(&@;@O]+%3LW.5#E&*
*M9T36ILJQSEK(I,;)SL767LC0@"HZ,)*PDZKY\=L2,J)ET8,R[TT'6-_3 NNU M6N@#W;SDQ9=R2VE%OJ9)5MY.ME6U>S^=ELLM3:/R.M_1C/UDG1=I5+&*
[Q69: M[@H:K9JB-)DJDF1,TRC.)HN;YK&/Q>(FWU=)G-&/!2GW:1H5WS[0)'^YG_#U6U+FB6 M^$],7\]3VZ1^*D]Y_J6^XZ]N)U!1C2ARZHF(O;?,*
[VG25)+;#W^;-')<HI/=Y\GN\]JK:W$W-"5G0=[9/]M_S%H^T3TFMOF2=E\R]Y M:9>5)F2Y+ZL\;8O9&J1Q=O@_^MJ^$"<%LG:F0&D+E'Z!>J9
*;00A2PNTHD#K M%^AG"O2V0+^TP&@+C$N?]*PMF%U:8+8%YJ5/>MX6S"\=099>?W/2Q27'7_9A MHSML)/LPO')F>)4\Y%FU+8F=K>AJH-X1U\\%*
M]5/V4AQ?#^7U]?B@",%'NKLFLGQ%%$E1!];G7ES^$'TCLGFVVKJ@VCA;;5^P MZJITMMRYO%P;'?_WNB>N-*
RB2U9^_G7W+WCE]+/5@:CZE_R9_=)G3;DR4!Y> M4"Z90^7<-J@>,ZDVGCHFDP.K]>' ;,-,O3-^7^ZB):V=L+UM28MG.EG\^_9
MD/XUM&$C.0N)V4C.06(N$O.0F(_$ B06@C N6=HQ69I(7]SG:)L,Y0#(3 V!TC.0F(V$G.0F(O$ M/"3F(I$ B84@C,N4<KDB4K4C)0C<4-$Z-*
F@'3#^9;\BJKLPUN3?CL 86E&>& M-I,,?D$;N7H.$G.1F(?$?"06(+$0A'$!,8\!,5&'-T)H;":0F&5>-&WD6,Z*
M2,O%8AX2\Y%8@,1,:E9GY,S5R8FL=Z1T)V1;P<3(JP>&Q2D)AUP,R3I&C7 MBM|+"7)$!XFY2,Q#8CX2"Y!8",*XG,A2=ZY($B;E%U]QG.1+2E?*
E%8G6%2W(MBJ[VRRK.-J3:4O(Y8X<]+T5<-0<_J[A! MT\|FI5TZ/31!_$:C8U?JQDGD=%50Y)Z4S?*
HH#94=VQ7Y&ZS>@FJBBY2^NIY&#BH'T04,V":C94]>5#-AVH! M5 M1&I^RKK-"%IY>_NX3P&)V=.B@O190S6ZUT[/.BJ:8:O_LM#.PH%'/87]G*
*M#]R!Y51=G\^,'NA!GX.<6<]5^Y>_&ZC X-4K.AF@/57*CF M034?J@50+41I?+:Z]@I9W%_A%GE9'L\;#^8&VF,!U2RH9K<:]]:1/%?-_NQL M8#'=G/?G9@-*
*+S55UWI^907LCH%H U4*4QG]RM&N/4,3M$?^F;#OO=SFLZ7!C M@]@:N\U#-0NJV:UV>@CQ3IGW-_FAI;3>GM,=7,A4>QL\=/5]J!9 M1"E\1M|*
MUX:@B-L03ON!VG:@BS=_:"\"5+.@FMU]_)\HJL^UB7+^XKO7_Y_A]JD: M_01
NP@6@#50I3&)Z#K"E"$YT.Y=Z1(0>OO,*G/LT3/49Q$3PDEZ[P@992P MHXA]W1K7-,G=?7H0?N1./.;H;$ ["*":#=6<5CL-AZ'-^X=?+G10#ZKY4"V*
*M:B%*XZ/6M08HXM8 P>E,\B?YO?GN"'9\?O=,BVA#A:5/.A6@#5 M0I3&IZQK*%#$W\SPNC|[%[7[L^;S263'II#->< !P$%["Z":!=7L5N,_^C17*
M^H=4;Y=2KC6M/QU\NY1^K;UY3P%ZCA^J!5 M1&G\AM^=XU?$Y_C%T[Q+/N8@ M'F!T#!G^ZG:#=4T&BKC=X+L^YJ"\[2Z8*_J:*
[@+QT.C!.TN@&H. M5'.AF@?5_(%?O:&;;UIRH(.& X/V/N; ;_U=0X B:@CXE1W2O+M+DKQ*:<;F*
*M>;OFR[6%4SIH@P!4LZ":#=4NLX*5=Q9\8D6:=V#W23I^%U!@PF" MMDM ->LOGJ0JD57T;?"Z&=#U<*":"]4\J.9#M0"JA2B-C[3)924N^'*%\U]T*
*M)ZX>G2/L]20.FGQZ,*I>S^=O=D38:T5@+Q:!O5H$]G(1V.M%8"\8 >UWF)Y< M*RFEQ::YG%?=MKW/JL-E@HZ/'B|9=M=*
*<**OWN",_=P_78.J8PW7(')B$VB;D=+UC$V@BL.EO0YW]GS77)'I*;^]/&UN;FG$CL_]!=C/UWE>O=ZI!SA> M8&WQ?U!+ P04 " #]@V998H_S=R@& #J-*
*&0 'AL+W=O[;OEBSG;BR3.Z"U'Q3Y-"7^ZI@E[O!SAT?..NWB[$^6.\6*>DRU=4?$Y MO^5R:]Q2UG%*LR)F&>)TA:9<)5<0?,7TL#MZC\E3N&?*
M2;OR^OAP9 MY8QH0B-1(HA\>:!+FB0E2<[CGP8Z:L\%KO+ MT72$UG1#]HFX8X^_T>;$>G)
(7L:2H_J+')M88H6A?")8VR7(&:9S5K^1K8PP3Z18#4)UDM'L)L$^Z4C.$V"\](1W":!?>D(DR9A4A6KOKI5
*M:3PBR&+.V2/B9;2DE6^J^E;9LB)Q5DIQ);@\&LL\L5@)%GUY?RV+N49+EDJ% M%Z32R'MT>,C_6AZAZ*U'!8F3XA=Y_//*0V_?*
*_(+>H#A#GW9L7Y!L7_KT%S<;D'"O!KF"%X]/*B#KXB9#&MU'(.Q.1F4ZCC(G4W4 MA7+;0KG:0I4K*F(;M"()+=!?-S2]I_QO50VTG'-K GS(&$^)"R A(5*
L)Y, M)JU,)J_=PB>0^H$>9 P'Q(60,)"(%A/7]-67U/P%JXEGBL82)@W/5JGS:DY M: K',7AB#YK"<*9@9 $@.E>: T'Y06 M@-)"*%I?*
*9P>&&0O&'KDV<*I'D-K=P6" MI'F@-!^4%H#20BA:7TV==8A?W3O$H.8A*,T#I?F@M "4%D+1^CKK+$0.]R'J*
*MD6<+!]1%;&B'J[MMS^QA/U&9C8XQ["?'+&P;UE%#4?B-AH%/&%2XLQ*QWDN4 MG]_JQ]Y,?OJ7+%O'55UN5Q^5-0&U"D%I'BC-*
!Z4%H+00BM973.=I8O?5FP:H M'0I\T!I/B@M *6%4+2^SCI3%&L]L<4GRE/T1 E72T2?C(V3]_B% 7+(0#$D-H9CAE!C]NO< MF:%8[X:>_/]!_D,?*
Q8YRV66RF'%Y4TNC?7E[JUX-0(U14)H'2O-!:0$H+82B M]?\CJ7-'S5=W1TU0=Q24YH'2?%!: $H+H6A]G77NJ/D-=
*[225=V;^N]YFH_QVXW=L^@'-5/78RV'^-+Y98L=_#%[Y]?X O MPOJQFV[8^BF@&*WL=180C=R"L:'B:P^KQ^LJ3<$RZOG.NZ9$"RMWNXH65->*
M!LCC&\;$\T8Y0/MXT^)_4$L#!!0 (.J#9EG:<#108)DL 9 M>&PO=V!R:W-H965TD9P^WX[TT>N#S]EJS9L'X^ED M$Z_(@O*
*OFX=*W(UWE#0K2,DR6J**+&]"'_2;N>XT!FV)OS+RS ZN45.51TJ_M-3?S]':D-1&1G"2\0<3BWQ.Y)WG>D$0<_W30TO;D3M"*5G&=(=!6R&EY"*
<]:^1<]=66V$DIIQ6G3&(H(B[?_MXY?N11P8"([< '<&>&A@GC P.@/C7 .S.S#/-; Z ^M< [LSL,\U<#H#Y]RW MY'8&[KD>O.[: ^6P;;^V\?V8QI-*
*)19]1U906M.:B55!K+=H*QNQ+W@E/LV$ M'9]^$M^G>9G0@J"W?U#&WJ$'4J'%,JX(ND+WM-C4/&YE29?H+F99@N(R17Z6 MUYRDZ,!\;_?6)SS."-*
*]!'6O(U0T&9DE1B'ZGM/87]6+S(W=O$KV_S M#BN!"[*Y1H;V'F$-FY)X[M7FO]>ETMQ7FW^,*V&NGS0/S@_>D)C/S@I>9AZ> M'!S,//]Y-*
S__X;KWA&#LOE9&RS-.?:WJ@E0QI]6-3-5;6U-NVW1O-VP3)^1V M)/HO1JHG,IK^^HMN:[_)) 4)\R%A 21L!@D+(6$1)&P.!.N)UMR)UE31C_L"
MF7:W"+M%-".II^F5KCF6/AD_':I25@Q[>%#,/RZF:]AUK'ZQ0$(S/-LUFL+:]<6EC*!^*2DHKL_MF4(LR!0""?,A80$D;
8)"R%A$21L#@3KR=;>R=96II"O[>2"I%?QD^C_5@2) M;%(P6,W]!.S+<;%6"\K5V)LV XG9>+>^K .LX)N85W3O&&:449SJ7(A8<%Q*
M'3S',5Q+&Z29&:37$!(6R9K!Q+:!+7N0!(]+NBYV', ^PY5G0V1 M""X5%"0L.[#"4%!>@TA89&D&;!MV88U'#[,CTNJ!>7N!.4J!;6= MP99BH)-U YV\G?*
1NQ.2U%95,/5ND>]C%:]?#UWZO='RI6?)1NKY4/I"P0!K_ MD7P@78:0L.@X?B&?P0QC+JGD:<'HVGYU3?N)=8#.&&@4#TKS06D!&T&2@M!*
M:1$H;0Y%Z\OW8'%85V:\#VDJ,ATG@LT1>=F0DA$DQE]8PS:ZIZ48E?'L,2?H M^{6}O6\S(UTB'K](Y:YT=K'<(6D^*"T IIHA^L?AC4<5<^A?/9E
MC/2DS678F%.WR_MZ^JU_28IDN62)&VNVXC.5_(LSK>ZRIX(8B2IJXQGA,E[M?=#E?U":#TH+0&DS4%H(2HM :7.H6E_@^VT 7;T/L.
T^8;HIMGV%9VZR)%Y MW:ZQ=,LNK'[\NU$_IRA8/#Q(-:[T<+'&(6D^*"T IIHAXLR6#=< M!P\S+Y#7OGKW&R>ZE^:"T)0V Z6%H+1(E^V[>":6K:-
,"^2W+ ^+]YHRN MWITYV/^SL2JNU//K\[?I%":=;%.0;=I)-4XL4\#ZC<$I46RQCBQ52,I>F*O M9GQP3%%,R%?*
*M&5KK&0H)TOA2KMV1+C5]ASL]H;337M(\I%R3HOV,RS0LR=G93EE>N*9$=R+"Y920KU9L-XCJ5ZY%M7E)S@U#CEF>M!.')S M3 MG,3-*
C2[Z8L4IM"!+#D25YYC_?4,R=I@[R'D:N?;G=0#[F)6XBU9$?E0 M+KEZW)+LDPCJ3S^:D"=-J9V/+Y_0O_13%Y-9HT%N679;S25N[DS<4!* M-*
*KC*Y#T[_$2:"84:+V&9,+_@T-A"!R25D"QOG%4&.2WJ*WYLB#AR4#C]#E[C MX)TZ!*\X^(V#?VZH'(SHT0-@YFZFX]=T-S#@[*ZM%9J^,>P;;\47*
*M+72CK"17;ZGRDXM?5"]^*A*6$W#Q,Q/B>[D'*QVF!/P$7RNI)"X2&FQ!1'- M*EU4L&22%)+BK#83('Y,LBHE*=APEH-;G"55ADT;L$WMIMX=!\I.*
EU$1&: MJ;&/0!C,F2O5Y'2*;M),Y*:>B/?*1'QPQPJY4]D4*I4>_VC8?SK@[RI26V:] M)V9OO$' %2DO@0_ JZ04\^M^>*
*[^WW3^7_1X_|UIJH+M=II9[67:K6; MM=U7TCJ:T&2C/VW]1>]-QN,QA#-W?URNEX;^9!1X03#I&D8O#;TI] ,O''4- MXSY$'T*S:O8]%*
(8MA>$@A2O)DB^ E9H9\0$L5Y_5KZ)$\:?5M)8Y]7U>_ZD^ MF4 R$^6RSYN!L.\M=UM@D4VP6)+8)U:C=I:C=Y-G48VRV43++()%EL"ZY1K*
*MW)9K_%6IT_BE1$ $ Q2,3]3II:$7A.%D,O5/U*G'<(*@'Z+IB3KU(4+HC^&H M7YTF+86300KOB9"<)IJ.6J@>"BH%N+A?/2@V?K\C^9KP/_K(&,1]:W_;!*
(ML M@L66P#K%F;:%F;Z;'$UMELLF6&03++8$UBD7@L][/A5"5*3SK$L3'P40'2B M1SUV'E*Z!4_UJ,=PZL.Q?R)P<1^@'P9H](H=J*
4B$JK)VJ4O&:&!314)P< M81;:OY?0P>3>NDRLHD56T6);:-TR>\|E|MY-VII0MHIF$RVRBA;:0NL6[7GO MC@:WFN\O;_X+E4%H&G@H]$X%
JES+:'B;R[(&7%KLMVCH[F<|*TY$Q6JPZM" MUL#:R8ER\WMCN"4<&V@WF^8TLOF00=H3Z\7_P)02P,$% @ MZH-F66%E3[MH P FQ< T*
*!X;"]S=*EL97,N>&ULW5C1;MHP%/V5*%VG M3IH:0M9 5D#:D"I-VJ9)[*D,KND5'GKG(MJ["^5*M\'035?TIQ4ET5)A4:R0N9$Z:Y?9\]O;LK'?_YOHP?F& -*
W[@%+TZ0?2RIP]4V;"8?'R;_#%Q M3'JP+VTN/]="EGB.T88G.3IB"!-.'ZV,_?GF1KTW/3S-AL;U'"!TDEM4C-C' M3.\G[AW)'9U804<+R(@'I4:8C+)"[/9#Y-N

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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 351 394 1 false 92 0 false 7 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.coherus.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995200200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 995200300 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 995200400 - Statement - Condensed Consolidated Statements of Stockholders' Deficit Sheet http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders' Deficit Statements 6 false false R7.htm 995200500 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 995210101 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 8 false false R9.htm 995210201 - Disclosure - Revenue Sheet http://www.coherus.com/role/DisclosureRevenue Revenue Notes 9 false false R10.htm 995210301 - Disclosure - Fair Value Measurements Sheet http://www.coherus.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 995210401 - Disclosure - Inventory Sheet http://www.coherus.com/role/DisclosureInventory Inventory Notes 11 false false R12.htm 995210501 - Disclosure - Balance Sheet Components Sheet http://www.coherus.com/role/DisclosureBalanceSheetComponents Balance Sheet Components Notes 12 false false R13.htm 995210601 - Disclosure - Acquisition and Disposition Sheet http://www.coherus.com/role/DisclosureAcquisitionAndDisposition Acquisition and Disposition Notes 13 false false R14.htm 995210701 - Disclosure - Collaborations and Other Arrangements Sheet http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements Collaborations and Other Arrangements Notes 14 false false R15.htm 995210801 - Disclosure - Financial Liabilities Sheet http://www.coherus.com/role/DisclosureFinancialLiabilities Financial Liabilities Notes 15 false false R16.htm 995210901 - Disclosure - Commitments and Contingencies Sheet http://www.coherus.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 995211001 - Disclosure - Stockholders' Deficit Sheet http://www.coherus.com/role/DisclosureStockholdersDeficit Stockholders' Deficit Notes 17 false false R18.htm 995211101 - Disclosure - Stock-Based Compensation Sheet http://www.coherus.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 995211201 - Disclosure - Net Income (Loss) Per Share Sheet http://www.coherus.com/role/DisclosureNetIncomeLossPerShare Net Income (Loss) Per Share Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements

Notes 21 false false R22.htm 99920102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 99930103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 23 false false R24.htm 99930203 - Disclosure - Revenue (Tables) Sheet http://www.coherus.com/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.coherus.com/role/DisclosureRevenue 24 false false R25.htm 99930303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.coherus.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.coherus.com/role/DisclosureFairValueMeasurements 25 false false R26.htm 99930403 - Disclosure - Inventory (Tables) Sheet http://www.coherus.com/role/DisclosureInventoryTables Inventory (Tables) Tables http://www.coherus.com/role/DisclosureInventory 26 false false R27.htm 99930503 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.coherus.com/role/DisclosureBalanceSheetComponents 27 false false R28.htm 99930603 - Disclosure - Acquisition and Disposition (Tables) Sheet http://www.coherus.com/role/DisclosureAcquisitionAndDispositionTables Acquisition and Disposition (Tables) Tables http://www.coherus.com/role/DisclosureAcquisitionAndDisposition 28 false false R29.htm 99930803 - Disclosure - Financial Liabilities (Tables) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables Financial Liabilities (Tables) Tables http://www.coherus.com/role/DisclosureFinancialLiabilities 29 false false R30.htm 99930903 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.coherus.com/role/DisclosureCommitmentsAndContingencies 30 false false R31.htm 99931003 - Disclosure - Stockholders' Deficit (Tables) Sheet http://www.coherus.com/role/DisclosureStockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://www.coherus.com/role/DisclosureStockholdersDeficit 31 false false R32.htm 99931103 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.coherus.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.coherus.com/role/DisclosureStockBasedCompensation 32 false false R33.htm 99931203 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.coherus.com/role/DisclosureNetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://www.coherus.com/role/DisclosureNetIncomeLossPerShare 33 false false R34.htm 99940101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details) Sheet http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails Organization and Summary of Significant Accounting Policies - Organization (Details) Details 34 false false R35.htm 99940102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Details 35 false false R36.htm 99940201 - Disclosure - Revenue - Net Revenue (Details) Sheet http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails Revenue - Net Revenue (Details) Details 36 false false R37.htm 99940202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details) Sheet http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details) Details 37 false false R38.htm 99940203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details) Sheet http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details) Details 38 false false R39.htm 99940301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details) Sheet http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details) Details 39 false false R40.htm 99940302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details) Sheet http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details) Details 40 false false R41.htm 99940303 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 41 false false R42.htm 99940401 - Disclosure - Inventory - Components (Details) Sheet http://www.coherus.com/role/DisclosureInventoryComponentsDetails Inventory - Components (Details) Details 42 false false R43.htm 99940402 - Disclosure - Inventory - Balance Sheet Classifications (Details) Sheet http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails Inventory - Balance Sheet Classifications (Details) Details 43 false false R44.htm 99940403 - Disclosure - Inventory - Additional Information (Details) Sheet http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails Inventory - Additional Information (Details) Details 44 false false R45.htm 99940501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details) Sheet http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails Balance Sheet Components - Schedule of Property and Equipment, Net (Details) Details 45 false false R46.htm 99940502 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 46 false false R47.htm 99940503 - Disclosure - Balance Sheet Components - Intangible Assets, Net (Details) Sheet http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails Balance Sheet Components - Intangible Assets, Net (Details) Details 47 false false R48.htm 99940504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details) Sheet http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails Balance Sheet Components - Accrued and Other Current Liabilities (Details) Details 48 false false R49.htm 99940505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details) Sheet http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails Balance Sheet Components - Other Liabilities, Non-current (Details) Details 49 false false R50.htm 99940601 - Disclosure - Acquisition and Disposition - Additional Information (Details) Sheet http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails Acquisition and Disposition - Additional Information (Details) Details 50 false false R51.htm 99940602 - Disclosure - Acquisition and Disposition - Estimated fair value of the net assets acquired (Details) Sheet http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails Acquisition and Disposition - Estimated fair value of the net assets acquired (Details) Details 51 false false R52.htm 99940603 - Disclosure - Acquisition and Disposition - The amounts allocated to identifiable intangible assets (Details) Sheet http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails Acquisition and Disposition - The amounts allocated to identifiable intangible assets (Details) Details 52 false false R53.htm 99940605 - Disclosure - Acquisition and Disposition - Unaudited Pro Forma Summary of Operations (Details) Sheet http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails Acquisition and Disposition - Unaudited Pro Forma Summary of Operations (Details) Details 53 false false R54.htm 99940701 - Disclosure - Collaborations and Other Arrangements (Details) Sheet http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails Collaborations and Other Arrangements (Details) Details http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements 54 false false R55.htm 99940801 - Disclosure - Financial Liabilities - Summary of Debt Obligations (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails Financial Liabilities - Summary of Debt Obligations (Details) Details 55 false false R56.htm 99940802 - Disclosure - Financial Liabilities - 2029 Term Loan - Narrative (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails Financial Liabilities - 2029 Term Loan - Narrative (Details) Details 56 false false R57.htm 99940804 - Disclosure - Financial Liabilities - 2029 Term Loans, Components of Interest Expense (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails Financial Liabilities - 2029 Term Loans, Components of Interest Expense (Details) Details 57 false false R58.htm 99940805 - Disclosure - Financial Liabilities - 2029 Term Loan Future Payments (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails Financial Liabilities - 2029 Term Loan Future Payments (Details) Details 58 false false R59.htm 99940806 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Narrative (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails Financial Liabilities - Revenue Purchase and Sale Agreement - Narrative (Details) Details 59 false false R60.htm 99940807 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Summary of Revenue Participation Liability (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails Financial Liabilities - Revenue Purchase and Sale Agreement - Summary of Revenue Participation Liability (Details) Details 60 false false R61.htm 99940808 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Classification on the condensed consolidated balance sheet (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShee Financial Liabilities - Revenue Purchase and Sale Agreement - Classification on the condensed consolidated balance sheet (Details) Details 61 false

false R62.htm 99940810 - Disclosure - Financial Liabilities - 2027 Term Loan - Narrative (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails Financial Liabilities - 2027 Term Loan - Narrative (Details) Details 62 false false R63.htm 99940812 - Disclosure - Financial Liabilities - 2027 Term Loans, Components of Interest Expense (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails Financial Liabilities - 2027 Term Loans, Components of Interest Expense (Details) Details 63 false false R64.htm 99940814 - Disclosure - Financial Liabilities - Convertible Senior Subordinated Notes due 2026 - Narrative (Details) Notes http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails Financial Liabilities - Convertible Senior Subordinated Notes due 2026 - Narrative (Details) Details 64 false false R65.htm 99940816 - Disclosure - Financial Liabilities - Capped Call Transactions - Narrative (Details) Sheet http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails Financial Liabilities - Capped Call Transactions - Narrative (Details) Details 65 false false R66.htm 99940818 - Disclosure - Financial Liabilities - 2026 Convertible Notes Interest Expense Components (Details) Notes http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails Financial Liabilities - 2026 Convertible Notes Interest Expense Components (Details) Details 66 false false R67.htm 99940820 - Disclosure - Financial Liabilities - 2026 Convertible Notes Future Payments (Details) Notes http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails Financial Liabilities - 2026 Convertible Notes Future Payments (Details) Details 67 false false R68.htm 99940901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details) Sheet http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details) Details 68 false false R69.htm 99940902 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 69 false false R70.htm 99941001 - Disclosure - Stockholders' Deficit (Details) Sheet http://www.coherus.com/role/DisclosureStockholdersDeficitDetails Stockholders' Deficit (Details) Details http://www.coherus.com/role/DisclosureStockholdersDeficitTables 70 false false R71.htm 99941101 - Disclosure - Stock-Based Compensation - Stock-Based Expense (Details) Sheet http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails Stock-Based Compensation - Stock-Based Expense (Details) Details 71 false false R72.htm 99941201 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details) Sheet http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details) Details http://www.coherus.com/role/DisclosureNetIncomeLossPerShareTables 72 false false R73.htm 99941202 - Disclosure - Net Income (Loss) Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share (Details) Sheet http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL Net Income (Loss) Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share (Details) Details http://www.coherus.com/role/DisclosureNetIncomeLossPerShareTables 73 false false All Reports Book All Reports chrs-20240930.xsd chrs-20240930_cal.xml chrs-20240930_def.xml chrs-20240930_lab.xml chrs-20240930_pre.xml chrs-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "chrs-20240930x10q.htm": { "nsprefix": "chrs", "nsuri": "http://www.coherus.com/20240930", "dts": { "schema": { "local": ["chrs-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["chrs-20240930_cal.xml"] }, "definitionLink": { "local": ["chrs-20240930_def.xml"] }, "labelLink": { "local": ["chrs-20240930_lab.xml"] }, "presentationLink": { "local": ["chrs-20240930_pre.xml"] }, "inline": { "local": ["chrs-20240930x10q.htm"] } }, "keyStandard": 270, "keyCustom": 124, "axisStandard": 34, "axisCustom": 0, "memberStandard": 45, "memberCustom": 46, "hidden": { "total": 18, "http://www.coherus.com/20240930": 4, "http://fasb.org/us-gaap/2024": 9, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 351, "entityCount": 1, "segmentCount": 92, "elementCount": 735, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 802, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.coherus.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_8Kg-XbyVJUyR3iA4CQqf0g", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_uThp0o4ITkaqDsnNiUNC6A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_uThp0o4ITkaqDsnNiUNC6A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "995200300 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit", "longName": "995200400 - Statement - Condensed Consolidated Statements of Stockholders' Deficit", "shortName": "Condensed Consolidated Statements of Stockholders' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E-Zh0vTg4kmA_nCTVemBGw", "name": "us-

gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HS5ZVryT10iNYAQUglH1Tg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R7": { "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200500 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R8": { "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies", "longName": "995210101 - Disclosure - Organization and Summary of Significant Accounting Policies", "shortName": "Organization and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.coherus.com/role/DisclosureRevenue", "longName": "995210201 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.coherus.com/role/DisclosureFairValueMeasurements", "longName": "995210301 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.coherus.com/role/DisclosureInventory", "longName": "995210401 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponents", "longName": "995210501 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.coherus.com/role/DisclosureAcquisitionAndDisposition", "longName": "995210601 - Disclosure - Acquisition and Disposition", "shortName": "Acquisition and Disposition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:AcquisitionAndDisposalOfBusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:AcquisitionAndDisposalOfBusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements", "longName": "995210701 - Disclosure - Collaborations and Other Arrangements", "shortName": "Collaborations and Other Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities", "longName": "995210801 - Disclosure - Financial Liabilities", "shortName": "Financial Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210901 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.coherus.com/role/DisclosureStockholdersDeficit", "longName": "995211001 - Disclosure - Stockholders' Deficit", "shortName": "Stockholders' Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:StockholdersDeficitTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:StockholdersDeficitTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.coherus.com/role/DisclosureStockBasedCompensation", "longName": "995211101 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.coherus.com/role/DisclosureNetIncomeLossPerShare", "longName": "995211201 - Disclosure - Net Income (Loss) Per Share", "shortName": "Net Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-

gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables", "longName": "99930103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)", "shortName": "Organization and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.coherus.com/role/DisclosureRevenueTables", "longName": "99930203 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930303 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.coherus.com/role/DisclosureInventoryTables", "longName": "99930403 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:ScheduleOfInventoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:ScheduleOfInventoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables", "longName": "99930503 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionTables", "longName": "99930603 - Disclosure - Acquisition and Disposition (Tables)", "shortName": "Acquisition and Disposition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables", "longName": "99930803 - Disclosure - Financial Liabilities (Tables)", "shortName": "Financial Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99930903 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:LongTermPurchaseCommitmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:LongTermPurchaseCommitmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.coherus.com/role/DisclosureStockholdersDeficitTables", "longName": "99931003 - Disclosure - Stockholders' Deficit (Tables)", "shortName": "Stockholders' Deficit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:ScheduleOfSettlementsUnderSharesOfferingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors":

["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:ScheduleOfSettlementsUnderSharesOfferingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationTables", "longName": "99931103 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_EPtzSplidESfjSSa0keAjg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_EPtzSplidESfjSSa0keAjg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.coherus.com/role/DisclosureNetIncomeLossPerShareTables", "longName": "99931203 - Disclosure - Net Income (Loss) Per Share (Tables)", "shortName": "Net Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "longName": "99940101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_3_1_2024_6p50J7G4M0qIzq41bOjyUQ", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "chrs:ProductPipelineNumberOfDrugCandidates", "unitRef": "Unit_Standard_product_zUsJF1WmY0miz3L0CEa4Zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "longName": "99940102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_-hCEq8TQR0yHE0R6D2ZVqw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R36": { "role": "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails", "longName": "99940201 - Disclosure - Revenue - Net Revenue (Details)", "shortName": "Revenue - Net Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_nCE1WcUctEyawyFHITKZ6Q", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R37": { "role": "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails", "longName": "99940202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)", "shortName": "Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_rBPFX4vYYUWeDaEFQLNtQw", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_Standard_pure_r1w4N6qVfU2bndkTxq81jA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_rBPFX4vYYUWeDaEFQLNtQw", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_Standard_pure_r1w4N6qVfU2bndkTxq81jA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails", "longName": "99940203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)", "shortName": "Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_12_31_2023_8Kg-XbyVJUyR3iA4CQqf0g", "name": "chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_8Kg-XbyVJUyR3iA4CQqf0g", "name": "chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails", "longName": "99940301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_oXsVHiLSJUmwmXUJhhtofw", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_oXsVHiLSJUmwmXUJhhtofw", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails", "longName": "99940302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)",

```
"shortName": "Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "99940303 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "chrs:ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_F1AE_iReDkmJ2IvTB7XemA", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://www.coherus.com/role/DisclosureInventoryComponentsDetails", "longName": "99940401 - Disclosure - Inventory - Components (Details)", "shortName": "Inventory - Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "chrs:ScheduleOfInventoryTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "chrs:ScheduleOfInventoryTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails", "longName": "99940402 - Disclosure - Inventory - Balance Sheet Classifications (Details)", "shortName": "Inventory - Balance Sheet Classifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:InventoryNet", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "chrs:InventoryCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "chrs:ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R44": { "role": "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails", "longName": "99940403 - Disclosure - Inventory - Additional Information (Details)", "shortName": "Inventory - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:InventoryWriteDown", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "chrs:PrepaymentsMadeToCmoForManufacturingServices", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R45": { "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "longName": "99940501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "longName": "99940502 - Disclosure - Balance Sheet Components - Additional Information (Details)", "shortName": "Balance Sheet Components - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails", "longName": "99940503 - Disclosure - Balance Sheet Components - Intangible Assets, Net (Details)", "shortName": "Balance Sheet Components - Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_8Kg-XbyVJUyR3iA4CQqf0g", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R48": { "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails", "longName": "99940504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)", "shortName": "Balance Sheet Components - Accrued and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails", "longName": "99940505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details)", "shortName": "Balance Sheet Components - Other Liabilities, Non-current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil":
```

"false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R50": { "role": "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "longName": "99940601 - Disclosure - Acquisition and Disposition - Additional Information (Details)", "shortName": "Acquisition and Disposition - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_3_1_2024_6p50J7G4M0qIzq41bOjyUQ", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliOphthalmologyInc.Member", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R51": { "role": "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails", "longName": "99940602 - Disclosure - Acquisition and Disposition - Estimated fair value of the net assets acquired (Details)", "shortName": "Acquisition and Disposition - Estimated fair value of the net assets acquired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member__u6ERcTllE6mOBbPwnLL5A", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member__u6ERcTllE6mOBbPwnLL5A", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "longName": "99940603 - Disclosure - Acquisition and Disposition - The amounts allocated to identifiable intangible assets (Details)", "shortName": "Acquisition and Disposition - The amounts allocated to identifiable intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member__u6ERcTllE6mOBbPwnLL5A", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_9nP9fRR400yGj-D_bLnJmw", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R53": { "role": "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails", "longName": "99940605 - Disclosure - Acquisition and Disposition - Unaudited Pro Forma Summary of Operations (Details)", "shortName": "Acquisition and Disposition - Unaudited Pro Forma Summary of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_7he1MiQ7IkGBuqSPda_Tfg", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_7he1MiQ7IkGBuqSPda_Tfg", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails", "longName": "99940701 - Disclosure - Collaborations and Other Arrangements (Details)", "shortName": "Collaborations and Other Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_3_1_2022_To_3_31_2022_7gpV-Asrj0epeOWj33xE0w", "name": "chrs:CollaborationAgreementOptionExerciseFeePerProgram", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_1_2022_To_3_31_2022_7gpV-Asrj0epeOWj33xE0w", "name": "chrs:CollaborationAgreementOptionExerciseFeePerProgram", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails", "longName": "99940801 - Disclosure - Financial Liabilities - Summary of Debt Obligations (Details)", "shortName": "Financial Liabilities - Summary of Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_TwoThousandTwentyNineTermLoansMember_R_gRvFD2D0iCPcnuIglSZg", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_SFwSmUvkt0aHv72BszMw5g", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R56": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "longName": "99940802 - Disclosure - Financial Liabilities - 2029 Term Loan - Narrative (Details)", "shortName": "Financial Liabilities - 2029 Term Loan - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_5_8_2024_To_5_8_2024_us-gaap_DebtInstrumentAxis_chrs_TwoThousandTwentyNineTermLoansMember_V518EIgQD024kALHaHhrHg", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_8_2024_To_5_8_2024_us-gaap_DebtInstrumentAxis_chrs_TwoThousandTwentyNineTermLoansMember_V518EIgQD024kALHaHhrHg", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails", "longName": "99940804 - Disclosure - Financial Liabilities - 2029 Term Loans, Components of Interest Expense (Details)", "shortName": "Financial Liabilities - 2029 Term Loans, Components of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_TwoThousandTwentyNineTermLoansMember_iyFp4LfcdE6im5IU1SEpfA", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-

gaap_DebtInstrumentAxis_chrs_TwoThousandTwentyNineTermLoansMember_iyFp4LfcdE6im5IU1SEpfA", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails", "longName": "99940805 - Disclosure - Financial Liabilities - 2029 Term Loan Future Payments (Details)", "shortName": "Financial Liabilities - 2029 Term Loan Future Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "unitRef": "Unit_Standard_pure_r1w4N6qVfU2bndkTxq81jA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_CounterpartyNameAxis_chrs_AnkuraTrustCompanyLlcMember_us-gaap_DebtInstrumentAxis_chrs_TwoThousandTwentyNineTermLoansMember_6YEC7ct-8EGd1qM_i_EyEw", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R59": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails", "longName": "99940806 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Narrative (Details)", "shortName": "Financial Liabilities - Revenue Purchase and Sale Agreement - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_5_8_2024_us-gaap_DebtInstrumentAxis_chrs_RevenuePurchaseAndSaleAgreementMember_s9NWF6cRYk28bTHQ72Lt1g", "name": "chrs:RevenuePurchaseAndSaleAgreementPurchasePrice", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_8_2024_us-gaap_DebtInstrumentAxis_chrs_RevenuePurchaseAndSaleAgreementMember_s9NWF6cRYk28bTHQ72Lt1g", "name": "chrs:RevenuePurchaseAndSaleAgreementPurchasePrice", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails", "longName": "99940807 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Summary of Revenue Participation Liability (Details)", "shortName": "Financial Liabilities - Revenue Purchase and Sale Agreement - Summary of Revenue Participation Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_RevenuePurchaseAndSaleAgreementMember_rR2OvZUvhkuvLj9SQLPUXQ", "name": "chrs:RevenueParticipationLiability", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_RevenuePurchaseAndSaleAgreementMember_rR2OvZUvhkuvLj9SQLPUXQ", "name": "chrs:RevenueParticipationLiability", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe "longName": "99940808 - Disclosure - Financial Liabilities - Revenue Purchase and Sale Agreement - Classification on the condensed consolidated balance sheet (Details)", "shortName": "Financial Liabilities - Revenue Purchase and Sale Agreement - Classification on the condensed consolidated balance sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "chrs:RoyaltyParticipationLiabilityCurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_RevenuePurchaseAndSaleAgreementMember_rR2OvZUvhkuvLj9SQLPUXQ", "name": "chrs:RoyaltyParticipationLiabilityCurrent", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "chrs:ScheduleOfRoyaltyParticipationLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R62": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "longName": "99940810 - Disclosure - Financial Liabilities - 2027 Term Loan - Narrative (Details)", "shortName": "Financial Liabilities - 2027 Term Loan - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "unitRef": "Unit_Standard_pure_r1w4N6qVfU2bndkTxq81jA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_2_5_2024_9qtifoFa9ki6I-HJePKEPA", "name": "chrs:DebtPartialPrepaymentToBeMade", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R63": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails", "longName": "99940812 - Disclosure - Financial Liabilities - 2027 Term Loans, Components of Interest Expense (Details)", "shortName": "Financial Liabilities - 2027 Term Loans, Components of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_Pl-61ELGzkufpjUUx4pE0A", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_Pl-61ELGzkufpjUUx4pE0A", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails", "longName": "99940814 - Disclosure - Financial Liabilities - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)", "shortName": "Financial Liabilities - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_28_2024_ad5hPwv_m0asRv_9HQVoFg", "name": "us-gaap:SharePrice", "unitRef": "Unit_Divide_USD_shares_uThp0o4ITkaqDsnNiUNC6A", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_ycWi796BO0igYPfK1FKr3A", "name": "chrs:NumberOfEventsInDefault", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["us-gaap:DebtInstrumentCovenantCompliance", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R65": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails", "longName": "99940816 - Disclosure - Financial Liabilities - Capped Call Transactions - Narrative (Details)", "shortName": "Financial Liabilities - Capped Call Transactions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_6_28_2024_ad5hPwv_m0asRv_9HQVoFg", "name": "us-gaap:SharePrice", "unitRef": "Unit_Divide_USD_shares_uThp0o4ITkaqDsnNiUNC6A", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_w7NSiEqngUm-XJvXOrcO2Q", "name": "chrs:PaymentForCappedCallTransactions", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R66": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails", "longName": "99940818 - Disclosure - Financial Liabilities - 2026 Convertible Notes Interest Expense Components (Details)", "shortName": "Financial Liabilities - 2026 Convertible Notes Interest Expense Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_w61nWfhtkUSGt5Vz2SYI8A", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef":

"Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_w61nWfhtkUSGt5Vz2SYI8A", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails", "longName": "99940820 - Disclosure - Financial Liabilities - 2026 Convertible Notes Future Payments (Details)", "shortName": "Financial Liabilities - 2026 Convertible Notes Future Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Lw0Wqh6ixUS7Rr4uBiiv6g", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Lw0Wqh6ixUS7Rr4uBiiv6g", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails", "longName": "99940901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)", "shortName": "Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LongTermPurchaseCommitmentTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LongTermPurchaseCommitmentTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "99940902 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails", "longName": "99941001 - Disclosure - Stockholders' Deficit (Details)", "shortName": "Stockholders' Deficit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lmqeCtBF90GZZC1kc27xyA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_uThp0o4ITkaqDsnNiUNC6A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_18_2023_To_5_18_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_Yy4A2sd6KUqQ1pef_NPwTQ", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_cLM3mzjt5UOrRdbv0QWHoQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "chrs:StockholdersDeficitTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R71": { "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails", "longName": "99941101 - Disclosure - Stock-Based Compensation - Stock-Based Expense (Details)", "shortName": "Stock-Based Compensation - Stock-Based Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails", "longName": "99941201 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)", "shortName": "Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_x7J-mTQd1Ua8BVq5TST69A", "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "unitRef": "Unit_Standard_USD_y0gNzSZ33E68UXcqInUzMw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "unique": true } }, "R73": { "role": "http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomel "longName": "99941202 - Disclosure - Net Income (Loss) Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share (Details)", "shortName": "Net Income (Loss) Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_cLM3mzjt5UOrRdbv0QWHoQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Zsw46NGJZE-Mt-rTzO3owg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_cLM3mzjt5UOrRdbv0QWHoQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "chrs-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts Notes And Loans

Receivable", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r238", "r881"] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": ["r80", "r86"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r69", "r720"] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable [Member]", "terseLabel": "Accounts payable", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": ["r70"] }, "chrs_AccruedAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AccruedAndOtherCurrentLiabilitiesMember", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents accrued and other current liabilities.", "label": "Accrued and other current liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "auth_ref": [] }, "chrs_AccruedCoDevelopmentCostsAndMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AccruedCoDevelopmentCostsAndMilestonePayments", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Accrued co-development costs and milestone payments", "label": "The amount represents Accrued co-development costs and milestone payments.", "terseLabel": "Accrued co-development costs and milestone payments" } } }, "auth_ref": [] }, "chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Accrued commercial and research and development manufacturing liabilities current.", "label": "Accrued Commercial and Research and Development Manufacturing Liabilities Current", "terseLabel": "Accrued commercial and research and development manufacturing" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Total Accrued and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r71"] }, "chrs_AccruedMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AccruedMilestonePayment", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments.", "label": "Accrued Milestone Payment", "terseLabel": "Accrued milestone payment" } } }, "auth_ref": [] }, "chrs_AccruedRebatesFeesAndReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AccruedRebatesFeesAndReserveCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Accrued rebates, fees and reserve.", "label": "Accrued Rebates Fees And Reserve Current", "terseLabel": "Accrued rebates, fees and reserves" } } }, "auth_ref": [] }, "chrs_AccruedRebatesFeesAndReservesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AccruedRebatesFeesAndReservesMember", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents accrued rebates, fees and reserves.", "label": "Accrued Rebates, Fees And Reserves [Member]", "terseLabel": "Accrued rebates, fees and reserves" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r71", "r669"] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "Accrued Royalties", "terseLabel": "Royalties due", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": ["r119"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r19", "r20", "r87", "r153", "r564", "r591", "r592"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r10", "r20", "r463", "r466", "r511", "r587", "r588", "r855", "r856", "r857", "r868", "r869", "r870", "r872"] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Useful Lives", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r297", "r665"] }, "chrs_AcquisitionAndDisposalOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AcquisitionAndDisposalOfBusinessAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Acquisition And Disposal Of Business [Abstract]" } } }, "auth_ref": [] }, "chrs_AcquisitionAndDisposalOfBusinessTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "AcquisitionAndDisposalOfBusinessTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDisposition"], "lang": { "en-us": { "role": { "documentation": "The disclosure of acquisition and disposal of business.", "label": "Acquisition and Disposal of Business [Text Block]", "terseLabel": "Acquisition and Disposition" } } }, "auth_ref": [] }, "us-gaap_AcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquisitionRelatedCostsMember", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Acquisition-related Costs [Member]", "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r776"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r81", "r720", "r991"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r599", "r868", "r869", "r870", "r872", "r929",

```
"r992" ] }, "chrs_AdimabDevelopmentAndOptionAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "AdimabDevelopmentAndOptionAgreementMember", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents the information pertaining to Adimab Development and Option Agreement.", "label": "Adimab Development and Option Agreement
[Member]", "terseLabel": "Adimab Development and Option Agreement" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel":
"Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r789" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r789" ] },
"ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } },
"auth_ref": [ "r789" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To
PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r789" ] }, "us-
gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Share-
Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Taxes paid related to net share settlement of RSUs",
"documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } }
}, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "APIC,
Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount
of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [
"r46", "r47", "r391" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label":
"Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Offering costs associated with ATM offering",
"documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but
is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r11",
"r109" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to
Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income
(loss) to net cash provided by (used in) operating activities:" } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary
Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in
Summary Compensation Table" } } }, "auth_ref": [ "r822" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-
us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } },
"auth_ref": [ "r748", "r758", "r768", "r800" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined
[Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r751", "r761", "r771", "r803" ] },
"ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate
Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r823" ] },
"ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]",
"terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r789" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive
Categories" } } }, "auth_ref": [ "r796" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } },
"auth_ref": [ "r752", "r762", "r772", "r796", "r804", "r808", "r816" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]",
"terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r814" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit",
"presentation": [ "http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails" ], "lang": { "en-us": { "role": {
"label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense
for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r423", "r432" ] }, "dei_AmendmentFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.coherus.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel":
"Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } },
"auth_ref": [] }, "chrs_AmeriSourceBergenCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930",
"localname": "AmeriSourceBergenCorpMember", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" ], "lang": { "en-
us": { "role": { "documentation": "AmeriSource-Bergen Corp.", "label": "AmeriSource-Bergen Corp [Member]", "terseLabel": "Cencora (previously
known as AmeriSource-Bergen Corporation)" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation":
[ "http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails" ], "lang": { "en-us": { "role": {
"label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Amortization of debt discount and debt issuance costs", "documentation":
"Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments.
Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r6", "r93", "r356", "r941" ] },
"us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails" ], "lang": { "en-us": { "role": {
"label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of discount and issuance costs", "documentation":
"Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r356", "r688", "r689",
"r863", "r941" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label":
"Amortization of Intangible Assets", "terseLabel": "Amortization expense, Finite-lived intangible assets", "documentation": "The aggregate expense
charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner
to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash
provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r6", "r294", "r301", "r683" ] },
"chrs_AnkuraTrustCompanyLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"AnkuraTrustCompanyLlcMember", "presentation": [
```

"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation":
"Represents information pertaining to Ankura Trust Company LLC.", "label": "Ankura Trust Company LLC [Member]", "terseLabel": "Ankura Trust
Company, LLC" } } }, "auth_ref": [] }, "chrs_AntiTigitAntibodyAndIl2CytokineMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "AntiTigitAntibodyAndIl2CytokineMember", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation":
"Represents anti-TIGIT antibody and the IL-2 cytokine.", "label": "Anti-TIGIT Antibody and IL-2 cytokine", "terseLabel": "Anti-TIGIT Antibody and
IL-2 cytokine" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel":
"Antidilutive securities excluded from the calculation of diluted net income (loss) per share", "documentation": "Securities (including those
issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the
future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per
share or unit amounts for the period presented." } } }, "auth_ref": ["r218"] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } },
"auth_ref": ["r30"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel":
"Antidilutive securities excluded from computation of EPS", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref":
[] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to
securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share
amounts for the period presented." } } }, "auth_ref": ["r30"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation":
["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative
Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than
Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity
or operations." } } }, "auth_ref": ["r454"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Assets", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": {
"en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic
benefit." } } }, "auth_ref": ["r117", "r130", "r151", "r177", "r222", "r224", "r232", "r233", "r276", "r325", "r326", "r327", "r328", "r329", "r330",
"r331", "r332", "r333", "r456", "r460", "r496", "r560", "r623", "r678", "r679", "r720", "r739", "r921", "r922", "r944"] }, "us-gaap_AssetsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]",
"terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"],
"lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for
present right to economic benefit, classified as current." } } }, "auth_ref": ["r145", "r155", "r177", "r276", "r325", "r326", "r327", "r328", "r329",
"r330", "r331", "r332", "r333", "r456", "r460", "r496", "r720", "r921", "r922", "r944"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": {
"label": "Assets, Fair Value Disclosure", "terseLabel": "Total financial assets", "documentation": "Fair value portion of asset recognized for present
right to economic benefit." } } }, "auth_ref": ["r473", "r474", "r708"] }, "chrs_AtMarketOfferingLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://www.coherus.com/20240930", "localname": "AtMarketOfferingLineItems", "presentation": [
"http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent at the
market offering.", "label": "At The Market Offering [Line Items]", "terseLabel": "Stockholders' Deficit" } } }, "auth_ref": [] },
"chrs_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"AtMarketOfferingMember", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation":
"Represents information relating to at the market offering issuance.", "label": "At Market Offering [Member]", "terseLabel": "ATM Offering" } } },
"auth_ref": [] }, "chrs_AtMarketOfferingTable": { "xbrltype": "stringItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"AtMarketOfferingTable", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": {
"documentation": "At the market offering.", "label": "Stockholders' Deficit [Table]" } } }, "auth_ref": [] }, "us-
gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"], "lang": {
"en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gain",
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r248"] }, "us-
gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"], "lang": {
"en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized
(Loss)", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt
security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r249"
] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"], "lang": {
"en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Cost", "documentation": "Amortized cost of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } },
"auth_ref": ["r245", "r284", "r559"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"], "lang": {
"en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "verboseLabel": "Fair Value", "documentation": "Amount of investment in debt
security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r246",
"r284", "r473", "r551", "r708", "r712", "r882", "r933", "r934", "r935"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": {
"en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r811"] }, "ecd_AwardGrantDateFairValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair
Value as of Grant Date" } } }, "auth_ref": ["r812"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line
Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r807"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails", "http://www.coherus.com/role/DisclosureStockBasedCompensationTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r422"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r810"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r809"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r808"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r808"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails", "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r313", "r959", "r960"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails", "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r58", "r59", "r313", "r959", "r960"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "chrs_BasicAndDilutedNetIncomeLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BasicAndDilutedNetIncomeLossPerShareAbstract", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Basic And Diluted Net Income (Loss) Per Share [Abstract]", "terseLabel": "Basic net income (loss) per share" } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Organization and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r99"] }, "chrs_BiopharmaCreditInvestmentsVGpLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BiopharmaCreditInvestmentsVGpLlcMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to BioPharma Credit Investments V GP LLC.", "label": "BioPharma Credit Investments V GP LLC" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails", "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r295", "r296", "r297", "r298", "r299", "r450", "r701", "r702"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails", "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r48", "r50", "r295", "r296", "r297", "r298", "r299", "r450", "r701", "r702"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails", "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "terseLabel": "Surface Acquisition", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r450"] }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]", "documentation": "Disclosure of information about nonrecurring adjustment directly attributable to business combination included in pro forma revenue and earnings." } } }, "auth_ref": ["r12"] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionTables"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of unaudited pro forma summary of operations", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": ["r834", "r835"] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": ["r448", "r449"] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Total revenues", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": ["r448", "r449"] }, "chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BusinessCombinationConsiderationContingentValueRightPaymentPeriod", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The payment period of contingent value rights under business combination.", "label": "Business Combination, Consideration, Contingent Value Right, Payment Period", "terseLabel": "Contingent value rights payment period" } } }, "auth_ref": [] }, "chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The percent of milestone and royalty based payments payable as part of contingent value rights under business combination.", "label": "Business Combination, Consideration, Contingent Value Right Payments, Percent of Milestone and Royalty Based Payments", "terseLabel": "Milestone and royalty based CVR payments (as percent)" } } }, "auth_ref": [] }, "chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The percent of upfront payments payable as part of contingent value rights under business combination.", "label": "Business Combination, Consideration, Contingent Value Right Payments, Percent of Upfront Payments", "terseLabel": "Upfront payment based CVR payments (as percent)" } } }, "auth_ref": [] }, "chrs_BusinessCombinationConsiderationContingentValueRightPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BusinessCombinationConsiderationContingentValueRightPerShare", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The number of contingent value rights issuable in consideration for each share under business combination.", "label": "Business Combination, Consideration, Contingent Value Right Per Share", "terseLabel": "Contingent value right per share" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Fair value of the contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r451", "r862"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails", "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration, current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r55", "r111"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails", "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration, non-current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r55", "r111"] }, "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized", "terseLabel": "Inventory purchase commitments", "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity." } } }, "auth_ref": ["r53"] }, "chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BusinessCombinationNumberOfOutLicensedPartnershipProgram", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of outlicensed partnership program in a business combination.", "label": "Business Combination, Number of Out Licensed Partnership Program", "terseLabel": "Business Combination, Number of Out Licensed Partnership Program" } } }, "auth_ref": [] }, "chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree": { "xbrltype": "sharesItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in exchange of each share of acquiree in a business combination.", "label": "Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree", "terseLabel": "Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree" } } }, "auth_ref": [] }, "chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued and Other Current Liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets Acquired" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the

acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "terseLabel": "Investments in marketable securities", "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaids and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liability", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Identifiable intangible assets", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities Assumed" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total net assets acquired", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r51", "r52"] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Acquisition-related costs", "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed." } } }, "auth_ref": ["r49"] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedFinancialStatementCaption": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedFinancialStatementCaption", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Financial Statement Caption", "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents disclosure of the line item or line items in the income statement in which the acquisition related costs which have been expensed are recognized." } } }, "auth_ref": ["r49"] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CallOptionMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Call Option [Member]", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": ["r656", "r657"] }, "chrs_CanadaLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CanadaLicenseAgreementMember", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Canada License Agreement.", "label": "Canada License Agreement [Member]", "terseLabel": "Canada license agreement" } } }, "auth_ref": [] }, "chrs_CapPriceOfCapCallTransactions": { "xbrltype": "perShareItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CapPriceOfCapCallTransactions", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the cap price of the cap call transactions (per share).", "label": "Cap Price of Cap Call Transactions", "terseLabel": "Initial cap price of capped call transactions." } } }, "auth_ref": [] }, "us-gaap_CapitalizedComputerSoftwareNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareNet", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Capitalized Computer Software, Net", "terseLabel": "Software implementation costs", "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date." } } }, "auth_ref": ["r664"] }, "chrs_CardinalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CardinalMember", "presentation": ["http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "Cardinal.", "label": "Cardinal", "terseLabel": "Cardinal Health, Inc." } } }, "auth_ref": [] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Acquired from Acquisition", "terseLabel": "Cash and cash equivalents acquired from Surface Acquisition", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": ["r22"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-

term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r25", "r147", "r667"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r26", "r116"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r25", "r96", "r175"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r96"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of non-cash activities" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r787"] }, "chrs_ChargebacksAndDiscountsForPromptPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ChargebacksAndDiscountsForPromptPaymentMember", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"], "lang": { "en-us": { "role": { "documentation": "Charge backs and discounts for prompt payment.", "label": "Chargebacks and Discounts for Prompt Payment" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": ["r879"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r784"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r782"] }, "chrs_CimerliMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CimerliMember", "presentation": ["http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to the product CIMERLI.", "label": "CIMERLI" } } }, "auth_ref": [] }, "chrs_CimerliOphthalmologyFranchiseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CimerliOphthalmologyFranchiseMember", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails", "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails", "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to CIMERLI ophthalmology franchise.", "label": "CIMERLI Ophthalmology Franchise [Member]", "terseLabel": "CIMERLI Sale" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CoDevelopmentRegulatoryAndTechnologyTransferCosts", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents co-development, regulatory and technology transfer costs.", "label": "Co-development, Regulatory And Technology Transfer Costs", "terseLabel": "Co-development, regulatory and technology transfer costs" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r788"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r788"] }, "chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of additional clinical milestones eligible to receive", "label": "Collaboration Agreement, Additional Clinical Milestones Eligible to Receive", "terseLabel": "Additional clinical milestones eligible to receive" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum aggregate milestone payments to be made", "label": "Collaboration Agreement, Maximum Aggregate Milestone Payments to be Made", "terseLabel": "Maximum aggregate milestone payments to be made" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds", "label": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds", "terseLabel": "Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram", "crdr": "credit", "presentation": [

"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.", "label": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program", "terseLabel": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementMilestonePaymentsEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementMilestonePaymentsEarned", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of milestone payments earned", "label": "Collaboration Agreement, Milestone Payments Earned", "terseLabel": "Milestone payments earned" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement.", "label": "Collaboration Agreement, Number Of Undisclosed Preclinical Immuno Oncology Drug Candidates", "terseLabel": "Undisclosed preclinical" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementOptionExerciseFeePerProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementOptionExerciseFeePerProgram", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of option exercise fee per program under the collaboration agreement.", "label": "Collaboration Agreement, Option Exercise Fee Per Program", "terseLabel": "License Agreement Fee" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementPercentageOfRoyaltyOnNetSales", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalty on net sales under the collaboration agreement.", "label": "Collaboration Agreement, Percentage Of Royalty On Net Sales", "terseLabel": "Collaboration agreement, royalty on net sales, percentage" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalty on net sales for each option program under the collaboration agreement.", "label": "Collaboration Agreement, Percentage Of Royalty On Net Sales For Each Option Program", "terseLabel": "Collaboration agreement, royalty on net sales for each exercised option, percentage" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee": { "xbrltype": "durationItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Period for payment of nominal research maintenance fee", "label": "Collaboration Agreement, Period for Payment of Nominal Research Maintenance Fee", "terseLabel": "Period for payment of nominal research maintenance fee" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementRegulatoryMilestonesEligibleToReceive", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of regulatory milestones eligible to receive", "label": "Collaboration Agreement, Regulatory Milestones Eligible to Receive", "terseLabel": "Regulatory milestones eligible to receive" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementRenewalTerm", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Renewal term of agreement.", "label": "Collaboration Agreement, Renewal Term", "terseLabel": "Renewal term" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Technical milestone payments obligated to pay", "label": "Collaboration Agreement, Technical Milestone Payments Obligated to Pay", "terseLabel": "Technical milestone payments obligated to pay" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementTerm", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Term of agreement", "label": "Collaboration Agreement, Term", "terseLabel": "Term of agreement" } } }, "auth_ref": [] }, "chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.", "label": "Collaboration Agreement , Threshold Payments On Achievement Of Various Milestone For Each Option Program", "terseLabel": "Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program" } } }, "auth_ref": [] }, "chrs_CollaborationAndLicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationAndLicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreements.", "label": "Collaboration And License Agreements [Abstract]" } } }, "auth_ref": [] }, "chrs_CollaborationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborationCosts", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents costs associated to a collaboration agreement.", "label": "Collaboration Costs", "terseLabel": "Collaboration Agreement, upfront amount paid" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborations and Other Arrangements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r133", "r135", "r141"] }, "chrs_CollaborativeArrangementRegulatoryAndSalesMilestonesEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborativeArrangementRegulatoryAndSalesMilestonesEligibleToReceive", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of regulatory and sales milestones eligible to receive under the collaborative arrangement.", "label": "Collaborative Arrangement, Regulatory And Sales Milestones Eligible To Receive", "terseLabel": "Regulatory and sales milestones eligible to receive" } } }, "auth_ref": [] }, "chrs_CollaborativeArrangementUpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CollaborativeArrangementUpfrontPaymentReceived", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "The upfront payment received by the company under the collaborative arrangement.", "label": "Collaborative Arrangement Upfront Payment Received", "terseLabel": "Company an upfront payment received" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails", "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r454"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r76", "r122", "r562", "r610"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r104", "r315", "r316", "r661", "r910", "r915"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r729", "r730", "r731", "r733", "r734", "r735", "r736", "r868", "r869", "r872", "r929", "r990", "r992"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r79"] }, "chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "CommonStockRemainingAvailableForSaleUnderAtmOffering", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the common stock remaining available for sale under the atm offering.", "label": "Common Stock Remaining Available For Sale Under The ATM Offering", "terseLabel": "Common stock remaining available for sales under the ATM Offering" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r79", "r611"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r79"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balances (in shares)", "periodStartLabel": "Beginning Balances (in shares)", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r11", "r79", "r611", "r629", "r992", "r993"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 115,213,407 and 112,215,260 at September 30, 2024 and December 31, 2023, respectively)", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r79", "r563", "r720"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r793"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r792"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r794"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r791"] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r57", "r112", "r161", "r163", "r168", "r553", "r573"] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r32", "r33", "r62", "r63", "r236", "r660"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r32", "r33", "r62", "r63", "r236", "r594", "r660"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r32", "r33", "r62", "r63", "r236", "r660", "r833"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": ["http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r660"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of total gross revenue", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r32", "r33", "r62", "r63", "r236"] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": ["http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": ["r31", "r32", "r33", "r34", "r62", "r115", "r660"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [

```
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
"http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" ], "lang": { "en-
us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of
some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier,
lender) of the concentration." } } }, "auth_ref": [ "r32", "r33", "r62", "r63", "r236", "r660" ] }, "us-gaap_ConsolidationPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label":
"Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Consolidation", "documentation": "Disclosure of accounting policy regarding (1)
the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the
inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for
example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the
equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and
transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } },
"auth_ref": [ "r56", "r673" ] }, "chrs_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "ContingentConsiderationMember", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": {
"documentation": "Contingent consideration.", "label": "Contingent Consideration" } } }, "auth_ref": [] },
"chrs_ContingentConsiderationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"ContingentConsiderationPolicyTextBlock", "presentation": [
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"documentation": "Represents Information pertaining to Consideration which is contingent upon some future changes in assumptions.", "label":
"Contingent Consideration [Policy Text Block]", "terseLabel": "Contingent Consideration" } } }, "auth_ref": [] }, "us-
gaap_ContractualObligationFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractualObligationFiscalYearMaturityAbstract", "lang": { "en-us": { "role": { "label": "Contractual Obligation Fiscal Year Maturity [Abstract]" }
} }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConvertibleDebtMember", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" ], "lang": { "en-us": {
"role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at
the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r106", "r335", "r336", "r346",
"r347", "r348", "r352", "r353", "r354", "r355", "r356", "r685", "r686", "r687", "r688", "r689" ] }, "chrs_ConvertibleNotesMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ConvertibleNotesMember", "presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL
], "lang": { "en-us": { "role": { "documentation": "Convertible notes.", "label": "Shares issuable upon conversion of convertible notes" } } },
"auth_ref": [] }, "chrs_ConvertibleNotesPrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930",
"localname": "ConvertibleNotesPrincipalAmount", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails" ], "lang": { "en-us": { "role": {
"documentation": "Convertible notes, principal amount.", "label": "Convertible Notes Principal Amount", "terseLabel": "2026 Convertible Notes,
principal amount" } } }, "auth_ref": [] }, "chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "ConvertibleSeniorSubordinatedNotesDue20261.5Member", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables",
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL
], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 1.5% Convertible Senior Subordinated Notes due
2026.", "label": "1.5% Convertible Senior Subordinated Notes due 2026" } } }, "auth_ref": [] }, "us-gaap_ConvertibleSubordinatedDebtNoncurrent":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleSubordinatedDebtNoncurrent", "crdr":
"credit", "presentation": [ "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label":
"Convertible Subordinated Debt, Noncurrent", "terseLabel": "Convertible notes", "documentation": "The portion of the carrying value of convertible
subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This
form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the
holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets." } } },
"auth_ref": [ "r18" ] }, "us-gaap_CorporateNoteSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CorporateNoteSecuritiesMember", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": {
"label": "Corporate Note Securities [Member]", "terseLabel": "Commercial paper and corporate notes", "documentation": "This category includes
information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise
of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)." } } }, "auth_ref": [] }, "us-
gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Goods
and Services Sold", "terseLabel": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services
rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered
and other revenue generating activities." } } }, "auth_ref": [ "r89", "r90", "r546" ] }, "us-gaap_CostOfSalesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Sales
[Member]", "terseLabel": "Cost of Goods Sold", "documentation": "Primary financial statement caption encompassing cost of sales." } } },
"auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations" ],
"lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total costs and expenses", "documentation": "Total costs of sales and
operating expenses for the period." } } }, "auth_ref": [ "r95" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails" ], "lang": { "en-us": { "role": {
"label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r178", "r179", "r338", "r367", "r512", "r529", "r558", "r670", "r672" ] },
"dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": {
"role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype":
"gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.coherus.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-
gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CustomerConcentrationRiskMember", "presentation": [
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
"http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" ], "lang": { "en-
us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the
percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net
revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [
"r100", "r236" ] }, "chrs_DebInstrumentPartialRepaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "DebInstrumentPartialRepaymentPrincipal", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation":
```

"Amount of partial repayment of principal of the loans subject to terms and conditions.", "label": "Deb Instrument, Partial Repayment, Principal", "terseLabel": "Partial prepayment of principal" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Convertible notes, converted amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r27", "r29"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Financial Liabilities", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r105", "r176", "r308", "r309", "r310", "r311", "r312", "r323", "r324", "r334", "r340", "r341", "r342", "r343", "r344", "r345", "r350", "r357", "r358", "r360", "r506"] }, "chrs_DebtDiscountsAndIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "DebtDiscountsAndIssuanceCosts", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of debt discounts and issuance costs incurred.", "label": "Debt Discounts and Issuance Costs", "terseLabel": "Debt discounts and issuance costs" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables", "http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomel "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r18", "r70", "r71", "r118", "r121", "r180", "r335", "r336", "r337", "r338", "r339", "r341", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r685", "r686", "r687", "r688", "r689", "r719", "r865", "r911", "r912", "r913", "r940", "r942"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "totalLabel": "Total minimum payments", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r18", "r121", "r361"] }, "chrs_DebtInstrumentContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "DebtInstrumentContractualTerm", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to debt instrument contractual term.", "label": "Debt Instrument Contractual Term", "terseLabel": "Contractual term" } } }, "auth_ref": [] }, "chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes": { "xbrltype": "sharesItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Debt instrument convertible number of shares per thousand of principal amount of notes.", "label": "Debt Instrument Convertible Number Of Shares Per Thousand Of Principal Amount Of Notes", "terseLabel": "Initial conversion rate, shares of common stock" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCovenantCompliance": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCovenantCompliance", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Covenant Compliance", "terseLabel": "Convertible notes, covenant compliance", "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure." } } }, "auth_ref": ["r18", "r65"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails", "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Principal Amount", "verboseLabel": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r335", "r506", "r507", "r686", "r687", "r719"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated Fair Value", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r348", "r495", "r686", "r687", "r932", "r933", "r934", "r935", "r936"] }, "chrs_DebtInstrumentFundedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "DebtInstrumentFundedAmount", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of loan funded out of amount available under loan agreement.", "label": "Debt Instrument, Funded Amount", "terseLabel": "Funded amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": ["r73", "r353", "r940"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r73", "r364", "r506", "r507", "r719"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",

```
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" ], "lang": { "en-us": {
"role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate", "documentation": "Contractual interest
rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r73", "r336" ] }, "us-gaap_DebtInstrumentInterestRateTerms": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateTerms", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" ], "lang": { "en-us": {
"role": { "label": "Debt Instrument, Interest Rate Terms", "terseLabel": "Interest rate description", "documentation": "Description of the interest
rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or
percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets." } } }, "auth_ref": [ "r73" ]
}, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentLineItems", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]",
"terseLabel": "Financial Liabilities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r180", "r335",
"r336", "r337", "r338", "r339", "r341", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r685", "r686", "r687",
"r688", "r689", "r719", "r865", "r940", "r942" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" ], "lang": { "en-us": {
"role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument maturity date", "documentation": "Date when the debt
instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r152", "r685", "r934", "r935" ] }, "us-
gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentNameDomain", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables",
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "lang": { "en-us": {
"role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that
distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r18", "r180", "r335",
"r336", "r337", "r338", "r339", "r341", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r685", "r686", "r687", "r688",
"r689", "r719", "r865", "r911", "r912", "r913", "r940", "r942" ] }, "chrs_DebtInstrumentPrepaymentPercentage": { "xbrltype": "percentItemType",
"nsuri": "http://www.coherus.com/20240930", "localname": "DebtInstrumentPrepaymentPercentage", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt
instrument prepayment percentage.", "label": "Debt Instrument Prepayment Percentage", "terseLabel": "Prepayment premium percentage" } } },
"auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } }
}, "auth_ref": [ "r126" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption
features." } } }, "auth_ref": [ "r126" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Redemption, Period One [Member]", "terseLabel": "Through March 31, 2023", "verboseLabel": "On or after the first anniversary",
"documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref":
[ "r126" ] }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Redemption, Period Three [Member]", "terseLabel": "After the third anniversary", "documentation": "Period three representing third
most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r126" ] }, "us-
gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentRedemptionPeriodTwoMember", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Redemption, Period Two [Member]", "terseLabel": "Starting April 1, 2023", "verboseLabel": "After the second anniversary",
"documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } },
"auth_ref": [ "r126" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentTable", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt
Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or
arrangement." } } }, "auth_ref": [ "r18", "r43", "r44", "r64", "r107", "r108", "r180", "r335", "r336", "r337", "r338", "r339", "r341", "r346", "r347",
"r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r685", "r686", "r687", "r688", "r689", "r719", "r865", "r940", "r942" ] }, "us-
gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
```

"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Less unamortized debt discount and issuance costs", "negatedTerseLabel": "Less unamortized debt discount and debt issuance costs", "terseLabel": "Remaining unamortized debt discount and debt offering costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r346", "r362", "r505", "r506", "r507", "r686", "r687", "r719"] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r557"] }, "chrs_DebtPartialPrepaymentToBeMade": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "DebtPartialPrepaymentToBeMade", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of partial prepayment agreed to be made of its term loan.", "label": "Debt Partial prepayment to be Made", "terseLabel": "Debt partial prepayment to be Made" } } }, "auth_ref": [] }, "chrs_DecreaseInResearchAndDevelopmentExpensesForReleaseOfCertainLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "DecreaseInResearchAndDevelopmentExpensesForReleaseOfCertainLiabilities", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in research and development expenses for release of certain liabilities.", "label": "Decrease in Research and Development Expenses for Release of Certain Liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r939", "r940", "r942"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r436", "r437", "r561"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r6", "r38"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense related to property and equipment, net", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r6", "r222", "r228", "r233", "r678", "r679"] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Royalty Fee Derivative Liability", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": ["r488"] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe
], "lang": { "en-us": { "role": { "label": "Derivative Liability, Current", "terseLabel": "Derivative liabilities, Fair Value", "verboseLabel": "Royalty Fee Derivative Liability (Note 8)", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r156"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r379", "r691", "r692", "r693", "r694", "r695", "r696", "r697"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r379", "r691", "r692", "r693", "r694", "r695", "r696", "r697"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Net product revenue in United States, and Company's net revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r924"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.coherus.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r390", "r393", "r425", "r426", "r427", "r704"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "chrs_DiscountOnRevenueParticipationLiabilityFromDerivativeInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "DiscountOnRevenueParticipationLiabilityFromDerivativeInstrument", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Discount on the revenue participation liability, resulting from a derivative instrument.", "label": "Discount On Revenue Participation Liability From Derivative Instrument", "terseLabel": "Discount on revenue participation liability from allocation of purchase price to the embedded derivative" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails",
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r143"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails",

*"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": {
"role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not
limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } },
"auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails",
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": {
"role": { "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group", "documentation":
"Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": ["r7", "r14"] },
"chrs_DisposalGroupIncludingDiscontinuedOperationAdditionalConsiderationForProductInventoryAndPrepaidManufacturingAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"DisposalGroupIncludingDiscontinuedOperationAdditionalConsiderationForProductInventoryAndPrepaidManufacturingAssets", "crdr": "debit",
"presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": {
"role": { "documentation": "Amount of additional consideration received or receivable for product inventory and prepaid manufacturing assets,
including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Additional Consideration for Product Inventory
and Prepaid Manufacturing Assets", "terseLabel": "Additional consideration" } } }, "auth_ref": [] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": {
"role": { "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Cash consideration", "documentation":
"Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] },
"chrs_DisposalGroupIncludingDiscontinuedOperationConsiderationInFormOfInventoryPurchaseCommitments": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.coherus.com/20240930", "localname":
"DisposalGroupIncludingDiscontinuedOperationConsiderationInFormOfInventoryPurchaseCommitments", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": {
"role": { "documentation": "Amount of consideration in the form of inventory purchase commitments assumed as part of the disposal of assets and
liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration In The Form Of Inventory
Purchase Commitments", "verboseLabel": "Inventory purchase commitments" } } }, "auth_ref": [] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including
Discontinued Operation, Inventory", "terseLabel": "Inventory", "documentation": "Amount classified as inventory attributable to disposal group
held for sale or disposed of." } } }, "auth_ref": ["r1", "r66", "r68", "r103"] },
"chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCosts", "crdr": "credit",
"presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Carrying value as of the balance sheet date of transaction costs incurred by the company for the disposal of assets and
liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Transaction Costs", "terseLabel":
"Transaction costs" } } }, "auth_ref": [] }, "chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCostsIncurred": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"DisposalGroupIncludingDiscontinuedOperationTransactionCostsIncurred", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"The amount of transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation.", "label":
"Disposal Group, Including Discontinued Operation, Transaction Costs Incurred", "terseLabel": "Transaction costs incurred" } } }, "auth_ref": [] },
"chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCostsUnpaid": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCostsUnpaid", "crdr": "credit",
"presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Carrying value as of the balance sheet date of unpaid transaction costs incurred by the company for the disposal of assets and
liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Transaction Costs Unpaid",
"terseLabel": "Transaction costs unpaid" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Disposal
Group, Not Discontinued Operation, Gain (Loss) on Disposal", "terseLabel": "Gain on sale transaction", "documentation": "Amount before tax of
gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": ["r306", "r863", "r906"] },
"us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails",
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Disposal Group
Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r701", "r702"] }, "dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-
QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] },
"dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus",
"presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal
Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a
2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example:
2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentPeriodEndDate", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": {
"role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of
Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all
other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
"dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentQuarterlyReport", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": {
"role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } },
"auth_ref": ["r743"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentTransitionReport", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": {
"role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a
form used as a transition report." } } }, "auth_ref": ["r775"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel":
"Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to
the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] },
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not*

Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r786"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "netLabel": "Basic net income (loss) per share", "terseLabel": "Basic (In dollar per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r169", "r186", "r187", "r188", "r189", "r190", "r191", "r197", "r199", "r215", "r216", "r217", "r221", "r446", "r453", "r470", "r471", "r554", "r574", "r675"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "netLabel": "Diluted net income (loss) per share", "terseLabel": "Diluted (In dollar per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r169", "r186", "r187", "r188", "r189", "r190", "r191", "r199", "r215", "r216", "r217", "r221", "r446", "r453", "r470", "r471", "r554", "r574", "r675"] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net income (loss) per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income (Loss) Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r196", "r218", "r219", "r220"] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Fair value of the Royalty Fee Derivative", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": ["r113", "r933", "r934", "r935"] }, "us-gaap_EmbeddedDerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeLineItems", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Embedded Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeTable", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Embedded Derivative [Table]", "documentation": "Disclosure of information about embedded derivatives." } } }, "auth_ref": [] }, "chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "documentation": "Employee and nonemployee stock option restricted stock units.", "label": "Employee And Nonemployee Stock Option Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r71"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Stock-based compensation expense capitalized into inventory", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": ["r424"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails", "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "chrs_EmployeesAndNonemployeesStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "EmployeesAndNonemployeesStockOptionMember", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeI], "lang": { "en-us": { "role": { "documentation": "Employees and non-employees stock option.", "label": "Stock options, including shares subject to ESPP", "terseLabel": "Stock options, PSOs, including shares subject to ESPP" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r741"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where

multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "verboseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r741"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r741"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r825"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r741"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r741"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r741"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r741"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r780"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r821"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r821"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r821"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r11", "r142", "r164", "r165", "r166", "r181", "r182", "r183", "r185", "r190", "r192", "r194", "r223", "r277", "r278", "r305", "r369", "r440", "r441", "r443", "r444", "r445", "r447", "r452", "r453", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r497", "r499", "r500", "r501", "r502", "r503", "r508", "r509", "r511", "r571", "r587", "r588", "r589", "r599", "r649"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r790"] }, "chrs_EquivalentToConversionPricePerCommonShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "EquivalentToConversionPricePerCommonShare", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Equivalent to conversion price per common share.", "label": "Equivalent To Conversion Price Per Common Share", "terseLabel": "Initial conversion price per common share" } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r748", "r758", "r768", "r800"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r745", "r755", "r765", "r797"] }, "chrs_ExclusiveLicenseAndCommercializationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ExclusiveLicenseAndCommercializationAgreementMember", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the Exclusive License and Commercialization Agreement .", "label": "Collaboration Agreement", "terseLabel": "Collaboration Agreement" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r796"] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExecutiveOfficerMember", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Other Senior Executives" } } }, "auth_ref": ["r879"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",

```
"presentation": [ "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial assets measured at fair value on a recurring basis", "verboseLabel": "Cost, Unrealized Gains or Losses, and Fair Value by Investment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r473", "r474", "r487", "r708" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } },
"auth_ref": [ "r473", "r474", "r487", "r708" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r488", "r710" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r488", "r710" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r348", "r382", "r383", "r384", "r385", "r386", "r387", "r472", "r474", "r475", "r476", "r477", "r486", "r487", "r489", "r516", "r517", "r518", "r686", "r687", "r698", "r699", "r700", "r708", "r712" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r488" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r473", "r474", "r475", "r477", "r708", "r934", "r937" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.coherus.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r482", "r484", "r485", "r486", "r489", "r490", "r491", "r492", "r493", "r549", "r708", "r713" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r348", "r382", "r387", "r474", "r487", "r516", "r698", "r699", "r700", "r708" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r348", "r382", "r387", "r474", "r475", "r487", "r517", "r686", "r687", "r698", "r699", "r700", "r708" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r348", "r382", "r383", "r384", "r385", "r386", "r387", "r474", "r475", "r476", "r477", "r487", "r518", "r686", "r687", "r698", "r699", "r700", "r708", "r712" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } },
"auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r488" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r473", "r474", "r475", "r477", "r708", "r934", "r937" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } },
"auth_ref": [ "r348", "r382", "r383", "r384", "r385", "r386", "r387", "r472", "r474", "r475", "r476", "r477", "r486", "r487", "r489", "r516", "r517", "r518", "r686", "r687", "r698", "r699", "r700", "r708", "r712" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r708", "r931", "r932", "r933", "r934", "r935", "r937" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
```

"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r279", "r280", "r281", "r282", "r283", "r285", "r286", "r287", "r359", "r368", "r468", "r494", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r572", "r681", "r708", "r710", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r721", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r884", "r885", "r886", "r887", "r930", "r933", "r934", "r935", "r936", "r937"] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Total financial liabilities", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": ["r931", "r932", "r936"] }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionTables"], "lang": { "en-us": { "role": { "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of amounts allocated to identifiable intangible assets", "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination." } } }, "auth_ref": [] }, "chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in each of five succeeding fiscal years. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, for Each of Five Succeeding Fiscal Years", "terseLabel": "Expected amortization expense for the remaining finite-lived assets for each of the five succeeding fiscal years" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r149", "r290", "r300", "r683"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r293", "r295", "r296", "r297", "r299", "r300", "r303", "r304", "r547", "r548", "r665"] }, "chrs_FiniteLivedIntangibleAssetsDerecognitionUponDisposalOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "FiniteLivedIntangibleAssetsDerecognitionUponDisposalOfBusiness", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in assets, excluding financial assets, lacking physical substance with a definite life, from derecognition upon disposal of business.", "label": "Finite-Lived Intangible Assets, Derecognition Upon Disposal Of Business", "terseLabel": "Finite-lived intangible asset, net" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r293", "r295", "r296", "r297", "r299", "r300", "r303", "r304", "r665"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-lived assets, net of accumulated amortization of $2,052 and $639, as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r547", "r900"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r785"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfInterestInProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GainLossOnSaleOfInterestInProjects", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Sale of Interest in Projects", "negatedLabel": "Gain on Sale Transaction, net (Note 6)", "terseLabel": "Gain (loss) on Sale Transactions, net (Note 6)", "documentation": "Gain (loss) included in earnings resulting from the sale of interest in projects." } } }, "auth_ref": ["r14", "r67"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",

"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on debt extinguishment", "terseLabel": "Loss on debt extinguishment", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r6", "r40", "r41"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r148", "r291", "r550", "r679", "r682", "r709", "r720", "r891", "r892"] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "label": "Goodwill, Written off Related to Sale of Business Unit", "terseLabel": "Goodwill, Written off", "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r292", "r682"] }, "chrs_GskAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "GskAgreementMember", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to GSK Agreement.", "label": "GSK Agreement [Member]", "terseLabel": "GSK Agreement" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset." } } }, "auth_ref": ["r665", "r905"] }, "chrs_ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of Impairment of out-license asset and remeasurement of CVR liability, net.", "label": "Impairment of Intangible Assets And Contingent Value Rights Liability", "terseLabel": "Impairment of out-license asset and remeasurement of CVR liability, net", "verboseLabel": "Net impairment charge" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-Lived", "verboseLabel": "Impairment charge", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": ["r294", "r863", "r904"] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "terseLabel": "In-process research and development", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": ["r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903"] },
"chrs_InProcessResearchAndDevelopmentSrf114Member": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "InProcessResearchAndDevelopmentSrf114Member", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to In-process research and development - SRF114.", "label": "In Process Research and Development SRF 114 [Member]", "terseLabel": "In-process research and development - SRF 114" } } }, "auth_ref": [] },
"chrs_InProcessResearchAndDevelopmentSrf388Member": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "InProcessResearchAndDevelopmentSrf388Member", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to In-process research and development - SRF388.", "label": "In Process Research and Development SRF 388 [Member]", "terseLabel": "In-process research and development - casdozokitug" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Pretax profit (loss)", "totalLabel": "Income (loss) before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r88", "r124", "r129", "r555", "r568", "r677", "r678", "r874", "r875", "r876", "r877", "r878"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails",
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r701", "r702"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails",
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r307", "r313", "r314", "r479", "r483", "r488", "r584", "r586", "r634", "r665", "r711", "r961"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails",
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r313", "r314", "r479", "r483", "r488", "r584", "r586", "r634", "r665", "r711", "r961"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r131", "r139", "r193", "r194", "r222", "r229", "r233", "r438", "r439", "r442", "r575", "r705"] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "presentation": [

"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": ["r5"] }, "chrs_IncreaseDecreaseInAccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "IncreaseDecreaseInAccruedCompensation", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued compensation.", "label": "Increase Decrease In Accrued Compensation", "terseLabel": "Accrued compensation" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued and other current and non-current liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r862"] }, "chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "IncreaseDecreaseInAccruedRebatesFeesAndReserve", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued rebates, fees and reserve.", "label": "Increase Decrease In Accrued Rebates Fees And Reserve", "terseLabel": "Accrued rebates, fees and reserves" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "TSA related operating assets and liabilities, net (Note 6)", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Other prepaid, current and non-current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid manufacturing", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Receivables", "negatedLabel": "Trade receivables, net", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "chrs_IncreaseInAmountOfSharesToBeIssuedAndSold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "IncreaseInAmountOfSharesToBeIssuedAndSold", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of increase in shares to be issued and sold.", "label": "Increase in Amount of Shares To be Issued and Sold", "terseLabel": "Increase in Amount of Shares To be Issued and Sold" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares", "terseLabel": "Restricted stock units", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met." } } }, "auth_ref": ["r201", "r202", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r217"] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "verboseLabel": "Shares issuable upon conversion of convertible notes", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": ["r205", "r206", "r217"] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Stock options, including shares subject to ESPP", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r200", "r201", "r203", "r217", "r392"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r293", "r298", "r302", "r683"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived assets - IPR&DIndefinite-lived assets - in-process research and development", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r290", "r302", "r683"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r293", "r298", "r302", "r683"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r752", "r762", "r772", "r796", "r804", "r808", "r816"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r814"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r744", "r820"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r744", "r820"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [

"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r744", "r820"] }, "chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents intangible assets, net and accrued and other current liabilities.", "label": "Intangible Assets, Net And Accrued And Other Current Liabilities [Member]", "terseLabel": "Intangible assets, net and accrued and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Total Intangible assets, net", "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets." } } }, "auth_ref": ["r889"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Expense, Operating and Nonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r222", "r224", "r227", "r230", "r233", "r504", "r678", "r679"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "positiveLabel": "Interest expense", "totalLabel": "Total Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r93", "r354", "r365", "r688", "r689"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Stated coupon interest", "verboseLabel": "Contractual interest", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r93", "r355", "r688", "r689"] }, "chrs_InterestExpenseInclusiveOfAmortizationOfDiscountAndIssuanceCostsOnRevenueParticipationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "InterestExpenseInclusiveOfAmortizationOfDiscountAndIssuanceCostsOnRevenueParticipationLiability", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Interest expense, inclusive of the amortization of discount and issuance costs.", "label": "Interest Expense, Inclusive Of Amortization Of Discount And Issuance Costs On Revenue Participation Liability", "terseLabel": "Interest expense, inclusive of the amortization of discount and issuance costs" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense [Member]", "terseLabel": "Interest expense", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": ["r15"] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of Components of Interest Expense", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestOnConvertibleDebtNetOfTax", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Interest on Convertible Debt, Net of Tax", "terseLabel": "Add interest expense on 2026 Convertible Notes, net of tax", "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash." } } }, "auth_ref": ["r198", "r204", "r217"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Interest Payable", "negatedLabel": "Less amount representing interest", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r119", "r955"] }, "chrs_InventoryCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "InventoryCurrentAndNoncurrent", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails"], "lang": { "en-us": { "role": { "documentation": "Inventory current and noncurrent.", "label": "Inventory Current And Noncurrent", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCurrentTable", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Current [Table]", "terseLabel": "Inventory Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureInventory"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r288"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryComponentsDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r849"] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryComponentsDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Gross", "totalLabel": "Total", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r853"] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLineItems", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Inventory [Line Items]", "terseLabel": "Inventory", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r154", "r668", "r720"] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Noncurrent", "terseLabel": "Inventory, non-current", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": ["r846"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryComponentsDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r851"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [

"http://www.coherus.com/role/DisclosureInventoryComponentsDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r850"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Inventory write-downs, net", "verboseLabel": "Inventory write-downs", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r289"] }, "chrs_IssuanceCostOfDebtIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "IssuanceCostOfDebtIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for issuance cost of debt.", "label": "Issuance Cost of Debt Incurred but Not yet Paid", "verboseLabel": "Financing issuance costs in accounts payable" } } }, "auth_ref": [] }, "chrs_IssuanceCostsOnRevenueParticipationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "IssuanceCostsOnRevenueParticipationLiability", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Issuance costs on the revenue participation liability.", "label": "Issuance Costs On Revenue Participation Liability", "terseLabel": "Issuance costs on revenue participation liability" } } }, "auth_ref": [] }, "chrs_JunshiBiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "JunshiBiosciencesMember", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Junshi Biosciences.", "label": "Junshi Biosciences", "terseLabel": "Junshi Biosciences" } } }, "auth_ref": [] }, "chrs_LeaseLiabilitiesOperatingAndFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "LeaseLiabilitiesOperatingAndFinancing", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents lease liabilities for both operating and financing leases.", "label": "Lease Liabilities, Operating and Financing", "terseLabel": "Lease liabilities, current" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r102", "r510"] }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdsAndLeaseholdImprovementsMember", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Leaseholds and Leasehold Improvements [Member]", "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement." } } }, "auth_ref": ["r102"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r18", "r70", "r71", "r72", "r74", "r75", "r76", "r77", "r177", "r276", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r457", "r460", "r461", "r496", "r609", "r676", "r739", "r921", "r944", "r945"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r85", "r123", "r566", "r720", "r866", "r888", "r938"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Deficit" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r72", "r146", "r177", "r276", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r457", "r460", "r461", "r496", "r720", "r921", "r944", "r945"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails"], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "verboseLabel": "Out-licenses", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": ["r54", "r435", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r927"] }, "chrs_LoanAgreementFundingFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "LoanAgreementFundingFeePercentage", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Loan agreement funding fee percentage.", "label": "Loan Agreement Funding Fee Percentage", "terseLabel": "Prepayment funding fee" } } }, "auth_ref": [] }, "chrs_LoanAgreementPrepaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "LoanAgreementPrepaymentFeePercentage", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Loan agreement prepayment fee percentage.", "label": "Loan Agreement Prepayment Fee Percentage", "terseLabel": "Prepayment fee" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "chrs_LongTermAndShortTermPurchaseCommitmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "LongTermAndShortTermPurchaseCommitmentsAmount", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term and short-term purchase commitment.", "label": "Long-Term And Short-Term Purchase Commitments, Amount", "totalLabel": "Certain firm purchase commitments" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Net carrying amount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r18", "r121", "r347", "r363", "r686", "r687", "r719", "r956"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025 - interest only", "verboseLabel": "2025 - interest only", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r9", "r180", "r352"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2027 - interest only", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r9", "r180", "r352"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "verboseLabel": "2026 - interest only", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r9", "r180", "r352"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "verboseLabel": "Remainder of 2024 - interest only", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r867"] }, "chrs_LongTermDebtMaturityAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "LongTermDebtMaturityAfterYearThree", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Three", "terseLabel": "2028 and thereafter - principal and interest" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Certain firm purchase commitments, Long-term", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment [Table Text Block]", "terseLabel": "Schedule of Non-cancelable Contractual Obligations", "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r18", "r911", "r912", "r913"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesFuturePaymentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2026ConvertibleNotesInterestExpenseComponentsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r18", "r39", "r911", "r912", "r913"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [
"http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r317", "r318", "r319", "r322", "r433", "r684", "r916", "r918"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [
"http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r317", "r318", "r319", "r322", "r433", "r684", "r916", "r918"] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual", "terseLabel": "Accrual related to legal Proceedings and Other Claims", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": ["r317", "r826"] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": {
"label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r236", "r693", "r723", "r726", "r924", "r958", "r962", "r963", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989"] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Investments in marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r848"] }, "chrs_MaximumAmountPaidCoDevelopmentActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "MaximumAmountPaidCoDevelopmentActivities", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the maximum paid amount for co-development activities.", "label": "Maximum Amount Paid, Co-development Activities", "terseLabel": "Maximum paid amount for co-development activities (per licensed compound)" } } }, "auth_ref": [] },
"chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "MaximumAntibodiesPartiallyExericsedUnderCommercializationOption", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum antibodies partially exercised under commercialization option", "label": "Maximum Antibodies Partially Exercised under Commercialization Option", "terseLabel": "Maximum antibodies partially exercised under commercialization option" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r318", "r319", "r320", "r321", "r388", "r433", "r477", "r545", "r583", "r585", "r593", "r601", "r602", "r652", "r653", "r654", "r655", "r658", "r662", "r663", "r680", "r690", "r703", "r712", "r713", "r717", "r718", "r724", "r923", "r946", "r947", "r948", "r949", "r950", "r951"] }, "chrs_MaximumNumberOfAntibodiesUnderForResearchOption": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "MaximumNumberOfAntibodiesUnderForResearchOption", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum number of antibodies under for research option", "label": "Maximum Number of Antibodies Under for Research Option", "terseLabel": "Maximum number of antibodies under for research option" } } }, "auth_ref": [] }, "chrs_McKessonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "McKessonMember", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "McKesson.", "label": "McKesson" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r788"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r788"

```
] }, "chrs_MilestonePaymentsAmountPerEachInstallment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "MilestonePaymentsAmountPerEachInstallment", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount per each installment of milestone payments under collaborative arrangements.", "label": "Milestone Payments, Amount Per Each Installment", "terseLabel": "Milestone payments, amount" } } }, "auth_ref": [] },
"chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "MinimumAntibodiesToBeCommercializedUnderCommercializationOption", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum antibodies to be commercialized under commercialization option", "label": "Minimum Antibodies to be Commercialized under Commercialization Option", "terseLabel": "Minimum antibodies to be commercialized under commercialization option" } } }, "auth_ref": [] },
"chrs_MinimumNetSalesConvenantLevelAgreedToBeMaintainedOverPastYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "MinimumNetSalesConvenantLevelAgreedToBeMaintainedOverPastYear", "crdr": "credit", "presentation": [ "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum amount of net sales covenant level to be maintained for trailing twelve months.", "label": "Minimum Net Sales Convenant Level Agreed to be Maintained Over Past Year", "terseLabel": "Minimum net sales convenant level agreed to be maintained over past year" } } }, "auth_ref": [] }, "chrs_MinimumNumberOfAntibodiesUnderCommercializationOption": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "MinimumNumberOfAntibodiesUnderCommercializationOption", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum Number of Antibodies under Commercialization option", "label": "Minimum Number of Antibodies under Commercialization option" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [
"r807" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r926" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r815" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r236", "r693", "r723", "r726", "r924", "r958", "r962", "r963", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r789" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r174" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r174" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r96", "r97", "r98" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "netLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r91", "r98", "r125", "r144", "r159", "r162", "r166", "r177", "r184", "r186", "r187", "r188", "r189", "r190", "r193", "r194", "r214", "r276", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r446", "r453", "r471", "r496", "r570", "r631", "r647", "r648", "r737", "r921" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToParentDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToParentDiluted", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent, Diluted", "totalLabel": "Numerator for diluted net income (loss) per share", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToParentDilutedAbstract", "presentation": [ "http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [
```

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r788"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r752", "r762", "r772", "r796", "r804"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r779"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r778"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r796"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r815"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r815"] }, "us-gaap_NonrecurringAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrecurringAdjustmentAxis", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Nonrecurring Adjustment [Axis]", "documentation": "Information by nonrecurring adjustment directly attributable to business combination included in pro forma revenue and earnings." } } }, "auth_ref": ["r12"] }, "us-gaap_NonrecurringAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrecurringAdjustmentDomain", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails"], "lang": { "en-us": { "role": { "label": "Nonrecurring Adjustment [Domain]", "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": ["r12"] }, "chrs_NumberOfEventsInDefault": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "NumberOfEventsInDefault", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of events in default.", "label": "Number Of Events in Default", "terseLabel": "Number of events in default" } } }, "auth_ref": [] }, "chrs_OperatingAndFinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.", "label": "Operating and Finance Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, non-current" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r129", "r677", "r874", "r875", "r876", "r877", "r878"] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Axis]", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": ["r42", "r60", "r61", "r114"] }, "us-gaap_OptionIndexedToIssuersEquityEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityEquityTable", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Equity [Table]", "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as equity. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date." } } }, "auth_ref": ["r42", "r60", "r61", "r114"] }, "us-gaap_OptionIndexedToIssuersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityLineItems", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Operations" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r71"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets, non-current", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r150"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments, net of tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r3", "r571"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive loss, net of tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r11", "r17", "r160", "r163", "r167", "r190", "r497", "r498", "r503", "r552", "r571", "r855", "r856"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r157", "r158", "r275"] }, "chrs_OtherFeesCoPayAssistanceAndReturnsMember": { "xbrltype": "domainItemType", "nsuri":

"http://www.coherus.com/20240930", "localname": "OtherFeesCoPayAssistanceAndReturnsMember", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails
], "lang": { "en-us": { "role": { "documentation": "Other fees, co-pay assistance and returns.", "label": "Other Fees, Co-pay Assistance and Returns"
} } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities,
Noncurrent", "terseLabel": "Other liabilities, non-current", "totalLabel": "Total Other liabilities, non-current", "documentation": "Amount of
liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r75"] }, "us-
gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncurrentLiabilitiesTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"], "lang":
{ "en-us": { "role": { "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Liabilities, Non-current",
"documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit",
"presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label":
"Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "documentation": "Amount of income (expense) related to
nonoperating activities, classified as other." } } }, "auth_ref": ["r94"] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit",
"presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label":
"Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash adjustments, net", "documentation": "Other cash or noncash
adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash
flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting
period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r788"] },
"us-gaap_OtherSundryLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherSundryLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails"], "lang": { "en-us": { "role": { "label":
"Other Sundry Liabilities, Noncurrent", "terseLabel": "Other", "documentation": "Obligations not otherwise itemized or categorized in the
footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet
date." } } }, "auth_ref": ["r75", "r120"] }, "chrs_OutLicensesWithGrkMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "OutLicensesWithGrkMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": {
"role": { "documentation": "Represents the information pertaining to Out-license - GSK.", "label": "Out Licenses with GRK [Member]",
"terseLabel": "Out-license - GSK" } } }, "auth_ref": [] }, "chrs_OutLicensesWithNovartisInstitutesMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.coherus.com/20240930", "localname": "OutLicensesWithNovartisInstitutesMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails",
"http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation":
"Represents the information pertaining to Out-license - Novartis Institutes.", "label": "Out Licenses with Novartis Institutes [Member]",
"terseLabel": "Novartis Institutes" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],
"lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous
Compensation Amount" } } }, "auth_ref": ["r750", "r760", "r770", "r802"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount",
"terseLabel": "Compensation Amount" } } }, "auth_ref": ["r753", "r763", "r773", "r805"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel":
"Name" } } }, "auth_ref": ["r753", "r763", "r773", "r805"] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": [
"http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]",
"documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs
Performance Disclosure" } } }, "auth_ref": ["r777"] }, "chrs_PaymentForCappedCallTransactions": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.coherus.com/20240930", "localname": "PaymentForCappedCallTransactions", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": {
"documentation": "The amount of payment made for entering into capped call transactions.", "label": "Payment for Capped Call Transactions",
"terseLabel": "Payment for capped call transactions" } } }, "auth_ref": [] },
"chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname":
"PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails
], "lang": { "en-us": { "role": { "documentation": "Payments and customer credits issued from reserve in discounts and allowances constitute
variable consideration.", "label": "Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable
Consideration", "negatedLabel": "Payments and customer credits issued" } } }, "auth_ref": [] }, "chrs_PaymentsForMilestoneBasedLicenseFee": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PaymentsForMilestoneBasedLicenseFee", "crdr":
"credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": {
"documentation": "The cash outflow associated with milestone based license fee payment.", "label": "Payments For Milestone Based License Fee",
"negatedLabel": "Milestone based license fee payment to Junshi Biosciences" } } }, "auth_ref": [] }, "us-
gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments for
(Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities, net", "documentation": "Amount of cash (inflow) outflow
from investing activities classified as other." } } }, "auth_ref": ["r829", "r858"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs",
"negatedLabel": "Less commissions and fees", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity
security." } } }, "auth_ref": ["r24"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
"crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": {
"role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Taxes paid related to net share settlement",
"documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } }
}, "auth_ref": ["r172"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to
Acquire Marketable Securities", "negatedLabel": "Purchases of investments in marketable securities", "documentation": "Amount of cash outflow
for purchase of marketable security." } } }, "auth_ref": ["r883"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [
"r787"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer
Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r787"] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid
Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r779"] }, "ecd_PeoMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r796"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r789"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r778"] }, "chrs_PercentageOfCapPriceCappedCallTransactions": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PercentageOfCapPriceCappedCallTransactions", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of premium on cap price.", "label": "Percentage of Cap Price, Capped Call Transactions", "terseLabel": "Percentage of cap price" } } }, "auth_ref": [] }, "chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of option fee to be paid on partial exercise of commercialization option", "label": "Percentage of Option Fee to be Paid on Partial Exercise of Commercialization Option", "terseLabel": "Percentage of option fee to be paid on partial exercise of commercialization option" } } }, "auth_ref": [] }, "chrs_PercentageOfPremiumOnConvertibleNote": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PercentageOfPremiumOnConvertibleNote", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of premium on convertible note.", "label": "Percentage Of Premium On Convertible Note", "terseLabel": "Convertible notes, premium percentage" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "verboseLabel": "Performance Condition PSO", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r780"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r824"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r779"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r78", "r366"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r78", "r611"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r78", "r366"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r78", "r611", "r629", "r992", "r993"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Other prepaids and current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r854"] }, "chrs_PrepaidExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PrepaidExpensesMember", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to prepaid expenses.", "label": "Prepaid Expenses [Member]", "terseLabel": "Prepaid financial instrument in Prepaid manufacturing" } } }, "auth_ref": [] }, "chrs_PrepaidManufacturingExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PrepaidManufacturingExpenseCurrent", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Prepaid Manufacturing current.", "label": "Prepaid Manufacturing Expense Current", "terseLabel": "Prepaid manufacturing", "verboseLabel": "Prepayment made for manufacturing services" } } }, "auth_ref": [] }, "chrs_PrepaymentsMadeToCmoForManufacturingServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PrepaymentsMadeToCmoForManufacturingServices", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents prepayments made to a CMO for manufacturing services.", "label": "Prepayments Made to CMO For Manufacturing Services", "terseLabel": "Prepayments made to a CMO for manufacturing services for UDENYCA" } } }, "auth_ref": [] }, "chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents prepayments made to a CMO for other research and development program.", "label": "Prepayments made to a CMO For Other Research And Development Pipeline Program", "terseLabel": "Prepayments made to a CMO For Other Research And Development Pipeline Program" } } }, "auth_ref": [] }, "chrs_PrepaymentsRelatedToSaleTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PrepaymentsRelatedToSaleTransaction", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of prepayments made related to sale transaction.", "label": "Prepayments Related to Sale Transaction", "terseLabel": "Payment related to sale transaction" } } }, "auth_ref": [] }, "chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Principal amount of notes converted into shares of common stock at conversion rate.", "label": "Principal Amount Of Notes Converted Into Shares Of Common Stock At Conversion Rate", "terseLabel": "Principal amount of notes converted into shares" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "verboseLabel": "Net proceeds from offering", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r23"] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds, net of original issuance discount", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": ["r171"] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Cash received from Sale", "documentation": "The cash inflow associated with the amount received from

the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": ["r22"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "chrs_ProceedsFromIssuanceOfCommonStockGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockGross", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity, before stock issuance costs.", "label": "Proceeds from Issuance of Common Stock, Gross", "verboseLabel": "Gross proceeds" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from 2029 Term Loan, net of debt discount & issuance costs", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r860"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Net proceeds, after deducting the Underwriters' discounts and commissions and offering expenses", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r4", "r596"] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": ["r830", "r859"] }, "chrs_ProceedsFromRevenuePurchaseAndSaleAgreementNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ProceedsFromRevenuePurchaseAndSaleAgreementNet", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from revenue purchase and sale agreement.", "label": "Proceeds From Revenue Purchase And Sale Agreement Net", "verboseLabel": "Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of investments in marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sale of investments in marketable securities", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r21", "r170", "r243", "r274"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r4", "r13"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from purchase under the employee stock purchase plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": ["r4"] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": ["http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "terseLabel": "Other revenue", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": ["r925"] }, "us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductLiabilityContingencyLossExposureNotAccruedBestEstimate", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate", "terseLabel": "Claims related to certain sales of UDENYCA from October 2020 through December 2021", "documentation": "Best estimate of the loss exposure for a reasonably possible liability for product liability damages for which no accrual has been recorded." } } }, "auth_ref": ["r917", "r919", "r920"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails", "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Total net product revenue", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r691"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails", "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r234", "r546", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r666", "r691", "r722", "r724", "r725", "r727", "r728", "r919", "r920", "r924", "r958", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989"] }, "chrs_ProductPipelineNumberOfDrugCandidates": { "xbrltype": "integerItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ProductPipelineNumberOfDrugCandidates", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of drug candidates in the product pipeline.", "label": "Product pipeline, Number of Drug Candidates", "terseLabel": "Product pipeline, number of product candidates" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails", "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r234", "r546", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r666", "r691", "r722", "r724", "r725", "r727", "r728", "r919", "r920", "r924", "r958", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r144", "r159", "r162", "r173", "r177", "r184", "r190", "r193", "r194", "r276", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r446", "r453", "r455", "r458", "r459", "r471", "r496", "r555", "r569", "r598", "r631", "r647", "r648", "r706", "r707", "r738", "r857", "r921"] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedLabel": "Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": ["r831", "r836", "r909"] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "presentation": [

"http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "totalLabel": "Property and equipment, net", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": ["r836", "r907"] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "terseLabel": "Total property and equipment", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": ["r828", "r847", "r908"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r8", "r510"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment, Net", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r510"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r510", "r556", "r567", "r720"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r8"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r102", "r510"] }, "chrs_ProvisionRelatedToSalesMadeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ProvisionRelatedToSalesMadeAbstract", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Provision related to sales made in:" } } }, "auth_ref": [] }, "chrs_ProvisionRelatedToSalesMadeInPriorPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ProvisionRelatedToSalesMadeInPriorPeriod", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "documentation": "Represents provision related to sales made in prior period.", "label": "Provision Related to Sales Made in Prior Period", "terseLabel": "Prior period - increase (decrease)" } } }, "auth_ref": [] }, "chrs_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "PublicOfferingMember", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to public offering.", "label": "Public Offering" } } }, "auth_ref": [] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryAxis", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": ["r852"] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": ["r852"] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Obligation", "totalLabel": "Total obligations", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Obligation, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInSecondYear", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Obligation, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInThirdYear", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Obligation, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"], "lang": { "en-us": { "role": { "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024", "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r777"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r777"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r318", "r319", "r320", "r321", "r381", "r388", "r419", "r420", "r421", "r433", "r477", "r519", "r528", "r545", "r583", "r585", "r593", "r601", "r602", "r652", "r653", "r654", "r655", "r658", "r662", "r663", "r680", "r690", "r703", "r712", "r713", "r717", "r718", "r724", "r731", "r914", "r923", "r934", "r947", "r948", "r949", "r950", "r951"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [

"http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r318", "r319", "r320", "r321", "r381", "r388", "r419", "r420", "r421", "r433", "r477", "r519", "r528", "r545", "r583", "r585", "r593", "r601", "r602", "r652", "r653", "r654", "r655", "r658", "r662", "r663", "r680", "r690", "r703", "r712", "r713", "r717", "r718", "r724", "r731", "r914", "r923", "r934", "r947", "r948", "r949", "r950", "r951"] }, "chrs_RebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RebatesMember", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "documentation": "Rebates.", "label": "Rebates" } } }, "auth_ref": [] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": ["r80", "r86"] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current", "terseLabel": "Trade receivables, net", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": ["r720"] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "terseLabel": "Trade Receivables", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": ["r239", "r240", "r241", "r242", "r880"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r745", "r755", "r765", "r797"] }, "chrs_RegulatoryMilestonesEligibleToPay": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RegulatoryMilestonesEligibleToPay", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of regulatory milestones eligible to pay.", "label": "Regulatory Milestones Eligible to Pay", "terseLabel": "Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products" } } }, "auth_ref": [] }, "chrs_ReimbursableCostsForBusinessSupportServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ReimbursableCostsForBusinessSupportServices", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of reimbursable costs for business support services.", "label": "Reimbursable Costs For Business Support Services", "terseLabel": "Reimbursable costs" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "negatedLabel": "Repayment of 2027 Term Loans, premiums and exit fees", "terseLabel": "Outstanding amount paid off", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r861"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r178", "r179", "r338", "r367", "r512", "r529", "r558", "r671", "r672"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r434", "r665", "r678", "r952"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "verboseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ReserveForDiscountsAndAllowancesConstituteVariableConsideration", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "documentation": "Reserve for discounts and allowances constitute variable consideration.", "label": "Reserve For Discounts And Allowances Constitute Variable Consideration", "periodEndLabel": "Activities and reserve balance, ending balance", "periodStartLabel": "Activities and reserve balance, beginning balance" } } }, "auth_ref": [] }, "chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "documentation": "Reserve for sales discounts and allowances constitute variable consideration.", "label": "Reserve For Sales Discounts And Allowances Constitute Variable Consideration", "verboseLabel": "Current period" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r746", "r756", "r766", "r798"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r747", "r757", "r767", "r799"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r754", "r764", "r774", "r806"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r845", "r864", "r953", "r957"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomeL], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r82", "r109", "r565", "r590", "r592", "r597", "r612", "r720"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r142", "r181", "r182", "r183", "r185", "r190", "r192", "r194", "r277", "r278", "r305", "r440", "r441", "r443", "r444", "r445", "r447", "r452", "r453", "r462", "r464", "r465", "r467", "r469", "r508", "r509", "r587", "r589", "r599", "r992"] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "terseLabel": "Income under TSA", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": ["r132", "r928"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Net revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r127", "r128", "r222", "r225", "r226", "r231", "r233", "r234", "r235", "r236", "r378", "r379", "r546"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureRevenue"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r140", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r380"] }, "chrs_RevenueParticipationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RevenueParticipationLiability", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of revenue participation liability.", "label": "Revenue Participation Liability", "terseLabel": "Revenue participation liability" } } }, "auth_ref": [] }, "chrs_RevenuePurchaseAndSaleAgreementCertainConditionsPurchasePriceMultiplier": { "xbrltype": "pureItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RevenuePurchaseAndSaleAgreementCertainConditionsPurchasePriceMultiplier", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Revenue Purchase and Sale Agreement purchase price.", "label": "Revenue Purchase and Sale Agreement, Certain Conditions, Purchase Price, Multiplier", "terseLabel": "Purchase price multiplier" } } }, "auth_ref": [] }, "chrs_RevenuePurchaseAndSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RevenuePurchaseAndSaleAgreementMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables"], "lang": { "en-us": { "role": { "documentation": "Represents information pertains to Revenue Purchase and sale agreement.", "label": "Revenue Purchase and Sale Agreement" } } }, "auth_ref": [] }, "chrs_RevenuePurchaseAndSaleAgreementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RevenuePurchaseAndSaleAgreementPolicyPolicyTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "The description of accounting policy for revenue purchase and sale agreement.", "label": "Revenue Purchase And Sale Agreement, Policy [Policy Text Block]", "terseLabel": "Revenue Purchase and Sale Agreement" } } }, "auth_ref": [] }, "chrs_RevenuePurchaseAndSaleAgreementPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RevenuePurchaseAndSaleAgreementPurchasePrice", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Revenue Purchase and Sale Agreement purchase price.", "label": "Revenue Purchase and Sale Agreement, Purchase Price", "terseLabel": "Revenue Purchase and Sale Agreement, Purchase price" } } }, "auth_ref": [] }, "chrs_RevenuePurchaseAndSaleAgreementRightToReceivePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RevenuePurchaseAndSaleAgreementRightToReceivePercent", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The percent to be received pertaining to the sales of the companies products and services.", "label": "Revenue Purchase and Sale Agreement, Right to Receive, Percent", "terseLabel": "Revenue payment, Percentage of U.S. net sales" } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RoyaltyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyAgreementsMember", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Royalty Agreements [Member]", "terseLabel": "Royalty Fee Derivative Liability", "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": ["r54", "r435", "r894", "r895", "r896", "r897", "r899", "r900", "r902", "r903", "r927"] }, "chrs_RoyaltyParticipationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RoyaltyParticipationLiability", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementSummaryOfRevenueParticipationLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of Obligations related to royalty participation.", "label": "Royalty Participation Liability", "totalLabel": "Total" } } }, "auth_ref": [] }, "chrs_RoyaltyParticipationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RoyaltyParticipationLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe], "lang": { "en-us": { "role": { "documentation": "Amount of obligations related to royalty participation, classified as current.", "label": "Royalty Participation Liability, Current", "terseLabel": "Revenue participation liability, current (Note 8)", "verboseLabel": "Royalty participation liability, current" } } }, "auth_ref": [] }, "chrs_RoyaltyParticipationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "RoyaltyParticipationLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementClassificationOnCondensedConsolidatedBalanceShe], "lang": { "en-us": { "role": { "documentation": "Amount of obligations related to royalty participation, classified as noncurrent.", "label": "Royalty Participation Liability, Noncurrent", "terseLabel": "Revenue participation liability, non-current (Note 8)", "verboseLabel": "Royalty participation liability, non-current" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r815"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r815"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "totalLabel": "Net proceeds after commissions and fees", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Sale of

Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "chrs_SalesMilestonesEntitled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SalesMilestonesEntitled", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of sales milestones entitled.", "label": "Sales Milestones Entitled", "terseLabel": "Sales milestones" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "terseLabel": "Net Product Revenue", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r236", "r832"] }, "us-gaap_ScenarioPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScenarioPlanMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Scenario, Plan [Member]", "documentation": "The scenario under which facts represent plans as distinct from actual." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r195", "r389", "r826", "r871"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": ["http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "terseLabel": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": ["r80", "r86", "r238", "r881"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetIncomel], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r30"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Income (loss) Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r30"] }, "chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureInventoryTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of balance sheet classification of Inventory.", "label": "Schedule Of Balance Sheet Classification Of Inventory Table [Text Block]", "terseLabel": "Schedule of Balance Sheet Classification" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails", "http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails", "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": ["r48", "r50", "r450"] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Company's Debt Obligations", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of Cash and cash equivalents, marketable securities and restricted cash", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails", "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r454"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of Basic and Diluted Net Income Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r873"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails", "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and

Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured on a Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r931", "r932"] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill and Intangible Assets, Net", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": ["r890", "r893"] }, "chrs_ScheduleOfInventoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ScheduleOfInventoryTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureInventoryTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of inventories.", "label": "Schedule of Inventory [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Future Payments on Debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r9"] }, "chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of product sales discounts and allowances.", "label": "Schedule Of Product Sales Discounts And Allowances Table [Text Block]", "terseLabel": "Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r8", "r510"] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionTables"], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of purchase price allocation to the estimated fair value of the net assets acquired", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r110"] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": ["r16", "r116", "r957"] }, "chrs_ScheduleOfRoyaltyParticipationLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ScheduleOfRoyaltyParticipationLiabilityTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of royalty participation liability.", "label": "Schedule Of Royalty Participation Liability [Table Text Block]", "terseLabel": "Schedule of royalty participation liability" } } }, "auth_ref": [] }, "chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ScheduleOfSettlementsUnderSharesOfferingTableTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of shares offering settlements.", "label": "Schedule of Settlements Under Shares Offering [Table Text Block]", "terseLabel": "Schedule of Settlements Under the ATM Offering" } } }, "auth_ref": [] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": ["r31", "r32", "r33", "r34", "r62", "r115"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r740"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r742"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r92"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Term years", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r704"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Share based payment options grants", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r402"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails", "http://www.coherus.com/role/DisclosureStockBasedCompensationTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411",

"r412", "r413", "r414", "r415", "r418", "r419", "r420", "r421", "r422"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r390", "r397", "r416", "r417", "r418", "r419", "r422", "r428", "r429", "r430", "r431"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesCappedCallTransactionsNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Closing stock, price per share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Share price", "verboseLabel": "Share price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "chrs_SharesOfferingAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SharesOfferingAggregateAmount", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate amount of shares to be offered.", "label": "Shares Offering, Aggregate Amount", "terseLabel": "Shares Offering, Aggregate Amount" } } }, "auth_ref": [] }, "chrs_SharesOfferingAggregateAmountDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SharesOfferingAggregateAmountDecrease", "crdr": "debit", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "The decrease in aggregate amount of shares to be offered.", "label": "Shares Offering, Aggregate Amount, Decrease", "terseLabel": "Shares Offering, Aggregate Amount, Decrease" } } }, "auth_ref": [] }, "chrs_SharesOfferingUnderwritersOptionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SharesOfferingUnderwritersOptionTerm", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "The period for exercise of option to purchase additional shares by underwriters.", "label": "Shares Offering, Underwriters Option, Term", "terseLabel": "Term of share offering" } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Taxes paid related to net share settlement of RSUs (in shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "chrs_ShortTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ShortTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the short-term purchase commitment.", "label": "Short-Term Purchase Commitment, Amount", "terseLabel": "Certain firm purchase commitments, Short-term" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r79", "r83", "r84", "r142", "r164", "r165", "r166", "r181", "r182", "r183", "r185", "r190", "r192", "r194", "r223", "r277", "r278", "r305", "r369", "r440", "r441", "r443", "r444", "r445", "r447", "r452", "r453", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r497", "r499", "r500", "r501", "r502", "r503", "r508", "r509", "r511", "r571", "r587", "r588", "r589", "r599", "r649"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r181", "r182", "r183", "r223", "r509", "r546", "r595", "r600", "r603", "r604", "r605", "r606", "r607", "r608", "r611", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r624", "r625", "r626", "r627", "r628", "r630", "r632", "r633", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r649", "r732"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r195", "r389", "r826", "r827", "r871"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r181", "r182", "r183", "r223", "r237", "r509", "r546", "r595", "r600", "r603", "r604", "r605", "r606", "r607", "r608", "r611", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r624", "r625", "r626", "r627", "r628", "r630", "r632", "r633", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r649", "r732"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r749", "r759", "r769", "r801"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Stock Issued", "verboseLabel": "Non-cash employee bonuses settled in common stock", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": ["r27", "r28", "r29"] }, "chrs_StockIssuedDuringPeriodAcquisitions": { "xbrltype": "stringItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockIssuedDuringPeriodAcquisitions", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period on acquisitions", "label": "Stock Issued During Period, Acquisitions", "terseLabel": "Issuance of common stock in connection with Surface Acquisition:(1)" } } }, "auth_ref": [] }, "chrs_StockIssuedDuringPeriodPartialPayoutBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockIssuedDuringPeriodPartialPayoutBonus", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period in lieu of bonus.", "label": "Stock Issued During Period, Partial Payout, Bonus", "terseLabel": "Issuance of common stock - partial payout of 2023 bonus in RSUs" } } }, "auth_ref": [] }, "chrs_StockIssuedDuringPeriodPartialPayoutBonusShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockIssuedDuringPeriodPartialPayoutBonusShares", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of bonus.", "label": "Stock Issued During Period, Partial Payout, Bonus, Shares", "terseLabel": "Issuance of common stock - partial payout of 2023 bonus in RSUs (in shares)" } } }, "auth_ref": [] }, "chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of accelerated vesting of equity awards.", "label": "Stock Issued During Period, Shares, Accelerated Vesting of Equity Awards", "terseLabel": "Accelerated vesting of equity awards (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"StockIssuedDuringPeriodSharesAcquisitions", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance to Surface shareholders for acquisition (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": ["r78", "r79", "r109"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under the employee stock purchase plan (\"ESPP\") (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r11", "r78", "r79", "r109"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock under Offering, net of issuance costs (in shares)", "verboseLabel": "Common stock, shares issued and sold", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r11", "r78", "r79", "r109", "r596", "r649", "r659"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock upon vesting of restricted stock units (\"RSUs\") (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r11", "r109"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r11", "r78", "r79", "r109", "r403"] }, "chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Number of shares settled related to taxes paid related to net share settlement of equity awards during the period.", "label": "Stock Issued During Period, Shares, Taxes Paid Related to Net Share Settlement of Equity Awards", "negatedLabel": "Taxes paid related to net share settlement of equity awards (in shares)" } } }, "auth_ref": [] }, "chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock related to accelerated vesting of equity awards issued during the period.", "label": "Stock Issued During Period, Value, Accelerated Vesting of Equity Awards", "terseLabel": "Accelerated vesting of equity awards" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance to Surface shareholders for acquisition", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": ["r11", "r79", "r83", "r84", "r109"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under the employee stock purchase plan (\"ESPP\")", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r11", "r78", "r79", "r109"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock under Offering, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r11", "r78", "r79", "r109", "r599", "r649", "r659", "r738"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock upon vesting of restricted stock units (\"RSUs\")", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": ["r11", "r78", "r79", "r109"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r11", "r79", "r83", "r84", "r109"] }, "chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards", "crdr": "debit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock settled related to taxes paid related to net share settlement of equity awards during the period.", "label": "Stock Issued During Period, Value, Taxes Paid Related to Net Share Settlement of Equity Awards", "negatedLabel": "Taxes paid related to net share settlement of equity awards" } } }, "auth_ref": [] }, "chrs_StockholdersDeficitTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "StockholdersDeficitTextBlock", "presentation": [
"http://www.coherus.com/role/DisclosureStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Disclosure containing information regarding Stockholders' Deficit.", "label": "Stockholders Deficit", "terseLabel": "Stockholders' Deficit" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending Balances", "periodStartLabel": "Beginning Balances", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r79", "r83", "r84", "r101", "r613", "r629", "r650", "r651", "r720", "r739", "r866", "r888", "r938", "r992"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' deficit:" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.coherus.com/role/DisclosureBalanceSheetComponents"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r844"] }, "chrs_SurfaceGlaxosmithklineAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SurfaceGlaxosmithklineAgreementMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Surface GSK agreement.", "label": "Surface GlaxoSmithKline Agreement [Member]", "terseLabel": "Surface GSK Agreement" } } }, "auth_ref": [] }, "chrs_SurfaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SurfaceMember", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Surface.", "label": "Surface [Member]", "terseLabel": "Surface" } } }, "auth_ref": [] }, "chrs_SurfaceOncologyInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930",

"localname": "SurfaceOncologyInc.Member", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAmountsAllocatedToIdentifiableIntangibleAssetsDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionEstimatedFairValueOfNetAssetsAcquiredDetails",
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionUnauditedProFormaSummaryOfOperationsDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Surface Oncology, Inc.", "label": "Surface Oncology, Inc. [Member]", "terseLabel": "Surface Acquisition" } } }, "auth_ref": [] }, "chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SurfaceSrf114ProprietaryDrugProductAgreementMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Surface's SRF114 proprietary drug product candidate.", "label": "Surface SRF114 Proprietary Drug Product Agreement [Member]", "terseLabel": "Surface's SRF114 proprietary drug product candidate" } } }, "auth_ref": [] },
"chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "SurfaceSrf388ProprietaryDrugProductAgreementMember", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Surface's SRF388 proprietary drug product candidate.", "label": "Surface SRF388 Proprietary Drug Product Agreement [Member]", "terseLabel": "Surface's SRF388 proprietary drug product candidate" } } }, "auth_ref": [] },
"ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r795"] }, "chrs_TermLoanGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "TermLoanGross", "crdr": "credit", "presentation": [
"http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Term Loan, gross.", "label": "Term Loan Gross", "terseLabel": "2029 Term Loan, gross" } } }, "auth_ref": [] },
"chrs_TermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "TermLoansMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoanNarrativeDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilities2027TermLoansComponentsOfInterestExpenseDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails",
"http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables",
"http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents term loans.", "label": "2027 Term Loans" } } }, "auth_ref": [] }, "chrs_TermLoansPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "TermLoansPayableNoncurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Term Loans Payable, Noncurrent", "terseLabel": "Term loans, non-current" } } }, "auth_ref": [] },
"srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r879", "r943"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.coherus.com/role/DisclosureStockBasedCompensationStockBasedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "chrs_ToripalimabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "ToripalimabMember", "presentation": [
"http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
"http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents toripalimab.", "label": "Toripalimab", "terseLabel": "Toripalimab (LOQTORZI)", "verboseLabel": "LOQTORZI" } } }, "auth_ref": [] },
"ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r787"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r794"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r814"] },
"ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r816"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.coherus.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "verboseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
"http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r359", "r368", "r468", "r494", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r572", "r708", "r710", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r721", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r884", "r885", "r886", "r887", "r930", "r933", "r934", "r935", "r936", "r937"] },
"chrs_TransitionServicesAgreementPayablesAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "TransitionServicesAgreementPayablesAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of transition services agreement payables classified as current.", "label": "Transition Services Agreement Payables and Other Accrued Liabilities Current", "terseLabel": "TSA payables and other accrued liabilities (Note 6)", "verboseLabel": "TSA payables and other accrued liabilities" } } }, "auth_ref": [] }, "chrs_TransitionServicesAgreementReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "TransitionServicesAgreementReceivableCurrent", "crdr": "debit", "presentation": [
"http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails",
"http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of transition services agreement receivable current.", "label": "Transition Services Agreement Receivable Current", "terseLabel": "TSA receivables, net (Note 6)", "verboseLabel": "TSA receivables, net" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r817"] },
"ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r818"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r818"] },
"ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r816"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r816"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r819"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date",

"terseLabel": "Termination Date" } } }, "auth_ref": ["r817"] }, "chrs_TwoThousandTwentyNineTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "TwoThousandTwentyNineTermLoansMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanFuturePaymentsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoanNarrativeDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilities2029TermLoansComponentsOfInterestExpenseDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesSummaryOfDebtObligationsDetails", "http://www.coherus.com/role/DisclosureFinancialLiabilitiesTables"], "lang": { "en-us": { "role": { "documentation": "Represents 2029 term loans.", "label": "Two Thousand Twenty Nine Term Loans [Member]", "terseLabel": "2029 Term Loans" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r454"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails", "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r674", "r698", "r954"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails", "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r674", "r698", "r700", "r708", "r954"] }, "chrs_UdenycaAndLoqtorziMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "UdenycaAndLoqtorziMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Udenyca and Loqtorzi.", "label": "Udenyca and Loqtorzi [Member]", "terseLabel": "UDENYCA and LOQTORZI" } } }, "auth_ref": [] }, "chrs_UdenycaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "UdenycaMember", "presentation": ["http://www.coherus.com/role/DisclosureFinancialLiabilitiesRevenuePurchaseAndSaleAgreementNarrativeDetails", "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to the product UDENYCA.", "label": "Udenyca [Member]", "terseLabel": "UDENYCA" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r813"] }, "chrs_UnpaidTransactionCostsAndRetentionBonusesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "UnpaidTransactionCostsAndRetentionBonusesPayable", "crdr": "credit", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of unpaid transaction costs and retention bonuses committed to pay.", "label": "Unpaid Transaction Costs and Retention Bonuses Payable", "terseLabel": "Retention bonus" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r35", "r36", "r37", "r134", "r136", "r137", "r138"] }, "chrs_VaccinexLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "VaccinexLicenseAgreementMember", "presentation": ["http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the Vaccinex License Agreement.", "label": "Vaccinex License Agreement [Member]", "terseLabel": "Vaccinex License Agreement" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r783"] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "auth_ref": ["r477", "r528", "r662", "r663", "r712", "r946", "r948", "r951"] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "totalLabel": "Denominator for diluted net income (loss) income per share", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": ["r873"] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Add effect of potential dilutive securities:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (In shares)", "verboseLabel": "Weighted-average common shares outstanding - Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r198", "r217"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net income (loss) per share:", "verboseLabel": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (In shares)", "verboseLabel": "Weighted-average common shares outstanding - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r197", "r217"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": ["http://www.coherus.com/role/DisclosureNetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator:" } } }, "auth_ref": [] }, "chrs_WeightedAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "WeightedAveragePricePerShare", "presentation": ["http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted-average price per share.", "label": "Weighted-average Price Per Share", "terseLabel": "Weighted-average price per share" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted

in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r781"] }, "chrs_YusimryImmunologyFranchiseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "YusimryImmunologyFranchiseMember", "presentation": ["http://www.coherus.com/role/DisclosureAcquisitionAndDispositionAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureBalanceSheetComponentsIntangibleAssetsNetDetails", "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails", "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to YUSIMRY immunology franchise.", "label": "YUSIMRY Immunology Franchise [Member]", "terseLabel": "YUSIMRY Sale" } } }, "auth_ref": [] }, "chrs_YusimryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "YusimryMember", "presentation": ["http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to the product YUSIMRY.", "label": "YUSIMRY" } } }, "auth_ref": [] }, "chrs_YusimryProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coherus.com/20240930", "localname": "YusimryProductMember", "presentation": ["http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Yusimry product.", "label": "Yusimry Product [Member]", "terseLabel": "YUSIMRY" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "44", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-44" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "48", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-48" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "48", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-48" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-51" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-52" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-53" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "54", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-54" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-

1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",

"Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r479": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99",

"Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976",

"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",

"Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r772": { "role":

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r826": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r827": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r834": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r977": {

"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 92 0001558370-24-014648-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-014648-xbrl.zip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|> (Y";AUPZ6Y5>W/5@JG@9 M[6!Z M"09;HJR=KB1"&(4;3&8<5!FQ1= ZCZ@>I+0&(P\-2[YR'>R47R4&IQ M"4Y7*7AJ0=0)6^V'4!YY7@.SY'5JP';H@4#9'0)&[Y/IF':6]G]3'G,/)H M6^*..:%.^;_4)5FHS)6#52K_0;7:YI5&&;9\8=. M7MF@!>VT+I13<;.-1,R>0#!AJ<=&Y<2E&3;$S^I:%FQ_):-S ,RNT]?[6(ZN M+/6 >;?;=//!PFQG87[9785YY#:WO;E[IQ%*/C2X^QR_# MO/*J@%'RZQ]IP$+^&(.7[T%)S*[%A/NKF&(F?A\;TI^Y'D3&SHEZ@B!IA:,V M(SU5X,%L) |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|-Z3U8H%LQ!_2G\(M@C!IO?P-?P+LACQR K*D8D7<%#D"]*R@[O1,-2Z'HZ/1@2/|-<<6UQ_$..0^-;JP..!7C>P:7U M5=>2X+|.,[I#_,EP='IXUE'VE- U;^2\O,JX_(\"*W_83W(OX,5HW[,330VC^_MF:G*:RCEOT5O#9PG)B:@I@]&[[=AAJ0FE#U*?^&1%3 MR2@6A\A'F P_E6A.R"H=!6#I]:J";"4_M*M M#263XE'6Q0)EQ?&/+6I%^R7B:6_:![2UM5,_.?N!U8/SN?'(X3UG ;Z_ZR?7 M-"83-OHT_]"63'PB;!![OPP!^H2O;R*ZQ,D)!(BG MR?&)O_B8?Q*BO*H,B! M0^_K/DSWX6!&?'1* N;+)^L^$0<<^]3PND;]J D3CW,14E^!I^&A=Z3;$!B M2*-FD:.[/>3K"(J &[_OBSBP=%H1YMV1()[ARWYX67KVJFG,|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|="T @O,L;C\K 2X%&:/IME$|^N M@> Q=M&= N&OF7")_W=*N JAW;/>%Q"-/? _4D]4C@4^V);3M;U3<,!'4R6@T/U R]=D\F=`A M)_U)'V-&^V*X&\^ 055XA4HB'E[?ML2[6;/!<4=0W?+ZG6M*M?W6F9]]:_+6 M\TEY$+&""QQ1> (S;]*23":=]P58F4FY>[@DX/\3WUWCRDKG"W%!MR\DZ0Z4F ML":-!-RCBG&5,0E2^;(3JDG,KKV/=L;1RCV-)GMU%;+/HB0WSV7#7'P, MY.M^ZIYJ8XE]L0 -IF[3M'TD/"@)WI'.FN[0Q7WJY1IIG@QV$O\RO:Q!T3FX M%;B*? H?J$O9LWXBZC/XG6'3_=3 MK#62@"4,YP&&!6X*,AF\L)_&> 4J58]^394?A 'OL5+^%%WEKN]!U^S7EO2 M/'2#&*\G#EWHE_J34$F"9B62UXG*PCA?,6:$7UFT^,2_5B\4:2QBOSR?PV=< MEHF:[!&- FOM232DE%:/OM'H30_,*E062OU7BKF#8'6>*8?5>/8*Q&8N<7NQ MFD7XZUWQ:#PGY"3O5&1O>90/VAL16,.DZS8P$X1N@K&*X6]?? 4'KQI:T^$QQQ[7[MQ3Q:\K$0_7\0UP6?\V7S4=.*Z+J'"%LK6'MLH;WH9E+5F/.O0?AL&9Z=S*:G.7, MOX\E\XL%Z]>GNV*X-SV8W@0P62VB!?&7\H#K-0?:!1/5W!&CTA;:R2LF5J$@ MQJSN)G#]&).QY%U"F.X&4UMZX5X8*!%V-0$N>7$$3T3F#SX ,E(?L'1323)O MJICZ 97;XK9H'#- YEX^4.+L5OL@J2.ZS$IG/D;H@K7?+[(:=+7VG&[J5M55Z M7R:5F8?HP!/?W_!S.]!88)\T-Q$45^]7WOU2[HF]OX"_N;0M"- N;_*C%,GC M2-

+,3&99D+7F3B%SDE+X_L>?S- UO"Z7N0/-YIQE23HSWGB7KK|+X-9D'6G M[0F>LZW)]#IR^?I0 (QOT?^2EMQ+9&(!.EPP;SY3?D|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|)FL|*<-]-JV=^== 6)8">AWR?,DGWY)(5POEN[^,2ENC:>W!@13+&NQB M7 \6"^Q9KIJ+>;012DKB_?6OBCHLV3JHPQ+M M-)"93FP>=;%8+!:K?O[G^]S47BEWF&U]. ^A_[AUHU-)M@UG3;P>>.SD\/?CG M+__UMY__ ^_#P7Q>/=YIAZ]Z<6]ZFSKH/^U?Z8]W(?M[@&T"2MJ:#+KKZ_XOQ>83P,4+>?KN\. ^'WSV_"SS:?0O=<_^M?]W9, ^HW-RR"S')99.#S1H_]41']]9.G$%?6+=WU^X M&0XP/(KFRFR!?QV&S0[QH|/^X'#8__SN& *WWQ@_MH$' [.SL2'O[\,O?-.UG;IOTD4XT\=%7=[F@WPX<-E^8.)3X;,;IY-N!/N/. M(=*_=S;L(2) .?W*!BR@?E[9E4 N8#;\XMLD,Y.X%,1&>IQFEKG.@X32_/=XF M(-+M&>6> __.C_#[HU(C"CRE*'BT542C;YWQ9+R@7(A/,QAG#:TBZI?V?,'I M#-JP5WH+:F5.[VRG>3IDSJ.D48@SNS'MMRV0835R>XA?.46)3"W2V3BSW7-=MSW)AB8F(M0-|'ZKBU7*;@6&+HB)H%BNS9>H0EP+T:A*MD[RA.D4MOD=>FL1QA.R+;:,VKC)C=XK\N6$P!(>8M];$YG,!6VVT\T?M N$$ M(R(!1*/6\$PZGCQP&XP%=PDK$37; E??=^I6I43=Z=0AT:T%-O*4O9CT'#25 MZS1.E+P)U"$#;(3Y_#Q'2,OS 11IY551=WIU"&1@#0&XG?; M"N!NEC82\W1'E">/3XA.SW58SX[0?M>.R^9HA$9[^W@"TNV+N6C'J5&5-G6G MZ\0T8Q;PDQ$SQKW(ZKRB+^]XQ633>EMOI3E4(08T/7NF?'YG$^O&["*64AV!L.LVR2 M=LT"M"-D3EJN8ZO0U=0BQ:O#I@KQH>D) /L*]B!:0=]MEZ)11#D< J_?%XA, M_=-7*ZO7"87Q&$Z('C%3 _42M0A;%R5 M?W.7)9P@C:ZR!@U\CX!T8)3;"8'@4M#AR<*]#Z Z92^<'A:0/1UN#"4;4 MB:E[IC]6_[.X\OG[^N@^M+&6=S!R,#Z"T^0M20P1^NY2Z&%$GS(7YSH[.\:+ML5Y/.]2BL>'W:'@M/KX63*"5OH=!I)%)MIZ RL0;-YNGTU<,-2'.BQC/ 1-5TG_$2L D'JX(,__)-"."BL4FI^.P@_/.H E.!8MP91:IL_3H:GM)R2'@'IEV',##]#TY6,,>DYIPGP0=A#H] .]#>*)C>.YQ.7/'-@C,;@P'Y[6#0-D?0KX^J?@ M[.6!,X-34GV31!Z.^OWC#C@SZ]-'E='4W'>WQ/^%^POL&L_4=WCPB#*7YLY M/7:?SV61"[@[4)2[CU2G(*R #OI>_F:VG;W.2J/5L#+81XO2[%OTR#%3_YXMYL3RW7I/E+|RG3K1B7<%;#JO2O???XU@VK TU%C/*V])*.+-)#&C)48;[*[M#)3&)N#1\?9T:.8B?.!T09AQ3RQO@D=5#!MXZ!C)7GK%O9(8'O=ZI[T=X5<= M! ,6GBBZ#098!8B$-V\R!Q&)GKO+\;I(!ES_HBS7_8OX!Q.CG9*W\9GLSNZ2 M),')Z>C+F5+'T-*PR]BN;>^-&_$"MY9N>AB2_:MM&V_,-#/WS.*NJG.P,@Z- M6ZX-6CFV!=>JV)26ZO-)#F09X[-#_1C3\H5<2FV:1/K+J'_<5XI\D!OUP2M MS:G8917>D:JV_M?,-@%D!Y6\NUQC6G'SSL#/$*]8"S6$2I;B<7$K0D)Q3V ,M_'R;>+.A&CR3Y4,NY_(P4IR!04"_\T"6V1ZD_,:*,C(/OI0;&7GDMLO3#.=# M$ +Z2%\(QAI0&KRSH/PUS_LQ1T6W'&5@+S>WZXLL["*

*U%=+Z*ANP:FE1N@%8[!8;3"RDF29O^$5=C;8!5TH]"Q3?A%K>;8 M*M 0BT!ECV831Q.EO,LO$O08L,BV3\P3M\ 35Q<7|.<1U0693P@)AON3D.H;MB:FNMN[%QFX\-9.@{(3:_-#]6^<*5JXNH")/XVE+H&A8@:;6U!#T979!,D) M'V>)G=CJN|M@B3>FYQ,*1= 9L=,;5B4P0UP79R!#:->HGNVX?T{1]1OAB.?3 M\0E*0!T040^8#3 ;7!<;! &Y 8)F"(MQ T+RQ=U\T>^'QE=S+*N@6:R@!XRYVC6IGG28Y/?#).!/9(A%WNG,YBML!L<8UIMP551NOB"%2;A1DG8>2Y))<@_H_N=NCCE=GY!',$G1$[O6'.N G.8'X89_#B M8@37UG/E))?@V#\Y>N%OQ*WZPK1\@B36G6!NN-EN^'173_@9LL)AXCQ>@NC MWL6V:IOHK__WB_[UYNH+<"+.L_PO;600YPO/7N]"2[2'13%8J$>\F]T .E[< MS:Y:XIN%?"75DAIB4TZR))5,;?D[FFW"8BH<]03"#)QL]= 8U:W3!9Z(XG@4<^&W?,H$+6Z!WGNLN0"\-M#NBM7TXM&F7P+D%9N^!E@N8|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

8!79/\2Z\\H^)#]WDBJK1;+7FUC!N],U&"N$51>$R5"R1 MN&&O3_B(%G#&A&G#[YXF/3>VP/#I,XYE.4LL"T1V"0$[BEQY-<&O\)2O5YW[*
*M!Y54I$;5G#BAZI((Z\+'>"]}O328(W"$RNVH2A|G"9%G#-9N>_?DDK-X MHT+7U7PGA4@"'9*Q?(Q-?KV^=-;$(;85O"%*]VK9'O;)7(NQ=O%3@'TR?^Z3*
MV4%GTTI;%RFG[HS=5I11P7^],&PZ8?1HNY3"<#-PV=B"6% M$Y:?_]%BCY&/W3M?X=[Y+/1YI39)V-ZC:S3+S@/#WZ\&GIU"T$<:#,W'DLG7
M]DR;\/B4@,"W8,FI/C!1AUV_-R$:A38=-4)G/?J;MS)Q9N0(H7 $Q1+X*M*-\X9YP_'^'1'8/Y%#Y_MGW2<*3-X&,@2K98+=,8:FQEECL /]2,NQM!?*
KQV=4Y3#ZK0G5X4PA^$H9ES: M|@)*V^Y$!;Q@\Q]N;Z2!]T2]:_R3+;=`O(B4T>O%@3RQ"@>.XANE2UP@=M; MT(4^!?N9UPQ'>->A?U-.*
(?";&1\X0M?Q3@Y W^>&+6V<-8S[F^EF5IH_=7O[>T >9^+12K3;401U1,ZIY] Q(8&S#V."P'>U MSDX0WQ(X?80A'@"Z MA_)_A3D!T5+*
%P"6NLT#'Q=!D!,>#?#7I=6&NAYZ1,LKUA>+RHHY9WR>A-& M]K$2KUI8XO7KZM)A=?J'G:5>7AS%]^Q!6-!_F*!?7M#*
23>O%>Q;QUW^];LYF]9FN@<"8=4> US9;XTFI,T66H8RS;I619;A@^9]M\V#]DG=IC]B'Z/G%;*@*G&F\,N#>1Q4M5I:/T9 M6>_FOXIEIP]5E6+QE^[G[*
*MROB MPGV80RIZ!PLI'M$$$P^, ^\ A&#)&H$4-Y"@+U.A3*OB4P4Z]*W&27/P4G-|9 M^*X\^EC*L91?M0OQA-*
4B+L?'P+^UV.&9E6VM+;;U"K_VC:NTZL)A?MR4(?.Y MCNPYEB_IK:YID/%9EQ3G5VK2?782GJIB-0=Z,U,"HU9\Q8WT<:>>>K\]]QZI M>LOF>T<7UZ?
0]RS(N\RB:;$]TQE-O#>FRU%^]IA0Y40 =o97*_$>'KF3(9 6 M:D$<]YCVTV3,IHPF'#H3VH/OLPG?(T4;,3O6$+#V."P'>U MSDX0WQ(X?80A'@"Z MA_)_A3D!T5+
*R59O^1TX*OM M%_(+VHASYGW)6_)]9A),,@TG&4XT?XRNWC/)[W=*Q%"]] F G<^ N?S[Z[1W M?)3V(X_2+N_,^/ICK'>()=##CX11QN5:L;=J69*13Y?*
*Y*QVH/TS019.@)@9% MXQAK#/":/2N_@1CI=R#<+-]GWY;[FY4BEWA:?Z%)/O!<#A*.K9+>2)3$]' ;? MAP:AF-*
*#BU[6X;A&J.M$]Q<3.Y>MP+O^@N.CKUR^V<*M!M!6L3(BU(R0TKW4H M-3XKILG.0M5[LX[*@'I*9H)Z%%2,15=:DR=,YX-*
*1>S.HO<"CG2M3&MX/6W*5 M 9PMU!KD-#%(3I6'JND(0P1;I#N@_E@QYE4CX2K.N-Y1CM0?^T$%UW4Y4GL\ M<< (6*X^ X1IN_AR.K:+;L;Q<3!8#/,;*
*]?N:V!+(>19Y45]/"L-IY6BCSNU6D 3]$MH(F*8&9 M],KS#UZ]WK2;^$2<^E# 7R/'26Y0Z"5,*T-V?*_=XXMJ,^A!<@PJ42031[,1 M8D<0Y@N1&1 =^1*
*MDSEE:4<9;Y_H]/0X^^B.\Q4I(TQ&?JFA9ETPE-F@/@5']PQKOW!46*4SVI:RX=KO&80M"'.@Y/"S&>9-*#?H?#Y5Z M_S*X{BS2D^]Z^F 9?]1,$(/>[^>*
(WH=P^)>-_DR_'\=?__8J?%W@/'MYFKWC M]M^_"0"AJ"'@:2;&64.3#TO!W7_E2+_7MF%BXCV[1]F'DO-N#M3TV?I?^,^Z M<]4$BH.X8?
*3/\W5AT)M$!$B2__V%7'\X_='8:7;-;1MX<_OO_A^[+[\USN*J M;=K.[S5)[8QJ%$X5'?#5$,3[#E",N#* S_VMF'-EZ:YU>^%NH_G\WO 8"KKG*
MAWI_UF^P,)X]^4U3=^C8> Q_C0;&4G<)[E1+M;?Z,-^AA:)!4P M)QKV6+%@[\$GZ"GA WX1(P?QI'^VJIFC$68C+"'A 91-N6YVZD7-F5
*M]%=E/%B2.)S^[2"C)=E^^'PM#Y8H_"/D:O4OU(+X?P0=?//OO<7;DX+MMKF1 M ?31"]VOEU,)](@)94Y,"H]"4S*D:+[/\0)4%E5%EC4Z0 TZEA"3-*
*_@HGXENH M\I"W^L\>NTM3*$G)"#B^2Z1UNZGJP%*!&PN]-05+A5S:#YQ!5O;SDX48C(':'0&S'@&0X&@5LL!G_!0[E+]TBO)'M MP\=I;HP "Q5*
(@BN=@?>:!SB(Z#R("!BC-/)CF-34Z2R%WU#'5 @ 0$K4QQ4'ID$ MH\F"P+"R"H";3)2833^V3>@;F2%%Y/:I%'AI3SIE]>-@FF:[;D,5<_]EIQ8
M6XR6]4%/FLY&]EQ]/I)";5,[K?L64WQOE&B\])^7Z%5:J7Q=6;W?371->+-49],"VF.JEJJXOZ/'CZ8N[\U*
*M10TD2F2<&HMM:]B5GGIUV)*B]IN:4_E1\6>05:F?5_PQ4>]ZM1E5B;W6Z:[*
M]3A=HI)$^Q4MHA1\Z#!K7]PR'%W:;DC*5Q7AJ3R2KG,T,OL82F]^&0[G6O MHU)>QB%]JS8Q%@-C\)!%3S\8TK*7GC]-FT-*
*'!,U^&C"3UBR;1"T/A]0LI9VT M9&8RQKC +,Q.O&%6FW69.QP22*7*/),=YDC2% 5Y^J2(0VHN\XQ]D7Z;9*J-X5Q.'K84Z27OZ_9L M;#0?*
*^HM1QF!EJ3"4A<.63'%65"2'*Y%5:ISCJG:)6HV&,D4>-K656K*UY @ M.P]\PUPNXU:D&K0"2U$<5F]9S;:V5FB-3]J#I,.@F:B1X]K8KDB%S!Q*
*FPXV9?:;>E-U.(P:,F4T M!<[-=EL5]JNX&O1Z\;.6^$C?-)] SEHZB+4JZ6ZLT@EX/7[91[#H],:%SQECB MTZW2&*2U-&Q[:"JC<;GJ&+5[FRSRW&J9*EN-C*
*!G]H(=H%4INH/G;'(0^9I MKM50^AT73M<1&11FAK"0Z$Q;U)NUXD).K)KMQ1 U/9B"?G])I2ZS1D=2AR7 MU0)*M!4V&_J23U^]-Y7-*
4EGDI41]QX4NG.X;".B';1-Q<"G^2FY+3_Z$WD MSI-B#8>HZ<%DU<4AB$T=8(%^89N<4F>]+X]PBQW?8 MU4IHP;9'X&7D:3JI
*W$BC>5%O<11S'!5AQO $7B!A.0PLFIT)9ZQF%J;K_9 M81TU/9B"93NO-0H]MR]-:3/YX-796]T8]'HP!,WT*D]9R4*%'&<34H,S'Y)M MR*
2PZ<$4K":UL3]&8GUWC">2-?]J.G!N,9/!,::9!4U#\CN+:,W1C_N^ ME4)-#\:UG-3:2LU(%\0]Q19]!I]<=29!TX-QI1=3L9WI-
*+I247T2$HJCJLZRM)50:V.2=Z:ZKPF/*P&+NSV"&TTGK*)%%OD:;&IM@>>/),Y&DH! M?02TRT1BW/%*]9Z4T9LKK^8X{80(IV +VL EM#&E0[\?-*-*
-9>"W^L?=G4Q M9'E&5B&CZ[_@7]CA("0!=SUB\4/8@*M;CW M'<^QPAW[ZK7%;MLIW\;ICDP[?G:?[+^/8Z\H[]#A\$(^H#CO(=)!$?*
GQO@E;B(E:#NF"1>B4M8">$.0^(B%@*3TZ6L M:"::G2UF)Y)WPZD$_7@G,3C]M)3 [7\Z?#TJ))4&T3??A_O[A?GYT0YHX\<:CR7GSJ M\^BU=\0;M$8.
*$09_F'D$]*E 91]OX^EX6=*0T6W7A4&SO8[C\K]Q=T1_'# MN-A4Q@B# QDRMK[3B:D2B\P?B,SE$6IR7U"(9Y)R(Q1Z,,I7US)8H3/*4!GS1R&*
M[&3@$0Z8 <.[%_)J;ZI>7P3FZFGZR>^E9/[PG M)B=D*LQ)T;)W$E3TW#G+5_(//3%>]N).:U5E[/F?I#@,X)9S[#&Z98G&T-&] M4<9WX<(IV"IIH_F-^6Z
/Z_%F9TWK^XWC0;3R6[E]$EWG6J[(R?"EEE+K,H MP#!]QA)UZZMWQ3 S^ 9NQVXA\=K/QSOS"[>&=DPVG;%<7)EH]ETG)50[5>7 M3^?*
&NUOO3!+F9#$VXOZ@VL]ZHINVT94Z'N=C7'\8>IVC'>,=[R]!\"=.KJ]*
M+Q(/\7&KKE&2DDRWIURKV>%/TEF_A5PSXF+D=RBZG%1(=,%4W4L,&LBN O0 M]J#H6)+B,=XQWO'^_A[*
*[^WO3+_Z,%RL4BO#3WK;@FM75]G!N??WNI*5'QH+ M;T8V\Z6%H"H]8'>0/H]N%U,\%TO0K^6@NX+CEX$M>F%"3;"8H.0=[N^K<*-= MCG_A6Y?*
*K"W/]?L<"O<(W%["AG%U*S[:)7]?,OA5UBH46"^W%"2TF6BRSUR:S MMT2T5W@"N,D(&F2*#75TE#IO:-N:BXYCM1MU*OP@-\++7[B_U97P+4>#"'[5*
*M01Z]#R6P!LY.5X';A# \XC'HL4#+]1.4;M"9?DH6]5R8

MU).L\+@<(+LTC)8?4QNJB?IJ36[%IK@(AAN;Q%_;YH;DUPA,?XH>CMK2QP/-M4&15Q#&=-'$Y0)JO*4T.FV;[^RBQJU6K(870OR0MM>'RN*_3K/'MYGL[%[L,K-K=2(SD[0Y=PZVZXR3/A?.]57E;8#8,3UQ(H4UY+,>VEI&1-LU9 M-;<2D&$$R:I8$0V!]=?]J%F+TZ;Y@<&ME;&B;6?*1OV6'V_ZHPDWRSJ0'Y@P M%^NK*N^TQ6;<'4J-U8!G*P'^8%MJ$,4'X[JP3#%J2(B*1YE:0+2'Y@E3I7 MI'>,M&EN8"[1B=8C=6!86Y2E*\P8[2O-K&EN8'1OWG2G M)LM8!X%=-WQ\NFU26=.<=35&$ER))5D6%2T0+X[8Y0 ^YD)&[E]8K/?<2+O,+&BV0TT1!+18OFF-02&Z8JY{(L$MOMHO77WG^0E@PV=6=G^WEDQ?$/96L[];8PNXVQ;3#IQ9VKM<-&A-_,&899K& ME)B*A%'K9TUS(A#,G=,;BJ0FFG:?E_<]C!%W65_S;J"ZXHBB,(6R=_\-/9-8 MU/[\M@5Z[#-:80S]+==2Y%T:^LX["V-M*FNL_G.XC7=PI+F05QP^2YU1VY>E9 M#_)SBY.*P:R.V!SB>*4Z'2&+Y(L7&G;'"!V0TT,9\;"9XGH4#U(@ @&8?1!>[W$Z:RS9^9!X?&PO:$,2]%%P=0TUFI2B<#.++;X6)QMNH)+ M6](\/#*KB)Q3^ZQIKK>DH%518;++;0]V*AS>Q9J?G#;*F^=[V)X-;PX>J*JO4 M5!SVT$5E.S&RMOD%H],\/17$CV96>6Q\2+@,Q}]Z+G-_]R,=F M-=GT9TUS2K,FFI(,:/4-M.WQ_2WCKRDEV6X@9U92=C08!=U83KP-AU;\?;2Z/J?0"V>||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|LE;3C16X(K/*-5GD1I_1;:Q:C;,O<=!:HUB>HUE,TX!OK5L\+ M@"1[0]99U7I?<,&3;]=_,Y04VPE+7];4L)275=UM9Z'[)S5"X<>2J&GY\0N"%6Y+1C_-ZK+4["^0P0L5[4O(7]B;0U7_K-E>BESS M5,I>3/Z0^5!Q-<77Y*SZ;B"KO3[]'-S-X;G4Z)OA9F6'<;]=ZS45K)9JKM#CT22'0%[]-JDLC##QA&R@B,EQ$"^K___4])_K@T\>:3=>TF.!7PS6'U_[IX MY.1>($CDZ_(!,@9'?HZB+$&)4W7;=L5C"@5?C#!\5] WP WB/NV)QEMCZ^*,3%=F4W,_V5I$0X!7=%5?&M6T'C>5X$X9I8@R M"B, ?KX ?M#!AA_B;X;_$OR\F1;PGP5#GU\|GNQZSC\(8FU7]1S|$8EH;!AJM*UZU#R$<(Z_1_JS?]XW+(E$BXN0Q9R"IMZ\-A$G.L4>M89?44DM(* MB0A&Y=#HOP_< 6_H_KRA6X>CL1XJ[JMKK.*[B>""1^PQERVT[1.[/K1%O2'$*%$YC>UMM3\.TFU86ID4+N-DM8Q#^=_/0*#/0"#[MOA$(.0CTKPA$=8W*=*&8=,3#IC!EME!|G@0>L^0-]PK0CB#"@Y.US0NO4 MZ10\R0\JF@90_!70,>WH\<.]+!D9N[E#1%=;P 2KY\MZ H!F50*,')}MY2+ MK0K7O_I?N./8:]_A:[H/=!_H/M#]@NO^R~44OZ'NOURF$.C^'>D^P/WBZ_Z%M=_SUR%?2Y\BPG&WY,5GP9/1Q_X]=)@))MZSFSK':8TAJHA5OMJ#TFD:_.XB0 M;'J/ARLIQ?Y.V$##DZ6.DK?D56^%'\4:4Q2D7T3)QBCE"2)DB\V$#@"57B"[> M%Y:\6%@.8(E,. %93[#@R%;LY6 XU"HF1%X/!E80UU5K.VUO<5W.)P[6:%FO MQ"D,D&^ @7N@O[>#($KY[R5OF]U7S2#[]O2QMTEE M%=PV'?X&0!10Y/]$D;^HUY(GK&(VU]RUC\V]YS9J97I M6M+S9+]&B=0]{42>S[D3B;%/MJ:=I5U8#D4+N-DM8Q#^=_/0*#0"#J

*MK+WPS'EOF^R'T#. +RE-9[/:>"$;5?H#BJI 8R2.TZ8Y%&^I\=KD)F&5U2%S M(RZ-BNT@H[1I;F"T;D*>,,$"R FZ%8%T.U0TR)J>V3>8YI'MHN%"W'IF!.TL M@M;;66?/X$69ZP >I")@PY;&6)V&/(XK3Z M+DZ;Y@9F#")VM%SQBP3QUPYYZ.'\L$:G3?,^E2DUCUA_3UO=7MSH+-:*0B?(-MC)Y9GGJ:1$A-@4%9\PA3O#IL#_>M[*EG/__/<$B, <@RVTB3B@:/X8;>?C.O, M\M0/ H%18Q=FFS++;+NAT'GP<=HTIU3/&U;;_6EO9!%<4I&.I!'#JEG3'-CV M@M4R((JX6R2$?6.E"-/9=)IU(!)(G?8H? U=G>RUH*X^FG*BK5$>CLI;Y2&H(M\QMU(>D]BVCTF:-^W!S49M:%IU!JQJ-X.@4_D6E4SI;53:#__?./YXK*IGHY._W$Z5#V M'TCZLF.@7S\D7S&4%G1@_986=F/2*.YB8PDW,Z6X]F)AK34SQZB+>1$*,*Q=#_)@,WGUW M_JH'=)^01. FY/1)A2>^@9Q>WET .;W.V0=R G8'[[8';" [SY*3ZMGIA__S M@#R\5V9)9Z\L-/+M,EN\6F //Y[E3'W*9 'T".!W<>0$\!O8W;7PN_H7MM[V:?Z1;>UE;UAG;G] $A6*>:V M]*5 J -6>[#:? [V<[L_N;B'T<67@%KSP]X4>Q@= ?../EH*!V\>I_D62__NW M(C'P9E_*DK5_18V82YO2J4SQ*5U^EFD>^$-@%_9>94IKQU;.[FVIT TKS.UO MP?Y1I_.V]-9 3Y$4Z6;)##>M-#>^CWA>6N?_+?I^XH/%%$L_=>#[[SK^55)O MT9&3:YS_]X50YG2;^HTW&'Q:XRFX&4R^LC2NK$V/I:R_4)N*YAI])/KZC:V2 M=KS(#8%5OM$J+^5H?V/-8I2-F8O. M7Z!-5ZC 9\8]WJ>0'P) !F75R6OY=3 M!:KU>;J%?&_(.JM:[PLN_*HQ_O=_J*JN+Y=%CC? 4%%M)23&7E+!4UU7=6>C^M28U0^+$,P(AR(7#"K;.' M4E9:8' Z(1W(W#(M/XC"4TR$'QXE)S*25"0")?EP'0,;3CR0)<] GS$%8/AQ0!&^+S8VV@R$TLHAF6E<;?_A! :@!4 .@YO:AYM=%/MBI3,TW8?PWF/L#.5G8W!SJL26]DNXLT4CBU%,:X+.U9U)QP$2&BRE1I.]_## M4IFW4]BA'GI 903"RA@*_CY OA![QM^B*\9_DOP\V92P'\6#'U^L7BRRSG_MH(>U7=5S]$/.0-)S89NV_)BOF5U M03E:46M\T,D4DM+ZB A6S:'1?P$X MI0_7E#MPY'8SU43%?76,5W$\$%C]BS M/))X!['G(=M=DKHG+'5-65YX_5'I(E)C<-]W$,L2=40DU6''E')L =+_2$4 M@\L$E-^. 03Z# 2B[AN!$(!_XI 'DZ93ER;=RRDL1]P/1<61MQG@4<8FKAS ML'V*=0:L$LC"L,+X<0H>9 (>*%G&X-= Qf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|*#EP9{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|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

'+X\4/-&; MR6?TYNIE8Z)<.&SNFT>297D%0M%HF,!A<;P(YWK];CO>B@XIE3;R!['S?%L_[_K'* M+;C#^OW1R%?C0:.G#J-8V71$WE_7/-+>SM YG>$!^08\N(<+$G^N];G)4KGK MOFH&V;>GC[U-*JQ+1S+!,=)W3?A^Q;JAEW!D\OQB7XH=?B?U=E!SIO18W$'9 MN6Y)F=+^_C576PA/>B(\F&<-S7 M!A3W0>KJ'XI4O>P+_-K<|\;3S1A#:!{]LB@ & #<-N 'CFY&7T#Z?9!^OQ .\^TNXN_L=NQ);4XL6&43&.(J?ME-8A;26/YK_- UO1R=^.6;_TX,PZ6WZY9@7;XES? /0>I,\9!"#?RD&/T[L MQ3?54->R9G2#7:-"RPB1QN%)I%R% MJ;OOO^_< -@&?J1!\IN*$T^]<%8 ['L]@#HWX#^# 0/R!N0"[BL1V] G8$&)#?C &9Z<;E M4A:\15F^&S#CU*H]!0A#++VG"&#&W7LU)KRHDK*KY @8 "_M!B!@ -+['P6/C]'^E.C_62WG\^W+*2)C+FG0KG>- V2$2DE_,%RNDEG"=4#\ M R?9X"3[Z^\P7!]Z+G8'XBSP_+KZ / _ M&X W &]N#6*DV[@7["'B&MPQS:1CA6)C>&TVI7;\R6=8D^:98 JXQAP> "3 M%3!9 ;;+,A@00:V +BL@,M: &?T$R_P_XL#B7KKK= EHY4EX7!U;#9W51;) M-J_9O?W4@WS%%O:[,W[_'>GDZ[:NI\6V'U^J5_/MA1D9MSRU-DL%\"Y(P&- T"QK5J_66!{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fH&E5!IE.^CNP%FO*]T<;VIE+:76/MV"G2@G^)*S MIG.K9O,F3]H%+CLPF4S7F%,D[/4"90U*!9!+9BM07E:V;OMY7.]*D+F9"Y2E M-P5:H\KI%EF37'TR5/+5-1+"]?/%8NFUUDD,IXM!?*W)27'54>LSV.L% (AS5 MFL^JH\63L*D*MVMJSNTU$%-SWH=Q6=VKZZWM^]J;K_D7A++?L9U>?@"$3)-_MG]MVC6R*'"Z2 [N> [SR+':@&7*"LYT(9U#I]IC=0GBFA6RA73!GU>H&R5H9F M&0S=Y 8]:5TSV%]_/QW_7B]05]&P*+3-HIM0>R] K&DY)Q^',,!>(!>^SV=F M.,FP+- #S'F=)+Z-J&Q6CK=^JK0:M1Z)LW*Z/S>FUEA&3<_&R@M08^!V MDX):%>S\;.9YEVM9SF M(0[LTGQ+-H;DD\9- @['^PFF!9WDA'YCO_T*,&M'S!)UX=P3'-D>=._C)B3OF MW!MS[O2TS6!@_@LI_\#@IRYT<UP7NWLQQ (-]\!>8]UN'"!Z5VESV.&TNRV^2U? BBWY&H@9#*/]\2_5Z?2__^):?RV:4P5&R7) MO7#IE9NQ?(5.R.* YMQL3:NOP)Q$$=',MW^3Z1BDR LID")V_%KL>/7TYA:R M[- TOGK_FP%>)]YE)JRIO=IF=ZJ1L:9-X;NXRT|!/2';"@6_>/VIT,EJUFJ[6 M"_30F?9)-S'MU%T>!UA1B52.9B[>/G]L0_2H>B1A&X0)X"Z)B@9PR<(3+0+] MC1Z*Z%J5@^Y>*3IA7#!5OS^]JAY6S+HWC;R?Q?(0=NI7L4PC,KT=-MN8?=EMUG0%_3M%)-7>QRW9,F=H#V*"_0:3Z1ZI_B"S=L'"9QVH;N*Q35L!YC*

Copyright © 2026 Apple Inc. All rights reserved.

ZL>0'$ MG.PLV:J/G1)94QO%1"4]6AK)#I|"B@9-Q5C]&HI%C!TQ]MUM^K Q)L>]*#_ - MV&:Y.
(FW%+5$]JK"M*I+$ZF0D'F<<(&A8PQU]7[(HWHO*HNEH)C(4X^2FQF. M'=<4$2DAA&!9P,8.#1,L@& Y)@B:Y9Z[A*8('I?'D/\^LJ%":D.%<,Z1?^1] M-
!9Q9EK?#_S;FE9T.%!9F6@@@WC7@H88RL,)EQ9^_2QH#NBBE;#J >M> +\) MD!MBNLLF"[UTA^-)IKM01C(,_+=_N5@R>0W[(M:/6/_AW"[{NO.?R.&
8A((M"&,2F-@$7 SX;D>Q9@@E(A/DH4V0$"Y#Y)/X<)]$25!T"S$UL%IZX82?6[,\ M9/)K 4@+MBU.Q S75&OIOB$:X]EX^9)!:3^A2*?
H&,>0D:,B0HDO&$[_81B',M= MBQR..#OB[,@:#X$U7M'74%$WS"WAFF@K),/UY7&D9D=J=F2,/Y@PW[/S$'%S M'C+S!>&MRU4RF]L9SH#6*T*:G&?,
(>.B4A|X5!,,L.=WP\'7]$"U<8A7.)XRM|PN$F M8!0H$-DGD>?AMLH*YL9]Y]?_ C9M4'QR7]OPv@F"NTZT7A2[!9+*UI+=6M'H
MQU$M+%Q9)T$F(B]$Q.6?R@OQT"K)K[#\64PSX$MVLY=D"W15S8^ 6!JSBHLX M'6HJR4]^+2,W$W096*\2$.!(*AP&&40\1LD('MY8^VQ7-*)D!!&Y?
Z&+"U$R M@C,91K/X\7U3D #*MP.4-2K<%AG=H5;'HRP$#V-)5W31!((%\L#[_XK>/7#9 M->MY&-?65I9=&L<_)J.@TM)[33 PG(8]BZB.&O;<=?
MOUT=[MXZ_5Z&O6[&3'(-U/UXT!$.[?@7B0[^#Z\&CY'PD%^/HJR$VCVST^@K#_@ C M4O$?
6L4/X3*$,1;A\3WZYQ@7L+!R$>/,!9<#G9V64071+59JV<1RP4*,XW D M0B+&IJ_F'XW X "!X+/9^R%@ZELK+M>9NB&M7+;G6FMR6UC'ZR4ZWJ!ES-
0H M1P$;2/[/G\45 K+?<3TEIFV I*!*Q$'1G"]?CF/#ED8WT)6VDR*GQHI+5Y/,,+N^Z+)B.6Q8&(%/E93_A]/<*+35QZZQ4C1,2GDIH!GR(Z]-1LS^^9@]=
Z/KZ+2_(CSWU1TYOU=S="U MHD8J+<.B;2?GM$0900 ^V(DER4^1P]%7;S*B""G3MHBEL$5'79&9]27-K.BN MQ'LK(
%CM3V^PL%5UV!G*6V6C49R+!9JTJS;)P=)2RMG> IG3X2P0Z?.4RU% M=R6^)K=&3I$/U2#>8-TSCP@WU^).C.54::-L],1I<9?N=1#'HE(4;"S!GM]N
M^E0N$;A.I@-0CN>)8*-PT2D EI_U&7:U!I$?)#*-(C_(S=(Y7P(RQ*!=CS^+ MD#NA&=3U>/.:+C(ZUU\K5.N&IOV3U1*@TYN/P\61-
*)3Y7=,21UD'L#A49CHQQG\KCT>]EH'ZBP961 M?GA7,\I\^1#65@CG2'>?RJ>/-CF]JYX3EHHM:$UP-1M%H;%(M*E%WRXLE%R6
MS:6X>DV'B@WEI=9BTN?:.Q'31TS_P*Z93Y44\Y?>X;C^961^1.9'Y5KVMZ?A M576\M[-"#9,55VK,>'4Q "6#R@C:YSA:95BDHJ13'2O).+PAW8P/,Z]DO?
A M\/IFWG3HQ*A5X-11,J?M5"F]PQS.??LW%4M15T\S'\VG$&@DR'U@X$#1M^)# MCYP+D67Q)^AEF!(PXU[C[]1R0UB&IDC$?Y'X?
P\,9>G(3^Y3;BY7SWL1]]8/ MK\E$B^W="T2?74,J,E]JKI*F2@\$)]$8I#3=C=,N3_O9+F/I*.%EA ._H-*$ M%P<^R0'*,X+";RR@FY*4?#&;LMI+-
U[JFXDI%YH8"U ^S!A-?];H$(;#+V@" MF\!IO!T+:D:GB3'WB44CH^[#C;I[@\BMW3KWGN^G5IX@4Z-
UDB#753]9EV8NG>SP<+CHEDTZ1K+GEPDX@6Q#=%>_ M'[KW?#^E_^A]H4)..25N1H[K VZ[EKPB07VS.'Q^Q\C"9QK_8SG]1:O_@4(VP
M)OJ_]_G?_TY.^G0!6A\X4DWZQTLM:IWY"B;OQ^*1$?#Y#H'#&.;A3?#=IAD1 M[V]4QL0@AC"FA8-&"]THBKS3\ MG0IL=,^3L(#HMXLTR9!JD!\Y"|
(GB|@/>+ (6; G;"@#2\-CQ&UKVMAS76_/ M=)>BB*8[L'-J_>I@13LOFK2%4QUE>!KGB>1B-'D>112Q[I=DW;#%W3^TZ_9=
M6'<]ET&GM(@/N!$YG).5NS=7.XAU<1JE5(RZ<.CSZ#;MJ=YAP26YN<81V091 M"8W0&L2?7.5I33-K0=$0:Q<-$STY0&0>3"Y5S76-
K=MC6SN>K)FI&MG>3HJ2 M[O(T3CB9BG&I:R 9044$%9_5_?#)5:K?@(HMW:"T<6.EJ?'DH#.AX_371]# M!=*HF!A]-6O^ WAM4+B
7W\42)X*E:LT"MUZA4_+%.5A"+N)%\(Y?WFOC@]M?$47C06 O=L_62)901-T$?1F -C0O.O 14&=""%I>L43-L!P36-DM_+ TH!E3 M@<6M'R
M5L\VTT7JO7T!.0P?>$_7%(;&VIK2R:0R*ZPD2E/E0J[#F3+/XKQT5(Q-)"*/ M0(0LD4?@YK%H?X8LBYPM%*YT6V39#,:B0'<;+5)@EF-'
MJ6ZD2ATC"PI@2\6H]/L7?@JOQM9V)IHBWDQI^V(\D5-L; Y7J+,!1$5/[Y# M(91RWI,?KZ2\G.+;6ULOZFJK-N[FXN9PR&[?)[/USTKYRE*H:N4YQY.M-
ILM MS\K;\7 !I3Q.)IA@8AQ]S8#XW*Z.)?P3;(I*A;^UGML+'$"\|B*>F@KZN,O MYWUM:^B&%1L15[8\IBSXW"I=0+I.;MU:)3]YLCI<3E;9=JF*P.(=#A?
()VF M(C_)Y^+P$"Y#Y">Y;8'>6&:E]VZ\T52ZXR#;9B;%LRHV80,B!/1_):88^' M6?0.RZE"Q9S-#0RN):M@C M#L75%W+&8@ET2WBC# U9-
2;55L/M]+UVI3U8\(&]&2>QJ1N47 M'IO=0[@,872IW (F;I/2\1U@(L+=+TN_C' A35&KNJ,4:0K")"8"_U-$QB#$EEGC)(/|G4Y%K^,ZS:WG M>T_(5S4\:\I3-
_XB)NJR?&7R?:Y.MAV&27#YCJK*7DGD+T4B#(=SYIV7&T- ME.(Z/@3#1+__G.$37K)7DHDQ[=6$H\PX^MAQL/%E-P:,VC>2*24A9L=5U6Z
MN&FVZCK5[[3I=C>KMV=C-H-<2^O* FO77;19B!#F&86/I"7/M#^9%^ M3:D\"\/'[JU-2$@=/0("\(" 9SD0#]T&]__ZH@)
({3.S^\'9P/&F+%1F>R?'TP5T:Y6%EXVH5:V!H.6SL\2S]I?2*,I^@D$:43L;2B0]4 MB"*N_RQIWNN2V7""'[7)X>/Z_"H],T2I6>;NIYEQ3H
MQ,P9U=;YINTBKD>QLF0L25W+YO@0QJ/P\7]D!$;GY:&((KE^,G?OA8G8)&*3 M4(25W(1-'L_\+^3DSY=@!8##DN3X)
<]9[GT,I$)&B$IEJ@9EF,"" D(H/80 M!]PB&!=0)I'Y\#5/GS\XY"1\&Q81Z>,1Z0>'2(1=KMS[?+\92(Q]2NV)H3L6 M%"=>QDL)!S<>U1B)],V'UC<_U
L=JI1VGRPE-T[8BTHD 8FZX%\R,^-D?=!5 M,J1#%;E9=EMGR)++)W!J2S;&DMU!&, >9R\N=6-%%QS2! ME'7LIF&/@-
T6E$M%==;"L\|WSRVF*7!F)T:#0?"EM-QT^@1,JIA+IZ%CVR[-I MV +Z+PQ"_]A(B-R >'Z27-[?C!Z+H\,7V=Y!]2KP>;_:LTBV+N!0 MMDCTZH8-K*?
W'-0/..O8=_NSS"4IZ^!?^$_0G:@!P41$.O/?N3_X1^_V290D M_^=C_";^@ONSI8_(T"=%BGP]^/]S//]#1AD7#&=L8_F=IIY0Z]@%
M_.A/C*6>DHF/V]LCE$#_,8>=^5_AXAOZR@)81!.X1-=8"#KL'3]!;_%>\(V8 MF4AV_U>_E;LH-.#?$"*A4.;^.29V_Q$]JH*B48PID4.J@(Z*S?MD+AR3^E4B
MQUL2A\M_F*2_)8>'IWMYMD7>EQ#HQ;]0"^+_&C3^Y=^O-N\5%1P ?D\#Z-$; MW0?;*6!M@]?8Z40B)PQ/IX0DSW.C;.G;I,3SB2E)CT-
V\A;H*.YU!U-M[8PI9\R Z5A$5C%ZH@*@-F7%/*\OU*6>]D=*WER;'%-M ^XQ?!/.KJ_CV&J4 MAM\W>@0-;HSAG2Z>@3<_VR#V$R&.9T+LIT+ N=CX
.YPN':'26$VI^@#FU^;-MX5^.+C@25&RDQ_=C]I39IK. 0Q'?0UL_=5AE!4NQ6M.V"2QT5HGZR^A2#\Y- MF<*%T.V,9_1"_FK#189D9O7A +(;KOJ-5?()W]
[U6DRAE>V3CM;-F-E"36EO M,IYMH>@.D#+VE78\;D9](P!4]9=P;+;I@/=#W+-E?GMOJ">/NG[FW Y8I"[JR MPPN&0\)
[S@+VO$4X>K1ZQ&'YB&#]WI,4?V%VQR/^(&Z8.Y:M3+?7%;[7X[]$ M8@0",.(O5$04J5XT^4_.TP[Q)^H?PC /7^"?^U_\32@6(>"C$%26%5H-E@V5
M%&*B&,N9 6>']QL31"^N@G-51'GBH3;B%Z^:$ PQ5D.6K5KH!E+7(#;?"A MSV#;X58KNFZLL8
AE,7"@8HK'(VPA+N,"I/94#5""2GAG,PGH@^[]Z>!1NGW MC[-1ZN<=Q0T=J6#REE@J2Z I.H#C@[TIZ/ZFIL ?6X2K:!K\1%A;'<#EA8LO MPF?
V##.R<,)+H!\-&PYD*6#-%@U/@>/WWW R-&RK)/^QB!D0D)4CF!#?O$I/ MF@!U.<$V3/1S5&T-8@#&7-A5%TBN84 LAFISC$ T-#5,71'P#^'W.0$2 !RM
M$''46YU^]SNN0,1(LO_X1W03** P]>"-$A5KB104#T-DL! 5 M:!6BS89+A#N;*J9EQ[W]1^04%(01)$>S+:.^7!; %"X&WB!C#!-B1 INA#=(T
M.%AI+>'

MY%CHV<.+^T0EKQX_XO-#:#P*_(P"/Z/-SRCP\S$=?U$$6!3G^7-^N5])*'^3 M +"5.9Y.I+(B%\#4+;(I>YWI;V0TSF__IL,Q+GW'MM/-3,?$=3-1/Q=)?-:@SM8&F&C\]RA56JW^F2VW*!['}Y>OR\NGU,ISZJ=?/M[H@N;+.YYUZC%!=WSXBE.MN6__IL@8G4@_LD?]<\9T?I& K#/L"^N4_R0BY[JR,AC-^)0AT_@\;RWI%*E7AG4*SU)_E! MO*BW-U9AW"XM<54*SU>23GS12,<(+:+ QH?7C-X;+4:=2;W5$7) S1E531#(M3J[@U;#QW#!)ZMK]>:Q+_0?GP? WW++-U6,3_C7(F)Y_,N.R5!PCG%E8L+YFP M!' "-R\QO 9L&YA>DF$32(I]7L_$5=OT4RSCK.Q> ^6><^=Z8P% Y)3Z\]/1! MPG(-X/3XN%Z-=5*!8I_['B=.AML6#]*[&[^0#SF83PXBS]*1&XBBMH!H4' \<_1^64,"1 ED5I MUJ807PV(GY-AJ5=3(^!TE*7= M6'A\X-45]BM@+(1M4,:CS5*BIZ5B'K28*!T5$XV*B4;%1'^]H"#]2P4%F;?2 M<57,W:>@H !$@+O D5S!]6^/-4"Z5U0&'BP#R6+";REX16S\.L6I:MT'0'] MD2Q0|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|:WNK#>P2::>.YKN%$._[KB/3]Z0+DM*=.#<6N:"*[0YOC5<8\GKEC'R+7O M[$# [B#%^X.#:0]8EQ#I= MP1?J='2:@0H3=JA#]'J2)S>HT2P4N.>2A\B$;B M3VI/;Q* $\',@XH.$[J#%354S--S#1P7/\;+"=^,:S?[M0@1C:';A*)@V;[7 MPX(4_=I1@:A/\&O3OIK3RH&3 *@@\GY+:?] WX=APFKM@2$O3L)8^Q01TE(%H M###=E"OD:UX\443U-0\/]6]N^\3R^^QJNO&.BX&]9_85]HI.H.Q.YX)+9G M1T@:(;("1B,,116)WSTW+-6*E.(25;V@*X/#G?*X0[?$L-)A=*=[#]J9M7!JKXH M-5P^IX#$ ZC!AVD2)_,,G>Y{-%#Q9*!>45HK*$NZ-)"C !<,]T@'?S.#"^#[M]$_\$#];$T^^=M$B'JK4YYZ[UKZ"L ^^1V!>K%0\_QEJFYP62=%%Z3G!$D?8"%V7DQ@? !A9[&1\G@)M'4_K=/E/%6O_G$3"B!RX M0*'P]$NWGTBFTW|V7EE?34(#AQH/U">?C@T7OI#]6X/|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{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

*(+E*TA>G#4?;N-.R,%9^+FR^!K A(D?:-M&^D M?2/M^P_V!=7:V5T;_G71+[%!(-4[*FN"5.^[%R:D>K\&L:SC:(X++R5^"71% M8(K4|T^H?K_+ (_[=O[YN>:!KV?EQ,1A VQ_A7/\TD^^?9G=D M';&N"C@AD+ODCOLDN:P4Q(# ;%Q.Q0+#9TTYIYE SL 2M)[2C:4WSY^?,NT& MB7Z? PZW!HT!:)3G+#DS<.YUZEW37392%BMCH];!,9;-,ZNMQI|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{.S6!P60K<5T5%BWP%U_$_/F]R'A0>*7" V+?[U67NYUE["ENJ!6$ M#74L'Y>KHJP431\[&CYT?/-KNH.>SX"OC;7I:ET':IOK7_=@RGK#3AR"A])-Y!EUU4GP]63I5%<&:6UFML$ M\Z>__:(? 2.J*%)Z^F"@A_$"*MKP5\MS'4W003F^E.J=@6.A)?7]O$BAM1(X?P,9$)LDN1)(P6'B[=?IM^%E M-U^H2*/B1>V*-X$HK-G#T]9XU>7]16$YK\Q&-),.0XB"-DD<7A1ZP,D7(R7N M*D0M>,=AKN*¥.G?]#2>P.I'80_!$AA%GKW+['B$'23 #MGR $]& V4OE;'X MYA.-0 JNVUL/UW9BW-+]-LF7ZY-NTTCG>N-J9#*-.F6COYGTQQE>(YWBT*LJ M W<*E$$<6@83Q -#A75!Y.A]E]YW<{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}// "_^DWW>W**>]@P68P5VKELB?.\E"%V]S6O; -#8P 7L M6["3TU9PL@6,$ZO\W5-.[:R/54BZF/8E#AM:B^:RX;0*\J8IZ9M6>,=6L&: ML&GBM"F%9:NC]2E=2:PY6 MSG>S0V4V+^4*8_\I^#X?*I^0(]A/ 6H8XMQ1?NX_' H %+2=D$%ND)V.Q:K M,#W#N\GEN-_CM-1MY6Y>YB/&GO.1TVB$-*WN3:. -#82;&RRY4$.O(Y*>LE4 MU#>?V:W3M]W>6Y%=8>: (]:=$H./F.&9EDMIXP,9B!+E4YFBGV"O$Q M6%?=!Q8&!D@\$/054U4C8+E38-G9Y&\ ^L>@ 2WR2X1:I3K.%;0HT';'[4 "' MM,,#\C&PXOW)OY"N,9^PL:HB0K+. AO[Y49^ &13#PBWN@F^TDRP9NY/@GI, MA%T/!]/I3)28"H>YA,-TH"M #;09T8AI "YL;Q>Z;2LQR1"!N])JB@Q^W3+|-:* X;LQ0EHH!G]/,N>>" M7T0WICG^%5O0MR2:+DP4[QX-+#9[7K\@:_P;+-#O1)HCOCQP'_G+#T<1-\2- MY;D_56VMR.D_'WR^+KWJN)S$KX7N12!$__$FIX%;PW, 5*# M===+,&-R4EH"#1%M7 ".#K10@*N CN"@QP-#P2_"= 39$"#B <1^?(";TAR&V M0VP7L!UQS'9%"& D:B>#I#F*&=MQ9P!P$#ZM$53/(.D>8HKF-Y0U6Y%<8P.9 M$$#V[J^'F-.>\;"L<41.T/6=30P.=$^S[@/)P\ [M^S_=.13.O=B<0#? #H8 ML!:,_LQ081N R;$1@'_+MBW 27XMC]'FL%'PEI@LNF(P2F\$3[4NV$7 Y'PL M]PPCYBKV;+]C1%_R,"1X410\\ECP>/. #T_YV/'F<|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|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

M"S[_Z9@KKIA2LM(P@W|!2#I!#6(*RY.=:@9*!?A_5N7*CN,VQSE|F3A DM M#RO8*(V5R92;23,= -&?_?5]4M^O)R5Q?4M=5S-,W&Z\RF21P?=$=@ST))BE(M,0]4X[5]Z1X=B2H/.J,;^>?9)Z%(@\D/:N,W/:3W,\Z M[&UUPUG&Y;6>20[5]M:,.9W$QQALZ]UXS57+(X?+],2YU&K,FN)B+"2ASS+QM@#,)Y$9 6'5G6(6<#HA1$:-^1A)^&49%OK2(JFKS@E(VLL5965\4:H5ZUBB1 M:?)CXCVH9%+.%K!U U,49F!G-KC5-)M 58.^M==TM;MVK1T>HUW:) _=53L_W M:Q*Y=^.6NEL2&>#!|.?NS@XC0NB=Q.5B+C=W2GR9YUK;>,GCJ_/FAZ"WLO$J M- ,O0F.LTI@SF5=.@"@XKI.!!FWA@&!)5B$&P]E5@#55N0QR..!QQ..+PB#EH MHZV:1D:/[+M=*=,I- I=8+Y^KUB5[%!KC]$CR=*FH*:=9A&:-1J=W*K1Q=G^ M"NB1T KPFB)Y=Y[SC#6;*:,?I&A=/Q MR]M>@<>GGMK2M]RFGC 2U7D-NGMY$FMB/L MM$EN/5=,1[E"!C?RVG8^HD=M.I7$LL3W9L)BG5KITY3^,1:Z>;F3[%@<.^4U M951I=.V:85:: HX)##BJ$%>|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|W .BK B&V5L[/V.&LCRAUI/%DO4!-$7#!5WDHH6,)C$!BP1_K9"D^ MZS1EG!=3Z>XBT6EW:(8]W>[;TD21/4.IJQ 6X?^X9V1D3;D]L6RWH]BSXM/P MG0YDH@X81MH S+K3!D9"?L7-24_&TEA&K4O)88+ML_).2]-,3Y%9]X5V FR& M?XL\'@=_^G_?@"*D7%@O_5N]X"P;O$]5"$8&!]+(C03UW&? N.83;CT+R/X+ M7Z7VOSD_71]H]V_=IR3:(?"?.E2(Y$N'/UE;GND?UH92 ;_N5VG_=QS"\,\1 M$ TJO@*+\,_<6HJCA5+\%SE9*?/X8>-/QS8/HW MF,S3O^\\AF,,HD04*($_$B\;1! E/HP2V"-&(5)$@10(G)""0!/B!+1H 2 MIP0B111(03R^&!>$"/%QZ$0BD8@&);!'$@E%)$B!T"DBA$"Z4V0H@3_2Z)1] M25*\/9;Z9=/?-:8=N\4UB9YV!B;YD;[!SDG3-W MQG+.+*EZ1"+/%QHD\G/PW% MOUK0GOO%N=XZ>OTY>.M/0\-],:SZ4IB#0KB+"<^/DS4^W8];/.%) M_?""(J1D_!WW5Y:B9L#@IIQEMT5#R2HC]SD.G9U9@ `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l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| M7]:DJK*M^WY^!3'//C?6BJ-N&D6=_^]X588-]K]B]& @I(A*8_? K;R9@5U*] M%E9-=L1>L\|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|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|_X5*D # -,]I&#SB>H/69/?W)0Y"6T0RZZ/(4I,^ M"O"EE&1(15@5DZ;$1&W1[1M 1LCT=<5;&#VX??0@<$&XIS_RB.L-6O"_P(5Y M3? +S2U6=Q(UFC[$-/2\1?3O;U#QD?RH>25 W1/?Y^AC$@8(8O;PMK,\?$X4(MOBSU7M<4@2\L:.US?[?#*;KW43J%.3/: 7E?P>GHENUE.*73K6=<%&""2$? P M%VMJP]#%&[R+P+G[7C<5@2\L:+']_J?A.;GM3N5^?I1H%9GN?KSOJIU.+S-"MN<%L.7%./<7(#1GV1V"7FCH%BI(U9VJ>OCQ M$KA%F0? ZJHL[N\:\DF\.85MRMU6F/-MO5*4BH/>@_BZ>:EB4R\0]0N9GN?KKO@<IS,JL02A$4 MJ*4M3/K#Z ;*(QV![J_#(#NKB$> <3'K(/);N5'GFRG6F4RMC^OD68+/#'CA-M/T(^^RR?C6Q37AB[

*(%'T2Q%XX[9=Z+B _-OV3;(_L=M&/+72 ML^6^K$0G-7%9RXJ2&H>[3<6N|R?>O&|ND-O;WAU\|7'@RL(UR:?6%?T6"MRTM L%70G)TFZ.XA]#&*NBYL(,L[/6BO M.ZZU^IH4[>K3(@-]DJ+W9;!(IC?WZKAVU@3XO)&MWSGV\$WTQS>R[:W:]H4]*

MT[YYWX_/Q&,3(24>@1)AS[1'H438,^U1!"V3'L42H0]TQZ%$JD818:4N"$E M'CY7)Y K[-<ZMH/TS/M/1C^^9\\#-ZIA5D#1%)A3ZX3[TEX?5OE2 IMS@Y:WE?*M T9]? #2]:FLDZ.4)J),5CQQ?8=VER2+>Z<&WFBG MI'E9:#8'LP:>3#/L2](HVP:[A1-76?Y12#CO>]J_OR6\6:V.7!9?* "S.^8 M-!PBJW^=TCQ/,3AE^,[FTMHLK%(%A5/UML$G*[F*WG8[Z9&)2#SQ$CI-6 ;Y M36',;Y3R3_Z9TAN()?*

<77WN2MCDV01287<>@6RICYGO3C=NT+D Y$4LG;H&4^ MQP.!Q#S+F@!FUSXP%L5D+;HT=!Z8**O/!)S!2XX[(@#H=>@W!*$-BSP8T&H M@L+ _/$:ZV[^QDD6?946L^55&^WG(?O*#PY<*\ZT87J*LUP^+;R+XT(_!3)N M/SHR%4DE7JHQ>N!0SB.P=Q#04X'@=+YX_E#A/A^;L<-I+AB QVLJ5J"7; ; M*[L9TO&VZ;6,>U6*;^;(!,Y8'W8HC'"$$%,_&F{JQ.$.(9+N%4 (?+T_U]*_ M8,&W;&9=*S5Z%"/O1^7*"E2JA;+H-AY+QU_"?WV\)Y(&W@%3[% [&$\8$0U2A$ M-;ISS. JLEG67C]A3('=DKAD+H%W>[T\ ^A9M"YNO+9A\0A%A!#5(2[1,SY& MX L+6ICO&3OXD#2OQ%5SE=;L)B-*

OAM4D6\BE!,/K\I4D(G3R58?CSLA"W[G< M^--SS[P"/G1Q_2(_=:1^ /[0^09 "J"7_!^ MA)@8/#J@#=> 2ZZ-

*;$G.8W+E.M.IE;$N7#$& U!W+B")PU0X/[K6\IBX$6FI).X>UW"P)ZWTL7]WE@ %X7-6=U[%+7#DN"^V>; MD-],?RFIE39$!_ 3B5FP[')=U8U5ONA(R?6=_H4^$3VK&[+5=V:KIQ&;@2%; M%H J=M9Q[7!/1[MT8B)$4%]&]JY4GB6B9E2Q6^TI&2U/Z>R \J_5&;+=<[XR.6]]B0Q5*TB]I/??+G*/[CBA-=V-*

5>D+21UX] M_?+CF74$&6-AL,J+A:WYMYR;8/Y5A_YT-!#PH[0%?!)]0RIL]\Z:G(/^#19#9SG3M,@./1@YN\I2-GC73U3PS+F%#1 M0#&R5S8:<,\@2?6>?A @NTQBZV^VN4,M.> M73O^[AH\KW+EQKSR2*D/ @D;)W V&!0Z'4_F'P&/TZY"./'S$#B'U':T' M^M2/4W3;BAY85; --

*])V3QW_AZ+O>.G5TUS>2#']'_,A[1@$.0HP'3R(F@//1 MQ @F @TJ7M5%[!4@U\JF93CE\<=CLW=P@7P@H-\%!R8+W63(%33J$? MU?BW I[TCT@^B? X0;P*N ,%,>3O DV@+I!!=%$'5!%3@$S/V;4S?@)-H'#-5A)OX'. L9[!U^/ 5< >/,I:^ M_$T2,72<+H9@%B=BR<2]:/?D$H\ZXTG.]PT]Z**;6 -LL(Z^X#3X=. <3]!;W M!;\P*/M0&?]WKYGS+2Y'/T/.A4I0O2@P]SZ"AM!!5X/BFM,=F#3SR/;<.93$ MBTSND"1*G*._>20Y?7A)RRL2N7^$JI7_"XW _A+M-G0BBO<$-*

IP9.+I MR%IGO>;J\K;(R&4K65^P.TZKM2?D!'\ZL]_3"2VZ30UP;MM?],(S8K=1T?7V%C3_FYRQ&S+1S7I4]69ZJ6U9A);|

*MZNU2HZ^Q6M/(L71AS\]+ ^0[!U5%YS=7;]^)PL#;[?$&Q^1[%UU8J3:EHY-7; MJ>5@U>?;FP$;53NE!,V.*7XM3N+7;*

[>'EFK%02[#K&AVE5M;B7(IW9XDKD?R MN19;ZN^XHB(&[I+VMNX/$/A^*N1DVAFE532NQV^6TRI.+ZO%,Q)VPWGQ51GL-VF+'%"$-

*=/K728^71"#C+,@NDW"&8*BJ7.!@V]XA(I MP>'KX62_Q,G17%[LTJL$-\Z@H5=L,ILVRI*>VU>9565"RU0]W^O:&3^QPW.% MP7[;*

[E)=M5F;2L(.O]G]\O8P/]N9< M]!,[NE=**SBY C@']'Y]L0#EFNKEW%R.7/-[>VN5=B-6EDP[,ZSF1]@3AX^*

*MFMG>=!AE4E6%VPF<,,IGC&BF[=Z37XZ=/IB7%'H+]Z&UPLO]'A+0] W,9V<]>2]U$[@S]>(O2!.T%#B+H]?ZX[P"U=AAW.(18< M]/GAH<*O(F-AP\1!S@<-&QP+11EIO@?@<=C+ -=] U,#!Y;T--Y[X9M"K[I MO= KT2#&6^/YMA9T@X';U)P5X!>ZQ_TI.-LS0KOC>X1<+:E]G35LEK5Q:;S7 M6_54#3A-*

9+/GB"__']ZQ&I7T#5.,^6!K 8W!C[.)V;"=N(J -2'G&UC. M-@#26ZG)G+-&&?KHV!&-X\MPH;V)GB\1@_FF6W-

M;G#0G[^O/]MPW=EPWMMPJ6S#7\#G_O9B<2O$Z_/C&6=;^N79S/GDZT&Q4R&P MXU/TMX#GB* 3M,A%/.#4")$G7T(0J1BR61(B4>@!%1.(6+_@U

*B$5+B(2@18F(' MCHG]LN_Z4\HG7O8+0TSL3RW^P3&Q7S.\/QL5]L%I?R?TZWMKM0= OPY$J87H MUX^+?GU_/??]L/^_/W=\&A,[%1 *Y.4MG1< Y_7%*

*AB\[*7D/8<"B"TXS9YQ MO.5D!-Y,60:^+#8' #S NF]4]Y_\,_%,;U[I]P!>R*9.TID1A,ZGCS"'',G*

M::R?"^/9W9QW:>A3/;P@Q(VSX$>/@"D,*CLM<(\YZ$6$^E(DKP+9J!K -G M]D#@ 1YAX2%]\6-! -Q=S%49<"*U4LJ*G%N6-Z)43[=Z'KHQ247B2? RF]$1? M'ZHZN2W1<^^$UTW+='P6^!)@6KH&L"6W6[BYQM__9/=UGLE/7^1KUV_1'?= MV4,Y4U(Y)'10;!4/@M?RY,X/N3A:.6?65)%EY>:

(&RV:NVZENW&1BPDRDL!? M4D_?]QC^A2['3U]EB%Q\$]?C@_[GLX5)3'>FGAUNQ_L>]LA44EE/,QB.I(B MKH%;?DR@Q-*

*!WG(]\KS#X\=V#'T%Y'7_B(>INH(B>7'8.8OG\H2@K%S+C;KP9 MQ1?#^+ %2A)!5#*3A.-U1(AT&/KX@:&/H%R3/U'&[X>5^'8ACY-2F\/-/[!SNL*

*"6A\/7+FC"(2RTP_YJZ!; M4G^^\8XPWA'&.V[E9IQ$[4T!6+ J#,EJ@<^RN74_0?>+_0Y%>[6DZ0B<8!C@-M" ,Y#M@#30;.(A:,B\OW0+E0[G?+G*L*

+RY(0U\Z>%!/SSH M?SL+[$0L/:^W=2ZS1Y?W>3.\ M9_@#F3X\\C^RM-_(?@<3=7=J\\,3[>.>:&_9U"'\]/'[BH.K AES#=3QO(_5<

*M7U^S^=62766J3:F&9RK9@3A).6'Q>"1!7L.*AF?5!SZKWKC-X(^7Q/M%K=\M MBLW6;DC/TLN=LNC1TYJA&]M,M@U%$?*

7VB=#D=9>/;W\;KP'.!,=@.\?S=WCL M#H_=X;$[V&.W(YUGJLOKEJ^)&4THR!JG\?!G'T7&CO3%2[L#;9:6I@9995C M\-0&31)=M=-AE4%X[OYCSMW?*

*Q&GYE+RWITV<$:.X8(KIL;*JFXS6FB#,8-]) ML\43W_S2'>&5PU>X)0:;*0M>MX';.RL_761=SR3H/N6!ZRW'30EZ%SX3/ P/ M_FQR4%3.' ^OVXB_-*

*A_DV,]2'"<&@#EM,74]3X"4[Y9*IRYY;J#9=EK5&5 MW$S,/:VLFJ/]?-*A)L+:@?.'5IR*4"]6Y7S'\,,1/9=V7M#3+4[%WH0(',8F M;A^;"+[7^-?*

*@ZO(3@QTJ[-^]3N!-PE_2\]G5)M2>+,?2XD(K M&4KCD+M#(>'>Y[

UYH[I/LY>7\H$W'-J6X,_(\SIE\H MVX$N^E^W$\V[K^/,E#MAD_,%44\7]M;4YO?":WQ5D5F4>D>-F<\%S754#X6R
MWA#70U(,_\""J7F\BAM28IM5Q]IL,XDC;4P2D63:KW#X&SNB7H/""Y C M9[]"1_3;,J!J=)0;_X\O>DI",9%NSRBLEWV,#WISQ%5&. #KI%4.+*H-LO5*
M<9D:/1I:'SJ!H-(_:] M]]RIA+YMZ-L^B{X^07$*8";#"8$:RD4L:W!:HGQ4IME=G9OKA@,(>H$#6M9: MKB;H>(H
*JL_\20UX;U%9GN$SNV&>:9),WP1**:'=/H8E>+I21_?W)$XKZK]P MD575QP+0O7:"+0VE#5,,5[BXV4AN!B3":$ >-!TA*:\V+M_8@V[:5M2K.ON) M3G.*
*6CS Z\X'5NE![\H/U.^%#^CVVB&A_)@#? !PUE*Y-IX2^AN6+&;Y:;G5 M%K>;[ZO/P5(9]AJ,EF.X3F53%$1+F^VW)TFDSPDJD]!^ODO?;1%*
*M/HK6O]Z62V5'094GZ#:Z'G@(2W##;[^'7/L/TO*XS_N4+E]XW!AY=UI MG8WS\;7$7D9)[>[^<_^>XG\(6& M2O0KE&@#6#*
*[*LV7L\^8N7TLR))=E5:9FM>VNTS\%58'%(XDT_9KV/."V_?L" M[2K(_H\7*N02YQ.!@WVS1KGG@&Y3H,I@[70&X:P(!G_4,*<3&68 9 U,!VD0 M 13*'G?*
*PQTX?"_ JB<6XZI?.N;P2@8]P8,D/V''>%X[-369,*Q$7+ U-Q6U) MZ'6110CF#H":]V7YC%'?.@,7/?V[RWKB+9UL#L)^E0ISWE]\1&++(7RHV0'CY/3-.CZ*
*M\X@WG3;(QG=3(DPTZ&82?#L)/AL?4;P<8WM:I:%Y6B*F;$ M5"?1BL#GIFGTN8^RE39$H=,JMN$\49&AE_.K+?9>3Y?+G=*IRZ:C23-!"[*
*M9MNOCV**+4F@,F0X9/X]YDLB*>SRW9E2@,I.&&3X_Z&;\^ MBHLYEYJ6:F*37:UGO::>UDO$6/3KHVB0DWD\.^\R;+76XYKS046<;'S[**8Z*
M=KXG6ZDV4^UF>NT$D%:LB49>K7TI2#U&M7M1O+O)V=9]JHV[QL:/FM.46IE)Z&ECY;VOA1T^Z0"RM9-A?KM43B"9.U];L+S6[DZC-D^9@P^Z4
MPKXXK-:V=L67FNRRTXE'!V1!Z6[;A#%7+:D^:L.15V]?D9J(#PQUST93B;I2 M;BG1^#+C1TTQ(?3IF=E7E!VG98EV?
=$:.Y@-5V^O:T2R,)QV:3S*C=)D=H?W M*0IQR-7;2:9L,Y5L:L\6J5HT$UULX-YO_.C>;LO\5BI?3=8>\)5NLB8V$B;B
*MD*NWK\4<'U_%^V6&W%3+\76Q1D4U-/+P]O=W9;QOG\5W> ^2(K'Y-1C!9RGF\%CX2D'1\0!IMCC#:LY\SI_/0 ,7]G23 M5EAZC4?70FF]KL3K@l$FA*
S^*LC@9V$=J1@5(F^^%EM\1VCQ9IBH5(Q(AX1Y M0,(D8ZD01?@1"4/%TD1(F "BGST+C;KSEH#X6[?:.B ME]=\G^\-N_T9M^,'06VS)IC9)5LC9+*
(;L0W+WL]Y<5M[OZ]7ODG?PLA7| M$W(O(/(U@Z2@@-I%.2WU;@\T]YJ.1\NK? ,.%1;%+KO0WU%F M.TC7$A6!Q.5=M[L#H?
*9Z%A\B'2XCR#2=&:U14)IM%4VNBK,!JER11/GHGNC M1R8BJ9N6A]S_7'@C2^YU OW1Q!*OMM@_V#P_#GF_T!;_88M^->X8VN0OMLE0*
M01_25MOD7HT:4HW)%48!)C\5VK=YNSN&);:ZT M(>\[1]A@(;7&Q6PT/TW_Z8?HM*45'M>6D% 6';ND\$O)PS0.R*
M'AQYWNO"Q>)]4+MO%,4OU!W[PPIX$3KX,J M";(#)P(W;%V39^"H8]AI:XGWY&I%B:Z7.WJ44OA6P\M[(Q+8#JI<\ZK\)0QG M_.QP1F!>51C\>#
*ME=9:Z5FG$\)2O7S>$4^F-:VRV'Q;CZJ00$:>RI VV-6\ MV%-FE51:3(IN[BX92>"0%@1^KR#'10/5T-<-# MQG=WE0[L>%6)P7BI-2/4[M*79&WZ1I?*
$7>YW?KK/2>:7Q6527=99E>C%!YO M9-I"/HDJ1;["<_]SYKLH$R:&B%$3U0JHM.K3S6 M*JG9-VY3PU_&Z&YJHWU\,RR=%-.KI
*CT40$9R,__B8E8M@\W*Q5!C& M^GEAK(?>EC#:\DJT)7B@H."R2X)?^P_R&!X8).DC!IW<-"C6WI9QA2YLB,F< MS*
*HBCRK7T0U4.I*D?\T*"1&4]ENO?;&:<^F>.?_[CUO1K9\%@JYKMPVP1#DP MFH4M=53;*T./!BX'F):N 22X]J_K,TU8M*;J>'F^I\QBN!^LCS-*
"5NZDW((SPEK!R)AW:(DS5,0UPK M LT#2\)X]%<#X1=!(P2U4,0O_HC]U1CWTQ3^M\-EQ6X5^PO^)TZEB 1-_AT[M\-(!FLN4. -(N@K9S#RQ7:*
[?,1W4KL-4EL! \3%.A"[P00@V[^%H2,.A(%M M.!TQP':JPJ21,,N_)275%Y&W4-WN^2\\JDN+'DS7PX%9CB@NQ+B2'3'N1$ MWP/-A^W?&I&@3
*GKHD1S-4PJB/$G "%2C8MPZG/1 +K-8SUK+3S# ^84^0'$ MD(^CUM!/3DC,$4?3@O^XU@QR_@GK@7/+/I%HZ<[W-P;RK/79[(#*AL2'AQ38*
MH4$7>&U^\OV2!0YE[EXR=_"C7QQ(I=PVHE$_P%;!1-;,0Q(4E>,,V!\:UJQN[\[GLA4.8?'BIAT])$F2"3)\;-X0L*O.H M=%CC;$%&D@Y=?*R*
*=A;KV@OX\)WC[1TM$%S?XYXT+]?I'C)=[" '9+H84Y*^ M,1U-9Q_7#$\0+C=AYFG-9U87N?$.6*ID -=3UR_80NX%,G$)RJ@'7!TG*X M%Z-*
*PQR>F'+]==K7JX:QP7HXJ<0*F\TZ+,_B#AE4XS4;O)IROD\BUA];Z-#=9 M?5?0H?76='@VMHVE;E@.=.SQP+R1/)A7S\,^HLQ"GK0=Q8_<=.C>Z[8J*
MP'E -V4@';8+/?<>5H9>NSLC2#D'WGM*!G*J;-2T]>.G4] M(QYMOX-*
M#,\!,]N"Q@@=E&1=^'T>UK@S9)N/FH)BX$A!^;3IUQAL);.ZYUOC M3H(9%($^ZPP20,NW0PRVK\)@C!$#'J3P6(M>C1*I/]<1*@'(P49(\B0$H] B5*
]/0HE2"(6#TEQ2U\,V/L5??U"Y>=^JK4 MG]<\V?QY^#A"'WX_WZ1OSZ>'"/G\NW74+,^\PJL5L^)?=3=D ?CA#QN MA#'WFEG^\YCA_DT!/AL-*
#13_>H$9'D\)HZRP%.I/3*TX&ML?@SJ MNEDG%!YQ?T#AW5#[W57[_1EL\S$]&6S.]+&>P$#=$.T;-2S' T^1#RCYFPH\ M"?
*Y&R=Q>I.LAJ^7OEJA]O']*NO=/U/G]TZ?3/9,2(.IR.UE6BEE[U6T)W*0W M^SRDT$NU40LLZM<_R7@D05\G M'\S,+@8N&/^?*
O3==3ES9VH3_]U4HJOM\4;L;.$+,M?NK" 8QF'D0&/AA 80 M: -#+[ZSD$2 @F,;3"XBC?.6]O&(I69:^7-3[UZ2R5*]L#H2H1'Q*
M#NE"A3'IKMCI9%/9]3C-?K5$6(_(@;$5Z<2|*>2GY4S,9'(Z;'67_/$[FDR$ M4M1E8,".\=5-?&8-P21DS;BC-A=7T1!L?3SH:D$RR5P$,&+ M-46H@=,
(I!/80#!Z4.&W/)Z/8XE7A53$Y8#,).-;S5PNBB_'%)9X)9=+^PN_+ M^(%N;-$_3O=G E[?_'1_=ZWC|--MF6TZ/5OU.TQUVX_6R5YU4M?:X'0#)80B MXZ$,[-
*]^_'A_ASK0^R[Z/)U]&UC.YR%XV"DMX#0#E[D$%06>,>;5]A&N;(\W&]8)X!&Y6'6V4/M%9*O<%,GK;)Y5,O-6R_*
MKE.YXN2290U=8<&"K1#DI;ZZNZ<#_I.'[;&2!VI0_L')!,D&@&ENZX-T..%L: M5S\%U["LNO5ARN#):BW&-9)A83A/7;1XYNI]C& FTEM1?
9F^^]=:,3)61G3OW!4EY6&TSUC!{> ^I(=T?37XPT4!BYKV[F M\WZ1676[KT(7[*X:! H [8;_<, ^FOTWW\P>DK MCGE MI)P6]C;V@J_F?*
*^&AO&;,#FU9KO7[+Q4;!$5"GBK70,*WF)*X58A'$4_C35^ M&W(N.&C)P!L)7FCX-.59E>59B'AS/T1F$)X3NE8%73%PY"HOJ*!3[[L^&;HY:NL9;G-*
G4NX^ MRV4QM[FBXMP(XH[/A 7>QM%T)3 MJ$BSW9WN*M-! "ZLU*48' MJP6OTLEQUIIH0FW"12<0;YJ, ^ .!#C !IH.U$'6PC>A,[&",D,<4*
3]IF_AEH;::-/X-1F0!CZ9()I"@.;QQF'J54J7GGB;4 MG8\DD^<,S/KPJ005<+V 9%2E%J8(;FMJ<_)+K+>H5I--%/"W_!LU861RTZS MJ"=8-%9.*
*<(ULF*XS@XE8*$]M6K%?_#"(V1Z3NN?>P3$#T@+K3 +? I87,"5@ MK*"B*).J.?9.0;!FKWGU)3N5R-(T?JEDM?S,V-@;B4(W(QP M5?4]8\13) ^*I?*
*^%D@=5AT&+Z[S[J7PQ*NZL4P!S-;*3B/F$+\Q7WBUS^QU[U MCGL@P[8%8&=G>I9E5PU1*-(R$<*X.(@5P8M_L?*;W1H.3&XFXN9]_G(3/&-(*
M/R0CL<1_",_/<#]\FPFKT#U;ME>(;G]MOQ;=^?"-(B6;J;V@.$C6/;NJ<6/ M1R.IQ+5H=: GQSRZ&AOXAIZD -G2$-9$1U-
8%8R./H%OP2_X00!C%)SN_]EK MY@,S@9&;>@KUJH=P L"U"S%4L,YJ&T:LMR3])),CDH2C7AP#FR2[#_=IZ2,1 M_B,X]MQ/^ 3Q?X"^!
[_YSP'Q#KA@%_!S>6!A'AW>(>>!W7W:YG)LJ7=87M15 MCK6TNZ3"E.>6>E;S27+>7_3GR5ZE/2^\/I7BBRP,A_HNJ?!X M8),0>0:"QAEPV
*]9&T@UL18$-JG8"5@ Y(OKZ-D8:>HF!.<3U;S1' D,6^O6 M5*X8DVKI2RC6+L7K[$92+*5EXWXVU;P)U3T,$)?'NA^B/]S%,R#B:+ ^KG/-*
MYWQ]Q:,F27HSFNKL:O-2:O_X'4N_K8\#[5)3A;)+HT=H]YCL++<5 (&J^/L M7+&ZI%D0E'!B :FI :L;L@+F)!?9U+@O\[&B$G745QMC%QU:A]
<#MXMAGJ6\ MX';4#59], 90Y^1 N#(P2P6V]#D^]IEN MY^5\F&QUF6KQ>3G)Q*U-'Z*:Q1(GF,=E$<%^#^0/"#MG6T! -C@XD[9]%"&Z*
MUM@0EA9DIIDF@7^]SA#H8I<,$Z%903?*"1,?.TW 2>4C;\LNHND!VL(.]P,T M6E95P7*]![*K)1!A8/,)BU#%$+3"^.(RK:2/HVHX:.(PM%+%1:$,3.VL&
MHQB<+HUQ6/#4DKQN)CR433+'N73&2@,MU_UK?"&#@P8?=%05^/-:@AWGM;5 M '-K?*
M2+I>$5[,T.PI$9%C"%'7Q2SP8Y@0RB(N[[Y&R,,1"_Z((*I!STB=[< MXS%6@3DL0;Z098@CYE-$X"WD1K.<<5S&% 5(NBM[@8((^QFWC^N1M!V2"'[W
MP">XNS#LFXE+"HOZNE.DD\6R$>NWY?!&N>C-]%X9,BGIK9GYS#QR<:S2?>5 MY(CN9]^2(2BRIUY/9?PP48ZI!!6IE'BJK9D:&=:S:GQ$U9]?
EY.OT@&+FDZ# M&QG3Y1 :>WJA.K2VF\$B-F:DY'-&R!CJ]Y59__@=]5?N!.N%(5N_NXXV=Q%: M%+]SM,5-AWG::O>'Z\++:Y)=?Q
/.Y@8KM;E4=!V"E%3[&-U].XH/B?IXSTM M8E4)-_.#^'HN&"N6'RP:N%\T\VD\'IZ'[8XX4 :BO8ZK2&@(KB W[1Y M'"D(4'"%
*,QG=*6]&/_QK'FB443,({UA<^2C6=$]XV(V/LZA8P MDO):8;=O67?:_CF54A.3.DMW7AE++-0V$I?<-DQ@3E!O"[=%$&&TA/"QJ8QHA*
M=BE+\G:?$24#Y=! &P+Z*KUM.%C#T(!8@.KB@=UJ"MQ4Q;XO$R9&B>!%.#D9 M?O]C3'J,07?\]0N2,@9:LW L4HS_<]$\(D$I-Z(',[!)L"MLVV"*
<@S>W$>O MA1X_';_/ @;DT>%M:!&"05,&65B2@JRE/>OS[?==]^;W(,"S M,FRYTYT@EG3,'8_8?*PZP%0;<'=G>4XW4+]PE VCPW%*
[ND=]GEGWG#22+# MT>L+]923]>FVDBLRK0_>_O9T7;W/OO"##;.1_EIN-#^9;PW\8)A /7%;^=R,9PXU MS8,>*RM*I)X]U611+N397%)/-X]SYD?*
5Q0/B&+;B"#;IK+;D6"JD66C7[;(M,K.<6HII2)OJ=@8D9)0ZLU[C--4$,(40#'%@&0A)AMS^MH R!)CE?2BAL"JG MNK+RF"A+1.Y0X8+^7MG--#5W*?*
^N%>7UV2.K"GM,41T+RW&0>$Z7!L/N#>5!I M$6'8'1:1T2?(PHI%MA3Z&GRC;LFVVQD.!_?IRO5Z!PG7GQ!D U9S, ^.V2?O;K0O:V%\$28L
*M]\/41A'B8U*BPD+\)5Q^R@D?O#T+ J?#C:FH)UD1NJ$Z> M=1Y5'(P@4VUVJ ML%5?>:FQ[GJB.U2RLLCO1FNHP6D1=2M/:J74>$_&(/14A.F\R%A*%*
*M-RHT_@#/+.+*B[R(SU;TH+\1Y:;9J?:,)]P>$WB>WO-RP;&S2"MG)!!DI)L:S MMYPDLH$F][0#^ M5$4:43E9$#?&9@AA0#O$L)M&O27VI^*
Q#G9EE$1)N#P?.%V8#PE_VF3Z N-(-M]\FC$94IM>EP.25.F^6G/DM_4/'><\MV7.WNWLGBW/'Y/#F_8WN7KZ2C)!MA01SP1U[T9KB%Y MWLUQN_I?
*I#H;P'J"B;:.?9['FEN4JT=)D0VY)6:G)W5BWN[XIBS6MO#+?C*H\ M4QWRVUXX+^9'"E 6R(@?D>F P]#60&Y!2<@>9O(75(7.=_#OCP,T1Z>G^'WE*
MKKUMY_90+!B?0S>0{^KW1\1[9)3=UIEUD2MYP"1'PK#'-9BN7!YGY^;3;[OV M\2O9EOXXJP(+EO\ UYO;'IWHCJH1BY*0\Y,/4EI*N16YFCTO(A"%T:*
]O-^_M#\;Q^Q2W851<,Y U":#OV_@:LB875N+N&27(>63PD;(S;X2A. ,+$^_>BC5 M65VP<\A@2U7"6L#OXG:.$$721 $O=./K
AA/"+G96SN@#!$'Q:.P$27R3FNP ME & ^D'$Y4PI?@O\M9\L-XVN]# M8/=68OLVH\($2PN0ATH%Z7F'$;Q=S9_LJ<#E(:.#-+:PFRJX^!:5[[EUNT>J
M; $FA@@(Q4'\M+ ^*/W0>#.V9H>NI!!V$WBF#BT"U+P?\S>!Y6YYH4-QF@[R0CL0M<"/MEVP4X7=UPF1U09'!_04F5V'@?+8P
*MHK16=M5*28UY,D_VR\E)OK3>_'D,O*>^HT0T-W)CT."&@*'"GF8S=B!?LV3W M*;O MJ\T*2#'6C+SC(\W(<,LKY"V>0:#R?*
*^B#/9([$R%.XQ!JT_+F^*\]^5'>_"AO M?G]Y,_6N\N;8550.?=DQ>P MT^5?$-XA**=G]KV"[H31NIM5SWKD>(?@)'\(J7D, +.6_KY0!T=0176K-P#*
MF^S1+.;S 20%*@16.NV"PG!W2]H/*[, M\X^"+O/=JU@+7)\LUT2=\GVAM=2]:H#X^VIFQVY1-SQ^9])O23&+ND M GBM<5.])-*.,X?*
*>_;W'D0_(UJBX*9B>_-C+\)1^\C Q$*EG8$:N*>WFWG ' M(7L)FAS 'N&VM@_IOOTU0*D2EE\,B9:*I$_Z:YHJT=!6GF9T<6A^13.GO#([M5TR@YP4O]*
W"'WXH6W)U=O2!^\P. BT [RQ?]=.=6B4$9C(&F]H$M@Z(V)6@ M&_8#-0MJ=H -?P&E\;2JP5DZC\(Q\QA'EXSH"X-11.R!N#M#,9;23:"Z$(7*
MPB(X6="CS%PRH@]-I'%TP3]@%38:S&&_^ZI&]"=E_.') O?ZDD..W M#X^!%(-Y- XU_ZCPQ?NYK;+4A-D'EOI4W!V906'/W!B4LNM':?#>;[@ZT^ ^M"&A/
'M).#;U3R ZW-?&1=YB7(OEQ(/8/1QUZA7"CUK=RI?E2+_?3S6FW%3,0ZL.IJ[J. M)O@#!7=%7V_-?L:.=AP57^@/6() ORFXB0ZN4R (NH#HVFN
*7_7H]V#.]%V6 M$@WR:\/*'EE 9QL6N(&##-:)#'@;",$9>O\@BD @<%- M5 E7(@)K#X&7@=-]&433.T8("5/;N0MDIBR'P4TZQ0@*O ,L=X6<-R<-W58U*
MDXL$^90]Q>ODLO*ZC$?'S=F6^7CTK2 9P&IAY1+8ED5%!=(1&C40 -714VW+Y2"C4P["ILZ0(,+]3!B13!)]!D3UQ2$+CWM!4K]3-UBB'#E%9O*
M3^*I)SJ,]OY4:B#D:>?(+/_"

*-S!<6+LBJ0=3)X!E:L0KD#&^,043)<=?4F48(IC6U/[&'WB7#P M#+S)=V(K84O.XXL]S*0>]CPTF;)=]K@=VD? M+DA4DS,U>)R L90.$79G!*
[2YH[7:OE=1!E]M(LH'T:Y604?4I0TG;#XV7ZF M,R@$+C/UDRT)_2 M(0_RE3/[_X]5%O]VG)7Y3+]0'3D.7.9A07_04NQ@/!X>SQO-!FPNT-VJPRY*
M.PI';>H2(D04(SLRA;)TW#$@%M1]J?WVKKA&\Q&+V8.QIHUQC3\!=(JPQZ1>;[K,KX%> M SC&DF4,]1:V%LC[BNUKY/7?2
*S^78G6IT+,M$<+0QN8NT17>Z8>ZH#;39#WB80C MV%=#:8Z22(F,I]'3%_P2LW\[P^N+I^_%=%]Y?(7X4%/,(O^4-:=#TN*UM5BL*
M&]M>\\/0S3:PA(/5G'6/)CIL] H%[UUSL:?:>Y&99]65-6H5GM/D0,NU:^55 M.S=_SB(_L%^[W!W^$,%--3"?G7/49BS[7+IN6LY_>AW7O.O'Q0YZG-8,.M
6ABR-?I P(R$;#>SOSK MCL_)ZP&?G]VYZ6DYP4L^@7_W2[Z[*# S&%CS.O_X1+Y0*XLEOU%+V@#3[;UZ^B&2 MN<+.A:",,E1 @E.Y=O0$
*NL(,>'O!W<_E,S'A8^G;'IGS,"P[/YT8=PY"//4 M7B32,:^,578GDN33<(Y0KX%7H ^OHNEL;D\#'P4Z-4OS.]M8\=Z8V>9-;EX3 MMQU*M0TKF/P9O0&*
*(CDF*IO 8!D.,\-.?L@:%!TAZ5-&,N!7V7TGU%S63&4$M\-MTUTSKF@B51VUG]N!7]+/M9-[.Y-+U*Q=&HB#R:9"&&>#U6T@ . ^Y/:+6H%TX*
*MKMGXC'UZOU!G94LF'MF2CVS)1[;D^[,E8^.*EHQ_73.8'6)Z.$RZG:INP 0L M.U.=1\GX!(M G4(NB-"!@G((OQF@48'1@XLZ'IK+6<#*"662/? H,M)/J+:]<*
*MM%&GMV9M*6>V3)C-;T@](4>K(V 116-GH4VCVW""7T&=[RI'K>-2$<,VG^IA:E4NT$[HU8&=ID M% AD_[RLO\)-KX-3&@ 4DM"+NV?*
TC\VM#0B)7K>@:M!3KFIAO.\//D1 M'OY ..\W=Z(\"Q'+QP%;E\]TN"CY@(&IR5,RU8&C_1G)D=E2^)\GX!T<^:/= MFR%BRJZ@LO?*
*G(!1BID&8@BT4Y*P[^BAPQ VA A*3 5+;0+#JZAQF/' GT" MP ['2"JGZ0O<^,%)RW=7"WU-,HS,P$PWF.H 'MC:*T7.3V.'V+\3P#\Q?"M+ M'%#C>'*^-*
U#IB0SA-LW1;-R^WN&?_E.VIQG<9PRIR7<>\-$3@=.F"X !%W(M\00&=6\)>=(=A9 ;7#H>3X)B\^@N?65%%I83$R^BEE_HP_-?E[=&PVV'JGH=[O:
*[ASLH0=% R8Z X$(G\X%O[H6HVN7!{5$_-EO%;6A>E< MWS#8'1F 0\,/91 O2^0S4[^6H! L=]

*Y;_@]J54;&H2!UI5P;$G5O'@&L8',;S%7CNK=M? MQ[GWY]TP3GXM_+/'#!787-E M(,|;_4ZE=-1"|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|!5DO)+=D2-R,,GZY2N5=:MQ8 <1$29(J\5)3T=?@R<3AD|- P9SD4VAQ-*\];5ZAVL]5Y'(Z9 M.GRRO)UH?<5ZG3,6J43T4QZ6*#@/*, ^B9EK4-$54\U2N1V<_7Q%#T: M.WPT.L5c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|"W ,1V(9)T78#0PM M-@3]S$8XR345E% PM\ M17U)QR:!FLY:=O(Z^]1BP()#H:,#5CS*Y#]W>C]+.@DWNQ M\XLUK/M;YM=3VS9;_CXVMVV1NV.!!Z<_./TAT#]DP-S?*A]<_N#RBW+Y7TI< M;&]]$_+>730F""&&Q.4N_\).ZU2&@("1$UCU8M93E_+DO_K,A+DEOQ$Q/:@ M.\YMI78N;%C6%3RF8@V:Q7[RU@[*`.$9PC@_KG0+OW);]\>R4]2$W IH M#-_C%75AF09Z@+*`[:,77859S4V2+:]25,X DT[LH_W'SH <\]9'[E92!/3% M<2\7=BSVPRVZ%J(&'=^68G0IEJ%[:G?8+.=@>3;UXWPB+*7I=3\ ]5HOBYU*_D80_7C2ZW4WO9:M?97>(KF&A>-.M3;C6$Y,G.ZE>OBCGZ"4$O:/ 8N1(9*\HJOHSECS;PYH7Q0%V=QB9G(N M+H-ZGE0[W*%K.+*HA,?5T? I*I0O:2!?J%0HG8E>S<=U9]SXD"\/^?*0+]?S MGT7YK#J:/9<*C,*\OO3+NMC;MA&6>/3'[VB:#"425[&K[N2(_4495(%NM@_Y MV8XM[>8 !YX'WX/K\.V2K&Z^Z*^(K]S7BK\H/:^"^%GWS*,=-%OTUV4;WM>@' M>_\MB_[I1/27I&[9[KTCY\$7\0(RS$>,*.F=W M@XVB;K"Q\!++# ,:>O/$HE%X^Z]S_JO! >'AP^H/3'P+]$25^^/V9#:839<+]?_6R:;_/%9)5%J%$/=?&/W4'/%4>QVI2:RO;G" M/=.:$AXOHLDO06T(+U_'$T&07^CDG%3*$SE7H,NP"SG,Q4]<.1?_+]4S[D\B M_,VP#7^1)+A$PCSYFJIWI)E5I(5\?IYKQ;0VK4"!D? CQ.Q9*1*^9,/^0%W>FYL:+TM+++S>;4WK]>;\:TV6K6!/(*IYU<5" _LA@=VP_D. MG@=VP[?S!]^;&+^/(J.<44SF.SE1%*%K+*HA,?5T? I*I0O:2!?J%0HG8E>S<=U9]SXD"\/^?*0+]?S MGT7YK#J:/9<*C,*\OO3+NMC;MA&6>/3'[VB:#"425[&K[N2(_4495(%NM@_Y MV8XM[>8 !YX'WX/K\.V2K&Z^Z*^(K]S7BK\H/:^"^%GWS*,=-%OTUV4;WM>@' M>_\MB_[I1/27I&[9[KTCY\$7\0(RS$>,*.F=W M@XVB;K"Q\!++# ,:>O/$HE%X^Z]S_JO! >'AP^H/3'P+]$25^^/V9#:839<+]?_6R:;_/%9)5%J%$/=?&/W4'/%4>QVI2:RO;G" M/=.:$AXOHLDO06T(+U_'$T&07^CDG%3*$SE7H,NP"SG,Q4]<.1?_+]4S[D\B M_,VP#7^1)+A$PCSYFJIWI)E5I(5\?IYKQ;0VK4"!D? CQ.Q9*1*^9,/^0%W>FYL:+TM+++S>;4WK6

*IF4JQ(!%))6)";OK>ORQ2?&\X+M3DEF 8W%S*S2;X=1,V,T8B) MG6)B2V_506E2YK51Z^FN|?;:D>6,"P%,>9M"^(-3QWR MVWC;4>V\]5? KMOHY#3&X1!@;J-#@.VC.#30_68/[T9&V]^)S5] YOM)DE$Q, M794%==Y/MZ_52-5S<7LOGZ"LY=TWX1_/S&'^KIW$DI'XW]I)#*N[$3(1?,IO MW$2)BB0S#\+<(6& (?"W-K>Z;\)D_MZN8U]"F/>65;YUM=QN%[ZL8=1;0OS2 M? =@"=N!X6S8G',+_U]NOQ6G.F>]UOW32KZ;]1UX]0^7**D/W.__42\2[UV&?^7I8&]NTSI=(K"KC;_ M\E+G%+J;F9)Y.M,KOE2? PU'6=N/&.J%8^I(0RG>@3/L!HX[G1/R!6L-7BKU; MPR.=VI2+P4-E J!-[@L*RK_XJR-#W958O![DUK:4&6AV%?FI>&&32U/@C;- M3W#OI$PHE? +G\GP"W^D^=4D$4/_0&*^O.=X>/.EF*N7ME_[0.4_KG#CU[&R= M4Q(RV^>7V=.0EQ]3:5N9:]>\,L$A>2H32D)!R=%'X:!V4>:,Q=D/1<5^,ARL M'0OPQQS)[;X6L-35FHYM]HHW?8>\W>Y]J)>%53ZZRV4?^P)?F#\03D<1)?,D_..AVH_ G6E0L$4G]K7D; M=Q9VIB*9QPFX"TI$(^G'F;@/2L0>A^)6R1?':/+F5?V5,_&>K?@4)[YY4?Z1 MJW[K3KK*HN\ETP10/'W;3).O3BVYX9%/OXL-KI)>8A_Q6Z=/G+\+.=N" [T(+ MGM@W_B^6"3>K?-JL%RX-9L\1D¥\>DT&EL W+S7SAMY,R``!A]_!^?O M'?U;KR_+<;IEPTAAR"X'3=U9HR1<)B:>N0=RWB*XD[X',E^DI4? L9D2\GR8> MWRP2DS_:\[+W7&1*\TEYQ$AB5"U%M22]F<.JSSAL5!1-7[!QW$T,N#J7RDJZ%\W\3EQQCWTXJL'? M/D?I"U7\VR_V<55<+AN+;*]? V],@)4\KK7AQO?7I;3$# 5+B=Y*.]0U;\QV MX!,W3^1Z-W\YD1¥YL@:;;#;F(N9)*/+&]!0%CP)(IXB>$$U<0".Y>LSFT'W K MCK7!RTE:.\H"JG9[N."OP*%T T.@(P!Y"*^+<,L)0U E\(,A -W' ?M%TQ-9 M#H/3:"(!.U^XS5FN#0I]NJDG6.("+3$/IBL!8;$2#!.AJO5+BW?T]SQ,48N; MTI;?M)9,5R'S SHA)+O+]V-(V?)%\&MD$6=;@*A#XLOQ0((3=9[D2CK/%F MUN.ZW0OK?9\<%CQ9IPCR7"QD%S,SQPSX M8HE:::_%CM8&\BAQBB (BEI$8V-4[D/QQ=J>81? #&IS&ZW2#N3'I@I_O"+R@ M+. J6T B;_P>;O'I1WMKS1ZZWZXDUMM,.D-WN6)XTZC4YVEN#\HZ_N%CZ]!6 M=5@3HRSS=@,R=B(V'&^6P>| $+M.1P M,DK72]JS2US,&&837]#D'K1LZB)T*J#V:IA+CO2)>THN^=?F1*>EX:@Y2N?K M[5(# /KF%E!:QIAG].HT$@G,3LAZ[CZ'/H/0JO^[GST M\>*U'&M=Q:@,DME(LGCK(N[QP(2[T3#3C3; MK!+R>>M"U)WFG^BM>]O1>G;0;/^5.]7U+3_:/%],UJE1?TB'GX0_4IV2\L8 MD/.Q(,O:>Y$N,-@, (0]"WW# YP_2#5H;X?54DSV=")TAX+&7D1D#1P&G&;N4 MT%CG]23<%S@<#.L"\?$X].\_]"78P+>F =/4:*KT!G;$M21C"N?@2@&@PX%1 M \5!+985:9'M)>F2/DCU"M'61"\CW?:4. "J&[JWX%5 "'LO=8S((_+AM.* M#_5]@]V?[7;-HMW=TKX(@N_*D'NM@;M,GP@[N00_6\/^Q&'/MP&G@]W!K87! M1/< U] G^ZAK(?LP!!T5_+<3AR+D/Q5_5$NK&/EH:?5H:?5H:87;^XS&<3(= MS\3%$9E*<*.X1R9'&4%(C;@D$"PICHL#;? S'[_V&0#U5W;8'1JI,5ADF:W1G MIEK=!#;![M7%DM(64UW2DC;K[+ [DTEZ IY,'SZY8DOY;=(I4>3H'99['0XG-2I99_,QS*OS;)!IXHM M^&3B\,GHLI0(3S]D1B>[_4HR5QPH^0Q\NV=>]=)DV\BN*PHCZ;UX=VOT^ET> MM8SR=6TJ;;6I..R41\R2&B^]3\D7CIRO@SI!O0Q(LMTJ">MY.*NL1H/&MB17 M(+2>;TGS_*)08G**0EN-QHA>=CJ%2;J-0? @,>D95!6$;$X8+FK+T\+@XJVQ? MPO#MOL7/GA:4"7;*FEO)487?OO3?51H^Z5O\,BEHB70M62&%Q[!;G4C]?D[2- ,9Z5)T$MJJH+O52<=G2!+E4[+SQ;WJZ*B8FG M9=6.E_5EF4ETQETZ3U6;JQ$_Z8[!ZY/^,7-M)CZF1],.T^3;0KVQU0=1%3[I MYU!C87165K+*A+>-49>/+3*;URQXTO=V?E)(:-_*5C)??2T>;1:NEO"4 ^ZW'"%=TI%4\D&8 M.R0.D&0G.6D>A'EL@=A'EL(@=+/'1)13(/G>P>"0,DV>/$W"=A'G2Y1[H]=+(J)/N MNL3V8(TC4<>I5C1*M;H0_,E;1LH? TG'XX[P2C62NO$$7YA788N84JSQ$YQV*.MSF]^2+! O6< X:NTM'](W>M*W;^.H>Y/-G]*I[L*B/U?(HP_C.:>B63^+%GL MQW:_FB/KP3O1Z)_&.["G? V0.P^Y<]>\$R4CU)UW(/FTX/F8;G=OWL M$;-8V:/E@ MZ8NQ-$Z\NG^6OE:A=0H7I\2\Q2FQVQ1:5[1\VBZG+]2D)Y>E9-V.9R:8T>3>T M]6$IC%/Y F9!;V#U,2!E5M$ E[RB+0@ NA9+JYA)2_R6%.BX,JOGE(4\A35E MR1^_TZ%4YE27FT^:)O=VQAZBYJ^[/;\6T^'R;)E?)26,E^5X/'N91LG2JE1> MFXO8;&)"*9'Y\3L3RD3]> P/A>2"4@(F3=W;/EQ"3."LH[]>3!QH).]6)A*+_MV;1HC#9,OE=2T*/*.+ [NO;]/Q@7$1*;=K-.I;&D]S^>DCD(M^@VKE86%WQ1$ M(O%R?CE^BK=0Z#?NQ^PZO8L+)<_,*;TA=K2K1NRW=>>I&^>R' '/HN_C.:/ M+/=71X[UL, (5>P+]L6QD,+4$HZX5&4\W\VQ$>IZ?M!>;9Y8Q M$]WL* $]'%3"W]CC#PR]/L32XW]^O5BZ2Z?(1R0*N19F2B:VD1EIWN=>7MO/ M? 68(H:@R/WY'0U3J_['W94V**TFZ[_,KL)IIN^?8)+06$%"G\P$"))]7U\P MH0VA%2T(^/4W(B21 I%K)0E514]/=289Q.+A_H6[AX?[2[4!ZK.!UP?UY:? MVR)*X#6Y-E%N"E1NRX7R$5"I"_4&WDSKUK!8L&BQ[75<7(451Z'O)$>^=_S M>T1J' E2E/E-2T /"B$;)5 5ZUAVL\]^.G'3M+GJU=3URQQ?[> [J^DN_AX;< MA>+&8D>NQ_3;T$-^7Y_+F?N@,^1+DM/QXKIH=9@*S4BC2GM8DDHPF2T%;XBQ M[`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| M>#FK>4[X_'I$,59R.%Y5LAA%MZD>#+_1C;C:&0>L5\$G%MIV>\+[@7C8&XD6 M&D2$10"VNNO?7X)/10%=9@!5#' "SS^=6L]%(T#M_VDSP6$)^H-YISCTUA2> MFY:K!I?'0#*@]H"&"C3 PS"'@7D#*8N:(#A!ETBQ\E5[>&(N9!$H&JROAAW$ M%^F+P7=UP;^- A<;"8+*6;\P'4X)C0=79ALH4]!#A#!T9!/X49:.\._R|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{T TQ^@M3FTHF=GA9(_OE^LT;TD B*#7+'\F!()? M-"[M^DN_#4#_ UUQ9VY#SD XKG;$9FN.YS%97/;J*^T1YY.P2A\)=4D\?Q$K M]QZE]MXHM>O+\=7"V*Z_])N"L)O622\?YW;.3=/8,] ^_7%^&H1)]=?^FT@V!_HWGL;@BT*[F!M86R! M83GB42CG&E2#@4I8_ML/\B&3QW\K!+LUP'HF N[Z4GL'K-L_K)M6N2X?0W<& ML,IE]E&FJ,R&*

<15\H6T[^^V^U@6 !1U__+&R\3>)ZZ_?Z-;(S}."VM|FNC(M>C+(8 A8Y4B6GG]K#O_X1LRYH7*$E]"QL@YKP|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|^V;P3+G@ZI0X\8#K/=A]N MYXDXAR^21YJE;BI<<3<<2P:VV9=[S&/??VE,/?^M%]\GG\6.V"FVYDEVOF!SXAS+LR0A$(A#&5EUZ MJQ(M>W,BWM(1Q&]MY2H=C"H6]%IO]CC"F[E<=K2KNR8466?3 [!LC0>9#:# M63T+@RIC?5;],6S#=PM=K"VV>F[#6E#29Z]ZGXRWSZC"MM+?%S+#2K@Z,_+C4 M8@;T/!-O*7]SQ\6F@VE#E[7[? 7?#NIEF, M,&D0Z<.VQ68;-02JCBL"BP.VED&'MFN:Z@XJ*:9E\"[GV*D$_4S"C >4:B.8 M(L1//N/G=#AJUOH75*1NF.&9.8B9$9/;M&WH=F&NH>#1Q9VDHLC\7.I6]XF MU]$1%W+&$V/$97ENCFOE5CW38/H5:C M&E+3=:.28='Y6^I"H]L>ZCG&L^]%/ MOC[#"/FG9ABYL00)1"K[8@G7^TY\70Z1[(N%B>X[\54[D7^Y0M1](RZ>).3E MT^&SDU; <9E:0Q(42@KR,]Q>@[44S@+R,F5\H(+E0:_\8,WS)'=HKP'9I5_>K M](O)WF43B) W$A(4?9:9_C09O^[*KG1'G+UZ*OA/N@:.WV)9#O+HENK2E[ZJ MMA:*3]&&'WUF0;'#N1 MZ.1XU<7:0ENR-TIL]5'K^LDVL@$]_]7:1;>G$++V*2YE?0O>X'1#ZW5?YY:K$ M[PY&)5=X4_**KC7<[OM5C,8J>5M?/S+1F=- SK^LDK,MD"]J, ^'7AN34>B[CK2 M+Z\C70FQ[AK5Y4&L#RQJ*[GZEL5I'&3.>)FZ:1 M:E/VKC:]#Y>N_? #@)D#]VD3XTO!KL)2MYP!+3=1@T!BR?:DM,V925DW) MS[:PV:G";D]9\I/0& =J?<[KA;OF=6M5ZK[.?77]H?Y!V'8&S<:.5A#C 39!PQ[U6UUZ7IW/RNCMQJ 9?OQ5Y A(&7AKRB(R8_P M!1^[EHT"O!>P6!E\&.S'9P7M$S#%#0MV.&%8$JO+>Q^/4;4JTQ(X5=:A>(+% MNSP,C$/Q6N&'SE,,%XK="DM<10.XP,C'[9^"O_PR9T\SA_%5D]++%]NJNX0? MKX4"MA[\.6]8_RF<:1EPT^ T+4%B+3ZJ]@:?Y8"/4XFJF&"? EHB^S"9L$S"X M*'.!3%K"$\!X@'0+X?!E@3^*'TMXAJORD3G!5, "P??!R"7Q)S\]#9 P 79] M(W. 4,Z2=8[Z6K(\F"XGR!OP-;_>TW'A.! [5BQ,/(6C!:A!Y80>L:;J C!#5 M0MJ@OXL"K!A7U>&"=<&'%+1DV-%TV*\V>]-$GX5D?*R7P= VD"W^XL4*WP!# M[RD/6 C8%Y!S$5"F(;-(<_%? TI8,2_&5+4,["N3TTP3T@.4HZ?#MZ=DJ@70^ M,ZEIJQ<;<>XWF?A'%@_SPS^1Z,N#X6;%T36 M56$2;Q3-&5$Y(P&?X3X>PF_I,.CS& XX! <+L#)-2*@R$D4PALGND("ZNLD" M<\J$[YS!>+XHV^?#35-7BC"NN*S% @8*H+P*:*#I$!4C>OCU7D-47SF[CK?C M_/F'X/(L:!? A,/PK#!FX1DP"PX*)C[D=POX 7(1 [P)R!.>=.BDV06$\L$I MD)!/2.:?8[<1Q\+61''W3UP&5A*9E=@SY3P&ZK0[YB75M&.H.@<0 M+7!DP#/OX8 D.?- &O.KAP'7#4;" 1G<1.<,!7!1U]&4S40(?, MP\FY9*.VB'<1E_MC@R6CKUK"V14MOP8ND"8A/(U\ (L4R)61\G%$G*B\I1*/ MAB< ??]X>+@Z"\:N +UB"7A!L$\6!*;'0BT%27$H4B^.$]61P&DGP/^B'E59 M$51Y:1@\[G]F0<3 OVM7%X*BC5:AS7YA'B ,_# :0Q_%S 'G*$?BKY * : ML']T ,,Q.!:.YBT1_D0FL@ C"YM0,8 K8FU#!SV 0P/T@![R^[K$4[> BV0; M'B"RXQ>?Y?V7"[/XH'=.=GB7,UVH%9P4"S"V&+V"?QA=^* MB+@O=U#*T&(6L*[(018A%OG=0+4=!5- (/-%&P D+_#^)90B>0&1UX^G+ ;D/ M7U@(CH,.'%9'"&= 1D.0ZS<,,S\'^41.OQZ,A_0H>"#9 /-]8T3@PQ6'!MQA MZ>>PS_: ,<@J*(1P%+1:\" @6=;N(K [#I\.>PXQ#LPGS[8? >]A_:GA8ZL ML#TZFH)I^MSWQ"W^@0%&0AP,--';K9]LV(,- RAW4@\!BE#GF< 2 M3+Y0Q'G)@41Y[A44>CF, $\W H%_P*7EZ[L.#/%Q,X@O+UQ=8%9Y4_:4@. W# M/\&?.GYA@%MG-"$V04@01]2)H]8U17.FC%]6E>\\40UAUIA/>ZYWM9D1]ZW'Q>A M)$[,2? 22C/Q$4M::C30+SJ$BMB/)@L#/]_YS;L"*>N[C#&O9D?LD)@NL^2P MJG?=2??;#RIU[N[V>0OQH(B/_E'D&7QIJ!.H2>+89@![Z$"/2 7"D!=/M$ M"FMWPYMG0;>A4@A43'AKAD99^.1/V)#^0 >\\"'^HE+RT;N'TV0GOV9J$_*> MVN2>VN2>VN29)"4OOMZ_LL,'XG6"- BU9#9+;$<=ZRI//)Q)&@1GU5=Q1A:?]5^$$?!6>#G0D8FX3S*3+Y]VQ4D]C MHW.]2=?7ZX][<#O^U43HM=U%CF9X4C.!&MHRG$!7* #MD@D4S+/']+S8 5#(M6P93QG(I(%OMZR6H>#I,XY;_T%6>#:C#8MN+;2Z M,J/O$U19;2]0MB)9SW M<:D2S!SL*59O[G?X<$C"@GD MV$^6!G)V(P:"4PL,\\B24HD&,E>.=\S+G^#=Z\,N^CC]ZO^#11LC7"R%[JDTHT41P14#&KH"0C4L81#$+, O,V$Q75 M6 "X:K*6(@ I<"MVR16]D-T\W639T?(/VAVG"@QB*&N]C*<#?OV#>(E]K M4'?^8D\G'O 9G.X#O)*'Z<;=\P@)ZR) 90E,&F@-OIM4DF"LD>^M?Z-)8"\[MR-MSKM$DM? W*R0S;5H]?;++#N^#$4\AC>9.8XY;OX . \_1+Z^_HAY.Y@0$]; M1%+TY/#S&3;DU\##MZ2JVZH^4<=,O4]9:2?9M SYR*2HMLKOL"G0F%5$(C:M M,$X'C&;P?;1:8-&C/ST],<.B41^ OAQ?,^-*,KSG1T9< ML&ON8&E81KHZ4-AUR=9;\K!5I.AS;MG/V2696>^=WKQ*8>W]XU8N5[-*IM;] M^"X5$2'0R!W6:EN *X$BC]RO8+\0\H 3^<2\1VU.T1 AT# MFX1B6_CX-* .9<(A'1#1^9:3_\.2&+9H]2B5=5 FF ;C1[L]:P_6_6+ TP; M;JZ[R2]ETWRLT4>;"TX,[COO6C"U#T#$8]4"<6A(QN@Z_5%@OKC(CF;5[;!O MLA4:2[:9OI1+&QD/ SM*8L"DV-FG'N G$R0:D/@L]8VG\"; [/YYPA[V\R:A M\N,;= 7(G.)>M[I9<@NFW9%Y+],Q!4?JPD=M/F+&RQ.'B DC;R-H>"2* FH# M#'T()-&_KS0DWZ@]F#T1M#TZ68\!^"%RCAZ)G] >+D>%K6!Q08P O./W#603 M<)T0@H?I8T3@@##E5P*"K[C= D[WE1\;XM7WHI2P49?I]CJD"N.Q)N%.08Y27(+0:,W'?<(!%LP$C(M->C[C",M?.?N ;KZ3#'&F:>1FO924&$PJ"']3;CG^R)*!?M8PX)#6XC+&?>@Z$I2$[@:TT_E.6DV,E'8+++-]//+THQK M*FQ=J.FUXJR;OMY_TW%&(Z)#6^VD2.#1- 49GU_$<8[&ZAU366X(F=G7X35& M!GLEZ!\Y9Z/6X!FSPQ+ 3"'!S:!!^@:GOVP21^"..,0[\U],*'5%GSCT+XOV P M0TMCC? X"8ON)Y3(55'DG0*.$5A1DCJ5@E M M9YKPA0OYD"'R#VG\C&$7:GQ/@7!^I..Q"A>S#R+N/_BBJD01[KGZ15,<->K M"T[H#/?# [K[F3O8J7/#>"UU$%/CJ)BR9!XQ[-!UF[EBVX>7 M%2%ZH6A)'<;(FW[-Z\1B%\6%BX%;[F>]P?2@>5!6+ND)SGTF"!\4$A^#3V(K M?'4)? G)>-4DE:-4VCA2;L_T<.Y2#F_N((SFT&-'GSWB/BX8GZ,%]&>KU.(QC M4/);O-6'"Y4FY,=]4IKB)^R%U:C) SNM,AH@/>/A])<-/A MY/!*]EI:(X_/1$\GQ-Z_PM]XG'XF:>1FO>24N_:$ 8#@]9W_M1C)VB1*=)-AVGQ6B6^!/X;#EB_YP^N@_/&G7(0]2G>'B!=8>A9(ZGZR&HHP5)(U2ZQ+N_D; MT?-B!]>3? %R6]+Q'S;P%5>.P2L?<4/*Z*R;'W@7DYRSI,T9GJ?<9AE0HRFKD M)>:1Z%J]!29RKU,^12V=?,A&"/;_-4 M^#.@2:E6ZO5%9U11B+K^*&ZD)L?E? 2M46+6R=JR MO2$VJEGM?A7E=V3%71@ZLV#:E-8>F0(VZI:!X.2)5/RJY6R7:62IZMF>XQGLIP$(X-CE66)Y(1;<8K++K-N8S!%* MWM"2-&B9.VVYRFL- @J$<8C@N-=M#AYZT>R7Z7*WK95;Q\;/XF)KFXQ&3-5.019K0Q[VF3EM.:P.W.%JSO+,N+\8+'4UO<8 Y'Q_'81+/;I;&H906K;VK<6);X@?XH MG2O5:QDVA8T[I;2RYJ5F:Z[8P_I,\I/-'[>467D;;;;ZG"W&1>>R>JU-L M+-S.8R>?E)2V62H5;5DSJ@9L&5O\5,]M-LFVNE? ZCI7Q.+'W9G\\==;8EI@[FB#W)EK+>$]91CB_<:[']+G M!ODQ)F2(B6ZHNME_A"WCBQ_F=+[7L:@\4Z_.\7%M5ZMELM*YTLOYYA0SU?I> M4N16KC9:UDQZV0V23QZW7&!+HD)):[EALB:-YJZV;V_[WCP:[S-)SVR,M0Q& MV77:M)WTYGK&ABWC!:HER:SNLYJC5&K=M+YWVG8\D#09YZ$OOBDX(N?A+XE3,2ONHO,$K]^K:N!-F @^^CYW5-"2%MP M'%4XK>U!9'"&^2H=<#KZ]P0Z?%RC&;!&\BR@!^S79Y)K0%7X^^4?D7!+@7>1 M]ORT&G3W=JS;HM,Y_KS$))8<+@TW&K;>YR<#9V(G]R9]J0P$GDK?9>(V=H)(D? >"W:>Q%7>AN,_$ M?2?N\'2C6Y'*9^\[<=^)^T]D6M^)^9M_,3MSAZ49V@DB]6++#ROA/OW(FW ME^!U@? UFCOP*RGQ'E)Q$A_<=X7HY0X5$^+]OF6\?7#N1 M3V'9ZQ;A/ E!/PX$>0.U!NB>Q"\AGF".KT=\NI'8PS,$O,P9\H52 HD7H\D[MI>;GN8C$4ACU:W-1"]ZQ?8")?@G0S;T+?OY"[XD-%_3%VP^HS(#I^,&T?OVA M\#$_S,7"_OU)0G45%(X)U6>($?%1,<+)5.[7EB)XA?QI(/NRR73I$,2O@]T_ MFU_(7^90CJ'H\WK:YVYS.D5>N5#Z'1=^*5Q(IXA?7*F/\,["\P'6M?75*Z^W M7?]2F=9KV+'B[AN:.)DF=\FC9U]=5?H^Y\^A:V_0H+][W]UUCY.ZK, MHT? RQ#_WC;XQ_#?E\ NF@\K.H^]#_8C=GWT?.FX3Y&P[,;Z'[H+L2Q-,5S+] M+T\["M]I/'K]?KM [A16[*[R@TQEC3'P]04%M(&'-)%[(,\DA/HTP^&VY.D: M;O!;I,_=5[X"5\Z_!/@Y7&&*92V=S;58C"K(7;?L?)E_!JX8FI[-;DS>B16 MK$T:N%[M9H@)Q)7\MQ]4:GO SB0KOI_2=QCYX'WV'X\BGZ]=:),5Z6&=656I M]XUR*>MK,E6Y!HK8?7PH5,0&I[C!V;ZW%KT*GO< BN#$MQ_D0R:3?\A2+ZDG M'W-??*W,C)$+1N"3+"QM(H5)T_W/;_#+<]7FFA'_C?2W"9XPX7/Q+ ["_15PS;7=N?E/Y^9+%"=XQ<$0SZT3'A2T?TY\2HX=MT#7T_E:_M4\!VV^Q\)7;!U3#CO;=_!7]G?#*[%ZL9@+-]IN7'BP%K+;#VL""N%ME;+IOI MSM/0Y!.Y>,)"W^)V\K;. ?SL7NH.W+\CLAQWH7P-<@QI.XTS%K-14;H;9+E M[&9;KVOO+FW$$>3 =\T^U3>'#J.)W@#G'^?VFH?(D? _V@TBETY=S+/R!2LAO M#"6WL+ ;0Y*KZ"!U/4W+RTQAA?4+-1D?<:V*B'V)#N(NC#9;PY9SC!KPZ==M.U=\A MJ.'VSOL[$]_0H?[QK-;7"5I(OJ?T(3JHSJ8N$B.%BM$Y=3BRR<.17<'W,Z&X M5XK8>BF92KZC5-R^-\] MP&./^3)>%KD^_7:+[_P.R#\+"\(<)]K@"P!!?M>S MG-);@S])=N>N*O/\#4/U0J9G\AEJ-?"'OZ-RJO^")L%96T_C^=E/1F4F(B6@7_9_,?>;OW?2-EB M"OBZ8"O:1MFIHQ7$WY V2B+A@;6L$LL63[!FJ9E; %_. (*Z2_S/)\L#;<_; MX]<=MH,,,2VE]V)RV$^2N2'9F%7L_;$ 9-X,[1,)Z^D)&BOK8!AZP\HJY,BR M8<%YH=K'M*.%TS@(>4+08NUK#FVFSN..68:3&6I9]*K^4P9E.AO/ZAT*G[: M)@"+J)"N8'=DQS[.'6J%\TBPX410T6@;C/E<5>G49S)B6)/8,#? <;FN7LTZMFVFNDHQ:2B+RO;4GO@PGD>JM(?FLZ+;HM+VIT< M5MR7"H;G)#T-+"D=7U)FZ>!F9K_RE#I=Y"9]/5^W"_^TC"VI8B_E1DY66TI[M38TFK,ZYI0KL,[8DL4DT32U7=(;%W<9M'1PN]$4:M(PM:6OENL5=LM<:JAO; MQV4Z+VYR&_1L,+:DILQEK&I3&6#%1E9*BKVJ/%W1\TQ\2=QBVVU5E5:=:4^\ M11M3&;)&P:"'6,N%-U)ZK39E8)4I571TK,J7^_!HC[6<5EME+|, V)] <#D0& M6#_+70$:'#$R6;O%>)K5=BVEWEF+|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

<6+\X_8"1]S#7.^)\>KS+U==[.XCS92H.;4[33D;5 MJQ@QZN4E?F$UE^4K.*L>::+2$KAR66F7]?5PW^[D3!X6183.*@)[P/#LKQPN MJE=RY]]#:-
[GC[IZ]?-+/1BX^L)N !+/NYEFMI>F6I7:C$DVG:0U MV+=)P[O"#?IZ,-,,4^F;0XT6)ZHVW!O]':R\2B+;C,K=[]1^2BVZN@3<1?NK
M'3]*,C):EE5N*OV^9>WS[45[M[]":.^3TL)4U:JNR&EZ4LB->DUC"DLE4]]^ MY!_R&?(NVG?1/N=,N?K";D"TWU?[^LLC8::
[6:N\2WM*GYLUU&6V:/2:4+3S MP-K ']+X_=B^R_99M\75%W8[LGUR;).+=DW:[NF]XN8(5C>Z+/
MIIU&;5]5Y/R@TYIFU%:&H*&N07S[01(/)/Z2]_(7C7NY5B[>/W+A-Y&DY/)7 MSM>$LG^NE%_Z%G;V=FX@[AQ]Y^@[1]\ 1]]DQH@[1]\Y^O?
*>O!3"WSEY!O MN'A,<*PI.V"(/6@@ZXX!_MD(X'^MW?U.\GXG>;^X^,H[R<^IYUY\DFA: TCK MG(N^]*^\3FZC#S!-
<>F:I%=E2N_"E7W[0>+W>XZ[+_2.!->\POPZ).#W8G>7X<$&7]T:>G<>(*M1_Q8 MR4M]P6E[8&4P!OP!QUZ*Q[QCP1^*!?<;TB^\(?TZ+&C9?
3D_F4[*BC;H+XR" M,N5T!6H%\$]5RK\:FOUOAP4<\"-LUG(U,#X'6 U^'&YZP#BNS>^?C$S'@5"K0]"V:;>-8!];SC*2';">O MN0G6!E^,%?
+PE@(L)"8D4,U@T,RT#-[E'/AEV"! [Y3/F"=L^/FXLW)M1Q9W M_D>R#@X2YSN11F5%3AX%X,0!C3YT$D5*"4=*)'.JP%H0L)'IU(^13Z)
<3@IM>2Y&9?R4B/T-ZQ(BIL=MDA&2!A"55082%8=#7 MPL^LH%],_^$K=:PC.$3@*?@R1 ._!@M+XZELYE)[=<*#Y-/._(<].\) U@0[
MT1*\1,_06!WTCCZ!H_@#?$LL+7@"_O>@73R+_!G(3@:%/]V01%AH*/OOT8 MH+, 2'41'JBZ8Q_8G(VR^HM,CK8D"<@?@7E_2YX^/-[+V!;Y?
P2XS/T%6R3^ M-T&@;_Y]LGDG7/ $S0<>,)UGNP^WDPT/6(DWL-&\4>THU'[ESDAWB[&/7:A$ M?/,)<&BY-';T@L:'E6$2P]>3(I=Q7-(#+7.G+6U@R=>
[K;&E]+=TWZ:D$I') M=.=$O$\P8'*P'4HSI;WH)"ESU>/ZG 1:YD];DMQ^/]3FKL,D-79/M>9\<:[3 M)S4!GYHH' M6F9.6U:K]4RMU.(-I2Y,DJ/!M%-
(9KN@96SM3:F[YVE#F##4WI"]%5YFYP,) MM,3QTZ8:7]K9Y66SK;BE35O=;^A"IP2S-,>6M*U6V+Z@,H_8SFCR!#'JX'H-
MID^+M=P/]EEC)S_VAD6QMM(?9\Q2JL '^[&6O7RS4<6&;8]9F\;LL;EL#R=K
MF$LD1]:ZN%X>RPT]]>RVR:XR7:;U00V^R8V1]6!/:PRF&R;3MOD+N.5]]() M1X^1220]9:[,5A;##N\E$<4L-:>4/).;H_AN]< M8DOJ-
"1L7Y^(M,P.+)4MY-C<4UE19MYWM>"Y*0*V, M]ZEG)HLM/NP-^QE>?EPW1E6V#(W1&)DV#IOMK6>[-=,O,)[42W=X>
8BH95784F]O.>)8&&\37EV3E=ZFPJVG"]'$CR:VWJ;D-/9* ML46W1AZQ?E3E+FQ*GC95*GEZU1OPS%!.$G:FEY](Y07JE8IA3WV<;[G=BL(4
M^S6I6DB.B*W%?6O08NVS@0\@Z:0'P3VFE77&?$T1);L]F& MF9],FF,=='L&K4;C74M7QF-Q*/?G[K(O"#@X8N;X&13 \GVIVDO/2TIEM&Z0
MA1*UWM* LF=@@&-+H^6"Z.0PJN@NQ&YMUJ$R8)G<& OYC*9-+YO#8N5EB:F
MRP6*RW5ATQ@7]+#:O,!D\Q0FD^N.4.O@>S=#PZ8Q+]C+/%UMC]:N0E$;O5FT M]V-Q@280YX)!.K]K[8HLQ1#2P-P*/6M-@(.6P,Z EDB*5;?M4%C%[-
:Q0;O= ME>]H:6RRE?5PP)$%N\@03E_:#1K;S6C@P::QR9(XV7,UN4XQ[H8?:+K4::TQ MU#0^V;23;H[G']XJ8WY3&:ZYZJP
F(LX@T;K67.D#BK;-2:L%M*NUJV/<450E,G$]DCC:0M0]@P> MQ;;:+ \.0^(,'MK["=NBI[LE,\Z0CDK43,.L>+!I3!0Y
MU6H*3<;I8[L)W]*G4UY+]E"O,5$LE9,UBC/Q-;8CUF(UWQX6TG,TUQ-1G'/I M11K/9=/S[+'YFE.H.8+CEK,TT*:('(YGB4%+L8-=+/7-.JLRVAEC!RE<]Y:
MA.=-?'74R$TS)6::'1:)UHSI"JUV%QR,9S:MLN3GF5IUTV#&?9T>,_(6Z#W> M.<5QX(Q7*Z+]5)7^8[OQ2&,R36E0Q8P#+:95\=UT-,"*?4UO5F:C9)?
KGE,' MMZ"O(3O]][&BH1;*^&#N4AY4W=(QYBHW*V2+(8O8SM[;U6$UKR@F;!D;O9V'?9G)X'UK-,Q[9Q7'%]LU$5E2F/CW5AM=_6.LUD)Y[3!44-25Y[1
M'P['74&H==VI6%"]<]H@3]SPM:1F@9HSZ -]<[?9[3'OG#;8;@W$:M8N;ADW MN^;,UA*<"Y+G)WHZ;OG8GW%>(3>ZTFC:I3(J/]V)&+XS,N+$Y\CZRE
M V/'[@@6\CL.0.\%U>"4P&>XF+>S^*;DYJLFLUO62&+;6K2(Q\!?*NNNP-/. M"^WFL!G^+2'8'&N"<1W+%3]/_HT:H*C*[?-.&9Q(/5C+78) M8/3*T+!%
[K7X-T$+^ >?F@*?9#>"Q4J@I0L3C$"#'O5KPY_]S0#.@8 HR0, MU[&A@QUV+1H6ZL5$?NF'A"<[2_!WR"RVS L^PZ)6I@&= S*K@GFI+K2I#[VB
M85+' 7S1 $,1_0<0H02_"1876'-;ZY#UYP!$N3=?!MUPZGZU@":[O6+B"X)@"B\NB;A@D):C\D.OTV M^+?7']HH4R[3[W30#T^=R&(2[+T5H.^(UW
OP5_D*'G1@>3!M2/TE8-7#B M3]Y 8/0-V/1UCGHK65YB)$CP5Y@I(:Q=><.JT!L%_^'#IL\M!=Y5A;9X>NP@.(/)N/V9(A]B_"AJ3/%]EQ6K(V4]
MLYFT8(J#'VB@?]A['#P;;4_=_\:-F*_"0;]82 M9 =>]$Z_ZAF[%WS\Q<\?9V7/[?:A"+,QPA3G%@@HPFR*,$:AJG19+BE3],Q-
M(%.$4;I,$29#F&*AHLQ_+BFC_+*\$D;ILGP21OEE>:6,\LOR2ABER_))&.67 MK98RCX1K>"A\N89-V C8REHZ
2],^DG;TDK\]+T139>^OB,:9_@BUZ@G;AMUM;^^Y^68H:]9(9SVYW+"]NG!)4. MW!3;;[(]SY+%XIH-0NI_PY-WRD5=XEKMI**+3;>U.D);B5RVY_N
M62QVE2>+7:50+>^AV"UNDV;MW.K-5,,AQIJW#2]L+%7U(ABZ'>@:^V7!OHB, M(TR[25*EVF9HOMP=I30K>7*ZX)2>*CA&J5"= "79:L'!7*FEL<'\2-
SJ96-= M7,"#P;O%!66E#)0R4,I *8,IRN!)9_G-@H_U5R%N30+L(%%*T[?'*?SJ\6]X_0*O5-A+-S M+Q,
[K.\?!"C<286O?)NU<_=&=/RRN'N;KB5K"]S"8F&D&7K^JUT+WRQ-8O=- M/!_*5,V/+.8XN*28=!TV9,>9=..:=%-'@'U;M%*Y2N7FGDFW1^5N^74#=]O/
MQ^\25*!I]8&FS7>(F+=1R^B$,3NVM/FU/TKTM1=;W4$/Q)N#LB$DVS,M@$7# M"%,:7)R>W[7>U@=W/TX./OB_6OM68:'&Q'%61QV"< M4A7K5!4S
W6;7WN^5,5]6^PMK"]&)]UZ$)W5!R=FN]9[ZUY\^G(\['*,SG)3 MKU56I2J45['OJF)+O8KRA*K8ZA9\XYIB7$%\/?UBG-X<\Y4KLNWY0KD0N^O(M[$I\
[OTZ;7X_OOO^A5UW&_[H M[2?[_6=T)1 GW;W;&+TKT,[R\O"IS'J/U&@!@V M'ME7C+QSD7U53*_X6"EDI9#WDI'SJ)"?
SL@[<1W[;;SEQ\Q&'RJBNN\1DV5; MM%QNP$K"JER:?E@?/Y7[OW^&U2\7_E6[=5__.V=]WG)U[7%1\1-I/0?[V;URZU;^ORC09>X
M1E4O&46]V)R\GE'15Z5+ENM4Y'(#\]9+'GV?NTY=_97LZ[7RPV]6IP,SBJW1*D2Y9:L3Y4\]<)WG;JD=O/>N;[] MUK_Z;]I?;VY:
[OM>^<05$D3W9**7]]5]5*UIMP2I4N46[)Y7?+HN^%UZI*_ MW_7#1M"_._OR+71N+[[>_GY7_P?=$KPQ;C3T4KVN-\OS=,GVW1DO@/]CKB7^
M0"MN7 .L*V]NXPM=:A+,,?9-9I0"([1==-,;%+W*V7<:0]E_= !FI;+?;KZ[;_K'Y^[MR"W_\RVX>E>]U88POQK* M_DJSZI7L[Z;L;X/=?
^P1YP]%_ZD!DV6(_KC$>S]^?!Q^[!Z=?KF^/OWYZ]/- MWW]__>_LK>'Y^U!]]9T4'3>%MW?
M1N7[(6GO>U9,JC2I8M+M8M+MT:2[<9.R@=8K^=D#=6Y? M<_7--LBUBDHI[MZ%8)-J :FX6^ENI;L5=^^*[MZF6X!5MXC92[G<_B33/,:@
M]]5/B]8S'[4VWE'>C M_OT/V[@HLHL;X^WM.^OPZN,0!78=[5*4P&ZEP.; PNY9SY+?YS^^!V:U6+Z] M^_R]?E>_GWQJ7>(8KJ&IB5*2K=22O?
+K.:KEY'"\U?*HZ\;E@M8_!+"SS';N>CTC1/6? ;WZC'^4"X,T9)!:N5".4G/7[C M&[4Y$5)62(G0'EJAK3Z)GPE_]<(]2KS48]8*P?>_Z-
R8OZ9X^U_^N2C_^O+] MM%2]^_'E4^_F\^?;WB&Y%: M-15R_P/EL"$H37%Y#>_T)R$]=_+7X8AK[=BD(3MOO&NP29=4-1A#HO4EBM
M?.W\^'GW^<=M?W16_>C6[[[89^ [5-6-N=(&"FAM6^_<_MQ9'[[7UW\/.#]]O116V@KN.5-MAEWV#'P@B/4 ;C.N#*,>KEPS<7'[]\^&'= M?
F@THN+]=_((FL_^:I3T>K.B[OJ5"E .P59E"SS1(6##J'[?KCAW7]@'Z^M! MY?
J\=VZ00[!/B03SD7Z8Z_5M5Q41]U*='2U$>WK7<76YH"1@%XK5%%*J$@!E M I0)4!*PMR;@Z1*P?=?#]2,-71"W5(O-
G:WUV"GPO;4V!'[]'>\Z&P(WCOZN M'3FM[Q=?[.$'# 4YEZ?AX0^C3M>[1E4O&46]N,H$,271VRO1.2CAVH1$/_]> M=IT2_>7OV\&Y^;4T_/+V^]]W?
[]YWSGM7W51HFO/_FK6]7]YH5>GM,)5)EH) M]-Z9Z*?>M:Y3H"NUPP_71Y6;'R=W-\;?=YW#T_] 9GH)IKHBEZJE?52M:9, MM))H9:*?
>G.Z3HG^Q[!*S?[7]G'Q^NJS=W9Q?G/]S_S2C1>FC8:>JE>UYOE M>1*]^]>F6)P-,V06%5X/O)"YH6TZ/!G=OF=:P*S(MT.;!>I:544454Q=Q=25
M!*B8NK(!2@*4#5 V0$G WMN [;M7O0X]ZU;S!GC8"W2\3'4BG *_1 VT(&K] MQ -1Z&DGUY>7*F2K CSY#-
DN&^A),>CV,F@N(Y#+AE%2#+]]#)I+#9K#2Z^S M\]-' 159/NLS-S2=(Z_?]UP>'L_6&=%G;\R M2_-$3Y\Z/NFVZ7?!5,BY^S' MIY-
1V6@6;P_.#CNWI>X_[[V+PQ]&$^_"2D99;]1+ZAY,"?FV6]&=N-:Y8@'(MN(6(00$=:%!W!2HVIR(36QV;4W"VBK-W,^:F4&859^^+SMZ/<]41S]V&IYR
M1F=!$.&G_+DIAZI!?WAY/:B;]R?7M^V;[];==33R#F'VE&!8]>BEN@*(5:IA M_XS>%EX@\7LB6XB\%@WB=B8!:CNO,]G<1,5_TAL-XU-G+--
F8;EMGV(S2I0 MJ"1A%9!F>R4)RB8H2=A>F[W!T7A&UYTL(O(=5Q4,>6@>'W[[N+R[[.@>W+D M%KV!\=LH?3OI_B@9O!)-
;U9*NE%5%W!*FRB[NA,X,+,;A8B_E@\(DY\M MR5WX:/-HNAL./6]^ W+CC=G/D?FM]&AX5 M+_X>O/UV8GD_JW5P-
$IK0Z51:F7OUMJN!ZWCSZA6U@2-H[3*WFL5Y:SD&)7G25KEYO/ES_K@_.+]R5%W."@?
MO*D=':\/4:M@5*14TZNULEZ=TB9-.2M*K2AG90^@@9ZD5D[K@7D4M#MO;Z,O MI>N#XQ\L_/CQ$-7*:D&"-AM04IUF52NI/>@F-
['RAUD'=OW=IM1(RFA^J*; MWJ#H5 MG;PS_WY?+!UVS?=>_<#X_D_W!VKE9W_!_LSM'*7NDI3X[TLGN>6(_Z/#-"L6 M_[OWO=_#ZQO'O8VN2E<-
NU8]NB@/4?QK*/ZJEZP2_YVT_H\]]?RA]#\UG+(< MZ1\7^I\'QIN[T9O+RDG4>?O-?7ORY>/U.[+Y313Z6E6ECRB95R9_24+_Z&#' MBDW^#?
OJW]1ZK'/RX9_*@)5^GAS]/CI$Z:=^L87ZP\UB_T.I:W_)Y\ZC/A## M6@41,3IC=T;\(]L%,0U?E2]%ZB1/&Z4_DO/,2I:AQ+-TNK9ZK!TY[*)SZ(:V
M!%!.4OU.?B'.&&N?^E[_R.L/HI#>>=$9)_-3.N-XUFW@IZM'V\C$+NP?5F\ M/?CXV?C][6;0_7 A G"V&['V83CGN1_XF/%,8\ G YAPZ$=L)>*X."5K,2%O
M>@Q$P7&\(2*P>4G8+H&@3E"I!4#;D/E,8V(]M0[LIQ;"," %5N30IF()SNPT MJ3C*I;4CAC!O\&O;UTQXR4'\5HZ*_8HXAV1!;I?0@!9,VAP$[)7\1WIC,,[6
MXT#;??/7 ?&:*W?AP&&=\-5!L5"N%YO%6J/\;ZDI^3,Q<*0U5)A+NQ(V[Z?,KP'0W: 5E+.Y-\':"A>M7QFWAX, M87]>#[S 1D*\\AE2Y)Z-C2GL![U8/FJV
@])EBSUWRNQC^/](4@?+FHTP"+ MB?_[IUY30U$B%Y0 D9SKP"I2**'8.THHH<@-*910Y(422BAR0PHE%'FAA!** M)9/BD:DE#YWI_GS5C?
%%;Z9SPER!7R-M&X^@K5BSY3GXX?\]*S][XOI+I4)I MQ5=KC6QRFYS.F?8(O>H%VXF*49FG-PQ3QU#AM[X\I?.TGE$"-
X@.HM(W_KQATE;;T;3!SC\9<,T>W[PXZ0_M<+P1@X_<]KGG,ODG\?<%L??NTS'J M_G!IAWW@EFG%DV][UT.WZAI1\5O]_=W7"(8.CC__J/PH/?L+CC-
&L:(;E?]* M,HV5;.Z@;(XETN90-]]_.VK7:T!O-\@[+YD8P$_=;B*=G3^=0B,O1IZ.O MEV\KO[]-5:$D0+
(58&=K6P'#F4S<_6U3NW?'P=G=C]'Q_>_^[]"G_=YU V#XLE M_[!_7OQX/?/WZ/P$&2S00:V"+)9+RX1-V03]Z K[#&Y_NNK9>N2 M/5$=S_O2%
M[7QE/\W+(W9R7;8N*K_9_?MJ]/E'%0_+C;*A5XJKPBY3DK95DK8!$[V8I-V< M"4N?GR[+'ZI?7;[Q\7#^OE=+X=AJ=K0/[0.R]WRK=UKW]1_?1ZXM4X7)
V/ MOKI105E;XR*4FSO3+B:4M\&IV;C_>/F[.!I6P1G]U7K_KIY#=[E5 M,T^;S;_=RR^C#Z5_^L;/8NB_1?.'H,#EHEXOKS!0K,S?]DA:;LU?\?KNU]_7 MIY?
>EXOA65!WKR^8>YI#21O=6%7W)/A1^7+@5+YY/YWB/Z/Z$"0-#Z9ZN5K1 MC=K2SZ4;CQ0MT),3^*FF':4:8IXY[]QT(X?GBGJEF)VXG6A
MR>3[L179F0LZ+T)TW*D_NV:N[?G7B"O2QA9KT#'4<,I7 MY]WKXC>[#885G]]#2O'-UW'WZ-#K]4&WW9BA,00E45%*0BF).4IBJ1VN%2-
L+R/LY#%YS=:B6:J=%OMGGW^= M'!CMF^[%W>=_#CHY/&\WZI\^O_EZ=GE1/#H?W@Q/JJ-RO8K6HK&@M%YJ;4!^0-#773Y]R'.Q_D0X+
[H\]O[[Y8]LGM1??P\MNE]:51 M?=>%1<&A$*2W4;_K]6)1A:>5#*RB2V,^9.!#O?YW:';,HR]@F?]Y\^[BU]OW M+LH G'G*#;T&U0_N#?? M& =?T&
TR&"4BT6=BHOG'WMFP"M5+$.X#QK*7?7?6NK?N!\3FXE(Y:DMRV"2BY]E80A^U/%BE(DGR8I>4$B?B7(-36"WQ"^U^M1+]\.4:\ M,2Y(5'+, X-
PYO"2G"#,HE4!1^<7;0TNZL;]<=0\&YR,>N_+I5_GK?/2NZ%H M5S#S5W.;"#-D?Y9?AS(G+3.P(X+)FGU0+-=ZIS_^QN8+>\^[JN@F>Y(UM;S
MI>S"Z,XHR; 81#[\RPU% P7MZ.N5=MCU&YL'U0JW/P@(7C?73=@)8X0E8GEMD ML.K*8"F#I0R62<;FAVD:U4K',G^T3/#,*]5]Z8?)+/:C;!7K#:-E--
K5]C.^ M$?P7GTP7>!Y567!L!U848.X9'!$.7=,9!7;@=4YM^-O*_.CLYN13Z4>I5FTV MRN*+);'3A/*:;15P$OR@5RK,PM5YVG^3/:'KT?KK0$OV!LQ,6Y.
[@TS&]P>; M_1Q)]T'/7)&UH$;"X5VP #H\&&W$*,LDWU2@>?*9]H6=7N,7@ Y"U;C$P MV"9-#RSPS\CEQ^&A'?;(QD]=%([JXN4>/N(SCY& "!'_ #.7RC.
[1">EOV4>-$/@K'_IX)GAP^6-" *0,V;Q[8 M(BL%K.3;P2TG*I"?^;@,?&L:C2GL>3"D6'NRD0&?CQ;:H0.?(NU*Q==7,)YV
M:EJPB8%.GQFOX=$0IP1L!;^]!!G@BS@[DSH%R Z/72!' 4%2VWX&TQ;2<0C\ MZGA#FBMS C9$]HM%RR>!TM/.*'=682H1$-,7[
%+;MN=#KP'7@&B:SH@C=1N M+$5Y^;#'&XA9]H 857QU(] YGAB8[M!Z$V\+UV9 $;?3D^.?]^= C*"M<0V+"SH-=@[',6.28L M#K]Q//!_,
8&0M+U33=R/&L4,O*C\:05VGWJ70=?=T@BM!="2MX>'%V?"NEX M2/'YYN+]GS,<%];&'.WR^," .?;@9 (_+6ABE\7^X*#@]DULQ('GXNN[
M(VU@#YB#N-TD$D.&XF/#CT$3.0[J_F#D,B I3-/B.A_W 7;@GKGI#;/,@4F' M(]Q=$#?Y A2#_/"@()@V-/-,4&7]5B:=_"0RSD-
8[SPU35J1%K/>R"7@=T[1#ND,SH]"S M752V*>H?GL6/#9#QW3!F;+D,^.L3RH-63EM-^G2DE4K\0R2J"0R FIO/T;PW M@5'Y438]W.$932A%UK@B-
Q&DHSMS,7YFXOC[W)W"O$/^.>9DTXZFZQ#_\]LEL MDY&D4?HL1*V(]@1^Y:/WXN-CH!'YKK?O39KH^>41YV688M^3BGL4OVSF&Y(Q M(Q<9RZ(
EXZO2[T/@[O"S "EUNO"X[Q>R"6+CF$+C:\YZA\(WPWU*>B, MOIQ0(=E-.R!)QDZBD)/Q7\2^4K$*EWE^:HO?1V[0L[4W8$@LF\$V
M!%R;9T27*RU<=?)BH;$*UP6>!%@Y;"-*OH?\>)P.:"/XK\GC"6RB=D/8IKB%I*SR&D[573B M+3>Q?
RT859,,BMRRGCT0=I6VGWL^N,/T(K1#IH7E^=P@XL MW#/8[2XM@38%QO5<\ !2/ V;SF@Z9Q\/4-G@[_A4?=9%=\8#%@0W!P\67/Q@
M7B$C7H6MPT,:N*CL%VI_<5H0YPKAD67.%CT&KK5GP>;!T+ZN.1'Y->AKXPSQ M"_@9Z&[7ZYL%[2B]6B GLU'#>3XXF:[6]N%#\.> KO6:C8-
H=D*Q_:>=' \5*N5YIU.LOA2X7 M$TY-%W9GH8&]Y6]S43->DD:40@>_"FUD<%,#M[KM]4%SM*>_0R@U6G)FRZ?(M:WH+<-
HM^+%E_X[$EI"M\U!93G@#>5)^]![_'ENHB .9B@(74.%8!@5[45: M(< '0#ANUL9UPEGWK3%-&QP=7360,\E&HNB3^ W0>>O!N14&3D0>]CNE*VZ(
MPX)8;F[@._Y16GQ(_I"+M;YM^1YS[VW?YLC [#!P MQ,GX\&,P;1WP",6I)"XC.$A_(<7I1RYA22H5]]6*N67FW59)ZRR2Z9X)%@S M?:H?

9\]BL:A+#VN,ZWH@FRY8HIN*+M0W]VKL/CFW*:&;H_,SX4 F,*' 1IG/N04>%PR7#;5MQ@5L]%M =0NH;@%7 MIQYG6VQR3.$\[L"PY(U(ZW)V?
IP)&$EUR_PCN,-N;H#96>QB:.\",*C(S#F MKY QP7,@_QT%\;W461YYGC1KQO<\%Q@Z-E*OC\A-A'$"EB!CLMHC+TMN" M?)T4,T=D.-
.)$^.DI_3V^D.EW#"J-3A>#WLV',5A REQ)@ N O\&J.?<@!.$ M'B87A$*I W.DU8%O,6 !?1)*P7!X+CO@!QEO!.9[=- R\;.Y*PR>0 6^"*_QHL!"IV."
M3"51\NF!9LE3-!\,'8,0B;1U3&;2D/NQ_/@CHB=QB$=$N?4 MCV7(!S@'Y&ZY.O$1MX5O0'FYP%S;EP'JBZ2WD'#R.AUR\B9&Q"1YY68HDV2Z
M2.L:@U^+5*9%P>/KB .D%>AM$R^^1%Al 'ZNV:4#[.<+LKE2O-K@+XQ(D$C) MC@E?F[,YAK8.4)KL,,F&0-&P4/!!((X<]@4Q>,7\31JP*^B,4X"\P?
1QRBN M')GND48\D<2/"#6;7T#A!-&$B* 1'>#;&)JE5:.F248(JZ;[&$5&-T!P[Y"Q M6UQ$')]JR,CQ&S-U]YH:*L!KLPC#ZN"4
JG@F&EA,J@;T>]A+$*+IJ,W_R= MA3C,C,+@,/Q;'F.E*DFO#0T>;8IT9A&FN6E2T83^8P#5. 3;1MAW%H1#8'Y M#BYS2]1?_^%_R^P*8+
:Z,IF@5.,:=$E;UM,=,]Z,1<+XOC#?LBH."T.V1M8P#P/(> M/M96N-H^69@X$FWW18*05!/6Q/0S=[VT%M)\0V^.QN.2"_L>)\XM+@CJ:3$ M?
M!%+BR3;BK&LKK%D[#:Q>;U#>]2\XN7(N+/[0CZ5P'9 %S;#%+ M),]S=V!;['A* @R/?,OSP2"]+1-GCN!5GKR"66$/D:0YA4P7TAM-9_;58@D9
M"^.UC'21.PC8*_F/U\N(&6X-Q6.HLW 61R A(^Q?-6Q?[^VM/U)Q3-DB(UO
M119N1/34YAOX[#_IKQX79QI;QEA]*$T0%C"GK7=EHN;S__VK6:LW7X^7GHX5 MADZ0]L\\YH?B85,32AZ=!T:97?
K3TY"T.1E(,N$&MN7P;-.10YD$!F]*'M'2 M,H>R24!ZRASSA<&F9G^>HM1$IA'/K8/]1C>67RF,IQG]2=I0K%0FJF'7KV** M2L/D2\,\^RN^V)-
\D@<=A[HJ26%"N:0CGE %>+AS\!@F\E&!VWG9M\QC@6>! M3B'"*V,CW^."CP=TI^!?H&O#$6V#+4Q'HT]>@+[V!/'S2J/(JF;2*=(_IK?C#
M&2\>>Q=Z*%]/.0,1,.]I(:]4%-DKP2B@7')189!:GAF&F!Z"(]WB49I?0],- M=4&;+=#3KY7(KI=76FN[;<#_7VER253I@D]/%]SF&]ZFNN%5-[SJAG'
M\XQ7?-Z?MZL9GD_S(_F)EX9H>, &QROYMG#-P?G1T'B<-1'2MPPD;W^4/R$^RF-:-[#8E1O/ (AJ[,(IZ M9+*7\4:<=1@8S+8.CE3(N1BY9\RPY3R03R?
1)]IT:0BKU'"*9'[RPD\$/QJEU M46#;9SQ:FU1197P%<0G*#XIRF:GUP&N"]!6PNXBF2^/R.V_ZN=UYL)C G"KF M4L*5_#QAYJLN9YBB++-
IVDEF*25YT@M\UN62.J!4Y/)X_DPJ]7/".4V\;5%> M;4_F&)++N?_/QYC#1_?!RQ^YCK$AD4LY*VA;JX>/UP?71QR1E=7X&*260UHK- M:K6!":1GYQ=?
SRXPT3I5L@G'NC/7*A 5@FQ&MMP&OGI8) QP4#;,$]_QSF:< MC^L!G1*]0!9>W?YU:C]QVC\+|@458R.W"[#;9V>GEN0RO%*E(UJB$]MAQ$<
M^>1&'%VEJNQHZL ^DF?&YS:A@4[.WZ"J ?FE70C$N7&28EBS@4\?%(ME&58: MB$1UG@_,ZZ-U62!]EJ]7'6F7H#?P9E>[EDGMET*3X-
IL(#D_P[WZ:V/UW?7 MS,?MN+@W86Q7:L+\KBOZ.7LMQZ 9I7FD;#:-1>QD4;+4:A?^;+>^;I'@:\ MSVRG7GQ#+X"Y>=$@V?
FCF[=)HC88PO=X_A8G47YE3V<9>HM,0,*!3>TCSV=* MY2+1:P\'<)C_I6?@B2B?A@;#TEMQ:\S(G-+YDC!.,#->,B1G$E>*9QB M WGI)_)OLCPBJO?Y-
+==HZO;CA7&(LO\B+D5X*D-^%>A,D4F3J M8_4(^EZ6$QNT+2@KHSG1(N,I8&:M3]DL+)=*V5:!$;@-
#I>%YQC<"L8]SD'M!CI+63BE)3&PNY1:UM#F,Q M64]T'W6%A0*>ZP8]\P' VX4R^FE:(6 M)D2X##,P\%5YK!2*6MZVAL'!ZJ=1CB@#WHP9PSE7
M[AK4ZN8-ZM9<[CVZUE(HY&# +$S)$S;4[$26%XRXPIU14 /F(/X2528\N4HS M*<64O$_E;W(A=I 4W9G2.#HCC/
DAMT3.$MMAAE4,3X/*+P#4B4PZ>0U>LHF MQJ8AK9ACHRB49VQ3FCJLBD/,.9Y M.4%ZU9'DL@"9JP&/6\H O3\ MCCCV-
<9N)\F9F;0]$Z%]@:B4!J;H>VWF!`]0WTP5RSFO5-Y2YJ#H^EV65*L M@^1V\\%"\IR5CI^=' ^]4.>5)]#P)E2>A$E*5I9VHCZ?[=/1R
M'U\.G_PBEG;T5"&4"[G04AW\S!U:*(8)] MPSS-U*7G^8<,ENJ-3-[,3BGM!?"4UE B>)MQP2>?H;CMPG_K%,Z42:RR_%<&
MI3.SRR2.SGYW.CE5PK_QEZ,ZTA\ZG@O19L)X5;-> ;@.1-+-$/?(_\D M/I' 9 8>WG;)VAUZ$:_#IN@SGC 8/#A:&7S!EJ(6S/)Q5M=YM]+8BB2-%9=C
MG4G>'&D2!OP:OD%JOOMP.M&0YON7Z[-/5]^U:]-AF[W27),Q4P'8Q8V99(Z- MA8U>F&V\6L#+A -/S[KZWR:A?IF -;Y.BONV;6FJ*
(BX] ;ZVQZ -R/"1\)%Y M<1F"D-C!.)]YS?EIDO$AR8#G;!O+2^5%;9@O8VDU,BSMBAY3E]!90-=\K?Q\2?Z M!B(?+T D +3=L%. Q2VI;V%U\P2. TQ0GK%Q?
>F[8K_'(AS7;FM@W'MX @;K M^S.Z9ZZ--[5MVX,I]3#HG7P]"."H3+F.J0]-]W;D>'2ABU:X/7+XYT>^UW/C MRA,Q>3E&8(OV"XY%72ONL?",?
DCWN$E97;%DZ)/E=&*SI9,V9$G9X, M>NH9NC !=N-^KYQP&F8$.!LF3#Z;ST0_$VJ;$&EN7'=AV MG^?
SQ:CU]%F24DQI4CBX3,;BS4?"4*#=QQNI:SSYV.1-5V3%$24[&TT=1#P< M,DKSY55;_-TO<.C,JR>SOF)=LMV^S<6@!V1P^M/=FVN\U?X]V7+OI-
/)U<>S M_?%PU"]$8%QP1R;W! $\)YA/(E#MB=[V[6Q?D88;@7TU=C7T>?6?LC;K MFZE#JX]A#_"K[C&2X5D4/<'GV[;9PIW(_C#U.?V0_(X1KW_LC[P!?&
/U/!\ M%<*CC:FQ)V/<&. M,%+SS_I'B Q%N?9^[";JS;V.O4N<)IFY,>Y>8=4-N->P8> C>W XP,SV]!AZ MRDYF/"_@Y(,9WI=13[M? R?BL<@$G I]KT;\-
W3B?G+2%7BC(FV$0/3;H]A M3H$_Q*58YWF11(FG)LGNTG/_JJ1XS^E'B?O :ZI: J@!4Y9R^=J0!?'MJE: M(%->\?!N2&-E>0<+]4A+.HI-
#B,+6:84F\Y$OHQK'[:0*%_B0PU7F3(X/)T$ M1"^2^>=&-.U-A/XA4B0%)LDA;**B=L8FTEV'**/DCP8T.Q^O/D03NP>(=G/V MINPFIH1JF&A2+M44&-
L%U@,U-W!=@3=A81MR)B=>I-'QB+G&R=%G7PXQ<_$6J M@F;HX9'1#BS'XV&7V4UV*#TZ 1*CXZS7&C_.\D((K2]# F1=3W(;_ $Q,%_@'
MA]>>9QEQMIKJ<>>P@A$-+IQ]DO MU&)!?+811A@TG%2&PD07M.L$:.'G!SHZF(.(!YH@C!W!>2&QI7!-28L MSL;&I@X(;81Q17Q?
0J1V/<**0(^{8;IC[#]2.0!Y&9>\.9[V@H#".NENVC.F M[G<Z!S,9[)S^\X*6.&SS?#0>"Q]W'>3S,51?>G_'S3QDGQ_,NLD(@
M,IU%C@3A75"Z9+)!P;0[GK@HTI4 \<,+-SJ=EM*\,YCV5OH44R *VF%\;'5& MG)H$WDL9'HAUS8$9A7L&!U+/LD6?ZHSS$#*K)ZI8>5HK(=,'P@G)
L;,#.^$S MN]\"*K)91Y0@LGI\^,T*J"OR%L^"# | LVA';$T%-Q!D2YD\M "1@+(@-W>1 MS15?Z@H%5""[-
XDM:$B*"48.X_CP8ZI$^(;Q2V>J$(IP@N5Q.%JU2.2=!DA9 M(BANE\-VQCW@@;,"WGQ>9L&4TSJ#(X9;EA^1@GANE K5>)*Q#QI/=ZJD9Y+& M!FF8>-
A\T&U4]TKGAL%(Z-KR9F4?CGWYV/$_%209V*:02J;B5I8^+*!!2$X M1 ,0DH"N3O:.9DO4@(K8SWA!?1=,]QC>\-?4& M S,F)OC(+R9

[_6S8%"!Y0UBT/TL ,'JF%\5"%&7UP;P82N0S,$*K88L).+ \+7!$B% M+^=@0G[?=CF,E7C%S=G;LQOMTO>ZQMF/08@(>NR]Z48(//0R^#K!GIK0A1N7 MFIJ2FBV0FE(*+!'YN,.&H.3)(+1MQ$8+TI!M$@Y,HHNE10$A/4&4#+PV4FRI MV/*/V-(HE"1;\MM/@>D8I-*

$%!5#R:]2DBN,4Q_TAQZ7A7=&/#3R"#R2\OM"S M;@]:! V+?B]XR]Q>2\]YPM<5>K0_<+P10XS-V0RZEJRR"XKHE<)V1 M0DZ>Y_$:E<(FM/OL6)", 2TC&/0DN&P5"U*BNU%GKKQ<;\[,B$Z/F6T+)A#J MJ"^<*+#O^6O+]<8(7,1"/T*$<4)+[P$7 0DINH38TIG6":!?+#87P%P%>Y18 M_*%8U) (V#\AJLM$0/UA/,'W;#A"JXY$R2,H@+6"0RJD[NX=O'\1YX]'+!W7X M5YRYU'NQ/;E-5C%J%7)0"N/IT<+B$X+4ZDR_$;XK\R/(KK!>-=4A;^L#U0\K M_;35'0^C/1S(3O6\XQ$):G-'=C,5CV8PW3Z%*'A?NT"V"J1NDA@+,6V7AK;! M&-MT[@D6-

[P3YC991SC6WE2T&)QBRS*^,,X)IC>P!]CTC]VB=6>*21_LEW;-M'.R]IVMOF8OA'']J.PS;LBHV=_'"[]J5U6K%042BQZ2B)0HE5E% HL3FAA,*P MS@LEE';*#R64=LH')91VR@LEE';*#R64=LH')13"?EXHH;13?BBAM%,^*,';! M.Q4E-

D\)I9WR0PFEG?)!'';6=\D()I9WR0PFEG?)!'"76RVW#OM(@JAFZ7M)K12V_M"9J6V\U-M/^TDL7%L]+CJH)NJ.C S50<* 5\A

MX.]2>X=R1:]7*JJ]@V+N'63N2D,OE11S*^;>G=XE9;W2**I&:HJE)R-\^6+I MI^AKHU33*Q7524UQ]TYR=Z6D5TN*NQ5W[XX[4M.+T]P1U4IM-

K3%.'IV'1*#0 MZ6E=U:."99LIK&",JU'+*H!O[7H<% 2P%$X'UWL6TSJ,!;.AEQSOQ$0\UBZ; M@"Y&%DT&1\ 3'C!]7DEAG\,K9",+6J<6%3T9.:,9 : BXEZ;M5-

06Q%3+P,_. M@F'FP$CC:S:R:^Z8%C*/S0)=''Z+!P+$%% L"N/BVZ?"_/-AY'Y[O^*;$8F8Q M$*T@$,&MX!B>'PJXEWZ?^18,,OY+!-'V36%5DQ;XKD'/K,BG]

HKR.?&!!F:-U% M-I_5%-.#5<(S\+L4;N6\[>3(W@LP/)#JGCG\+8+K"MK-&&X0;/UTV""(E$,8ZA[0*1 MNC8B^I@!OE5@HB6DE4!)'1OUE,_Z,.<(_X3\

MGZ_-22,4F6Y)8Q29;DDS!ZC6^6;,$J5Y98P2I7EDC"U0D71)8=T49HLMX11

MFBR7A%%.64X)HU19:@FC5%DN":-464X)HU19:@FC5%DN":/.ERNERV/K/1^Z M3][<+NPN6M&Q=2%^K MU]>-AQAKYX&_)M>\)@@*..:5=THJMAA?

9F.,D'^4L,8 M8*LAQ90N4 9!,8$R",H@K-8@/.TM9N-2P%$X'UWL6TSJ,!;.AEQSOQ$0\UBZ; M@"Y&%DT&1\ 3'C!]7DEAG\,K9",+6J<6%3T9.:,9 : BXEZ;M5-

^WZZ_[{[>:!.4_V&==_4 MK7]V_'3+3%; CZENO__GHBJ_#[M<%|KL#>_M@H%+U5N3?27E+HS7ER,GWYD:8D+*1OW'BCO+T4EX]4J%YD.)T:
Y'AKD62OW,!ZIX%ZZ]M 6%[]&U6UDBP.S7U MG1V@VR_,?9^I3Z9L_\UZZ.NB78__P8)P3\KUHU6)5*[O>1T?G#_R(&#_7;>K
M_J(^H11^GA5&^R7({586A2Y%0;F"ZT9?G3Z$Q6Y7OU]9?T&:^2K-ELGD/\"= M^72:!J#>>^5E2I^5OY8>L;>?
CKGY6K_2PM.3IN;9M%&&_*XUR%TQ@_MY)1_>A8PFPG=W8C\X.S2!UHPGQ4U]?2;"XHT>O#XT?"GO! M_)V'658$"N^AG8:_/99DE6LLIJY:
MF^"U/6RN6_/9/]]XD,-LN"]W=^_@V[::@2Z,KI!;E:N&VD(W%0E2 M(@-1:R-NA6)P'*"Z#8!=%F:"H8I#"V$!18].9F>#&F&/_UE_P5\)[+B!*[+
M3O_#V[\I3&!85G'_@G8_ZECTIC''8"&*(V73D9[1>6=F/[\$]TJ65"^,P8:[_M9J@+7E|O.P7&XV-?;.D=OLMJ+7[_1S)AW+T9>46+_\SQD1W>4Y->3E%
25Z/_M,/?Z9TK_-@NXZGS1^P1_G43@,YN:CS,KA)I@S_0*)D[ZL>+-SB'\'NEH4#:5_MG9A/|[,WK]BS\T=>8+LK,;WA[_N=<-
%SXMRG^H,PX.VN03V&HXEY..:*]_9V MU;85'$;#E*;88[_FD>@1_AR(IYOIF6MS313,_%Y#[:,;X&'"QW63EM<^7&*: MS[WG\R8A'>|^GL3<2GH-
]17/ZK0C$GU^ODUMO-PK_>#Q$^?[$E,0Q$;Y:A;2_M8Y?'_OF*-O7$?$$8VK,10SMB:$<,[:>S&7O"H@85&S%/!Z".>W64CJ,-H,+,_M_NO
MB;!Y)KP5D+6MH9CTCK M!E\2,:R"XD+'G$FC,.N!U/"#Y#_UL#F[']\S.3H[%2IP'@EX6953#Q8A;!J,5 M(A&KE=;=>-J#6+6 /8N(D;*.D%TO'40[(2J-
IH<92R3FDPC5Z_MGT7SL;[" 709!4-CT^W*%FEPX??$8/ MKAXALQVJ16^9=.MQ_K/MA;LK())OE9*V*4.31+_YS%BE)Q?')X_&'O1#@ .<
M'9]=CCMQ"#MQ>GQQ,>[$(>S$Y?'9V;@3A[3HW8ZE)T8M=.A[1HIW$G[G(G M;MGPM]-Y_.MI^YN4%4;L]=R
MEVV!X\^8/7C)V8/GE#WX7:BJ4^,S&_;W#A[SD&-F7&U;SSDUB9LP[[M,-P.5/D5Y?G*%JZ5U@_O#&{[J:6_]Y^%\-_W_#LOUVG)\>/'7[9<4]I^ MW.?
=^WS/:)P[V.?SN]!5 PWGG]>N_6P:SH:WM?1CV8X+8BNCE]P[D^9[?]W/
MCRS@D/S>7_S!';P*9]SNXU6\HTJUCBV;ZC_]JC(4.6/]]:N+R_CDXNG#NW9# M[WUG1Y'^W6F:+U6D3Q^?QI<73_HR?7B.\Q;+(Y,
<:=@/JES4G\KZ_&>=!WV'>QW!,XAGPE@3;T+T(*$T2U.R:=D%(X M-K*ICR'IUZ,WO'M5$4@_N-G_FG98]_Q/5&+W)VQO(<7NPO3^"@^OSRY<\,X
MBO:7*]H'\6)W'34^CI^<;;!9=\QB\KLE\Y,A9S:C8O:OGAT(^.G9KH>E>7 7 MEQY,30$R^^">;;RJLH0:R,4'4T9%08Y10A.AE=_F?
%C7>FZ7&&!TDQO!]> M$(1Q67N3S(G>0]@Y$%9EBIK09))"4IV"D^H.S4S<],8[RLJ:IRZF9-/ Q?.TV MJQ<*74+^GL?NT]ERE625_M$;2XXP07A\? 4$/
7<%Y59@A?45A8/]>#Q\5-W M3<:VVW?RY^3Q9\\\)#=BT 5Y)C.PO-W!1V"'7RN/)D/F/WBO3%#8:/%W.9OC4
M,MP,'WY.YA;.2>"%0!>)^=GCTZNQSF,ME/P$\? MG|HIX+>1\/-A"==59[']#&SQZ^FF$_/SL^-Q=US(H;)2R)[Z4;1*0CY&\BW-W MY4\!_PH-
;RKE'3_,,5;@:N?[?5.I/O.3SY.H#>H;%U-B,13D>BG3YQRBV95 MN63FJ!!1^O,TBW=#>/WH.@4J5"
M[Z8FN8*'3>F!Z1'[Y'F'B.+^*+NPUU$Z/;GTIC#_?MMP)I)X>O+T^-23QJ]W M8D[/G1'A(_/)R:PQ&+(AX4 =GMN!PC>!@\'U]J4$:#F'V_UA)?
N9!V_=;EE MJ>E "\%WNTE#:V!U_MD=6I4'9X)/O+,%M_9'"<_:G ;A(M&$L"\B=Z9:AG]
M5,+R1%\Y'M",")_J1B@],P^VC\P+R8#KMW[(@MZE[4Q^=0_!I*:IQBP\#!LD MNLFMB__F[3]JRVFHWR/VC3\ T]++YR+0T,BV-3$N'R;0TY(,^.._8;>=
[6X:9 M2Z=#8\UC4%($^6APK!?IQ:Q&QM(IU02?42&[TX/RQIRC]*UMGX U.- ?%;FF$ M\\#J47_#XA.2&WY-MIGCM1^2VX'4[
>]HUR[$Z"MXC_916VFEXGS#=2S#E*.R>O[V]6LUQV2% MAT^)=\E;VOQ/YGSZ>)(M^5KTB9&7\FI*9Q5EXG4).Z(${FF\]ZJJ_MNE\::NO
MST%RETA/&8@C'/I5G]S_G!448D[R5]QRT'&Y],D7>8)(Y"72)F_N'JZC5(84Z-?C$* G+Y(,)C"X@ M+2?
1Q:U\+GN09N2#7R"?,;*AH>])'/2@:6EY@\IG"KM&S)F][' M=\+W4T;O6[P\\9'=F#S'_P=/7(D2AWNCPXSO(%SW!=7WB8/GX)$RION"W<7'
M_Y<[+I.RY?6=)E6UQC]:[O0-^Q&,,X#G2E&M)BLD?(--)'4EW+:P O1@!W;<_M;L&!-U4EE#@EY!;X+JCQ=MR!1M9.)*TN-@W-
F:K#S/'G&F)"7GW@;N:9+KH MV3F7P(?' UE271O#5H>31'AP3\[^0;?]0@^=83_ .(OS[\ M!F0&?DSY[GM]%*=?
^5I4#"@DO+]:BYM%F>.ZU4W5+F76 \AK4A_!HI(&UMDL^_M),3B2A7!1?=:;$G[031?FMTLSC%;(4YF8Y@:M)'T>E'L5//769^P:NL[WMCP% M[L_P))?
A0T2&J:V97,9$SY(J1Z.^Q-%,5)XJ4Y.+WR+>+EVMY<+R3[!N>70. ME]><(!T_.5E9L6K1>72!(WZ#G5Q>_FQ)!HJ]<9Z09*QU$M\RYE<4HY1&(KP
M2'3<+7FP?+2.K7-,]T!%TSENLI!55G_K]M[J&,-(>-$M0EZUC*Y!3_6')@7 MMI5AX(W!?&T0]U5E ?^>&F7VG_QEW]#NC)]D(".
[[VFN#7M9*X]1FEIR>"A8 MQ4OA^5:K8"F*2ZG${Q4E+D:,:<_Y&8JH[Y>[_"ZWY7=WTR51 MEO[/G]Y?I.8LO4B3]Y?
G9Y/W%X]/+M]/GLZ2]V>/+D_2L\G%Y3IV9\X&\S? M^#L./@*_"W42K#[\E,M/W]F0M[Z;E,&77KQ[_O+|_>79Q:/S"_G#Y\^UX$,(M'='Q)B:4W_-??
V5(,+VUB;S%B:XH"U)Q='H#2BZ?8_YZ?GQQ?FA'/1O:-@, MQC9@%\J:;2!7?%E[>YDWKP')EO8J&JT276T@QR>]^D62NAE8/0P"9C4OG[CN
M$+B83UMOB<"]I\1244S(QF.L:I;ZT#.(RN #RV2-3K(.+?R2ZWT78[UOK/>-_M\;[/4>^#^X">"Y0;:T&>EH<3-V80H:'286<_FZG>"36B!5]=1S^6-
SC;*L99 M'0GY\0,:C529<^#K!2C HP8K@G"KM.5X,@YRK1@BB#_/&>KA)^<2(V6)O:Z> MFC*B098)@(M'QH5_ P\M?*S^OK;7:Y0^=_#3-
/M]TT7TUM'5I["&8S,>"<_ZF2U,A,3=0=_M045-9Z710&&.T6XH0YPUDJN5ZJW KBUXT!P&;?" Y=)47!U]7B64@I+/[QI7 M1W. N:14TQ9&19-
C7U)#C&?12,Z&IH01^]C[TT!-4D@BJ{K7*2!/&+'MY%$ M!4:ILDR:0/T#2:CG70XHJ>[&8+F)3!QI!/L@]G Q'YQ[M/<:H3"'X6X'
@)ONDO2V-,$U7(C\3J=52YI;'@]^[_08K'J(%)R)HEW&T2IO M.=_3@ 4W1U1$B=Z^^OY-S*^0X+B:DH9*G\)723C=%.VT9'UITCE; ?N:X9+P
M^[Y;]'[O:CBS$D>D]B9@W\#+H]N+L:[F_56T6*\PK\EU#S"EDK);E1EI>(<0 M;G]WD[7J[X580O@D#K&"
[[8KW+0D>A#V#887QR5,/8K3_'T904%_A%(W-L,<[&L]?$[XASP=[HB@%^5XTL*W*N*PR'"(>_E M,IL&(L.N3G>>\9;(U+I?
_30M/Y03QL5K!F[P8SUAV/A\V"API<5[07F*H? MNJS4+M=64.=`DWN$#[^0A+4X6K 94^/:)1:@8!APY#T;*Q6L@&^]DQS>8/0R
MEVK@)W[4'.TX)9<+V'KX-M9!MK:;B6<@7;S=5T<[+78[]3LG=*8L#03_K/;T MR;%'GJLY)"^T?MM.T#)(U04=>UEZ\H3(;L&%0
8+$C60+NI%2=$90=?C'_#5 M? !@(P;)|\PIN?ZK5*%(Y/QZ!5WV.[JL39$_;RO\&DTSMDU59 /U9F[T(2$X M4,$!\Z,T^0_N^6U6FG^K?NV_"]X 4S?
4;@.&!.59QMW\OQM/S MDL8@GW!WQBI1;LAGINH'(5,,Z0W'"=]0KEJL%+'J^Y*K;#'SBZ2(C2|\>;B5]7 M-_A)&XAAEF;PJC&
<9/""PC|V>7EY/W%V85Y_]0\3=X_?G(Y,R=G3].S\UF0PL9\ M257F2/7^&KL64TSEOC]['?';QY**7Z[YX_Q3V_A!2W1>?)-6MBT$"Y);CDS91
MW]K=^CD:%MM*^)Q:^>#8:0#]LO'19WB5WUM"$ZN=8<==VU#/AW\IV.N4]]L5 M#E]OO?SW:WB5+-4>B6>=$,!]_&]F+14E7LT@RC6L@4D-
T=]=]4O^SN9;]BE*.MS'27%+_OF>ZIOZPKNZS8Q)2:F9;1WK2YHL=.SY.CTT=?F8?\(W[M]%'J_\KK M"E:[U1];HTL5^L(C\OQ_Z"@^H9
M^P5]XXQ]MONL@LU$\2]PP@'\#O+"\&^>+73.*C=4R>5=_Z,OH-)H5'-##K<^_M"<(3>P9C-[LV%58M:=U%'T0&B+;*HY/GP?US@8>X0&3L!
[!R#VHD,O M-/-.AQ<]ND)];15.C?A?N'L2$&+69GKS-P$^I1]0G?T/E:S_4(C G\:+EO)FL?8R;D=E\C_J+KT(_&.O18AQ[K
MT/>!._5TM.U95F<'K,%&=5.0^L8*P0*L+D&+K&/D'$1T7S S*>!&RM,-^X>(MM"'=:W4>7*WBI X^0512"1)3(QQN>].CI-SN,
Q@+MDC0,O1%G15:F8=SR:M@ V=8373<)-LO.3*+58E%UZ]DQ?W8H&OKKS(EWC/GLBTQ##1I)63?:.5CH# MXPK?TH(7?8?"+W5/T&?4"WQO-
G[!?BVSWOW:;0;B%7 M/V5+ZD,D.KBBGP[Y G(@=^%"?8&ZD'Q'33Z7GZ_N+Q;/;^Z?G)H_?ID]/':3)+'Y^D3X-L[.NK-^]>O,"T[I/S M1\%?7KW[\?
F:%S[__^K-RZMW+U[]_/[\R>GI_:5L\4$Y;G_Q0E.M$-.??A/1 M@T;>DWH+@HG>T'\@_,U?,Y0>5KY^?_'DY-'EHP/(/I]^DNPSO6_DO? 6H,4F
MXELWEOG^,@//3AX]/KFW=;G-B^_]WH);^OSN^>GVWH;_ MSK8]]K>(DJ>\L22NU[92X3*^/LL#<6U@2=]V$:NC'[2I8%:[%0< VT%@0=?8
MRD:X7KY/6AKN/@:'J$+75?HN%"_BTIC8J^*WVRA$WX.?\1>\W#OI/G1P]/65 MWD#O"M.O/T;Q=J<\,\ <%M,
(>%6Y!9)'@#\D<%K_B"B4%]]+>R@G.J%:GV&N M//3'P)6LT+5LRKFA!Z#6!$4<>YG\8@\5BVG$;,<&A_G]0:H5+E-PR8";MXBA/UF7;_)D:QX;.IY5
5))4EA(D(A=_M] 4&@,V-[9*OO=P#L;)0A>M:61B05<4?YTN305*_Z6*WJ6!2"K%:3-
M\H@YLV)M.6OTU]12GIH5ECZ)W(.S%]@KA]>2QE4L%ZZ(W(F/05HR2ARB&ZSZ M(3&L%YE 99V\62-.$^4"($Z=8RA.T ME'+^=%MRRPD>;;I?
GDR-LE84B;@1*9YB=G$;9X5U!@_;^'V"-2MOX8[+[2 M%9!Q424UF1ON)\F]] @9[-;8LPX70_,-3D^589II&O8]$I*+>:G*8LZ0+F>-
M/6:@XXT>YZ>5'=]U'U7+|%IZXG%56\N)U3H>N)+ZMBDJ*U_34"V-3NY/K_[^ M[M6;__?BGD1[4"U2*V^%M0 &"972YB4=%Z!55"O$D?L7^+
(8UFBO-8A$B\$% MURH(==9DM=>Y#R=C@GD>C)\P3JI2;MI-TNN$ 1+$ALVXNRF"DU)N(N$.8?]V MY!DDN4WK_*,@;X=R-K47TMB= 1U3(7*/&,
[O2:>,.[LJH4[:(!I8D60]#NRQ[MQP&L*3;T(,A;_>.8_9'"H /O(UZ]$P_>00NNS7]+#'ZA'3B/QPZ"]J.8U!(9M8$RBWO+R' *U.#O
M8'2\+]2+MCE*RYN"XN-Y7D[P>7(E1K_X7.U],$N,DT69^!2"K<=6"8(%PTZ MD-3"#A>!6#HOU]$'LX[@)&+4B_U,[G''EZQQ'E4N\P;+@JQB5A
Z7H/3:/Z,9J<"YUQO[MHGW"\!P% M KW 4(OS79QFM2(,88#C!V>KF8V+8)CT[B>,1O%;RAWSC)P#S MG1/G,6+]I@ZYL7$R8\/P2$N
Z^KL^D4"5S@6\/ZEZ=BO%@D\TM2TM-*U.QI* M955T62PR.4X1;$""3<=40@LT1;EO;RQU'!Q;1'6(LOL_&28T.T2SE$6A?P]B&V$!) M&#T0]S;X-
\^[D;*"5KH]/V%#3#\>IO$P;3E,H,VY@,(6%@53VCU0<'L&-68P M9(*KU^9)W20Q=K585Q;/0#;S*5;49O>OY=L$!B9212@6-A#)[0ZX'WB&ZA:)
MR(_'6LHHW;?S@7YT9=#*T!@<8?NO?9 N2NR+8B8L\6\,RAW^ZV]JA$UGT5>-_MH_M_\>9*VI(>,A>N9>_JA#4_F[9(3\\A9LWG@F&17#Z5\T*-
^E*"8%X1 1T0* HS1 MR^/HIZ28F40H.#(*6&SG#THJ%3#HU#%7ZY(H#NVS>=@-XMB:5FW6^_P_/K+? M-
C50*Q%BPQLT:O[;!.>+"BJC^1J/U%Y'2BOGU_7#HYLWW1 / MV;#*'LBIMA#7_3T=)J&PUVD\HN,1W6GUO,IXPKVG,E$1!71@=((%H
3AIV.^6%9;"'"T< UG3NRDE= M(IF>1V+H#ST*DX(6FZB]NHYZ]@;'HFF%9N:N%F.*I9J'1->5K/+FTTX=B(HJ M'E@2/8ZN"IL0\7N?
_X@$!CE=5#E#E1=YE<0F&I"(]-DZAFK704\C4=V/+)[M=LZ%ML_W+Q[554&\!"PZR&C :1;Z,F5BI.N@*JF)5:L*9)^4P0T.%WX_!H,(M^TXE4>DK8)]
[P 6.Q6PU(0]!@#GCF2:)IE2'-BA6^@3D!.,9UO/"_43T9E$ M$CNO);^,IF5C#FB'U2IR:YSH9RIYZ@>?E&25C4_G85/[9:!UIEQ_W-;N_;F1?/NNL(5\.
[!!&I=[!]+>P MNY=$]],_9>_A=U"GT/+O39UR)VOJO$VBRF#2#!L=6?X4C(NPQ21L.>4!]<4Z MJ$,6AJL6P=Q%)C&4JB#ZE@7WEW.>L$]"$)
(,Q.P((R53G\N%B% :)ON@&F9Q M7>94)_5F>1'XN'',:Q]_EJU2HO3Y4+R4,UX2!X53/H1++/0KN9B:6+G.*QCQS
MD20J5&02#X(G]FDT*8_$_)%D]$-7/A[JC8N'>Q0T/4N]^UX0X)-0$EX^[,#C M^$!7I[,6MG1,;T_\A/0Q! ' XV/I[,V&5<5ON7ET'\ ]+3# :2D;H&PXWL Z
M8Y9"C[\M7;\&9OHQ"/%?HMM"2"M;&-N"]-U3LH8:'@VN)/YA>#5=PH,7U!') M?'+U;?6$KPDW,]:Q%JQ!\FSU
5,WCG/M6=!5^2Q9H2Z#C[NZX[V3V]U2\?76 M8.1M\7E;[FD?!^S;+_AB,MG+K#3+SW-8R3(5-,\8C Z=VP?@MI]Y8QUYNA]F
M_6G^98US3A"0/C"9\\'1^5GX79Q+2(OUX.GE\=/P+SCGBS(Q0@6ND10I7]1[PY#/Q=M2C]&%!L:@FQ!K:#]X57]&E&:=X5;,D)-R
MLNY\/B2.T6'"SF$)2L=B8WKL,S89[9TU+OANC../<\0|>;.M6IZVEL'47SE_\#AUTJ0\]SRESK1U:($-I26OV,@'X,1)^HW@GS$*(7KWBT M0"Y9M
%)OFX4:($=0;#VO\DT))G;T\N8!E7]6(E]K)4>[F,B\B)\))ED+1[= M$CY;$Y[HFH9ZD0?XAGX?Z^'(TB^6ZD65,+X,;!1R0C;&:C6I$
M:5%^F[/0.O*7^[P4D,9\V'B+H]??'9W2OR9ENL9;64X3TM[_;9'[']X[M35. M68V#<)_ZC<5X3'FL>@-GDS\X-*??:L('$;N*URY[JQ0]PKY$KSME-
4'GS5F0Z93+9,53W\+ MU :%=]0WP;G6':4&E]*;I-XW+0F995EO<[*H3S"%U$K!-<.]B"K<3*\^/Q>.T9!,_R:*INT$E;-_MJ@1^QBG3/!@[I}'>7M(+E
:>OXU0I6\.N<++]>!3< Q!*\.CO1CM M!=S19CRV(MP"6MQ-CLSHG8S2MD/:0)P:')KM![>>T'EM=]9-T:3DYM!\E+M1 M[G:%EJN3+=@TTN!C]
(V2MO'HI?"O/\2I:8L*/0)62L^Z*W2A; MHVSM\M>88@T+RVE]:0&\$A]EN*U@V1]\$(.XH21QU$C'GB7U)W@'N'KX.0+F
M9O2YG$9:]B[@3/2U*=*2?V&_-HKR*,H[1+DVYL-P77)+&89Z)[KT?"O"W(_:M=!3!CQ'!H&LCP5(PU@BGU++(4#1IY-A0*HW*H=X>QMB 9&+0C"
1&D=L5*!=S' C' M+M^T;(O:<"]0B'!)NO)<*&+'6IA\A4TV!JPV-5-0O?VZS%+%]G*Y=!W!!S+N MNC((:9@::1N]!?)XE-Y1>O>3WJR(<&S$7-
HB77TREBDS+BSR? 'LDI.;CV(\BO&^_M=C]I.+AGKEANO?R0@<+T2#Q'<1K%:5?*B-Q'O^32[U?23F[T(GV<'^(%5NTD MSZ:*UNP-
MNMV1]JR'YCNWTWTG7P;/E1>D?IW56ZT99ME#[BA2$C^[]"D ZB M9.NZ-
6*2/>QK,BFOC6_^)VU#O:T*T4/NQ"1#=2H9H]B2KA%BEL&:R)0_,TA7 M0[>).R2)_$"QYU0PXY--:TT72+I3S$T_.'L DY/-I6@=(_:%;-)R@QK^U ! M)?
*_2E<3Y2RP_DW:,_$SO \@8D2P879@ZZ]MX%T&.@RW<>A\5BZ!B\N^O-TO ME\!M<:;8Q=]6Z DR%L2A_JH MV8A&R09LQR5,NKK<&X#-:,++A
,]Y%"!%&'_M<MH/?T>H/YH/AG_A?K,.KK&9LY&9$LL\+';W+.O7G0(4H,F_8]U[/ M)W"]&1,I=(8!-' R$?.T<\GF|C+\Y(,*//P;5Q2]3Y+OZ-_M7TP
SYJ8/H.3AQRI$AP4B&,0"0Z$,$FG*74ZHB_FUV)N VP4'),6*;:EF[M08#'T??P.7&:I$^;<$Z.;&DJH/>;A2F(.M@PHIO2'C*,@HR&D@FBU_JAL-GJ
M66UTI9RP>2B[3['"M]*\CWN]MU<;49S4C)'4BYC^&Z%Y!&MD#PT:*G8(X?!5 M-!22@9H/+]\:DU"UM>(A:W>)IU@56(=\7!#FT1NQ(5')ZP?
LT>8M.N,.TBJ0N-X2A^W MKN+K&MO>T'82*AT3B8;84]5-/E=_-+PKB^#QMCNX?XY&X-,8;MTBW.H M,'V+N]]0O/J0V=G'D/X 90S4+E)3Z"P
8ONR4[#M,%K^8\?PN$%YS!HU+RF2 M,$L(A-$7^\.!ERY'\-((7AK!2Z,A^;R&Y.M#LAY*BS%@+FQ6"!F66XZA?,;K MTW..-T<7Y5 DZU!=%
(L4B;.*TC(S[N07)G#.F=HIHY+(ZS:@Q@&@3MNMJ7Y& MR1J=X93@%.ML['$9)7-

/R52A"RM1#]U9M7/MQ&H))FKZJ.A./C#LY>O)/IKE]W)T};22E")_3;^.IP!+VZ9-O:LW2K[MU0SU8>UUM/$?C M.3J$<[0"EP.1,'-
RI]WPZ%PVEV:VDTQ[T'IHSHM^29KL-'!8\(F"M;)6N:, M+E?P_%@@&<5S%,_=XEFTE"&@D,X2Z\+23VN)_0:!B#=&6]E&SWB4LCT#MUC- M.#?2-
M@%1D(V!(4=Y6J4]WT3 F0B;6=9$/+OIK"<)BLNR8U9J%'H]HR,J#4N ME#K'(AGV0%95(H, ^:^9UYO[GK0! O\732K/?[H(WLPR7C)
(1DDO;4NGZ)T>A M'H5Z_W"?.GNQ>ZZ6L2DZSPQIPFONT!4AH[JBNZ!R2GE==ZF9-'&GY;?W19P(MQ$/ L#<:N\-+G%S"5T.$P!&>--
+J6S03H)62V+CQ30SSH!0XTR+VS@,G=RDUK M"J=3Y9FG\TW36![O"_<#4[E5 M&^H50N7"YD_L2<"UM!LZR"MZ M644>JL3-ZH5Z#UZG/3?
2(FN_M-J_+"M37BM^1CKQ6<3<+70-7 #^/H&N":I>. ^.W])DK;09G5-V[[Z)GX?8TI. -N1<)|]P%E/X#B>%X?H MFOX]9,I,Z2-
_5HPUF=ZP4/LPA%2S=\8)4+@T]'AP3GA,O#-YF,,NHJMW+Z-7 M(,\Z8@/6-XVO-0\XZ.\D>FA>G!L2FB^*1P"$/>PW1&'AV#:
*ME$>,R."XLY.SR^BG$A2";;")]*V0/H4N0!&]A =X*J/D;G1LWM5<<2;N2@BO MT1RM$+]Q2V8"VUQD"$5$4<-W0!.I3UR&815=Q M\0*
F3]CYH&W_DD06,8NA-WMK:ZCA>C(<8,#N -Y(LM2XY4[99,M5TM>W,L(K M& QJ]RT)9H/RMK)69FT6;HZ]>9&46BI0R@-
DA25'%4^J;2/$A2?/\PO@I-.. M_!%6@0$>OZ"F(VDQ..Z71L[A]=&>3>(N*(!]I%)*F0!A!.5,%DARTP.)[D2 M54< "/>]&YTA"Q*65600-I^6"JM;|".\HL:*|*
HRV!''7 =AJRXK<9P$|5X>T MRWMJ/7YL9-IBEER7E6^6!%?LS*Z,^W3S8UDLT+B3$2XZTW4#P;+M0V[F;_1< MYO[4JP M6P'9/GQ.Q-&-/[-*
S(D2@&<>^Q/?OLS&ZL(@IQL_+-3BETC&"#N M0;?"W?.8P;KDZ&>U&Y?0GP)NN78=9^12H)-, 2W!01_&]T!P;VSLL,6:.^*OC*
M$?]UAHE:NR9:GH*]T"#!5Y LHBTD3$AJMKPT!HZ,'#L+_C1T%UX.##@7E]{! M-H'CZ$N99?X3SZZDT>5#FX2Q_MKO2/!^$3VS.W77$\Y[C_X[8?
2=2>7.9="9 MY1Q+@>M7S=EAL85)4UQG52D3077(([K=1)L:2-A!S@AG#9-$D]YP9:4W8A:9 MW|\X,]Q'#5?)$VXKR);+MBB/R@(]B+D[[2I1
*"]H77Z6,O1GNA0TP1!Y(QC?E! =)? M%78^:MV8E<|5X;H*K:U:FJ2 79NUN1V[FM7R05B17 P/B:GOB?M;J*%9W(/M*
MVLFODJ<)P932=FL9M;GMSQ_]PY^QQ!>#H\0]%^R.0HR'#?;NE6VPL#.!&-H M@[FK(YQK%?*
WX&A#H#96MD9)V/##OG>XH@J_&PJ,'.LKBKE&\A%G"IBKI?"I:$+]RK6V=CP!XRKLZ MGV7Y"F\LR4/WDC1PK1H8VRFA-
,$+]^M"0!JA1C=W%$F=\@DF.2\64PQ@^=-_M#EPE;ILVM0)=QZ21;.EBIL4N;F^HED%\WIK&8\PJ¥MYAAT>9'&7R-C8;I[@*
M0ASN;_22\"&H]8;)6R7A%%^FRRQZYC9.*ER0+WAKVU[Y#B@W6ZC8Z M=DD=76><',*Q0UPV9"[740!' =PC!,XY!O:I\\BUL^QF04%Z*
XAEE+51UG;(.MFLB1+1L3>L:.2.%L&W3\1@4V"M4>0B4C&PE]!'Z:"A=/;\2?P(?+LUDVCG <.MQ>HC=554PX-%F.3 UO33^$'(HTK;;NQP&<*R[Z?*
7Q=UL^ 082G\##NB+!R MS+[,Q_9ORXWEH"T7V:I6=)F/]64H55)8H!0!)N5AQ:O$1.+>+["-C\"C]+? MZ0@UZX?NC;P!EH-*
*N@H+:Q*M5)KNAA>FO!4-29:W&LSJ>U5TF($V1)EH)2EQ5 MQX'2U*>U\FA%=:N/\85"]TY':-4(K1JA5:-Y&,T#W#'#;BM89 H1 C"=F<*
ME_<5(ML(R@X_?8W2[DBU"@^;2WCEAU$!:SLF049IO+4T%F9>XHQ1XORAK]Y1SD=Y7!',F9F6!:U3Z]#
M>M:5.0)^>T("YBA76=^GCRYJ5M&I5MRD0$.M)C [C0IGO,OVIT:T^]>/TF M(N)SQUIS8\<*YPCN1NP=S4SG.<1*XI6;>)B;[?*
;TY4XI8,LE+32)MYNI47+ MZDW85&I3CWE<&+Q%AILIC%"T UY7)5+BU3VP(P^81+87>0X>](OS]0OP^P1A
MK\11L.GK4C#E/,):NH@SRXQ@R0J(#X]&4# WVO,6]1Z<@YP"DCE-U]%7 M^$>~)W%V\LWSEU?TK]-O'L9V)5K:<O!- BK($[RN\+R#\!4G-
9$WOXW/C M6,DC_JLA->R=BKY XWKQ^&6AO^MG+YGV -QDB/&%$0PNC$49F^D+IVQ9IZ19 MK_A(2+,_N3/2S4-
*,/\2@I=+@1CN[O28BO&F"SW"#-+*Z"]I1@VONWRMSV4 M\-F"@??SCDPJP?@))=>S,^_1M-$9C;-V5?)IKJGK;>;E.FL]Z!XX.NQ.FC/:*
*M6.]Y6;"$%C]$L^,H[0Z8W9NWP*Q_I,CH"?A"W$E R69D?]*QKO+:\AG7U#>' M50KZ69A8:LU?EV=+&NW[2PT1.!%KZU+UGXPJ*
*4\@*Q)Z,@>9W TV28%+]583 MY;TKPY=!= =I//"KY/92W@^>U;N?RD!%+($2_&U.,8=UTG2"78'NP\U_%Y M,Q640WN:I-*
<)S=NP5U#^P.TO;]/A$V*S@[>=5%S#FI;S@M^_]%CS!A+^;KH' M=PACM_!#1O,+>^(-\?!1F$O&21#K<#]A&M-5A$_!31YVB%.4]FNFQ*$]WFLX
MM+[\[YODIR>QU(M\AA+MEG^(1@!1DD=:'WX$090U0[P2M!M$4T:D2@9N]Q62[!E)18&U][1ZY<20F; M%\PVYKC+T4T]"0<'?*
*+&N01%BG691TEOYWYRW64I8?4>F0Q2AB@#SERF @#%_MHW)B.NH!(T9<%X'VL4<(U,7D<%]EM]0C] 3;]7%/,N*0'X=(TUJDDKQ3,@G?*
MHR0NEUORV>RB=WD7GA/%T'6I+GVJ(>)3%5")PXWDN=@:9UZ/FD=MV5]/ZNZQ(4&OM& MV!E2D=.$]4R/#K)>8"V28
V6O]MQ)HD'@^NFSO6N;?4(C^^)V.3QL-]MX4/) M-P639?SN:$QYEEIW)\/2TBG65S+#9HN!BK\CB!OI\H*2K9Q(.SB-$4BTDOQ ME_%.R(6UCCU*
"TEEL.TDK"3T^P)=0(SD'CD2!!M073&%"T=,%(E,FE3$3V;@ M<%XY%C#KFD[8B2A]JV;U;4+@V.YAQ//GG3E]HWCP==0GLFY";TV8"W?;Z>\Y
ML8IYC%6];'%RO9W:$'!YNT<,<,XGQ7"AK/PLSP@ 'I,YMR:TQI,G4Q8-$]TF MTW4G@2#|>$OPU? DPT15U(51(LSR&@K XS\G/M
DI%R59)G9'N3%;.\):\^2) /VVH5S M/2B%C7[3,';)5CU&P\%*S(4L3BB)@,:'P:&+:-$AO)]8[P(%IN2Y"M3"?OX MQ!1FE@EA>/=;3;1 "O&$)PG43**
*O&406_C%P' 5UAZ!Z>0U)N*59S7):>:,E M7!CI_5XG3GE>[V8MN^8=!0TS;_&W.4VQ3I>3DUQVLW@8L@Q83M*\JTE#8M& M\ R%E"RI*
PM;?!HMQOE-&5C;]]8$XD!?,UEE@L"%;[HZ'G.=2?4;/\@#1/GC MHUB.8KE/I0L463%O%JZ*:[%'Z-IEDY8$4L'45 &W@\LE4Y85#1M@&8KD)]=&
MKJE1'&\ACO!"QI\EO,&[(__/1N41.X3:>X,BN"AKFG-&G0"-F7.)%L-N6$(: M_7935A]J92M(YAB@4Y]?
*-4)*F4$T"NTHM#OCE7:2@S4FYCT(6]BBVNM'_RZ,G.9^.L:JV@T\,,^TR(H6] MJ=9=NBA4=ZX+H![++Z/X{1:_9"H0W.2#(4#$P @/'S0'5I[F3,2&*J*
4SDD?4RX0'CP:1V7$EDE,@^&5AYE1V MM;/2&5:7>+9H5<*!EGYS!.Y5F6WJJ1QQE*AV&< R-<(YM?7CC,H805+N<,M5-IKF9&=A1AG89N$
*BXX5[8\-_ ML!NQV5*3[@.!-N%O$'2*&RO9W$#EUG"_J1&D4K'1 P[,?D_9 +9HO0F\&Q-1[B';B/D.GO0M3"'Z(4/4%*
*.F^%J8>N7N$IFQW6*F0(@@Z$'@ MT#:Y<1 H9G HL DEC60JS6N*_V)LQ>P6A#+K-M[;G M%BD6@A.:&B&[Z'S#;J[LZ"'B'5]7B$.=Q]L6K+,CMP3*
*Q<&$39N5<>RV> TO MCX,\,@EXBRVR9AB&Z5$$73NJD"'4 #9&ZYW\D8>3X'#!+] 2H9;!^W91UB%? M!S&@B+& K4;MUN9- Z?&'LX7 EA/*2 WT-*
*TJL2PNAB7 ^& M9FW9 5!'+A6FLP,\U)-:W_$@0L7$]8>V1]YBU9&L/$QX4Q*1UD"SN%-3?9=3>Q?!R])>2\CX:L MVPDH*
GH%7#5LO;7L+80WI66;5&62QFH_ATHNS%[352;.+)*,J[P,HR>IMU MB$$XLXF#@DJLAF]MF\<(KR3>BP?^YF_QF?&+,'A@[(:FX6Z&*
*&$0|&L\'O), M65&#(4D'WT#1 9RB_#@DQ'1 PL?PD_O_9 G&'N&_2:B/D^T^C)UEFPBG_1N&_ V7 MA_$X'S$ (P9@Q !\,E?#[3#<9V*0.*
*N939RFN1D8.!%)I493,*W,X5>U$]1T,8TW!41EL5 M&C5FQ35N=MZ?RU 3 M$1ENR3|*LCAO&]{0OGT+^"[%/N*= H](7"*
BX$1[$9HXX1,BW_(Z/[S*EFB MK#H7.)?MPJ4%R$^9=&?(O,'I{W;.=GF2,?^]\RYH022-XNP^ MN[+V]>1!^,,0>? J$]*
(4!+9%]A%R01X_(OZW/#45\R%A_'&S,F"0YB-9RK% MOS"Q#Y'>8N /SA2H0]P6'"%P=@0W(?M/X99#>1]ON?V$68T:==3Q'_'6!\7|*
M+XIM1KQRI8:X[$PXDIBE >GMK,/@[BB!(/G.' *BYX3$(V5]J9$;EHKRQ M&- MQ0>E0^D1X0-9M4UL5R5V1
*BKW,!.@_!2,P_B*K'1MI^QA13W2)-9 G$"]W MBM5I24O6Q'(E-"@[0E94A,-GB8Z2$D/%&H1TSE51PE'.B&20WFY7R"$%(I%L*
*MXEBJ44_2D>B[H*0[D/YF:R097A3YA029&J:E2/SHRK2N^ \(IOP(S!^O0I5[MRY/DB!SM<^AQ5F<$EY -NZ3YN&)@3S8/QVM4'FH,9@I$,B*
*;N4U.#S4O**A\KXJVFM4KBL MJG=X%5#3'))9>6XY@?X*T752Kc<'5.,V.HW\/!I M^H$R#]^Q>P,BFS.UFB:3&]%PE+.,]*3K,03D?VD|[1H|!*
<^#L_%C>8-HS[EQ& M&/;FL&1(+:#VA#<*)S7^/"6SU!?/L]F(/KK*3I?Q%R%QYRB6"0/Y:!\S7ES M>SRF&?8@*M>++*
(E47#NETNV+^E\PQ+F5N'2,A!'FN%LOZRYW18(=F&[_-6C MTTO$K^@_U8&'D0A-&A,].IV>ISW\O XG<82+T=LZ/7T#B# YD'Y')FV3G$C.
M>D@FFO3(0-O;QG2TG/0MA1D-Q-4]P"_@<[7G03!=C=(Y8J6LK#Y#GTY\-,, MTO38I[!4FG593?@&@YQU^,8+3/RGK'@Y>R/TDQE1-*
=]0.CB/]>O75IVAAV-_MHY=XGY55P))HJT3J6[JRDN;!Y>%#$Y%FM+L+4':'I.M>M0WQULA2=&QPIX"B MM(S"*
LCI8HR(ZG;R+UDWR1++15/W!;R#18\] "" MG,H2T4E2%9O@I5X1Y-R]AT'-(]ZWNRM\"XF.LWD)A'!,0#=SU(22PJK7=6.6
M\!2OZ/GL,TA4Y4A1X3ZS[%?QS5"IRO.AQ/0><-"4)<%MAF(W>9GXLNM)2=;.M^W2*EIROLW96-3-M,Q5Q5(3=,DIEP/8QD(;AJ%$Y[UZ(K75"Q>?*
*DY82 M*E9;U5"CP>MJ2(?QA8TA;*%V*)$^X*H/N=!>XIG-#TN M"Q/!FF+EO';@V^$:,2ERN&+ES]=&./#%.*Q-4#'?U4&N.6KI=<7"BPX+T*Z4*
*MRW"T"]E_LC="N\4Q$\T(Q1/K%)GFR[U.LYB)OK9> !_23':=&T'P>,0X6[' M+6$ZZ8&NN(!U[*R;FB3<\\.MLX1J+<%M4W*
*R_M&S6MV4(V!8#;.V9,,37$4 M*F.*[/E3ONK!Z94;5SU*V>GA?@JLDS3E35(YY(<30Z5@MK+O"!D05=(K=G0D ME,,.JS1S,\]J!=ZS@ORT]>??*
*4VQ^-5C-&O#$NL3,L;93X+KXEL_K"*JG%0A+ ML3[VB[A)E*7_\Z?WT]5[U$SO3]^?/_X3IY((H[Q[NQ5YT5N12>_'0/!?>F;Q MVT_%IMJOH,:6<]["**8?*
*DCG[LX:O)MA=0H>\R6J=CK,L.851)]C A;_DMJ&C M#\:LI$S-\U4QCD'"V2^Y.G4Q5J?&ZM18G?I,U2D'#=;A*0FW&RRSNA;8+S"7 MKVW",@C-*
K[AD)0.94NF%XKQ;N'}#]EC289PKR4 O42=M054%#3=X&F>O)1H? M27 PJ3,91NIDG/66,YX2[IT;')?Z,JR]#9_+HVY^N^-PT,/8&U!%;\7//7]T*
*M^E7R4#WPUP0MC7YDIU/RN!#Y-G9I7O_XUIO@Y%_EPT.Z$>:%KZXZX;*N%G== MT@O1: 7LLBRK#]RHY"*
<+:^HMPH1_C'D#8XFQ,5^/+XG#$=!AYN#+RI-;-E^$ M.C[.RE$']&Z4NXK40>6GKHIP#(N;XR1)# D'@_F8.LA&V[BVY35LMLY):<#9 M7(1E>.'5-
92;K3=P(LDE6?ERWM26S(1-B?;-TO%"E>"R[Z/:G.,U'W %1\7 M\MAZ3E-E6MP$E7%MX F?Z0?\MI?VA6,>Z'K<>2<'3&3"W8 .]DF]).NT=BY_ZAF*
G6SOAC?,-7"W/ MD?PO:Y6Z(5FAH>!B,UX3!-FG#Y$C"G,83W%"PBB)4X?VDA; M.RJQ"IG5#1?S)%/@>1GJ-FSG-0_-B>:
*^/4[C35,/N$XK>/1D6LI.+K.$D(]3*0 '98 M%K?]R&>Z^HEIJYI%6B4W2=YA";)"?4A6&O.PO3F66/.J!0<'*0:SLJU=9M+:.M!-8?*
*MA@>VY:HCDF!96@+-Q?2G[^ 1.&P\W1/SAU[5Z;^=O;>US)"LL-PX[FM M9*NQ1PFG['@7\%*
*(J:B]PEI4]M[/>*_37@T;^+I&G,U2LY&0DKOD)RLWWWUBN MJ489R(7_(I8KG1]01[Y7C9VP1>+I=?& M!]U-I&(;1P'.,)D;\?]C'Z,SDH!QP29F$?*
&B5%N=LH-Z]9I=IV12P+>[Y)< MCA4VE#8C0^,H1+N%]&XY]X!A1C;H0S$*$FC).TI25ZA7 N2W>AKE*91FG:.*
M$YAACPZF;3B/@%8ME9@PIQ.C+F%1>QI/P\^Y?/@$1Z. C@*X'[>53=R)6V M,IR-"J+6:5[6B] >KA'UIVO.*
*()W%,51%+=95D/(2Z1#4+H1VPRH$!@'KZ@, M O&_ /(D+&UX0'N&76;S1$F^X2W,G%*D9>Y:V//DQJ80??0/-OL1[-]A([&> M*"E^I="A2[D#K*
*M9#A&T /<$I2RPU3"V:\P/_LB*(S"MFD9@W/^><;9OFPVY-YC7E#=_X{[%.&W MK>V$U+YMK8&+!]17QSRN*W]W7\ZBG;[0)K!'8Q/8V 0V-*
*H'U&VDOI)&V_Y=-'M]]AB:Y'R6&MW=5C;)C9<9E?'S.**]3V!RIG=AFO/8'F=0MH#88IDRD@[@H;B M;5F1SFYB9:V]N"*
_](6W=/5S>8,]VHC+P9I)H6B6)$U6CE2NULECV[7Y&UR$6BR%W)I8:N:?E5MC0C2,5[KPD0[L>*H-]3XOEG+-% M46'$TQ+Y(,V:8D5ON
*X\9%,554"9VH4@'\ZM+N;]24^ ADRW /KWQ]4<[O MALO=(!,<.,!X=@*F9!],GBW*,HT1X=4RI%5X$>"-!]76<2@F55:+4R'X2+_= MA'"0#JQY+=+-*
SL4R_TYE7=@5KH 2#^ M])?OLKIJ5^)=T?K_U_\Y?7SR#6D<_,<0RP$7%5&W$/B(\A#(VTBU\P427,QQ MG;POU(NV.4K+&\YRS/-RXE!
[TDZC71"+C)K\&)OG>9+#/$FE5$>OM2L\G(= M?3!(+9D@I'21K?PF6Q@-8F)R[>7DG@*_99'*\W[A@MF8[N_-QEQ\)'BT[Z2*
M99F"&^RU@["\30RU,7%'$G;EE)5+X72:DZ@A#2{=],MS5"GPJ 2?0CK)/%>-_MP&OB$:,JL,A3"U[HY441>:,;2/5K%B .T/&!O3! R)8
*MK^D)=ZT,HP$W:%(>%,5DT2Z;RC V*9"F MU#\,#CU8*N0)E" *@D!! LH. .1E)O9J;+]F.9(B4K<&&4;,+J(UN'ZUCP'1*
MT(%X2ZNK;DEXA]0'O1E^<8\'U\;N$2*Y])@2DSVN^ 8XYZ/*\"UIV2 M=;2D"UE!S<;$\9&W&1OBMA!+@Z;_.+J%]K//3#8&31?Y+@22P]#
<<3PH@G(MMH2\PJ23OE,#X]>.3M7?3@=6]A5-Q+*]-MA#Q4 BYOV8M'.4) M]M5AQPZL,TE /(*
*K\!Y@@1!MT"IE*C2*>,PB/&:LB:7%KMND0H_LD2K9K8CA MBM07-FNKO&SG"ZP.T[9W=LLLT208A5M B&<_Z?*
5'V'A1Y/Z]D\3AU:&ZY!Q56JS'8ENW:V>3D%%WS M^^DQJB=]R7F3U1_JZ(WC27OF#1\8G%??TG\S0@@]?I%;7=<@LE./Q=J)R9B MG[7VSE5F)N*
2G^Z#DXM=%G@_Z1RBLSM#\[B?=FT\F;E?).FV:TESN,/ BL M)8 ?)E;GOWX]NCT]&*(0A]?>/O[\@MU>>Q]RK!>*
R&VKAIE1Q)EP[>L34"+XNYPC& YM1ZU/]'(WV4>1D&FR7$L(%HB;S)+,._.1 M ?'1&C-
=%'SV/&X9?!93_*M<#Y]AXK!"QB0.DM7A";BHHSG..L2(0!,\\48/.M.6;X1]PA&YG!X4?;W,6/A5&Q6V5;5A)V."]-Z(^,(",N:,MD^N\VXU3K@2%#-MK>
]EN-46E&HCQ-SF;X3%V XXM-QOGD1%NYQ@9(HIR8[>@W>&)H-^/]/I_2K M29FNQ7"\AY^IM9-U6;)N &/[GX)OIJ9983\-RRW]IE,GG(7WP)9_^#T-
T]XQ)8 M#-';]-CB(^D3#B#Y:I5FUZ5>$LY\F7N7^[;*P,',CUX2BT%U7V;[TD+/-OG8?\ 42MP&,%C[8$X?\MTP^G;855//?1]2[_P\^ M/P4W-*
*9_;>WJ_=_?^%C8&SI%\&_C1O\;SE]\A8K0L2EX1E.]7,Q#'*HY^RD - MK^TWI^"$K_(.OGM4W>33AU]T0?#Q6! <"X)C0? SL4*0JGECJ $"W.G78>#1*
*M4<;VF[BC% 0LN*6(;3%>V.W1OBV?(1G.0J_35+BGG=1C^"GUNUG7=CX20= M\Y(}-0L!8\%93HP?FOH/NLAC\&&H';T-*
*1Y,\AINT,_(*6IS@29#J=$I#V#G M& F!T[XT#4U+.8#\EU-TPV$PA_R]L-=C[YRQ I>I;=MT)N_EBT5?]\NX/X05L?1U63RS\R@,T&DMM\CF^YLAI6;*
*MHY\2T,A3V"G89OC@$LXN;'GR,P1K)-PO:*LABIB;;PY!^95DN+_@@\>+'2]^ MNV^S<@J?^],FJ@/UQ7_UV#9@%(ZTB@YCW15"!/D.U=?*

6#=9Z/H[_]D%S9 M:]@OZ&4.ZH2]H|C7Q:>V?D'!B@::DX[+5M,20E:;[4&V0Y[YD'D&B1[""^0<= M?X7A#HV I%Q(+5P '|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{Q0!U,/ @M]H^\9XR"TZL$MZTV 26S]R>J!.ZK[M,#5&II$E8(8$N<9 Z!1Q<1#F,:K)@M>5FC)(=W,#F\R)[@!Q'>" [(FUH'C*B M+2V'CB"6J1FY(-0-0<+[[[F3^Z*.L5"B_"JI#>$)P1(@2@N<+= M><8*L+8S-6#?T"M%7"M-_> 1%3G/&>]JT\ <@[*PM6=Q8=OQ+A,5O._:9F2=E<-MXID2GBP>+NO)%OQ,*?.A,5])!@O#!%@*O*)L](MN):GSD_;NI0CS/.>=6+? MNP4/KY81.2[MUSU)LL%=0+#8JT3G M]JOY1Y2+4D\IKI8"(A@48.&D!)O@W8^Y*9<@I%-4ZCF/7,3).D6P]OD: M5 .2)PTTU#- ^B6O50]!O,HEH*+,IO$E%C\RFU0,5826[JE!SL(DAJZ7X]!I# MS*Q>2#:0[L^L$UU%0@>R#[FG':YT A;H]8)IOO%0V]0-> J@1MR(.T\)=181 M+^+4#^\'H@^W87/CR@/] U'Y7;Y D(O0C$UH]^S7)R^F'@"SX&U6PZQW" MXB;V]6=$.@D(""]POTF=BF2EY?!BTV'O+]:@,E;5Z[$W^,FT;0;Z&,$V?E6B M8^X'AB1:+CIL!ADR..#"(]L>/9#M(AFX4%L8.,GE$I6 V)S4U!G/_<2,WJ0N M<3Q>W.6[I/FLEEXC*WQBAPV#'>=),DB$6N*>S,7O\1E>S 8 D)C^+ZMLE1!X MDQ"%_FS,":QIBF']ZV(?.V>YX,PE&_9BPJ MZ2&V'01*Q>]*3Y 3MUP[QXD)?K!=]_FWC2G1 M9.R%S3V3@*%J_ ^D+C%\|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aYVN:-Y!2>1)!1F M[UZWJEBM(I1A3'40\[HE>N:F[UA7^_R0>]^G\H_I"DM)_954?: MP@'6-%2H(?VW7-4]C2R.:>/FAI<@T:(&0-?26'B2U>Z4X%'R /9K_&O+$E3! MB;- ?.8$//AJ_1\%=+AJ9/##Q((H'U_Y(9VRB_X>RW6+0AT^SPNW1Z')(J5$: MP$B[L66>-N-@^\&.X\=? +KX+28>P3%0FP;6""%NPD2\@*/QHC^DC9Q#N%;V MYP7)2Q1F\Z'9G[@_2[\J7YW\DT2A(C33^?@$YI-_*EA#%G7;CX61\1%E@0)_

M1XD1_01YQ^]7A/KF1T3R9B3ZRO_]>6<$V.&79L6)HI%C]3O)(1]RSZ63QXR-MBX(,%H=20PK)ZE?\CI3;GM0_*+0RTJ2BW[A-<<6$H#RHN\[Q=+D$_M)'-R3!\-7@!I.91.F=\!>6PDXQS"F&.<7P!Z<8WD@;CGR!G6FQ^,NCRZ_^CVKXNDX5_M<'C&.W]?"I8GEGS9A!],J*

M7]G01A#V@[(FP4+PE#G4E93-\W"7,J,/^QX%T1A)-!CY-OD':3(F]2V'I=VA-MMC@(6TK@8-48-Q!V5_.KY(8WIT&H#X-0?W8OS"'51Q?

*OG#OX_[RO@3DH2Z(]M!F\!9=0@)]%UL;+T#;Z4-"_]]6?>BN2M#7]*HHI4D-5&DP@S=[EX5=G*]!P8ROE-M-*

*2:Z2%3)A'0G?!P&2N03EDWFHVG#OW?W%=S\"05E3;G",^%_/445W!=75X0J0(VT-M(YR/)3/9P4\'O<*__OB*W/%*

*>36EZ6[P%I:=8^.C,R*K)7%THB,,@("]I.,L\-MACX;]?/LV/X?S2EQZ<8-/<&KP+_-@-M>]B&2SXUZ=%,AP5@CV>RE$O'AR+))<PU?*

&F22F]CD&ZH:.:LVR-M4XQ","7([F7Q#OV<"WE_F@MY8:YBSBY18@.,--H5-M.,?-&DX#W-;_L5WG*W.?2L8="'&&V,>\$&%OIP]MQ.0-3^X@XQ?-*

*=ZXGL-P7-M,EFFZ*SW3Z:N#5"GDNF:OL;_WB-++0V&C)4^:R\Z%OA]K@GARP[T6R&8IZQ_M.L(B_?$\F,LTERFIR[!@;<-CC?8.[-DF5.-ZU-M;-*

*<,9MPM]BYO\1:J]Z6E(A[AJ;#2D";O,6'*K/W(36LK'W!YDRLJ+P<_+6#-_M+?(@)0)G,>^N*"B#-C-GRU.7Q=?R8R#IHR#;Q0.@?X@)LKN$C\?G@;*

(Y?'C3]-M(!G0'_P@>GY^E@%"[C9UGN,Q"1N&M7TX:XRJN&?SQY',O)3-]Q!O&\WU2"1-M(]!9X30W%A<.@DSOF-K',];]V$@A;4"K8?*

_NYV1E%48G^'IA%%CW;8Y#XQLD-M>"2_F]A/[7@2,K\R:DX,;PRV&8FP'<;#-0-S#;D/;V#@/2AW?5?&]B3A8-M@6&=FU;]J#ZA,K.&*

MG@;'@HF4)TAE2Q3"+N,U53O)+N),@>5%KXF:S+M2G-@96G-[(TWS]4V;A,,-M.D1X1TXI&%"M;U>^@\L@52[XW?)0/P>K+5R+C03JA_-

*(B)N23V#7@QX4-F\-M-9=62NY!\0_NFN9<@DGE&U4E**@0"ZF_K=-QH/*=?Q/UP0.B-J6Y80(&X=GS[74V87X%,]M1-?!=^E5*4\N'>>P?*

*5:@F(9C7!XG-MKO=3,#XJI23S*D*I'48\WH+G6-Y_-6TY1)K&=+;-"5#[J,X!V1T7F\HF6"A]-MXX11#2JB-^NZ7+R2I!1!BZKH2UKS@.L0@0UUT2N[JF0*

*'(G4;2#.P[BNTC9J-M00O1:D&\?M@>VW)5^V-YCVY&((TKKMUB%(OU?+YH!O@SO*L%B0-+R[;/:.MX48@=)X*+=&ZU#5%IZX-N3-*

RLH&"\@U@IU(S!K7OC-MX",7%;'#_<\'D&K/K;/K^MMML,EHAP-8-T

M3658ERL"3M)]K>TW.9S&.W\Z[WAWYEV7K[8A0RMS]CF7N[Z>RUUSN6LN=WVD-M$<8,_0E_F)<@;)MV<9'[V)78CO!RH$$#B1%A(".G)$^R($B

M;K[R)S+H[USLRK7WA?/U*#BH_E%FZ]==]3;K7D-)SD"&"9?O'/'@6N'B"WR-MX)>+IZ-M)UD29#N-*TDA#M:>-Y0$-=Y>_"RFC!K4JX!-N8,:BX\-8C?*

NYV5=-M[I2A(B9-:M_!=1Y>-#I1&',=/I/?@X>]UG-H;-_-7SJ%-@_-S&%OX>NMV=EU']

MM;SF;)TQ'NZUX93C;0%OB&Z'%U&$S[^<47V1$YW!>1@H$XLP!T4.:*B/K8[&\L?G-0ZD?$9;>L(*

ML=DS8CC]G))3+P=7?"#%LH;^AAL4P6R+^"O8ZP<-$(D-MXJ,9?3"9GZ>V33@C3BZ#%BSJ9N(\I%(&EX#,UO+'43?.N8?JA]V6&MY<"=724OS9H

2AG\"AEA-<.TF(8-MD')0;PX'-2Z/]TF$^-2T"QU-M#?3%ILKBL@A1^W;#S3H#]H(!O!M5(;50)1_9:?2PRV_:O@Q[CIL51U"=YY6B-MK7"#:(!AZ?*

4&>71MDZ@%WFW?+:_/:%&MOT>CQAZ5_^$O-&K%D\LWO7DXC>Y-M!;/0T*9A":-A*ZH)655\?HW83#!0:@_4\&E]=**U8HPR88X3FXJY"/-F2*NP*

M0OFR@)J(6_)QU6A.-MVJ\1-'/8XLVE(*H%TH#N)!_'OC.$ZA/GCX<:K*OYDA^A+MX*)6IL-"AK/K-M3/%NC"G:=M-UJ]6%\XKY8YB0+*NT6*

*QO06C2R0+9CRV0>Q)5:@N-*W2U8%JA-M4SNT);_+Z;T775'XYM%NMI0?$MYI!'9.",]3A-\L1_]@B%M+,Y9=L/=L()>M0#H.J5KQ-:'<1W?*

A,RI$8[F,:]U-.16N[S<$Y5P-MP">M\]8Y)CY<5N(T#_1-CP"+>SSUW4/?M'U.MW0AEV7OYF-[X#$-S"(T,D'!.M6->8>C*R^@.=4MG:BRCH$

*=2/'2W#*OT\V->NWCA=]<[&R2Q5]]O\1O(H+!-MD+(0XW5#;8TZEGP/2N!R(D/O)9P,^084.4@PSZEDWB[<5]_L-7YB%9DMBH'A*

MM+"+);8I=OH+O9IBBF,KC;N$Q8["@=#31B?V3A0K(93"R,,-\"-U'WG[=-E-MDY8WX,B'#5\VE]-&?MC0(@R1]_-D-%'R^\,>[Q.$Q^$9E:T)^/D-

/PN(MYIP-M4GE/EA,U#TCQ/OCS8TASXOZ!?+'P77@GMH?K23A^&+O/3XF:B-LH.D)^K0!#-MW->5Z^!1GW/Y[<]S^6TNO\WEMX]4?O-

^KRGH")$X(-R5P:N2YZ.TL4G31VF%-M29E)I-QD"0!^15-M3*@WG?0,V1N,LD.]+3>X9"OR>7L:TF9E9E'G64KN-T%)35,7C+,5K;;HL5'/*

MMG+]Y@WCA.-M-TJ];KZ-%EG&W6QZE(7]NUVI^,L&J[OB_*+3'F(CO&N6RU[T7B1^RYCGIZ_D-MX3-&_,K6-2WPBM6_B1-VA'MNQST972UT5I

D@W+5O!GFS7#[9C#5#^;AWCIH-MG2FEOD&I=@Y5CDRLSAHFO9^U+56?Z&/@8G'314RG4&RQT:DAQ(M()-MQ5Y6*7I2-*

-#JU$B@6[<#:AVLW;$#%89(B-&D-P.^$%=1J43?%Y-R4MN+?LS**2-H,]22F@7?:5=[5AJV]?"((L<-M0-1XED(-M=*

*(G*6]KN73868IPAZYX&S&&G#!K]A.HS\),L:;L!RUA\HY]WXQJO8P(E%@]"S:?PJQN0![AIN-HF6L,#]4G7EQ:NG%P_@G_S__?$!-M_M.R+D(-EJ3*

>/W^8]>R^-#&H!1+Q=7R.$,K:I'@^\;#CTB)CB-3@D$$V@)-M=NOWG%';'@F66Z?%+TD*5=!BT$Z)+5.;.!G]1YD0"L$]PZ"/G9/.U;XGB8S.

*M30&>R)4K=GYD.'P>I(_[:,-M?M1Z]@26_GG5^5#&$6?%*T*10V5]^4=[Q1,O-7BZQ<:%AY:>=-MV]!;ZI]*^[H'>5TL6+*LD2%JB;FWPL5?.+3>6JI*

*PF8@D"'U$S("!&]JY+-M4=T(T+>/X8TQ69(0E:!@\#F>72_!N)1)\!NEP0%,$6ISPX0A^_AU73+(V\R-MWO8Z94Z!26Q*BJTFEDK@F@'UAWKG*

M@U\#Q$VKD",^$A/&?,Q\[:2@2H,?-M?S]-/70/VBHB/S=ZPX-B1ORXD"5X:SM(4-ERJNCSQ;=\,^-;9GS+C&_Y2/B6-MQ@'[A3!D61>WI%9N<%*

*<_OWGU]B4?*PVP<]34I"VW8_95-2-0P:/^U'M7#]PU-M\>(@'C3*=Q%OH*!5Q$[:^;(\;J#*UXP"S$3>5I%ZB$Y>(8I3KSNWHY-16-M!?*

*BNZ\,_1X@,H.73=0W4E&WW-D661:F3(RB:,-=-S-9&)3&P],-MG6Z3A]DYY1M?$LC5;\35-KM#@&+$"HA',@1E>++>E*UCCF/\1V)AKD:!&K)*

*MC\M*D'2'4>MMAHD^{X}U$0-?+2JZA'/>SJH?EEU;[$G49;,TU]V]XXF+V1]J-MKO8;5T72JJ'URB\+WF&,((_IRZJ0HSS8L,E^W*<-AO\HJ6QB"4>9*;*

[>\-?\-MAJJ;77$#!S\V*4B%K>N=?R3W[Z(*9@#HY*!Z[+;9A0?0<)1MR2JV>"&(V=&-M/Q6GRY$C(LCAT#E,:^@MA%;0]UD,@XST:L?*

D.5$0#CV&H.WZ8X'PF/;9-G>M==NZP'_N/[3@V3],<&#)'3$YV_I?ZC07B]P''^\.N/G^O6RBF!9;2Y"O-I,:-MF"Z/^3M_X=MTR$F'FX=NBB;EB1&'*

*MQ4-11._I[*DU0R^5FLB-=91/D"S^LH6V8LE;J[X)-*>Z-F+-M3*@WG?0,V1N,LD.]+3>X9"OR>7L:TF9E9E'G64KN-T%)35,7C+,5K;;HL5'/*

9EK1QK51.BYZ7/L7.9DO'!UJ%;-M115NEJNQ[2!;0*ONBF1>\411!CE]99@O2#G:W%Q2]-1\DHZ/\'S9U'FAZ7EE-M?*\;PS+!:_E>?)DO_)E:8T?*

(DG6A4V8)KXA)=_1#1Y=36R>>O\(-+"3RVF5S-M(K98%$\84E-@T0&2?K-MU5@HF7#*'GH=V*8>NX+5"<$Y\=%-JMQEZ"Y)B/C>7*>N+=:QEVD9P*

*M2<,-'I@'"L7E'GIDE&,(1BGZ!O;[N/*P:7GMT:Z,4:.]PJ)6:/494,GY)<46-M_U6."Y3+,&DH75T-E%-ENSG[^Z]B?L/D44C-I\#UD?*

L'/_A&A%,WR&@B@2%1-MSP6>QG(K[V/2HMR%<73K',614<>%S-MY23$QM)A55<7!^Q)6L$F<2)5&4RHJLU>T5P["=FB/V0;0&T&+!_?5*.@RHC.*

*MU2@$R]&J=I5-M*SPYHMUOK!.,;1I:@&@;U;$&];LPN\;?I;<3AO12+5GUY-?7WQXAO%]9!.'-M%EJ*82?(X.VB-I]D8A;MC.]UFB6CPO"O!+']*

I%RB3[3(]]X^-I4[:XRD+O-MP7-O%S_O2):>"]$Z1"XQX37'VHVBL=K@OW9ZV(NZU'DVH42-'Z($5%36T0^NG;,@%-?",F$)E%#GDC<+^Z.-MT&![)*

E-?I3-89."B3LT\HW!$\(V;$-(SYSJA-&!?U4]9?V,O3*-M#$'\M;^(5TCE=*X2\@[>.;"\":5=>S3*.XC8.%R-M5Z_>478O]*

*(T/Z*I&I1)WMRYJY%9&!ZV@>CF38AH1RBDCF4C&41;C[U(Z7H'+-M0Z(MNE#9[\'I%'T)XV:12]-LMG,FEE6BCXCW)(-9$7Y1@UHB8!G4QP;1%F]%*

MEB&N)A8G+)K-M$MDTR&//_0-9"SP=!LT:--M7>.0(C^(I>,NJG:"#?5-QAAD_:>J5!.^C@\I:PLDX@BR0DZ((0&[+-M)0EA2>K'OK#>E_3-<;']1/;-

F550GL0_3>E->-<1.-UJ[:[P-@GNF(7S@^OH5]D1$;E.O%RQ-8/>HS2?RJ9AYKE,.!\@<=^/"Z89BJ.$!GQ.M1QU"V]!BF-M,X7

_<=@A(HFM7:@/2)XVW453>0GQ(-M8$[$/^O0=U)>8WZ.F&82RN]-NRT/TW!'690HB^;W[:]UB94<.1C3WZ:.)?<2-MJ?_C-PU,9_@>79-K:-KD.M-(

AJF9%+'/Z;%]HAFC4Y;"D7\+=<_I4WK=0G_-M(WU!9L]M1=$%4RN#@@GM(\-M!*^[X9K<+-ZH-BL<:;^($0[VUQ-H"D6)AZ#

<].SRYTM0ZI2B)RB>_-MTU.W3+-M_N+.&-=JQ3$61UE_?3:?O8,N0TI:\L'!VT6R0$2PX"'^@+@Y'>R=W9HS"Q]=-M[VOR;^,#->'+@O?*

B'5%H011.GFQA^J:5A\&5_DZ'M3K+"B9_-&,,N'"M)*4-M1A"U(P@16!,5>-A,E$-2M>-^+';+8!!G5?0D'55/2KW]NLF5M%_JIXM6+IA;.*

MTEYI_*M6C&?0&KY>,F+%R0UF]QI#'JLW-B#AYAW5$54QK-V6S24(,-R-7!P!-MC-.P"YIF(#CZ<6W$/R#LQPB&+3S\2H).ZZY-M%-'$S4SL?

67,VYH>6U!=1?LMLG8Q4M&<@0H553Z%)WU5-]M^3V67.&E$@AH#-M-X2UHQ-[1==7-@U=]X:RQ,,=!^.4$%N^B63GH$I$)'AJYB7?@!"O0/?

7/#5#-M!/;-'7-6)O0]NZ89EM46^H&[IXX]4SO+U#\0^]FVU45F+X/L'EID"S1@3-(7.PY1,AW5CH

M1P.Y[>AAH/;&%P/]%/H@N)\U=56N1E^RQ!9F!.VQ[=P^A6-=,\A#H0^?<27]-MFR_G2M1-$0%*YD%,4]>[P:P-T$QY8T7F'E7=MV(F0L(0N

M@>.V)MXPH8N/H2E[ASF9+D-2W^_TH4/$\8(^>3:J]*QLE.EZHL&{(]Y]C^-MSC.DEBUWO!"4$Z152X$83@OPG,]D!@AVXR?

A(DR"R8,D"#GS)2K<0ZK'UL\T-MWX^8>2I_2.5'5T\:3#@?(RTIH2)JR$C8/2"CNBND!I)96%-4-6&M=5PTRI_#

*MPRI#6)*4^$(,']:0>$ATI;,&)B7!W!1*CX0=(UM3B%_H^:A.5-L)/55-Q;W(-M*[F?8WG.OPV6JT=@Y9/-)*?0QNA0QPFN--X&I.,IDW!;P<_1'=-*

*;C?:UQ6G-MOOZ*81H[^7-!UWNMZ9&HE$<#T]\]K.S?H_!M3-MJGL3!/#$VQ^SOZQVWHSJY35T-1+(L$%77-MX,@=EA'@C6-/U!]Q4E>XO@9-:+A**

(=>G;9924+"]&@QZX>C[)J=!-QX^!T(^-ME&K&^%"BSBU;X;3!(@;FJ@M5C))A4JI:RKI!5Y.S(#(EW(TF4=9R&PS'>+H1\617YF1-_M,4WV\OGH?

NQB'F]%1)-Y8'>BI?BOJC&R.M-84X:\E&5V&]1G/H5Q7)m0:5()RZWH59V^U-24G?Z1$D0A"7?G84"77M87%-M@6FK-CP+"N09.$DJ=#H$U3]H_*

*=^W.CXLQ0P-4<27=M@1AD-IL<0F1D<4"/-M'6TKKO10.#C2<(O^]FV0(CF6J>691YJ<_0@Y1>&GPLDMA8&$&U#>MRT*WLL?*

M8/0%1K:KL0>;3SV"VZAMVIC5!'[1-M/]5>4Y9PDVY3;%!<@$>-#?<"79^E14T;@K;<\@HKM:SY!&\,/U?B(T&[K.B+P-M(KP(7\=)-Q@:;?>E,

(+4SN!7X>20J7T&O(%>&EXBRA3!9VJV^1GGM.[\LZ$4+5-M@793*Z?(LO9W2_),C=-J@FGKXYS/D3\)=0V\+T($-K<'/^$\<8C$ZRO"+LMZ

M,80@Y@=23,6P[&&O\(@$U?8@F[6@&[PM22;TJW]A1YC=&\,+Y%6JV_-LN#K[I\,.)R\6->K:&[%/UFO.JX@9%GYG+QHKFDK\CG;_(V>DG\G%X.*

*M_'I#?RX*I>-?5)K1L)SSY8BO^KZ/D.O%&U>5V-C,*Q<\#=/_M=2[?\^(2XW>^JB&/L#S-'W3)B(>*@,S()Q(!UJRZWH\9#5:+FJ[7F\S/3Y_]-J/-MKGC.@-*

T=KF:&0:^3N7N9MJE!K^C-J.3F&^H(QZL4:N+A-^\6D+)QJ\])QZ1-MB>AJ!QWRFZ"UC:=&@=G9$I5+J-VX:SA_$6@_ICT<)Q/3NXS+GGTK%Y=0.*

(N\-M61-RD["$IQ@-()TD>S"OPB\>O@P'24@*3"!RS<7:-KH8_T!+>RJO2/_T)Y-0PO?E?_H7Z)@\HZ!VDBL0T-M(/C,]RA?D86;#-._1'(68*

*F#E<(!ARG/%.H>PN1C5%..PU"8FKW1+'_=22@'88C<.II\+>]!Y)M"U5J4?MZI9]:O'B0T*RAV']DE6AQ&L%>[-M"80TZ-/?1:FB^6>?4.+'UEQ5DBP*

32S(66KZ.]@=8.%6A:-MLK&495>17-5_,(#]H^X"]AX2BX]^%P.YVNR$_0^D:,R.X9PX^/182L>W"G-MS),O%[%*

<._:\Z.J8SBIYW6'=9\!5@ZN.$U4'8V&+A=8U,R-08B:YT1;Q#G%-M8!$IP8W-XFSKBC4Z4\@G?

*DDUO"%OF1&:!RE0K8,%%RJ%42@X72Z>CO%DM[5_-M1P8>GJECFN7K9R'2#RA$&A7"DXUBUA^J%0Y$5-)UY85L)I)KFM669PN\@P4**

M#KCF$S/=*\.]'T$^H)H"'^Z[C8UO(]1+28@D/.]OL;+-W\9H(+V#CL2V,@YO;-M;$ZS.=U!#5RO6>G[T,01?(-WS]#&0G]+1^X%3#Y$ML?

9'N_@W@;\/XJ#!:O3-MM.P\>B.6>-(5485<(PL:9I117JK(]8Y$RHW_H:XD=S<-MF-789N,"B58H&QINL#%I)F;-$>?H4AWRW+:4WQTJ.

*)P)&\\@F&3FZH*5RRY2-@I("7Q21-$]RPMR_!Y>(]AG;S=EJ78OO\;<3*-M:R=))XI(7\ZD689."UM;(X""<&#U%;7;R!S&&M)9B9]&(.[6%_Q*

*M)&XJ<0IH.S4)]4%/JCEHUPR13;.'14E'A+3H-3N4?3PM4-Y@702LP#)UFVB@A0_68DMI"N;RJ)I*FI*6(=P&%N7,>M-M=WI/:.*

(N+JH\VTV$^PJEV&Z%P_#PXRV&6=A\-Z9;/:M2=()..+H)<:]M0"W<-M>2U#G,]D@P'.Y[9H=>@!1&FF*3^HM.=/9.,5>+-[5H&7.)])HI=?"Z<*

M!TH:*A*D54.+^C1,$&M,+QE-FB-BJZ"R6'QF#1-ZD2:7_60]U<.;3GE/.;4-M[\QU7#?#$XU-GYIE#1L#*UM4IE*;VAK@\)9YZXI/YXQ/&6L(.]K*

*(&,ZD4E-MO71K9N%-T/'2=3>@40MS8MXY2)P*HXZ952D[%VZ?"^"?27]:B-$I%B)&024[-M19()AOZ6K?X^XM_8!C"*

*(\&\1*$W6KD"*%$6'5O1FQ!H$!U!Q!'O#&_\YC!VF-=5N3D@-^D[8&P1X"/T]##-M8S-$-/&S+8RO\&=F3;%S8#Z\^+?"2/"Z=#<#&A?*

*W&VRV#:TD_UN\H-299^//-MR!_'GBB\!V^/\";4'>N_N)_!5U\]O*U0\=ZO\=Z5B@??C.H4R[/K43Q-+@:-MMMOO@JU=A8PB*97C/EP4H-5,(L[PA>^?*

7]D^-C@QOV>-#H-<3M=&-O';O"5Y-M;N_MWV+^H)UO0+>=-19;!3XH^1W'"%Y1H)-M#O-4;X=.8!-&Z?9-!3__-'6_,]U.#\]N.STON,%;F]A?

*P7M68$]OA".$=]+7-MO)-XWQ7<(=7X]V5YT,ZIR)1C.][(I0R)'^6-0H)):H7N&F]SX4-)WY76]A(**

M.+O21W&&BFD5#\59\Q;X6RVPJ.SVPIOE$-.PIG1P5*4\KF$413A1\8?#%89-M)93%L.VRZ0-8MP;RV(E]/!]'0:2!]Q5P7,BEC#K#NK%T/',)N-

*\.)>NO&7)[-M?]F14PC/GF;3[P.9?0@%(YGY;'-#XTEMBE#L*6Z=^>A!P%XTM.N$Q29#IY-M:E**E<HS(7XSN:K.S.!MG*

M\=7Y.XN7:ID#9<_)+0^AI9YPUQN=CHPC&6(5W3#?KZ.!P@-:Z78X_T4Z4O)5F)44B,!MHF%F/(Q<&A!H$=86R#_Z$-M!FB"K^ED#50-UL,T)=*

*(BUS=0W@L)SGO"-@"?I8!,6FUAF/RQ^R;C@X4)!"Q1-MV*0I6"04TB%&H2$,.8H/97(@1=-))"B9JXD-C2Y$-02G>15.%*>2LXJM|S_I*

MF^)G\#!LGXIG9550-+T2=GW=#7-J/N*M=[0?-,\7>3%ZH!VL\>A6_!-MP*._-]0"[KF_G]'U?MV,:JZ:"(:,Z6(<9W\5L@7Z;:+OFZ!!-&GS(L:OPB%*

*M5F44B.<(-A2^P]784(I=?4MJG=\S5N.UV_CQN#FW-L78',Y'H#.JB*F5Z!?A(:*NC:G5\+.(:%5OTA[H:-M"QIS"8J@M-N\,,\N=\\V(`5/+*

*<6S44!!)0/_RW)+UM"/.MY^&7CU49!P#QQ-!.@A:,'5Q1BJZ;+&"8$=.<"L?DK@"'_7@\4B-B))UR9DC-M50OV>1%&C*IK\,I'UT4TE20#3=*'0"^?D>*

*(8\1="ZR4*8-/L<"4]9-,AIDVB-M>]NZ*'C,8IM.&I/&6Q8;_$Q?G]>7B#8"T__YO7Y3_GOD(?4?DZ+-B]\K[^&-L:X)HA-42*

MFX%:Q8%HXZB1_E)7Y)5\>.\"(N-1Z!@(!C5O"D!Z\H;:^G6-;?A$"H)]\C7-M\%4X%[&%X#K70WI<0"6;C<'5+O*BO8-@!#!_/#'U<<96@YZ%()*

MPG[@TN!M&T1@2K M4Q'R83F1GX!E@XP6\)[R5I3V%=[L?I6?^C?%B\&#K^Q M#@\|""ZR_2,/?Y3?"IY^3F*

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

*J!_RW'ACL(5:'$Q3*K22Q1]YH7WO;.O%);AWBOAR_BJ0S-.'GHJ92 MH(V_@$@78ZT4?79XKW,XE.5_^+WZLQZ@O%DR9J^01A,(L-JD.\< O*56:F]B MAYWA#O8+!?X1W)G*2T)S5(.1B6P%,HF8'!2/N.H8P1#LA6V/5IF"PO:M]HI4 M[B;LR!M@QH\U#X//-F_%NPT, .]&81Z)^\!?$&G=M)P08:-QG^'_FWS3K?8+?Z+8_Z(Z!AT;._\]W9!-(+!W M& !@%HD!W29) ;..A>RC-B*:XQD<-[S$[/ RC VD#7T\7"K;Q5/.C$DL'AZ MX<-X$H4(A ZX&7-N2VU:UV^W9>&G&_DBOWGXY:/'G]HN.5F; MWHR$6 ?UDR,1XH#"$VJ*#NABHJN:T6Y)\++ M"4:JS+Y)7Y4%*

*(XN_!$>Q74E:HN3>WDJ,+:5_9C>0@?2]<95C M-@<(:Z\=Z$MAZD+F#UA88+])RT\5 -%=(@+=^YZ^9?AGA0EQL:&+[HF0=.ZU# MA#0*55L>#77C:9=T+.F7H'3 +5,>X$;L_&U?[[(H40YM]^:]0)$-'\A1ONYP MO>EH/Y*=?&!41OJ:6I1]$GOTTU\$(Z_+Y],RD*

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

*M>'GAW$:)\;W8K.0@_:SUU:$!^7G$ FADGJX2VOTWY)]"GW2 2$-4S=W-QUL! ML$_C2 :6-'%]F#P_(G*U(*

*[SR8C6NRM;_$3K9S2'^H)&K5GDQ/PWZ]:_BDSY MOJZ AE%LIW%0I@@E$RQ:L&1M3>*Y@EDB(J@)?BL#% IU%UYRQ"P%_* A9CP]?? KQ$V3//'MV!1BPR@\,<_=7XZ\JZH/GRV_69MRVUWH_ JG'YXAZC00SW M&0QRG_;)\GCKJ$17E\^HC(_9\)JM5-[P1D ?)(U-^1^7BY\8+W(#07Z#'OON M(1FB)$!@L>M$TE%3\G=E=2."@=NWL\1]8:^*J@6Z+N2;I7GV"_&^#WWV!!Z0 M7D(37YY75 A[&KUOQ,;%:1>NQ# C7),\/J//##;$+*4=*

*V0Y=.\36'3"48F," M*1*O(R(+*G1)(#,,ACAI!.F?EC"#&K"!4\(*GEY78EYW2J?^T/M?7OS5T5WV MM6:HK@I_:*%DN?STDVU9^8WWPU]? 7SVY'V9OS?9O+_ 9!SS%*.011'QQUWN6+ M=DO59PW/U0WY;..IC5K=)N% 0JY41^R.!P;9[&%S M1W.,(PSY23]C4+O]K&M9?YIK67.M:ZYE? 23&^!"N 64X06*NN.2:X=4.,?S M#P]^[>^89/>&A*-%R7?^+@SD8%%OQA%-P@'ZFH087H-5Q58@P3 THX\\[$ MV8&[+Q'X)(,$)%&AT],5DY>&*

*<;)N2C@D4X9[/R*N -&[PDJQ2%*R D^5[< M95'9X#V_C^UA0EUDSU'TXJ_!C2?7H#;$N\.5$??*75#XX^8$H!(M3V4J*

M,88"C";+4HF\LTK17ME@XT3:@;(&HJ1^*F5>6U,V$/;07M:-]KT34&KRS\] MD>FLN/;>BFL8_\&2DW(7W0:' ?*

ATL2$2MH*L9^FH7TE0AXJ(U@U/17>Y$/]2Z^5_?A6T]JO$]M"OXC#[!XYM$7 M_@)HKH]:O[+OU-R2.S]1(Z='NEWK

((^JWS.F_8.FQ9[6YO437PB(X2;8&5+ M)$E;)RV<:)DHYWUNJPE#/S!;YVR==[1.$]$#T1H?')M>G/H@3IEL2GL%U=9$

MM21YLNR.BV53YP65KQD/CIM]%..I4?X3;E MZX\UTQ%W\&-%=\<8=^I$F7?GO#L_SME!@E+#%@&,)#%^S'UH=^P4\.7C-_,O

*M6N$V:*H0;.Z'SFS6[VW6*=GZD6_]W63[KHDRGK.!IY6+1??:Z[!:8 M',(3)6)48+H@]-]M75R>[7IVZS_*74NF23**\J JO]7608SIP:V4*

*M10#=LO\J2RKJ[4!SHM ;6,?*G.'77,,==QIG(>S)_PWW2@2CC0#\A(4ESH-Y MJ\Q;Y=:M,BJ&/3O*6^C>'*+#4(8,VH21;6;K;,F?*

NC)XK@V;HQQC(O>,&W@N! ^>#*? M%N D)Y'04OL@ZNMX 0&/%>&V+A=7U7%00%I%E&O-%$R!85(B]Q?]3NEM;!7# M7FR)"SM'V?6-V2F*

/(C,Q0!HJ=.FVGS00L@?#39\HMNAZ6(!+/) 6,$ P<% MWB4=\<(> ,T;%.CY-8'KM8M4%,W:I7)7TM\K1Z.-#U,) XX96^\ZVC63@D/R

MFBH^X#32SN(<(7[?,>./@GE-&CTJ!4[XOQ.JO4,"RZ[HN]N@_6C:P"H_@__M1?!\\$9.2K+(2K&"AIFRC8&VW#QRN?

B>W2L\L5ZMH(#.2"B"Q6S5WL[^4?:@ M:FV(2_<^/PG6\D.$0_)WE9'X'(&7'Y\#:WU^CQE]H5:QZ,5SCL)&BW-M]0TBJ_8(1]6G>K/

*X4X\E0Y_Y, A8>2H_ZIU'>")\"G@B]S?>D=]1P%6-A[G M6R&JR9'J0D\]-.QUG9PA7 +'/ U-W?NOC0_4-*X !H<39]KBDJ\IOA&F2@L$*

*M@']+.L@F)S:T](@ L>'Z.86R?,V!LZQDW-N/&9MS81*_89W'H0Z,.+2IXT2X M/,>>]*

(I^H$Q/,AAE\]ASLVLKJ<$M#^8>^C(XF,!G;HK)MTZ5=_Y*WU@ECG&.PB52.X%[M(H8O$[4AWUC;\7U*VZ!UZC#W1'-*

*V\@JH@&_KN<\L0F1\L/5(1#1446(@7BMI M $AB&:X>23]%C:%58EL91_S03U2>.X$\4*2VM32>DZ!IN&[Z/T+>W.P-!?C M1>8VIE#>]'.%*

[&2BETK19P&3T:ZVKN@!ZU^N,.3<^16ZTK@&XCY#D3#ZK5$X M2J$8A'_2@23=&M)UD@I?M%HL'8S4^Z@T5425BHQ^ILL1[C:TDA/7^_BV"F|

MAU"\G(F' QQO!N#-69$A#[OWTH(/3?' $.3>*3]X./F MW W$N!?7Y74-A,8??]+@Y3_A:W?-IWIO/.P'T,J8P!;S&W,%?79$[VM;(72J

M;ZS,:HO!&K3SM\);/R9381S7D:&$LZ7-EO8[+$V5L""N5H#$ M"#;'L^8$?1 M!,@/GG]DB/U09;27VL%5TU?]1Z1*D#,M);L_+;TOE''45S(H?*

*XCZIF&H<(H M)@%D@(\?_V=D (8$L1N 9LJ M99.S2=MM9"^I06K75"L"R1)@ 4A$)F*B*"-4GO/\Y^>8GK'^_1":N=@ MVMY$L:\S=,U%'\/R8*

[@9O+U$XT(1\O'4S?6[^(#6A+ASHZ@!O!G7 M#4E0!.V0!6VVQD>L,:[-'T7N(VM2%,T2:1Z!T>9!R"G#Y@@9*/1O8;&^W&IBD*

*M\8%VRKLFNG\)54'I8U)1 E:YD;Q A . 5.*3VS*YS98W6]X=+0 .4M>L_3]C M17:U\A.--.W;ROK]TROMRMC4M;F6'P!J7JZ0I|/2>#836+Y-7Q;*

*(0YSB49MM M=K;9,X>'&@I*81'J_1H2L(W,'0 > ^)/ M;#1^.?&'J &N!I@'P':X06YVGK-=WF:7U%?#E^LT_S;<8.",#C(MJN8 B21F M)T5ZEHX$<=U-Q"*

*[0U=Z>9F.0N2'=K*2" M9LN;+>\V-WAW;Z-_(C]'C/1$>"RL)=?:/V'I$B.50Y159;^I7E>N2_#O/?>; M$-*

XS)9ICF]SR)8B=ISELF=ME;NJ=M\'[7:4&!/0"P6EGYS8Y:_](Q<_ID8 MX?%_$D||6W=@F|>4O<+L6C*XO_7@I;O3&PZ1J DHL6'*3&T+ FM9S;):NE>)*

MQ-'OO!HE#:WQ6?:5 /GN:|F[JN9^VH^G68>=+9'OB? WP/LW46$3'&72=2Q M'O>IVV@ F]G]XZF,':WO53.4;E24,VOM# CM2:=HS]VNAK*

*$*$B\]0@!FEP4 M,>MP6M7+47(B$;Z8UF(4N",1JWU=D!!YPOD#D!9I_D*W&(E02,-95Z+:T9@I,&@P!S!FTM9=/)%8AP&_A QQ&X.^*>%R-*

XP0EG]+N4=4$=8@F1 M/)%^]D8@%LQ+JC].'+^07E.DY[6K5R1;6?"TPWR'8"TT^SF_KN4MH N2>N2! MD.OC[JQ /]\$CXN\#7-

@9$^TW<)PQDS1/[R!#GR.ZL#GE($=7-<,6Y%8@<_Y MP!6;X;B36P,]_'_'[SZ6-.,>>5'[Q;W"TFYQK6V*

*)J:"H6"/QEDJ.O1MAMV83FTWL#K7ATC^'QC M^L89$/DW-,0#,_VH$&K 9"&KD;+!IAV:Z[Y4 M-F1^?+:DV9+NP&T?*JC[MNBH[VP8@-*

*'K>9TE7.W#[85^V]A#,9C:,V2T.JZE_@SH.96NB].VHE.GM]LQ5 MK-0L8I*SLW6TQ.2,73_5)LB MLZ-[:1J!T=0':,PSE*[^]HIB"@$X<3EM@A|*

*NRY[8[203X@9P[\S5389$$"I%+>&PP$HB("_<; />@] MB\!]FU+1C!#Q"#DK.V*H5504W@P1)2=(E&KHBP@:@_S+:#81@@&)#K1(P(H7$*

*M=.:O8^HP>Z8")*1'"5.0D$,.YB(PU!*&;0(Y1/3_(PYM@'L@O_:-(\YK1.RB MZ4.OOK"O0>.T]PO53WG9++P57,.%!;%T^#[X=8&>E-5ZUU,/X35VNL!W*

*+ 'M*T#MVM"D=;EXB7J1)H0]#>L)JR=}(L/],< @6C 68)99[45:PYB6@%L3DF3$ M,H>[KMX@^27'EXEDXFB;$90SZ(PRGK%8-6&F1D/HY 86"U?*

O5U8>|:#4/\!- MGI!#NIL\R^7G+,WPS0PAGR'D,X3\XV/F$J?XK1CCMZ@12I* M@IQ\U=0=|_G!^U]!TKW W?L$PKBK58=?Q?;M\)L_.'\4;^DC\+5G?*

H3T_J\= M(:]R4C_Z;^_N <32M=&""WA^\R3>?7D2G@R"?:[Q*]9(<*AXD9(_-[PV_ M]*<'][=UY?IX)-T'SB$AO.D=QFS=P)E+AL6[CU:@=*

*[4:_Z/5,3:N#H M9P6NH)HQVA^2HD%%#VJ$4)Q-K,J(7?!M*S,?2!K-VALV1K]K7OB8"*Y3$V/ M^'B9*2)E,RDM>@#)]Q4ZW.O%3_X%&]C ;:>*

(9A0"$;W,A>+?.?/Y,*H9K;+ M;UK\.9X*:9R:T38/NP0+&-R>4J6'T*W0V-X>Z(7@__MM_^8I8C:C78LV"UD;_+D_<'](Q*VZQG?';40&-O7Z*

*M.IAI3/:U9MRQ9TK#QY2W*_[WXCI@(XP"1AL\"7 MH+&531A#)B4N;G(!W4J9*U8W$M%SL/V[3]9GX!I_QG"$B)NZQ.:+GR_MELY2 MQI%*%Z*

96H\)DKP|=TLGS#D!_8@_U'MOO(-F^K(QSF6!=X@+6$E2)I%+29UC MFIT(DWLO;.;[,M,^WG Y+'"1-($3YBGB<$;3UD;+ Z4PI&,2I%$F"G'&(G@6

MZ&E^.,D77W@'06^M+PG]#CAL-"7%:+J]N !;]RXEF0 M'24D8K3P4<,N8,8P]6K 5)DX">0E)NVIHV7F'PRO6G;WSCXP-'BGV +J#-FV*

M;:I.LVB,D,14/$8K9>MG"9V%^ZUL)0E, ^++SVI/>#3[K(4^;R?&;WF1K3$C M'/GH>(D)0@S,%_7!3P30 4:'\K,75W3L(T%+F_C $Y:27;-*

IPS\EA)TYFN;+>1^(2'ZI)GWX3_4 TFN@C@20T=OFGB9FR!U5%AC%K"(5PX;$U%Z@=<,6P' M0N@F1+=7[',QS.,)A4#\8H/IO.5]P-'_ *2=3*

*M4S+8]7":0B-YK9LJ'DX99Y3)'ORR5N*8P78=QGQT=2'*QBB]R[8?&? M?HK\/V.PAK<^.N!!FWD'JE,,/6?W9$H1IY(^.@RI?,9+88G+33B@L"XLA4'*

M4Z,R2$D!>U$?P-/KNNG=_:X;/X#\4',&XD4,-8 ROX^ U<895ZA?B7?H+W7C MHT+.9+QL-GDE1\"I)_TRQZ=^U^1_+W?W+Q>_;$O&T:

(V-.S877Z04WB2#F_5 MU&1;5H"^KY@. DYE"-@BJJZNN#G#K?DC:I#L@"W:H"&6<.-SKOAQM]DC.'Z*

M45)$QIOXZ%AV&X($<_.!=?/_[0K[0NLFW[N:NGG'83024E%[.4QG="Q#]#) MKGGQO(U0+0<$JQJ..B'5<:A+C,9S(?

*+E:8K\0HG.Z^!GD0Y7>,FQKP@B11B? MQ<2P:?TKK*1>E(5U&,OZ(<4&.!P=H]__[H!H$5]-05A..B@).<8E&]T]-WHE M4Q_D?"C<6NMJ$%L,?*

\LOMS>'3()"PDRCJ:2O?-U-)4Z4*?W]H#F+L:)0XLN MJ<-C1&,<*L?:WZ+R&59'XUU-MY_*KMWBGKO<7&:)E-/G7-_ZRUS?*

FNM;3\?/IHY#X&2(4#F4!L M].PP89+_R?EV)!VG9MR 7((1'I"A_C@7(MT,ZFUOROISCY%EB MQF^$)=58(TE."]?=!G/)-3BZU"

<2DYC_8>C1M&ES]YC>OEPJO613G;"]"/C M1P.I61,BYX\YQ@'M#:Z)<4E<$1P_&&+; MZKC8E!#RK7-@]6[_BI"BZ=-V-<]74*P@/5V(R*

M<%O'Y,TZ-O^+L-,WM]@;YO!T:.2[;6C^VE$3T##GBI1L+HW=QS7=[-3F5.IS MR\)7K4NP.OB\M<"E.]; 2^1+G//<09O=^3,KV#

<;%TXP@XPEM(;%"Z[#RD M=X!=#54Z1G'Z.PD4RT(:T._M/60FT M\Y-P-P$'L@_H-@N6?]\[9_#)YU69"V/29(_C.$7 0HXR[G]PP&+1*

*[1:#*E#H^^9"APPG6P('>0 M'NSE@JIV9[63(*#9Y4M'I)5^YZ2"#S0LB3^\@R=R:#B+EFZ5]ZW+TA"6M;6B M4-N)L :W!) <[1#Y70]?*

*T6,#0_"0L|=B/OBTX;#N1;05 5K9@B8*1W;>)5\/'S-.O4^_!U74,.G. M5*KU^MO%O0?WR< @LX;5+VY@U(DW!?60N!?Z;/S$A.T^7MQ[R_|_\ VT3W;;*

M5F5KVWIGRAZITC](>ZHB,U8$(5#\ZB&ZE">T+_[\>/'PZX?W=O?O?>WO%IL< M/CX(?!C)(\758?PH<>S)-\E,V8@C".\(FB[48@(S!_I2NV*

;Z5(K8!E8$YT MP(CE^FGS9US@.MQ4_7GU]S^D5\Y/Z2.>4C\1T93:!. =7]C\#*8=;-^/ R:T M0I+VQS-I][Z:,*KWFH'!7>)#C7B;MTS5Z@\Q+$G(_-

&8:1+I?]-,,IA3IA-2 MY#V "I)>HS)TJ-51:_&W^XJH2B? $.FI,MEV,X6$E_5G%4CEHFDGO),)AP(P MIXLH3Q+O$97;B#_D]E&KZ=K$T3Y'6BD(HX?

$QO@KK,&![Q/4JR$ P%F"AVJ MA4WU5M[LLV91'4#"OP]"CB<:63B.5$I+|YDH#KR)P%8]MWF90\$N*UY&=_#(M)M$#Q@$($_]*

(:#GE\WYAXSO]_/39 M3__]Y"H9VE"'#FL')Z<685V(2&7WC%]R7;2OT1B4T$:3H^->7&OFU$ J6U-CPZZ7H!FSBU> M-O5OBR\6/I)C_?:O%W_-

"_^[;RZO+M4))SL9HJL4T\2?3$8"[L4UN"V>Y'YT M2\7+-^;"W5RXFPMWGT[; MY#D5-,3 'Z[SY@BG]P3 AWH" M8

*LH'8N!64P!X!/E/-7#^D&+)RLW]!ECL(0,)Y2OXH;(UCY"0E42*_1!W;A+1*A! %,'",_A#|(:# M>F9%LA/^$\|7KWFH'!7>)#C7B;MTS5ZG@\Q+&G(_-*

*$MVHRA/A1WR1?-G5. MQQJG#;F'&I1![?<&@#R+?I5^_JX>WN&1$BK/1TIV"*SSV8LTDGP.]7/HEF"3[M8T0*$*"$/)X3O|[2/9][__W-OZ0\(%S*

=H"IE"<;I8JB=G3Q8XQ0;CXS44<8 M]YQGL:V ED&5GB=-,O\CORL/#K7HNHEZ#7[!+.:IK3@6)EF7O$-N1G=%F.24?5%]RAFF>2]\D(1,

*M&D7GB1OE1R_:W_T2F*C;QY(R(;TM)2A#SUC" > 'D FRC?C![=*8&EB"_>-_MR_%7NXYX.7*J;.=,S;]'?2"9#YH#JO&LZU7?"D@N,"@%-@J1130\K];*

[)&\K M^"."LD_I:&'!(_0^1H@'+ Y1&UI+36B#M,5XW88#N77A7OL]!-W&JAYJGXOJ MSHDDD!1&

[<1V_IS!B;:"H9#)R'D@OMFY8+6$<-'WL43>>/2Y!78'RDSKZ.ID M5@K/(]#9VA-3'I4KJ6S05\'VB2W%PC?EMW%$..3.Z\6Q=+OBJ,1A C672"&M*

*MU96T":HM!(^@(<'X&ZH"|*N%2881BTH'OK;Q2QN,Y-TO0=)U|V)DT"V.OHG MN]V26^R0M[1EN4N\737.83 FU/^S=1ELCN]ECA)2 FYA!:!)/$BH=*

*'X^[XI M=D3<99TK56A'I.KFN:O\(*F"@ZIXFP2TD2/&FHMP.^X;O ;-*S2?\N MD_;.TNW1/@+,.*L0W\($5Q5%4**8VPI-*

*AQVR*LRG>8HH3_'=BGGCZ4_NY522. M9"SIHD/2%[.]S?9V"]'J1L !?!,5C.ZU4YXA!$E,&&B];&L4RH8:/=Y^*

MNPXY_0EE%_JO!9Z5//P)7<"=_HJHGX@2V#P4+&L"C,L3AG\F\+SG;T&T4B(.

MZ_5^'E>KOM&VZB5>4%=TBU2&SHD[L$XL7+7Y!JVW[O01]X]FC@3G0;D[ZFG5 M%)XD[V" F+JK!OF10 TC-

*Q>@<]>E6T.?""=22*Z"5/DTZ,$Z+V51S)KEAZAQ!%1$V!]9UE*__M':8YF4,^MU1IFNB0>MWQO1'GQGAJY0T#+V 261;]S;KEY/IK_!8LSC98 -)P*

M#;#D)1.?,M\A#.G]"3!$(/.ACZ4+\18F[(@3GT]8/J OL*U'9@$=_'%^%=)#E%*^0)SW@!*

MA<>\+!9/@7_HM5O"^[UBSRY/>?'T=7@,;!,@^+#FO!ZVWP'LUY6Z[ZE_X%(M3?R?>^AQX3;\LOK5Z41ACP\"ZF!U%!.$;]=@2IYJIQVD6V'Q*N?*

OV.XWORL* MQ*7A8_YD9HJS$OY\1**GFJ%?HXUK[H\(LG.=5GT4 NR!/0Z%WY"RKWCNNE9#JO"&)@L6CK{I\CICLX!CB4B8<)90CB.E^Q5,VP%'<M=(NGQ(%)]HF/^BORB.RP&X3NT1$ "&(%,,[!)\@YA7Y8BK0[HP 8:K]]O6KAP3)U+7J#^1JPR$A'W8YZA$I3Z8/D"X7+ZO%?_3^7'WP9Z"^ M?O@@A2Q[TQ\ PN5_ QMTJ.N&S0^I?;@Q4<86?E[*]?ZGO$E07R*0S@)7&_;) M^+0;.G?KL*RY'_X70F@HP=H2E]1&,Z?PGL%D"O5 M?8MY@\,!7ADB ,_N$6H.#]7-[(/N3[/]@%@:CU$U'10Z+]1A[35N$HRR-GG'L3K\C6H):SH'0_[T?W'2,WW%R$:]]U./&E< M!7"-_V,) ^A.3Z\..$'\C_=@:MX);5(.>YX;L)$BBREE_ACV[Q-2S$1K1S\[3]@OE4IY8@F@T9# MB46\9LJ0P6N\5 -.^^!]3HW..TAO$ 3EN#=#[WD]V[9T.GPE34SZ,K")F!@T8$..<.5 MZ?>-<[AK]W7A=DR-RIP;C*A]@A=>_(N:4W! _IAZSLS=M02]8]GN.M_U.0N M4/AID'Z[^L9)4Q29/AH[-K;O:RF0%!/*:PF2.:_)Q@<:QB@W_;C\4;1&04) MI<>@T E?3,9$"18Z^\&;<&9MD+Z5R(#:Q<[JB'QK)BS*I\3[:5IF8U>^ SPA M>L4]@XYU_R"_+BEMX T#G'F/\2Y38)J02N++."@N*SAA2Z?L(R'L4IT.0^Y1 M.#Z_NSJ=1^25"1E.=5J_*_?+OFGY;/!+7A<(LA%A!'S3%/V50O&16%!BJ?XW0-91"Q7X!C97+APC,KR'RADA#>_M]D#O?%4=J7M7B)AC(),$/5R2GLV-KZAA%^N"BO1TS7CBP^61+S_U[IA&QU; MY8II7,'D>&9X_G4\HS5JF=(H;GF'GBI:PX;PC,H1^<8WM9K0/ZR=/.PV#EE M-^?D%)]KGEQNNTGOQZI!;7V[7^+3AM;&M%MAN&F,*N;D5*C9UKX]<" M5'ZJU='4++&]JHR9L-7Z[$O[WFSP.L1D>-0W@8)CN/6(/S19;J[!PIEW@E" M7]C(YYB=3FQ_*6U*_!X.>&0Y%!/.J_.L 26=H&H$K DM:<\&PY ?@L]UD=:_M/?@S!V81-\.)>)F.]JGYO> AB#, Z!OV^';3NI[U #$GZ4GR?*:16KOLA@94 MD M,4(*=52@SGSP?].3YG&MF#^>:V5PSFVME'ZEF]L\2HY[38??<\@KHL5P#M>1IV&&]";<@0&5" -+%L7FGY--D4E"$72;Y\:Z@OG0RH29Y.8MJQZ&W9@[R(E MLQ6JEC* ++H$1X-GVE[L\@=Z+GX2MKM.AYF0\3N6QYKL1$2)0M%%*W[WV]N>K+94ZN^0,+C0U>.N+QVP;.9F2WTUH-MB0RTRA9;D9N"YYE56O;%AHH$Y]Y$85_+.G?6N/C=R+HI>Z^4I$4Y]1D M7D(1]{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{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|_QSX.]{\$/_3'W=W@_*SQN_J^6E@U8#_2W=*3VV_NRN(&&F_OW MZ4TZEY,R|I9N#U">YGF_@8%M2X)E)7_!G;PDPZ?_X_67PIVR(MDYIKK\=ZO MEGLP':QRXHYAG$@[$T/,;O .;M T)[$">"NP)GYW4]XM/4"+%>NA_D2NA7%M<]))KNA]N)*^DRLI/G28G3<%:4E1I]+$#(!!LT<]Q&$VW&;Y#5^TD(-E L+3 MGQ0UA,G^LH"Z4,7+B7Y>38E=U[N^8M26T@!'"[7;8?Y/@&.*KAI\#\']{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{JU3O[''Y"'CAYO"CT/Z!;W[_R.OSCCREWLR*WP&(EP4B7>$ 2I M(69BA9F)+XVWM+8Y(B")H][+8++0Z;+X%5@/$^:C*0$B$VU] UT3X/Z1YK#$M&G@1LQM>AK,''ZQ9*GZ0"(T*J0Z2%$[?'+!5F&+A &F"UN&Q_Z3'D]4EE18- M.!J%0 S&"6X]'AU3=^GN:6WX?K.MS0@C)N]+OT.M6_"(K1'Z;_)K+);R^ZQ[M4-?3T%5]S86C<43A:%G&RH(3T0GB,8I$@,F*,(& <\UPB3LCG0[_/-1+'Q-\ M45 !#_@!)?4T"4?7(*0L0M_F_YL,9(37Q+?#.W?O/9D?_6^TEWC4BYPD>?O'@3 ^FI:4)O!+,HB &U:BTQ55S N'Y?6XNBB <'M&9$:OG@59A<=A!!$8$R4T^6K)/JGV1+/(YF5#Y+\F52N7$C[,LJ/Q@<$4&W' M3L=8*X2BQ(/H0+B?0'*WV1,L$W8&4'1<&*3$;^BDY^R?!@9Q#B47,D5_@1 M:A,Y1*[\IPF3B"9*%E+B/O].4$++L]=(N_8Y_^%_-1?MYZ+]7+3_2$WX(MN M,A38K42%VR/SH>*X0&R.4E]1:RK%9&O4<9H!52(-#Z!(_WA.I:!D7R_A.TW=#NNSO]#;36($<))HC(COXZ<.N1TH; M@E%!JZ5KP&=Y/R+Y%TX&Y#>YS1?A.>?O*L"7C+&HB/Z4<"8AQ;7_,G9WK^]F M<=382F@LUMG D(H[SQ%5*L[=@*WM61YF$;ZT%$XA?CRP_:!9BE(N!ZI$ L\B M$L8MT!MRX(@?J[UMED@*2<,L>Q_"KWR_"'*.AM$RTT.9:"F;%UNB=)@G;* M8R'#%7 =MD)11:MRBE3V:8)4]KM%YX>VD9#Y;JRRLE9RS14SBRR%%.IAF6Q&M##9]35(@<:/$=L9OBRM<*SB1G/NJO8TL7F'Q\#6%9G>@R MTDV1RT]>1P:&23V;.!Y#89NZX_WP^LT59WMYJCBT%!9^[P*:32@'E,@V2Z5YMN41H6TA54YH>B16GWO08S1]['*VFU.10Y$M><7:\V21C.)W.0AU*>H=R4;\ I M^#[J9T$;KE_67_)%DFC?U HG[HGP4O9'HQMX3%*A?7_&9EK8I10L0/9E9+\ MQ;PY;,@!B7%B+DRVC43GZ0A"US_^.!HZ;H#444X7=_SSH2>M"[R7[>%;2;N[MI$]#C0FR<<2C:RL7_G_GC?:2)<[0Q"M)BAWS4)K1F'3A(YDAM+BX"98 V$RT M3"K,M,E'&PG, ,>DTAFX0F:D3&GY<&WK72^=Y4BZ*DWX9)CIMK8R<2'#6!RH$3GV:;DPUK"&C6]'W.CNB(SH+R//KS.H!SP<{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}U&E,)A4<&2QT0Z6JC/0+%_#&4>;'^>-Z"!; MK\I?\[\SDNVWRHNN$#[/),RI/M;BR-IH-9Z_WC8VS]>+^K#KG;?]V Y%.48B MQ![%R"5^6#I@M1O%.N>5;3I "8AW"0?LG;B

(Z.W@MD8!#Z;N\H]QWBHXL/\7E\8Z<8[PKO)"'^*R,N(;Y5Q! >-22(?C%"^\;&""K5!8#_C>K#Q<;B_[OQW%^G>6,-)KL)GD MFZW4H,!!S+*"ZTD=D(^/9X75$XD-2";1,N3@D?7/ZM1@ EUF-SFD,-K1./J(M6=^P&E6R3WWCA,,:RRPY%B8%Q!1K0&6 -=L0'@K*7 MF-A,3:..$H_.274>-[V$8 '4I_L ^*+2E:(#<%#MW)<2%[X>3|9.]O8--*@\, MM^@_)G@7],K,YL70VMG2K#"830G/[C"*>2O2_A^3)V-X'+Z61M0>T.UFW&XX M7/A,2G@"=GEN;%6P]Q<(UG9W6N.SXGL"52]7]Q/00.NC9Z;D2/19D9WAP](4 M="Z8R? UR?U7!./*BWS'9RL &77O1 KEM&YLDM>+11 M1 M-!?R&1Z")@?&A35_@>8;4TVL6U%?9+)E7 D:RQA$,&[M4%A!U2T104*MW6(P M:1#/DT>_$(\NIF%&-BY^J;" <@&$,/WRS0N|C|E"L*$!PQ_ 6S*RLS!_MI43M*J, ^#&8I0U!2*-1ZT6A4"O"0K(@#JYD$W|&@WWG1=,EU'WQA/ M+.+/T8<2O:T7)#9K0HO0V,);XLGCL4M "\)GU'/*H%X)?T0?A M.H0'I9F\#H/3LQEC#+<@* @,7?(WRU(A*4%M7*2- 4#$UQ_;D;X#CS<%KT0VD M8FU:#S_).'*TFNB1,Y!1B?CW0 =RJ_F]+G.579>E-.Q82 ^A[B2_/AS01'H MO&7Y.GDK%X'RWVGDKLG;&"@!Q[DX#PH!Q0)X'$Y#."9J'-/\)E-:H#P(%3)?' M\OEX8#)T(&ETZ8R5NG(BYSY2$,Y96DLK!5%:5]9&D>!?78$..%+D,U_ 0J5Q M";*

<.,B:I*LZQ,D22U1$E#3%2(UE@VG@7%&C$Q?:ACX5_G3H];+&Z8IZT0(-I M]1ECE'TD$UT9<2HW<'GFPRA$B,LN" 47S)ING@LGA MD<'+BQ*UI;A=7@-J/_'@>(?Q_K+?Q-^*#%(T@4XGWE2"!]7@ EX4#'@H+6C2 M/OCF;!G@S9KB';-62[;AD7 MN_L[//+_L6!PGDFBJ3W0,QY-YY>%:2/2P.. <+K! CEM3]";8RY0)":.[N! M,6=DWA.(FVZ(59PFW,0&K]D+5X3,8YR*G2H0:8S' M5Q;-YOF5(WWG"4O.$ M6#1 ;

(H<)@=KUW,ZR73O^]9TC0W%""E!CG :A @%6-*7H$O.T2,"_ZA!<@$# M:NSQ4J]],I01=T0R@1P$K2AHR1_A4K,110DPW)H04 J.^KD4$1%BLXO%

(G3N MLHTK=HXK5%6I(W&V:8;!G MMC"SSQ) ^0WF?FI)4V+ ^F2FSUHJ3Q-J9^^4B%T94^EEH;SM0#R4RL(_'8Y&CK M?>A%Z3; =8;N%8A^7T/^\;

[%2]H(C+&J LV+@MPCP0O,V"XI^%I1F)^BEUB@ M2YG\TI@=@DM0V&B0NT'N+FNOM +C>[YFFX-^P#Y?QM3D;O15-V"\>XK5J5E& M@")$

:R5D(5.!,H8E-S\VZ_,B"GL*/#(."E6 K,.7=) 79;.Y ^B/(CR9408 M9:%(UVGK>F=D%$C9>8FE>#ES.>3U(%"#0%TB4(;R@BDE3R*B3YE1:A(1."!L M,Y-@;(8*>WH,RDJ2BU/"7-<*E<)'<8&B;-D^)1O4MQ$GOD%DWC+-72-/[D;/

M@1F3"0)0C,\>RT&I$>#]_H.6<4+@%DXP46B)ON*AMOH>5A(J:4G5K6;S!X=# M-ARRR{4VNE1L@!"1C)4RJ47@L)&8&L1/R%65I?7G^!<"[[!IWET=,1([+U' M^Q:C+ TV5L4YHX=CCD_F84F>1?7Y_3@&:1ZD^3K2?!;/,)?K**-Z-*G(.*:] M/6LZM(C=ITE0J:)_3C4(%(3%,W

JA%ZDW^/HMZ8HF^4@KX,\7L?]R\/^3+!-GF]-LG)X8>DP.LGAE/N+;-!TI_(5RRC$V"N^&"=S?ES V7Q H

M:)/S]I$>\M#R@5]$7N\)H^3)=9(OE^2]f1T#_3"[I=MN ZD58,%Q%D=+NP/D< M<8&AEWH%B8'W(DHS_FR*,TO^XA*N-

AE[81IVR\KCO*ZBAGVK<^VN9V.\!+;6 M3/9/(W"*BY!O(KPZ85-!3M;NOAXLFQ#_LS3Q\8'X?T= V?Z"#I2!&_BGP.4@C1_K2Y (]#9*#>!$?

@8T08R'6Q/*^E@(XGBDDQ_8CQNR[19 MJIY+RPO+N"W]GT>"UBA7Z)4AU(ZN:A[DO&7C%Q-V';^OI.CN\PO!9>/>!K

M!WSM@*^]\>ULVZRHF_EZ>KI($U#K9/D>PX7W\^48MV18YD_H]NAB$2]_N)0 MI]_"MI:&M7JAOT^KS]%KKJ'XST?

3&P7YW=)&W#B]T/;_7Z@%A%^I57.U1X= M:"]XTP@,X9(BUP>V-*<8LBFP*GI58/'A#%MR6L_P_A"63MFVB50#A"6(!8)S

MM<"6T9ZN<@7,*0QWBAWW,2=D[PF:$M6M #JW>*\#*^YQ>ZP!\)MPG8J##C?8 MJ^]1D_6< 9?

T)06I^<6X@A&//4J4\))D4R)@67:IXMKJ"]NI>)WG'_JKDU2*_MGJ=%-4NY 0*\]\4"I&87R5"/8/.65X1TP93T.^PZBD*+84IBTD#F]4JHXR,

(\&PY"3$ZCOB MA(&,&,Q=H[V%W9?)/K9/@#^)XWLYIPT9T$9PJ3Q^XOQP5F[84<*_-B_H CM< MD(..N9,Z!3GDL%NM1RS-

>#:\H'L30&9UX+C8JY?T$BUE'3 MP)*MAP,S')C[=F#:YZ.JL5^E1'4(KR&=GNF]JD*U5_#OAO,R1#Q^@",4WCFM M])$]0AH[1:

%69_I!P@B>\\/9!:9D_MGWEE8F-S55:X?90B9F'4I, <&'] Mt$M=(?(;TI-B6G-SV5%?FI(8$8UNH-EZEG$/';$1UW34A)>L@XS9I&I#W\C$V9.

MG]YUJ#O1J;J<*R'8_TC'&NXSIJ2VK%5,=B'6%)O 5 AT GY]^5:]*.JYS%^_M\R'-!9S-)1](^X0FQT J-ORI"0/+Y105AD='T;18ST

LD%NYP4[,&0+P_<[/9CS@<*2&(_4-CE2 O92?VK24I9.?QUEYBSE2JT MSN*7HT_CKFY M95-5:1Q@4*9%DMK*MD[?N7/['EB?

8X^H71YBOPE5@%&G:5%\ M5G#KK,.D7ZM9QDQ?+1.=Z;8*J/TBA:_4VGP5]5B7/&8W]7*P,E0&3A4!@Z5 M@5NJ?+ F7PJ5-

8Z/+M&L#@N%_$:$/$$N9C;Y65H6@O('8[" PQ5Z<8*,O:'\C M:NBW)#/2PU>ZAEN!B8GM@>GRNHW6D]]"7W^C:K]OZ:?)_2!VKIAE_=<@76,

M+9@U@EI3_]6J8_\!M#6FO!1?!724%B>7N[@QEW0E)BW--4'1";5>)>PD-V#&[P0)#_A[*%T2I*6IT*IHEZ1U(Q_RR6(A5']Y&Y+PH45RPO0XX3^ILF

MS+C%YAJ;6,.;U[8G()VE L0*7^$?I$W+*-08<8(MT6N#79L]Y#$SPI72(WC# M$[A9FMI36-Q#R0#7!50*_K2/.]%5F!I7[YSY+F1=)7V D9(E?

-0B+"]XMZ97.*GX#?LEK M:L,:CNTNJVII^[QBZU!L!]I,<2_^,1+7GI#:QJ&G &>@I$)#VT.5,JK:3SF1 MTA4F4M9\ML TIS?

2^#3&APB[Q,HHE0L(AU";N":0F!R*3PG(0)XOKJ?@=='&B M8+/7*5TO& %NGV(22Y.?@I&D!",DFDL4%$,/2-(*&Y@V)7<[!%=7ZS^)V8+Z

MNPB+20+G6$AL,$B&?Y$FHA;_6Q"_$;Z/-$8_$Y DLO#RQ^7VJ& (]5NFA,LE

M/F6"!H>\WVW)LFX#+B#OKY$N"Y2?"ELXN':1I\2&7W:N.1D[<]+PPE%?>IHO M7E(D"W;Y.0Q2I]5\S7*(%Y;. :9'>TL$=JHA4#-A%YQ<0"2

,,ZX@K!5^3G[NV9P67$&4\]'&< M^[V <00GKUZ(I5,Y:/LLHSZVWO&(R@9VZ;PE/-V!B$X2=SO%7KUT]5(]%1]H M^Y:@J/I&VZ;?1AWR]S-

@KB6;%XJE?V QTTU%# 33I8+)Z&2K[4,*[2P^1PU) M TPK:48]>7&OS[8OT]0\G+<@VB(/>K"C(5+M0H8Z/@[M.P94)E5IMH6V%3> D S< :52 T)&

(U MSPBW,,,=7)@EF71ZO0?/MTTUEVE%UQD(EK8NEGL2[>8?F(FEY^IZ[D@-2_0P M.GL+^RD--A7YWZ!'VI1!S1AVPDFP,QC>&_"L98.

($.RBP/!E%HGV=G&F;$G& M4V4,.0]*]8T^2(7.%S;/@5\\N\B(K3E$]TNA0/U$XEYT^.B;S.;8DP^I7LB'! M=G8\#A!S4

P0.09DV:U%^7/Y^@@V"^,?/#H&2EK$Y>8.@P^DFM#;>]5]C[5 M?MG>WIS+H@^:2GW&TRH,<&AV U^%[=M187)OM2FX_CE%-

>SPG*QKOPQ=0"]? M@EXY>9EN8/5Z)9$/QTLHW=PD*](1"VD\H$=+IN5VP'^CEW?U96 8,NR3T%S2IBT)?XNV^KYH,AP

MSJSE\.$L;G(\5*!OR!UQX8V1EE*+ ^*(31+$21.-'N "C(.[!C.C!?42\Q 6S MWH(<9&CI;S095YP\"T8C[.:WUW-W(P_:=HG.Q6/10'JJ7%XB&,2+.T7(2^,%

M$%:@BY?@'#<,&(67P#LE]X\!:%(/\EMK)'J>?(]SHR=J M& XO1@>90J35 C4;1TM!YEA%HT:U-?CV#L7L7H@P0"01P;!>[Z4)I=)@"(MN2#\"+)<>O

>4KZ7QGQL0%+V"./ED4&ECNXWQ1M/MK6541&/>H9*78&S-E!C'D409=8> *SHSLP83*=_U&KM+5^XKS@)43 33EA-M M-

O^\Q#AOC(0R9,^,1RW\FG[A>+1[M#^:'.^1D!R/)O#3X=Y>]$" VQWUH.E> M@$A1"O;9"IO6./]VUR;A=@=I.6O26AN8QS:;9RD6TW)I.&V:4?

>1&3[2>2/Z M\6:%?6\-$)!:RB<2&F2/2=9E'#VKN!LON-<4NR[_!@YQWLAK @D"'?J7DYW= MQS8?#I)_+6,3]U^3Z-*(9(D]0[LG

M@=U!,$V#D*\H0$H0>&]9M)ZM$_8T7HJ'@)R.N'?_G+L>"C1KRL'!O)J#*9DR M--0Y_#+W2.IT0W&K8PF6H.JAP G8GJM2C(0!CH[-^_/'3ON9?&.

<]S)TR:F,("RX.8V$B3.&\&$B+I""83(8JI4TW&7'-M=UK%-0Z5"2&.IF41)_P62KLIA2,A,G*#,0T,Y>G%V6MP]8?F(R)474?_:L Z M3;C&+-^^()#

MP1/ZT8> (+XA.!T$^\IE_065 M@FI.<;HUEDWD_GRX^%=0VJA*-5@O,FB_O#2@6Q-!KQG"_BT=\FEFLBQBAQ:!

M*"5N]B@Z8S#>B."=R)MD$@2O!\ MX-+ EF"]Z2MA;T::D.!J(WH:!AG34VPH7SC]FV)+DKJ,BQ+6#4S7;"WWS1>!

MN$KRO"I6>*"I25F"!*=@KF+D$APSAR&R(PEU^)O:GM:E;7*(5]T:6?Y$4K6L;[[>3U4>5S'I12IS[==YL_QS<.R3A? M:PN=3< .\=ZFV':27Z_I/_U

);5IV/NVV6V"_WT'G1MWQ+DM0JB:&6KK>9,% M(1>I$+VJD3N26(ZTO@3+JK(Z2:G1@!PR>

(4P",1I.I>EZ0F(G0CZFN04X^F4DO72Z>&/B+716D)@? MG&/$.XCC>;R\AJ301ZH$B)!SHX!04#_-"N]K;6EJIQ)I'N%>3*B;K@4C;/*C%H

M^M,&93$V?25H59=0O$_)^):3)G'[WN$MYD:WU^:!;:,.3]V 0N]!0 O<.(*Z MVJP/!'K4PM;IG_8-4;8BK4U)U4,6]&9S+S[]6,?SD>7Q]

(%WQ0(42]RP(<=7YT3X][FVO>'7/N0 M:Q]R[=\Q!DTV6H7QVOHB^+" -2<"%.$^IM[7&V5S$]]HT*MM_APO8C?">UJCM

MJ.@/6$6AH#0*"B"55RJ=+!$HS2C?)=-^P>_Z]>TYVEAR25$HT) [[R+#5/I: M@5-.0*>>61+*'F&N!?L0VL"$PH\X$*QIC?,

<47%ON#P,C2@76!"OG0#WZ" & MWB& D1[<:M'J0-0M0Z=HZE6#DT3V3JE(JXLB4@(8,3YD+LZ MHCM['#>M(

W>%0IAO)93SA;)=D:UXIQ.H">VA$OVYB9;4Y0B8SCS-*ZP M=ZS?0F9>E'9Y7)FCQ8G/2G16@KC,B-,*_N\(8X>P-33]M&C]DO=0D+4_7:/[

M*&O,VSCC=C,ZLL["MY H7K^U;F3IG+9(E[U"'N^\]?(]$Q*Z-:+?Z*Q-TZ(% MN73%W:?

&H8=@HQSZ$ED+2'*]QOZ,X38BMM:F@[EC'T2NL+$BMTXQ5 MJ2Y]DPER::194/HH>5_Z^8OV;M0J,9'2>' GL4J5(_,*XQDY]U\]_DK.;/EA

M8]\,VHU!16E]<(YY7);%.8*%;?'A((AA!9(:7M,H\>W M6=IQCR^/GL$'G!9<#4]QK#X (3=P5CGT^TTZ)@6&)+3*Q((C'.#P6HJ>ZI&B

M(N]5DF@[@!6.;G'T"]F0DT-$&4[VB;N"["W0WTF]8#Z'$MZ(_Y[[1HN,G]D M[]K:K)D1Y($T(7BV0%!T@YH'!3VV,G>-EXFN!&DO9TEJ.5[T@CH].

MS*UIP"BOY?$LR2EHA>08+.-%I^:"H#,.KU]EDWD_GRX^%=0VJA*-5@O,FB_O#2@6Q-!KQG"_BT=\FEFLBQBAQ:!*]<MZ@+UVO>7AUD+? @\!?

7C+.3C%6R#-P;GPX][E[ZZ4]N/DH+Z/Q?!L0 5BL?<7NJ#VR+$-_M"9\)UZ4//$QUNJ1W>']CK4:B@>[4Q0XNM%8D<3,DV@P$!3.3/=TNO"+5@@Z?

M5\5FS2*J-*W/"XLZ[3LY-#M+0! O/?&A M>?"?']P8[99($0*5BY%5(//\^C7&*&XY"@910/;9FP0C+(12!/;FHITA^98?[?X??]1M&+4+TN;=S=YXD4W

M4B]GJ\L VH*_OYMXL=XY6:("?[:$]9C%1*&%Y^X9"/(#_) ,.OCL3,?T<$3% M%%JY"V_'R^K$K$#*IG &1'(GL+M$V4Y,;#(\+0CWV'@V3XF4K/X918-

+LMF/ MUETUXCZ1)G1H"TJ6,<]9A3!ZB1/1I5VL,#;5Y,R&>\EE36QP04#$ET*-"Z'R

M7AL\Z28N881QS57V.?:/8'NML_BSF@,.G%WEAUIFCS9UQSCZ'JCG9WB+]3V(MW%74G.BI$D.?1",C?RPC^)UN%(+KR?J&UNW0X>V<#-

Q09QO_FK1BYQ#ES5\@T55,NYI#LW M\##5>$1C5PVWSF"^,3#TLO.R_2?D#99U@4CO[>Z)668/!UZ[Z';((1&32Y6C M_S&"R,O'N

CL@=RV']^]L'RI9/4S,0 &7.P#^]0R+\V9>_(%PB>',!Y\K((R M$(R*(E\'F4'M80LO4>5WF<>'!E%W-33>O6B108(2%DL)SF5KQ!5V0((3$F=X M*-

?.TN1[D9(^S%IR?K>+S@^&1/B0"!\2X=\(RBMZ=FI.8T[96!X6]!''HS'!A MT]44&JC-/"/K]\QSXFS?_5:*>AXU(8+.0:LE^

MS3<&Y9L&RRE,Z[MM\Y"N/(9V:ME;I0>3[0QC9+RA\M5(]?LDG%11P('GJ>Y] M4,%MQJ0@W53=F1!W9L7$ZV-3H!;DI'-

BAVQ3^C>5S>8E8@F4\6^1:.= GPZ MI-MFU[W?/ISB@%H9!91\^CV'XGK3=8[GP/&Y2P9TY")G"CUM 5KZG L'M"CF

MQ"D(6VV3R!52MC9B<3H9<;END##)H0:NW-Q)C,OFJA1W0C6."I.SFI+$%#J2 M5H93/^K\,XX5HY_WO#P?22L;KJ&7/^'H**@DS(.8TB,1\!M9$8-

VG&E1XWK1FBK1DR']^A=]PY0H>XX,-M2E%(D([EERW M)!%*H:S34*7[KFZC>+\T! IL6";9K\OKT94HF8H?N(3%UC]J6? X)H.:!A]]

M6<>UYD::$T.-4%]!6I+VB%8C?F/4^S8LI0O@#CUK/+9!6ZDE8P$&G#Z@O M=AO3M6R?@B8.JEYLPY)N>7/E&S>:X/61&:!)#5-

2H5MEQX!&!6)O&,1(I@.% M^1=-.;V2;^<,W;P!S>UH29Z\B?!Y4L5"KG _N WY$,H_ 5[-X1<"L7MR:RR?# M)8!>CAVX%\7GY+,N-HL<7NP;2L)

<+Q3_9F-F_ #Z>-W-^]ZZ[VXK;J/!$%PU M8=WBQFB8>K;-2FH]-$+!;.:5.B!4/(9442<9@$U=>G7H='1S!_-Q7$)=6+XZC MO["#E7/YHO9?9EF74/F1

MR1/NT^:*F8)@FBS> &V?JN.(S1D&#)>.-57"C^?PRK1=F,K"DGI5M[JRR,$" MK_ +XR3>\3/@M7(WG7 I:W="]W*9,7,_49M {[[P?O:

M>O&I[=+]E0E:F%+'EM7:0^GN)>T%2#P]FX/09:'$5!@:F#62YIXNX3:2[CD& MS\W:GCS.NP?8>.Z407X-]V_CQF[VWCK5CCYO>\?

FV1X$^R_8>41MKQ66A0B>1TW=141]J)ZD;A^YCEQ-DTEN?&34RMZ4OS.2I& 8>>(LA MJ&O5M>KLR33BJA'+]J6U]V&

<\A(F$W'&883DR(]"HY9BCIY92YDI>IZ2F\8E M>!K4(R07N]-5\(LK8G@&N&_WDPKDYECZ IZ'2V#J+A!_&D8Y\)E/B_*[.?N MN]+1=]\%

6O!1O@##8<2O3W9Q?<]<@9N]%&Z99D'T>U;?3D('-M?P.I(FL>6 M((YL(?N%.VO[B]JWP6O0_N[QI47S45X)%D-*'>E8@LM7YR*FX=1F4*T] MZ[5>

Z%":]24IX3%AB%Y2^7[_S&*8@4&.."7.+F.(ZD'S29I??4ZO *_SL6V^ M:@HEDY*>5QR1(Z"ZJY()'MU+Y6P[%07KC%,,HZJ_-+L*@K>=[;%ESV1T4CZ0

MEM8E(KV5W12@=20SMM,QMG,L:S\OX%@("NS14N)(4],>0>>E(Z)P;*7/)+,0

MY/,%YQT3!@.1[;&D!_KE_@/3J[MMT/BN<>W/.OPY7B#Y(B8A.9V>C#FB,VH< MBBC=U.1U'*98!J(-> U*R4 .>CURT%;S=9L*Q82.!PJ"?

8(COZ33H((F]JRS M;B^S,-7&:YU"C!!P)3ZGB5L6A&JR5:S=#U[W*X&(AA/R]VXSP^4ZYH'\V_ M@1KL.G1784]OZE&>UE0/A",L-4Z-,=^:CWXG>=

Z'.SE2O;1BG/ P!!TAVLG MG&29+0O .'IGB\BJ?@5PV=:,7)JEI/5TV "M3_(KL1T7/Q=@D'"DA=QI, MR@T29CEU#_.(%ZMZ=8VQI9K4>W^>Z:

[5/[TDCV/*_.K?JING=[K@OIF?93 M"GU\ISTDIP\PYL[2]I[/W]T"[.G:-'801(5+;V$E/43X>\ V(2BEERO&11IM MT.J.?

>Z),W!IG1%A4HZJ.OIOOTQU"1U8FZ8A06ZY&3(&T/"9$C_L4V M6M56# ^0CE+ZL>51:VO8:@6C4@5[\1B6[MWF C>21G7ZN&])S]HB;7!LZZS_(

M/+*=%DKK;^&L06%IURZD_AEOB-\"R@WL-JR 5F]]VK;O]ZO(VHAL#G82 7+ +:. M9?=LS]WCM5*>;MC=.(JRW8>XIP,UOZW=MKJ=QO

$[F)CWW*I9J1M*@NKUJX\Q MH8X0D4H@SQM6R+(*:,,778Z;*^NNTP2;W"_/(#E?P.UU[GHF7[&5*WT&)QHI!@W1:')RC7_Q%]X<0"W-KRS-

CK_K2DY>U1%Z*G8(/B MGE,W70>I\=5B79%4,3+.?1U>N$QM6P/]%.4&4 &)P[KVOZ2+TI>7VEQF=CE M9WA7R,.'<1W[-+

(*Z)TL>EN#!YS45ZHR'7N,PWH4V0?#/HT:0@,6Y2G8%W^ MVX/BV<&$3=.[+Q=MH:_ND")RI,0:;M;N5> '?X\3^=?0BO6BT5=?V.*; G"(M*

_9Q9P4'(F@LZUN(,MR+D,*S#-7V*44NN>^S5L8'VD3/EFU\SSX4NB,<)/-" M>L(>15YCSZ-
:BDFU$7|\^[UPKBT)DBQQ93_O:^UXO[U'G7G&'SJ:G+]'+HY8$ M$<%26#5@N>$8(FET!0-\4S@E/B3]>?)"$=1><&[>D%,NP.B/VD MR|"?
QHQL\):UTRX^M [4=_(B!SC1WYH4_'C#I!?A::9[&BD*Q]%K_ZJ*\Z#] MHV.98T7!H5"WM!R8\&[$#0OB-\7IS.(ZC:;PJ@4V:
M+CD5.K';K.\"B#^:/(CP|%Q6V)$8573B!>ULC(:K_'O#X2%L_V.IQ_)3^2O M@6[52C'OK92"\4T81C9;"\;>B!O3O995+,Q9CJ/G4N,A)6\7|6MM
M3$H[9HZ/TA8CN$-ZJ,<478V+Z[<*K\&"7]4^GMZ#*;F.(V[X)S$&=C,PNVE0 MIB_9 2V<5"DI02C:I&N6KQ4%FU_<5IJ?%N6OYCY^Y-
QITXCVEZOI&^XOE|B MNA3O<7UE\| M,'Q7#>FV$AT.R?/G\RR5:I(dR(".?!YH8QTK>WS4OH&ISRFTZ>6,-]5Z_QUN
MLM,@LNFJ70C2@3EO[^9!Q\/SMKHRM'&:Q.Z%'/J2&_3:HE(8SH\+F.0X0+S& MCRV+7.J%.%]HEY?
<&W"E&C*3+LJ>V4Y*EH;:M*2X=*00S:5/'4$ZR2X$:Y6Y#;Q:IAK=-Q0YBEG*"H/=&DO"WFVN/8#W\^J[ME=;P@L((-1,Q>FFDF@,#D3MO[9;NG"4 |
[U>@&7XV<^+YW%-=42P>W%%G>@T MS6]C^1B,3O-&X{KZ23(BN:EWAL49%W"X*S<)>#N&:UCT(4,VT!\KQV3+%5Y+ M)EJ8.(&5+,VNV N+*?
2S@IOBRB5X M-\C9$Q3 U%SV$WGH&3KFWD3D"=P'[G M$EWSB;V?':),=)H)-1US5_EW7$A8PGB[K@(_M4I^>NF3%]$DA=_>S>.9SZM
QEE;A'%'4G2$+'4G2$>?C:9\+84?C)'#]#L^/Q^&>AC?B-Y*MUU<^,Z%R,EOG+'BR.M@R)1M$?DFC,?*-/@#YD&G$):1PR1LY"
M8&%]"$36=_Y'O],4^E%!K5]I>GS@A#SN:-#:'!P^%,2/GTO$;=M4+WH6-K[R M"\P.SMLKO"E0^,![@5,Y11G6TXEPP8J-=U#M@Q405OWB(D]-?
8XYK/<-J"^^_MR/U%QW5FE6A:ZN[\BP$^ZD..]M#D,K\6+F@&:D[0A?L;F%>?*),\3>QW9 5 M.67S^BD8BN\;[CV8JHF85M$_^':'&;XW5#
!PWY=E,MHLKOS#[U05;$2=(^W M*&D%(83G!9$]=(N5L8"S.;:;,I0P)\O>H]&_RA,G+>/!H05K1Y.Y2&&X0K+>D MKX-V1QA/"?D]D8.:CM#&XUP_
#N>#5J>S:"X_"F; ?IU2KA!DB4>;:>XM-K MN*?T^SP+O$6Y2[0T-\A/"T;6RTZ&L/>VB[:Q7S*QPBVH0)VL5'Q_%Q6B%KM'-M[T "P8F!"LRWJ4FX;X?
T)!.)D(CY>P1OOV;$D6T5(NTD?Q"E_/6>NIA8GM*P MYT>#);&E)9+*Q4.QL.%+6,A*3XDQ8>D^-8J5&/?*G@#(
M_6#W0&_7DQB,4+C#=]Y^R6HP+$$5'S-+FM;90851!D:-]P;H_Y?FRU]H_#G^U.'(O M?<6LKTXI> M&A!F@;3AWWZ-JR3^+?HS^V&_,-N.;
>4FBY8@:&]XA,&V M>(GR8]F|"2E*V#U=2&L4=UBM&-W:QR<65FPX$0J)T]CL:!A4WM+W(]A=R21UB9GZLY@Q?!(5KMSN6R0 M|NY:<>BJ>"?
$0UF&M>"P;,6YUMJ*D))O[7VYY]P2%2]-]Y)U(CBBT3&%<] MD6NM-#ES*RQ^LH:HC0Y@V-160'BI22SY)^F(JZ]8I108H&]S16M7V=C @Y8<
MTV[TU1V#?T>Q:1XE2=QO#>9-T)=F2>8UH](#3A2"0=(H1Y8NFGXMU@FF=:U M8)_L-
REI3%1'^!CJI57R6CH$D2W@6*^,'$$;#W7JT[Y3&@;PR9,GZN^\;Q9Y M4$R*5:@#+G_CE==J&M*R1SY<:(_8CD[>MUSO1
WD:7]6/AUJY+QZH=;,:U"O METO1U;0>1!P/%S:,0#]1SH%W/<_3.E) 01?*,TI#?*@,0Z]J;7-+60F.41&,CO323!L13OWB5@:! M4R'R@E]\;"<0NDRT/(
74KQCN?]\36BUI6>803@'OTW*UGHG76V<=5 'B_UB M,:!8EG3XVTK2^O/N.427XTA]PT@4$GCBW[EN06IUK[?'O16Z3 Y.X\MMF(1'
M&,0/72'QE85@U.KB**:TBW-(@!3T?ST('R)+C/EQJNF.Y83SP3G:W%:LGVJK917Q69 M),!-?
L:6PDNJMX=^"@G@P4(],V0-.WY8/L"V#;.SO1!*0CV2E\XZRDQ.(N:_MYM@=RC>,O2H@2@\|
[>]%O4])/BBVXO=[4]GKBPHV6$TS2L7BQ\FAEZKM5AEY2 M/4?N+ 1CMK(6?WBBU<&G''')B'3?LK^5,,GC=!0/@ROTH)R_I#Q('+5)D-
MSA&WY5$K_5J^$7WU=SE(;2BLY/(N&F>]T> GGPI_91D_/1] S&_K?7L&-7@A MFJFQ)K5?T38-
[XXN\H)7HEW2H:>8#C"S>QC[4ZCNASS,U>C6KU#O;:%?C7"> MM]%)+]Z_]>*$7C5^JW1EY'(10K3F)^>T4)%DX]043HD3\:O$(KT$H0^F4L.I
M!;>X)#?, Y)\?1QQO_:5RD]DY_'$*;H9^'$$"C/6ST:/K"1 KA%(6/2@H< M28D/<)=@6 L3*/J!\?2D-(FU*7+F?)%?(KCBY 4 /&K6U[T@R2;[^6JI
YD(85A'FMI^%-,DP()@9O(05]W MZNU5 U"#2C2U%1%IZ;R*B$ MA,JC7B5BS/AZOLURHJ!J1YVA:G 3L+]M3\2; M,-!W-
4%\/"2(AP3QD"#^7JKFI:E6:6T4R,BM]2P2M8. &EV!Z2?DF_*P_R$R MW:L,,;%&D!+Q,A'Y+*6)/!#[@8:=%EEC(5T;@]3>$9U]B?0?<#:>-!@4M1TG-)
,B(UU8]F^[*D4= JO%[R7;YZ>O4 MKDX[-N)Z3HC_K=$T_ASL3"R!#=[55G#QNC;_Y;A0M1]NR/ZWV%]*_""7.)P& M+.EI=[+
<<*Y"8U2@FA[&S>\VY)^Q,S!YE3BAA-BN@0=FBX])1^4E;F+U\@IX 5UKC-[^#$9R6\9+] MA%2"1F$EA0\>
[H2P5,JM<5S53;)F8C5+Z)T9K3M6'*K_Z=1T8\6N?R]C+3H] M?!G::V*.=_B4Q-YI\D###4E4EH0XI&6%(+I<-&Z'J5:,>0R3*FN\QRX)VT+ 9 M@PSNG
7\/5.7J EA:SA_LY)0*>427LU/HC_]6OI?!7/EYT<'"OA/0H\P=E+ M=]M64LFK&OB;4\1\RVMYXX 12E[QIT3R!=I,3-ZDAW[VGO\0CTAX1U,P-!*
M4'I?],$\/*1(ATT'RT5T^^\Z8JSJN>TNN-)\ H":5AKSIP&[8&OJ7B) QL"6 M@*8/*+?J('8AC0*GZ%QX?
P;OR1QT#FGCP".@VF_N$GO1E>G@&Y9XK#=A&)#% M.BV)W_*?#58%CMJ]+SO1.V>?=/NO2X"FK1)%"_GEJ7$#*6?HZEH6*(CG8KMH!-
J#PE=]E[>0*XB3^Q/M^&[TD:*=B1G@,C,(^S>%Z7652A0X2<,HZPTNFG5F/:K/$=H M!Q4843_Q@I)4K&;P+JE3Y(T/2G6TN!
<4RAH6'1N]E=2%W, ^=+F*OX8,\B. ^_M0],O< JQ.#&*L?> Q4^4U-8T8_9B2A^Y/B"=*<"+^=!G6K-'/Y<&)D$12C&7 MT048V2HX++NP-
S[/>L@X)AYJ/"K\)=:'J@96UI'Q%"UB56X5L'\0XPX\=84#3 M"82CU2)(A66.Y'2)RXUM9-2#2)F27!=SF))E%D(S\93% M
H$L693%38X\MW;P<51C3+H>>>DVAQ1RR5])"GK#YXY(F=Q+6E0M%?-|>[EZ M*JF3T>Y"ZB%TDSNDH_&CL*^|*HP#DKZWV+
(36V4E#!U,B\21L[@*O0V3<50: M[AIV5+HIUX2KBVW-$6P R 5V+,BF]'<7.\1?7*$5F4_'3FMD<|:)0=,,]WN6 MEK-
F257G>CV,Z/'4V9VG:YT8AFL)Y6\QG3?5C#JZPDD!-3&#>Y7Q/8-JOW)! M,,,&I.,:[U"^#KS,KH&L5JOOH(KG2"=4PE!T7I66NRB#'"FH.P&DIT=A%?
0.G0&ZZ6MY+TF/]P!R%9ZDI=+Q9W<_MM6XD+>LL=#[75Q)?8!M,,(L%>*R-7GI,77F6;S;C#>A[U&TKW%?K;L.\;WCV M]AQ-
Q[;;+=@+N*V1'>3):#2HFX\.EVATIL:F2EC>.S=Q$)4^E#L8 K^(,)& M3Q87YE7TA@6PEU"HX&M[*J\9)N.@&&K.!O!'KY,-D?SF%?I$[.0YO. F4%25
M4*294A2Z,MV)PWU0-[5[^%IA0/JN&YX_*M^R:&Q 3X#]"'*'219+Z7?@-0.B MQ'; NK<64!&LA;Z,@R_4.Y)UJ@1H&NWQ)
NQPL6(5AP))4RF0""L>42'+2T M'KD#QIWZB)@U9\G_N%6%HB0K10Z5F,7CI9;.TV34'K';F7N%VK7S'7+97K-M)C1\V*Y"-
_UD&=]99"A2^_0VAX4/I[+MIVRTGRXZAWOW2]CHPNP9VW5YV*[%-MTC)@X4(*(N$6:HM8!GL'"MW*$!=%O$H3;#R!C"TV$B$P-^G:)0UC/.G/&S-B
MD+6,3.I'MI^%-6RNB]3T*9:!MB_,AM#1@J5EN%DV1=$3)&:!08%!+6PY*OM3K&K;--##3_;2-MY"CV<6,_<(Y%A0C'$<,;Y](6C20"2V VR *#,]-
:8DI:.)G/)"!)ECH+M*^O M%=7M""*F<:G4.KW3[OR&TU2TL3E-MTMQR!;#9CD?4Q?!];< SFIX6-#BM%MJ1
MB*TD:X0<,$S94ATK%X:Y'@5>H9**0(HU"_K+Z=]R*SI=/@_]\/3@O"/,ZM@3 MLZ#\SCIR]@:A9(1F^^S2>]I O'[:,:YPZH6*MN^ZW)QR
)!+P(,7O]WDW\8-NNJ^&4]KN6-_T-'C@-I>Y=B\68M=NJM/>2_Z%Q&+;%PSR M\V?|*3J($G^CO*SF25B?
\H<6!F1U$4BC'F;^&%V#G1%P/8PIP[NX;U1T3_&) MN/QFE).E3P01X_'MJ+G9+CGJ/4B6*JJ/8S=D9)L'N]"*E,CM*OF%GI62UL)^
M0O>!VP6\)N^2@RUU6C?\2OJ.*R>3LOHNLORA5[#EA,)7M/TZUA5V_H4'_9&
M7]X5<"=YHI3[AZ]FF/GBEG!W5#YQ_RYMWSYXI1GXP:1RG)7AK1$A=4-EOG9C9DO&4S)L>$5&L/:]C'-%$
M(NV6BM]E\R*V^'ROTZP7W^8KCF@;ZGTG'K]HZ5EI[.NKG11&UA.5 U,# M,>&.E$!*]#WZ0 V%7B]1E51#8>(W^L/+QQ+
AH8^F4LY?/3$M(DJ8@^&[.R M6M+B(GJ5EM1GX(=)36!],Y]C#S@FERP]FYLI&/F^YJPVY1K(Y#Q+B\SF&Y3? MX?!!_%
9'#9.DRJ_T4H18T5\.E2!;BM40\O.M@"M"ZXQM.%@.BZ\12&3 M$WM.R#@JRM!CD27K(;2^E\KB2E73GWF1>#;=
M\M0E95]CXH<<%GR_(UV(I]@HN6M+@R4GP C]FP/(*',B460'N"-)>UF1ZRHG M]VV7B+9&KM]$>_,CF!#T%'-W*)IT,XQP.J&E:5/ W54V*;,Z7K
LN*9?9F'5 MF9@@Z$EV'8ND7>,FC#PK1@G)[8;OL0]SO#4U>&BY65MP!GNZ=%N9?G,&?3K" M&;2KTC%:V&",>UDP
M9TA[QFFO>;7): /) 4.C8QF@";'$&PE*T/ C8UR;+P4I4R(04 _8=DXFC0>& M6(NVBOH?,]!M%NM%H'ZY)%''T?,U/I4([!4,ZO7:
,,'8"'X"N_7+_0^:N4EX@F5MES2)5Y*H[-%Q+6]2W M%9A:< ."1VF=1S':E&T$Q5\F9]63\%*?VAY>G0/W5DEY=?[/$?5AT/18=H+ MLJ,,NCJ K=^^2?
P.HX)AE8;B&.IJKPH]_PB(<5_V#!904$0J8JIC1.,]D-4I#W:\A4+.)L/HY.!$M+IVZ.URJN*@%LWQ4CGP+-BUT3XRJ{<5>5
M<9/P\TR\N3BJ2T/Z_AQY&BF8 MC[RJ^2EG7B0N4T1KF;5!.@%&=E?H>I>N!9Q (K7GI2Y]F)??C3$()P546I\# MEAZO*:(E>.!F0)J.:@6OK.?
JA3#8.$"KP!6))N B(#B[ZPJU;'LNVW#I"[H; M-V1Q/3H^6TO(R0MO72X,B7>XA!3P-9C;EXX5.X\F\?H2NCSG6E6S#[[C\2#
M'#S/795/^&D\H\"&YRVUJ,1Y"38J8=HU]4BVU*H>!8:9R\>HQQ:/#:,,3IAT
M6+QMRSLRYX)1:W&0(/9DFQGN4/V^E"A:V$AK)FEN%7Q'R<5.J]KL7&^@O'EY M\)EFE=A0>87ZY!1>F7>:IL
1^@6<@[W#$>C8R3&OYI_%RWV)^,V?258]NAW$ \,?X9ZA!B)/[!2; 7K5=;9. #R%M)8] M0J/Q+$6=-!\%511N)%[*I5-SQSZ]U"\P -<^\G8P?
RS(AAAWC3E5;X[=UGI_0 MG1$5,%6UD$)39S*[LEA<^09U$ U^/%H)S0$&B*T$Z9"1JQOS63'K%
MMY(I<@&U@=!4B^B)4FN\OI_7&PF@(>$C@]2:K$.P-'YSX[*G5I4<-R|&FP>">M MEI4E*+#*09X6=A-C35PY53P&KY*O?DWB84"\X89)?
\7[;:;N>O2J0U)V5$ M>SPEZG-#_C21#6/#RYWI>@?_RXIC'+W-87'A/9-=O'7V]D>;9Y44U)L+X_K/ M:&X@&2_-C.(&7(X@%Y*(,MZ>KS[N?
#S1RXMOT-?6*-!]>_GNM=TVM+:-Y8F& MOWC%HL0DNXCPZ4H)0V= ^&(WS'10NIF5W65AX*%4R.&Y(=W,SK-)+9-#% MY>&.G!X*JT'Z-
SGH)4HFN6MUV>*GI+EVUY6C'&K8BQ$1OCIX6?>D2;B:KYD0 M_$27FRMRJ/N>\GL]Y21-QL""F9785&(=U*P@_,?Q>G2*T-E149H!S?;C2DLS M
X&?41&Q?LFE0) @'*7XPG/K@ @@B.8,(IA) 35-A"L7>TJ.VH7_/70W:,(F>@H0/_9(;SQM M29EW+3N:UU&0O!-+8B3:S/]=](;\E+)?
59QI13,ZR'NU",B)"$Z JEI\: @ M\!OT'_D@/+SM6L,[ZS+;JB'8(>%CF1KXZ,+C\6U:-:*2_ MP;<2N-NOX-3@26O_&?.8[!DIALZE- 0EB6H?
5"Q>N].FMEP-OL5'0Z("/?LC M\(F5#';,3%P>IN^"HSLYVO]Y\GA\V#V[=A[SZ2-@HMK:4GASPQJ7F?+@QF@ M;Y4(Q]K0O>$?
Z5/"QI9TD[^=U05Z<9,]_S+_./[,:KU1?BE=$OPNIEA'HNR M H*0?Q?'0N'ONX*$AX*)_XF8\8:;_2I:[[*;TE_*P TO*PZ6>, L%18#B6Q
M<5+8]7.7G\=>"!BS90@VW^]\90@TUPNC!>UM,.E33-&>\G1? +_&WNM_YV; MX *5QI^TP$4P,V?7XP>"><?]5WMXI\M"_O86G-G4O8,)%<2[#(5?
W%KM=WXO0 MV+,_= +G_)F$H76G>U&3#O9=40H6_NY!CYM6DM>#8ZH>AO^'+'W @%*WM]D>U]S,0M
M1%+![H]>1X6X=$GW6PBG)$^&5O#)"7.#;EF*7; L+L#BS+#1*T.11-[F!];#Z M7%1 A&;$8U. TU9B?+D7?8 =4D 9HI4B/ U-
3KXX;L>=3D-.AC3DD(87\LH-K15#;*C&FF)U MW%,IW*W*8;9M,_ONVQ!8:P?CPZYVG.Q9[>@6W66+-ZTYU[%1SLAM0/1"XMD4
MW^'TG_VK/CLIL?6=>D7S GMCDG?&0LA3YHFD_IP.TW)4(.TV[QA?0<\).WFY
MY@CRD32'8RT?],E_%3D];Q"C4"WPNZ=*$!,4C,,2+INL$3J4:N95RHU)CPN" MJG\UE'G'-5VB!C-9!@[64DIP_*TO21=DOX8?!W\6EUS&(C6LB9G"
M7V^G4=J-JD%F7U8LNV!Y>Q1I6/0I^'6RK^.YJ=<;:M:\HJ%VM;C$9/QVW40Y M,'/LPHY;_/(DJ2T8>ZJ5C,4=)ZW35-W%G^[5;,PJY+%UN59?6I#I
M5U" _FE0WX*"#EO96HY>^TOWH#1'!UJ+ R0AG[BR *WQ1D1,43&+_2+^-SCS M&!>R,JR=-$6!!I?8(T$7A8A%]$F;V.0+^Z/NB?
1%**81%"G&4PMG%,;M=4; M K9#@A&XSW2JX)8P#2XJ$8:BM"=17YN*I(A-LK_'*D\\4-MF; ./*#: &Y-]=,D'KW
MJO2;.LVHDI*C/I>>>=5(N>H8JJ8CV6%U>LPTZ=%0:&%6:E>G41KNK3:7=6THT"J028J,H!*;P.0@VUO5W+8+F MXV
H7MA@AC>CQTFQFR9]W;X4I3M;(9HSZ&K@=V4.CTBO>,?"LYN9+Z,-1+*< M5^::&4IODR41 KQ\W0'"@<%1QD.)4:D]%[VTM7QZ:MH\^N)
(N,0"/5S([UT[MTEE<8K^S%*NVM=>+4ZU\QAQ?WZUT>_P=MWA@EH313/3,KF]&Q%&;_-=/G^+I M]N1@FIA/9G=__NE@/CG\-
$UFDT\FV7\RG1TF\[WCV4|<<^)OO/GPZI>]C[GK M<'T29R"_|U>_-?#*$P[5@EC*EVYHG3K&E@:7_)F'%6XP3LP2[OZ\-^;_WNS_
M^DL0T1]@#]/$J1&X92%_\HE\AQK8).(XOJFJ!DO+X.OOT]^_I-REK?DKG(M\M,_S.G_6L(V#=[=\C6N-H/IM[1[]X^N,"M4!FDBK-
8K&?[D]:LQ/(O*;2-< MG']#Z7K$JO(VP[*'_PH<3>(03M^8+ M&E4LG=2+?6=*D9 8:RYN./+H0OF3O?%-Z+[K*;KCV1/S>+:7?(J/=@\^'1R8
MQY^>'#])/DUGYLG!WN%^\B39[2BZ_9=F'F.LXG3:$3Q9&JFTXY('OP")ML)F?0O74'JIZ.CW<.CQ]L@-MBPP?'SR>[#T^^+0W M-^;3P='CY-
/QDWUPS/8.JO:W#P^/)H>3SN5P2# ^CY;LT'\A\>3Q[C;<"XL;L1G;CI1]A* W&1_-Z46T,.(RP(6&2(I]-P:\0+%;3
MCK[$:8>,==%_IE]@K/FO2&0DY#.P@N_Q8GXIC:H_/?XT^83/_/2A^/3DT_XN M__'_U?G!T:]__NO_OMKYI=XI/_S\[?YQ?OI3Q!KWOWY*OZ#^+S
Y,H^SROP4 MY?$2IFQFR=/W368FN]/#R;.R?,;U:Z^S&+Z.5]6O<5E^VHW+OWTZ-.P_>A4_ M/_^T_E)'^OBJ//_I3U+M]I^/@G'_"6?X_:?
RH5SF=7LFZ;LW'U[6OU75JV96 M--7C%)>/XS_#3)C%. ^Z;3*P<4/CP")^^,T%D"K=X*.FI'@;=O:;A\H7OLP:@ M*B[?T?^>3E.K@^?
[__>C^=>|^.^SM\W.R3.L/IR]>O419=3O5GMS(MF^ON-:?TA%#3/']#G74/=H^%Z,^KQ#G9^=M6J>??'_"X;7_RQW.6]P=G>7"6!V=97-]?
M7[[ZYX>WK_[YES?/W\WPX =_Y\?'N<> =?WK\>/?H&+SA3T>S@_U/!\='3SY- M#X_B3_&^.3PT^X?

3PYY@Z]&K+]0_I_IT?/CX\.#P9OWH:V3;G!M]=,-NM,[P MIO-TET#I[@YPKNT_@CUB2NHXFT]O/JGK? ,/^((_Z)(J 8PP]L#'_\$9O6P-MUSQ"D!'V^!K.+V_%9'?G'V,O04 /K M]W/<+XN#QBCZ\C?2 T1AK4C=ZX=#M ML$/M[5>5>;K_|-^*^EET,RH1(>@--$_VM/3"/ZL4-+L-D?'ST79?AN\SZ-M\'-\&7;_[NT^*"#\Y7_]=/C3#:T 7 R[1VH'6R=H]26JBBQ-(K6P;WV)+G." M+K0C\EE1PL432WV.O7N7LK5A<['5LH.4X>+A6=OX CBR4. MH?0X)R2Q[EZX0"\ZOF.<;W\LS$]U[< !0D*S MIX;O/)N)6]3U]GKZZ-'Y^?D8/C<^+/2MG"^1!>V22T[A\A%2,CR:'DIW'M1WN/X.Q,)D_V)WN'DX.#W2>/GQP_2F!A]HYW$_-E?S)>U,O?E]A[)NW&L&KL MO:'ZT"1ZP4R.,RH6G4'Q M_N/=/?C7_I/"NX]FB[+:V8.?)Y/)WA?S93^YZ1C6\S4RB@W1]TRZX9HU7:: M;D.T:CO-+XQ6'3]"/;F-VS-85G?1LAI,^FVWPH8-NF-FS3W8L1_>!!KV\,Z-M2_=@#P>;ZB[:5?;Z3_=;SNIMUC::'TTN+04$-H?[XU_Z+T93*2[/\/1+K[M,QQ,1+NF.0<3:1LF]@,*WA!VVO+Y#@;5W9_A8%/=_1D.-M5=TYR#376C8.3\R7@[W?CXY"V@9F[EPND?@76W'Y%7X# M1&JKC+]3G_Z&%Z=Y%]W8/C@Z?[.WN'ASOM30X>U4MPP0Z/CHZ3@T_FR\'.5Q3TO;%V&4U!1E%"Q7QQA1&L9ZLR5;+)8^]1 MMSN*IJ8^-R:/7A0+4S95]#PMJEF*B+!JA*158P* ?1R?C*/GE95Q2REGT;X[_P[=H,D;#M,AB'8L'M- *W%.SZPQMV!X\FCX=:P<%DVX:) M_8""-X3!MGP^VV'5W(,=^^$MH&$/[[ZU=_V<+"I[J)-!=?0#RU,0QCLNLBM MF4?"7!I5:2K09[!@U!EV.C[\(W9EIO7&K]DG)D^+,CHL!=#FE/[->B-E64 M- 8C9T=#G&NK+,(ASK6=5MZ]]I.RVV(7SV0ZKYA[L MV]O 0U]>/>MI7NPAX--=1=MJH/QX0\M3/O!@V>-+.9J:JB5% 6DGI9/)C P5Z;:=G$Y3IB*-C>$-#: M*M-OLKOSCVWGMM2E?S#VVB'CPXQH+65X<;!^+]+QM=@]6^[H39LT!VS M:N![COWP!M"PAW?26+H'>SC85'?1IM]?;&?ARSTWE*X6T=)PU,'ND_U=;"@XM^9J.@HX>*RUR#$N]*]-\E]JB+'KUQM]DYO_\87*T^_-D/]Z9'#R('_*/6*0X.4SX M5T,HZ]L.:^>N5(UG0(6PVFW-V8SV#*;?=\!E-NN^>S':,<70U;#<*UA7;<_ML$&#=7-/YC-8-]L]G\&ZV>[Y#!5[-SBQR>X0E?KFB_YA8:)YD67%.5*4+V,P MG=,XJZ)Y62RC]^8TK>HRSFN91^L_G[_|>/7B3M9VEN(O/!VN05.:0_;RKX357)"W&8?X_STR8^-0_ABL.L24SU-'J0"CSJ18'\ M4Q4\%?Y5%5G*+%3/XRS.9R8Z61A35R/X_"5?.*GA/TMP)BAL]G9E2@ZBT5>O M]=T7Q7)5F@5.Z,Q$?R\J>L;9=1YQ4A>SSXLB2TQ9R5Y$+\T\G:4U/.M:CWH1 M5XOH-6PXC *C=@_.=#+$:__K O:P@T/=)%!]^@QR?I=.W/W38<,!O=VSV

"2B"]"C@E:RC-X= R_H3^^XKQ]!%[KP^VR?;=E'#^J: \V^';/ M9[#!MWL^@PV^W?/93AO\41U/,[-%]YFD9_J_\#_Z[5EFXO+IM*@7\HH=^'==M+)_NXZM$8'9W__@M%G+O8%5'N^[_H[LP.6B/_O_SAS^-9Y]/RZ+)DYU9D17E MTS_LTO_]L,UKP1C$/9*,4[,S+4W\>2>>PYN?QMEYO*Y4D)Z,P03$OI?PEUT=_M%2X$6%7C_<,_1MZ_<4$ZJf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{IMIO=@S?L\A/:NQGU]YWUV45_].OEP'=[>?/NX[#/*K5&XU^=?J-Q-CKS M-P[JS18;&9Y8F4F=<-5H#,XKK!)CG6=IM-&:S67W6J6MSVQA=->)LH@X:2FLKMZF$65DY/J 1_!0]/3R8BXRR(N;$B>UNY&;VO'<$BDYD2IR>-Q7]O.];A_/0D ME%-FL[D2;RL3;FYE4LMTVNTTT^P8-1NX_<#FOC:3819W6\WF7X]3'H8RN:TI M$64HJ7<.5V5&WL:K0NT'US5"\4Q.!;5>:C=0@ION6&?Q\<,N-M5,%_4BG62U MB$^DFG=?C>1$6'8N9NQ*3WCRJNI+|-|*(Z-7Q\[:RO\(-(T!9N(^[W$E:]$X M.7OL9Z"+>XQ^6\4'ZG&\L<<^:H^-1 \?A}*3 :<>L-2ULI=SH2;B[%6(=H:MW,=R+#/6:=5;)XTQ9CG] 2,*@'!A2D/ZSJ/H#ZY&P_?#?F\TO#AG%^_9Y=7P MO#^\['UD@U\&_9O1\)\#%,-B<+6[H[R\N;]^Z9V/V.AB=P=Q/>B[16IU]O@^ MN[ABK<,]<)_6;/1AP'#WYFHX&@ZNL7#]#[WSOP]8KS^BVZTWG8/='7;OFO7.M+BY'@S/V^RRCVT2.?L@>LEC23K.]7,?>U;O>^>"Z=O'+Q\&OBR5L-YOM'S?D M?^O40NT4CRUHKOX=:-Y+T(-TUM20]JGPNF9 :_X7,@M?)U2E,:<%7T M[=R F\>S6&:B1E,FNHF>&9X6_K2/ZC2B8G(+EUIUQ!AAV:OU^\\!PE.'_26U M!+_,A*LUDA1%!"+^50P(Z92S!"T93&P]%O.#8BJYBA/M(DV&F:#5]#A5O$%>[\WJ;MI;A[UWW+HT M@4WF[X#4 (}1=5#L!>]+&JB48F@@:X3!A/YBQ/,I,+N(HTPZ4I0"1G$UP9 MR16+>(BP_0$(62FO=TC@T0 M);:.9E,^)U OZ4V+I97X'*@\ M1)O@0@F45?!(DD:D@#*QD-BIU(IF!<+M@Z[!Y-#EJU6RR!4,P"T- KCNK/,G MX#9FD=(SNR">$;?29H;C(TZ%WF]X62WQQRZ<>>3MCE*H^2>@T,'646BTAK>_ M_734;OU\;N2%,$U;>0ZBB0N'1*'C!OA, \,2T(4L,F$I>62-B9S,IM Q$C(MZ#J4-E#:YJA'\F:T\N!/C0Y$B&++]H#U4(\'M"#^R#FR:U@/2C'5:Y@T>KPM&K)5L>^]M@Y*?^4O)>5;B2<=M<](7DI<]-P@7?Y{<4;36482.:)P/&0H+BBN[MGV?=YF.UH_*IVC83\T=KVQI?#]+$ M@.?VZ54H8!L+<*7HR8>.C=H "(TE=9)&ZQ$XMJA)'PEBF5A]>>U(%\1 ZX(M5"U$EVY*""1\L5K)T)VKVWQL92BYD30 Z2-5)_4)M82T#-&CVZNL"S6=$&HK MX% &X:5**2<Y(J3?F-8SHE5%(H:/J8MA^+X-!9D"(E%?:![-R7UA;FG>^,M M9^Z3=>L1@9^N>$_F,;@_E2'1DUN=.&1S"VI3"DB,EGPLE110AV9-3(-%N2-J60?03M%-9?;L[C'-1>IH?;8X!@(^[\%38@'"^M!:4"D=?/Y!AXT62[38=X6<"_AQ3 MX{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|C_|\M",US-%NS$6P_$ V1IXD2;I ZE=1 ,=[E@2P-TU[<&)"#;W2) +80 MIQZTSA4/ $SV#!>/=Y-LJ=>ATRJF>LF?, <)9F+/0AGX['WE87A#![YC(#W0? MM*\^>XJ^ ^U7R&ODR\VFD[J^5 M/W?Z9*_QPF*WJ*XB% ;,,F)7P0HQ]P-,^U&6NE2-0J9JI-)+^"8,7P2,OM"E[,PY E M(^GI-GIEB-HB:IN!5>GZ7M0+W.+C>\FX\3"DA4(M*\^T\S(HL"]]VQ+UEZ/M;JZ<.&^#)25(5HB%Q,>*>Y/0PK+0.Q^_ECY\&G?U>8P8=]]FWM93WTM1698M]BGRN:NG!>5Y.)&M9U/ M.3SD?]=W1+?%V:G%L?O)>C!R\B;<[,GG]+%'IF?>QEN0'OM8F^>\=*>L3?F5WJ#F+.(G"\]J4[O'KZZ.9_0Z-_(DS& M2\[IT^!NHF26A,B/I?(*8)9^K+=>D=.5-B@B>,)}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|\^O\8\AN*Q]CU/GGIB%]KIG<,]9: 2A MH4!,_[\P6P9Y1!KRY%0_7=H_HF>9C.59[3(A6 P!=HL4L$(5-GM&AC R_U66 M>%@PD22A&;K2T25. H+Y/?O^SLFTIGO\>7F=\VN$>#Q[\BO(H^^],QI;GWM[UW<[^+^1=Z^B_OV^>JU]!?OVX9ZVUR]W7ABNGQCX/ZT'J-M1>B#DE$U6E ! MJST9DB'-RIX4V%#T#'BR3P(G\J-!M@BL^TT$0XL0JABBJG7<;(M!?8G3""?MD)CX**!1U4Y\ISE"?@.S:I#HLSBF65;U*)0T@+Y+$$TQE/9& *4W"5P"@B7 M/3 P RMPLI1<(/#O]S4O4AW.:^[,>K;W1CLWM*O=W#L+T("FSB*L4] W(!Q M(@GA0)2'NB?"];@_"2S3E:^;F"J5N]MS5N|&|MCJI:I%,37BG>XRBPVOF'4+ ^O8T8E>7P'D8LA4C=9%-[9JI^[^#U!+ M 0(4 Q0 (,J#9EE&Y?H%KAX "U3 0 1 " 0 !C M:')S+3(P,C0P.3,P+GAS9%!+ 0(4 Q0 (,J#9EF^2$A[S!D)=M 0 5 M " =T> !C:')S+3(P,C0P.3,P7V-A;"YX;6Q02P$"% ,4 M " #J@V998 $1+@Y; #(P8%0 @ '<. 8VAR&U14$L! A0#% @ ZH-F68&5X,S%D,BYH=&U02P$" M% ,4 " #J@V99I61BO-<& "S+@ & @ %K/ 8 8VAR K#,R9#$N:'1M4$L%!@) D8 ('A#!@ $! end XML 93 chrs-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:AtMarketOfferingMember 2024-01-01 2024-03-31 0001512762 chrs:AtMarketOfferingMember 2024-01-01 2024-03-31 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:AtMarketOfferingMember 2023-07-01 2023-09-30 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:PublicOfferingMember 2023-04-01 2023-06-30 0001512762 chrs:PublicOfferingMember 2023-04-01 2023-06-30 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:AtMarketOfferingMember 2023-01-01 2023-03-31 0001512762 chrs:AtMarketOfferingMember 2023-01-01 2023-03-31 0001512762 us-gaap:CommonStockMember chrs:AtMarketOfferingMember 2024-01-01 2024-03-31 0001512762 us-gaap:CommonStockMember chrs:AtMarketOfferingMember 2023-07-01 2023-09-30 0001512762 chrs:PublicOfferingMember 2023-05-16 2023-05-16 0001512762 us-gaap:CommonStockMember chrs:PublicOfferingMember 2023-04-01 2023-06-30 0001512762 us-gaap:CommonStockMember chrs:AtMarketOfferingMember 2023-01-01 2023-03-31 0001512762 us-gaap:RetainedEarningsMember 2024-09-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001512762 us-gaap:RetainedEarningsMember 2024-06-30 0001512762

us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001512762 2024-06-30 0001512762 us-gaap:RetainedEarningsMember 2024-03-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001512762 2024-03-31 0001512762 us-gaap:RetainedEarningsMember 2023-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001512762 us-gaap:RetainedEarningsMember 2023-09-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001512762 us-gaap:RetainedEarningsMember 2023-06-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001512762 2023-06-30 0001512762 us-gaap:RetainedEarningsMember 2023-03-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001512762 2023-03-31 0001512762 us-gaap:RetainedEarningsMember 2022-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001512762 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001512762 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001512762 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001512762 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001512762 us-gaap:OverAllotmentOptionMember 2023-05-16 0001512762 2024-06-28 0001512762 us-gaap:CallOptionMember 2020-04-14 0001512762 2020-04-14 0001512762 srt:ExecutiveOfficerMember us-gaap:PerformanceSharesMember 2024-05-01 2024-05-31 0001512762 srt:ChiefExecutiveOfficerMember us-gaap:PerformanceSharesMember 2024-04-01 2024-04-30 0001512762 us-gaap:PerformanceSharesMember 2024-05-01 2024-05-31 0001512762 us-gaap:PerformanceSharesMember 2024-04-01 2024-04-30 0001512762 chrs:EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001512762 us-gaap:ProductMember 2024-07-01 2024-09-30 0001512762 us-gaap:ProductAndServiceOtherMember 2024-07-01 2024-09-30 0001512762 chrs:YusimryMember 2024-07-01 2024-09-30 0001512762 chrs:UdenycaMember 2024-07-01 2024-09-30 0001512762 chrs:ToripalimabMember 2024-07-01 2024-09-30 0001512762 chrs:CimerliMember 2024-07-01 2024-09-30 0001512762 us-gaap:ProductMember 2024-01-01 2024-09-30 0001512762 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-09-30 0001512762 chrs:YusimryMember 2024-01-01 2024-09-30 0001512762 chrs:UdenycaMember 2024-01-01 2024-09-30 0001512762 chrs:ToripalimabMember 2024-01-01 2024-09-30 0001512762 chrs:CimerliMember 2024-01-01 2024-09-30 0001512762 us-gaap:ProductMember 2023-07-01 2023-09-30 0001512762 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0001512762 chrs:YusimryMember 2023-07-01 2023-09-30 0001512762 chrs:UdenycaMember 2023-07-01 2023-09-30 0001512762 chrs:CimerliMember 2023-07-01 2023-09-30 0001512762 us-gaap:ProductMember 2023-01-01 2023-09-30 0001512762 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0001512762 chrs:YusimryMember 2023-01-01 2023-09-30 0001512762 chrs:UdenycaMember 2023-01-01 2023-09-30 0001512762 chrs:CimerliMember 2023-01-01 2023-09-30 0001512762 chrs:JunshiBiosciencesMember 2024-07-01 2024-09-30 0001512762 chrs:JunshiBiosciencesMember 2023-07-01 2023-09-30 0001512762 chrs:TermLoansMember 2024-04-01 2024-04-30 0001512762 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001512762 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001512762 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001512762 us-gaap:ComputerEquipmentMember 2024-09-30 0001512762 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001512762 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2023-12-31 0001512762 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001512762 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001512762 us-gaap:ComputerEquipmentMember 2023-12-31 0001512762 2022-04-01 2022-04-30 0001512762 chrs:PublicOfferingMember 2023-05-18 2023-05-18 0001512762 chrs:PublicOfferingMember 2023-01-01 2023-09-30 0001512762 chrs:CimerliOphthalmologyFranchiseMember 2024-01-01 2024-09-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001512762 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001512762 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001512762 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001512762 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001512762 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001512762 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001512762 chrs:AccruedRebatesFeesAndReservesMember 2024-09-30 0001512762 chrs:AccruedRebatesFeesAndReservesMember 2023-12-31 0001512762 us-gaap:CostOfSalesMember chrs:YusimryProductMember 2023-01-01 2023-12-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-07-01 2024-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-07-01 2024-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-01-01 2024-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-01-01 2024-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2023-07-01 2023-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2023-07-01 2023-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2023-01-01 2023-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2023-01-01 2023-09-30 0001512762 chrs:OutLicensesWithNovartisInstitutesMember 2024-01-01 2024-03-31 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember 2024-01-01 2024-09-30 0001512762 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:FairValueInputsLevel3Member chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:RoyaltyAgreementsMember 2024-09-30 0001512762 us-gaap:RoyaltyAgreementsMember 2024-05-08 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-01-01 2024-03-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2023-12-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2023-12-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-06-30 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2024-09-30 0001512762 chrs:TermLoansMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:FairValueInputsLevel2Member 2024-09-30 0001512762 chrs:AnkuraTrustCompanyLlcMember chrs:TwoThousandTwentyNineTermLoansMember 2024-05-08 0001512762 chrs:TermLoansMember 2024-04-01 0001512762 chrs:TermLoansMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:FairValueInputsLevel2Member 2023-12-31 0001512762 chrs:TermLoansMember 2022-01-05 0001512762 us-gaap:ScenarioPlanMember chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001512762 chrs:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001512762 chrs:CardinalMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001512762 chrs:AmeriSourceBergenCorpMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001512762 chrs:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001512762 chrs:CardinalMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001512762 chrs:AmeriSourceBergenCorpMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001512762 chrs:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001512762 chrs:CardinalMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001512762 chrs:AmeriSourceBergenCorpMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001512762 chrs:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001512762 chrs:CardinalMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001512762 chrs:AmeriSourceBergenCorpMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001512762 us-gaap:CommonStockMember 2024-09-30 0001512762 us-gaap:CommonStockMember 2024-06-30 0001512762 us-gaap:CommonStockMember 2024-03-31 0001512762 us-gaap:CommonStockMember 2023-12-31 0001512762 us-gaap:CommonStockMember 2023-09-30 0001512762 us-gaap:CommonStockMember 2023-06-30 0001512762 us-gaap:CommonStockMember 2023-03-31 0001512762 us-gaap:CommonStockMember 2022-12-31 0001512762 chrs:PublicOfferingMember 2023-05-16 0001512762 chrs:SurfaceOncologyInc.Member us-gaap:AcquisitionRelatedCostsMember 2023-07-01 2023-09-30 0001512762 chrs:SurfaceOncologyInc.Member us-gaap:AcquisitionRelatedCostsMember 2023-01-01 2023-09-30 0001512762 chrs:SurfaceOncologyInc.Member us-gaap:LicensingAgreementsMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member

chrs:OutLicensesWithNovartisInstitutesMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithGrkMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:InProcessResearchAndDevelopmentSrf388Member 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:InProcessResearchAndDevelopmentSrf114Member 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member 2024-09-30 0001512762 chrs:SurfaceOncologyInc.Member 2024-03-31 0001512762 chrs:SurfaceOncologyInc.Member 2024-01-01 2024-03-31 0001512762 chrs:SurfaceOncologyInc.Member 2023-07-01 2023-09-30 0001512762 chrs:SurfaceOncologyInc.Member 2023-01-01 2023-09-30 0001512762 us-gaap:MoneyMarketFundsMember 2024-09-30 0001512762 us-gaap:MoneyMarketFundsMember 2023-12-31 0001512762 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001512762 us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001512762 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001512762 us-gaap:FairValueInputsLevel3Member chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001512762 chrs:PrepaidExpensesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 chrs:PrepaidExpensesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 chrs:ConvertibleNotesMember chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2024-07-01 2024-09-30 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001512762 chrs:EmployeesAndNonemployeesStockOptionMember 2024-07-01 2024-09-30 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001512762 chrs:EmployeesAndNonemployeesStockOptionMember 2024-01-01 2024-09-30 0001512762 chrs:ConvertibleNotesMember chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2023-07-01 2023-09-30 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001512762 chrs:EmployeesAndNonemployeesStockOptionMember 2023-07-01 2023-09-30 0001512762 chrs:ConvertibleNotesMember chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2023-01-01 2023-09-30 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001512762 chrs:EmployeesAndNonemployeesStockOptionMember 2023-01-01 2023-09-30 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2024-07-01 2024-09-30 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2024-01-01 2024-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001512762 chrs:TwoThousandTwentyNineTermLoansMember 2024-07-01 2024-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001512762 chrs:TermLoansMember 2024-01-01 2024-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2023-07-01 2023-09-30 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember 2023-07-01 2023-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0001512762 chrs:TermLoansMember 2023-01-01 2023-09-30 0001512762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001512762 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001512762 us-gaap:PerformanceSharesMember 2024-07-01 2024-09-30 0001512762 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001512762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001512762 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001512762 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001512762 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001512762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001512762 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001512762 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001512762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001512762 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001512762 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:AtMarketOfferingMember 2024-04-01 2024-06-30 0001512762 chrs:AtMarketOfferingMember 2024-04-01 2024-06-30 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:AtMarketOfferingMember 2023-04-01 2023-06-30 0001512762 chrs:AtMarketOfferingMember 2023-04-01 2023-06-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001512762 2024-01-01 2024-03-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001512762 2023-04-01 2023-06-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001512762 2023-01-01 2023-03-31 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithNovartisInstitutesMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithGrkMember 2023-09-08 2023-09-08 0001512762 chrs:JunshiBiosciencesMember 2024-09-30 0001512762 2024-10-31 0001512762 srt:WeightedAverageMember chrs:AtMarketOfferingMember 2024-01-01 2024-09-30 0001512762 srt:WeightedAverageMember chrs:AtMarketOfferingMember 2023-07-01 2023-09-30 0001512762 srt:WeightedAverageMember chrs:AtMarketOfferingMember 2023-01-01 2023-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-09-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001512762 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001512762 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001512762 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001512762 2024-04-01 2024-06-30 0001512762 us-gaap:OverAllotmentOptionMember 2023-05-16 2023-05-16 0001512762 chrs:AtMarketOfferingMember 2023-05-15 0001512762 srt:MaximumMember chrs:AtMarketOfferingMember 2023-09-11 0001512762 srt:MaximumMember chrs:AtMarketOfferingMember 2023-05-15 0001512762 srt:MaximumMember chrs:PublicOfferingMember 2022-11-17 0001512762 srt:MaximumMember chrs:AtMarketOfferingMember 2022-11-08 0001512762 chrs:UdenycaMember chrs:RevenuePurchaseAndSaleAgreementMember 2024-05-08 0001512762 chrs:UdenycaAndLogtorziMember chrs:RevenuePurchaseAndSaleAgreementMember 2024-05-08 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2024-05-08 0001512762 chrs:RebatesMember 2024-09-30 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2024-09-30 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2024-09-30 0001512762 chrs:RebatesMember 2023-12-31 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2023-12-31 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2023-12-31 0001512762 chrs:RebatesMember 2023-09-30 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2023-09-30 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2023-09-30 0001512762 2023-09-30 0001512762 chrs:RebatesMember 2022-12-31 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2022-12-31 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2022-12-31 0001512762 2022-12-31 0001512762 chrs:YusimryImmunologyFranchiseMember 2024-07-01 2024-09-30 0001512762 chrs:YusimryImmunologyFranchiseMember 2024-01-01 2024-09-30 0001512762 2024-07-01 2024-09-30 0001512762 2023-07-01 2023-09-30 0001512762 chrs:AtMarketOfferingMember 2024-01-01 2024-09-30 0001512762 chrs:AtMarketOfferingMember 2023-07-01 2023-09-30 0001512762 chrs:AtMarketOfferingMember 2023-01-01 2023-09-30 0001512762 chrs:YusimryImmunologyFranchiseMember 2023-12-31 0001512762 chrs:CimerliOphthalmologyFranchiseMember 2023-12-31 0001512762 chrs:RebatesMember 2024-01-01 2024-09-30 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2024-01-01 2024-09-30 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2024-01-01 2024-09-30 0001512762 chrs:RebatesMember 2023-01-01 2023-09-30 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2023-01-01 2023-09-30 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2023-01-01 2023-09-30 0001512762 chrs:TwoThousandTwentyNineTermLoansMember 2024-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2024-09-30 0001512762 2024-02-05 2024-02-05 0001512762 2024-03-01 2024-03-31 0001512762 chrs:AnkuraTrustCompanyLlcMember chrs:TwoThousandTwentyNineTermLoansMember 2024-09-30 0001512762 chrs:YusimryProductMember 2023-01-01 2023-12-31 0001512762 chrs:TwoThousandTwentyNineTermLoansMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2024-05-08 2024-05-08 0001512762 chrs:TwoThousandTwentyNineTermLoansMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2024-05-08 2024-05-08 0001512762 chrs:TwoThousandTwentyNineTermLoansMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2024-05-08 2024-05-08 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember us-gaap:InterestExpenseMember 2024-07-01 2024-09-30 0001512762 us-gaap:InterestExpenseMember 2024-01-01 2024-09-30 0001512762 chrs:AtMarketOfferingMember 2023-09-11 2023-09-11 0001512762 2023-

01-01 2023-09-30 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithNovartisInstitutesMember 2024-01-01 2024-03-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-06-26 2024-06-26 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-03-01 2024-03-01 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2020-04-01 2020-04-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-09-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-04-01 2024-06-30 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-03-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-06-26 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-03-01 0001512762 2024-03-01 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2024-09-30 0001512762 chrs:JunshiBiosciencesMember 2024-01-01 2024-09-30 0001512762 2024-02-05 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember 2024-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2020-04-30 0001512762 chrs:TwoThousandTwentyNineTermLoansMember 2024-01-01 2024-09-30 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2024-01-01 2024-09-30 0001512762 chrs:TwoThousandTwentyNineTermLoansMember 2024-05-08 2024-05-08 0001512762 chrs:TermLoansMember 2024-04-01 2024-04-01 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2024-09-30 0001512762 chrs:AtMarketOfferingMember 2024-09-30 0001512762 chrs:JunshiBiosciencesMember 2022-03-31 0001512762 chrs:CanadaLicenseAgreementMember 2024-01-01 2024-09-30 0001512762 chrs:JunshiBiosciencesMember 2022-03-01 2022-03-31 0001512762 chrs:ToripalimabMember chrs:JunshiBiosciencesMember 2021-02-01 2021-02-01 0001512762 chrs:ExclusiveLicenseAndCommercializationAgreementMember 2022-03-01 2022-03-31 0001512762 2022-03-01 2022-03-31 0001512762 chrs:JunshiBiosciencesMember 2021-02-01 2021-02-01 0001512762 chrs:GskAgreementMember chrs:SurfaceMember 2022-03-01 2022-03-31 0001512762 chrs:AntiTigitAntibodyAndIl2CytokineMember chrs:ExclusiveLicenseAndCommercializationAgreementMember 2022-03-31 0001512762 chrs:ToripalimabMember chrs:JunshiBiosciencesMember 2021-02-01 0001512762 chrs:VaccinexLicenseAgreementMember 2021-03-21 2021-03-21 0001512762 chrs:AdimabDevelopmentAndOptionAgreementMember 2018-10-01 2018-10-31 0001512762 chrs:GskAgreementMember 2020-12-01 2020-12-31 0001512762 us-gaap:AccountsPayableMember chrs:JunshiBiosciencesMember 2024-09-30 0001512762 chrs:AccruedAndOtherCurrentLiabilitiesMember chrs:JunshiBiosciencesMember 2024-09-30 0001512762 us-gaap:CallOptionMember 2020-04-01 2020-04-30 0001512762 chrs:SurfaceOncologyInc.Member 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:SurfaceSrf388ProprietaryDrugProductAgreementMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:SurfaceSrf114ProprietaryDrugProductAgreementMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:SurfaceGlaxosmithklineAgreementMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member 2023-09-08 2023-09-08 0001512762 2024-01-01 2024-09-30 0001512762 chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember chrs:JunshiBiosciencesMember 2024-03-31 0001512762 2024-09-30 0001512762 2023-12-31 iso4217:USD pure chrs:item shares iso4217:USD shares iso4217:CAD chrs:product 0001512762 --12-31 2024 Q3 false 0 0 112215260 115213407 http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense P10Y http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense P4Y P5Y P4Y10M24D http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 10-Q true 2024-09-30 false 001-36721 Coherus BioSciences, Inc. DE 27-3615821 333 Twin Dolphin Drive Suite 600 Redwood City CA 94065 650 649-3530 Common Stock, $0.0001 par value per share CHRS NASDAQ Yes Yes Accelerated Filer false false false 115213407 97690000 102891000 14857000 167559000 260522000 31241000 47640000 62605000 10718000 23657000 14176000 11099000 369024000 475631000 2911000 5119000 71375000 67495000 54313000 71673000 7377000 9686000 505000000 629604000 21893000 35219000 163315000 169645000 33637000 15756000 21521000 60965000 105386000 295566000 331771000 36618000 246481000 227891000 226888000 3737000 5328000 29161000 12561000 592973000 823029000 0.0001 0.0001 5000000 5000000 0 0 0.0001 0.0001 300000000 300000000 115213407 112215260 12000 11000 1412587000 1386312000 -275000 -248000 -1500297000 -1579500000 -87973000 -193425000 505000000 629604000 70774000 74568000 212816000 165720000 20741000 32703000 83695000 74425000 21676000 25647000 72101000 83068000 34744000 48224000 126441000 142521000 77161000 106574000 282237000 300014000 -6387000 -32006000 -69421000 -134294000 5362000 10268000 21812000 29923000 -1086000 176646000 -12630000 2084000 2253000 6420000 5598000 -10751000 -40021000 79203000 -158619000 -380000 -380000 -10751000 -39641000 79203000 -158239000 -0.09 -0.41 0.69 -1.79 -0.09 -0.41 0.65 -1.79 115210091 97738509 114263256 88277936 115210091 97738509 126563551 88277936 -10751000 -39641000 79203000 -158239000 32000 -24000 -15000 -3000 -3000 -1000 -10754000 -39609000 79176000 -158255000 112215260 11000 1386312000 -248000 -1579500000 -193425000 102875000 102875000 174651 291000 291000 741213 650005 1507000 1507000 284275 745000 745000 7677000 7677000 -24000 -24000 113496854 11000 1395042000 -272000 -1476625000 -81844000 -12921000 -12921000 21583 1976750 1000 4407000 4408000 52000 52000 767971 1711000 1711000 471439 685000 685000 7327000 7327000 115198655 12000 1405698000 -272000 -1489546000 -84108000 -10751000 -10751000 22915 8163 10000 10000 6899000 6899000 -3000 -3000 115213407 12000 1412587000 -275000 -1500297000 -87973000 78851516 8000 1204431000 -249000 -1341608000 -137418000 -75729000 -75729000 24107 103000 103000 771167 1131450 7059000 7059000 289944 2781000 2781000 12288000 12288000 -29000 -29000 80488296 8000 1221100000 -278000 -1417337000 -196507000 -42869000 -42869000 8182 14000 14000 142982 13529411 1000 53624000 53625000 74000 74000 48529 305000 305000 321672 1337000 1337000 10034000 10034000 -19000 -19000 94442014 9000 1285730000 -297000 -1460206000 -174764000 -39641000 -39641000 27977 53000 53000 72918 11971460 1000 58540000 58541000 261239 1053000 1053000 65732 347000 347000 2428311 1000 11436000 11437000 25141 115000 115000 10152000 10152000 32000 32000 109113046 11000 1366502000 -265000 -1499847000 -133599000 79203000 -158239000 4243000 2728000 21418000 32312000 6772000 -12630000 176646000 2481000 4369000 -505000 78000 -93024000 106626000 25499000 34941000 -5582000 -4108000 4306000 -10702000 -10280000 24545000 -7617000 60602000 -2396000 -1039000 -8810000 -50905000 7225000 -49048000 -161947000 6200000 108148000 8688000 13282000 187823000 40000000 6997000 12500000 19507000 -652000 -517000 230863000 109437000 36979000 36486000 1455000 18198000 53625000 291000 170000 685000 1337000 2466000 3261000 260387000 -248000 -835000 -187205000 69234000 -5390000 16724000 103343000 63987000 97953000 80711000 4408000 859000 1. Organization and Summary of Significant Accounting Policies Organization Coherus BioSciences, Inc. (the “Company” or “Coherus”) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. The Company is developing an innovative immuno-oncology pipeline that it believes will be synergistic with its proven commercial capabilities in oncology. The Company’s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. On January 2, 2024, the Company announced the launch in the U.S. of LOQTORZI® in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (“NPC”), and as monotherapy for the treatment of adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a novel PD-1 inhibitor that the Company developed in collaboration with Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”). The Company also sells UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States. The Company launched YUSIMRY (adalimumab-aqvh), a biosimilar to Humira (adalimumab), in the United States in July 2023. On June 26, 2024, the Company entered into an Asset Purchase Agreement (the “YUSIMRY Purchase Agreement”) with Hong Kong King-Friend Industrial Company Ltd. (“HKF”). Pursuant to the YUSIMRY Purchase Agreement, the Company completed the sale of its YUSIMRY (adalimumab-aqvh) franchise (the “YUSIMRY Sale”) for upfront, cash consideration of $40.0 million and the assumption of $17.0 million of inventory purchase commitments by HKF. The Company launched CIMERLI (ranibizumab-eqrn), a biosimilar to Lucentis, in the United States in October 2022. On January 19, 2024, the Company entered into a Purchase and Sale Agreement (the “CIMERLI Purchase Agreement”) with Sandoz Inc. (“Sandoz”). Pursuant to the terms and subject to the conditions set forth in the CIMERLI Purchase Agreement, on March 1, 2024, the Company completed the sale of its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC (“Coherus Ophthalmology”), to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets (the “CIMERLI Sale” and, together with the YUSIMRY Sale, the “Sale Transactions”). Proceeds from the CIMERLI Sale received in March were used in April 2024 to pay down $175.0 million of the total principal balance of $250.0 million on the Company’s senior secured term loan facility that was entered into January 5, 2022 (as amended on April 7, 2022, February 6, 2023, and February 5, 2024, the “2027 Term Loans”). During the second quarter of 2024, the Company repaid in full all the remaining outstanding indebtedness and terminated all commitments under the 2027 Term Loans, resulting in a $12.6 million loss on debt extinguishment from the 2027 Term Loans (see Note 8. Financial Liabilities). The Company’s product pipeline comprises the following three product candidates: CHS-1000, an antibody targeting ILT4; casdozokitug (CHS-388, formerly SRF388), an antibody targeting interleukin 27 (“IL-27”); and CHS-114 (formerly SRF114), a highly specific afucosylated immunoglobulin isotype G1 (“IgG1”) antibody targeting CCR8. In addition to the Company’s internally developed portfolio of product candidates, the Company has a product candidate, GSK4381562, which has been exclusively licensed to GlaxoSmithKline Intellectual Property

No. 4 Limited ("GSK"). Basis of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the "Securities Act"). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K") filed with the SEC. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as, the estimated effects and uncertainty surrounding the temporary supply interruption relating to the Company's third-party labeling and packaging CMO for UDENYCA. Accounting estimates and judgments are inherently uncertain and therefore actual results could differ from these estimates. Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets, which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> January 1, </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> At beginning of period: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 102,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 63,547 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 440 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt

0pt;"> 103,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 63,987</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 97,690 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 80,259</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 452</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 80,711 </td></tr></table> Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets. Trade Receivables Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2024 and December 31, 2023. Revenue Purchase and Sale Agreement The Revenue Purchase and Sale Agreement (see Note 8. Financial Liabilities) contains an embedded derivative that meets the criteria to be bifurcated and accounted for separately from the Revenue Purchase and Sale Agreement (the "Royalty Fee Derivative Liability"). The Royalty Fee Derivative Liability was recorded at fair value upon entering into the Revenue Purchase and Sale Agreement and is subsequently remeasured to fair value at each reporting period with the corresponding change in fair value recognized in other income (expense), net in the condensed consolidated statements of operations. The Revenue Purchase and Sale Agreement was initially valued and is remeasured using Monte Carlo simulation models to perform the "with-and-without" method, which involves valuing the Revenue Purchase and Sale Agreement with the embedded derivative and then valuing it without the embedded derivative. The difference between values is determined to be the estimated fair value of the Royalty Fee Derivative. Refer to Note 3. Fair Value Measurements for details regarding the fair value. The Revenue Purchase and Sale Agreement is accounted for as a liability net of a discount comprising issuance costs and the fair value of the embedded derivative

requiring bifurcation. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the liability to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the condensed consolidated statement of operations. The interest rate on this revenue participation liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The Company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales could materially impact the revenue participation liability, interest expense, and the time period for repayment. Contingent Consideration Contingent consideration relates to the potential payments to holders of Contingent Value Rights ("CVRs") that are contingent upon the achievement of the Company and certain third parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within selling, general and administrative expense in the condensed consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts. Stock-Based Compensation The Company's compensation programs include stock-based awards. For awards other than condition-based performance stock options, the fair values are recognized as compensation expense on a straight-line basis over the vesting period. For condition-based performance stock options, expense is recognized only when performance conditions are considered probable of being achieved and is recognized over the period from the grant date through the time the milestone is expected to be achieved. The related costs are recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Company's common stock on the date of issuance. Recent Accounting Pronouncements The following are recent accounting pronouncements that the Company has not yet adopted: In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption. 40000000.0 17000000.0 170000000.0 17800000 175000000.0 250000000.0 -12600000 3 Basis of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the "Securities Act"). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K") filed with the SEC. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as, the estimated effects and uncertainty surrounding the temporary supply interruption relating to the Company's third-party labeling and packaging CMO for UDENYCA. Accounting estimates and judgments are inherently uncertain and therefore actual results could differ from these estimates. Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets, which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:8pt;text-align:center;margin:0pt;">January 1, </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> At beginning of period: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 102,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 63,547 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 440 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 103,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 63,987 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> At end of period: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 97,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 80,259 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 97,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 80,711 </td></tr></table> Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets, which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> January 1, </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> At beginning of period: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 102,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 63,547 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 440 </td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt

0pt;"> 103,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 63,987</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 97,690 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 80,259</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 452</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 80,711 </td></tr></table> 102891000 63547000 452000 440000 103343000 63987000 97690000 80259000 263000 452000 97953000 80711000 Trade Receivables Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2024 and December 31, 2023. Revenue Purchase and Sale Agreement The Revenue Purchase and Sale Agreement (see Note 8. Financial Liabilities) contains an embedded derivative that meets the criteria to be bifurcated and accounted for separately from the Revenue Purchase and Sale Agreement (the "Royalty Fee Derivative Liability"). The Royalty Fee Derivative Liability was recorded at fair value upon entering into the Revenue Purchase and Sale Agreement and is subsequently remeasured to fair value at each reporting period with the corresponding change in fair value recognized in other income (expense), net in the condensed consolidated statements of operations. The Revenue Purchase and Sale Agreement was initially valued and is remeasured using Monte Carlo simulation models to perform the "with-and-without" method, which involves valuing the Revenue Purchase and Sale Agreement with the embedded derivative and then valuing it without the embedded derivative. The difference between values is determined to be the estimated fair value of the Royalty Fee Derivative. Refer to Note 3. Fair Value Measurements for details regarding the fair value. The Revenue Purchase and Sale Agreement is accounted for as a liability net of a discount comprising issuance costs and the fair value of the embedded derivative requiring bifurcation. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the liability to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the condensed consolidated statement of operations. The interest rate on this revenue participation liability may vary during the term of the agreement depending on a number of

*factors, including the level of actual and forecasted net sales. The Company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales could materially impact the revenue participation liability, interest expense, and the time period for repayment. Contingent Consideration Contingent consideration relates to the potential payments to holders of Contingent Value Rights (“CVRs”) that are contingent upon the achievement of the Company and certain third parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within selling, general and administrative expense in the condensed consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts. Stock-Based Compensation The Company’s compensation programs include stock-based awards. For awards other than condition-based performance stock options, the fair values are recognized as compensation expense on a straight-line basis over the vesting period. For condition-based performance stock options, expense is recognized only when performance conditions are considered probable of being achieved and is recognized over the period from the grant date through the time the milestone is expected to be achieved. The related costs are recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Company’s common stock on the date of issuance. Recent Accounting Pronouncements The following are recent accounting pronouncements that the Company has not yet adopted: In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption. 2. Revenue The Company launched LOQTORZI in December 2023, YUSIMRY in July 2023 and CIMERLI in October 2022. Net revenue for sales of YUSIMRY and CIMERLI effectively ceased to be recognized in the Company’s condensed consolidated statements of operations on June 26, 2024 and March 1, 2024, respectively (see Note 6. Acquisition and Dispositions). All net product revenue was generated in the United States, and the Company’s net revenue was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.88%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> UDENYCA </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> 32,967 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 159,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 90,875 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> CIMERLI </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"> (1,215) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"> 40,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"> 26,979 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"> 72,939 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> YUSIMRY </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"> (152) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> 1,360 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 7,508 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 1,360 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> LOOTORZI </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,609 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> Total net product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"> 70,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> 74,364 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 205,769 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 165,174 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> Other revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 220 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 204 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,047 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 546 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> Total net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 74,568 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 165,720 </td></tr></table> . Gross product revenues by significant customer as a percentage of total gross product revenues were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-

align:center;margin:0pt;">September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.77%;background:#cceeff;margin:0pt;padding:0pt;"> McKesson Corporation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 44 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"> 38 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> Cencora (previously known as AmeriSource-Bergen Corporation) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> 33 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:52.77%;background:#cceeff;margin:0pt;padding:0pt;"> Cardinal Health, Inc. </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 13 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 18 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.33%;background:#ccceff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#ccceff;margin:0pt;padding:0pt;"> % </td></tr></table> . Product Sales Discounts and Allowances The total provision related to sales made in the prior period was $0.3 million and $1.1 million for the three months ended September 30, 2024 and 2023, respectively. Chargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities and other liabilities, non-current on the accompanying unaudited condensed consolidated balance sheets. In connection with the Sale Transactions, the Company retained and will continue to be responsible for sales discounts and allowance liabilities incurred prior to March 1, 2024 for CIMERLI and June 26, 2024 for YUSIMRY. Sales discounts and allowances incurred on behalf of the respective counterparties following the close of the Sale Transactions in accordance with the Company's Transition Services Agreement with Sandoz (the "CIMERLI TSA") in March 2024 for CIMERLI and the Company's Transition Services Agreement with HKF (the "YUSIMRY TSA" and, together with the CIMERLI TSA, collectively the "TSA") in June 2024 for YUSIMRY are reflected within TSA receivables, net and TSA payables and other accrued liabilities in the unaudited condensed consolidated balance sheets and are excluded from the below table (see Note 6. Acquisition and Dispositions). The activities and ending reserve balances for each significant category of discounts and allowances that constitute variable consideration were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> Chargebacks </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> Other Fees, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> and Discounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> Co-pay </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> for Prompt </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> Assistance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Payment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and Returns </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:49.33%;background:#ccceff;margin:0pt;padding:0pt;"> Balances at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#ccceff;margin:0pt;padding:0pt;"> 121,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#ccceff;margin:0pt;padding:0pt;"> 244,885 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> Provision related to sales made in: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:49.33%;background:#cceeff;margin:0pt;padding:0pt;"> Current period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"> 727,028 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"> 150,820 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"> 117,299 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 995,147 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> Prior period - increase (decrease) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> (969) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 6,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> (1,010) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 4,364 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;background:#cceeff;margin:0pt;padding:0pt;"> Payments and customer credits issued </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (747,070) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (159,737) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (121,332) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,028,139) </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> Balances at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 118,563 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 216,257 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, 2023 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"> Chargebacks </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> Other Fees, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"> and Discounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> Co-pay </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"> for Prompt </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> Assistance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Payment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and Returns </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:49.39%;background:#ccceff;margin:0pt;padding:0pt;"> Balances at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;margin:0pt;padding:0pt;"> 38,713 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#ccceff;margin:0pt;padding:0pt;"> 100,503 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> Provision related to sales made in: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;background:#ccceff;margin:0pt;padding:0pt;"> Current period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ccceff;margin:0pt;padding:0pt;"> 387,238 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.99%;background:#ccceff;margin:0pt;padding:0pt;"> 83,009 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;margin:0pt;padding:0pt;"> 69,362 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#ccceff;margin:0pt;padding:0pt;"> 539,609 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> Prior period – increase (decrease) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> (1,375) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> 1,540 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> 4,469 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> 4,634 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;background:#ccceff;margin:0pt;padding:0pt;"> Payments and customer credits issued </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (379,076) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (42,097) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (55,681) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (476,854) </td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> Balances at September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 81,165 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 167,892 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-

wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.88%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> UDENYCA </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> 32,967 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 159,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 90,875 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> CIMERLI </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"> (1,215) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"> 40,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"> 26,979 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"> 72,939 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> YUSIMRY </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"> (152) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> 1,360 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 7,508 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 1,360 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> LOQTORZI </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,609 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

*style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> Total net product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"> 70,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"> 74,364 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 205,769 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"> 165,174 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"> Other revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 220 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 204 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,047 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 546 </td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"> Total net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">70,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 74,568 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">212,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 165,720 </td></tr></table> 66089000 32967000 159673000 90875000 -1215000 40037000 26979000 72939000 -152000 1360000 7508000 1360000 5832000 11609000 70554000 74364000 205769000 165174000 220000 204000 7047000 546000 70774000 74568000 212816000 165720000 Gross product revenues by significant customer as a percentage of total gross product revenues were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.77%;background:#cceeff;margin:0pt;padding:0pt;"> McKesson Corporation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 44 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"> 38 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:52.77%;margin:0pt;padding:0pt;"> Cencora (previously known as AmeriSource-Bergen Corporation) </td>

<td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> 33 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:52.77%;background:#cceeff;margin:0pt;padding:0pt;"> Cardinal Health, Inc. </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 13 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 18 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table> 0.45 0.44 0.41 0.38 0.33 0.41 0.39 0.45 0.21 0.13 0.18 0.15 300000 1100000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> Chargebacks </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> Other Fees, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> and Discounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> Co-pay </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> for Prompt </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> Assistance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Payment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and Returns </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:49.33%;background:#ccceff;margin:0pt;padding:0pt;"> Balances at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#ccceff;margin:0pt;padding:0pt;"> 121,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#ccceff;margin:0pt;padding:0pt;"> 49,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 244,885 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> Provision related to sales made in: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.33%;background:#cceeff;margin:0pt;padding:0pt;"> Current period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"> 727,028 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"> 150,820 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"> 117,299 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 995,147 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> Prior period - increase (decrease) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> (969) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 6,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> (1,010) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 4,364 </td></tr><tr><td style="vertical-align:bottom;width:49.33%;background:#cceeff;margin:0pt;padding:0pt;"> Payments and customer credits issued </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (747,070) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (159,737) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (121,332) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,028,139) </td></tr><tr><td style="vertical-align:bottom;width:49.33%;margin:0pt;padding:0pt;"> Balances at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 118,563 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 216,257 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, 2023 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"> Chargebacks </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> Other Fees, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"> and Discounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> Co-pay </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"> for Prompt </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> Assistance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Payment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and Returns </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"> 38,713 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 100,503 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> Provision related to sales made in: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p

style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.39%;background:#ccceff;margin:0pt;padding:0pt;"> Current period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ccceff;margin:0pt;padding:0pt;"> 387,238 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;margin:0pt;padding:0pt;"> 83,009 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;margin:0pt;padding:0pt;"> 69,362 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#ccceff;margin:0pt;padding:0pt;"> 539,609 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> Prior period - increase (decrease) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"> (1,375) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> 1,540 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"> 4,469 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> 4,634 </td></tr><tr><td style="vertical-align:bottom;width:49.39%;background:#ccceff;margin:0pt;padding:0pt;"> Payments and customer credits issued </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (379,076) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (42,097) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (55,681) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (476,854) </td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"> Balances at September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> 81,165 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 167,892 </td></tr></table> . 73953000 121137000 49795000 244885000 727028000 150820000 117299000 995147000 -969000 6343000 -1010000 4364000 747070000 159737000 121332000 1028139000 52942000 118563000 44752000 216257000 42677000 38713000 19113000 100503000 387238000 83009000 69362000 539609000 -1375000 1540000 4469000 4634000 379076000 42097000 55681000 476854000 49464000 81165000 37263000 167892000 . 3. Fair Value Measurements The fair values of financial instruments are classified into one of the following categories based upon the lowest level of input that is significant to the fair value measurement: <table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1 — Quoted prices in active markets for identical assets or liabilities.</td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr></table> The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an available-for-sale debt investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. Realized gains and losses, if any, on available-for-sale securities are included in other income (expense), net, in the condensed consolidated statements of operations based on the specific identification method. In connection with the acquisition (the "Surface Acquisition") of Surface Oncology, Inc. ("Surface") on September 8, 2023 (see Note 6. Acquisition and Dispositions), the Company recorded contingent consideration liabilities related to CVRs. The fair value of the CVR liabilities were determined using a Monte Carlo simulation-based model discounted to present value and represents a Level 3 measurement within the fair value hierarchy. Assumptions used in this calculation include estimated revenue, discount rate and various probability factors. If different assumptions were used for the various inputs, the estimated fair value could be significantly higher or lower than the fair value the Company determined. For example, increases in discount rates and the time to payment may result in lower fair value measurements. There is no assurance that any of the conditions for payment of the CVR liabilities will be met. During the three months ended March 31, 2024, the Company impaired its historical out-licensed partnership program with Novartis Institutes for Biomedical Research, Inc. ("Novartis Institutes") (NZV930), which resulted in a net impairment charge of $6.8 million in selling, general and administrative expenses in the condensed consolidated statements of operations relating to the write-off of the net carrying value of the Novartis Institutes out-license intangible asset of $10.6 million and the final remeasurement of the CVR liability related to NZV930 of $3.8 million to its fair value of zero. The remaining CVR liability associated with GSK of $0.5 million and other contingent consideration are recorded in other liabilities, non-current on the condensed consolidated balance sheets at September 30, 2024. On May 8, 2024, the Company recognized the Royalty Fee Derivative Liability which was estimated to be $9.2 million in connection with the Revenue Purchase and Sale Agreement (see Note 8. Financial Liabilities), which is recorded in accrued and other current liabilities on the condensed consolidated balance sheets. To estimate the fair value, the Company uses Monte Carlo simulation models that require the use of Level 3 unobservable inputs, primarily the amount and timing of our expected future revenue, the estimated volatility of these revenues, the discount rate corresponding to the risk of revenue, and the probability of certain events. At September 30, 2024, the estimated fair value of the Royalty Fee Derivative Liability remained unchanged at $9.2 million. Financial liabilities related to long-term debt obligations are summarized in Note 8. Financial Liabilities. Other financial liabilities and financial assets measured at fair value on a recurring basis are summarized as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;margin:0pt;padding:0pt;"> Fair Value Measurements </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Cash equivalents⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 69,070 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 69,070 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,070 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Royalty Fee Derivative Liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"> 9,202 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Contingent consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 632 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 632 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">— </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,834 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,834 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;margin:0pt;padding:0pt;"> Fair Value Measurements </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ccceff;margin:0pt;padding:0pt;"> Financial Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Cash equivalents⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">88,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 998 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> 89,458 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ccceff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> U.S. government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 5,195 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> 5,195 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ccceff;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> 2,993 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;margin:0pt;padding:0pt;"> 2,993 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Commercial paper and corporate notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 6,669 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;margin:0pt;padding:0pt;"> 6,669 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ccceff;margin:0pt;padding:0pt;"> Prepaid financial instrument in Prepaid manufacturing⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 625 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 625 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 104,940 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ccceff;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Contingent consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,472 </td></tr></table> <table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Cash equivalents consist of money market funds, U.S treasury securities and commercial paper and corporate notes with original maturities of 90 days or less.</td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Relates to Optional Stock Purchase Agreement as described in the Company's 2023 Form 10-K.</td></tr></table> The cost, unrealized gains or losses, and fair value by investment type are summarized as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized Gain </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized (Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:44.27%;background:#ccceff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 69,070 </td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,070 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized Gain </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized (Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 79,484 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> U.S. government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 5,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> (5) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 5,195 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 11,967 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 11,969 </td></tr><tr><td style="vertical-

align:bottom;width:44.08%;margin:0pt;padding:0pt;"> Commercial paper and corporate notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,673 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,667 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 104,315 </td></tr></table> . . 6800000 10600000 3800000 0 500000 9200000 9200000 Financial liabilities related to long-term debt obligations are summarized in Note 8, Financial Liabilities. Other financial liabilities and financial assets measured at fair value on a recurring basis are summarized as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td

colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;margin:0pt;padding:0pt;"> Fair Value Measurements </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Cash equivalents⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 69,070 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,070 </td></tr><tr><td style="vertical-

align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Royalty Fee Derivative Liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"> 9,202 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Contingent consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 632 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 632 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,834 </td></tr></table> - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr

style="height:1pt;"><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;margin:0pt;padding:0pt;"> Fair Value Measurements </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ceeeff;margin:0pt;padding:0pt;"> Financial Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Cash equivalents⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 88,460 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> 89,458 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> U.S. government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 5,195 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"> 2,993 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Commercial paper and corporate notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p

style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 6,669 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"> 6,669 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ccceff;margin:0pt;padding:0pt;"> Prepaid financial instrument in Prepaid manufacturing⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 625 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 625 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 104,940 </td></tr><tr><td style="vertical-align:bottom;width:44.81%;background:#ccceff;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"> Contingent consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td

style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,472 </td></tr></table> <table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Cash equivalents consist of money market funds, U.S treasury securities and commercial paper and corporate notes with original maturities of 90 days or less.</td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Relates to Optional Stock Purchase Agreement as described in the Company's 2023 Form 10-K.</td></tr></table> 69070000 69070000 69070000 69070000 9202000 9202000 632000 632000 9834000 9834000 88460000 998000 89458000 5195000 5195000 2993000 2993000 6669000 6669000 625000 625000 96648000 7667000 625000 104940000 4472000 4472000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized Gain </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized (Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:44.27%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 69,070 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.29%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,070</p></td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> .</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,070 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,070 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized Gain </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized (Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;">

</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#ccceff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#ccceff;margin:0pt;padding:0pt;"> 79,484 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> U.S. government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 5,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> (5) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 5,195 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#ccceff;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#ccceff;margin:0pt;padding:0pt;"> 11,967 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#ccceff;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#ccceff;margin:0pt;padding:0pt;"> 11,969 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"> Commercial paper and corporate notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,673 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,667 </td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#ccceff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 104,315 </td></tr></table> 69070000 69070000 69070000 69070000 79484000 79484000 5200000 5000 5195000 11967000 2000 11969000 7673000 6000 7667000 104324000 2000 11000 104315000 4. Inventory Inventory consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#ccceff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#ccceff;margin:0pt;padding:0pt;"> 12,975 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> Work in process </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"> 102,989 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"> 82,588 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#ccceff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.27%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,291 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,537 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 130,100 </td></tr></table> . Inventory as of December 31, 2023 included $16.4 million related to the CIMERLI ophthalmology franchise and $17.0 million related to the YUSIMRY immunology franchise (see Note 6. Acquisition and Dispositions). Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During the year ended December 31, 2023, the Company recorded a $47.0 million charge for the write-down of slow moving YUSIMRY inventory, which included the recognition of $20.5 million in certain firm purchase commitments. Of this charge, $11.5 million was reflected in accrued and other current liabilities and $9.0 million in other liabilities, non-current as of December 31, 2023. Liabilities for firm inventory purchase commitments related to YUSIMRY were derecognized upon the YUSIMRY Sale. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current on the condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the non-current portion of inventory consisted of raw materials and work in process, as well as a portion of finished goods at December 31, 2023. The following table presents the inventory balance sheet classifications:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ccceff;margin:0pt;padding:0pt;"> 47,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#ccceff;margin:0pt;padding:0pt;"> 62,605 </td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"> Inventory, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 71,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67,495 </td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 130,100 </td></tr></table>
Prepaid manufacturing of $10.7 million as of September 30, 2024 includes prepayments of $6.5 million to CMOs for manufacturing services, which the Company expects to be converted into inventory within the next twelve months, and prepayments of $4.2 million to various CMOs for research and development pipeline programs. Prepaid manufacturing of $23.7 million as of December 31, 2023 included prepayments of $11.1 million to various CMOs for research and development pipeline programs and $12.6 million to CMOs for manufacturing services, of which $6.4 million related to the CIMERLI ophthalmology franchise and $0.5 million related to the YUSIMRY immunology franchise (see Note 6. Acquisition and Dispositions).</p> <p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Inventory consisted of the following: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"> 13,735 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"> 12,975 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> Work in process </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"> 102,989 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"> 82,588 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.27%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,291 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,537 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 130,100 </td></tr></table> 13735000 12975000 102989000 82588000 2291000 34537000 119015000 130100000 16400000 17000000.0 47000000.0 20500000 11500000 9000000.0 - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#ccceff;margin:0pt;padding:0pt;"> Inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#ccceff;margin:0pt;padding:0pt;"> 62,605 </td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"> Inventory, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 71,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67,495 </td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#ccceff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 130,100 </td></tr></table> 47640000 62605000 71375000 67495000 119015000 130100000 10700000 6500000 4200000 23700000 11100000 12600000 6400000 500000 5. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 13,124 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Computer equipment and software </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 3,566 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 3,546 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Furniture and fixtures </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 1,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 1,055 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p

style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 5,751 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 5,751 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease right of use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,294 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Total property and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 23,533 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 25,770 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20,622) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20,651) </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,119 </td></tr></table> - Depreciation and amortization expense related to property and equipment, net was $0.4 million and $1.5 million for the three and nine months ended September 30, 2024, respectively, and $0.8 million and $2.5 million for the three and nine months ended September 30, 2023, respectively. - As of September 30, 2024 and December 31, 2023, the net book value of software implementation costs related to hosting arrangements was $2.3 million and $3.2 million, respectively, and the amortization expense was immaterial for all periods presented. - Intangible Assets, Net Intangible assets, net consisted of the following: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> — </td><td colspan="2"

style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Finite-lived assets, net of accumulated amortization of $2,052 and $639, as of September 30, 2024 and December 31, 2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 25,454 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,871</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Indefinite-lived assets - in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,859</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 943</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 54,313 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 71,673 </td></tr></table> Amortization expense related to finite-lived intangible assets was $1.2 million and $2.8 million in the three and nine months ended September 30, 2024, respectively, and immaterial for the three and nine months ended September 30, 2023. In connection with the CIMERLI Sale on March 1, 2024, a finite-lived asset, net of $2.1 million and goodwill of $0.9 million were derecognized. In connection with the YUSIMRY Sale on June 26, 2024, a finite-lived asset with a net value of $0.9 million was derecognized. The exclusive license of NZV930 to Novartis Institutes, acquired as part of the Surface Acquisition, was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, the Company recognized an impairment charge of $10.6 million for the carrying value of the Novartis Institutes out-license during the three months ended March 31, 2024, which was classified within selling, general and administrative expense in the condensed consolidated statements of operations. Amortization expense for the remaining finite-lived assets for each of the five succeeding fiscal years is expected to be $2.7 million. Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued commercial and research and development manufacturing </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> 23,470 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Accrued co-development costs and milestone payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> 12,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> 26,812 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued royalties </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"> 1,199 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> 42,031 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Royalty Fee Derivative Liability (Note 8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> 9,202 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue participation liability, current (Note 8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"> 2,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Accrued other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> 14,526 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> 7,628 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#ceeeff;margin:0pt;padding:0pt;"> Lease liabilities, current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ceeeff;margin:0pt;padding:0pt;"> 1,629 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#ceeeff;margin:0pt;padding:0pt;"> 2,145 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Contingent consideration, current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,300 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#ceeeff;margin:0pt;padding:0pt;"> Total Accrued and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 105,386 </td></tr></table>
Other Liabilities, Non-current Other liabilities, non-current consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;background:#ceeeff;margin:0pt;padding:0pt;"> Contingent consideration, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 1,172 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> Deferred tax liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> 1,102 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 1,102 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue participation liability, non-current (Note 8) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"> 27,427 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,287 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;background:#cceeff;margin:0pt;padding:0pt;"> Total Other liabilities, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,561 </td></tr></table> Property and equipment, net consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">(in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 13,124 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Computer equipment and software </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 3,566 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 3,546 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Furniture and fixtures </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 1,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 1,055 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 5,751 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 5,751 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease right of use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,294 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Total property and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 23,533 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 25,770 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20,622) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (20,651) </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,119 </td></tr></table> 13161000 13124000 3566000 3546000 1055000 1055000 5751000 5751000 2294000 23533000 25770000 20622000 20651000 2911000 5119000 400000 1500000 800000 2500000 2300000 3200000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Finite-lived assets, net of accumulated amortization of $2,052 and $639, as of September 30, 2024 and December 31, 2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 25,454 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> 41,871 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.61%;margin:0pt;padding:0pt;"> Indefinite-lived assets - in-process research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 28,859 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> 28,859 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 943 </td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"> Total Intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p

style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 71,673 </td></tr></table> 2052000 639000 25454000 41871000 28859000 28859000 943000 54313000 71673000 1200000 2800000 2100000 900000 900000 10600000 2700000 Accrued and other current liabilities consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued commercial and research and development manufacturing </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> 23,470 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Accrued co-development costs and milestone payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> 12,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> 26,812 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued royalties </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"> 1,199 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> 42,031 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Royalty Fee Derivative Liability (Note 8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> 9,202 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue participation liability, current (Note 8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"> 2,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Accrued other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"> 14,526 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> 7,628 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Lease liabilities, current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"> 1,629 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2,145 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;margin:0pt;padding:0pt;"> Contingent consideration, current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,300 </td></tr><tr><td style="vertical-align:bottom;width:75.82%;background:#cceeff;margin:0pt;padding:0pt;"> Total Accrued and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 105,386 </td></tr></table> 19729000 23470000 12500000 26812000 1199000 42031000 9202000 2180000 14526000 7628000 1629000 2145000 3300000 60965000 105386000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">| </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;background:#cceeff;margin:0pt;padding:0pt;"> Contingent consideration, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> 1,172 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> Deferred tax liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> 1,102 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"> 1,102 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue participation liability, non-current (Note 8) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"> 27,427 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:75.44%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,287 </td></tr><tr><td style="vertical-align:bottom;width:75.44%;background:#cceeff;margin:0pt;padding:0pt;"> Total Other liabilities, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,561 </td></tr></table> | 632000 1172000 1102000 1102000 27427000 10287000 29161000 12561000 6. Acquisition and Dispositions 2024 Dispositions | YUSIMRY Sale On June 26, 2024, the Company completed the sale of its YUSIMRY immunology franchise which comprised certain assets, including certain YUSIMRY intellectual property, contracts, YUSIMRY inventory, and all activities related to research and development of YUSIMRY. In exchange, HKF paid upfront cash consideration of $40.0 million and assumed certain liabilities, including $17.0 million of inventory purchase commitments. During the second quarter of 2024, the Company recognized a net gain on the YUSIMRY Sale of $22.9 million, which included the cash receipts of $40.0 million less net assets transferred to HKF or otherwise derecognized and transaction costs of $1.0 million. At September 30, 2024, unpaid transaction costs totaled $0.8 million. The pretax profit (loss) related to the

YUSIMRY immunology franchise prior to the YUSIMRY Sale, which excludes any corporate overhead allocations, was $(0.2) million and $1.3 million during the three and nine months ended September 30, 2024, respectively, and $(2.0) million and $(12.1) million during the three and nine months ended September 30, 2023, respectively. In connection with the YUSIMRY Sale, the Company and HKF entered into the YUSIMRY TSA, pursuant to which the Company is providing certain business support services on behalf of HKF including billings, collections, and the remittance of rebates, to ensure business continuity for patients and customers for a period not expected to extend beyond December 31, 2024. Under the YUSIMRY TSA, the Company is entitled to be reimbursed for its costs which were $0.5 million for the three and nine months ended September 30, 2024. As of September 30, 2024, assets of $3.4 million and liabilities of $3.2 million related to transactions entered into on behalf of HKF in accordance with the YUSIMRY TSA were presented in TSA receivables, net and TSA payables and other accrued liabilities, respectively, in the condensed consolidated balance sheets. CIMERLI Sale On March 1, 2024, the Company completed the sale of its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. During the first quarter of 2024, the Company recognized a net gain on the CIMERLI Sale of $153.6 million, which includes the cash receipts of $187.8 million less assets transferred to Sandoz, assets derecognized, transaction costs of $7.2 million, and other related employee transition expenses. As of September 30, 2024, unpaid commitments for retention bonuses totaled $4.7 million. The pretax profit (loss) related to the CIMERLI ophthalmology franchise prior to the CIMERLI Sale, which excludes any corporate overhead allocations, was <span style="background:#ffffff;">$(1.2) million and $6.2 million during the three and nine months ended September 30, 2024, respectively, and $6.9 million and $5.7 million during the three and nine months ended September 30, 2023, respectively. In connection with the CIMERLI Sale, the Company and Sandoz entered into the CIMERLI TSA, pursuant to which the Company is providing certain business support services on behalf of Sandoz including billings, collections, and the remittance of rebates, to ensure business continuity for patients and customers for a period not expected to extend beyond December 31, 2024. Under the CIMERLI TSA, the Company is entitled to be reimbursed for its costs and has recorded income of $0.5 million and $1.6 million for the three and nine months ended September 30, 2024 in other income (expense), net in the condensed consolidated statements of operations. As of September 30, 2024, assets related to transactions entered into on behalf of Sandoz in accordance with the CIMERLI TSA of $27.8 million were presented in TSA receivables, net and liabilities related to transactions entered into on behalf of Sandoz in accordance with the CIMERLI TSA of $30.4 million were presented in TSA payables and other accrued liabilities in the condensed consolidated balance sheet. 2023 Acquisition Surface Acquisition . On September 8, 2023 (the “Acquisition Date”), in accordance with an Agreement and Plan of Merger dated June 15, 2023 (the “Merger Agreement”) by and among the Company, Crimson Merger Sub I, Inc. (“Merger Sub I”), Crimson Merger Sub II, LLC (“Merger Sub II,” and together with Merger Sub I, the “Merger Subs”), and Surface, the Company completed the Surface Acquisition. The Surface Acquisition expanded the Company’s I-O pipeline with the following: casdozokitug (CHS-388, formerly SRF388), an investigational, novel IL-27-targeted antibody currently being evaluated in a Phase 2 clinical trial in HCC, and CHS-114 (formerly SRF114), an investigational, CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors and head and neck squamous cell carcinoma (“HSNSCC”). On the Acquisition Date, and in accordance with the Merger Agreement, the Company issued to the holders of all outstanding Surface common stock (subject to certain exceptions) 0.1960 shares of Coherus common stock in exchange for each share of outstanding Surface common stock and certain outstanding Surface employee equity awards. The exchange ratio was calculated pursuant to the terms of the Merger Agreement and was based on a $5.2831 per share price of Coherus common stock and a nominal total amount of cash in lieu of fractional shares. Surface shareholders also received one CVR for each share of Surface common stock and employee equity award converted. Each CVR entitles the holder to receive quarterly contingent payments in the form of cash, stock or a combination of cash and stock at the Company’s discretion during the 10-year period following September 8, 2023, for the sum of the following, less any permitted deductions (in accordance with the Contingent Value Rights Agreement, dated September 8, 2023, by and among the Company and Computershare Inc. and its affiliate Computershare Trust Company, N.A., together, as the rights agent thereunder (the “CVR Agreement”)): <table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">70% of all milestone- and royalty-based payments actually received by the Company or its affiliates from GSK under a license agreement with GSK, dated December 16, 2020, which was subsequently amended in August 2021 (as amended, the “GSK Agreement”) related to the existing program (GSK4381562);</td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">25% of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for CHS-114; and</td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">50% of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for casdozokitug.</td></tr></table> The Company has recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement described above. The Company is unable to estimate a range of outcomes for potential royalty and milestone payments for CHS-114 and casdozokitug. The following table below sets forth the purchase price allocation to the estimated fair value of the net assets acquired: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amounts Recognized at Acquisition Date </td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"> Assets Acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,791</p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,260</p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,239</p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,530</p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,817 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Liabilities Assumed </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"> 7,722 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Deferred tax liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,499 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> 9,221 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Total net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,596</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company believes that, even after reassessing its identification of all assets acquired and liabilities assumed, it was able to acquire Surface for a price that was completely allocable to identifiable assets acquired and liabilities assumed with no residual attributable to goodwill primarily due to Surface's need to raise additional capital to finance its operations, the challenging biotech funding environment at the time the transaction was initially announced, and the value of the acquired net assets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The amounts allocated to identifiable intangible assets was as follows: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful lives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at Acquisition Date</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - casdozokitug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;background:#ceeeff;margin:0pt;padding:0pt;"> 25,899 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"> In-process research and development - CHS-114 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"> 340 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#ceeeff;margin:0pt;padding:0pt;"> Out-license - GSK </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#ceeeff;margin:0pt;padding:0pt;"> 15 years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;background:#ceeeff;margin:0pt;padding:0pt;"> 2,506 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"> Out-license - Novartis Institutes </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> 15 years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,024 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#ceeeff;margin:0pt;padding:0pt;"> Total identifiable intangible assets </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.19%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,769 </td></tr></table> The out-license intangible assets represent potential milestone and royalty-based payments to be received under two out-licensed partnership programs to advance certain next-generation cancer therapies, Novartis Institutes (NZV930) and GSK (GSK4381562). Surface shareholders received CVRs for certain percentages of these milestone and royalty-based payments, as further explained above. The exclusive license of NZV930 to Novartis Institutes was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, during the first quarter of 2024, the Company recognized a net impairment charge of $6.8 million in selling, general and administrative expenses in the condensed consolidated statements of operations relating to the write-off of the net carrying value of the Novartis Institutes out-license intangible asset of $10.6 million and the final remeasurement of the CVR liability related to NZV930 of $3.8 million to its fair value of zero.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="color:#212529;font-style:italic;">Unaudited Pro Forma Summary of Operations</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table shows the unaudited pro forma summary of operations for the three and nine months ended September 30, 2023, as if the Surface Acquisition had occurred on January 1, 2022. This pro forma information does not purport to represent what the Company's actual results would have been if the acquisition had occurred as of January 1, 2022, and it is not indicative of what such results would be expected for any future period:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;background:#ccceff;margin:0pt;padding:0pt;"> 74,568 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165,720</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"> (49,984) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"> (204,922) </td></tr></table> Acquisition-related costs of $2.6

 million and $4.5 million were recorded in selling, general and administrative expense in the condensed consolidated statement of operations during the three and nine months ended September 30, 2023, respectively.</p> 40000000.0 17000000.0 22900000 40000000.0 1000000.0 800000 -200000 1300000 -2000000.0 -12100000 500000 500000 3400000 3200000 170000000.0 17800000 153600000 187800000 7200000 4700000 -1200000 6200000 6900000 5700000 500000 1600000 27800000 30400000 0.1960 5.2831 1 0.70 0.25 0.50 <p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amounts Recognized at Acquisition Date</p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets Acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;margin:0pt;padding:0pt;"> 6,997 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"> Investments in marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"> 21,791 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Prepaids and other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;margin:0pt;padding:0pt;"> 5,260 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"> In-process research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"> 26,239 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Out-licenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,530 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,817</p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities Assumed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;margin:0pt;padding:0pt;"> 7,722 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Deferred tax liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,499 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,221 </td></tr><tr><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"> Total net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,596</p></td></tr></table> 6997000 21791000 5260000 26239000 13530000 73817000 7722000 1499000 9221000 64596000 0 <p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful lives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at Acquisition Date</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - casdozokitug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;background:#cceeff;margin:0pt;padding:0pt;"> 25,899 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"> In-process research and development - CHS-114 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"> 340 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"> Out-license - GSK </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 15 years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;background:#cceeff;margin:0pt;padding:0pt;"> 2,506 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"> Out-license - Novartis Institutes </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> 15 years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,024 </td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"> Total identifiable intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,769</p></td></tr></table> 25899000 340000 P15Y 2506000 P15Y 11024000 39769000 2 6800000 10600000 3800000 0 <p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;background:#cceeff;margin:0pt;padding:0pt;"> 74,568 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165,720</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"> (49,984) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"> (204,922) </td></tr></table> 74568000 165720000 -49984000 -204922000 2600000 4500000 selling, general and administrative selling, general and administrative 7. Collaborations and Other Arrangements In-Licensing Agreements Junshi Biosciences On February 1, 2021, the Company entered into an Exclusive License and Commercialization Agreement (the "Collaboration Agreement") with Junshi Biosciences for the co-development and commercialization of LOQTORZI, Junshi Biosciences' anti-PD-1 antibody, in the United States and Canada. Under the terms of the Collaboration Agreement, the Company paid $150.0 million upfront for exclusive rights to LOQTORZI in the United States and Canada, an option in these territories to Junshi Biosciences' anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to two undisclosed preclinical immuno-oncology drug candidates. The Company is obligated to pay Junshi Biosciences a 20% royalty on net sales of LOQTORZI and up to an aggregate $380.0 million in one-time payments for the achievement of various

regulatory and sales milestones. In March 2022, the Company paid $35.0 million for the exercise of its option to license CHS-006. Subsequent joint development consistent with the Collaboration Agreement commenced. On January 10, 2024, the Company announced that it had delivered a notice of termination of the TIGIT program CHS-006 described in the Collaboration Agreement (the "TIGIT Program") to Junshi Biosciences. The Company plans to continue to wind down work with Junshi Biosciences on the TIGIT Program pursuant to the termination. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay an additional option exercise fee of $35.0 million and an 18% royalty on net sales, up to $85.0 million for the achievement of certain regulatory approvals, and up to $170.0 million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of LOQTORZI and the other licensed compounds, and will pay for a portion of these co-development activities up to a maximum of $25.0 million per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. In March 2024, the Company entered into an Amendment No. 2 to the Collaboration Agreement (the "2nd Amendment") with Junshi Biosciences to revise the timing of the $25.0 million milestone payment to Junshi Biosciences that became due in connection with the approval by the FDA of toripalimab for the treatment of patients with NPC in the first quarter of 2024. Under the terms of the 2nd Amendment, the $25.0 million milestone payment was split into two installments of $12.5 million each, one that was paid in the second quarter of 2024 and one due in the first quarter of 2025. The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. There was no material research and development expense recognized for obligations to Junshi Biosciences for the three months ended September 30, 2024. During the nine months ended September 30, 2024, the Company recognized a reduction in research and development expenses for the release of certain liabilities of $4.8 million pursuant to the 2nd Amendment with Junshi Biosciences. Research and development expenses were $3.1 million and $7.7 million for the three and nine months ended September 30, 2023, respectively. In the condensed consolidated balance sheets as of September 30, 2024, the Company has classified $12.5 million in accrued and other current liabilities related to a milestone payment in connection with the 2nd Amendment and $0.4 million in accounts payable related to the co-development, regulatory and technology transfer costs related to these programs. The accrued royalty obligation to Junshi Biosciences was $1.1 million as of September 30, 2024 and immaterial at December 31, 2023. The additional milestone payments, option fee for the IL-2 cytokine and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred. Apotex On June 27, 2024, the Company entered into an exclusive license and distribution agreement (the "Canada License Agreement") with Apotex, Inc. ("Apotex"), pursuant to which, the Company granted to Apotex an exclusive license under the Company's rights to toripalimab to commercialize toripalimab within Canada. Pursuant to the Canada License Agreement, Apotex paid the Company an upfront payment of $6.3 million United States Dollars ("USD") which has been classified as net revenue in the condensed consolidated statements of operations for the nine months ended September 30, 2024. In addition, Apotex agreed to pay the Company up to an aggregate of $51.5 million Canadian Dollars ("CAD") in milestone payments in connection with the achievement of certain regulatory and sales milestones with respect to toripalimab in Canada. Lastly, Apotex agreed to pay the Company a low double-digit percentage of any future net sales of toripalimab in Canada that the Company will subsequently pay to Junshi Biosciences pursuant to the Collaboration Agreement. The Canada License Agreement term continues until the tenth year after the first commercial sales of toripalimab in Canada, subject to an extension for a subsequent ten-year term at the option of Apotex. Apotex may terminate the License Agreement for any reason after a specified notice period. The License Agreement will terminate automatically if the rights granted to the Company by the Collaboration Agreement are terminated, if there is material breach that is not cured, if there are certain challenges to licensed patents by Apotex and in the case of certain insolvency events. Bioeq On November 4, 2019, the Company entered into a license agreement (the "Bioeq License Agreement") with Bioeq AG ("Bioeq") for the commercialization of CIMERLI, a biosimilar version of Lucentis (ranibizumab), in certain dosage forms in both a vial and pre-filled syringe presentation (the "Bioeq Licensed Products"). Under the Bioeq License Agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. Royalties due to Bioeq were $38.4 million as of December 31, 2023. On January 19, 2024 the Company entered into the CIMERLI Purchase Agreement with Sandoz. Pursuant to the CIMERLI Purchase Agreement, on March 1, 2024, the Company completed the divestiture of its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology, for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Refer to Note 6. Acquisition and Dispositions for additional information. Upon closing of the CIMERLI Sale, the Bioeq License Agreement was assumed by Sandoz. Refer to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on March 15, 2024 for additional information related to the Bioeq License Agreement. Adimab Development and Option Agreement In October 2018, Surface and Adimab LLC ("Adimab"), entered into an amended and restated development and option agreement, (as amended by the amendments dated as of December 16, 2020, June 1, 2022 and July 18, 2022, the "A&R Adimab Agreement"), which amended and restated the development and option agreement with Adimab dated July 2014, as amended, ("the Original Adimab Agreement"), for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the A&R Adimab Agreement, the Company will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. Adimab granted the Company an exclusive option to obtain a non-exclusive, worldwide, fully paid-up, sublicensable license under Adimab's platform patents and other Adimab technology solely to research up to ten antibodies, chosen by the Company against a specific biological target for a specified period of time (the "Research Option"). In addition, Adimab granted the Company an exclusive option to obtain a worldwide, royalty-bearing, sublicensable license under Adimab platform patents and other Adimab technology to exploit, including commercially, 20 or more antibodies against specific biological targets (the "Commercialization Option"). Upon the exercise of a Commercialization Option, and payment of the applicable option fee to Adimab, Adimab will assign the Company the patents that cover the antibodies selected by such Commercialization Option. The Company will be required to use commercially reasonable efforts to develop, seek market approval of, and commercialize at least one antibody against the target covered by the Commercialization Option in specified markets upon the exercise of a Commercialization Option. Under the A&R Adimab Agreement, the Company is obligated to make milestone payments and to pay specified fees upon the exercise of the Research Option or Commercialization Option. During the discovery term, the Company may be obligated to pay Adimab up to $0.3 million for technical milestones achieved against each biological target. Upon exercise of a Research Option, the Company is obligated to pay a nominal research maintenance fee on each of the next four anniversaries of the exercise. Upon the exercise of each Commercialization Option, the Company will be required to pay an option exercise fee of a low seven-digit dollar amount, and the Company may be responsible for milestone payments of up to an aggregate of $13.0 million for each

*licensed product that receives marketing approval. For any licensed product that is commercialized, the Company is obligated to pay Adimab tiered royalties of a low to mid single-digit percentage on worldwide net sales of such product. The Company may also partially exercise a Commercialization Option with respect to ten antibodies against a biological target by paying 65% of the option fee and later either (i) paying the balance and choosing additional antibodies for commercialization, up to the maximum number under the Commercialization Option, or (ii) foregoing the Commercialization Option entirely. For any Adimab diagnostic product that is used with or in connection with any compound or product other than a licensed antibody or licensed product, the Company is obligated to pay Adimab up to a low seven digits in regulatory milestone payments and low single-digit royalties on net sales. Vaccinex License Agreement On March 23, 2021, Surface and Vaccinex, Inc. ("Vaccinex") entered into an exclusive product license agreement (the "Vaccinex License Agreement") which provides the Company a worldwide, exclusive, sublicensable license to make, have made, use, sell, offer to sell, have sold, import, and otherwise exploit licensed products that incorporate certain Vaccinex intellectual property which covers certain antibodies (each, a "Vaccinex Licensed Products"), including the antibody CHS-114 targeting CCR8. Under the Vaccinex License Agreement, the Company is obligated to use commercially reasonable efforts to develop, clinically test, achieve regulatory approval, manufacture, market and commercialize at least one Vaccinex Licensed Product. The Company is responsible for all costs and expenses of such development, manufacturing and commercialization. Vaccinex is eligible to receive up to an aggregate of $3.5 million based on achievement of certain clinical milestones, up to an aggregate of $11.5 million based on achievement of certain regulatory milestones per Vaccinex Licensed Product, and low single digit royalties on global net sales of any approved licensed products. The Company may terminate the Vaccinex License Agreement for convenience upon the notice period specified in the Vaccinex License Agreement. Either party may terminate the agreement for an uncured material breach by the other party. Vaccinex may terminate the Vaccinex License Agreement if we default on any payments owed to Vaccinex under the agreement, if the Company is in material breach of, and fails to cure, its development obligations, or institute certain actions related to the licensed patents. In the event of termination, all rights in the licensed intellectual property would revert to Vaccinex. Out-Licensing Agreements Acquired as part of the Surface Acquisition On September 8, 2023, at the closing of the Surface Acquisition, all the assets, liabilities, rights and obligations of Surface were assumed by the Company's direct, wholly-owned subsidiary, Surface Oncology, LLC. See further details in Note 6. Acquisition and Dispositions. GSK Agreement In December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target CD112R, also known as PVRIG, including the antibody GSK4381562 (the "Licensed Antibodies"). GSK is responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee was formed to facilitate information sharing. GSK is responsible for all costs and expenses of such development, manufacturing and commercialization and is obligated to provide the Company with updates on its development, manufacturing and commercialization activities through the joint development committee. In March 2022, Surface earned a $30.0 million milestone payment from GSK upon the dosing of the first patient in the Phase 1 trial of GSK4381562. The Company is eligible to receive up to $60.0 million in additional clinical milestones and $155.0 million in regulatory milestones. In addition, the Company may receive up to $485.0 million in sales milestone payments. The Company is also eligible to receive royalties on global net sales of any approved products based on the Licensed Antibodies, ranging in percentages from high single digits to mid-teens. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the GSK Agreement. The Company did not recognize license-related revenue under the GSK Agreement during the three and nine months ended September 30, 2024. Unless terminated earlier, the GSK Agreement expires on a licensed product-by-licensed product and country-by-country basis on the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim or regulatory exclusivity covering such licensed product in such country. Either party may terminate the GSK Agreement for an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. GSK may terminate the GSK Agreement for its convenience. The Company may terminate the GSK Agreement if GSK institutes certain actions related to the licensed patents or if GSK ceases development activities, other than for certain specified technical or safety reasons. In the event of termination, the Company would regain worldwide rights to the terminated program. 150000000.0 2 0.20 380000000.0 35000000.0 35000000.0 0.18 85000000.0 170000000.0 25000000.0 25000000.0 25000000.0 12500000 0 4800000 3100000 7700000 12500000 400000 1100000 6300000 51500000 P10Y 38400000 170000000.0 17800000 10 20 1 300000 13000000.0 10 0.65 3500000 11500000 30000000.0 60000000.0 155000000.0 485000000.0 P10Y 8. Financial Liabilities A summary of the Company's debt obligations, including level within the fair value hierarchy (see Note 3. Fair Value Measurements), is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> (in thousands) </td><td colspan="2" style="vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal
Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unamortized Debt Discount and Debt Issuance Costs </td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net
Carrying Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Estimated
Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> 2029 Term Loan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"> (2,042) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 36,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"> Level 2* </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

*size:10pt;text-align:right;margin:0pt;"> (2,109) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> 180,550 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2** </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.6%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;">) </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> 2027 Term Loans </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"> (3,519) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 246,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 246,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"> Level 2* </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-*

size:10pt;margin:0pt 0pt 0pt 6pt;">2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3,112)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#ccceff;margin:0pt;padding:0pt;"> Level 2** </td></tr></table> $ <table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">*</td><td style="padding:0pt;">The principal amounts outstanding are subject to variable interest rates based on three-month SOFR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximate their fair values.</td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"> ** </td><td style="padding:0pt;"> The fair value is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs. </td></tr></table> 2029 Term Loan On May 8, 2024 (the “2029 Term Loan Effective Date”), the Company entered into a senior secured term loan facility of up to $38.7 million (the “2029 Term Loan”) that was fully funded on the 2029 Term Loan Effective Date with Ankura Trust Company, LLC, as administrative agent (in such capacity, the “Agent”), and the lenders signatory thereto (collectively, the “2029 Lenders”). The net proceeds of $37.5 million, net of the original issuance discount, were used by the Company to help repay in full the existing outstanding indebtedness owed by the Company to BioPharma Credit, PLC (“BioPharma”), BPCR Limited Partnership (as a “2027 Lender”), and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC (as a “2027 Lender”) pursuant to the 2027 Term Loans. The 2029 Term Loan is governed by a loan agreement, dated as of the 2029 Term Loan Effective Date, by and among the Company, the Agent and the 2029 Lenders (the “2029 Loan Agreement”). The 2029 Term Loan will mature on May 8, 2029. The amount borrowed under the 2029 Term Loan accrues interest equal to 8.0% per annum, plus a three-month SOFR rate (the “Interest Rate”). The 2029 Term Loan provides for interest-only payments on a quarterly basis until maturity. The Company may prepay the 2029 Term Loan in full or in part provided the Company (i) provides at least three (3) business days’ prior written notice to the Agent, (ii) pays on the date of such prepayment (A) all outstanding principal to be prepaid plus accrued and unpaid interest, (B) a prepayment fee of (x) 10.0% of the 2029 Term Loans so prepaid if paid on or after the first anniversary of the 2029 Term Loan Effective Date and before the second anniversary of the 2029 Term Loan Effective Date; (y) 5.0% of the 2029 Term Loan so prepaid if paid after the second anniversary of the 2029 Term Loan Effective Date and on or before the third anniversary of the 2029 Term Loan Effective Date; and (z) 0% of the 2029 Term Loan so prepaid if paid after the third anniversary of the 2029 Term Loan Effective Date, (C) if paid before the first anniversary of the 2029 Term Loan Effective Date, a make-whole amount equal to the interest that would have accrued from the date of prepayment through the first anniversary of the 2029 Term Loan Effective Date, and (D) all other sums, if any, that shall become due and payable under the 2029 Loan Agreement, including interest at the default rate with respect to any past due amounts. Amounts outstanding during an event of default shall accrue interest at an additional rate of 4.0% per annum, which interest shall be payable on demand in cash. The 2029 Term Loan is secured by a lien on substantially all the assets of the Company, including intellectual property, subject to customary exclusions and exceptions. The 2029 Loan Agreement contains customary representations and warranties, covenants and events of default, including a financial covenant commencing on the 2029 Term Loan Effective Date, which requires the Company to maintain certain levels of cash and cash equivalents. As of September 30, 2024, the Company was in full compliance with these covenants, and there were no events of default under the 2029 Term Loan. The Company incurred $2.2 million of debt discount and issuance costs relating to the issuance of the 2029 Term Loan, which were recorded as a reduction to the carrying value of the 2029 Term Loan on the condensed consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the five-year contractual term of the 2029 Term Loan using the effective interest rate method. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense related to the 2029 Term Loan:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-

wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:68.16%;background:#cceeff;margin:0pt;padding:0pt;"> Contractual interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;margin:0pt;padding:0pt;"> 2,074 </td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 77 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 120 </td></tr><tr><td style="vertical-align:bottom;width:68.16%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,194 </td></tr></table> As of September 30, 2024, the total remaining unamortized debt discount and debt offering costs of $2.0 million will be amortized using the effective interest rate over the remaining term of 4.6 years. Assuming the third quarter of 2024 interest rate of 13.3%, future payments on the 2029 Term Loan as of September 30, 2024 are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"> Year ending December 31, (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Remainder of 2024 - interest only </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,221</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,222</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,222</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2028 and thereafter - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,712</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,693</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (24,033)</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2029 Term Loan, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,660</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,042)</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net carrying amount of 2029 Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,618 </td></tr></table> . Revenue Purchase and Sale Agreement On May 8, 2024, concurrent with the 2029 Term Loan, the Company entered into a revenue participation right purchase and sale agreement (the “Revenue Purchase and Sale Agreement”) with Coduet Royalty Holdings, LLC, as administrative agent and each buyer named in an annex thereto (collectively, the “Purchaser Group”). Under the terms of the Revenue Purchase and Sale Agreement, the Purchaser Group paid the Company $37.5 million, subject to certain conditions at closing (the “Purchase Price”). In exchange, the Company sold to the Purchaser Group a right to receive 5.0% of U.S. net sales of UDENYCA and LOQTORZI with respect to a specified threshold applicable to UDENYCA net sales and a specified threshold applicable to LOQTORZI net sales during an applicable year and 0.5% of U.S. net sales of UDENYCA and LOQTORZI that exceeded the specified threshold during that year (the “Revenue Payment”) for each calendar quarter commencing May 8, 2024. The Purchaser Group’s right to receive the Revenue Payment terminates and the Company no longer has the obligation to pay Revenue Payments once the Purchaser Group receives the amount equal to 2.25 times the Purchase Price allocated to each product. The Company may also buy-out the Purchaser Group’s rights to receive the Revenue Payments by triggering certain conditions and paying the Purchaser Group the unpaid portion of the 2.25 multiple on the Purchase Price. The proceeds from the Purchase Price were used by the Company as part of the full repayment of the 2027 Term Loans. The Revenue Purchase and Sale Agreement contains various representations and warranties, including with respect to organization, authorization, and certain other matters, certain covenants with respect to payment, reporting, intellectual property, in-licenses, out-licenses, and certain other actions, indemnification obligations and other provisions customary for transactions of this nature. The Revenue Purchase and Sale Agreement contains an embedded derivative that meets the criteria to be bifurcated and accounted for as a freestanding derivative instrument subject to derivative accounting. The allocation of the Purchase Price to the embedded derivative resulted in a $9.2<span

style="background:#ffffff;"> million discount on the revenue participation liability. Additionally, there was $1.4 million in issuance costs. The Company is amortizing the discount and issuance costs to interest expense over the estimated term of the Revenue Purchase and Sale Agreement using the effective interest method. For the three and nine months ended September 30, 2024, interest expense was $2.7 million and $4.4 million, respectively, inclusive of the amortization of discount and issuance costs of $0.5 million and $0.8 million, respectively. For details on the Royalty Fee Derivative Liability, see Note 3. Fair Value Measurements.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">A summary of the revenue participation liability is as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:86.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue participation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"> 39,382 </td></tr><tr><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"> Less unamortized discount and issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,775) </td></tr><tr><td style="vertical-align:bottom;width:86.44%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,607 </td></tr></table> Classification on the condensed consolidated balance sheets is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:35.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:35.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.53%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:35.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance Sheet Classification </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:45.53%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue participation liability, current </td><td style="vertical-align:bottom;width:35.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt;">Accrued and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,180</p></td></tr><tr><td style="vertical-align:bottom;width:45.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Revenue participation liability, non-current</p></td><td style="vertical-align:bottom;width:35.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,427</p></td></tr><tr><td style="vertical-align:bottom;width:45.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,607 </td></tr></table> - 2027 Term Loans The Company entered into a loan agreement in January 2022 (as amended, the "2027 Loan Agreement") with BioPharma and the 2027 Lenders that provided for a senior secured term loan facility of up to $300.0 million, of which $250.0 million was funded. The 2027 Term Loans accrued interest at 8.25% plus the sum (the "Adjusted Term SOFR") of three-month SOFR and 0.26161% per annum, with a floor on Adjusted Term SOFR of 1.0%. On February 5, 2024, the Company entered into a Consent, Partial Release and Third Amendment to the 2027 Term Loans (the "Consent and Amendment") with the Collateral Agent and the 2027 Lenders. Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the 2027 Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by the CIMERLI Purchase Agreement, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the 2027 Lenders and the Collateral Agent required the Company to make a partial prepayment of the principal of the loans outstanding under the 2027 Loan Agreement in the amount of $175.0 million upon consummation of the transactions contemplated by the CIMERLI Purchase Agreement, subject to certain conditions and (3) the parties thereto agreed to adjust the minimum net trailing twelve month net sales covenant level to be $125.0 million under the 2027 Loan Agreement. As a result of the CIMERLI Sale closing, the Company made a partial prepayment of $175.0 million of the total principal balance of $250.0 million of the 2027 Term Loans on April 1, 2024. On May 8, 2024, in connection with entering into the 2029 Term Loan and the Revenue Purchase and Sale Agreement, the Company repaid in full all outstanding indebtedness and terminated all commitments under the 2027 Term Loans. The May 8, 2024 payoff amount of $79.6 million included principal repayment in full, accrued interest, a 3.0% prepayment premium fee of the principal amount, a make-whole interest payment and lender fees. During the nine months ended September 30, 2024, the Company recorded a $12.6 million loss on debt extinguishment in the condensed consolidated statements of operations for the payoff of the 2027 Term Loans, and the charge included the write-off of the remaining debt discount and debt issuance costs, the prepayment premium fee, the make-whole interest payment, and lender fees. The following table presents the components of interest expense related to the 2027 Term Loans: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.01%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#ccceff;margin:0pt;padding:0pt;"> Contractual interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#ccceff;margin:0pt;padding:0pt;"> 8,790 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccceff;margin:0pt;padding:0pt;"> 25,404 </td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 255 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 830 </td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#ccceff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri', 'Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt

0pt;"> 9,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26,234 </td></tr></table> . 1.5% Convertible Senior Subordinated Notes due 2026 In April 2020, the Company issued and sold $230.0 million aggregate principal amount of its 1.5% Convertible Senior Subordinated notes due 2026 (the "2026 Convertible Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were $222.2 million after deducting initial purchasers' fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Company's designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables. The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020, and will mature on April 15, 2026, unless earlier repurchased or converted. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Company's common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. Since inception, the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock. The initial conversion price represents a premium of approximately 30.0% over the last reported sale of $14.82 per share of the Company's common stock on the Nasdaq Global Market on April 14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a "make-whole fundamental change" (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Company's election before maturity. If a "fundamental change" (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. The 2026 Convertible Notes have customary provisions relating to the occurrence of "events of default" (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. . As of September 30, 2024, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes. . The Company evaluated the features embedded in the 2026 Convertible Notes under the relevant accounting rules and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as equity components. Capped Call Transactions In connection with the pricing of the 2026 Convertible Notes, the Company paid $18.2 million to enter into privately negotiated capped call transactions with one or a combination of the initial purchasers, their respective affiliates and other financial institutions. The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Company's common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been $25.93 per share, which represents a premium of approximately 75.0% over the last reported sale price of the Company's common stock of $14.82 per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and classified as equity instruments; thus, they are recorded as a reduction to additional paid-in capital on the condensed consolidated balance sheets. The capped calls are not re-measured as long as the conditions for equity classification continue to be met. The Company incurred $0.9 million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the carrying value of the notes on the condensed consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the six-year contractual term of the notes using the effective interest rate method. If the 2026 Convertible Notes were converted on September 30, 2024, the holders of the 2026 Convertible Notes would have received common shares with an aggregate value of $12.4 million based on the Company's closing stock price of $1.04 as of September 30, 2024. The following table presents the components of interest expense related to the 2026 Convertible Notes: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> <p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.13%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Stated coupon interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"> 863 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"> 2,588 </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 336 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 329 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 982 </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,192 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,570 </td></tr></table> The remaining unamortized debt discount and debt offering costs related to the 2026 Convertible Notes of $2.1 million as of September 30, 2024 will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is 2.1% for the 2026 Convertible Notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 9pt 0pt;">Future payments on the 2026 Convertible Notes as of September 30, 2024 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December 31, (in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remainder of 2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"> 1,725 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> 2025 - interest only </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> 3,450 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 - principal and interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 231,725 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> Total minimum payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> 236,900 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"> Less amount representing interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,900) </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> 2026 Convertible Notes, principal amount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> 230,000 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"> Less unamortized debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,109) </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> Net carrying amount of 2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 227,891 </td></tr></table> A summary of the Company's debt obligations, including level within the fair value hierarchy (see Note 3, Fair Value Measurements), is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> | </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> (in thousands) </td><td colspan="2" style="vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal
Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unamortized Debt Discount and Debt Issuance Costs </td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net
Carrying Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Estimated
Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-

align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> 2029 Term Loan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"> (2,042) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 36,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"> Level 2 </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"> (2,109) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> 180,550 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2** </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-*

space:nowrap;width:8.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.6%;margin:0pt;padding:0pt;"> 2027 Term Loans </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"> (3,519) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 246,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 246,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"> Level 2* </td></tr><tr><td style="vertical-align:bottom;width:35.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"> (3,112) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> 150,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2** </td></tr></table> <table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">*</td><td style="padding:0pt;">The principal amounts outstanding are subject to variable interest rates based on three-month SOFR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximate their fair values.</td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"> ** </td><td style="padding:0pt;"> The fair value is influenced by interest rates, the Company's stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs. </td></tr></table> 38660000 2042000 36618000 36618000 230000000 2109000 227891000 180550000 250000000 3519000 246481000 246481000 230000000 3112000 226888000 150155000 38700000 37500000 0.080 0.100 0.050 0 0.040 0 2200000 1316000 2074000 77000 120000 1393000 2194000 2000000.0 <p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Assuming the third quarter of 2024 interest rate of 13.3%, future payments on the 2029 Term Loan as of September 30, 2024 are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"> Year ending December 31, (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder of 2024 - interest only </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,221</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,222</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,222</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2028 and thereafter - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,712</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,693</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (24,033)</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2029 Term Loan, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,660</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,042)</p></td></tr><tr><td style="vertical-align:bottom;width:84.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net carrying amount of 2029 Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,618 </td></tr></table> 0.133 1316000 5221000 5222000 5222000 45712000 62693000 24033000 38660000 2042000 36618000 37500000 0.050 0.005 2.25 2.25 9200000 1400000 2700000 4400000 500000 800000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-

right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:86.44%;background:#ccceff;margin:0pt;padding:0pt;"> Revenue participation liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,382</p></td></tr><tr><td style="vertical-align:bottom;width:86.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,775)</p></td></tr><tr><td style="vertical-align:bottom;width:86.44%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,607 </td></tr></table> 39382000 9775000 29607000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:35.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:35.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.53%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:35.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance Sheet Classification </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:45.53%;background:#ccceff;margin:0pt;padding:0pt;"> Revenue participation liability, current </td><td style="vertical-align:bottom;width:35.74%;background:#ccceff;margin:0pt;padding:0pt;"> Accrued and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#ccceff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#ccceff;margin:0pt;padding:0pt;"> 2,180 </td></tr><tr><td style="vertical-align:bottom;width:45.53%;margin:0pt;padding:0pt;"> Revenue participation liability, non-current </td><td style="vertical-align:bottom;width:35.74%;margin:0pt;padding:0pt;"> Other liabilities, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,427 </td></tr><tr><td style="vertical-align:bottom;width:45.53%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:35.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,607 </td></tr></table> 2180000 27427000 29607000 300000000.0 250000000.0 0.0825 0.0026161 0.010 175000000.0 125000000.0 175000000.0 250000000.0 79600000 0.030 -12600000 The following table presents the components of interest expense related to the 2027 Term Loans: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.76%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;"> Contractual interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 8,790 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 25,404 </td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 255 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 830 </td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26,234 </td></tr></table> 8790000 9916000 25404000 255000 1277000 830000 9045000 11193000 26234000 0.015 230000000.0 0.015 222200000 The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020 0.015 2026-04-15 51.9224 1000 19.26 0.300 14.82 As of September 30, 2024, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes. 0 18200000 25.93 0.750 14.82 900000 P6Y 12400000 1.04 The following table presents the components of interest expense related to the 2026 Convertible Notes: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.13%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Stated coupon interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"> 863 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"> 2,588 </td></tr><tr><td style="vertical-align:bottom;width:56.64%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 336 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 329 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 982 </td></tr><tr><td style="vertical-align:bottom;width:56.64%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,192 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,570 </td></tr></table> 863000 863000 2588000 2588000 336000 329000 1003000 982000 1199000 1192000 3591000 3570000 2100000 0.021 Future payments on the 2026 Convertible Notes as of September 30, 2024 are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> Year ending December 31, (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder of 2024 - interest only </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"> 1,725 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> 2025 - interest only </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> 3,450 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 - principal and interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 231,725 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> Total minimum payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> 236,900 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"> Less amount representing interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,900) </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> 2026 Convertible Notes, principal amount </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.69%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> 230,000 </td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"> Less unamortized debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,109) </td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"> Net carrying amount of 2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227,891</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"></p> 1725000 3450000 231725000 236900000 6900000 230000000 2109000 227891000 <p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Commitments and Contingencies </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase Commitments </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of September 30, 2024, the Company's non-cancelable purchase commitments under the terms of its agreements are as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December 31, (in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 7,293 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 57,606 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 1,654 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 450 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"> Total obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 67,003 </td></tr></table>) The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are generally cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees. In connection with the YUSIMRY Sale, HKF assumed $17.0 million in YUSIMRY inventory purchase commitments, of which $17.0 million remained as of September 30, 2024. If HKF were to default on its obligations under the YUSIMRY Purchase Agreement, the Company could become liable to pay any unpaid portion of these purchase commitments. Guarantees and Indemnifications In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown

because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible. Legal Proceedings and Other Claims The Company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business and that have not been fully resolved. The outcome of such legal proceedings and claims is inherently uncertain. Accruals are recognized for such legal proceedings and claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it is determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. As of September 30, 2024 and December 31, 2023, the Company had an accrual of $6.4 million related to such matters that was included in accrued rebates, fees and reserves on the condensed consolidated balance sheets. In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC ("Zinc") asserting that Zinc was entitled to approximately $14.0 million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company has an accrual established as of September 30, 2024 that represented its estimated liability to resolve the matter. Loss contingencies are inherently unpredictable, the assessment is highly subjective and requires judgments about future events and unfavorable developments or resolutions can occur. The Company regularly reviews litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Other than the matter in connection with the demand letter described in this Note 9. Commitments and Contingencies, there are no pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries' property is subject.</p> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December 31, (in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 7,293 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 57,606 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 1,654 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 450 </td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"> Total obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 67,003 </td></tr></table> 7293000 57606000 1654000 450000 67003000 17000000.0 17000000.0 6400000 6400000 14000000.0 10. Stockholders' Deficit Public Offering On May 16, 2023, the Company entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein (collectively, the "Underwriters"), pursuant to which the Company issued and sold an aggregate of 11,764,706 shares (the "Firm Shares") of its common stock, par value $0.0001 per share, to the Underwriters (the "Public Offering"). Additionally, under the terms of the Underwriting

Agreement, the Company granted the Underwriters an option, for 30 days from the date of the Underwriting Agreement, to purchase up to an additional 1,764,705 shares of common stock (the "Option Shares," and together with the Firm Shares, the "Shares"), which the Underwriters elected to exercise in full. The price to the public in the Public Offering was $4.25 per share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $3.995 per share. The Offering was made pursuant to a prospectus supplement and related prospectus filed with the SEC pursuant to the Company's shelf registration statement on Form S-3 that was declared effective on November 17, 2022 (the "Registration Statement") under which the Company may offer and sell up to $150.0 million in the aggregate of its common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings. On May 18, 2023, the Company completed the sale and issuance of an aggregate of 13,529,411 Shares, including the exercise in full of the Underwriters' option to purchase the Option Shares. The Company received net proceeds of approximately $53.6 million, after deducting the Underwriters' discounts and commissions and offering expenses payable by the Company. ATM Offering On November 8, 2022, the Company filed the Registration Statement. Also on November 8, 2022, the Company entered into a sales agreement ("Sales Agreement") with Cowen and Company, LLC ("TD Cowen"), pursuant to which the Company may issue and sell from time to time up to $150.0 million of its common stock through or to TD Cowen as the Company's sales agent or principal in an at-the-market offering ("ATM Offering"). On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement and in connection with the Public Offering, the Company reduced the amount of shares that could be issued and sold pursuant to its ATM Offering with TD Cowen by $86.2 million, lowering the aggregate offering price under the Sales Agreement from $150.0 million to $63.8 million. On September 11, 2023, pursuant to an Amendment No. 2 to Sales Agreement, the Company increased the amount of shares that could be issued and sold pursuant to its ATM Offering with TD Cowen by $28.7 million, increasing the aggregate offering price under the Sales Agreement from $63.8 million to $92.5 million. The following table summarizes information regarding settlements under the ATM Offering for the three and nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"> (in thousands, except share and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Number of common stock shares sold during the period </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2,428,311 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> 650,005 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"> 3,559,761 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> Weighted-average price per share </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.43 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Gross proceeds </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> 11,938 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"> 19,339 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> Less commissions and fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (298) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (40) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (483) </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Net proceeds after commissions and fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.46%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccceff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,856 </td></tr></table> As of September 30, 2024, the Company had approximately $64.9 million of its common stock remaining available for sales under the ATM Offering.) 11764706 0.0001 P30D 1764705 4.25 3.995 150000000.0 13529411 53600000 150000000.0 86200000 150000000.0 63800000 28700000 63800000 92500000) <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;">) </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"> (in thousands, except share and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#ccceff;margin:0pt;padding:0pt;"> Number of common stock shares sold during the period </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2,428,311 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> 650,005 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"> 3,559,761 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> Weighted-average price per share </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.43 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Gross proceeds </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> 11,938 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"> 19,339 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> Less commissions and fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (298) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (40) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (483) </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Net proceeds after commissions and fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,856 </td></tr></table> 2428311 650005 3559761 4.92 2.44 5.43 11938000 1589000 19339000 298000 40000 483000 11640000 1549000 18856000 64900000 11. Stock-Based Compensation In April 2024 and May 2024, the Company granted performance-based stock options to purchase 1,982,500 and 640,000 shares of Company common stock ("PSOs"), respectively, to its Chief Executive Officer and certain other senior executives with performance-based vesting conditions under the 2014 Equity Incentive Award Plan and the Amended and Restated 2014 Equity Incentive Award Plan that have a term of ten years. Vesting is based on the achievement of various commercial, clinical, strategic and total shareholder return performance milestones during specified periods. The fair value of each PSO was estimated on the grant date, using the Black-Scholes model for PSOs tied to commercial, clinical and strategic milestones (the "Performance Condition PSOs") and a Monte Carlo simulation model for PSOs with total shareholder return vesting criteria (the "Market Condition PSOs"). Expense for the Performance Condition PSOs is recognized over the requisite service period only when the performance condition is considered probable of being achieved and is recognized over the period from the grant date through the time the milestone is expected to be achieved. Expense for the Market Condition PSOs is recognized over the requisite service period. Expense related to PSOs was $0.2 million and $1.0 million during the three and nine months ended September 30, 2024, respectively. The following table summarizes the classification of stock-based compensation expense in the Company's condensed consolidated statements of operations related to options, including PSOs, and restricted stock units granted to employees and nonemployees: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.98%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:8pt;text-align:center;margin:0pt;">September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.75%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of goods sold ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 174 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"> 535 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 2,092 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 2,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 6,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"> 11,760 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,494 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,850 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,017 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,418 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,312</p></td></tr><tr><td style="vertical-align:bottom;width:59.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;">Stock-based compensation expense capitalized into inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 313 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,107 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 697 </td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"></td></tr></table> (1) Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold. 1982500 640000 P10Y P10Y 200000 1000000.0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.98%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.75%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of goods sold ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> 174 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"> 535 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 2,092 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"> 2,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 6,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"> 11,760 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.19%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,494 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,850 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,017 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 32,312 </td></tr><tr><td style="vertical-align:bottom;width:59.75%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#ccceff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.75%;margin:0pt;padding:0pt;"> Stock-based compensation expense capitalized into inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 373 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 697 </td></tr></table> 282000 174000 834000 535000 2092000 2929000 6552000 11760000 4494000 6850000 14032000 20017000 6868000 9953000 21418000 32312000 313000 373000 1107000 697000 12. Net Income (Loss) Per Share Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares. <span

style="background:#ffffff;">Diluted net income per share is computed by dividing the net income by the weighted average number of common shares outstanding for the period plus any diluted potential common shares outstanding for the period determined using the treasury stock method for options, PSOs, RSUs and ESPP and using the if-converted method for the convertible notes. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive. The following table sets forth the computation of the basic and diluted net income (loss) per share: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.58%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.58%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.1%;margin:0pt;padding:0pt;"> (in thousands, except share and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Basic net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:45.1%;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#ccceff;margin:0pt;padding:0pt;"> Net income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (39,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (158,239) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#ccceff;margin:0pt;padding:0pt;"> Weighted-average common shares outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,210,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,738,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 114,263,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88,277,936 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Basic net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.09)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.41) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.79) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Diluted net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Net income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> (39,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> (158,239) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Add interest expense on convertible notes, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,591 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Numerator for diluted net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (39,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (158,239) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Denominator for basic net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 115,210,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> 97,738,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 114,263,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> 88,277,936 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Add effect of potential dilutive securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Stock options, including shares subject to ESPP </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 213,872 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#ccceff;margin:0pt;padding:0pt;"> 144,271 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#ccceff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Shares issuable upon conversion of convertible notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#ccceff;margin:0pt;padding:0pt;"> Denominator for diluted net income (loss) income per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,210,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,738,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 126,563,551 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88,277,936 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Diluted net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.09)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.41) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.79) </td></tr></table> - The following outstanding dilutive potential shares were excluded from the calculation of diluted net income (loss) per share due to their anti-dilutive effect: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.37090683%;padding-left:0pt;padding-right:0pt;width:100.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options, PSOs, including shares subject to ESPP </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 30,104,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 24,558,893 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 28,103,519 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 24,003,706 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 831,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 2,141,403 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 930,737 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 2,354,166 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"> Shares issuable upon conversion of 2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,942,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,942,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,942,152 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 42,877,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,642,448 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,034,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,300,024 </td></tr></table> - The amounts in the table above exclude any shares contingently issuable pursuant to the CVR Agreement because the conditions that could result in a payment becoming due were not met. - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.58%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.58%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.1%;margin:0pt;padding:0pt;"> (in thousands, except share and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Basic net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Net income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (39,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (158,239) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average common shares outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,210,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,738,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 114,263,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88,277,936 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Basic net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.09)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.41) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.79) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Diluted net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-

family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Net income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> (39,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> (158,239) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Add interest expense on convertible notes, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Numerator for diluted net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (39,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,794 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (158,239) </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Denominator for basic net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 115,210,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> 97,738,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 114,263,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> 88,277,936 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Add effect of potential dilutive securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Stock options, including shares subject to ESPP </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 213,872 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Shares issuable upon conversion of convertible notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,942,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator for diluted net income (loss) income per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,210,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,738,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 126,563,551 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88,277,936 </td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"> Diluted net income (loss) per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.09)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.41) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.65 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1,79) </td></tr></table> -10751000 -39641000 79203000 -158239000 115210091 97738509 114263256 88277936 -0,09 -0,41 0,69 -1,79 -10751000 -39641000 79203000 -158239000 3591000 -10751000 -39641000 82794000 -158239000 115210091 97738509 114263256 88277936 213872 144271 11942152 115210091 97738509 126563551 88277936 -0,09 -0,41 0,65 -1,79 The following outstanding dilutive potential shares were excluded from the calculation of diluted net income (loss) per share due to their anti-dilutive effect: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.37090683%;padding-left:0pt;padding-right:0pt;width:100.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options, PSOs, including shares subject to ESPP </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 30,104,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 24,558,893 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 28,103,519 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"> 24,003,706 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 831,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 2,141,403 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-

serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 930,737 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> 2,354,166 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"> Shares issuable upon conversion of 2026 Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,942,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,942,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,942,152 </td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 42,877,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,642,448 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,034,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,300,024 </td></tr></table> 30104147 24558893 28103519 24003706 831401 2141403 930737 2354166 11942152 11942152 11942152 42877700 38642448 29034256 38300024 false false false false

"

*FO:3TD9H862"]'Q?VVW$Y](>GXHVX9M,S<65?CDO0"PS$+)Q5#UPA.W5%]EF2|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|VULVZL/$OV'6]VGR3>QX!WEP$!6]&97$/>'ZJ:A31)D:AQLMV"N7V M^7 24(1[(%GNR,!R?H3TD*0[/;AY$ "_= IU%-5%EJ**=P[::B&?R@.V4[" M+DX"&7)]12>4E::LCL@=+FKZ!5%^4FVM<!7D_.FKRR<[P(<3DE*$" 4EVT-9>A_* MNJ5(D^;,Y/*IUQ*E1MA3OC=%B9#Q[99ZS 0\YZY!ON.'9'DA4).J^]@S,0L MF= OJ=:*ZQC5'39)RR^CP6BOCBU;(4\H:JJ6HJDJ.HH9H-<3@E.BJ![JA1&(+5E%4; M_:>F0";;?FA7=,QY,\6&)IYHQ$MSWEM1X5&8GH%1/4<#U.QY,+ MSV$6)HO*"9MDU,#L1&_^[6R,KB?TR.)|^FHC_;4 M_G"]+.;JO::/RRV&_X1=4J1)LBA7I!6!IW\:E$U'!8I Z@A(,HZ+&0IIGC:N?@ZN74<#XN.B10A80D5 M"763VB|)C#,@AH+1G(),S-7M>880[Y7)3E%#/%1$:RT%IYF?[F;QC+O.9GR8$ MK:$R+[RJ#K>G,|Y6P)I]3P-&\"/!4S. M]3OE.G-H5G6)PGX?C>E2^!<^#6LA9=45/>XYG_9\,U<8?D^4S;3U=FHU^|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|=$I4M(2N3L:$#YX70B#&"? "V.2W@M?$|% M;.9/&LQ|& 3^N2"%N\S7*JBUE8DS|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|(-1LWH(,/X60:Z]!(^C M'/$X:B_VB!U[@CXZ'?6/CY74#>6>1.0AUU886|O/6?:&=P7X=9[H.L-;<@): M^)4"0B\F_6Z[%%-34DX=-[BJK5%-[+0OK981$"T&B29 T4)8M "8';M EB!D MCF\EM67+^7=B:57|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|C^+B:FQCG('9G2[]|[A?(1Z$HG;'G M.BZH4W1;&']ZCCA;KS&T\BAMZR"=B[!A8]*;P+9\V))L%I_!)D*-P-H^YYQ8 M4YI6?+"Y@=60_IK2D%1J6R&)XEI/"NM5[FQS*>Z],:N(:%='O+)'_9BR59(> MBA^495$&XCI1(&1ABJ*:HR8).1P->EWDM.] L,K00_%S>BKUQI,-PHEC5888ME1ICJX2F/O9UDNK\?.1S)#BC_O+_4$L#!!0 (_J#9EE@ 2DN#EL ,@# M!@ 5 8VAR&UL[:UK<^,VUB#\?:OV/^CM_;#/ M5DVGVYU))DE-GBU;MOOQOF[+9;LS.Y^F8!*2.*$(!23=5G[] N!%I 2 &\X MZF;53-J2<#DW' 'Y_+W__VZ'6Q2C!_NQ+D*QG3V2[1='L$Z8T M",/9!0W\%9[-SMY_]]-W![_[^8?9V[?_*<:X0#'K0Z*9&.S#=V?%#_-\.!+] M,CL[>_?CNP_O/_QU]O,O'|Y^.?MY=O^I:/>)@;8,FAJ&0?3[+_P_SVR^&4,Q MBG]YC8-?WZR39/O+NW=?OGSY[LOWWQ&Z8MW?G[W[OY]N'[TUW]"W010G*/+P MFQEK_TLLOKPE'DH$?2K=7Y]I6SP_;MR+F4+_NEMT>PM_^KMV8>WWY]]]QK[M;W(0^<|&DQ3-^;^!IGT%EZS]T?@Y#\|G(G>OR2[+?[U31QLMB&?57RWIGCYZQMO3>.WG%7O?_[^/XF7@!>0_IIL-HCNVIH)5O)2UAZ+DW/-(&B5L5[EGHN($!:$|*?J;V 79'O +CE)\AY/\K[9D4 _D$*V/E,1Q_G=\L:NP9)[&"=E@ M>A[?8^HQW8-6>+%|(@D*:YTZDJ-' !R2|=Q+@A>AP)B 7T7\7/: 8TQ?|4* M^>8>7Q-ZA;QU%3^FTU>$+P0^'!=_WOD\9+I=].A(V$%!LJ4D9*3LQF!46PM\TUV*&4G4H]C\$1N?+8$V/&57ZP/%T+_HM5N>E D_!RAE"T0[+/-Y)HOC_(^_MOF![BU@L_1/.:E(7Y)]3,$3/) >% ;](&);GE#*.9J>QMC2Q&!F*/:]DSB5^M3A;/8;#/J)A:MYH!"#-;TYR=,-[<$17>(7*6;C_3B(0'68'0P!T7;+= 0*PR=V^XB1)T[R72L^KL<7$D,DVZ('7=#8W-H3-)DBRIYN(;\7[94F9BB4#2(KUZ],/6Q?TW)ANT17AIF!]FE:,^V4]FP;>GH M!$9;9@AZ%QRQ%A2&"*(^5P;"9^;\-8@OR08%;.DO41HF\9N.@FXP@0$>2Q0_*

*M"Q*D\=L50ML,$8S]S;NK5T;\F&OU]RC=Y";AVR V 9V/'A?NKT=S<)S>808B M_X9/F*$I4.13UR!'U"N S_\|Y ..-^@[G%*RY?^(.=_A&"_?Y>W??0F8?GH;*
*ML9,.^8*I&?2'(A)26H[')WR;?V"0G_WT]NSL[0?AD/P_#N6XKL7)8Z^-V!W3-8*)>^HS?EF3H$5SIZ!6@F8 $49 IINCWVKR8 MJR^V610S"^1?_RA^*
*G^.$LOM:,7B(MGG'XZQOYCTF0<$0/?WPW/O#Y.V*TNL5L6WT(5NMDL?P<9T^Q![@8MTCC,3X&+<7)9;KLHE.XTHF4'L4-*
*N#^\NL/N(L(;.&D=*8C4"VV67C MS6Q+ T*#9/?KF_=O9H2R;>G7-V=.!*'PD;H/N5]YW5'J0 Y,FN:TTC>%)@46 MB.F%0#^0@0Q|<*,.Q!-[Y@Q%(NZ4RT*
^8+Y1VYQ(#6WMV=_$P(8)#PC?AT@= MB\.!-#R160-4.[3CCCGNC"'&$$VRL)]@49U]6G WV^\KE=@!;]]BE <+:WZ'$A9 M0Q][S(_M(/R;_?
*&2!RD(TS06YZ+R>5NYS[3MGB-JW|WKZC)C VD#V]C+2XL' M7U#V\.O6U]_?22Z)W2^//=C^>EK],4TJ*Y]|VJ]ZN%?EH%GWRY&UZ#?D#4-*
*E7U[!FKS#%1 MY%&12+!!RYP|VI9P<)3*MU%;/9[NY=R$5<0.UZK(:X;GDM\P+"3I+X'DMJUD M5XDO/)9_H[8YM1K:.L#T*
!"I[&O;Y)@IVKB3=3.V$#/LJE*N'9C+N6) UX>1 M>;H1[@HO^&]YQ%YRC]EUQ5\LS_T,*-G9W*)+<58WZ@($9:FTVW4R1-O]>K#B
*M)6E)AMKYW6!"OEQ,)X*T/_#L$PS"?;R>9/%HV^3T4K1Q8?FMQ!ZRH^D=X0XD MQ3=5=]U/-4M+\1#1'%" M4\6R43?*
*(:21KX!P1I1FHJ9D4*1A&'@TGB#%B58D^'I"+LWH@2')[2Z)5@NF& M0\M7ID1R=4UR:LB; $!'*KOZ1@J4W,NME@_$$*VJW,H&Y)*K&LCU2;^\H3QZ*
*MF.T- ='=6F5M#F^K]39C89%/^CF*M]@3F8.E4MK8KL!&W0[+57*!F*.G?2& M6AV4"ZQF_-";9?S\FA-+3K^27*I3N3ZW'1"0ZJ*NR5'85*
*M3R_5+I!VYP<<\HA+'F2^]YZ +W;57V3B9=VQ?*8S[^B8((KG254#"8+N]60+ M/A$#)&N2;CQ%]@IY/#2D%?$;T_/<@>B!02F1>]7/.5V.?*
W;.@E2&U0TD:+B7 M827-B0$[54D]'(C+HVP 2/(XI]@/DFOD"?\9F:U9V: PL4H:.$=$;D'6-)$B MXUXV-
*=0G1@C5++]'@PD[KW002#)Z_@517W&YE_Y6V"_KO[EXK^1QID=AP55# MX<5NWR8/C!=@[V&/?.[0KS1D#3E%<4,;9 IWBTHN,V046M9".*IPB'O@(/-*
 # M6LJ/Z7,<^ &B.YXC:|1(S.#-+4K1%/=S@5V>Q@X Q;+RGE5OGB-.Q3X&G1P M:#5IY!II@7/-A**:02P?@Y$A+89* OU**OEKBO](<>3)#F,6/7+B&?*
*5PB;L, M*NE:L>QAB+NNA[O58L-,T@;_ZL(QF(PO(:-)@*XA$>0FLNWI5XZ\W?%Z.6SG M$<3H]C@?Z,4!HHJ*?FD--*
,TA;7N?!L0B5L@5&8V^ MBO5>AZNVRGN'!ZAJ/_\KP!3QMGU[A:_X%"O)PPZ'2L-;2<@^VQ\#*3QCMO8 M5[/W:OJ"6,*
*F#%=LQ*9D42Q1SS1ZK;'2T[6UB6FE5C& MUIJUCI-^=0X]WR'%AYL/A!;0B!X9G^H*A7$,9$U/# <<)-U2KSHG#8%2-2@C M@HX;.$C:8=Y*
*B*N_@,OY)R2?2 MEZ[-/AT%G(4_.0D"3]/GT. M^]SD]_I?1$^2>"]0=,BYE/;%!":2D](\PX-*,/PD#3B'6F!=BT 5C.)"(0U M&!S4VE"EO;K8*;8%BQY-&*
<6]/2#AKEXQYCV:< >R9BR8I\7NPL<>>L-HK+7.=/F99Z0IN8DM &62$$/N$6NTZWE"]-,(WY/&X8&O$L4.8]!2O3:
<[BA'\"AW$H.6*AQA[!PF M3)(M :.=0C.X5/ AQ:E\0O\F-,M0A:G,4*=ND%-"UF DX+.7_QH 4O%M;)>C MHFGG3G0U#"#F]%7E]7A$+]::D2
*IYB(YHR@R(TIEE0GB@FCU@#T<"#L7=QDO M_E;Y$_8P5.%^V&DH)\$)53 4X0G])F6 @]R)0V^_/CA*C%"O.?=UF##8+9)!- M!VG556L6:O)0-*
*37+::=N!@0UZ7IH;JA!S_W:;.0-L4"O*OV]@;EDZP;$)-\+ M <9-Y.-743T^CE.V-699A++_2J3=KE-9M\"L$S B*'<)NTX&1("QDUCREK0D M1'4=F4V9E8*
*PFPK2"CN/DL#/*WH]\M=)87&N%?,BFVV:Y,6\KA"-V-Y9%O"Z MV,D'D!WKAI^I./4-.1,8'BG#44R;:ZD%)$QD!)DAUA2KG3&'@U D-&J$#)(R*
*M4<0)FP>7FT>3@P@?;XHM,6JKQ/|&C1A%;#U2"V7!9,#CR6I CZDCUW2GXJ MWO9J/SD$6_Y6J0ND@O-.**4O:0"_]I8&4*
|'XX4P!=C[[L5>7GGXR#C%?MC MSR+VX5^W>(7"[8-2.\ZBE^+!%2'OPX.;3:9/%6NY*UGI 4%H_D$W%%R=6+VH.OH54E"E3:"@9>\M#/IG9JW-S+:A-;*
MB#E^A]&=DF%%;=Z.$A2?>[_.\T<"^-K0N_PE]P.S(I=]Y1$[$\O3Q_JN:.V MZ5O-'%X1VS%,V*$;^VF9S,/7R_R|>$NE?F:*
*MYSBXB:IX!9$7;$/I*UV;OM*ETMC7A0^&&B;INC%N7_AC-+>'LJ),64OLJ:!> M7@V3"O^-YLD@K;4K2AE:A%*J]P*
*MN5G5O(=4S2EZN%OF@XH+:4.PJCX8 CIA436! MRK7[5P4-J?%4^FMI2#SX=7R8%<90Q>_'<+M?&RH2DV8\ZL;-VC"90?.HNVMI M*Y,B?*
*\1D1=%V'7A(%IC?V.XP.?9QN[$PP]O#^>46@*9V!4;]=@ 29"0O9 % MTT6FF8M=YDNL2 #18H1_G1W0M.48LB.TAT_Y.-9RE#;T4HW3M7AY.S:33C!W*
MK&JN4A'"'[H5DKS2>0?D %60>L ^W@@RYUIXF:T+EK_CZQDI)4S<'@:AVB:F: M6R#;WU)JI#LQ@V/T):,"O+I,= "[/J3R2!P4:HL>-K36':94[5UA.%]-
*_87_%WPAP'*PB57B^OK%2BM3-02"]73:]YA;(IK=<&NE.S. 8 M?9&H *\N#QW ;G-7I'$0X3@^]_Y(@SAH6!N*UDIYT;0'@BO_DV+][M+8SPK_*
MHYY=%TXS4X@E1,O(24*U35D!+IC,W..6Z='7\M1-+9:ZW'@TW0G)TK[XGCOYBR< -7@(_E7KT*=L=B:>VI2N,*
*M_A$D:Q$@SAV$U\'VB6CB3UN,8$:%YC':+DX3]I#64(VV[#1H\(75$GRG^^TM M1G%YWV3@/F&ZT6RLJN;*74#7 0BZVAU1W<$*Y?[V-*
P,_$%-81M^OU,!7-R8] MT&YMDB&))3$/U*2;L7F&"P#9;I"PUY]\IS/U@TT%L8F_JUH4./MD9C)A%+ MR,:W.3:A4C,[F]*
P/6H=.:OYGSD45&^'V2D99AX(>$5]MC)MX96S(8(4Y^; MCU@;PH,L4^POMCA+FJV_2HXQ>8.WT!C3N]8D37 V7EY;CF:F=>S&Z\>/:T2A M4ZDT.
[0=N8T-3R>EOK2CCU,M^H1>YO0SBLP1I;LEH5\0U;E2]NK?:IT/:!@*
*MW*A&&GK98=^O6C!A";&":/05]T&AYOO5#+K3Q<0K8XH5_H2]=13\D>H\LN2- ME8*D;@X"4>WB436W0+;_Y=)(=V(&Q^B+1 5X=87H*
*':Z-.Y(1(OJI/LZ@E!I]^9S!(:Y>*KHLEXOTM&2->$'-X1E\Z.@2]RZ<)(,E]/=W!Q2]91_% M#_6O-=%),P\'F6V/+7>+$4 M_G9K$C)XXDLVF1?*
LR2"8B5\3S,;P#XCS|||_?'C__]_OW_>[@/AV=_EA+/]_MC/LF\8PL9]5)_^=L/^TFC.(:8B7OV%S?"R(]HQB_*<1P'-_ = O0G7N)$Y79[
MT.B=&Q"S)/KEPV/>_OOEPI#'&9=,!?%K]K6@[#%LJFC"?QY G.GFKLDB!#1S6,- V)!)Z M29]X3M-N()8($KW=Y)/H^:$5K"H?).##X<'>H'/ O\FFJ-*
MD!0RX^&/F/R MYD-'WC2@ HA/GI=N4I%O?I&P@P?'C>(UUR#<#9G;S/0\,^|_)O^^[\H_<[3@ M\/(!)PP=[!<%-*
[2,4S4>DTM_[<@E%0YP6,+S1P=^@.CN$7%G#Z&M=0VBR$]--Q4QL.@(YS34)7(U/!FAU89BWIK'@PON?OW\OM.,&_^==Y\@G1WW&R6"XQOU1+92V)8!CFKDL<8IKL1F Q/?I17WOX!$0)!"I=P-///:QVQQW;4PV M_=3W6]JC G['$YI>PS7[ID 7F0Q'TR/-B?
$TSP37FJFR_@[M:P-P58:A(XU9 M@.+AD,>A8/\W=E@2N5,SZZ X+-GH4M,!'5KFVG"T#Y0=L3C7(;UQV' \AV:_ MOAELB+'3)?R$7G',?8U$
@GL/Y$[G(B?'G&29 \N'1=UFRD9MB.!R MX0\]%ZUG<&A]&D0Y.)6/NO"/A&%YZ) YODPZ^\#S@B&LZ3K."/) _;(*F.K MH([2W7/H:*
<<4LY^[6#2')P4<:=.MHSO\1?S2YAY8Z3OJ)?#]4;L"D+@N9=M MCBW9=]09N&GZ"$WC.Q](EAHIGSU6_+||=0(O%JEB=+PA]CZEWIKM03R=?*
*PL=K1EK5*9W]Z&R1Q \MS,5I<2@E5+7C09< MRS?*O;'6UQ$!CE14=%EYBV'W&IZ4DCL,,IRN"947_VC>!>Q'"%4Z.OGN=4(3*
*M#O\S6>%P.W&^/;#05 ' 2P!HY]"EG3 8Y(}$+?N((D'8]C8#@I1,"LZZ@L M[^0<:H9/(^O^_LY%&I_N%6RH@YBM?7(?FRQZPY&\0/[;)!|*EFQ5Q3"HAO,&]P?>]'*
*M*6IPBAJ9#M M8,ZH1L-@L5TG:Q1N2$A6NVNF4+UU$,NSPIAW [7=Y3X<@$N!:3_T3Z69'#3 5@S?8C'\.0!XZD7>(MQ5Z0 MU3ABI_D-*
*H4GPI^X]2]L#@%X8/72,5R'HNM@S]$*BXP M-YLM"FCF&WU84I:)UUP<]E?LYRP@/%BMD_@V0,]!>)R=]8\! 60+&IKE?9) MSD+_R*
*@;!%=O7*HTR!>9YA=XF?5 <"@'X"L16,M?P-]P&(YAW419;9^ M)K^8XIC1A%'AW]A3NJ2:= 20[6A,IC>1 P[7;Z(71A%"=_]@\.!+|D5=E?ZX M(8"|-F-*
*Q588^'"X*QH)1H5[2FERT/D4F?4'D!!E+)Y;4 6.*# :4%ZZ^1)G M_U:PSMWF&^[P-@, .-?UTE6,_)&GZ0 MF5?L,8$%\VI] -RL^V9>#3_(S+NGF-W]_*M7?*
LU7.3\V=P.@4?MFX2&)\#% M2[S$E.("9G9U%V>![")OR]N&P0# /BD.7@W/-(RLZ7]VC'-XXGBGSS M-2WO#. *W#>?*
*Y8@.;MR4P4%3[#_@9W8@CZ|QYL:V!QQC^G+(M58C +CGMF-= M*VPAK\OZE2S'G%T!S.\RR@$ 7&S[7I]J9)VM4!4"%U>:O|9K-U6@T+(_-*
)NJ%0G@2(FY::S0O>(8W,_IB<;L'SFE_7 MXSZ<^+0# ;@D=W+BTR(A|<,;]C/]YFF/.W+*:'/]$DY< MEEGH%#_V/_(2 M[KIEW6(< &;(|A)^X!)HBSM<*
5@LSU]0$'* >90]JL*M<0]P'P: (7,8]C>C M#I/[EX% FPDN0^$BC9G2XUX-!@Q7]@2@Q/OGL1);.&SE&(MTG!3['.1:DX% M.[4]X)[#+-*
*FHQ7+H^_(]VHGW:*84/@4A YM$F=_@;>!QV^DUEAJRC+H!,#QV MXY Y]G!660'N$\EERN:|9-87@%6R)P5]AB\|YC)9K"I_<4F7X-[9N-1 %@H*
*M^V6X,>9P6&],@,[W71!6SGX8;H,T>%Y?!Q&*O!YL'-J!)RK.MDXM,C!X7%5 M_Q1)9+4>[KH.<*T6!C*KNM(<(CGX4;@R]P-*
*^P5&*B\R>YY$O;"@KBH5<'C_\ MM1H!KK7!D&VML(:^!BN%NZV68JT?7"-#+RNRABM,AMH463;H!V!;]) ^AX&LH M'P&K2UNM:@S7#M&5=>*
R3A<7K)[23;\#;'0GO"/6X& MU_!@R<5CU.!PIZI5@828121H&F@?(U&@6MCZ*"5C3"'PWIS G0V,(!PF>]'*
MX39(P^$U!YG_GY>L>V&7,K&G,"0#CVTKX@U*N.)6OJBTS&I?'/N,Y7GV15TMEUAID!H;" !'/S-CUMB$^4KD<@@Q W%X'$%JH D!CVR^(Y'' M_MS;YR-?HE;W.5H;I-_=AP5P C47A6ZHPI&&2NFE,P5GZTT V+_]DF!%":JS M$4(G]7LLEL*VT%2'D=WD29W)/DG3GC=&YGAVI@K (MWGXRR0W[44C)[P'.L*
M4%CQWG^]1>HWU(YA4O+3^^]G;V?],=F'X[!?,1^<9YBL0M><+%_9'$8V?+5D MJ5E2Q:(WQBCVHJIDZ&;] !P7FN2I MW%W,,!]
!0U/N6H>&'8$BK=G<_$>09+GA)WQ:!((MM\Z(:[']F!S\XO[%+,#FCLE)=BUNW'L^]^T-3 :#$*@$=C8TZTP0_0EGQT M.=;NR+<*
*RBXTP*_>B/,CE&X//H%]#(_>&OLICTR:(TIW[-8E58=&KR)<;]TKS;;D.PP.T_3EX 7&Y0Y:IV' @SV M%UOKV".K*/@3^]F3+C[_SO7N"^/(SXX#&UM5I.*
!FWR$72WEV[$0D.(JE'X7: M9!?]?19G]J2!Z"6_4O:ZVWTUE]R>]&)LN.A]/@ 6KE,48^>WL 5=H2BOV\=? MI]+-!M'=8OD8,&"7@8?8+I+E3 ZBU3T)
X\;@RJ=+G&"@M#XQO;7]V?OSPYO M;-7Q9BCR9SD8,[<50"9[2&9%: <]OZ/')X3N.05R98J:7O8)E]Y9'9 ,QUF M]/RK9(-+#\0+%')/I\SE@0%L5^];*
*<^<::'.!ETDZH#O*Z MCD(TMT]_WY9L2[@A'OD9U6@8++;K9(W"#0G):G?- MKE7>.HBQYE7?I!N BV-'B=^_\IO@.P![_LD4VH;N;C:;-#+E37,? ,?5OAC3*
*MC*S; W"=$J49'@\!/'O%[L+S.!CY[O?-5MX<[?Q-U\%(_O8?)O1!<;$ CCM M_MC<#<9&;"]C>HX=XN;6N(Y"'.?>AW=8[G39T!; YF4]=[4[NAP;8.MGU_!L*
*MI>TQONI3Y90?1O7M,87%-0Z7G<*K]@"KZW2/1U],X)C\YVFT%4@<="6.-7$TIP>%8[_]#%,?"SB>HK(E8:NHUOG)4):/L03DV8@N5@^9V*
*M$WD_&,K24$0-.0;B8%B#+_O +IK+BQT_-]V11'[_U*K1;D,"T+'&']O*C]*%?)0@"8LTW'R[Z#0;&=8[[[#,PKK,\2Y;FT0O[@4SKNSCS*
MDC'!1.XK8]>3L^!Y>B6<<^4./L"K;_]_XJ^"P"[O"V?]0C!B:NHG5?TSPT, MI3CP|P\FASZKX0*
*$0]GRN#VR0T=&M87L)KHF=+-8\BPV$9ML5X2H|P3=0;*1 MY$@;83X <5:FHC$"-0#)SMX9H(9'5@['3[VDQ(1[&5.\18'_"47I$GD\@C!: MG<%5&+PC*
M6D/M5UZT(0O32]@LT|[ML-F'0K@6-_)D)BUU';$)ZO)S4J_6]!9H3GZ6%R0&*IS;]AK5N#=9,$ M'=! M;K8'\ [G.=_H(P_(Z5I/L@-XA_-F;W1=!Y2144^R*
WB'>]C9|$M"H,->M:\ MV!TW F!+U)-. C.$+62OCT4A(I,=1="%X7ION\$H,'']<",[$AY=L|S.X[< MGE)-,3IX@M$Q__A-Z5=H]6XP$*
M8"]N(P6M<'5K3_A(25S$(_D+?MX]@+]\WC_9+Q8/I%&@<KWG5K8(3ZH[1!B MZ.)S/'O>U4+L"YAF)ZAV1XN'HHO(#OL#]Z4<>Q*
K3%BJ!H[#QOWD_?_LKDXBM77WL(7CEZM&L2A-O(> #TW^RGBEO4''&/Z@O-D@?$U MH5?(6U>MVBC!*\)SR K_]#02+W |%>X7T:.%-?NHQ.?*
*>FKV'4"2.S6"7K<6-3<$R&@U=+4#]C#P8NH M_6*45]9RM)$K?Q@"=[&K *HW&'4;$HQEO:,XU"J'=*((G.-"'3]M,4K>%(85 MJ@^9K[^ERG*
=_,"|1NR,_HR\WSGXI=K-XI,VVR0O7:$Y3]L-_,>?"0!F50CX+P40LPR*XG=_QNN8S4I09@(6 M^*;DDM(9.OS$D->+#["Q%F=4%]CN,ZXW./XXUX"2|
O=A41N;XCQ1'WDYC M53;]"<9XW+L 5.^*1]2 <_&7]9T26*T1V:@G#)NRA6!+6:G#$#8KXU*(M>Z. M9ET!&)DMQ+6)D|?X*
63EQ4[H)&MVTS_'K8'XP0^EM8]) ! KNI/OO(RV[@52T1" P7P,-NE(X%:7 M%Y=BHPH3RM9@@A>&W9U5Z#MEX1-%4;SDD0)%.@R&R&(I*
*3;FK]VQ_"?M%MSO M%$"V7;WD5_G>+_I.A>7SXT?R@FDDT%VQVT; ?3R?DT>^ O)%HMEMS;L#V'^' M6!A5L3 GAF.6/U&A^';&3%9W +!?#\]6-?]. *
RGHEE"4\!5V)"7#7T /'L/ MSS6 MQFO-&$!.7E92WVC_5,+D-?BYA@+),_,3-FR'@ .5ZVD5|I+&8*P.??!FG,? M)V?!N'T%%I$,Y]#YAS%*
*[OBA+"S>#]2]1G_$*2H)#36(4A& M!(_CLF24$-$,HK::RLV8QR]XV M!(OU/(>SB+)!:*7Q6>ARY#GQ_"D9 4IZ[!V7%2*F:0])_PPE.!KTX=3Q*[>T*
M"O+F'#;N#>GZ.9BB,"4&I-B&.8F3SPQ+% 9_8E_4,5S0K)(ACZG=G|-Y==8 M5 L60=?VL0Y';>+5L0X$)OQFSV_Z E&5"=%Z& #G MA.$MB]94@6-P;*
*(#=\])-*E*1B-I_==/4!5X2BM75*7L;&\"9Q+4(F9+]].6* M6Q2'DJN#L0$@ IP$VK<>4+I&'%Y%'0K+:W43>=^IM2M,8P,9D*
*M+$SE5J3!9WJBF9YH)M_NNEA>L:7A^]BO!+L4M%DLCW\LXRT4$MA^. BG]J'% MKCUUALZU?[/9,DBX5"Z6AR=*GN^]C* 1P#X$]_4^*
*NI0%OH8|&M^BNF#/G#L MY!I$*K>4QP0EN&CDD0U>T#G9;"E>\Z/7"|Z^O.)FU)CWOXK2C;Q&PXCSNBZ_ MTLNBK.]?*
$6AV$H(99]B&'%M[\:KW_A8>]XR) 8?[Q<6!2>YS$ GA5(2!GE/ M$,]C8M;\SYOH?,-+ERR6BB[E(E.5#Q]M]F_A\7 T8IZB]);P,YIRBF;WBFXR*
*M*1US3$G[$;RD24ETTO(S[UMXYBXDYV^G(SES8[9QN6!!TY&3/1V_;@Y_/?8 MS:&.+'>_<827^S8ARV)4?B1DGB+ M,/?"U&=;K2@YR3?*
*=E&WFVWR_U;E6C34YF.=H8Q4Z%F7^V),,[]P-*YP4@N6@8<:W+P:>X&IXV2|OS:B M!)5-YEN@O!^,S3 M8R6CK;&&=)FZ)8V]5=L#3*
*F6MM>6.CH06:-5IPU]8*A2 YDSX! (%E$NH_L'@8??/+^IMZ[@A_'].RX5: 7YH MY]M;$]V>,-WPQ%5K0A/^]WU*O36*|9QL-D&2A:,+3Q:9B<-R*
*N:WIFM$$* MSD(I #\&5LI!\VX G+W,%E$S*D,O*8W$J)>102< 7E &2|< D:$9D%>-_X2B M=(F)\.5N-'D)>;FGD7$O .Y$!BPPP604'NRRX%[DXR^25[PC6]*
[N/MAB-BZ^IV1%T<:" M;3:#CLG+G_OFI0VB(S+X 8O\5T^$W]A%LE(F;\?Q0+>;=1K4YO.^#2VI<'/E
M5E^Y>8P+B3B8C]X:^VF(%TLF)^Q2ENR8%%W]D09"ANYP8NT<^8!PN;=E7\^HSP11.Y34U@HV.F28]89CJ+>36B)55#.&P|A/R
MUFPSHC6EK:\MH>L!P+)O(9RUNA$ZM.#PBV]]:8*I&:^4K0$8@EOR28D2'!Y= MIY31E!U<>&VPX)7_I7\BTW4 8
MNR2D=5G"8=8O906]-0O]FLZ7DQ2#5F;8' M &MQ2W9IT0+(+Q&7UIYYC=T!V(^[DA|A;_"[
M3OP17(F>V"1XA1DL)%;DYU@L/\=9$&J6]+R2&/T2;RGVLL+6W.,_^]^:@2X$R MRLR0SU5: 1R%.G!>'5NBZT((8]>[4%Q"-'[=H1NR:X[3B3/9F+

MUGZ.&4D2<_N1M9UDP1;=)K,;>[P$^%[%%Z[6V;HC]-,^CNTZQ7W87]:2"[MD4;2D<.MHHHX64=NY$*WR=SI,O)CRJ8]<71RG|)P|S3.HI3N3^-[UU=O: [MFY'6==]K[0+9%]CA M[2(=|*VI [Y=E@.^G794/GR*P3C@[*I.[8"G|,\;^A!_BKJL4&NY$.<[U][1*

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

M;N7VY@5)?"_|!7M47[JQI2E<]^K2KTS,U;2#Z62=T@Y.EVP3YIV*?4MX3IB(.VLF*,S%2=W M-%FYUXN,RK3VRDV7O(HN&3)R9/G[:1G MX#!-BD|J%\D_^)NXZ,PEN-E-KDB$+]F?APN;UH8+<:@NXCJ61<_"Z0)#31TCS^-,D M2KGSG7S'WUE]5.CCG#] MMI_X@X81|ST&"")-JBC0WA.F>[N$/J4)UA1A= MMQXYC8Z|F]&5-4TPD/N6/0/-!$NJ?K"UX+M^*?_*UZ,/0>TQ?BX93]1+!8 M3*H4:G:U(?UANM|@2W"7[-W9K9L&>;Z#>#IH["]JX6B9/RW&C][2Z@7;).>+ MO(*QX@#(EZR_F\+)FS!L?],HC_D6W%#)#E7\G,"= W/?=SA*VH(DHXUPW:6GUF5 U-T%>!C4M0X&AXS-G@6H\W,0WSK3-F:@+96;4?*ORL+$\ ':JY&003>X 5(?XT,_CF<+{X]4+CY(CQ M:W[.#H 'W=)XAVFZOV5ZI PY^.GPCL_M^CV

CBZP_$]O$NVB.#II5F\F;TN9"N0QQ#(&8(!R&?EAQJL]O8_CX!,)]88Q MZ@K='\WUKSMH=S_('MM#^N&#O&!2+B2O^=%7R0D5K"8Y!C-P['F-X.5&.)Y7MYPGR9]%7QOY&6L^";|IN06<|H6L+&|%:-50AJ[$A7(QJ%W?<5D^)1Y.&%BW[MV7,H67]>VPA#:M>Z\0#>Q^HZ'&]9P?6B

_FL7BN;V@.IMI7[CNV%N#H<-=851N8]5[MUY?PG*FOLOH#.L,;XA,GLZ$BF-E5V=8.BW%U@TNS^M:+<&?;-TL5TF#NT$ZH

M;J%A6+%PBVL252=66=FK6#::K]=6[3#PUZ ,\ M\[2/!B/&*N>!J&2R0AN_ M4YA#;E*FH4FQCN.B)CM9H@L8\&Q:SN1NHC%1X)!I5<6I[S+FX4&"_-!+$K(A MS"V]!-R]QOD,UW[?L9!#3:O-P4S=I(!X%W)&$]ZO]W"%#17+$XS<4,]B$.K- M28BVJV*.|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

M<<2#&ASY>O=I[P';G0RTK6]O:)O#=3<3H8)^RK.]Q*_?$UVE*R6,F7D-ZB/F\SX1G)F52/%VRA2G[,;KN M(UIGAL;IK%I_6EKFQS@(M!$>@Y.+A,BK%!5C2B7 JEBH#1&=4%0(8GKRYC M[%F_81W(&]9N'D1E !U'0I[6MT^/F\&&(IU>A[&)V@8N'&@E'3,O\Q1\3G$EMGR-EWITD&0ZH,^_FG;\2G/ZSXE:P=]E/R@L.] MDT!H'00B2]\+;ST27$:GWHZP597FA]*WAHT''5K6TE6;F\)%ARZ!!^=OEG01 M)|S?!\U)NTE4G5Y-7M+^A*GI-ZHY5PYYMLU$IKS8&61 M]X&4<)@P@6M,1; M?!4GO![AS>;!^ZRS56\]P-UWF%4.LM#[D #L[@,5&9'&7?#+-ZMK')%DB5YQ

MIM_*LJ7Q!C'.KM+9G5DG3_6N62=DS-P\H)QZ),+!N4- 8TZ MPD8+<]WK[RQW]8*+"3UD'SK0"Q:HX(%>]6,_9^.F.O$,Z]NZ!NY*HAUO9!CO M>(!W6[UN[5N <-VR1=:Q6W&'&V^WWE1'Y#M,21R<1T&_#;;QFHJE-GHGD^8G M.1N1]MVG'DUG5NX=?B)1-+5^G8>Q$V@FSV23IAU.B*5DNT^I==U@@ZFIWGU* MQL(%6F/)[9:(=9U ,8VN1UD50F,P'GW+R&!*L52=S7LWE"$XB\O$SO$MIO=|

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

MCQOBG0:G[4,&O%\/4F:DA\CBI 57)*JZ%WS5:AH%:V>WYES8B%\4D)*ODPJ< M1?W1|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|ETA2*^SX>\7MQBOJQ]\S#/2_!#R6CO!1CPST2T!7IT' MAS[.Q2'43:N]6# PM0-&C,4Q*@=G\ 9%X_D>U%6#8[D:;%\X=7:"#6)F.A\] MKJOM1>^#.4>O)TA"K>K],M]C9R%FR!E%K5)KFF^^OI6A"7N[G-P7"GR$$F4 M,:5ORBV8=W@3T[R*_X/W&2<,V:@7TX{*.*ED6.@-5S/M|LPWF-9@/*6_3#/3*-;9HPNP=IG69(.6H*W4%HE,IE8R7]3J22T.G8P5FG(9VP90 %>VSUK+%D:Y M+@&K1)CEH>Z#]_FO+,+C5[Z802]B*]SY[O#$H3MF'4 1-FY9L)9FO=>7'%S\ ML]&4C7+6C2=^9U@Y\6-2(44L=/,8DB?/^MG?H.7>[*;KEV@QL+S8^/!*("5? M_S)+C,.I@:1@]08^]2B]@%TX$+2*&TFPR(IE40@'8P(LP2OD'%U=Z23]X&Y8S034N2+)!KSBC;UGZ] M7;.V=H'MZ2;ZUO=G].WA>K:1U,-W6G+B?-AR|DC01[\6')R\RRQ]MI3MG1?R

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||GF&4[F\V'SSZ&T[Y^=|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|YZ!.K$ MFXWKI8B2."=RVAI.KVB13,JL'%IH%5TJQH#$G!1;:@B=I8(K]3N'&0^G MSC_[XE7Q.Q;-GF\V6)NK.KL0L*'+S6]R6)9@/@G@0J@C.XRI)K"20*S(L4*5

MB$@V\>2#0.]'|1Y2=M10S']%2@U0H0+B.B"IA!-<7]COQ.>&5X%2'KQZEL$7 MO\]Q-0CY?E'Q@_'O%S=;3/';?=E8;AV:OU"D!0.<4X"?3+L\CUKW R&8SP2T MD)!&P$L3UG4#G!KS/=CMY?LT@+2CIBX-%\T,BS8BG M"./@C<:,!TU@0TR3/BI/0I'4):G-?#UE$GVN"\|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|%U@1ZR#QW?!8L5$DSDN5C!QO5::$8[]'-PP:YNC!7/0W.[-WW)("]Z M(NPG*3?ZW\=Q\(F$8<_- Z#Z48*/"".LT;S<;DX&+&V.4L;.A4'!5#X *QE!0 MQ;652GO(3?<#DP& F[7OTPRK9XD]4<: P%+ O=06S9C2U7L)4&*L@YU,'<&L M=F@,#C9<6\3)? @!_N_J:>4Y&*0N*^F)#C^ZPD:&O'6H+=|. ^<%&:#E]_B MJ?2*$T1 F,T8*AQ(PRB|5MQ*)[D,KN_G^O%31'['P67_JQML" [RP,IG]RG* M_E7+4%KS$C'KH"|^GY!WY=_PVH9>O M9'/Y74#L!>%7'J_(BS#?913@3?7)T2*V,'1RZ|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|Y>P\5DYZHW" MMA'D8$*R+3NI8=Q06G##N=$:#?6N@@^2G(OB,/*SG#F]N+O&(>?V.EPWQI$, M\#9'5G,!1D5X6QQX,PFW)#4IV&?6$S;$]-!>11.#;G"!HX_P0\=|M< K$RDJ M-E 080Y#U%Z)Y>4O>.W<4*A_&D>B FCFA2,WD#I7?/SQG/F)X% [LG*,UI8P8EG>'\H65+(=QZNU(ZH51L@Z3!5=E0)9S8FJQI14GYD!!PQ 5838A;",B6\RRZQH494S:=W.RX M-'?EFV;BPX\125NRK<>1@XF,MNQ41KPC: $/>VUH-M3M2E?C2!55W%"'.:%8 M\%>?Z).?9UR$><-@$%;B3X@KW)'@A"1_5 F0?RY$?'VQLG=S2DRZB8>RO MSKJ0MK=]9FDQ[?Q-("PP|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|> MR;6WQ3>;FC[:/)*VMG!'7:>&Q>#3-H0Y!KO%'3\4AR>/:/8K/_A_P4D21_K- MRJ,6,$=6BS;E-F7]:^![E!IAAXZA@MR\6Y(3*6%O_*^96Y%[H? [3)]P=!K3 MG=X9VIL#]@P#/4LW:6D+W&=,)!]^,[^D?2*)(TY]7G]RH*##S)$IM3W%D1]3 M#[W:4?Q"XBP)]^BW*/X4\1I%&E/$&(P)OG$HP&)O+ E^^2P!6"0:=:F MRC^I?0T<2C3"#]^()\G-G%,RC1+S(\%$B]#_Q%Z8/HN;'8>_C)LMO:ZM^-8. M,*'!7-?6[;T%;+P;R&QS \SU7ONLZCIY+ [=|"W[M^[Q^0W(=ISBYBKV(WQ:Y M8! 2^21ZNBNK,+7MR_^G!MNO1UJI]BKO,%)P$6&L0H-C^9R;.%\ON:"*3>+T ME,"560[^O+IE:2+!&@G>:*TQE_73AAXH9&JB=WO%7/O6IX5'DH2-15;LI8+2 M&'IPDG,?.I=9*0 M)&51)F:.?H?3C&I>=NW;%["W]+5 Z4BF'8'[6&\UQB78;S!_-\2/3]A4QLN< MY]P$U%/);UX'G5G_"Z'_J=1_7=<_Y^=|'X.I+A:=5=#==?+1HSM,*!AJ!^U> M1$M?N$NWWAJ,W0)=R0V^5; [#I]L0=7^<,KME\IU/ON)9QWV^N/EDC"! B;]E)B\5'T@$<6MK0; M4;&5\Q?KQFHUS3'&*V40[TU((=!++D7]#8JYEPLP;.8$4%;>'(4J&5 E!"JD MF/Y!S1VF) [.&?1"M=W:3\F+>!@OCV:E*1^]D+-?(1R)AV?R?T]GH_O4H^EB MK?2(GT@4Z0TU[EV&%Y+P? A>- 4'#_&]%[*UN1?@]6.24L_?.6E1S? TU8/ MO=47&;KZ)]^^F@P=#!'WWMSOZ|M%#"V: MXX-(]-,4$:A0 M9((P=!1=P$YMTW(- >EPHL!AP:J*-D)3Z5K+"U !F(]'J4(.8+%]5X4A$$8| MS2AECHD!DT#A+E'49W3)>]9P[#F_'?8%#,U]+6 2=-4Z H?8WFI8*.RVZXQ: M6!/"3](%Z]F? P9K'(%7L=E=902+DA]P*@AVZ;7+Z:;=2Y[9$]6.C$_Z0+L7L M"_0]P/(OBQ?%\FP$#M_%;?!3B@.2)I=)DN'@@D'#!%NM|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|"C^H=|H_F&)H_A0:/NC^ <8H_C=OKA#N.^1S=[8 M9R$CN4UCS9KRN,,"1G.KV$/'?"FP/'F@5U1][MDH#K74,5&>HK%3_4F/^S]A5U<'H2,[=I[N*]%S+8N, 8*68]\<3B"YAQE#+(M9&K4R@^UO'C9T0&FOYOK6KUHV=8:>/Z_F>S#3PX+ZBZ+H,?+-@^8,#"I16V7S[J"_VS8-&K:V&+*2T-YNM)0<=16:2LO#77E^.TQ8.8M M@S1/&G=;&--+T8;;_D4L?)AI/539|I%+,7.M=9@&/(V3=(4^,OI>2'YG=GO/ M%H,)BBFZBIE\+. 5S^#5EI"7T0M.TH%/'H^>>:392BOR2I5AS(VFL7=;>]@S M0J>FM?<>=8WA(G6WR*,J +"QJXS;BKJ:)QLGT_4A3AG\;0Z T.GM1P70S/W4 MO#=LK^UIA<;;DNU=X7IT7P7&3_MJ(7'V^>RPZ'OAQ4]U<SBT="OKF=OR53 MOXFSWL8TY3$&CSE$&*/#ROYD8$/"4+O4YO>>-.""Q&!-AF_JUFZLL858(<') M)J8G7 ;V6<$7<<:3H 9WUM8886[#-&@* 2=\/]MFXD&6]Y0M0JK%"5^;O,/L M-\,/WN=A1C2FO6A$Z6?!'C!C1GBQV--3O6D!J1(&"6D.5^G\=5HN$6(BN5G3 M@##F@566A&=|BV4J/#ND_67B6:,%;>!9C?"7AV?-ZKG#,R[/9'C6_8(.+',J M=GG%*0]Y',XZIE5FJ!O%T)(MW9>%3%UV: ,?7=_EX$NG!A- "B*/SFME,4&U? M.=J\)2F^(B\XN(O2I@%A*LM=ZW?[#|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|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|\.'%35ZVZ MEG$:AXQ]S$MOON UI4Q!>;2ZEB\O:KY6[G E9C>9+#*"C173V;;Y=I0M+G Q M:4)=AR=&*IR0PDH&,LJ_Y8WK]-F+4+T3CB&M98"RJ7N#26CTG$4FQN-UU MR>)C>;U+;,0E^F5E9R?8F&:FK$W;IR M'K5#H;:7ZQIA413%4_;D:SM,[+M_>KMZ_<>W F7_Z4__+AB?<7;36RXBG1: M],/K%>(>*IJ<83__](WX](<5KUJUPS['D-#).GH-S9QPU^D$GZ/+V MJK[IV|V_GNF;D.AD1V,?)XFV_*8+',K E\7@1AL>P/=S:T.T(.3$(:?68A:' M4"..F\TAJ&@T[^P$VWG,=%9=JKT'7$=#:FO=H]G3BEW,JG:>2K%!M MFX!4=O":[#"BQF_+.N(,4^S'3^Q[)MG'71P5#T+>;-YE"8G87'Q@,3L483J[M16N518/'D0->3]BZDU0DU7XB*0L[41&DHI!LF* R <(^4W1"&5,*!<6#KTR(QURO>6L9 M_X-NG94:C(@+0@'\F!V:!"COG+ (,.P6S/X.TLB+,+*OU*2IIA-A9M:B>A* M_X], ^HX8UY0&S+E@E$6:EE9&!."&A;S[05)V)3Z"_9HS^!Q, ^8 M$#*I10T"S&$,%AMRCE1W?!!:.| [E3PGE<[DV$!6[FT^E1W<%I4I *A:1?HZ% MC_Q:@HA7?A>Q!,),92[0AB>3)*76[-]<;;3G>G^'Y.XO3GCT@2F1KX][493Q MN@'L@SA(T*=GAC#%]\6'/&.:XAU3EK$3@;&?4+L=C9FHWT()F!V-H-80>H4*J6H'DBLQP,[S'YK+ABKAD)0. M"?$@1=:.#%Q:L/%*#S9N/RP MQ93[TCH*FM^KJKU3>$6\1Q(RG\/)J73-IM_))G' ,[!U&Y93KS7*P.=<^WJ. MR$_@DHBGA*4H8M;2OM97?TDSK 0JIJQYIQYXACRM&_).-:3Z EW]E59% ()1+ M-/\T \?&@T;E!).%HOHIO\K&K/&!A#A)XPCG+W,UKLSZ$E@"Z/>QO3 M*1="M"GCWTF6\YRH(U[GOU@HTFF*4-X M7&B9R&6M:R')]PMW'[A)X[N";^<1$9SJ4D+ MPF[JX%#R(JY*=2YT#;O]D<3?>OU;O3MX7]FD=3#J[L4Q,O%R]ZMA\ZEKK+H M7:$+CU#TLQ=F>J=7S!]C!UJ+=%NCRXP1DT_.'IU':<8_?DP&7O$FBMG>>O1 ME/AD)Z+PDE_+WIMA/YBXU%OSJJ7"N,/E>+'D#QYLFR"4GR*YD-] MIXJQ0G[H)0G9$+%O[6:/:Q;[%)Y>X^(:V6=4GRV1H@S7?_T2Z9GZQ8&JG9U@3@G]=%:#U?8><,-50[F'#FQ96]-8;EVI M09S+J'5BK0M]8\ [&7I0FZL@JXM[L,"^U$3V5I6;9WTT89MH1IE/VU[T,U(QZ M 8_4^NDP?"XN-W9#D8*NGC+RK(%'-IA17/ 6FYF;@KOL,G/&^#QVD<6I:\!U M4S-"R6K^(&U."]36WPZCD3.\P8QY)\5_?65?+I[P82^GEK7=\|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`Z2&:C+]S2!6N.>"*X@C%^TV)Y(R2G/7,MPMGM(G**X]P&;?J):N<'RH8 M.KAFZ,H:EG%/1N&'2"W*Q*?,0]@'[^(H2W!RZ^TY_R9;#* !&&'6J2$P;X$ M@&/A8'7& Z)V&T(^'9"S1X^2OWA;@#_X)FY][[S]O/@XNYTDPX;- /E*16&= MG"O*VTIIKM8)$|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|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|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|/N+PIA:$I% MZS^@BVV^8ME^H2]F^U?,'TEA*_L73+TG_#'!FRR\IO#9][6MC:$'=VO.BE;#4TCR+;6+CF+)A0@HEP)(1"7PLEYQU.SE9;"P. MO."SWV4U"5['$>6%)2@OT!G\/1 M'V_Q59STF("U_9?KXXV6,/7T6N=E^GNS"E-Y/>.&)#OTBC/\%IS_V[4'US=D MA(#6S3H ML.UT7)>!-1-;O>/^@$V6\"%M:L7MWB^H1%2O&JA"KE E)E+D7*FP*I;_15GC MPY3Z>7$4JOV;-DU\OFGR!<+Q!.,9^<0+[U-&D2\L3[U=0RX4 '&^:@#O)UF M1':M+%|MY'=;9 %SP0J5:]!2#Y0K8B\E]F?/]YE*G_-%Y\V,GUEJOIL-466;S R)*+Y/?C-MO\96@&%.KU6)9|=-@ -7B|"3(]3[^[^XPJ$)U*YIXQ!6IE;-'DK\SRQ*GLD[M$B<^P\P.(M.JU&0.FI%WF!9[Y;WM$>,*B8:%HB2UMCX/!B)/JD&",E<+US/JD==*HZ#%_F MT+>H, ^&-B&EJ.0L))K]|BE^^#S"1Z0KLCRI+@?WC;U?XR0O/HY2D^X8KHQ.#TD"5JZR]D]K"2[QIN:#5_#'5!->A2C2?T. MYE!JE'#P9DV8CR+Q"-WP"VB:2.D^HQO/Q_K0Z+ !S$&CUZ4,?FK? H]VFF6= M?XW/R M^-6WA!=;&$@^>:QGG>;|%LA7(1'%;H:3)";WV>U@[+&\[Z MVCSZULL:TI96CP,&]?"*/=H*^/4JC=>8IS9TOI:;5A-_'$&8X_W_;^]K>QS7MD7._YU?PVYX#>#9W$623O0@">/KEH(&>MM/M.<'FX")02W2W=F7)*\D]X_WU MET52E&2+$B518FF2+V>.W23KQ:R'Q6*Q:$]7E;KY(T9#[M':DK)MVJG\'1[F\ER_=-WP7N_<%?5=JJVASBQBN$&3S&+|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|P,B+ MA/0QGY75HE"G]|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|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|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

MIHY.F#=+IJR/VR-=WBI6).S?,#;?%LTB>NN-UQ$^QM,)XK>;_=T'Y-H^Q$P< M[Q1=6F9'4YS&:"?\B(T[9#[#EU<#X[6\7$A1$<_9 XV" <38|_H)$PNXV9,[M): <>WZ?P,&O:])V**^_9.@[:3DF,.B &$R-9%:2TMD8.+&:\#T_|4F|C ML,E9]UF0-53$8/.6+ZWP)&@N@=M^9A=;E"*,???]"$]E MM%2G:&Z)$ZP,I*MN/!J:X=UJM#$[=&JJ\Q8YZ&JR"A;') OS|*-U1S&IA%0, MZJ0ZQQ2"[8 HZ1!OI'M3GGK=)'&>>GY^\B)=3@"GZ?<,M[SH MSJ337=RU,"QNA+"E-UU=\R%CXD45:Y+9J9^^(I*),]P.EO1@4184"9!TY(@X MUU1-'P 7Y%-Y62B)(R=WAGMHY2%^HM_SW3<:?= O;!_UKKM./';,'P:?]!H; M"$[7 _X0R-0BEGU8 EN&:E5.G!^W2F'6_||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|OB]HVU?Z*?(?4S.O@E0'6/AAN1=Y@P'E] M]HEDF7 9; 7'[8K#@)/Y/+W<;%FWQU>;1#0X)9M%#\\N$2[WC3@*"^-4YX M,)2RNAYKFN)=@[L8'CI%BW%).3#YC0]M|>G:KP&-S[['EM"Y&^LT]|#_5V[MEK8X9Y^1A&]=TC5$OF1ULFWASIRDP8,0!95Y%[/)I&P2S>$SM-/)>7OW].>; MM9!S\Q^[S?-_/2"XT=?Z!HVN+4ZT,9*PY6(>!K0QV6LVLVOKRIW;IV$FEG%X M'8\)_,S',*8/.3WHLC3;>^"V00-IVWU.U1RO/9HP;=7WA.$)']^B _H,1?Q. M=,LT\|Y(LX7OQ8MH6=Q?U>;,I8E7_D-.?WD!%KY-B@D>F@\3E|>|]WR3/U M*8-G66I]@,9TXRP7*ELU8PJ9C8,L&SK;11I3]E0^N !5=%XAT843""[JZ_#' M41D_&62ZP <_.1R]&+)\CFD2G'Q9/S.CZ0WQNS0;_-V)NWR1QP!.ULMK*|^44Y>$Q M"ILCJ?:&7BY(]6?*6Z;CKML*.\MY?]0!QF3GE9$4('[[,I ML^Y1DX-.)6,JX,KZ+YNX$!H>K8=<2Y#L,?1>PRC,S^+MV" (&4N:0-6EO_)"(MT=R2OLHZN^/&0X[>MJ0;7.2EJ&Z4Q-S33I4+56 4?*]8@ R.#O'Q(3O=(M4 ;^RG*^,U?OQ:+$34P4O-<4J'@@]^(!;*6SD@T'58"OZ(UI]&/BR=D6<>26 MY;GJWD2Q<:1%1+J5GDMY6XL@*W@P3+!8Q=.^RN&FUKFF]I.G,*|92 M=*MJ?2L6X0'%6M%8]EDYM>NK)\UP+E!+4;^5J>V^1+=X*)=MH+GVF#;5DW.: M])T>W7&N5T/UH*_;K> ^+-PNKMP16JWA? !$8AJ+H)('2F3KL@D/'D:"Q+[M@ M3[2?'[ED+W#:A:ZLB()0S^MT.C29 9Q M>4$25|4F765NT?&)C\!D,/ MN3MB?6;>)E!JWU A]OX&R9F==QK;Y*5HN9X9>|&MWCHK!G(WX M"W>M=V-U;7'/T58)JU.TL2'>&=K.[M)6AE5A'LT=V.M/01_?XH#&C06]>MN MC7/F&4]I>?^]VA3Y)L* <1M%7;V85VZ%6]LG_I4LE^5]>&'$:ZZ>^!,VO*57 M9(ZZ?/;=]BJN7D\3HQ.QO.L7WZV**B7SFB1S4'+TLY>%VGAH]=P M2T&484)9 QD%*K5G6(O-:,D$]7!AV?_G84@OVJ;%.Q:[Y#/]X@6-]3;Z.N T M#W-9:QL!;>L%[6Z>1^_'3@*&N2HB B7/Y 7P0^,'+0+\XSPIR!@5S#_7F Z M57!SWEYK08@/)-QL"2:6N.%WUTH| IR^B)KJ3S2':X@9#X?$7IP_T@|&&7RB M";G"&.XETF#S0=.ME^4-SR-;&1 QN%G1E0*_4:,A!T<[L@VU'TF]")LP<%2E M"XB?"$Y(!*PH#"WX(/LD7JGA1$OJ.'?NR0'_N#EO)B*0X../+|Q2>>@QZ<:@ M>R?#K.>23<'*7=M.2W#XL$;,"CH?VC#NO%P#:'^(PZSG,@W XD,=!DN!^[<[MO"@2?+8_VW'=#/?DULE5>ZSCH@W>":OE=/!>G@U(Y/QT>>>WS1(?PY@^Y%2; M&V?:%_=$[:4!4Q!6'?%.Z7[L3^B# #'"]5FL3[T5E6[ND_3&.QYI /:V2[TX M|WQ>C*WOM+N[#\ZIW$OB,C>EHP/VO!13]H=.W9UX2EX5 CS+O*J |H*J%$(J M$([EESE|S@/[A\%Z7N%BYGR5J74B"7 %"!*$KV15(@[25.846_=+V\,N)@0_ M,-CLV?^9 %=7!\2H922K@JS6ULCQRHSWH3/TF1X9UXQ^Q@N2LDDJSX=DA5+X MXFK*DI_4Z=']\P+5M,I@8\K;-TQZ^(HZ:56-V\J?[NIFN2I73@0L(>#E>? MWHA!K+|6&A.$V[LBA[M; M=,S]F<_9Q8WS1MCO[((8UPSE+=VS]O;(ŞZMY[O5: 3,[83,*+(I)7):9 M<."&32PS XT_7EW<:/BEG=1W9*I\9UQN7]/PC9O!_2D_I50^|"$WN=DSA<.0 M "HHW8<9|QX;7D6R-"1.[+.IKUH)R1'CX8TC6Y%J\)(OB9.2^DJ^0[/UPF!% M%%EP"03A^1_Q0:$[@ ,[_A35%_X2U3&*M/U7AJ6M&JA'38: MNRX)(=H%F P,P([)G:3^CF7%I@!_C,B.W^A\ )2+Q?BNM\B;?M:<@.K+CLM MSIX;6)_6DG??$DR6;%%^V$4@LN'=>Y@,,.%]MT5:\)7"0 MA(OQV;K,1T\]/S]Y4643KS;I146G]6O&FVFTTW\4W*8Y4"NU5.!^0^ UZJ&" MC BR%_0J1E\-=95USWXKJ#I)-7Y,,JC&G(?Q&XW]D&9M-_ZTC7%:0KN,UOG? MW!+4O.[@=^CTA6%);5S-M;QY/$/74HXXG%[?G]BP3-]]7*:W5.:K6/V*:/I M!\T:[Y;TZ(;3ZOK*K0ZJ#?H@/ZSN(X&%/!M/D".IH+T:1OV^>2IKS'EW/ M(;ZD09X+F8$,871(04AW&<^PY%:#_T5&X$8|=UY1:.^ $-G-96UV*1_RW MD QXMKGH/FKO&CGR+Z84UX5U?CYE3"(0\O :QGSY>@R]US *<\;1.@VA@I%\ MG;'D5"3?/%,_>8O#O]-HSUK@^.V>KLZK"*$G9'QHHEE^8::8L$&J?"Q(A5. MB&1%O9U:,E-4 20E/TZ0"HDJ'^(/YH FZ9D9.DA>M M\QLO3<_LRU^]Z&06U=#WQ8U/O32@=:UT'?&B2S_V+:WC9R+I(/!7IA)9#LNV M%9&7BUOB$7UC7\CGG!DAL>_8Y._PG%+DA59%X;_3K[=W3 MGV_6PM?;^'D"+RPS:/D_)']/D]/;.[FE/H_8P++_L!@1SK|XZ5]IOI'/U#>= MM|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|"* *>.#4]SD M^*7COE+>O6.3GEKT0DS4GGO%2=LEPD4S,_(!P^"V^]%ZT6|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|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|_$&Q;;P@F7;08)7+'_VA 6P720+0N.O= '(,UHA/T'*(F[J==']I.|L- M? [.\!'U%%OF9!YUEN0;4UPCR9XBQ9>AJ'ESVH.(9DF M.YD@7!_SR;6\!]=ZHU9O+J1;C2W6+@QQ1-CC)=6LFI@\WX=J;AM=2%< M_8V7H(W.A*'6$C*-X9V0TM%9V$P7(CVB>+MW?T+ARQR?[I0E8K32FSU@NWO! M;O>$M;K\:KUY;<&3?ZO##7--<7=]@]D|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|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|E M[+,2ORYI<+.?[;GK;=0^Q0O-'CK9EP+)#@(-A16ZVRW2'YU)=3K3U5FO=/6,9BZ1F=QA+ZIF MRJIB/=*91, ^X3FM[."V951OD>*59%@DREGWNETDO'P8!'V7_P<1P=,]594;9'JI3M*

0^/2%GZ[Y/CH>-==A-_O_:.VKG!R2HSERO@2!(U1Y]7#?52X6QD_(_@@]IT^*1*]FA?]N8K80
MNHZQE>]7S<>SW$AX97F6;Z.7.BD7*5/^,3RPGO1JO+!$&NMT2FI(J2O9>Q7Q)0.VR6-?RFR-N_M*DAJ1*C6I+A"SQ1:4R!=6ZFNUUL]
[T"^^]!BRMM7U^_]GN)S;C,>|M96;9G_M_UA=EF&MOD_)F^?:W^+,*+P=V>S'"KPJ4+2OKM9]2BC+"?'Q+4L(&KJ?]ZQ
M7!&;KI7U):]R@=!,Q>O87_TSB=Q%N'X*_R>Q8_;S@*IR?5&1_-^=_9:TI+U_
M%9!ZC&W\RHKF#;S)W&Z,"K$'KLB"MPPBR_L2!LD28VQ[B>/Z,U*&7L0ER)DL_MLSLXWJO[=CX.C:)-5HP.$=-T4NPDY+D2_L*G^S5;@\?
#SKBT3VR=F,*+_G#M_M+E#HN9/E/)Y;WH*^-[L+,=QS-T*<7);B:F4_+CK/LJM3CSN+>7W_M,%7UH)&BCF*5Z,$1N_9?
DH2IS_@27=ZM28!)Q^#N'HNYF=M;]!DCVC%(82_M6#HPZ7K7HMNR\!_(ERE.#6BTT7B&%XJIR76FD]F'(2MW:>+6@4<$-65*TV&@
MRQ')Z[V!F*#>|C.T_A2BI>4Z7RT_F5IVG)"WY;?O2Q(QO/HEOF2M8>B]IIR:
M'L:S=@N:'@=0X=9IM&_+0:_!]2*X"|*2L&FRW+V45X_,Y0$S71_T=,8+*5'P9M@_M*2_V'#F)AR933/LE"N,U'A2W_TY<.B0>4:S\C.EL/T[+SB/A;:26GT?
Y]T?!_M=)3W8&3YSFC3A[^.<"_@/W,JPIO12ISR3K92N^?2?4X\X6[&16+PWD/)5H_3J"X"(!];,0$1OK02_MUX3&@[J*4Z"_0'B(%/AJ8_D7WR'&':%LLPGXY-
/'3_!U*9D_M19DAIK-Y0/BX-_||YWZQ#(.51_9'3HWA:EI5:,Y55/>]IF%PZ^M=4/T_2%_'_M_>8U%9!-^_H/_!TU<$9KBVSJ[\0$_%
<+#*'"WH"N@38PH=)S&3Z+4H#;U^A_M:8!72=M.%DEJ94%8?-M-Z>_[EXL@C-T_>2E]6O@R-_+79)P"=0UC-[!_0?50_M[(+U'WQO&;6FL_Q%RG0?S_L,?K-
<+7<\C.5;?C>H)ZWBV_M'T"9?S4X^IH7J1]_C_L0W#QE(C_]2'Y(IY,56@4JJGS??+4%GY8CZ*OK:6+S_ONG\C)_M/25>@FG|
RN"G=F&7VFPE*DAMM&YIOT7]'(YW1FLJ9$1?E#T:2*_WLB#W3]Y_MV)6_WB.'O5PM'*/>]HNC|)-#?M.@6KDKX]YUX.$>!R08R0I=AB'64.J_D>4M
M8ORY\$HHDC,#ZOI0>7#BL?FIVRSP.@R'1K'ILR'(>_Q=" QJB0<5&_:._V4_M3?H"\$)@5!W%*M&#(_9@"_(K_"]P6G$((2"6#DQZ;X$\L-0^$,C8$:M@:-
Q!UR23"M-\04WC5C.WF!()*IQYWKAGKHM'U_M]17]"!LZ$6%+W/_M"Z1ANR&ZE];Y"6A\[&S?9AS4/N4'*4"P[!(=N\[:,H&YO8]V_)\"0+GA^MY
M3#.*6C/0"-;!_*8%LF$Y>_A(]D$>.2ATO<2"08J*"7]S$!/.2N*]'V2]#Y.N_M0/LP#G5J3)]"]) M,'Q198#W9BT>,--,H:8O$-_R78@$FU<<",
MU(>7T10&QJ="DKS#WCE3WP7AK67/)\,[7.$EL6V$R#[CSHULR_LGLD+%R;'> M-PZ8G.WAV4JFA-8C0MAVF&!X?(?FD<@2TSRXUIOKX14&1341)!H
0=0EEH1S0JRDG3+9.+_ZGHHBO'(?\IRE7"I)-/_4.A26]9A_MV4LS/)Z#M>6Q9QQ!Z?YRHHY@P[*-X].MNZ*;0N&Z(U.E_U10EDZ3"=-PJN&4
MVNLG$I?"=I?9KC85<,W99\C4ZZ_2FXD(RLK8>";@1X%L(I2>"_B5^DN,!O(9_M,/IR35._C861,B\#OW9)I8C_G?5#"!5L;^:;BBC_?-:N\,_^-R#B$]0;EI1T
M_YIZIL[HUMB/7"=S3Q4L%\T;[")^)#,D.*E&HKK.&]-HB.>U^ZLSTVOB\(2F:_MKIRAA4OR3@R?=#$MR/R(1TG):8'O>"
M6D,B4!U109E&Z]A!F/.+2M4AL*"QO,_RDM+]PTOB.R1)?"'[PE^-1-6&P)1&_MLNKR_@3$$F5^'
8SE#G1V*C*]0@V=_*YM/^=N!%U%"37S]1/,/U)2QZ0\Z/C_MW7-/X8O4I:/PS>Y2@3#OJO?1*7I1,HXR2G7_:#V"\?9-[:8OV[Y&5^O"3W+!_M_N2:*0^?
SYV9RY2ULS]':!&]SZ&S*L3FA!QBE(9'"*U:99]M9:0?&B?(/T$_M#\XCK_>-)RH*E:.#6%QX$7)>DG!]V6A"7'6#V1H?O']AAT%A%NZ#;L7:V3F)
MJDG:=;2;CW!VJC&QN]>IH:6J0S_@M4U:_T13OD4H5Y6"F\):BMH+5=4\J_MG7K<6;3KHM'U\MU9L+I!LZ$6%+T/5M=" /[N66-H[U0'A3['@&LIO'[W?
*FC_M6"5ZP-QK##N_@7&=PR55E++E#%,^LRY5]SV9%IX+|Y9MBK+0F.)H<5*7G9-_M=]Z=L&$_K(!5'4F_.^DHM@*-0?
*]W]>)#M'A'9GZ;"TDSNGGSQ](]O*01&G$2@&/#O!!,6^6G^U_A6$]/#_MV>@]M_"-5X:VOTT1,?"2&@RIMN(+;ZH46X%&KJ8L4.*5-"#P]LN3)'YP;>1'
M*/H=;_8>@Q5QL8_N_2AVXR1&U<=Y:P)$EWOFDVX_MACT(DMKPJD"C2WN.@WP(N@[EH-=DS+_/*ST*E#$7*S0'C5_*1!!8B9M"_>IM
M)6/1JBOP/8G]N2!QNU=8*T&X?DI">VY%B(3LF3P$4339A/^6F2;E6QL0*TT@_>I):?-)LF#$H0$H[]-7<4[#_MN9#5](#(91024$]2];/LF[^T7-
T<2QOJ8)@,(*!B!NKGEV9FE2$\[CQ[:H>_<_MJH1B6_E&4@]WLA6XPZBG\6H2C,_6R^8*38,0;6*2H.CV/0XMC(+K6^&;JH'F_M.O!C+!?
NVNS>Q[*AB/4"W^_7!T3=KM#]0^]29^0NWI(P(F8H.D[QB2]'^B59_M+H,P?D'ARK51Y=RH4'U_A-(B.JC@B_QVT$F<0I.+LKEB?48V';((97Z_M0^-
'8]DUA4TT')B;(^:3M28R1GFF&-D_FMK:/2!*-<,D-^_>P>::PO9S^YZP_M9#'$_P$P9SUH.\MTK/X[FF*9@F*_ML>#X%U>!C[L?93-_%6-
5VRBC=8+1.NTUW[3(G[,%1GC(QH?59X3'38+2DU!U_M;KU-_O9269_&02(^"]=)%..#$LM/7N,7!D3(MM#)Z0KZO]$BS.]C0MQ>)M.7_M.=9"=![]%"?
&YP5#,"2R3*4G#2[\VF>:!6*JF/#TM#XAWIE')^0;CYJ%Y3+P"_M'$\AWFH_H9#^CC'9,^:_N0T^_IOE)>C9G0,)8>A-%[ZE17A:9V3;
[65#W\051=H.9E!7S1H@>?;$NO,CXUS_M=^<[*U2MB5',S,:)H6_<&;X$@?/#]5A>E?F?!T07*=%R7]NF=PM=&2*V#W4<
MDDK$Q[V8N\NG,)B%UD+1],!MJXS>&)^>+OI*#/TXY"P";:N_7RPM-US0"7#W_MG1A>LJLFSFB3D::*2HT:'!J?](.1DVHP[P_X$!6>,&YBL))"Q-
51$I)T@R&:_MXQ&)"Z2_O"5I/")2_]9/%OR'5<:_"X7+AHA8X:O6":)ZWQK#'_A1BI]'!%.G_M<[$V%%+J=)%L('D^FS:]_/6=3YU9O_-9NJL/OY7
MI5XM!OFYIM>%]_[E(D@(IJ)LK<<,[K?T=6@C0,/4W25R^=0_D,M?>2@WN/!3_MP==O*")*@5&SCVS]\L=9%R\C6)W05)5WN'EC!XE)M-'%&?GC-
07PZF1@?%$_M+0/CIANC*>[':$4Z,@JFHWB.1CZ*1Q:MS\C*.C3HU(SCUMU0_*1F/#X?GWSN_M0VK&RA!<6D0?
8L"EAOD9.V2%5M6RUR<9Z0=)#/U)&@&0146K[OVG,+#QH'W&2L4*F9,S_EHA+U@R@ZPKU>T9E:257D6G_MNG#T?B'L+]CZ\:?.[PT-+8!-
$>ES,KSNXZD#X%53_BA12AJ0/B]VJ=,<>=6>_MQWW@IZIBEN\15:05NT\7-?U:/LOM"Y-6=S.R-OR&%NM75JR^YV\'ZP$%_&_RU9X%^F1:JO5\Q_$!I'
MEQ9NB=CX*E>(M\=/L_)&$^V.0,_%,_M?3/RS5KX'<6DY@NRDY"6:V/,B/I0TNG)Z?CDHMM44\,:0K70-Y#!<8@C*HMI_M=ON^),^E-N']JJ+3==]7LH['X]-
C&,|:AS?"E+4_*O,$J)&V:VN@2+[.+5_P_MEK?5/GR,+(,CJQ[ZH+)L@!I1K2U,'ZM.2[8#W@!H[',=Q)8WK_%0_$U[-K&*_MKT(=&D_,8[*
(@3]FR$>OJ#_M_HT\#A^;8RVWD6RE4Y";;;_:&*L.5.VZ+W>/_M81]CX7F3R?]JO;-'47L?_A@]IE<6!=Q!+2Z@1DV!0^5C?+0X/B0'16-SU?#.
M%H^HC:,$_DI9+V=X/_[I8Q"T_K(NRQ*7_!T\9D[C"T27'AUE>'$,BH#M6N%]_MO&H^57O5_#1'(ROMT\C*.S6*@Y%;Z-;(W?0K?^8\Y-?-9VW/C1!>-
WY4A*]'ZI^#%96&+O1O1_%:IS$]#J4@4K5PR."$A*]W[.8#&\_M@"[M6?SY$'R$-^CW$Z'NF:Q,.;/.%O7P&Y9+:PX09TWZ'9%451C#%0]M&?H6
MH6GB/:A3UKU[DR;+B'_"B!_UG;':X6C%.[0#7Z!OOI4X&"+G*0SN@G!AO22+_MA16N)!/),LO\4,<#Z$S-_VC3BQ'NQHCV8Y1UA*0WV'9ET#X_YP#V<#D-
[OTI_M^0_YU6/@AR1\0$B"=SG_2J*81N_B>0$U;QC*G*2L0:D]GPXPF$MBNQR]JC?'_M5,FN_$7GAA6WSQ!%2/H<-;%:5*X)DE<%&F44-2E+!8ZP?29#86
](X]X_5X'_MD2",)K=./^C_T29C)ZLD;Y\98TR[)\ADJRU14@3>DR7C,ZI%^42_M/J,5\A,%L\ANS2'1AJ]-*>9(P3.LRP$>"H\H3G.A/P21PNQ57?^#:G5!&GRH
MB!>$U87/FMYZ>\_W&EI^9-D4JDO'<5.9MT;^(J;DB)K%Q'0$-#7TU0]RMPOM_MX..:ZD3P#K?IVZ[EO6
.TEPHUO8%K)NQPNP.U$'4)K%;'UYJVM!K[&OS2OHZ_M\/!7@^QB=Q,Z.<2PS=+\0,KWSI^.CG?OGZNE4N=8YZRU!O_MPFV&),:ULD*]KH)
(%+]X0D6L<7?Q*FN_Z:9NTK[CMR;0_N?&H;)L&:.+\?CLO--ELB46[--/'AT.@SKCP3X^5C4D_M_/M)M5:@<4=>A157E1I$-T_,QN+
[FV7;>|_WOCO!LB\4^#6@:5*'-G;N&&H_MT/5%_T/YM^^VA[?Q*Y2+XCMX.[]_(=EXNW^F>A(SHD8S!T_37:B_,K.Q'$,=_M=V&]%5XKDX/,4I(^TI4/@#3-
L.CZM2Z#'5^B[Q(TV"]U_/]6%+KK]T\,Q?ZO_MQ(_F[I4;1+:+?)OF68\EO$7GE#T#CRN)G:C_O_MK1]*>E.X,=5>69Z%F?
XR1X@L8)5VWZMU_H+@2Q@DRP@WX26.Z\](F<"/73]!_MSO;)"S<<6AL?A\;;SLP;'<*M:2OMQ=V6NB_>4Q_M0H3L7V;!ZE<'N>F-9PJN0G]_6%.S%-
@[OXTGX@L(5/B)6S+*L8E"TV=E4JP0.QV:F]W)53N$$_MBJS+4>74RBT+1?5*&JA4G*1L[=V_ON+FEI9'[.]L676O$$'"%2"*[.\W*2=;U
M5,NZ=\)KRJL[!FS:[ZBQ\C5LHAX$X11T?@(:U3K;C1H'U8!GAG8#_M1NFM#_V+57F1MU<*&HN,*W/W,D\.$5#/?*2>T.4>1X\)F;$GTV^^D]Z?D_BV
MR,:-N;EW2\6B1_DD7)NPF1V;>&"CA4C,8$T?*,.]DGG:0DI[9I/(TZCX]-_MDO<)A39AP_RO*L_!VO+B|<3'1Y47RU/A)[>9#PKJ@C\0I&F@32@!M]2SQ-
WX#<_MOI/70Q&Z0P@/TJ*<#,_/N^RWQBSOGWP7AK67/4S246:?<_M]_<7S<'8N_/L1O[-U%Y8!;#2T"H=J=/?+-R/)/KJ8CCBP$?-2*OC:Q\|:A79_MC-J?^D?
M&MN;9NS6],&R&DX/VX#4"K@9QS]#YG@F_^6"7!X\6:YS'13?,V.<_M5_0RJ8]NLG4/G7F-<,I(=_ZH!Z%;E9!;+1Q+FJW2UZZ!11@24W<1]!IL2N
M)%'&?D3G3I)NUO(\%DFD*Q\Z;9H!E1-I($&HG[&ZL:KF)-W9=GK-0E0R[GFY_M=0Z87?
7QR4G5]!)CA<*WH()6J@D'&?/3#;)#9$7HWN>*2#9[S\@C)3?;P8*+_M3=7DI:?E_^:>:11SAFIZVZ=]Z2SM#I_1+/%(5>(%_HKLN4\O$RFNN**@"*
<'L)Q;9BXM.DCZ3+>EJ043CZ?,R3\30?H#V^\M.6/6_=<8_MIQI9]XOM$UEU8A]6V+@R5EXG8XV&Y%LUP*3F$0+!TPH76CEO#)SZ6"85Z5Y_MFYKM-
B>DZ-9SJ1O]:Y#)KT(WI88_6&@*Q)R<9JX-]).S8&A^1C[Z87FO*%0P_M_1W'_9(>$>.X;#?O6([WIR]W"LP?|\^%CWS<>]I[:JU)@UJ4J=5:>)0V>G
M#KAR:L&X!V%>]/D<0?=BU7,(5]>A@Z>9-M!RLFD*BVJ*9UL)7X,K5!00.349_M5[?),HSG&,;/A\@]K?#E+(21^U+-M928X\GSJKW+[\F;Y\ZL&#FO_?
Z5@ONH_M9(N'3D0#Z.4\A'%?HNJ$[P8.V=NFXDZFC\'"Q7W/=QQ?+=>/$4F,21XC*+G@_MJS3\P4I3(,:D[,L5R[Y;Z^4,_X(,P;VQ2=:0KY:C0$OD)C|
(J1^^G(J@;V5R_M$3<;E2_M^!D,^5M!$@E%FI*:FBYC^ZGS\,!M4],DC#E%8=SZ,"BZO0VMN@5E'&"$E0Z=_M5O4_R@D#^@)F]\;(&
M#IT^S<'*207ZIJ%:S,+=GN>6]3W*KE5UFRUC^GE\|NFPMO.F(_QI"3IK,*]-1JKD/&NJ%+J=?+R|C5-SY]MW4/L@<0:GAMD+@K_6D0>R_.=_G;W
MEYDL>]C;P1R%283_NTB_MLV>.<2$S,^M19>);TDBX45KB?3&_069Y&SH[]D'_Y/_(V%YT<<+$D7WJP(_=2NVR/N\5;*R[D^?
H"=YC&GC7:)0;V@,>P_'#M(GLSTWS@KU_8$V/("_+Q^?,EP8=@!Y_6_M8H1W*S&*;A*$]YT?_W+&R>_^NW,J0-*])>DUQI3O9MVVVPE?KS3__VT4A\6A;
M/Y_%IR=OEQE:(QI>_?? *4.EPI]S,H@I3;_?0"XQP2E-L#R3%WO'!+51]+/_MI\N-H/?^,HDC"MX)-T<;IT8)G?$1')[45BV'+I+B#X(<#>;SS8V#0=MH]:T&
M)_*VO2:_[/#[;IF2][J=9:,T!J>4)6U;?(@DXRM=9(038*-I"F2%F6P_M$=)_M^&^^M0CP4>=/Y-"]B2H*UYJ7.++[="B4920MRLT%-TCDJ,;"2]V16
M^H,W:M_8S:#6C>\,)M9%;@%^M,+4+ZF&X\R)K,,,^>"(?'%$/HE_L?GJ8?C-_M=#Q3\#Q@*DJ6A\%QYP_^V*"*1C9;'"",_RB,"XK%/VV5BG_XXYILDE"
(P8K7_MQ.!?8:%F%8.H3AD5;96K)%G?-/N,EOE]:GZ1NBMKI;U8J2X4#BAILDR_9K+"_MY]+\GH?6*EVTLQV)I^>L'SV;?
6G**0U)N,RWMW%6]RMRU@PD8?\->SO**_MLO7YGM"$YR_XG4O,Z[4$A#>5M^8Y"$[':O-Y;7D'-K$_(PI/_-*R#N?
B:U=DA46ANBIL;DAK6)4J,!3$LN/PQFB"L.BR,UY=6TV0#"EC*$]^0J_47QLQ6CEY@X;FUC_M8$K-)[P&AL6>AG(;V&UHCR=$[(;;:.4D%Q*-
'G>'$),5TO6&089FXK;B^Z23_M_W>)3Q)KJ1&@JM)0M2\M:Z9Z&&'[-2PB;9]3![7,KWB3&YKG^BVH5|;N=#P>
MG_20)|W$S:@".JQ^GG3JEN3.B^Y]+*F5>+MJYQ4MBSX>GQYW&[BUP8R@(F&F_MW*:!ZCU#>LU]_\G1B?
@.|XX1X@H#TK&ZG)FF8<1[;SSCY_O=V_511_M47(8/%_5,"-_T_CMRR!RB6MW]QSHP7.POG/+!!BYM0MTU/BRX->!3YW2$W9R_M>FZ%89"BIIRYOLV:-
[M[8A,1Y]7_)WNMR71O,E9^=3.N]^HF^NMHVP|2PC;O_MR2CKRF$\Q?G<[2+4Z"D.'G(7IYW/"]6@BI8&MCC#<T8#[[ED=QQ0TF29_,UDA??&YLH-
EG,K7%C7^.,N'A$K?'2A8>-^^[+DOIR4_M]PE)YFO:A*5UFDE:2[,.T+S29=LUWOW"W'_GQ$Q:XF]<8_MS;6T,|6KR@QS9N_6?-
|='71ORODˆ]ME\SWZS>1.0:.]IH_PI%K_JPR8%7|4B_M8BC)/*R@_L54$%^M&_M/S&3/^5O7:#)]PGC8[M+RGA&9=AWR_NK.C6S+^R>R
M6%%KFC8[++8906-H=P(*(-W[C^@]QH_IHB*?1SDJ/_D.!FVGA&&CMTIC$Q_!6Z@1FU8T_<_M]>44?Y+%%]F:O21;5_D=CP)7U"X
M_PPCN;?'.2O;8OMS54J_$5E_M\K#O',C%TL#6$^;G0_!O7.E/5ZBRO;)#T9Z<8_:R++1M/L5GGS07_#T&DH\0_MY;"?O7!J0--
]O2U374'!>5HWIP'W10RW#C0]J"I3F@X#W6CM/.3E;K@]R_:$_M_$H;,'E!NU[@X;R"[%[SS58!2?F&XV^MZ25D]WJ7U)Q(Y0(!X;VD$5BIV5MZ
MJ8HE$,Z.QB<7GP!I6:"LG:U^?8'[O+3OSXW=D\?@V>D8TP?%FBKQH\J6SG_ML/@B#P&HK)OU>'.-PABOG]>![[BD]U%IM'Q-O-A=>FZM'81LTX?
%KD:H#.O9_MRC[0=Y8;_F9Y"91,J[20>D:LI?36L,GAD,H8&GUXLU+R=10(7\4BE?H#HTQCT4&]:F'Q
MHVPCOO=M+XDP4I/I3K#4;/SL9F6L0RFSGRRKXABKXG.O6=@!6KJ>W,#8I95Q_MRAQ5_1E%AWB$YPE'&;LRV>K#X9T6R5O)S
K*G_HE62RL<#V9<@=<#6?K3W]=_MK;-^DG1ZFPK%KFX:71^&-_:G;B^PFL3C!3#-L$$5W52QO>GS=86NFV@QJI51_ME_(M]/#TK.<6&IS.F9JK>0L-
0/$_;J&A:5F@K.:WT-UK'6!L1_R?DXON7U#I_MF.#Y_G;H:"H8[-(F"X4C-#2M\G7#&-OR3Z_M_J]Y9=),)K.,.U$_'@._MUI87KQ5F'5Z%8;"BIIP#S,6
M1\;*RQRAN(:=Z;-.U.YRR\?_$R\X^1?FYZ/WM*NCR+2]\.P.ZEF'(%D_M=X(QWU2#6L/NI'*!V!W_M@J9E@:*:VYVZUSI$NJ.1N4,$_WJ3_-|
0'+G7@'G>O*Z)_2]6#KF*\IE?,@_M3UQ@:;WKL(_9!E:EZ]%P02_QL"0=9B%A]MZGL+-FH5:7/IW_=M=%%6O$C)5_MAL&,VI*V\@[@]13NG_)HR@V">1X?
61O_U3(WGYH<3M];^#,=S9^"M9Z_3N-M]@_E9D[5N/#X]@F3'86]NKK4N$Q">M4XFD3LGASDX_MS0D4L+,AEQ%M.(/U&3EH0;N?YB.5GJ2K*L*F0?
U)6UK6/D<;Y(NL,*%75X7-_M#6D-JU(%YL1OF"RO/P)N;$+)VOVBC-0*HP,!F&$,!5'AKXG3&PHQR/&:K,>,_MF/|5Q6#30&9549(,7-!"@6:?T3*_K-
RX<>W(RHS_+UT7"@>4-%DF0#-9X9T2_MKMQ@.;?"A76-/^[B$;%"44P3HO[V9?G@V>S#@UQ-2"IOIKN=_T8#\?N\92#)_MJ>(L.=4K_@[GI%%5%
H=FI\MI*739,P'H6WN^:&Z,#2-2^M-K/(Z$WV/(^KL_M\+04QBZF-3Y?!7LZT]>PC[/T_:\L+K7NRX;$%]_34&R_M
*C]SK*10A+O;7'8BN>K3Z1\@93]\,C:$2DA5^65FA:4'H:BZP@)*I"LYG&?_M1^!ZMN(T(8>3A=2U9G+W\;P&AD$937(/*SHL&XR;)'3]66K15&90L?
*AL$^X*7O>@AB"(437R\?\;G_<2-_MY@0([D0@K#<,IC03-^<*_AI^1LA&E5^-Y$!:YY@5AB&XFO*F6O._M>_N]6_9^ND3NY,BH\03RI-
X3R.BOHVT_2$#]O">CK"L'\2[RC],>OXS\!&)>_MJ_959'YBBS,<9XL&;R-AJ%9&72)%,V4;CIXUO8V$IG.FYD0J%PBHQOG.T#-'

*M;$H08+FSV9(1#=RX;^N1"335RLRI2I*!>Z@([Y%)=QQ0TF29 ,UD/?1')I\[M2UG27'<[TWL#\<'-^MVZ,'='"MW[:[Z X-X=*JA]SS3RAO]I>XGC^K-B? D<& M#V2KPR8&7[W[Y&@D-3"7Y\8,VDDS6[!$9IDZ&-01UAL69^J)"RQ$I8GI1GYF M&18A9 4<8"Z3PJ.P%^3COKPD;UA,7#)&$F,0H^@F09@[YTVB%HYE3?:%WHS2 M[HR*_1G1#HVK<+U?=TK:>8T?J4'=H*P%;B MOOJE1>/H/|=BZ]=KVI^H=Z]):7V(5BNP52G0 MR([179/T)M=7P3T;?8)QA5I9#K8]9698-=$X-@V]$ZQ(:5E' MO_G1$MGNU$75X5]Y9:$H3TT%.ZI3$@[(-C;O])-G^=P][Y!4#I3PGY_)924 M#HC2#-PS]G&^K".@T2 &'6]H-05/@D8%OD)%=!! (.2S38&=!=8;%&66YC89F M:IU%3V%@(^1$=QC@'<,..@S:<&B6\SH\P7]<]YHFJH)HN'EEWSV,3#T@+D(S?]ZY.XPI"I(933:,0EU8,4:]^R M.0N2+1GU.YWXQ1U"X)+R$U/^Q7 M&P91&DEK-C:3IJUG?IR[79'73_?^#9I:B5<9|YQ1M"S[,9;]N(>:5I9P8*&7 M;K(^IP[4:5"9Q\"WDY#@_8C8)GM!O6'0HYFXC4,OM3$3[%E\]%MS8GEDCRQE M-RM6&(;::\K93N"E5K<(VU-VP2]S<>FB5AM>*'*9ZL.@C!:I*:;Z7/(9&S|PKRTG=HT6(.]X.HU&KPR*4 M"3!R%IJQAW9LZBH:^VZG4V23-WT-W PJVA@RP^](GO()C.DTG]5:?LUJ+9?(MN;8\[S6T_CO_W#[49.G]^?23U?IIT?DVZ/BQS|>]1KJZH3R]1ZK[IU$Y"=S M*&8BN7**U^G_\AZN2M8NCYP3/'+&G4P:\H]9FP@F\<"Q]=V*6![. RJYRE"4 MK$.%=0C!Q*!O?! ^@)6KW#!^,#6H1@TK+OM-"W&71!6[\@K[[4%=?]D5;X> M=F^XZPAN],&!IAP16!QJ5)M,\;]D*,"M4(;A='QZU&UR0FWZ5Y<:U#L!"?>6 M7$*%R4"Z]F!IT1""825HKGTU,0Q"2$K9BKM^ZXEDSG>|O:*= <'W;M"XU['N? M%;+)G)?BTZ6QZ/:RR!22S'Q8^TQ=%S0)2=?AE* O)-W.B!_DN]/Z@9$ S/JR M"A2IGBD;1-NM>UW^4+:-2HU?KDW47"%W!4X2M\GRZ-I![6<;F==" ^]9TP]<0VG M>X$PV?-C-8=K- MS_ .KIMAK]%NG@DQK(V 5EM.=VI656(=6XY8_X-)Y0) D]+ZJ&?+$2FSU[8< M>-KCJ*"6+4?O7 S EM/@QK)[;=>?=25E@V@_-W)C"4V7"K.NDH '<&,)394" MC6B^L82UOAJPFT-3;_U9ER_@L.SF9%_RFNU+LE" +HJ>T3(S(!1"'#\C,E8< M$BW]#A\@+>^?R&+MR9HV"YM:?()4|[^UHV$XX7HG1S9)D.[]1_0>O_Y W@I] M#?QXSCNAUVZSC/HY1AU^D ,M')2$8FA6?26$R+!|_1'HX%W6U '3C8> X70- MFE[H5(B[OISB-9Z*A]M6AI\5UQH&*9H(;_0=1B=QY0J!]:PP7*=W[;(9HLI5 MAD&/VI+J2G10>:G8V:WRD[4F1Y?K-,#FI>]LHVT*;IDY-8? %E+H"-TV#<)$2 MQD> M5QA<+&[J),Y"PV*)4#)=:1.X^O-S3D\DJ9 ;T^,:)CJ) HVW8PC/MBAZL>?(M23Q$TE;YUX3['EV(MY&B)V^>.Z-? 5W>#NC@ZWG6#*O1E9/G.J-0;_/>\0Z-@ M.L)=^GG;IU&A4Z-"K^"[1G'P%WI,*=9M.9ME$MIS#.=6&ZG;VE?7=Q?)(G=> M4S$X-VFR/'8_C4]) M*?0^BZEPM0-@E'7KM8MS/OPW"1(VI8L67O 9)*7 M%U10'5.|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|'5:L\'#8T$[EIS*,V&+%CTN3M#X7ERR <=Q;?J+G>E:74 M%>O(I*HK5[=IX9C\)0RB2NNC7,WA]+^!O+F]Z0C(2:'YWG$3LGACA=L$>V/M M&CE5!D&2VH+F[*AMCA2$X&S? MK!U.+@._,C%XE'M/2,;N2OD3/R"!X+8)4[< MQJ#XTUSRG%"-K95:@@ S([IN)LXT^!;96:\LEP:HNPOH 8M:YR[C10YEU3)4 MIYU!\$6O]#EG>OV]X0KORAT," M4+ARR9MMW,4].A'G-SM+]+U]X)C>.U+)>)%*C'RK/)9/\%@^ZR:%KA8.E9;! MUN :5MB4RQ]6Z BR]);*0*%0^XK?)YT8&' ^7*IW?OL AB%QEZ(#\FJ]+9,- M4@K)%A??>?(L7YC)TL2GH!%53!;&!6,;N/29IWCPTEAL?C;FJZ/""$I#8TMK MF]^P2"@@9,0U]NVD,?A\@*AG#PUA+XX=QJD!CD8=KHZJ,$',R,R0@;N8<>M M(XB]D]357&>Q:=L-,B*7<98G6#'VRO5$ATJ3OIR00#1'PIIA>.8T> <&2 MR)U94+BZE*@Y1.W6%9LY);=\$D$>;F[V!?DHM#PLQ*6S<'V76 -B=X4R.?BC M6*F-(7*@.0!,EU;S;XM>B8UU,KWW'7? E.B3V4_7+R\IRT+39Q:9,#9R^/<;= MD^QW-YY38R+N=S1WEZ_!K1_C+63EQJU&"V743C%])YU02DVM CK4$!F&Y:%N '0<1AS5^!0C\ (1J8VH!U6"AVA99EE6$X?O$5?<,$XNO=3 M^*K\/0U"^1KUVZ!?C6LA3< .[>%S;=SH_SRC?R=NY,:YLE/TCG63G_>M# JW M"RVH=]S-?3U212"G&L#, L1R I&J_$'0AE@-*Z.C'OBOK:4;6Q[Y;>4S9,-? M*^MI/#X][C;E>C><;A/<5C;!*8DS;#!PKDTN8UPO MP=/$ID)>6-GO^&3?[Q@W.DI;'? V%=.0_1[CU$6T^3768=XEAY@4IRRQ ""A'4%2=0>OO*OFA;V3O/PQ\3 M8E_/8P-,DCB*\6J,9]1T?/%GB5IM02&/]5E$'RC#L@(HX:*#<%"(II\8#4EG MG)P5%."1I-,QP80__N:80WEU66/20" MR0/0U#BYB3P1[U'DK&N*9.-%DB19Z4.F"0^"I@8\#E$ZGTLRN44Y /FUH!!' MQFS31"0#6^_+2@8/B@#H-A+- /%I?.O)*+9!.L03KY5 M:/S3PAQ)0C9$:6B;.SND#H66ET7.H["4%X5]5\-"D [F[UIPV7TSSM_TVB" M3%6[/2.X&65MZQ9W*9#P;CG&FL"EO#6-.8M_FY9K0EEVJQ]\U06:T=M(L&3% M:HJHZQPYV[T@.\']=1N3E='J!UEU@;;)G9FU7_W4D_V]WGWJ8=)3)UBZ'(PK MC^GY'-JR@W%!>HJ*NT)/08R_Y%I>BL_MN^TE#G)(2H)KR[,3+W-'YGG=U'!% M/E%S12YT?)3W?+3I>EHL&N6='Q'NC0K=)^[+%4[+?_%V/O3ANZRWN]M7OY=8 M44ZFN.UZ4&);T? E]5P"Y*,@Z/@)EXE2Y=6L!@6$=VLFNY-['@"9TD6&'<=PO M"(4?+>I^GW"2L'!(T]E%2+GKPJC#K.)E>3]A>3]U2@-)C8A4*1!03VP_9OJ. MS>7<"_(Q05Z2-_Q!UR>O)!_Q6A_=) A7.S_^Y:PR(DO-5F"K4J"1K4)U2]=E0A@\D MAF/#&>UJ7=T +XR]N2]"HUDG"T?;^$*,%UPM@G E$E6#QJ^V52U+MBZ7N/R! M='3IX]G81_F/-,E/&GB%O;))5^X'$]06MF;"]_X]Z#/""^P'7)F8L(O WWXVC MYY=OHCC&[#H#XTA]F? 6$+Q9O:>GF2VK;6B@Y,"VI2FHRF'![V] '0>0_7*G^U>/&6-CK)61SO-REX#$9'__FLZ%K+? M_=?_#U!+ P04 " #J@V99,_Y_YE=Z! !"/BX %0 &-HR]:9>]2M8N^OW^"N]Z[SE5-6ZQ%IW=]EW[#$7L%16Q^\) M""6DE4;%7W\"FTPU-9>9J2EF6LW>FD) S/G,?D;$7_]G8>BQ&7!<:)G__0?Q M$_]'#)BRI4!S_-]_9'BF5/K'__G[__GK_\6P&.QE6]688LF^ 4PO)CM \H 2 MFT-/_1UK6[8MF;$:7 M_"2>?V0V(X<_$|2OQ"\2)^E8^C>)_XZ3L4;M^3 M/TDRGCZ\F@?.#,H@5K&;L5+N=XP;24F:I.*80@(,2 M,:+H]1BJAVB%Z&6ZOWT7&TN2_=|?JN?9OW_]&DGN*?EC']EB]\H_-Q3HT MM:5D%AH1!T_4D M4WZ^"XVI>$|W[CXB_FO]X_92N/ P%\A[#'T??XZMV2]HHM8YDNB/+ M,20/414-1,0Q/(51Q'8$@#]<6_R<'%]Z@2U\ [3MY0X8G215XA?Z=7>^ M!\6[']M)' 7"?.-L9HQ_V7]BU:))(OC;T^HK-#<=X1:33Z5^+$" ;48&L'"\| M^F'O\8L7:-D:,_SU&2COP(FL.ONWR98*'-]%_S96+X*G*7P'*8D!B9 MV$,F/(K,Q!J9\,???ZE 4O[^RP">%),MTT,:YK_/+#P?]VI&-Z,@:D/9__] ML? D=\P(;_/CU|U\>]'3P]U^_MO]>#S6TE.#OOQ0XB[E>H(/_C D9PQ-S+/L MWQ1N>_]!#_V%?MZ[1H&NK4O!;],R07@!7/P.1P/.^B-4%&"N/J(+\HXDAU.. M^2;T6B%N!?1!Y!&Y%!5WY?Q'0>],!ZZL]3W@>2PII)#9O;I ME9.85-*\2A^PB3+D1:'HB-/$6*3"5\8P@D2*_S/?-[?Q,YY?.(_^XCZ][]0X M+VI!T\ [CP:27XXJ]13/5&XMT^+KA(V[WK@WT $O9?]M [%;J?E8H""#=$4%* M[O]]]EB,AV_;I#[S73/H1975R^K2^.G]"F(V"^J02@M2S\YV*CJK6/FYF C? M;R3I+CCOBG_2%ZXJ.< 5Y6J-,I83+RYP3DL9SO!FMV@UWZ?X%"!# [W2?W^4 MZOE#E=% '@)R08'">Y:L|:NGEUS7!\]>QJA*,,N5AWH)Q_P")'%F0DR:&22: MVVENYW6U>9ZA#"\Q4:\ZH">DWJ'8KC@A:T4Y.9;[XWN::&@$+/,/[!SKLPFC MQ!4AV59#Z M-2$08;_1[P*L2H[#&<=)@]+QY*D9GZU3]W;;''S=T:2##@4.^K6."B9\L\;,(; >;H]#Q%I017.@%(RT9$&<*B# MC.L"S\T&-6EB.8PNH=&? AD1SKZ) S72!VT4Q9MV:28X'W1)R:*'G>|#=/&) M";L_\@NO/ KNI\U0WJNJ+?'G_JR1T_21:')3A?=\3B8SB1OT/SQ]VOA MXO_P0$=>];@ 3#2DCER>C&*@5W.J\ $S]%0[),9[C$5:3*U%<&4L-I_R%=Z MP?5 OI"=X=/&0LAC]=K$;3WY<.'-O[3%N5#9D.S)I?,ZDNZ# M%ARK7D,*0OJOC>@>31&'1AU9R]ELAV^PRXYNAG#7] M9RYD%*2,7_L@-7%&SY +Z^4,Y[:QWW%FH_R-3=HXY^">I(3MK ,:J69&Y1VHD3*;8T;N;0B%]F6I2*JE/<5P[[XX>](#15 MOJ2'8^W->NID]69V,E.TKN*I75'MD1Z/X-6(?UCNG^WU1:;=T&A=ITC#P'R5|SF\!K))W[Q,D? S+.A8RF" MK1:6FC^R)X*PH&T6?Y&4V!^M(SE00DH$J2. /!NOA71/*(E_5B\EJIAW%9W) M"5ADYYI3\;4]E'IC$W XX9VA6D]I!$(843/I>W1L[3+ZO@G9]+=OC+ M>H(O*/MK/_NS4&H MVRUSE4X).;N]*J,H*_.&(E<)(FO%2#;T)/W H/'^$!EN*#D!+^E(?:ZP2J)LOR&_'T? M0>#$5O0$1S/43*FRGT,YO'D[G O&X=S77Q7TL(6M0QEN%'@,;?H0=Y;Y#-A7 MZ?7C[^UEKQ+LKU|''_>6MSA%Z1]_KS3(<5*??.ZO VK\.D9Z>V64GBCG(=\C M3 ZM,BD83]#_/8WS]-L3#Y6=2ZE5FFC_E^WW]4-^[0'Z(_A^%R8S^+# HB%X M/!@PL_E,D^ON.+]8? *#A"0U)D=@)8];&BX]2MI/BTTF_7.'8Z6AN,9-:-S^$ MS<@BZZ'M7N*;PO#DF?A&EZ8Q"K\@OND=?"=NB>^&/T14/4!W OI2V:2"C 8T M+D? DW&K7CC_0_2#$08;_1

*M>XC: ^?OP_D]N(E]4C5*M!F7-4S%ZGV8']*I8N1"K(=G]B70?TLW*@&'*:O7 M3]Q;A:,EP7ZPW/Y3$R_(8WZM$C9"B3="S)C!^R=-*! RR_UB/X4 MYZJS.9M,#U6]&MVH_"V9TZG?A_7[IJX]*@[R/3!AA5J% M;$77O;P+YL"8GE'8GDC"OEDE(WZ<,Z?GT+*,"P0X(W5M,Y M*'"|=FE[;FV& [C1+\7F03J597LYCBWJIIJ7DR#FD7Z7%ZYU/.L;IW6K+6:R^ MCP3@D77F;Q22"Q2ZRHO)-?DU4 M,A92/HX7YFIY8$++X? VAY2!3&1Y_@$P[<',^0",EB)_QZP&W2C UR)<82B [M]-0]-(-.HQK=7.$IX+Z=F]LO[_D\KIKDS$UWY':CN]ZX6ZYDAF\P9^96VW5 M\EW)1.8(_1+4H0E>Z.]YMBES!),4#+'/SA/->K;6NS=/Y!4J7=/].(.^42\! MK<'X="#&6ZV_6*AP?(:J.((_4PK4+&TIO'],&N_3F+:[!_DUDHFW<]ID4@IF M9CS3U@RYQUH&-K2)"&_-|W#:/C/"6FO+>OF$TPK"T6<%/MZMR[6LYG1>B=S#\ MPS]J2:&/#)/#._-)'(Y\2:BV!*E&=J:U8:EKC^_+(#[\T^|IF|=/'KAO_]1N M9LA!%S9EEAMIC.7/A\FZ'+D5!P__-#(2&,&S/^[;/TU5M*0,*8P0I-823"=5 ME079^Y+ AW_ZD,"OXI^]\F(*ND":"Z2DCS@IE6Y:^<@U5C[\TX=LGCGFQGW[MISCA9E(Y:P99)MUA:U2QX263]V4=`_[I)TO@S<_'^%+^Z;B,+T4QVPWP@A4L MBV"0R96M1_[T(8%?1 +OS#]MD)VZD7:DI,;!*N^R?L.WB/L2QX=_^]UD\]22 MX]>^9';JA]O-6H9MF>CK_N:6Z,^&9?*>)6\E8&93<]_R< -/G@@4<6W;? F1&1 MJR \H>RU6>ZV(1],\Y(0N-YBVI>;][R7]Y8CE>FX3:(G*,? M7:Y>K#E'L-!/9FJUA_"0^1 I=,[MXR.K97*6NNS[PO6Q-R+UB MSBWZ/;MQ-=2DR3/#2>W!UINLC'MYNNI[N=1MJL:$X%-%H3NQNWF1D[:*&" MS^7J50SKQ[E:H.8YLC_4TZP17[K90E[*TLY#5L_FZC4,Z\>YVI2HQBQ=FNML M89[("4([0SO-R)4IHLO5JQA6\L-L9;&:BL_:8UHS,J+)M#O R!8>PGKNZN6+ M&M:X2"0.A-4?NE"!DK/:N);K:;TG$EJ^$,T&VXT COGP$!VNO1:8BF!<|OB M N9+M!8O1U=03\UPD]HY-L7K"6D<(Q(? Y^8?:M=;YF9]%YK =3,R K,+GW:; M7;&6]YV1) /.E%>;>I9, ^>=:];J]NF<[V_)F,,O'7&S+NB?O.R"V@ARN>&%B@GJ+6!R4ER?3R]=IK.SPKG54)_ M!]IO5+"=D*UW:>"6 M3 6,W@`>DMEP+!D]MP5<$.X/E4&2>[_9-DAE39/T069E3-!+|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|=R)-MQ@5:, M+Q8/(+_<2_Y-3'@&\UE<^)[?HM&7@W)^=Y:- P"W"SVU;LV0-8)NN.$0]'SO MZ1#;KM:MF_E^HJM5C%:U-##+]=$#TQ]3SJN

MVRU[_H>W)G"LN0;+W@M_:?!X*]]D,^C&#_]6KDNV"WYO/VSLXV\|? L/^8R> MLKUEM?T,\BDV. @D_3/^;,6W8+]H|[>E MPPYE0LN^>=0^&$>AD^;]]P=$[XU";P0%2O]*NFYY0VOQXSI8;?]2@SBO!RU@ M6XZW]M>&F1-74W%!;]ABOJ,2B;^<.<>6![Z[P]A2|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|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|\'V^5O= M%\>>+VPE/%8L3SH'E\S&YY"""^#FL_!)1#YR>;@VJGQ9Y+A3Z2_'T- XXO$3 M_:ODK7,KH.NYS =3F0EG9^/9%"UG>!9 MYA(]?*[#1\/'$A:8HP A!\"I#!P:EF*INF*BD!^4&0TU=J-21"Z!$GOHVJN7 M^YB_E.<1LL]B;^ NN81!P%>9Z?$X MKP07GL$J1L-[QD5!Q&$=Q!?TH]$=21G0[W]%B<](_F7,M&I0@SY2Y [^#*1 M(!ROJGIVD/&<"C.>QXAHR7-!Q"? $.2KJ%:SH1XK'/0W-0LS7KZ="QYQLKH]&;|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|Y] A,*9A2S@&0=Y(LB2P8Z*KN8=W@!M@@B=G@9M@@H[BCG'E*-D!/(. C MYM@M< O@ITB,_FM!?\7V@.O9;_CX/>5SZ]Z#SVFGOU)3S_F@:OE >K:>. / M#P]IF>8YX1.1!=O#0_HV#@_+BJ4,0RAG=5?U75>W('6D6(^L_1 MRK;WS1VM[5."U/#KYR#M8LLOB(#":ZZH30.XOKGOFL3$